SMILES,Drugbank-ID,CAS Number,Name,Synonyms,Drug Type,Affected Organism,Dosage Form,Dosage Route,Dosage,Indication
C(C1=C(O[H])C(C(=O)[H])=C(C(OP(O[H])(O[H])=O)([H])[H])C([H])=N1)([H])([H])[H],DB00114,54-47-7,Pyridoxal Phosphate,"3-hydroxy-2-methyl-5-((phosphonooxy)methyl)-4-pyridinecarboxaldehyde
3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde 5-phosphate
Codecarboxylase
PLP
Pyridoxal 5-monophosphoric acid ester
Pyridoxal 5-phosphate
Pyridoxal 5'-phosphate
Pyridoxal P
Pyridoxal phosphate anhydrous
Pyridoxal-5P
Pyridoxal-P",small molecule,Humans and other mammals,"Capsule, delayed release pellets
Capsule
Capsule, gelatin coated","Oral
Oral
Oral",,For nutritional supplementation and for treating dietary shortage or imbalance.
C(C(=O)C(O[H])=O)([H])([H])[H],"DB00119
DB11194",127-17-3,Pyruvic acid,"2-ketopropionic acid
2-oxopropanoic acid
2-Oxopropans��ure
2-Oxopropions��ure
a-Ketopropionic acid
Acetylformic acid
acide pyruvique
alpha-ketopropionic acid
Brenztraubens��ure
BTS
Pyroracemic acid
��-ketopropionic acid
��-Oxopropions��ure",small molecule,Humans and other mammals,Solution,Extracorporeal,,"For nutritional supplementation, also for treating dietary shortage or imbalance"
N(C(C(C(N(C(C(C(C(N(C(C(C(N([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H],"DB00127
DB02564",71-44-3,Spermine,"4,9-Diaza-1,12-dodecanediamine
4,9-Diazadodecane-1,12-diamine
N,N'-Bis(3-aminopropyl)-1,4-butanediamine
Spermine",small molecule,Humans and other mammals,,,,"For nutritional supplementation, also for treating dietary shortage or imbalance"
C(C(C(=C(C(C(=C(C(C(=C(C(C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])([H])([H])[H],DB00132,463-40-1,Alpha-Linolenic Acid,"(9,12,15)-linolenic acid
(9Z,12Z,15Z)-Octadecatrienoic acid
(Z,Z,Z)-9,12,15-octadecatrienoic acid
9-cis,12-cis,15-cis-octadecatrienoic acid
9,12,15-Octadecatrienoic acid
ALA
all-cis-9,12,15-Octadecatrienoic acid
alpha-Linolenic acid
cis-delta(9,12,15)-Octadecatrienoic acid
cis,cis,cis-9,12,15-Octadecatrienoic acid
Linolenic acid
��-linolenic acid",small molecule,Humans and other mammals,"Capsule, gelatin coated
Capsule","Oral
Oral",,For nutritional supplementation and for treating dietary shortage or imbalance.
O(C(=O)C(C(C(O[H])=O)([H])[H])([H])[H])[H],DB00139,110-15-6,Succinic acid,"1,2-Ethanedicarboxylic acid
Acide butanedioique
Acide succinique
Acidum succinicum
Amber acid
Asuccin
Bernsteinsaeure
Bernsteinsaure
Butandisaeure
Butanedioic acid
Butanedionic acid
Dihydrofumaric acid
e363
Ethylenesuccinic acid
HOOC-CH2-CH2-COOH
Spirit of amber
Succinate
Succinic acid",small molecule,Humans and other mammals,Tablet,Oral,,"For nutritional supplementation, also for treating dietary shortage or imbalance"
N(C(C(O[H])=O)([H])[H])([H])[H],DB00145,56-40-6,Glycine,"Aminoacetic acid
Aminoessigs��ure
Aminoethanoic acid
Gly
Glycin
Glycocoll
Glykokoll
Glyzin
Leimzucker",small molecule,Humans and other mammals,"Powder
Injection, solution
Tablet
Irrigant
Solution
Liquid
Liquid
Solution
Injection, emulsion
Injection, solution, concentrate
Liquid
Emulsion
Liquid
Injection
Solution","Topical
Intravenous
Oral
Irrigation
Irrigation
Irrigation
Irrigation
Irrigation
Intravenous
Intravenous
Hemodialysis
Intravenous
Intravenous
Intravenous
Intravenous","1.5 g/100mL
1.5 g/100mL
1.5 g
1.5 %
15 mg",Supplemental glycine may have antispastic activity. Very early findings suggest it may also have antipsychotic activity as well as antioxidant and anti-inflammatory activities.
C(C1=NC([H])=C(C(O[H])([H])[H])C(C(=O)[H])=C1O[H])([H])([H])[H],DB00147,66-72-8,Pyridoxal,"2-methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine
3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinecarboxaldehyde
3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde
3-hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carboxaldehyde
Piridoxal
Pyridoxaldehyde",small molecule,Humans and other mammals,,,,"Pyridoxal is one of the natural forms available of vitamin B6, therefore, it is used for nutritional supplementation and for treating dietary shortage or imbalances."
C(N(C(C(O[H])=O)([H])[H])C(N([H])[H])=N[H])([H])([H])[H],DB00148,57-00-1,Creatine,"((amino(Imino)methyl)(methyl)amino)acetic acid
(alpha-Methylguanido)acetic acid
(N-methylcarbamimidamido)acetic acid
(��-methylguanido)acetic acid
alpha-Methylguanidino acetic acid
Creatin
Kreatin
Methylglycocyamine
N-(aminoiminomethyl)-N-methylglycine
N-amidinosarcosine
N-carbamimidoyl-N-methylglycine
N-methyl-N-guanylglycine",small molecule,Humans and other mammals,,,,"For nutritional supplementation, also for treating dietary shortage or imbalance."
C(C1=C(C(C(O[H])([H])[H])([H])[H])SC([H])=[N+]1C(C1=C(N([H])[H])N=C(C([H])([H])[H])N=C1[H])([H])[H])([H])([H])[H],DB00152,70-16-6,Thiamine,"Aneurin
Antiberiberi factor
Thiamin
thiamine
thiamine(1+)
thiamine(1+) ion
thiaminium
tiamina
Vitamin B1",small molecule,Humans and other mammals,"Tablet
Elixir
Capsule
Tablet, extended release
Injection
Injection, solution
Tablet, extended release
Powder, for solution
Powder, for solution
Liquid
Elixir
Granule
Capsule, liquid filled
Capsule
Syrup
Liquid
Injection, solution
Tablet, effervescent
Tablet, chewable
Solution / drops
Kit
Liquid
Injection, powder, lyophilized, for solution
Powder
Liquid; tablet
Injection, solution, concentrate
Solution
Solution
Liquid
Solution
Powder
Tablet
Tablet, film coated
Kit
Tablet, coated
Kit
Capsule, extended release
Liquid
Tablet
Tablet
Injection, solution
Liquid
Capsule; liquid
Lozenge
Capsule, gelatin coated
Tablet, extended release
Capsule
Injection
Injection
Solution
Tablet","Oral
Oral
Oral
Oral
Intramuscular
Intramuscular; Intravenous
Oral
Intramuscular; Intravenous
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Intravenous
Oral
Oral
Oral
Intravenous
Intravenous
Topical
Oral
Intravenous
Intravenous
Oral
Oral
Intramuscular; Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Oral
Oral
Intramuscular; Intravenous
Intramuscular
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Intravenous
Intramuscular; Intravenous
Oral","100 mg
500 mg
400 mg
.05 mg
.05 mg
100 mg
25 mg
50 mg
100 mg/mL
100 mg
100 mg
100 mg
100 mg
2 mg","For the treatment of thiamine and niacin deficiency states, Korsakov's alcoholic psychosis, Wernicke-Korsakov syndrome, delirium, and peripheral neuritis."
C(C(C(C(C(C(=C(C(C(=C(C(C(=C(C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00154,1783-84-2,Dihomo-gamma-linolenic acid,"(8Z,11Z,14Z)-Icosatrienoic acid
(Z,Z,Z)-8,11,14-Eicosatrienoic acid
(Z,Z,Z)-8,11,14-Icosatrienoate
(Z,Z,Z)-8,11,14-Icosatrienoic acid
20:3, n-6,9,12 all-cis
8,11,14-Eicosatrienoic Acid
8c,11c,14c-eicosatrienoic acid
8c,11c,14c-Eicosatriens��ure
all-cis-8,11,14-eicosatrienoic acid
all-cis-8,11,14-icosatrienoic acid
all-cis-eicosa-8,11,14-trienoic acid
all-cis-Eicosa-8,11,14-triens��ure
all-cis-icosa-8,11,14-trienoic acid
C20:3, n-6,9,12 all-cis
cis,cis,cis-8,11,14-eicosatrienoic acid
DGLA
dihomo-��-linolenic acid
eicosa-8Z,11Z,14Z-trienoic acid
gamma-Homolinolenic acid
Homo-gamma-linolenic acid
Homo-gamma-linolens��ure
Homo-��-linolens��ure",small molecule,Humans and other mammals,,,,"For nutritional supplementation, also for treating dietary shortage or imbalance"
C(C(C(=C(C(C(=C(C(C(=C(C(C(=C(C(C(=C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])([H])([H])[H],DB00159,10417-94-4,Icosapent,"(5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-Eicosapentaenoic acid
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate
(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
(all-Z)-5,8,11,14,17-Eicosapentaenoic acid
5,8,11,14,17-EICOSAPENTAENOIC acid
5,8,11,14,17-Icosapentaenoic acid
all-cis-5,8,11,14,17-eicosapentaenoic acid
all-cis-5,8,11,14,17-icosapentaenoic acid
all-cis-icosa-5,8,11,14,17-pentaenoic acid
cis-5,8,11,14,17-Eicosapentaenoic acid
cis-5,8,11,14,17-EPA
cis-delta(5,8,11,14,17)-Eicosapentaenoic acid
cis, cis, cis, cis, cis-Eicosa-5,8,11,14,17-pentaenoic acid
Eicosapentaenoic acid
EPA
Icosapent
Icosapentaenoic acid
Icosapento
Icosapentum
Timnodonic acid",small molecule,Humans and other mammals,"Capsule
Kit
Capsule, gelatin coated","Oral
Oral",,"EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy."
C(C(=C(C(O[H])([H])[H])[H])C(=C(C(=C(C([H])([H])[H])C(=C(C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H])[H])[H])[H])[H])[H])([H])([H])[H],DB00162,68-26-8,Vitamin A,"(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
all-trans-retinol
all-trans-retinyl alcohol
all-trans-vitamin A alcohol
Retinol
Vitamin A1",small molecule,Humans and other mammals,"Powder, for solution
Ointment
Emulsion
Injection, solution
Capsule
Capsule
Liquid
Cream
Patch
Tablet
Tablet, extended release
Tablet
Capsule
Tablet, coated
Injection, solution
Tablet, chewable
Kit
Liquid
Injection, powder, lyophilized, for solution
Liquid; tablet
Injection, solution, concentrate
Solution
Liquid
Syrup
Kit
Tablet
Tablet, film coated
Solution / drops
Powder
Lozenge
Capsule; liquid
Capsule, gelatin coated
Solution
Solution / drops
Capsule, liquid filled
Tablet
Capsule
Tablet
Tablet","Oral
Topical
Oral
Intramuscular
Oral
Oral
Oral
Topical
Topical
Oral
Oral
Oral
Oral
Oral
Intravenous
Oral
Intravenous
Intravenous
Oral
Intravenous
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","10000 unit
15 mg/mL
25000 unit
50000 unit
10000 unit
.57 g/19g
1500 unit
700 unit
5000 unit
5000 unit
10000 unit
10000 unit
2000 unit",For the treatment of vitamin A deficiency.
C(C1=NC([H])=C(C(O[H])([H])[H])C(C(O[H])([H])[H])=C1O[H])([H])([H])[H],DB00165,65-23-6,Pyridoxine,"2-Methyl-3-hydroxy-4,5-dihydroxymethylpyridine
3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine
3-Hydroxy-4,5-dimethylol-alpha-picoline
5-Hydroxy-6-methyl-3,4-pyridinedimethanol
Pyridoxine
Pyridoxol
Vitamin B6",small molecule,Humans and other mammals,"Capsule; liquid
Elixir
Tablet, extended release
Tablet, extended release
Injection
Tablet
Injection, solution
Tablet, extended release
Powder, for solution
Powder, for solution
Wafer
Tablet
Cream
Capsule, liquid filled
Spray
Tablet, delayed release
Capsule
Syrup
Tablet
Liquid
Injection, solution
Powder
Tablet, chewable
Solution / drops
Tablet
Tablet
Tablet
Kit
Liquid
Injection, powder, lyophilized, for solution
Liquid; tablet
Injection, solution, concentrate
Solution
Solution
Liquid
Solution
Paste
Tablet, film coated
Kit
Tablet, coated
Liquid
Injection, solution
Solution
Tablet, effervescent
Powder, for solution
Capsule, gelatin coated
Kit
Capsule, extended release
Tablet, extended release
Tablet
Capsule
Injection
Injection
Capsule
Tablet
Capsule
Tablet
Capsule
Tablet
Tablet
Tablet
Lozenge","Oral
Oral
Oral
Oral
Intramuscular
Oral
Intramuscular; Intravenous
Oral
Intramuscular; Intravenous
Intravenous
Oral
Oral
Topical
Oral
Topical
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Intravenous
Intravenous
Oral
Intravenous
Intravenous
Oral
Oral
Intramuscular; Intravenous
Dental
Oral
Oral
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","500 mg
400 mg
2 mg
8.45 mg
6 mg
8.33 mg
10 mg
100 mg
100 mg/mL
100 mg
100 mg
50 mg
250 mg
100 mg
17 mg
200 mg
200 mg
3.5 mg
250 mg
100 mg
25 mg",For the treatment of vitamin B6 deficiency and for the prophylaxis of isoniazid-induced peripheral neuropathy.
C(C1=C([H])C(=O)C2=C(C(=C(C(=C2[H])[H])[H])[H])C1=O)([H])([H])[H],DB00170,58-27-5,Menadione,"2-Methyl-1,4-Naphthalenedione
2-Methyl-1,4-naphthochinon
2-Methyl-1,4-naphthoquinone
Menadione
Vitamin K3",small molecule,Humans and other mammals,,,,"The primary known function of vitamin K is to assist in the normal clotting of blood, but it may also play a role in normal bone calcification."
N(C1=NC([H])=NC2=C1N(C(=N2)[H])[H])([H])[H],DB00173,73-24-5,Adenine,"6-Aminopurine
Adenin
Vitamin B4",small molecule,Humans and other mammals,"Kit
Injection, solution
Liquid
Solution
Kit
Solution
Kit
Solution","Intravenous
Intravenous
Extracorporeal
Intravenous
Intravenous
Unknown",,"For nutritional supplementation, also for treating dietary shortage or imbalance"
C(OC(C(C(C(C(=NOC(C(N([H])[H])([H])[H])([H])[H])C1=C([H])C([H])=C(C(F)(F)F)C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00176,54739-18-3,Fluvoxamine,"Fluvoxamina
Fluvoxamine
Fluvoxaminum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, coated
Tablet, coated
Tablet, coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Capsule, extended release
Capsule, extended release","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg
50 mg
100.0 mg
50.0 mg
100 mg/1
25 mg/1
50 mg/1
100 mg/1
25 mg/1
50 mg/1
100 mg/1
25 mg/1
50 mg/1
100 mg/1
150 mg/1",Indicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) [FDA Label]. Has also been used in the management of bulimia nervosa [A250].
C(C(C([H])([H])[H])(N([H])[H])C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB00191,122-09-8,Phentermine,"alpha,alpha-Dimethylphenethylamine
Fentermina
Phentermine resin
Phenterminum",small molecule,Humans and other mammals,"Capsule
Capsule
Tablet
Capsule
Capsule
Capsule
Tablet
Tablet
Capsule, extended release
Capsule, extended release
Capsule, extended release
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","30 mg
15 mg
8 mg/1
15 mg/1
30 mg/1
37.5 mg/1
30 mg/1
37.5 mg/1
15 mg/1
30 mg/1
15 mg/1
30 mg/1
37.5 mg/1",For the treatment and management of obesity.
C(C(C([H])([H])[H])(N(C(C(C(C1(C(N([H])[H])=O)C2=C(C(=C(C(=C2[H])[H])[H])[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])[H])[H])([H])([H])[H],DB00192,74517-78-5,Indecainide,"Indecainida
Indecainide
Indecainidum",small molecule,Humans and other mammals,,,,For the treatment of life-threatening dysrhythmias and sustained ventricular tachycardia.
O(C(C(N1C([H])=NC([H])=N1)([H])[H])(C(N1C([H])=NC([H])=N1)([H])[H])C1=C(F)C([H])=C(F)C([H])=C1[H])[H],DB00196,86386-73-4,Fluconazole,"2-(2,4-DIFLUOROPHENYL)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol
2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
Biozole
Elazor
Fluconazol
Fluconazolum
Triflucan",small molecule,Fungi,"Tablet
Capsule; cream
Capsule
Powder, for solution
Injection
Injection, solution
Injection, solution
Injection, solution
Powder, for suspension
Powder, for suspension
Powder, for suspension
Powder, for suspension
Tablet
Tablet
Tablet
Tablet
Solution
Capsule; cream; kit
Tablet
Tablet
Tablet","Oral
Oral; Topical; Vaginal
Oral
Oral
Intravenous
Intravenous
Intravenous
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intravenous
Oral; Topical
Oral
Oral
Oral","200 mg
150 mg
50 mg
2 mg/mL
2 mg/mL
200 mg/100mL
400 mg/200mL
10 mg/mL
1400 mg/35mL
350 mg/35mL
40 mg/mL
100 mg/1
150 mg/1
200 mg/1
50 mg/1
2 mg
100 mg
50 mg
150 mg",For the treatment of fungal infections.
C(C1=C(C([H])([H])[H])C2=C(C(C(C(C([H])([H])[H])(C(OC3=C([H])C([H])=C(C(C4(SC(=O)N([H])C4=O)[H])([H])[H])C([H])=C3[H])([H])[H])O2)([H])[H])([H])[H])C(C([H])([H])[H])=C1O[H])([H])([H])[H],DB00197,97322-87-7,Troglitazone,,small molecule,Humans and other mammals,,,,"For the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise."
C(N1C([H])=NC2=C1C(=O)N(C([H])([H])[H])C(=O)N2C([H])([H])[H])([H])([H])[H],DB00201,58-08-2,Caffeine,"1-methyltheobromine
1,3,7-trimethyl-2,6-dioxopurine
1,3,7-trimethylpurine-2,6-dione
1,3,7-trimethylxanthine
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
7-methyltheophylline
Anhydrous caffeine
Cafe��na
Caf��ine
Caffeinum
Coffein
Coffeinum
Guaranine
Koffein
Mate��na
Methyltheobromine
te��na
Thein
Theine",small molecule,Humans and other mammals,"Tablet, multilayer
Capsule
Tablet
Tablet
Tablet, coated
Tablet, effervescent
Tablet, film coated
Syrup
Tablet
Tablet, multilayer
Injection, solution
Injection
Injection, solution
Injection, solution
Solution
Solution
Tablet
Tablet, film coated
Capsule
Capsule, gelatin coated
Tablet, coated
Kit
Tablet, film coated
Solution
Liquid
Granule
Capsule, coated
Tablet
Powder
Tablet, coated
Capsule, liquid filled
Capsule, liquid filled
Suppository
Cream
Cream
Tablet, multilayer
Injection, solution; solution
Capsule
Wafer
Tablet
Liquid","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Intravenous
Intramuscular; Intravenous
Intravenous
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Topical
Oral
Oral
Oral
Oral
Rectal
Topical
Topical
Oral
Intravenous; Oral
Oral
Oral
Oral
Oral","200 1/1
175 mg
175 mg
100 mg
200 mg/1
200 mg/1
200 mg/200mg
125 mg/mL
20 mg/mL
60 mg/3mL
20 mg/mL
20 mg/mL
20 mg/mL
200 mg
100 mg/1
100 mg/1
200 mg/1
5 mg/1000mL
20 mg/ml
100 mg
60 mg
200 mg/1
50 mg","For management of fatigue, orthostatic hypotension, and for the short term treatment of apnea of prematurity in infants."
C([N+](C([H])([H])[H])(C([H])([H])[H])C(C(OC(=O)C(C(C(=O)OC(C([N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00202,306-40-1,Succinylcholine,"2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
Dicholine succinate
Succinic acid, diester with choline
Succinocholine
Succinoylcholine
Succinylbischoline
Succinylcholine
Succinyldicholine
Suxamethonium",small molecule,Humans and other mammals,"Injection, solution
Powder, for solution
Liquid
Injection, solution
Solution
Solution
Injection, solution
Solution","Intramuscular; Intravenous; Parenteral
Intravenous
Intravenous
Intramuscular; Intravenous
Intravenous
Intramuscular; Intravenous
Intravenous
Intravenous","20 mg/mL
500 mg
20 mg
20 mg/mL
100 mg
20 mg
20 mg/mL
20 mg","Used in surgical procedures where a rapid onset and brief duration of muscle relaxation is needed (includes intubation, endoscopies, and ECT)"
C(C(C(C1=NN(C([H])([H])[H])C2=C1N(C(=NC2=O)C1=C(OC(C([H])([H])[H])([H])[H])C([H])=C([H])C(S(=O)(=O)N2C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C2([H])[H])=C1[H])[H])([H])[H])([H])[H])([H])([H])[H],DB00203,139755-83-2,Sildenafil,"1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Injection, solution
Injection, solution
Powder, for suspension
Solution
Tablet
Tablet, film coated
Injection, solution
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating","Oral
Oral
Oral
Oral
Oral
Intravenous
Intravenous
Oral
Intravenous
Oral
Oral
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg
25 mg
100.0 mg
25.0 mg
50.0 mg
.8 mg/mL
0.8 mg/ml
10 mg/ml
0.8 mg
20 mg
20 mg
10 mg/12.5mL
20 mg/1
20 mg/1
100 mg
25 mg
50 mg
50 mg
100 mg/1
25 mg/1
50 mg/1
50 mg
100 mg
25 mg",For the treatment of erectile dysfunction and to relieve symptoms of pulmonary arterial hypertension (PAH). 
C(N(C(C(OC1=C([H])C([H])=C(N(S(C([H])([H])[H])(=O)=O)[H])C([H])=C1[H])([H])[H])([H])[H])C(C(C1=C([H])C([H])=C(N(S(C([H])([H])[H])(=O)=O)[H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB00204,115256-11-6,Dofetilide,"beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide
Dofetilida
Dofetilidum",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule","Oral
Oral
Oral",".125 mg/1
.25 mg/1
.5 mg/1",For the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
C(C(C1=NC(N([H])[H])=NC(N([H])[H])=C1C1=C([H])C([H])=C(Cl)C([H])=C1[H])([H])[H])([H])([H])[H],DB00205,58-14-0,Pyrimethamine,"2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine
2,4-Diamino-5-(P-chlorophenyl)-6-ethylpyrimidine
2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine
5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine
5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidinediamine
5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine
CD
Chloridine
Chloridyn
Diaminopyritamin
Ethylpyrimidine
Pirimetamina
Primethamine
Pyrimethaminum",small molecule,Plasmodium,"Tablet
Tablet
Tablet
Capsule","Oral
Oral
Oral
Oral","25 mg/1
25 mg",For the treatment of toxoplasmosis and acute malaria; For the prevention of malaria in areas non-resistant to pyrimethamine
ClC1=C(C(N2C([H])([H])C([H])([H])C3=C(C(=C(S3)[H])[H])C2([H])[H])([H])[H])C([H])=C([H])C([H])=C1[H],DB00208,55142-85-3,Ticlopidine,"Ticlopidina
Ticlopidinum",small molecule,Humans and other mammals,"Tablet
Tablet, film coated","Oral
Oral","250 mg
250 mg/1","Used in patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke."
C(OC1=C(C23C([H])([H])C4(C([H])([H])C(C(C(C4([H])[H])(C2([H])[H])[H])([H])[H])([H])C3([H])[H])[H])C([H])=C(C2=C([H])C([H])=C3C(=C(C(=C([H])C3=C2[H])[H])C(O[H])=O)[H])C([H])=C1[H])([H])([H])[H],DB00210,106685-40-9,Adapalene,"6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid
Adaferin
Adapaleno
Adapalenum
Differine",small molecule,Humans and other mammals,"Cream
Gel
Gel
Lotion
Swab
Solution
Cream
Cream
Gel
Lotion
Lotion
Gel
Liquid
Gel
Gel
Gel","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical",".1 g/100g
1 mg/g
45 g/g
.1 g/100mL
1 mg/mL
1 mg/mL
0.1 %
1 mg/g
3 mg/g
0.1 %
1 mg/g
0.1 %
0.1 %
0.3 %
.1 g/100g","For the topical treatment of comedo, papular and pustular acne (acne vulgaris) of the face, chest or back."
C(C(C([H])([H])[H])(N(C(=O)N(S(=O)(=O)C1=C(N(C2=C([H])C(C([H])([H])[H])=C([H])C([H])=C2[H])[H])C([H])=C([H])N=C1[H])[H])[H])[H])([H])([H])[H],DB00214,56211-40-6,Torasemide,"1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea
Luprac
N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide
Torasemida
Torasemidum
Torsemide",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Liquid
Tablet
Tablet
Tablet
Tablet
Injection
Injection, solution","Oral
Oral
Oral
Oral
Intravenous
Oral
Oral
Oral
Oral
Intravenous
Intravenous","10 mg/1
100 mg/1
20 mg/1
5 mg/1
10 mg
100 mg
10 mg
20 mg
5 mg
10 mg/mL
10 mg/mL","For the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Also for the treatment of hypertension alone or in combination with other antihypertensive agents."
C(N(C(N(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H])=NC([H])([H])[H])[H])([H])([H])[H],DB00217,55-73-2,Bethanidine,"Betanidina
Betanidine
Betanidinum
N,N'-dimethyl-N''-(phenylmethyl)-guanidine",small molecule,Humans and other mammals,,,,For the treatment of hypertension.
C(C(C(N(C(C([H])([H])[H])(C([H])([H])[H])[H])[H])(C(O[H])(C1=C([H])C(O[H])=C(O[H])C([H])=C1[H])[H])[H])([H])[H])([H])([H])[H],DB00221,79490-84-9,Isoetarine,"Isoetarina
Isoetarinum
Isoetharine",small molecule,Humans and other mammals,,,,"For the treatment of asthma, wheezing, and chronic asthmatic bronchitis."
N(C1=C([H])C(O[H])=C(C(O[H])=O)C([H])=C1[H])([H])[H],"DB00233
DB09367",65-49-6,Aminosalicylic Acid,"4-amino-2-hydroxybenzoic acid
4-aminosalicylate
4-aminosalicylic acid
p-aminosalicylic acid
para-amino salicylic acid
para-aminosalicylic acid
PAS",small molecule,Mycobacteria,"Granule, delayed release
Tablet
Granule, delayed release","Oral
Oral
Oral","4 g
500 mg
4 g/1",For the treatment of tuberculosis
C(C1=C(C2=C([H])C([H])=NC([H])=C2[H])C([H])=C(C#N)C(=O)N1[H])([H])([H])[H],DB00235,78415-72-2,Milrinone,"1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile
Milrinona
Milrinone
Milrinonum",small molecule,Humans and other mammals,"Injection
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Solution
Solution","Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous","1 mg/mL
1 mg/mL
10 mg/10mL
20 mg/20mL
50 mg/50mL
.2 mg/mL
200 ug/mL
1.0 mg
1 mg",Indicated for the treatment of congestive heart failure.
BrC(C(C(=O)N1C([H])([H])C([H])([H])N(C(=O)C(C(Br)([H])[H])([H])[H])C([H])([H])C1([H])[H])([H])[H])([H])[H],DB00236,54-91-1,Pipobroman,Vercyte,small molecule,Humans and other mammals,,,,For the treatment of polycythaemia vera and refractory chronic myeloid leukaemia.
C(C1=C([H])C([H])=NC2=C1N(C(=O)C1=C(N2C2(C([H])([H])C2([H])[H])[H])N=C([H])C([H])=C1[H])[H])([H])([H])[H],"DB00238
DB08311",129618-40-2,Nevirapine,"11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
NEV
Nevirapine
NVP",small molecule,Human Immunodeficiency Virus,"Tablet
Suspension
Tablet
Tablet, coated
Tablet, extended release
Tablet
Tablet
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","50 mg/5mL
200 mg/1
200 mg/1
100 mg/1
400 mg/1
200 mg
100 mg
400 mg/1
50 mg
400 mg",For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
ClC1=C([H])C(Cl)=C(C(ON=C(C(N2C([H])=C([H])N=C2[H])([H])[H])C2=C(Cl)C([H])=C(Cl)C([H])=C2[H])([H])[H])C([H])=C1[H],DB00239,64211-45-6,Oxiconazole,"Oxiconazol
Oxiconazole
Oxiconazolum",small molecule,Fungi,"Cream
Lotion
Lotion
Lotion
Cream
Lotion","Topical
Topical
Topical
Topical
Topical
Topical","10 mg/g
10 mg/g
10 mg/mL
30 mg/g
1 %
10 mg",For treatment of dermal fungal infection.
C(C(C([H])([H])[H])(C(C1(C(C(=C([H])[H])[H])([H])[H])C(=O)N([H])C(=O)N([H])C1=O)([H])[H])[H])([H])([H])[H],DB00241,77-26-9,Butalbital,"5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
5-Allyl-5-(2-methylpropyl)barbituric acid
5-Allyl-5-(2'-methyl-N-propyl) barbituric acid
5-Allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione
5-Allyl-5-isobutylbarbituric acid
5-isobutyl-5-allylbarbituric acid
allylbarbital
allylbarbitone
Allylbarbituric acid
Butalbarbital
Butalbitalum
Iso-butylallylbarbituric acid
Itobarbital
Tetrallobarbital",small molecule,Humans and other mammals,"Syrup
Tablet
Capsule","Oral
Oral
Oral",,"Used in combination with acetaminophen or aspirin and caffeine for its sedative and relaxant effects in the treatment of tension headaches, migraines, and pain."
N(C1=C([H])C(C(O[H])=O)=C(O[H])C([H])=C1[H])([H])[H],"DB00244
DB05376
DB06396",89-57-6,Mesalazine,"3-carboxy-4-hydroxyaniline
5-aminosalicylic acid
5-ASA
m-Aminosalicylic acid
Mesalamine
Mesalazina
M��salazine
Mesalazinum
p-Aminosalicylsaeure",small molecule,Humans and other mammals,"Capsule, extended release
Tablet
Tablet, delayed release
Tablet, delayed release
Suppository
Capsule, delayed release
Tablet, delayed release
Enema
Kit
Suspension
Tablet, delayed release
Tablet, delayed release
Tablet, extended release
Capsule
Capsule
Suspension
Suspension
Tablet, extended release
Enema; liquid
Tablet, extended release
Tablet, extended release
Suppository
Suppository
Suspension
Tablet, delayed release
Suppository
Tablet, delayed release","Oral
Oral
Oral
Oral
Rectal
Oral
Oral
Rectal
Rectal
Oral
Oral
Oral
Oral
Oral
Rectal
Rectal
Oral
Rectal
Oral
Oral
Rectal
Rectal
Rectal
Oral
Rectal
Oral","375 mg/1
400 mg/1
400 mg/1
800 mg
1000 mg/1
400 mg/1
1.2 g/1
4 g/60mL
4 g/60mL
800 mg/1
500 mg
1.2 g
250 mg/1
500 mg/1
1 g
4 g
1 g
2 g
250 mg
500 mg
1 g
500 mg
2 g
250 mg
250 mg
400 mg",For the treatment of active ulcerative proctitis.
ClC1=C(C(C(N2C([H])([H])C([H])([H])N(C3=NSC4=C3C(=C(C(=C4[H])[H])[H])[H])C([H])([H])C2([H])[H])([H])[H])([H])[H])C([H])=C2C(C(=O)N([H])C2=C1[H])([H])[H],DB00246,146939-27-7,Ziprasidone,"Ziprasidona
Ziprasidone
Ziprasidonum",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule
Capsule
Injection, powder, lyophilized, for solution
Capsule
Capsule
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral
Intramuscular
Oral
Oral
Oral
Oral","20 mg
20 mg/1
40 mg/1
60 mg/1
80 mg/1
20 mg/mL
20.0 mg
40 mg
60 mg
80 mg",For the treatment of schizophrenia and related psychotic disorders.
N(C1=C([H])C([H])=C(S(=O)(=O)C2=C([H])C([H])=C(N([H])[H])C([H])=C2[H])C([H])=C1[H])([H])[H],DB00250,80-08-0,Dapsone,"1,1'-Sulfonylbis(4-aminobenzene)
1,1'-Sulfonylbis[4-aminobenzene]
4-(4-amino-Benzenesulfonyl)-phenylamine
4-(4-Aminophenylsulfonyl)aniline
4-(4-Aminophenylsulfonyl)benzenamine
4-Aminophenyl sulfone
4,4'-Dapsone
4,4'-Diaminodiphenyl sulfone
4,4'-Diaminodiphenyl sulphone
4,4'-Diaminodiphenylsulfone
4,4'-Sulfonylbisaniline
4,4'-Sulfonylbisbenzenamine
4,4'-Sulfonylbisbenzeneamine
4,4'-Sulfonyldianilin
4,4'-sulfonyldianiline
Bis(4-aminophenyl)sulfone
Bis(P-aminophenyl) sulfone
DADPS
Dapsona
DAPSONE
Dapsonum
DDS
DIAPHENYLSULFONE
P-Aminophenyl sulfone
P,P-Sulphonylbisbenzamine
P,P-Sulphonylbisbenzenamine
P,P'-diaminodiphenyl sulfone",small molecule,"Mycobacteria
Mycobacterium leprae","Gel
Gel
Gel
Tablet
Tablet
Tablet","Topical
Topical
Topical
Oral
Oral
Oral","5 %
75 mg/g
50 mg/g
100 mg/1
100 mg
25 mg/1",For the treatment and management of leprosy and dermatitis herpetiformis.
O=C1N([H])C(=O)C(C2=C([H])C([H])=C([H])C([H])=C2[H])(C2=C([H])C([H])=C([H])C([H])=C2[H])N1[H],DB00252,57-41-0,Phenytoin,"5,5-Diphenyl-imidazolidine-2,4-dione
5,5-diphenylimidazolidine-2,4-dione
5,5-diphenyltetrahydro-1H-2,4-imidazoledione
5,5-Diphenyltetrahydro-1H-2,4-imidazoledione
Diphenylhydantoin
Fenitoina
Phentytoin
Phenytoine
Phenytoinum",small molecule,Humans and other mammals,"Capsule
Capsule, extended release
Capsule, extended release
Tablet, chewable
Tablet
Liquid
Capsule
Suspension
Suspension
Capsule
Capsule, extended release
Suspension
Suspension
Capsule
Capsule, extended release
Injection
Injection
Injection
Injection, solution
Liquid
Solution","Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Intramuscular; Intravenous
Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous","30 mg
100 mg/1
30 mg/1
50 mg/1
50 mg
250 mg
125 mg
30 mg
100 mg
300 mg/1
100 mg/4mL
125 mg/5mL
100 mg/1
200 mg/1
250 mg/5mL
50 mg/mL
50 mg/mL
50 mg/mL
50 mg
50 mg","For the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery."
C(C(C(=C(C(C([H])([H])[H])([H])[H])C1=C([H])C([H])=C(O[H])C([H])=C1[H])C1=C([H])C([H])=C(O[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB00255,56-53-1,Diethylstilbestrol,"(E)-3,4-bis(4-hydroxyphenyl)-3-hexene
(e)-4,4'-(1,2-Diethyl-1,2-ethenediyl)bisphenol
4,4'-Dihydroxy-alpha,beta-diethylstilbene
4,4'-dihydroxy-��,��-diethylstilbene
alpha,Alpha'-diethyl-(e)-4,4'-stilbenediol
DES
Diethylstilbestrol
Diethylstilbestrolum
Dietilestilbestrol
Distilbene
Stilboestrol
trans-4,4'-(1,2-diethyl-1,2-ethenediyl)bisphenol
trans-Diethylstilbesterol
trans-Diethylstilbestrol
trans-Diethylstilboesterol
��,��'-diethyl-(E)-4,4'-stilbenediol",small molecule,Humans and other mammals,"Liquid
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet","Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral","250 mg
100 mg
1 mg
0.105 mg
0.51 mg
1.0 mg
.1 mg
.5 mg",Used in the treatment of prostate cancer. Previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.
ClC1=C(C(N2C([H])=C([H])N=C2[H])(C2=C([H])C([H])=C([H])C([H])=C2[H])C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C([H])C([H])=C1[H],DB00257,23593-75-1,Clotrimazole,"1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(o-Chloro-��,��-diphenylbenzyl)imidazole
1-(o-Chlorotrityl)imidazole
1-(��-(2-Chlorophenyl)benzhydryl)imidazole
Clotrimazole
Lotrimin (tn)
Mycelex (tn)",small molecule,Yeast and other fungi,"Ointment
Liquid
Cream
Lotion
Cream
Capsule; cream
Solution
Cream
Suppository
Cream; suppository
Cream; tablet
Cream
Tablet
Tablet
Cream
Cream
Cream
Liquid
Suppository
Cream
Capsule; cream; kit
Cream
Cream
Cream
Liquid
Lozenge
Lozenge
Solution
Cream
Lotion
Cream
Cream
Cream
Solution
Solution
Kit
Aerosol, spray
Aerosol, foam
Liquid
Solution
Gel
Spray
Powder
Cream
Cream
Ointment
Gel
Cream
Liquid
Cream
Liquid
Cream
Solution
Cream
Aerosol, foam
Oil
Cream
Cream
Cream
Cream
Solution
Ointment
Kit
Cream
Cream","Topical
Topical
Topical
Topical
Topical
Oral; Topical; Vaginal
Topical
Topical; Vaginal
Vaginal
Topical; Vaginal
Topical; Vaginal
Topical; Vaginal
Vaginal
Vaginal
Vaginal
Topical
Topical; Vaginal
Topical
Vaginal
Topical
Oral; Topical
Topical
Vaginal
Vaginal
Topical
Oral
Oral; Topical
Topical
Topical
Topical
Topical
Vaginal
Vaginal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Vaginal
Topical
Topical
Topical
Topical; Vaginal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Vaginal
Topical","10 mg/g
1 g/100mL
350 mg/35g
1 g/100mL
.01 g/g
1 %
2 %
200 mg
500 mg
200 mg
10 %
1 %
1 %
1 %
100 mg
1 g/g
50 mg/g
1 g/100g
10 mg/g
1 mg/mL
10 mg/1
10 mg/1
1 g/mL
10 mg/g
1 %
2 %
10 mg/mL
1 mg/mL
1 mL/100mL
1 g/100g
10 g/1000g
1 g/100mL
10 mg/g
4 mg/mL
1 g/100g
6 mg/mL
10 g/g
1 mg/100g
1 g/100g
420 mg/42g
10 mg/mL
50 mg
10 mg
10 mg
10 mg
10 mg
10 mg/g
10 mg/mL
10 mg/mL
.01 mg/10g
1 g/100g
1.1 g/115g
1 g/100g
2 g/100g
10 mg/100g","For the local treatment of oropharyngeal candidiasis and vaginal yeast infections, also used in fungal infections of the skin such as ringworm, athlete's foot, and jock itch."
N(C1=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C1[H])([H])[H],DB00259,63-74-1,Sulfanilamide,"4-Aminobenzene sulfonic acid amide
4-Azanylbenzenesulfonamide
P-Aminobenzenesulfamide
P-Aminobenzenesulfonamide
Para-aminobenzenesulfonamide
Prontosil album
SA
Streptocide
Sulfamine
Sulfanilamide
Sulphanilamide",small molecule,Candida albicans and other yeasts,"Cream
Cream","Vaginal
Vaginal","15 %
15 g/100g",For the treatment of vulvovaginitis caused by <i>Candida albicans</i>.
ClC1=C(Cl)C2=C(N=C3N([H])C(=O)C([H])([H])N3C2([H])[H])C([H])=C1[H],DB00261,68475-42-3,Anagrelide,"Anagrelida
Anagrelidum",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule","Oral
Oral
Oral",".5 mg/1
1 mg/1
0.5 mg","For the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events."
ClC(C(N(C(=O)N(C(C(Cl)([H])[H])([H])[H])N=O)[H])([H])[H])([H])[H],DB00262,154-93-8,Carmustine,"BCNU
Bicnu (tn)
bis-chloroethylnitrosourea
Bischloroethyl nitrosourea
Carmustina
Carmustine
Carmustinum
N,N'-Bis(2-chloroethyl)-N-nitrosourea",small molecule,Humans and other mammals,"Kit
Powder, for solution
Wafer
Wafer","Intravenous
Intracavitary
Intralesional","100 mg
7.7 mg/1
7.7 mg","For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas."
C(C1=NOC(N(S(=O)(=O)C2=C([H])C([H])=C(N([H])[H])C([H])=C2[H])[H])=C1C([H])([H])[H])([H])([H])[H],DB00263,127-69-5,Sulfisoxazole,"3,4-Dimethyl-5-sulfanilamidoisoxazole
3,4-Dimethyl-5-sulfonamidoisoxazole
3,4-Dimethyl-5-sulphanilamidoisoxazole
3,4-Dimethyl-5-sulphonamidoisoxazole
3,4-Dimethylisoxazole-5-sulfanilamide
3,4-Dimethylisoxazole-5-sulphanilamide
4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamide
4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulphonamide
5-(4-Aminophenylsulfonamido)-3,4-dimethylisoxazole
5-(P-Aminobenzenesulfonamido)-3,4-dimethylisoxazole
5-(P-Aminobenzenesulphonamido)-3,4-dimethylisoxazole
5-Sulfanilamido-3,4-dimethylisoxazole
5-Sulphanilamido-3,4-dimethyl-isoxazole
N'-(3,4)dimethylisoxazol-5-yl-sulphanilamide
N(1)-(3,4-Dimethyl-5-isoxazolyl)sulfanilamide
N(1)-(3,4-Dimethyl-5-isoxazolyl)sulphanilamide
Sulfadimethylisoxazole
Sulfafurazol
Sulfafurazole
Sulfafurazolum
Sulfaisoxazole
Sulfasoxazole
Sulfisonazole
Sulfisoxasole
Sulfisoxazol
Sulfofurazole
Sulphadimethylisoxazole
Sulphafurazol
Sulphafurazole
Sulphaisoxazole
Sulphisoxazol
Sulphofurazole",small molecule,Enteric bacteria and other eubacteria,"Granule, for suspension
Powder, for suspension
Tablet","Oral
Oral
Oral",500 mg,"For the treatment of severe, repeated, or long-lasting urinary tract infections, meningococcal meningitis, acute otitis media, trachoma, inclusion conjunctivitis, nocardiosis, chancroid, toxoplasmosis, malaria and other bacterial infections."
C(C(N(C(=O)C(=C(C([H])([H])[H])[H])[H])C1=C(C([H])([H])[H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB00265,483-63-6,Crotamiton,,small molecule,Humans and other mammals,"Cream
Lotion
Cream","Topical
Topical
Topical","100 mg/g
100 mg/g
10 %",For eradication of scabies (<i>Sarcoptes scabiei</i>) and for symptomatic treatment of pruritic skin.
O(C1=C(C(C2=C(O[H])C3=C(C(=C(C(=C3[H])[H])[H])[H])OC2=O)([H])[H])C(=O)OC2=C1C(=C(C(=C2[H])[H])[H])[H])[H],DB00266,66-76-2,Dicoumarol,"3,3'-Methylen-bis(4-hydroxy-cumarin)
3,3'-Methylene-bis(4-hydroxycoumarine)
3,3'-Methylenebis(4-hydroxy-1,2-benzopyrone)
3,3'-Methylenebis(4-hydroxy-2H-1-benzopyran-2-one)
3,3'-Methylenebis(4-hydroxycoumarin)
bis-3,3'-(4-hydroxycoumarinyl)methane
bis-hydroxycoumarin
Bis(4-hydroxycoumarin-3-yl)methane
di-(4-hydroxy-3-coumarinyl)methane
Dicoumarol
Dicoumarolum
Dicumarol",small molecule,Humans and other mammals,,,,For decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis.
C(C(C(N(C(C(C([H])([H])[H])([H])[H])([H])[H])C(C(C1=C([H])C([H])=C([H])C2=C1C(C(=O)N2[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00268,91374-21-9,Ropinirole,"Ropinirol
Ropinirolum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet
Tablet
Tablet
Tablet, coated
Tablet, coated
Tablet, coated
Tablet, coated
Tablet, coated
Tablet, coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","3.0 mg
4.0 mg
0.25 mg
0.5 mg
1.0 mg
2.0 mg
5.0 mg
1 mg
2 mg
5 mg
12 mg/1
2 mg/1
4 mg/1
6 mg/1
8 mg/1
.25 mg/1
.5 mg/1
1 mg/1
2 mg/1
.25 mg/1
.5 mg/1
1 mg/1
2 mg/1
3 mg/1
4 mg/1
5 mg/1
3 mg/1
4 mg/1
5 mg/1
.25 mg/1
.5 mg/1
1 mg/1
2 mg/1
4 mg/1
5 mg/1",For the treatment of the signs and symptoms of idiopathic Parkinson's disease. Also used for the treatment of restless legs syndrome.
C(OC1=C([H])C([H])=C(C(Cl)=C(C2=C([H])C([H])=C(OC([H])([H])[H])C([H])=C2[H])C2=C([H])C([H])=C(OC([H])([H])[H])C([H])=C2[H])C([H])=C1[H])([H])([H])[H],DB00269,569-57-3,Chlorotrianisene,"Chloortrianisestrol
Chlorestrolo
Chlorotrianisenum
Chlorotrianisine
Chlorotrianizen
Chlortrianisen
Chlortrianisestrol
Chlortrianisoestrolum
Chlortrianizen
Clorotrianiseno",small molecule,Humans and other mammals,,,,"Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth."
C(C(=O)N(C1=C(I)C(C(O[H])=O)=C(I)C(N(C(C([H])([H])[H])=O)[H])=C1I)[H])([H])([H])[H],DB00271,117-96-4,Diatrizoate,"2,4,6-Triiodo-3,5-diacetamidobenzoic acid
3,5-Bis(acetylamino)-2,4,6-triiodobenzoic acid
3,5-diacetamido-2,4,6-triiodobenzoic acid
Acide amidotrizoique
Acidum amidotrizoicum
Acidum diacetylaminotrijodbenzoicum
Amidotrizoate
Amidotrizoic Acid
Amidotrizoic acid (anhydrous)
Diatrizoate
Diatrizoesaure
Diatrizoic acid
Diatrizoic acid (anhydrous)
Methalamic acid
Triombrin
Urografin acid
Urogranoic acid",small molecule,Humans and other mammals,"Injection, solution
Injection, solution
Liquid
Solution
Liquid
Liquid
Powder
Powder
Liquid
Solution
Liquid
Solution
Solution
Liquid
Solution
Liquid
Liquid
Solution
Solution
Liquid
Liquid
Liquid
Injection, solution
Liquid","Intravenous
Intravesical
Oral; Rectal
Oral
Oral
Oral; Rectal
Oral; Rectal
Oral
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intra-arterial; Intravenous
Intra-arterial; Intravenous
Intravenous
Oral; Rectal
Intravenous
Intravenous
Intramuscular; Intravenous
Intravenous
Intrauterine
Intrauterine","300 mg/mL
180 mg/mL
50 g
997.4 mg
100 %
50 %
18 %
18 %
30 %
60 %
60 %
600 mg
600 mg
30 %","Used, alone or in combination, for a wide variety of diagnostic imaging methods, including angiography, urography, cholangiography, computed tomography, hysterosalpingography, and retrograde pyelography. It can be used for imaging the gastrointestinal tract in patients allergic to barium."
N(C(C(C1=C([H])C([H])=NN1[H])([H])[H])([H])[H])([H])[H],DB00272,105-20-4,Betazole,"1H-pyrazole-3-ethanamine
2-(1H-Pyrazol-5-yl)ethanamine
2-(3-Pyrazolyl)ethylamine
3-(2-Aminoethyl)pyrazole
3-(beta-aminoethyl)pyrazole
3-(��-aminoethyl)pyrazole
Ametazole
Betazol
Betazolum",small molecule,Humans and other mammals,,,,For use clinically to test gastric secretory function.
C(C(C(C1=NC(C(C([H])([H])[H])(C([H])([H])[H])O[H])=C(C(O[H])=O)N1C(C1=C([H])C([H])=C(C2=C(C3=NN=NN3[H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00275,144689-24-7,Olmesartan,"4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet
Tablet
Tablet
Tablet, coated
Tablet, coated
Tablet, coated
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg
20 mg/1
40 mg/1
5 mg/1
20 mg/1
40 mg/1
5 mg/1
20 mg/1
40 mg/1
5 mg/1
20 mg
40 mg
5 mg",For the treatment of hypertension.
C(OC1=C(N(C2=C3C(=C(C(=C([H])C3=NC3=C(C(=C(C([H])=C23)[H])[H])[H])[H])[H])[H])[H])C([H])=C([H])C(N(S(C([H])([H])[H])(=O)=O)[H])=C1[H])([H])([H])[H],DB00276,51264-14-3,Amsacrine,"4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide
4'-(9-Acridinylamino)methanesulfon-m-anisidide
4'-(9-Acridinylamino)methanesulfon-meta-anisidide
4'-(9-Acridinylamino)methanesulphon-m-anisidide
Acridinyl anisidide
Amsacrine
m-AMSA
mAMSA",small molecule,Humans and other mammals,Liquid,Intravenous,50 mg,For treatment of acute myeloid leukaemia.
C(C(N(C(C([H])([H])[H])([H])[H])C(C(=O)N(C1=C(C([H])([H])[H])C([H])=C([H])C([H])=C1C([H])([H])[H])[H])([H])[H])([H])[H])([H])([H])[H],"DB00281
DB05291",137-58-6,Lidocaine,"2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
alpha-diethylamino-2,6-dimethylacetanilide
Lignocaine
��-diethylamino-2,6-dimethylacetanilide",small molecule,Humans and other mammals,"Solution
Kit
Liquid
Patch
Kit
Gel
Solution
Liquid; spray
Gel
Gel
Gel
Gel
Gel
Ointment
Swab
Gel
Gel
Gel
Patch
Liquid
Cream
Liquid
Ointment
Kit; liquid
Liquid
Liquid
Patch
Ointment
Lotion
Patch
Cream
Implant
Gel
Patch
Gel
Liquid
Cream
Gel
Cream
Aerosol, spray
Cream
Spray
Liquid
Spray
Cream
Gel
Gel
Spray
Lotion
Cream
Gel
Spray
Spray
Spray
Spray
Gel
Gel
Cream
Cream
Gel
Gel
Tablet
Liquid; ointment
Kit; liquid; ointment
Liquid
Patch
Cream
Cream
Gel
Rinse
Patch
Solution
Spray
Kit
Cream
Cream
Cream
Cream
Kit
Kit
Spray
Kit
Kit
Lotion
Spray
Kit; ointment; solution
Cream
Spray
Cream
Gel
Spray
Cream
Gel
Liquid
Cream
Liquid; spray
Swab
Spray
Cream
Spray
Gel
Spray
Gel
Kit
Aerosol
Gel
Spray
Ointment
Cream
Gel
Gel
Cream
Liquid
Soap
Spray
Soap
Injection, solution
Liquid; ointment
Lotion
Kit
Gel
Lotion
Spray, metered
Liquid
Solution
Lotion
Aerosol, spray
Cream
Cream
Injection, solution
Injection, solution
Ointment
Ointment
Ointment
Ointment
Ointment
Patch
Patch
Solution
Cream
Injection, solution
Cream
Cream
Gel
Solution
Liquid
Liquid
Liquid
Gel
Gel
Injection
Injection
Injection
Injection
Injection
Injection
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Jelly
Liquid
Liquid
Lotion
Lotion
Solution
Solution
Solution
Spray
Solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection
Injection, solution
Injection, solution
Injection, solution
Solution
Liquid
Solution
Solution
Spray
Gel
Solution
Solution
Ointment
Cream
Solution
Patch
Patch
Spray
Gel
Spray
Cream
Solution
Liquid
Jelly
Jelly
Ointment
Liquid
Patch
Patch
Patch
Liquid
Gel
Patch
Patch
Patch
Patch
Patch
Patch
Liquid
Patch
Cream
Cream
Cream
Kit
Spray
Liquid
Gel
Spray, metered
Liquid
Spray, metered
Kit
Cream
Cream
Patch
Aerosol
Gel
Gel
Solution / drops
Kit
Liquid; ointment
Liquid
Solution
Cream
Spray
Cream
Cream
Spray
Solution
Stick
Liquid
Liquid
Gel
Suspension
Cream
Lotion
Liquid
Cream
Patch
Gel
Liquid
Gel
Liquid
Kit; ointment; solution
Cream
Kit
Liquid
Liquid
Solution / drops
Spray
Spray
Solution
Cream
Ointment
Spray, metered
Ointment
Spray
Patch
Packing
Patch
Kit
Kit
Kit
Kit
Kit
Cream
Cream
Cloth
Gel
Gel
Gel
Liquid
Gel
Spray
Solution
Patch
Cream
Liquid
Spray
Gel
Gel
Gel
Spray
Lotion
Spray
Gel
Gel
Cream
Kit
Liquid
Liquid
Kit
Spray
Spray, metered
Aerosol
Swab
Patch
Ointment
Kit
Patch
Liquid
Gel
Spray
Gel
Gel
Gel
Gel
Liquid
Spray
Gel
Spray
Gel
Cream
Solution
Spray
Cream
Cream
Injection
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Jelly
Liquid
Liquid
Solution
Liquid
Solution
Solution
Liquid
Solution
Solution
Injection, solution
Injection, solution
Injection, solution
Liquid
Liquid
Liquid
Liquid
Aerosol
Spray
Liquid
Liquid
Solution
Liquid
Solution
Liquid
Aerosol, metered; spray
Spray, metered
Liquid
Solution
Powder
Patch","Intravenous
Topical
Subarachnoid
Topical
Oral; Topical
Topical
Topical
Topical
Topical
Topical
Ophthalmic
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Infiltration; Subcutaneous
Topical
Epidural
Topical
Intravenous
Intravenous
Intra-articular
Topical
Topical
Topical
Topical
Topical
Intradermal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Dental
Intravenous; Topical
Infiltration; Parenteral; Subcutaneous; Topical
Epidural; Infiltration; Subcutaneous
Topical
Topical
Topical
Topical
Topical
Transdermal
Intra-articular; Intrabursal
Topical
Topical
Topical
Topical
Topical
Topical
Oral; Topical
Buccal; Topical
Topical
Epidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue; Subcutaneous; Topical
Topical
Topical
Infiltration; Intravenous; Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Intra-amniotic
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Intra-articular
Epidural; Topical
Topical
Infiltration; Intramuscular; Intravenous; Topical
Topical
Topical
Topical
Endotracheal
Topical
Topical
Topical
Topical
Topical
Infiltration
Subcutaneous
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Infiltration
Topical
Infiltration
Rectal
Rectal; Topical
Rectal
Intravenous
Epidural; Infiltration
Infiltration
Intravenous
Topical
Topical
Epidural; Infiltration; Intracaudal
Infiltration; Intravenous
Infiltration; Intravenous
Infiltration; Intravenous
Intravenous
Parenteral
Epidural; Infiltration
Epidural; Infiltration
Epidural; Infiltration; Intracaudal
Epidural; Infiltration; Intracaudal
Epidural; Infiltration; Intracaudal; Perineural
Epidural; Infiltration; Intracaudal; Perineural
Epidural; Infiltration; Perineural
Infiltration; Intravenous
Intravenous
Intravenous
Retrobulbar; Topical
Topical
Topical
Topical
Topical
Topical
Oral
Oropharyngeal
Topical
Topical
Epidural; Infiltration
Intraspinal
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Infiltration
Dental; Infiltration
Epidural
Infiltration
Infiltration
Infiltration
Infiltration
Infiltration
Topical
Oral
Infiltration
Infiltration
Topical
Topical
Oral; Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Buccal
Cutaneous
Cutaneous
Cutaneous
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Auricular (otic)
Transdermal
Topical
Topical
Topical
Oral
Topical
Infiltration
Topical
Topical
Subcutaneous
Topical
Epidural; Infiltration; Topical
Topical
Topical
Topical
Topical
Topical
Topical
Ophthalmic; Topical
Epidural; Infiltration; Intravenous
Subcutaneous; Topical
Infiltration; Intraspinal; Subcutaneous
Intramuscular; Intravenous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Dental; Subcutaneous
Subcutaneous
Periodontal
Auricular (otic)
Topical
Topical
Topical
Topical
Topical
Topical
Infiltration; Subcutaneous; Topical
Topical
Intravenous
Infiltration; Subcutaneous; Topical
Topical
Infiltration; Intra-articular; Intramuscular; Respiratory (inhalation); Topical
Epidural; Intravenous
Dental
Auricular (otic)
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Dental
Topical
Epidural; Infiltration; Intra-articular; Intralesional; Intramuscular
Epidural; Infiltration; Intramuscular; Intravenous
Epidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Soft tissue
Epidural; Infiltration
Epidural; Infiltration; Intra-articular; Intramuscular; Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Percutaneous; Topical; Transdermal
Percutaneous; Topical; Transdermal
Percutaneous; Topical; Transdermal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Infiltration; Topical
Parenteral; Topical
Infiltration; Subcutaneous
Infiltration
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Intrathoracic; Subcutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Infiltration
Infiltration; Perineural
Infiltration; Perineural
Infiltration; Perineural
Infiltration; Perineural
Topical
Intraspinal
Infiltration
Epidural
Infiltration
Epidural
Epidural
Subarachnoid
Epidural; Infiltration
Oral
Epidural; Infiltration; Intracaudal; Perineural
Epidural; Infiltration; Intracaudal; Perineural
Infiltration
Intraspinal; Percutaneous
Percutaneous
Epidural
Infiltration
Oral; Topical
Topical
Topical
Oral; Topical
Retrobulbar; Topical
Epidural; Intracaudal
Intravenous
Intravenous
Topical
Topical
Topical
Topical
Intradermal
Topical","20 mg
246 mg/1
25 mg/mL
1 %
0.5 %
0.5 %
2.5 g/100g
35 mg/mL
5 mg/mL
4 %
4 g/100mL
4 g/100mL
.5 g/100mL
.5 g/100g
2.5 g/g
1 g/10g
1 %
5 g/100mL
1 %
.05 g/g
1 %
411.4 mg/1
246 mg/1
4 g/100g
422 mg/1
2 g/100g
.3 %
4.1 mg/mL
0.7 %
2 %
2 %
2 g/100g
2.8 g/56g
40 mg/1
10 mg/mg
3.4 g/68mL
20 mg/L
2.25 %
2 g/100mL
2.5 g/100mL
2 g/100mL
3 g/100g
3.9 g/100mL
0.72 %
.05 g/100g
.5 g/100g
200 g/L
2.4 %
5.05 g/g
.025 g/g
10 mg/g
.04 mg/mg
1.0 %
20 mg
560 mg/1
4 g/100mL
40 mg/mL
5 mg/g
40 mg/1
50 mg/g
38.8 mg/g
1.2 g/30g
1.5 g/30g
5 g/100g
10 mg/.08mL
4 g/mL
10 mg/100mL
20 mg/1000mg
40 mg/1000mg
50 mg/1000mg
50 mg/1000mg
50 mg/1000mg
40 mg/1000mg
40 mg/1000mg
40 mg/1000mg
4 mg/mL
10 mg/g
10 mg/mL
2 %
40 mg/g
500 g/100000mg
.5 g/100g
4 g/100g
5.0 %
.8 g/100g
0.8 %
45 mg/mL
40 mg/g
50 mg/g
.5 g/100mL
4 g/50g
96 mg/mL
40 mg
40 mg/mL
30 mg/mL
.64 g/127g
40 mg/g
50 mg/g
10 mg/mL
10 1/1
2.5 g/50g
35.44 g/g
5 g/100g
50 mg/g
140 mg/1
50 mg/g
30 mg/g
20 mg/mL
10 mg
10 mg
20 mg
30 mg/g
40 mg/g
10 mg/mL
10 mg/mL
20 mg/mL
5 mg/mL
20 mg/mL
20 mg/mL
10 mg/mL
20 mg/mL
10 mg/mL
20 mg/mL
10 mg/mL
20 mg/mL
20 mg/mL
5 mg/mL
10 mg/mL
20 mg/mL
40 mg/mL
20 mg/mL
20 mg/mL
200 mL/L
3 g/100mL
5.31 mL/177mL
20 mg/mL
20 mg/mL
20 mg/mL
20 g/L
4 mg/mL
400 mg/100mL
8 mg/mL
800 mg/100mL
5 mg
2 %
20 mg
10 mg
1 %
2 g/100mL
1 %
2 %
5 g
39.2 mg/mL
20 mg/mL
4 g/1
11 mg/1
20 mg/mL
7.2 g/240g
4.6 g/115g
10 g/100g
4 %
10 mg
20 mg
2 %
5 %
2 %
50 mg/g
700 mg/12h
700 mg/1
700 mg/1000mg
3 mg/100mL
22.7 mg/.24mg
25.3 mg/.24mg
25.8 mg/.24mg
28.1 mg/.24mg
29 mg/.24mg
21.5 mg/.24mg
32.5 mg/g
37.5 mg/g
39.5 mg/g
10 mg/.1mL
2.36 g/118mL
10 mg/100mL
1 %
9.6 mg/100mL
4 %
5 %
40 mg/1
.04 g/g
10 mg/mL
1 %
50 mg/mL
24.64 mg/mL
5 mg/g
5 mg/30g
.04 mg/mg
.04 g/40g
40 mg/4mL
4 g/100mL
4 g/100g
.3 g/1
7.13 mg/mL
2 mg/g
1 %
41.2 mg/g
2 %
2.6 %
4 %
40 mg
400 mg/mg
.005 mg/g
9.6 g/100mL
10 mg/mL
10 g/100g
240 mg/1
18 mg/116cm2
.04 g/g
.05 g/g
1 g/100g
20 mg/g
20 mg/mL
40 mg/mL
4 g/100g
2 %
2 %
560 mg/1
1.1 g/12g
2.0 %
40 mg/mL
1 %
5 mg/g
0.5 %
4 g/100mL
.057 mg/mL
0.50 %
.5 g/100g
1 %
96 mg/mL
9.6 %
0.5 %
1 %
4 g/100g
1 %
2.36 g/59g
2.36 g/59g
5 %
5 g/100g
15 mg/mL
4 g/100mL
50 mg/mL
2.5 g/100mL
2.5 %
.5 mg/100mg
1 %
0.5 %
0.5 %
2 g/mL
4 g/mL
10 mg/mL
10 mg/mL
20 mg/mL
5 mg/mL
.5 mg/18mL
5 mg
15 mg
20 mg
20 mg
50 mg
17.3 mg
100 mg
15 mg/mL
5 mg/mL
1 %
1 %
1 %
40 mg
50 mg
20 mg
40 mg/mL
20 mg
100 mg
200 mg
2.5 %
4.0 %
.5 mg/1
36 mg/1",For production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks.
N(C(C(C(O[H])(P(O[H])(O[H])=O)P(O[H])(O[H])=O)([H])[H])([H])[H])([H])[H],DB00282,40391-99-9,Pamidronate,"Acide pamidronique
Acido pamidronico
Acidum pamidronicum
Pamidronic acid
Ribodroat",small molecule,Humans and other mammals,"Powder, for solution
Powder, for solution
Powder, for solution
Liquid
Injection
Injection
Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Injection, solution
Injection, solution
Injection, solution
Solution
Solution
Solution
Solution
Solution
Powder, for solution
Solution","Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous","60 mg
30 mg
90 mg
3 mg
3 mg/mL
9 mg/mL
3 mg/mL
6 mg/mL
9 mg/mL
3 mg/mL
6 mg/mL
9 mg/mL
3 mg
6 mg
3.0 mg
6.0 mg
9.0 mg
15 mg
9 mg",For the treatment of moderate or severe hypercalcemia associated with malignancy
O(C(=O)C(C(C(C1=C([H])C([H])=C(N(C(C(Cl)([H])[H])([H])[H])C(C(Cl)([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])[H],DB00291,305-03-3,Chlorambucil,"4-(P-Bis(beta-chloroethyl)aminophenyl)butyric acid
4-(p-bis(��-chloroethyl)aminophenyl)butyric acid
4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid
Ambochlorin
CHLORAMBUCIL
Chloraminophen
gamma-[P-Di(2-chloroethyl)aminophenyl]butyric acid
N,N-Di-2-chloroethyl-gamma-P-aminophenylbutyric acid
N,N-di-2-chloroethyl-��-p-aminophenylbutyric acid
Phenylbutyric Acid Nitrogen Mustard
��-[p-di(2-chloroethyl)aminophenyl]butyric acid",small molecule,Humans and other mammals,"Tablet
Tablet, film coated","Oral
Oral","2 mg
2 mg/1","For treatment of chronic lymphatic (lymphocytic) leukemia,  childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease,  non-Hodgkin's lymphomas, and Waldenstr��m���s Macroglobulinemia."
C(C1=C(N2C([H])([H])C([H])([H])N(C(C(C3=NN=C4C(C(C(C([H])([H])N34)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])([H])C2([H])[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB00298,72822-12-9,Dapiprazole,"5,6,7,8-Tetrahydro-3-(2-(4-(O-tolyl)-1-piperazinyl)ethyl)-S-triazolo(4,3-a)pyridine
Dapiprazol
Dapiprazolum",small molecule,Humans and other mammals,,,,Used in the treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents used in certain eye examinations.
N(C1=NC(=O)C2=C(N(C(C(C(C(O[H])([H])[H])(C(O[H])([H])[H])[H])([H])[H])([H])[H])C(=N2)[H])N1[H])([H])[H],"DB00299
DB01730",39809-25-1,Penciclovir,"9-(4-hydroxy-3-(hydroxymethyl)butyl)guanine
9-(4-hydroxy-3-hydroxymethylbut-1-yl)-guanine
9-[2-hydroxy-1-(hydroxymethyl)-ethoxymethyl]guanine
9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine
PCV
PE2
Penciclovirum",small molecule,Herpes simplex virus,"Cream
Cream","Topical
Topical","1 %
10 mg/g",Used to treat recurrent cold sores on the lips and face from various herpesvirus invections.
C(C1=C(C(=C([H])[H])C2=C([H])C([H])=C(C(O[H])=O)C([H])=C2[H])C([H])=C2C(C(C([H])([H])[H])(C([H])([H])[H])C(C(C2(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])=C1[H])([H])([H])[H],DB00307,153559-49-0,Bexarotene,"4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid
4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid
Bexaroten
Bexarot��ne
Bexarotene
Bexaroteno
Bexarotenum
P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
p-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl]benzoic acid
Targretyn
Targrexin",small molecule,Humans and other mammals,"Gel
Capsule
Capsule, liquid filled","Topical
Oral
Oral","1 g/100g
75 mg
75 mg/1",Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.
C(C(OC1=C([H])C2=C(N=C(S2)S(N([H])[H])(=O)=O)C([H])=C1[H])([H])[H])([H])([H])[H],"DB00311
DB07727",452-35-7,Ethoxzolamide,"6-Ethoxy-1,3-benzothiazole-2-sulfonamide
Ethoxazolamide
Ethoxyzolamide",small molecule,Humans and other mammals,,,,"For use in the treatment of duodenal ulcers, as a diuretic, and in the treatment of glaucoma, and may also be useful in the treatment of seizures associated with epilepsy."
C(C(C(C(C(C(C([H])([H])[H])([H])[H])([H])[H])(C(O[H])=O)[H])([H])[H])([H])[H])([H])([H])[H],"DB00313
DB00510",99-66-1,Valproic Acid,"2-n-propyl-n-valeric acid
2-propyl-pentanoic acid
2-Propylpentanoic Acid
2-Propylvaleric Acid
4-heptanecarboxylic acid
acide valpro��que
��cido valproico
acidum valproicum
di-n-propylacetic acid
Di-n-propylessigs��ure
Dipropylacetic acid
DPA
n-DPA
Valproate
Valproins��ure
VPA",small molecule,Humans and other mammals,"Tablet, delayed release
Tablet, delayed release
Tablet, delayed release
Injection
Solution
Tablet, extended release
Tablet, extended release
Capsule
Capsule, coated pellets
Capsule, delayed release
Tablet, film coated, extended release
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, delayed release
Tablet, delayed release
Tablet, delayed release
Tablet, delayed release particles
Tablet, film coated, extended release
Liquid
Tablet, extended release
Capsule
Syrup
Capsule, delayed release
Syrup
Injection
Injection, solution
Capsule
Capsule, liquid filled
Solution
Solution
Tablet","Oral
Oral
Oral
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intravenous
Oral
Oral
Oral
Oral
Oral
Intravenous
Intravenous
Oral
Oral
Oral
Oral
Oral","125 mg
250 mg
500 mg
100 mg/mL
250 mg
250 mg/1
500 mg/1
125 mg/1
125 mg/1
125 mg/1
500 mg/1
125 mg/1
250 mg/1
500 mg/1
125 mg/1
250 mg/1
500 mg/1
500 mg/1
250 mg/1
500 mg
500 mg
250 mg
250 mg
500 mg
50 mg
500 mg/5mL
100 mg/mL
250 mg/1
250 mg/1
250 mg/5mL
500 mg/10mL
250 mg/1","For treatment and management of seizure disorders, mania, and prophylactic treatment of migraine headache. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome."
C(C(=O)N(C1=C([H])C([H])=C(O[H])C([H])=C1[H])[H])([H])([H])[H],DB00316,103-90-2,Acetaminophen,"4-(Acetylamino)phenol
4-acetamidophenol
4'-hydroxyacetanilide
Acenol
acetaminof��n
Acetaminophen
ac��taminoph��ne
APAP
N-acetyl-p-aminophenol
p-acetamidophenol
p-acetaminophenol
p-Acetylaminophenol
p-hydroxy-acetanilid
p-hydroxyacetanilide
p-hydroxyphenolacetamide
Parac��tamol
Paracetamol
Paracetamolum",small molecule,Humans and other mammals,"Suppository
Suppository
Suppository
Suppository
Suspension
Tablet, coated
Tablet, extended release
Tablet
Tablet
Elixir
Tablet
Tablet
Liquid
Elixir
Suppository
Capsule
Tablet
Tablet
Liquid
Liquid
Tablet
Granule, effervescent
Tablet, effervescent
Tablet, orally disintegrating
Tablet
Tablet, extended release
Capsule, gelatin coated
Liquid
Tablet
Elixir
Elixir
Suspension
Tablet
Tablet, chewable
Elixir
Suspension
Suspension
Tablet, orally disintegrating
Tablet, chewable
Liquid
Tablet
Solution
Capsule; kit
Kit
Tablet, coated
Kit
Kit
Kit
Kit
Tablet, film coated
Liquid
Capsule
Tablet, orally disintegrating
Capsule, gelatin coated
Tablet, chewable
Solution
Suppository
Suppository
Granule
Liquid
Solution
Capsule, liquid filled
Tablet, film coated, extended release
Suspension
Tablet
Tablet, coated
Suspension / drops
Capsule, coated
Liquid
Tablet
Powder
Kit; powder
Kit; powder, for solution
Suspension
Solution / drops
Suspension
Solution / drops; suspension
Tablet, orally disintegrating
Tablet, chewable
Tablet
Tablet, chewable
Tablet
Tablet
Capsule, delayed release pellets
Liquid
Tablet, chewable
Capsule
Tablet
Tablet, multilayer
Injection, solution
Solution
Capsule
Liquid
Capsule, coated
Capsule, liquid filled
Suppository
Capsule, gelatin coated
Capsule, liquid filled
Solution
Liquid
Liquid; solution / drops
Solution
Solution
Solution
Tablet, film coated
Syrup
Tablet
Tablet, extended release
Tablet
Liquid
Syrup
Syrup
Solution / drops
Powder, for solution
Syrup
Kit; tablet
Suspension
Syrup
Tablet, extended release
Solution
Tablet, film coated
Liquid
Powder, for suspension
Granule, for solution
Solution","Rectal
Rectal
Rectal
Rectal
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Rectal
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Topical
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Topical
Oral; Topical
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Rectal
Rectal
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Topical
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intravenous
Intravenous
Oral
Oral
Oral
Oral
Rectal
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","120 mg
325 mg
650 mg
160 mg
160 mg/100mL
325 mg/1
650 mg/1
300 mg/1
500.0 mg
650 mg/1
500.4 mg/556mg
500 mg/15mL
32 mg
650 mg/1
325 mg
324.9 mg/361mg
500 mg
160 mg
80 mg
325 mg
325 mg/1
325 mg/1
650.0 mg
325 mg/1
80.0 mg
160 mg
80 mg
160 mg
80 mg
80 mg
160 mg/5mL
325 mg/10.15mL
650 mg/20.3mL
80 mg/1
80 mg/1
160 mg/5mL
500 mg/5mL
500 mg
500 mg
500 mg/1
500.0 mg
500 mg
80 mg/1
325 mg/1
675 mg/675mL
650 mg/1
160 mg/5mL
500 mg/1
500 mg/1
80 mg/.8mL
1000 mg/60mL
80 mg
80 mg/.8mL
160 mg/1.6mL
80 mg
160 mg/1
160 mg/1
160 mg
160 mg
160.0 mg
160 mg/1
.8 mL/mL
80 mg/1
500 mg/1
500 1/1
10 mg/mL
10 mg
160 mg/5mL
500 mg/1
500 mg/1
120 mg/1
325 mg/1
16 mg
80 mg/.8mL
80 mg
160 mg
80 mg
32 mg
500 mg/1
80 mg/.8mL
500 mg/583mg
100 mg/mL
80 mg
160 mg
80 mg
160 mg/5mL
650 mg
500 mg/15mL
325 mg/1
650 mg
120 mg","For temporary relief of fever, minor aches, and pains."
C(OC1=C(OC(C(C(N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C2C(N(C3=C([H])C(Cl)=C(F)C([H])=C3[H])[H])=NC(=NC2=C1[H])[H])([H])([H])[H],"DB00317
DB07998",184475-35-2,Gefitinib,"4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
Gefitinib
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
ZD 1839",small molecule,Humans and other mammals,"Tablet
Tablet, coated
Tablet, film coated","Oral
Oral
Oral","250 mg
250 mg/1
250 mg",For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
C(N(C([H])([H])[H])C(C(C(=C1C2=C(C(=C(C(=C2[H])[H])[H])[H])C([H])([H])C([H])([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB00321,50-48-6,Amitriptyline,"10,11-dihydro-5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,D)cycloheptene
10,11-dihydro-N,N-Dimethyl-5H-dibenzo(a,D)heptalene-delta(5),gamma-propylamine
3-(10,11-dihydro-5H-Dibenzo(a,D)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine
3-(10,11-dihydro-5H-Dibenzo[a,D]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine
5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,D)cycloheptatriene
5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,D)cycloheptene
5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,D][1,4]cycloheptadiene
Amitriptilina
Amitriptylin
Amitriptyline
Amitriptylinum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet
Tablet
Tablet
Tablet
Syrup
Kit
Tablet
Tablet, film coated
Tablet
Kit","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Topical
Oral
Oral
Oral","10 mg/1
100 mg/1
150 mg/1
25 mg/1
50 mg/1
10 mg/1
100 mg/1
150 mg/1
25 mg/1
50 mg/1
75 mg/1
10 mg
25 mg
50 mg
75 mg
2 mg
100 mg","- Indicated for the treatment of major depressive disorder in adults
- Indicated for the management of neuropathic pain in adults
- Indicated for the prophylactic treatment of chronic tension type headache (CTTH) in adults
- Indicated for the prophylactic treatment of migraine in adults
- Indicated for the the treatment of nocturnal enuresis in children aged 6 years and above when organic pathology, including spina bifida and related disorders, have been excluded and no response has been achieved to all other non-drug and drug treatments, including antispasmodics and vasopressin-related products. This medicinal product should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis.
-Other off-label uses include irritable bowel syndrome, sleep disorders, diabetic neuropathy, agitation and insomnia"
C(C1=C([H])C([H])=C(C(=O)C2=C([H])C([N+]([O-])=O)=C(O[H])C(O[H])=C2[H])C([H])=C1[H])([H])([H])[H],DB00323,134308-13-7,Tolcapone,"(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone
3,4-Dihydroxy-4'-methyl-5-nitrobenzophenone
3,4-Dihydroxy-5-nitro-4'-methylbenzophenone
4'-Methyl-3,4-dihydroxy-5-nitrobenzophenone
Tolcapon
Tolcapona
Tolcapone
Tolcaponum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral","100 mg
200 mg
100 mg
200 mg
100 mg/1
100 mg/1",Used as an adjunct to levodopa/carbidopa therapy for the symptomatic treatment of Parkinson's Disease. This drug is generally reserved for patients with parkinsonian syndrome receiving levodopa/carbidopa who are experiencing symptom fluctuations and are not responding adequately to or are not candidates for other adjunctive therapies.
O=N[Fe-2](C#N)(C#N)(C#N)(C#N)C#N,DB00325,15078-28-1,Nitroprusside,"[Fe(CN)5(NO)](2-)
Nitroferricyanide",small molecule,Humans and other mammals,"Powder, for solution
Injection, solution
Injection, solution
Injection, solution, concentrate
Injection
Injection
Injection, solution, concentrate
Solution","Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous","50 mg
.2 mg/mL
.5 mg/mL
50 mg/2mL
25 mg/mL
50 mg/2mL
25 mg/mL
25 mg","For immediate reduction of blood pressure of patients in hypertensive crises, reduce bleeding during surgery, and for the treatment of acute congestive heart failure"
C(OC1=C([H])C2=C(N(C(=O)C3=C([H])C([H])=C(Cl)C([H])=C3[H])C(C([H])([H])[H])=C2C(C(O[H])=O)([H])[H])C([H])=C1[H])([H])([H])[H],DB00328,53-86-1,Indomethacin,"{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid
1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid
Aconip
Indometacin
Indometacina
Indometacine
Indometacinum
Indomethacin",small molecule,Humans and other mammals,"Capsule, extended release
Solution / drops
Suppository
Suspension
Liquid; powder, for solution
Capsule
Capsule
Capsule
Capsule, extended release
Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Capsule
Capsule
Suppository
Suppository
Capsule
Capsule","Oral
Ophthalmic
Rectal
Oral
Ophthalmic
Oral
Oral
Oral
Oral
Intravenous
Intravenous
Oral
Oral
Rectal
Rectal
Oral
Oral","75 mg
10 mg
50 mg/1
25 mg/5mL
1 mg
25 mg/1
50 mg/1
75 mg/1
75 mg/1
1 mg/mL
1 mg/1
25 mg
50 mg
100 mg
50 mg
20 mg/1
40 mg/1","For moderate to severe rheumatoid arthritis including acute flares of chronic disease, ankylosing spondylitis, osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis."
C(N(C([H])([H])[H])C(=N[H])N(C(N([H])[H])=N[H])[H])([H])([H])[H],DB00331,657-24-9,Metformin,"1,1-Dimethylbiguanide
Dimethylbiguanid
Metformin
Metformina
Metformine
Metforminum",small molecule,Humans and other mammals,"Kit
Kit
Tablet, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet
Tablet
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet
Tablet, film coated
Tablet, extended release
Tablet, film coated, extended release
Tablet
Tablet
Tablet
Tablet, coated
Tablet, coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet
Tablet, film coated
Solution
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","1000 mg/1
1000 mg/1
500 mg/1
1000 mg
850 mg
500 mg/1
750 mg/1
1000 mg
500 mg
1000 mg/1
500 mg/1
850 mg/1
1000 mg/1
500 mg/1
1000 mg/1
500 mg/1
850 mg/1
750 mg/1
750 mg/1
500 mg/5mL
500 mg",For use as an adjunct to diet and exercise in adult patients (18 years and older) with NIDDM. May also be used for the management of metabolic and reproductive abnormalities associated with polycystic ovary syndrome (PCOS). Jentadueto is for the treatment of patients when both linagliptin and metformin is appropriate.
C(N1C([H])([H])C([H])([H])N(C2=NC3=C(C(=C(C(=C3[H])[H])[H])[H])N([H])C3=C2C(=C(C([H])([H])[H])S3)[H])C([H])([H])C1([H])[H])([H])([H])[H],DB00334,132539-06-1,Olanzapine,"2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
Olanzapin
Olanzapina
Olanzapine
Olanzapinum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Injection, powder, for solution
Injection, powder, lyophilized, for solution
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Capsule
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, coated
Tablet, coated
Tablet, coated
Tablet, coated
Tablet, coated
Tablet, film coated
Tablet, film coated
Tablet, orally disintegrating
Tablet
Tablet
Injection, powder, for suspension, extended release
Injection, powder, for suspension, extended release
Injection, powder, for suspension, extended release
Injection, powder, for solution
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, coated
Tablet
Tablet
Tablet
Tablet
Powder, for solution
Kit
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating","Oral
Oral
Oral
Oral
Intramuscular
Intramuscular
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular
Intramuscular
Intramuscular
Intramuscular
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular
Intramuscular
Oral
Oral
Oral
Oral","10.0 mg
15.0 mg
20.0 mg
5.0 mg
10 mg/2mL
10 mg/2mL
10 mg/1
15 mg/1
2.5 mg/1
20 mg/1
5 mg/1
7.5 mg/1
10 mg/1
15 mg/1
20 mg/1
5 mg/1
10 mg
2.5 mg
5 mg
7.5 mg
10 mg
15 mg
2.5 mg
5 mg
7.5 mg
15 mg
20 mg
7.5 mg
2.5 mg
7.5 mg
210 mg
300 mg
405 mg
10 mg
10 mg/1
15 mg/1
2.5 mg/1
20 mg/1
5 mg/1
7.5 mg/1
20 mg
10 mg
5 mg
15 mg
20 mg
10 mg
10 mg
15 mg
20 mg
5 mg","For the acute and maintenance treatment of schizophrenia and related psychotic disorders, as well as acute treatment of manic or mixed episodes of bipolar 1 disorder. Intramuscular olanzapine is indicated for the rapid control of agitated patients."
N(C(=O)N(N=C(C1=C([H])C([H])=C([N+]([O-])=O)O1)[H])[H])([H])[H],DB00336,59-87-0,Nitrofural,"5-Nitro-2-furaldehyde semicarbazone
Furacilin
Nitrofural",small molecule,Gram negative and gram positive bacteria,,,,"For the treatement of bacterial skin infections including pyodermas, infected dermatoses and infections of cuts, wounds, burns and ulcers due to susceptible organisms."
N(C(=O)C1=NC([H])=C([H])N=C1[H])([H])[H],DB00339,98-96-4,Pyrazinamide,"2-carbamylpyrazine
2-pyrazinecarboxamide
Aldinamide
Pirazinamida
Pirazinamide
Pyrazinamid
Pyrazinamida
Pyrazinamide
Pyrazinamidum
Pyrazine carboxamide
pyrazine-2-carboxamide
Pyrazineamide
Pyrazinecarboxamide
Pyrazinoic acid amide
Pyrizinamide",small molecule,Mycobacterium tuberculosis,"Tablet
Tablet
Tablet
Tablet, sugar coated","Oral
Oral
Oral
Oral","500 mg
500 mg/1",For the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.
C(N(C(C(C(C1(C2=C(C(=C(C(=C2[H])[H])[H])[H])C([H])=C([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB00344,438-60-8,Protriptyline,"3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine
3-(5H-Dibenzo[a,D]cyclohepten-5-yl)-N-methyl-1-propanamine
5-(3-Methylaminopropyl)-5H-dibenzo[a,D]cycloheptene
7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene
Amimetilina
N-Methyl-5H-dibenzo[a,D]cycloheptene-5-propanamine
N-Methyl-5H-dibenzo[a,D]cycloheptene-5-propylamine
Protriptilina
Protriptylin
Protriptyline
Protriptylinum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet","Oral
Oral
Oral
Oral
Oral","10 mg/1
5 mg/1
10 mg/1
5 mg/1
10 mg",For the treatment of depression. 
N(C1=C([H])C([H])=C(C(=O)N(C(C(O[H])=O)([H])[H])[H])C([H])=C1[H])([H])[H],DB00345,61-78-9,Aminohippuric acid,"4-aminohippuric acid
Aminohippurate
N-(p-Aminobenzoyl)aminoacetic acid
N-(p-Aminobenzoyl)glycine
N-(para-aminobenzoyl)glycine
p-aminohippurate
p-aminohippuric acid
PAH
PAHA
para-aminohippurate
para-aminohippuric acid 
paraaminohippuric acid",small molecule,Humans and other mammals,"Liquid
Injection, solution","Intravenous
Intravenous","20 %
2 g/10mL",Used to measure effective renal plasma flow (ERPF) and to determine the functional capacity of the tubular excretory mechanism.
C(N1C(=O)OC(C([H])([H])[H])(C([H])([H])[H])C1=O)([H])([H])[H],DB00347,127-48-0,Trimethadione,"Trimethadion
Trim��thadione
Trimethadionum
Trimethinum
Troxidone",small molecule,Humans and other mammals,"Tablet, chewable",Oral,150 mg/1,Used in the control of absence (petit mal) seizures that are refractory to treatment with other medications.
[O-][N+](=O)C1=C(C(=O)C2(C(=O)C([H])([H])C([H])([H])C([H])([H])C2=O)[H])C([H])=C([H])C(C(F)(F)F)=C1[H],DB00348,104206-65-7,Nitisinone,"2-(alpha,alpha,alpha-Trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione
Nitisinona
Nitisinonum",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Capsule
Capsule
Capsule
Capsule
Capsule
Suspension
Suspension","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg
2 mg
5 mg
10 mg
2 mg
5 mg
10 mg/1
2 mg/1
5 mg/1
10 mg/1
2 mg/1
20 mg
20 mg/1
5 mg/1
4 mg/mL
4 mg",Used as an adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1.
C(N1C2=C(C(=C(Cl)C(=C2[H])[H])[H])N(C2=C([H])C([H])=C([H])C([H])=C2[H])C(=O)C([H])([H])C1=O)([H])([H])[H],DB00349,22316-47-8,Clobazam,"1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine
7-Chloro-1-methyl-5-phenyl-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione
Clobazam
Clobazamum",small molecule,Humans and other mammals,"Tablet
Suspension
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral","10 mg
2.5 mg/mL
10 mg/1
20 mg/1
5 mg/1","For treatment and management of epilepsy and seizures associated with Lennox-Gastaut syndrome, a difficult-to-treat form of childhood epilepsy. "
N(C1=C([H])C(N2C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])=NC(N([H])[H])=[N+]1[O-])([H])[H],"DB00350
DB08225",38304-91-5,Minoxidil,"2,4-Diamino-6-piperidinopyrimidine 3-oxide
6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide
Alostil
Apo-gain
Lonolox
Minossidile
Minoxidil
Minoxidilum
Minoximen
Normoxidil
Regaine
Tricoxidil",small molecule,Humans and other mammals,"Liquid
Solution
Liquid
Solution
Solution
Solution
Solution
Solution
Solution
Aerosol, foam
Tablet
Tablet
Liquid
Aerosol, foam
Tablet
Tablet
Solution
Liquid
Solution
Aerosol, foam","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Oral
Topical
Topical
Oral
Oral
Topical
Topical
Topical
Topical","20 mg/mL
20 mg/mL
2 %
3 g/60mL
2 g/100mL
20 mg
5 g/100mL
50 mg/mL
2 %
5 g/100g
10 mg
2.5 mg
50 mg/mL
50 mg/g
10 mg/1
2.5 mg/1
20 g/mL
2 g/100mL
.02 g/mL
5 %",For the treatment of severe hypertension and in the topical treatment (regrowth) of androgenic alopecia in males and females and stabilisation of hair loss in patients with androgenic alopecia.
N(C1=NC(=S)C2=C(N=C(N2[H])[H])N1[H])([H])[H],DB00352,154-42-7,Tioguanine,"2-Amino 6mp
2-Amino-1,7-dihydro-6H-purine-6-thione
2-amino-1,9-Dihydropurine-6-thione
2-amino-1H-purine-6(7H)-thione
2-Amino-6-mercaptopurine
2-Amino-6-merkaptopurin
2-Amino-6-purinethiol
2-Aminopurin-6-thiol
2-aminopurine-6-thiol
2-Aminopurine-6(1H)-thione
6-Mercapto-2-aminopurine
6-Mercaptoguanine
6-TG
6-Thioguanine
TG
ThG
Thioguanine
Tioguanin
Tioguanina
Tioguanine
Tioguaninum",small molecule,Humans and other mammals,"Tablet
Tablet","Oral
Oral","40 mg
40 mg/1",For remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.
ClC1=C([H])C2=C(OC(=O)N2[H])C([H])=C1[H],DB00356,95-25-0,Chlorzoxazone,"2-hydroxy-5-chlorobenzoxazole
5-chloro-2-Benzoxazolinone
5-chloro-2-Benzoxazolol
5-chloro-2-Benzoxazolone
5-chloro-2-Hydroxybenzoxazole
5-chloro-2(3H)-benzoxazolone
5-chloro-3H-benzooxazol-2-one
5-Chlorobenzoxazolidone
5-chlorobenzoxazolin-2-one
Chlorzoxane
Chlorzoxazon
Chlorzoxazona
Chlorzoxazone
Chlorzoxazonum
Clorzoxazona
Clorzoxazone",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet","Oral
Occlusive dressing technique
Oral
Oral
Oral
Oral","500 mg/1
250 mg/1
375 mg/1
500 mg/1
750 mg/1",For the relief of discomfort associated with acute painful musculoskeletal conditions.
O(C(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])N1[H])[H])(C1=C([H])C(C(F)(F)F)=NC2=C(C(=C(C([H])=C12)[H])[H])C(F)(F)F)[H])[H],DB00358,53230-10-7,Mefloquine,"[(R*,S*)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol
alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol
Mefloquin
Mefloquina
M��floquine
Mefloquine
Mefloquinum",small molecule,Plasmodium,"Tablet
Tablet","Oral
Oral","250 mg
250 mg/1","For the treatment of mild to moderate acute malaria caused by Mefloquineuine-susceptible strains of <i>Plasmodium falciparum</i> (both chloroquine-susceptible and resistant strains) or by <i>Plasmodium vivax</i>. Also for the prophylaxis of <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> malaria infections, including prophylaxis of chloroquine-resistant strains of <i>Plasmodium falciparum</i>."
N(C1=C([H])C([H])=C(S(=O)(=O)N(C2=NC([H])=C([H])C([H])=N2)[H])C([H])=C1[H])([H])[H],DB00359,68-35-9,Sulfadiazine,"2-sulfanilamidopyrimidine
2-sulfanilylaminopyrimidine
4-amino-N-2-pyrimidinylbenzenesulfonamide
N(1)-2-Pyrimidinylsulfanilamide
N(1)-2-Pyrimidylsulfanilamide
N1-2-pyrimidinylsulfanilamide
N1-2-pyrimidylsulfanilamide
Sulfadiazina
Sulfadiazine
Sulfadiazinum
Sulfapyrimidine
Sulphadiazine",small molecule,Enteric bacteria and other eubacteria,"Suspension
Tablet
Suppository
Cream
Tablet
Tablet","Oral
Oral
Vaginal
Vaginal
Oral
Oral","500 mg/1
500.5 mg",For the treatment of rheumatic fever and meningococcal meningitis
C(N1C([H])([H])C([H])([H])N(C2=NC3=C(C(=C(C(Cl)=C3[H])[H])[H])N([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB00363,5786-21-0,Clozapine,"Clozapin
Clozapina
Clozapine
Clozapinum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet
Tablet
Suspension
Tablet
Tablet
Tablet
Tablet
Suspension","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","200 mg/1
50 mg/1
100 mg/1
12.5 mg/1
150 mg/1
200 mg/1
25 mg/1
100 mg/1
25 mg/1
50 mg
100 mg
200 mg
25 mg
50 mg
50 mg/mL",For use in patients with treatment-resistant schizophrenia.
C(C(C(C(C([H])([H])[H])(C(OC(N([H])[H])=O)([H])[H])C(OC(N([H])[H])=O)([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00371,57-53-4,Meprobamate,"Meprobamat
Meprobamato
Meprobamatum
Meprobamic acid",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral","400 mg
200 mg/1
400 mg/1
200 mg",For the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.
C(C(SC1=C([H])C2=C(SC3=C(N2C(C(C(N2C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C([H])C([H])=C3[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB00372,1420-55-9,Thiethylperazine,"2-(ethylthio)-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine
Norzine
Thiethylperazin
Thi��thylp��razine
Thiethylperazine
Thiethylperazinum
Tietilperazina",small molecule,Humans and other mammals,,,,For the treatment or relief of nausea and vomiting.
N(C1=C2C(C(C(C([H])([H])C2=NC2=C(C(=C(C([H])=C12)[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB00382,321-64-2,Tacrine,"1,2,3,4-tetrahydro-9-acridinamine
1,2,3,4-tetrahydro-9-aminoacridine
1,2,3,4-tetrahydroacridin-9-amine
5-amino-6,7,8,9-tetrahydroacridine
9-amino-1,2,3,4-tetrahydroacridine
Tacrin
Tacrine
Tacrinum
Tetrahydroaminacrine
Tetrahydroaminoacridine
THA",small molecule,Humans and other mammals,,,,For the palliative treatment of mild to moderate dementia of the Alzheimer's type.
N(C1=NC2=NC(N([H])[H])=C(N=C2C(N([H])[H])=N1)C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H],DB00384,396-01-0,Triamterene,"6-phenylpteridine-2,4,7-triamine
Teridin
Triamteren
Triamt��r��ne
Triamterene
Triamtereno
Triamterenum",small molecule,Humans and other mammals,"Capsule
Capsule
Tablet
Tablet
Capsule
Tablet","Oral
Oral
Oral
Oral
Oral
Oral","100 mg/1
50 mg/1
100 mg
50 mg","For the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism."
C(C(OC(=O)N1C([H])=C([H])N(C([H])([H])[H])C1=S)([H])[H])([H])([H])[H],DB00389,22232-54-8,Carbimazole,"1H-Imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo-, ethyl ester  Ethyl 3-methyl-2-thioimidazoline-1-carboxylate
Athyromazole
Carbethoxymethimazole
Carbimazol
Carbimazolo
Carbimazolum
Carbinazole
Ethyl 3-methyl-2-thioimidazoline-1-carboxylate",small molecule,Humans and other mammals,,,,For the treatment of hyperthyroidism and thyrotoxicosis. It is also used to prepare patients for thyroidectomy.
C(N(C(=O)C1=NC([H])=C([H])C(OC2=C([H])C([H])=C(N(C(=O)N(C3=C([H])C(C(F)(F)F)=C(Cl)C([H])=C3[H])[H])[H])C([H])=C2[H])=C1[H])[H])([H])([H])[H],"DB00398
DB07438",284461-73-0,Sorafenib,"4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
Sorafenibum",small molecule,Humans and other mammals,"Tablet
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral","200 mg
200 mg/1
200 mg",Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.  
O(C(C(N1C([H])=C([H])N=C1[H])([H])[H])(P(O[H])(O[H])=O)P(O[H])(O[H])=O)[H],"DB00399
DB06286",118072-93-8,Zoledronic acid,"(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
Anhydrous Zoledronic Acid
Zol
Zoledronate
Zoledronic Acid Anhydrous
Zoledronic Acid, Anhydrous",small molecule,Humans and other mammals,"Solution
Injection
Injection
Injection
Injection, solution
Injection, solution
Injection, solution
Injection, solution, concentrate
Injection, solution, concentrate
Kit
Solution
Injection, solution
Injection, solution
Injection, solution, concentrate
Solution
Powder, for solution","Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous","5 mg
4 mg/100mL
4 mg/5mL
5 mg/100mL
.04 mg/mL
.05 mg/mL
5 mg/100mL
.8 mg/mL
4 mg/5mL
5 mg/100mL
4 mg/100ml
5 mg
4 mg/100mL
4 mg
4 mg","For the treatment of hypercalcemia of malignancy. Also for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. In May of 2007, the drug was approved for treatment of Paget���s Disease."
C(C1=NN=C2C(N=C(C3=C([H])C([H])=C([H])C([H])=C3[H])C3=C(N12)C([H])=C([H])C(Cl)=C3[H])([H])[H])([H])([H])[H],"DB00404
DB05925",28981-97-7,Alprazolam,"8-Chloro-1-methyl-6-phenyl-4H-S-triazolo(4,3-a)(1,4)benzodiazepine
Alprazolam",small molecule,Humans and other mammals,"Solution, concentrate
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Kit
Tablet
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","1 mg/mL
.25 mg/1
.5 mg/1
0.50 mg
1 mg/1
2 mg/1
.5 mg/1
1 mg/1
2 mg/1
3 mg/1
2 mg
.25 mg/1
.5 mg/1
1 mg/1
2 mg/1
.25 mg
.5 mg
0.25 mg
0.5 mg
1 mg","For the management of anxiety disorder or the short-term relief of symptoms of anxiety and for the treatment of panic disorder, with or without agoraphobia."
C(N(C([H])([H])[H])C1=C([H])C([H])=C(C(C2=C([H])C([H])=C(N(C([H])([H])[H])C([H])([H])[H])C([H])=C2[H])=C2C([H])=C([H])C(=[N+](C([H])([H])[H])C([H])([H])[H])C([H])=C2[H])C([H])=C1[H])([H])([H])[H],DB00406,7438-46-2,Gentian Violet,"Crystal Violet
Crystal violet carbocation
Crystal violet ion(1)
Crystal violet(1+)
Gentian violet carbocation
Gentian violet cation
Gentian violet(1+)
Methylrosaniline
Methylrosanilinium",small molecule,"Yeast and other fungi
Bacteria and protozoa","Tincture
Solution
Liquid
Liquid
Liquid
Liquid
Swab
Solution
Liquid","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","1 g/100mL
2 g/100mL
1 g/100mL
1 %
10 mg/mL
20 mg/mL","For the treatment of bacterial and fungal infections inside the mouth (thrush) and skin, also for the prevention of transmission of Chagas' disease (as a blood additive)."
C(N1C([H])([H])C([H])([H])N(C2=NC3=C(C(=C(C(=C3[H])[H])[H])[H])OC3=C2C(=C(Cl)C(=C3[H])[H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB00408,1977-10-2,Loxapine,"2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine
Cloxazepine
Loxapina
Loxapine
Loxapinum
oxilapine",small molecule,Humans and other mammals,"Aerosol, powder
Powder, metered
Powder, metered
Liquid
Liquid
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Capsule
Capsule
Capsule
Capsule
Solution
Tablet
Tablet
Tablet
Tablet
Tablet","Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Intramuscular
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg/1
4.5 mg
9.1 mg
50 mg
25 mg
13.6 mg
34 mg
68 mg
6.8 mg
10 mg/1
25 mg/1
5 mg/1
50 mg/1
10 mg/1
25 mg/1
5 mg/1
50 mg/1
25 mg
10 mg
2.5 mg
25 mg
5 mg
50 mg",For the management of the manifestations of psychotic disorders such as schizophrenia
C([N+](C([H])([H])[H])(C([H])([H])[H])C(C(OC(N([H])[H])=O)([H])[H])([H])[H])([H])([H])[H],"DB00411
DB02487",51-83-2,Carbachol,"(2-Carbamoyloxyethyl)trimethylammonium chloride
(2-Hydroxyethyl)trimethyl ammonium chloride carbamate
(2-Hydroxyethyl)trimethylammonium chloride carbamate
2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminium chloride
2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminum chloride
Carbachol
Carbachol chloride
Carbacholum
Carbacol
Choline carbamate chloride
Choline chloride, carbamate
Choline chlorine carbamate
Karbachol
Karbamoylcholin chlorid",small molecule,Humans and other mammals,"Liquid
Liquid
Tablet
Solution
Liquid
Liquid
Solution
Solution","Subcutaneous
Intraocular
Oral
Intraocular
Ophthalmic
Ophthalmic
Ophthalmic
Intraocular",".25 mg
0.1 mg
2 mg
0.01 %
1.5 %
3 %
.1 mg/mL
.01 %","Primarily used in the treatment of glaucoma, but is also used during ophthalmic surgery."
C(C(=O)C1=C([H])C([H])=C(S(=O)(=O)N(C(=O)N(C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB00414,968-81-0,Acetohexamide,"1-((p-Acetylphenyl)sulfonyl)-3-cyclohexylurea
1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-N-(cyclohexylcarbamoyl)benzenesulfonamide
Acetohexamid
Acetohexamida
Ac��tohexamide
Acetohexamide
Acetohexamidum
N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea",small molecule,Humans and other mammals,Tablet,Oral,500 mg,Used in the management of diabetes mellitus type 2 (adult-onset).
C(N(C([H])([H])[H])C(C(C(N1C2=C(C(=C(C(=C2[H])[H])[H])[H])SC2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00420,58-40-2,Promazine,"10-(3-(Dimethylamino)propyl)phenothiazine
Frenil
N-(3-Dimethylaminopropyl)phenothiazine
N-Dimethylamino-1-methylethyl thiodiphenylamine
N,N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine
Promazin
Promazina 
Promazine
Promazinum",small molecule,Humans and other mammals,Liquid,Intramuscular; Intravenous,50 mg,Used as an adjunct for short term treatment of moderate and severe psychomotor agitation. Also used to treat agitation or restlessness in the elderly.
C(OC(=O)C(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])N1[H])[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])([H])[H],DB00422,113-45-1,Methylphenidate,"Methyl phenidylacetate
methyl phenyl(piperidin-2-yl)acetate
methyl ��-phenyl-��-(2-piperidyl)acetate
methyl ��-phenyl-��-2-piperidinylacetate
Methylphenidan
Methylphenidatum
Metilfenidato
MPH
��-phenyl-2-piperidineacetic acid methyl ester",small molecule,Humans and other mammals,"Capsule, extended release
Capsule, extended release
Capsule, extended release
Capsule, extended release
Capsule, extended release
Capsule, extended release
Capsule, extended release
Capsule, extended release
Capsule, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Patch
Patch
Patch
Patch
Capsule, extended release
Tablet, extended release
Solution
Solution
Solution
Solution
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, chewable
Tablet, chewable
Tablet, chewable
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, extended release
Capsule
Capsule
Capsule
Capsule
Capsule
Capsule
Tablet, film coated, extended release
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, chewable, extended release
Tablet, chewable, extended release
Tablet, chewable, extended release
Suspension, extended release
Suspension, extended release
Suspension, extended release
Suspension, extended release
Capsule, extended release
Capsule, extended release
Capsule, extended release
Capsule, extended release
Capsule, extended release
Tablet, extended release","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Transdermal
Transdermal
Transdermal
Transdermal
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","15 mg/1
10 mg
15 mg
20 mg
30 mg
40 mg
50 mg
60 mg
80 mg
18 mg
27 mg
36 mg
54 mg
17.3 mg/1
25.9 mg/1
8.6 mg/1
10 mg/9h
15 mg/9h
20 mg/9h
30 mg/9h
100 mg
25 mg
35 mg
45 mg
55 mg
70 mg
85 mg
50 mg/1
20 mg/1
1 mg/mL
10 mg/5mL
2 mg/mL
5 mg/5mL
10 mg/1
18 mg/1
20 mg/1
27 mg/1
36 mg/1
5 mg/1
54 mg/1
10 mg/1
2.5 mg/1
5 mg/1
18 mg/1
27 mg/1
36 mg/1
54 mg/1
72 mg/1
18 mg/1
27 mg/1
36 mg/1
54 mg/1
10 mg/1
10 mg/1
20 mg/1
30 mg/1
40 mg/1
50 mg/1
60 mg/1
20 mg/1
10.00 mg
20.00 mg
5.00 mg
10 mg
20 mg
5 mg
20 mg/1
30 mg/1
40 mg/1
300 mg/60mL
600 mg/120mL
750 mg/150mL
900 mg/180mL
10 mg/1
20 mg/1
30 mg/1
40 mg/1
60 mg/1
20 mg","For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity."
C(N(C([H])([H])[H])C(=O)C(C1=C(C2=C([H])C([H])=C(C([H])([H])[H])C([H])=C2[H])N=C2C(=C(C(C([H])([H])[H])=C([H])N12)[H])[H])([H])[H])([H])([H])[H],DB00425,82626-48-0,Zolpidem,"N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide
Zolpidem
Zolpidemum",small molecule,Humans and other mammals,"Tablet
Tablet, coated
Tablet, coated
Tablet, orally disintegrating
Tablet, orally disintegrating
Kit
Tablet
Tablet
Tablet
Tablet
Kit
Tablet
Tablet
Tablet
Tablet
Tablet, coated
Tablet, coated
Tablet, extended release
Tablet, extended release
Tablet, film coated
Tablet, film coated
Tablet, film coated, extended release
Tablet, film coated, extended release
Spray, metered","Oral
Oral
Oral
Sublingual
Sublingual
Sublingual
Sublingual
Oral
Oral
Oral
Oral
Oral
Sublingual
Sublingual
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","6.25 mg/1
12.5 mg/1
6.25 mg/1
10 mg
5 mg
1.75 mg/1
3.5 mg/1
10 mg
5 mg
10 mg/1
5 mg/1
10 mg/1
5 mg/1
10 mg/1
5 mg/1
12.5 mg/1
6.25 mg/1
10 mg/1
5 mg/1
12.5 mg/1
6.25 mg/1
5 mg/1",For the short-term treatment of insomnia.
C(C(=O)OC(C(C(C(N1C([H])=NC2=C(N=C(N([H])[H])N=C12)[H])([H])[H])([H])[H])(C(OC(C([H])([H])[H])=O)([H])[H])[H])([H])[H])([H])([H])[H],DB00426,104227-87-4,Famciclovir,"2-(2-(2-amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate
9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine
acetic acid 2-acetoxymethyl-4-(2-amino-purin-9-yl)-butyl ester
Famciclovir
Famciclovirum
FCV",small molecule,Human Herpes Virus,"Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","125 mg/1
250 mg/1
500 mg/1
125 mg/1
250 mg/1
500 mg/1
125 mg
250 mg
500 mg",For the treatment of acute herpes zoster (shingles). Also for the treatment or suppression of recurrent genital herpes in immunocompetent patients and treatment of recurrent mucocutaneous herpes simplex infections in HIV infected patients.
C(C1=C([H])C([H])=C(C(=C(C(N2C([H])([H])C([H])([H])C([H])([H])C2([H])[H])([H])[H])[H])C2=NC([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])([H])[H],DB00427,486-12-4,Triprolidine,"Tripolidina
Triprolidin
Triprolidine
Triprolidinum",small molecule,Humans and other mammals,"Tablet
Tablet, film coated
Tablet, coated
Syrup
Tablet, chewable
Syrup
Syrup
Syrup
Liquid
Liquid
Liquid","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","2.5 mg/5mL
1.25 mg/1
.938 mg/mL
1.25 mg/mL
.625 mg/mL
.313 mg/mL","For the symptomatic relief of seasonal or perennial allergic rhinitis or nonallergic rhinitis; allergic conjunctivitis; and mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Also used in combination with other agents for the symptomatic relief of symptoms associated with the common cold."
C(N1C([H])([H])C([H])([H])N(C(C(C(N2C3=C(C(=C(C(=C3[H])[H])[H])[H])SC3=C2C(=C(Cl)C(=C3[H])[H])[H])([H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB00433,58-38-8,Prochlorperazine,"2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine
2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine
3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine
3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine
Capazine
Chlormeprazine
Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine
Chloropernazine
Emetiral
N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine
Prochlorperazin
Prochlorp��razine
Prochlorperazinum
Prochlorpermazine
Prochlorpromazine
Procloperazine
Proclorperazina",small molecule,Humans and other mammals,"Suppository
Tablet
Tablet
Suppository
Injection
Injection
Injection
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Liquid
Solution
Syrup","Rectal
Oral
Oral
Rectal
Intramuscular
Intramuscular; Intravenous
Intramuscular; Intravenous
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Intramuscular; Intravenous
Oral","10 mg
10 mg
5 mg
25 mg/1
5 mg/mL
10 mg/2mL
5 mg/mL
10 mg/1
5 mg/61
5 mg/1
10 mg/1
5 mg/1
5 mg
5 mg
5 mg","For the symptomatic management of psychotic disorders, short term management of nonpsychotic anxiety in patients with generalized anxiety disorder, and for the control of severe nausea and vomiting of various causes."
C(N1C([H])([H])C([H])([H])C(=C2C3=C(C(=C(C(=C3[H])[H])[H])[H])C([H])=C([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB00434,129-03-3,Cyproheptadine,"1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine
4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine
4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine
5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
Axoprol
Ciproheptadina
Cyproheptadin
Cyproheptadine
Cyproheptadinum
Dihexazin
Glutodina",small molecule,Humans and other mammals,"Solution
Syrup
Tablet
Syrup
Syrup
Tablet","Oral
Oral
Oral
Oral
Oral
Oral","2 mg/5mL
2 mg/5mL
4 mg/1
0.4 mg
2 mg
4 mg","For treatment of perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, cold urticaria, dermatographism, and as therapy for anaphylactic reactions adjunctive to epinephrine."
[N]=O |^1:0|,DB00435,10102-43-9,Nitric Oxide,"(.)NO
(NO)(.)
[NO]
EDRF
endothelium-derived relaxing factor
Mononitrogen monoxide
Monoxido de nitrogeno
Monoxyde d'azote
Nitric oxide
nitrogen monooxide
Nitrogen monoxide
Nitrosyl
NO
NO(.)
Oxido de nitrogeno(ii)
Oxido nitrico
Oxyde azotique
Oxyde nitrique
Stickstoff(ii)-oxid
Stickstoffmonoxid",small molecule,Humans and other mammals,"Gas
Gas
Gas
Gas
Inhalant
Inhalant
Gas","Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)",".123 mg/L
.98 mg/L
100 ppm
800 ppm
400 ppm
800 ppm",For the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure
O=C1N=C([H])N=C2N(N(C([H])=C12)[H])[H],"DB00437
DB03027",315-30-0,Allopurinol,"1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one
1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
1H-Pyrazolo(3,4-d)pyrimidin-4-ol
4-HPP
4-Hydroxy-1H-pyrazolo(3,4-d)pyrimidine
4-Hydroxy-3,4-pyrazolopyrimidine
4-Hydroxypyrazolo(3,4-d)pyrimidine
4-Hydroxypyrazolopyrimidine
4-Hydroxypyrazolyl(3,4-d)pyrimidine
4'-Hydroxypyrazolol(3,4-d)pyrimidine
4H-Pyrazolo(3,4-d)pyrimidin-4-one
Allopurinolum
Alopurinol",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, coated
Tablet, coated
Tablet
Injection, powder, lyophilized, for solution
Tablet, film coated
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Intravenous
Oral
Oral
Oral","100 mg/1
300 mg/1
100 mg/1
300 mg/1
200 mg
500 mg/25mL
100 mg
300 mg","For the treatment of hyperuricemia associated with primary or secondary gout. Also indicated for the treatment of primary or secondary uric acid nephropathy, with or without the symptoms of gout, as well as chemotherapy-induced hyperuricemia and recurrent renal calculi."
C(OC1=C([H])C(C(C2=C(N([H])[H])N=C(N([H])[H])N=C2[H])([H])[H])=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])([H])([H])[H],DB00440,738-70-5,Trimethoprim,"2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
5-[(3,4,5-Trimethoxyphenyl)methyl]-2,4-pyrimidinediamine
Trimethoprim
Trim��thoprime
Trimethoprimum
Trimetoprima",small molecule,"Gram negative and gram positive bacteria
Listeria monocytogenes
Escherichia coli","Liquid
Liquid
Solution / drops
Solution
Solution
Injection
Injection, solution, concentrate
Suspension
Tablet
Tablet
Solution
Tablet
Tablet","Intravenous
Ophthalmic
Ophthalmic
Oral
Intravenous
Intravenous
Intravenous
Oral
Oral
Oral
Ophthalmic
Oral
Oral","50 mg/5mL
100 mg/1
100 mg
200 mg","For the treatment of urinary tract infections, uncomplicated pyelonephritis (with sulfamethoxazole) and mild acute prostatitis. May be used as pericoital (with sulfamethoxazole) or continuous prophylaxis in females with recurrent cystitis. May be used as an alternative to treat asymptomatic bacteriuria during pregnancy (only before the last 6 weeks of pregnancy). Other uses include: alternative agent in respiratory tract infections (otitis, sinusitus, bronchitis and pneumonia), treatment of Pneumocystis jirovecii pneumonia (acute or prophylaxis), Nocardia infections, and traveller's diarrhea."
FC1=C([H])C([H])=C(C(=O)C(C(C(N2C([H])([H])C([H])([H])C(N3C(=O)N([H])C4=C3C(=C(C(=C4[H])[H])[H])[H])=C([H])C2([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H],DB00450,548-73-2,Droperidol,"1-(1-(3-(P-Fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone
1-(1-(4-(P-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone
1-{1-[4-(4-fluoro-phenyl)-4-oxo-butyl]-1,2,3,6-tetrahydro-pyridin-4-yl}-1,3-dihydro-benzoimidazol-2-one
1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl}-2,3-dihydro-1H-benzo[D]imidazol-2-one
Droperidol
Drop��ridol
Droperidolo
Droperidolum",small molecule,Humans and other mammals,"Injection, solution
Solution
Injection
Liquid
Liquid","Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous","2.5 mg/mL
2.5 mg
2.5 mg/mL
2.5 mg",Droperidol is ssed to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.
C(C(OC(=O)C1(C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C1([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB00454,57-42-1,Pethidine,"Isonipeca��ne
Meperidine
Pethidin
P��thidine
Pethidine dbl
Pethidinum
Petidina
Petydyna
Sauteralgyl
Spasmedal
Spasmodolin",small molecule,Humans and other mammals,"Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Tablet
Liquid
Liquid
Liquid
Liquid
Solution
Solution
Liquid
Injection, solution
Solution
Solution
Solution
Solution
Solution
Injection
Injection
Injection
Injection
Solution
Tablet
Tablet
Tablet
Tablet
Capsule
Solution","Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Oral
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Subcutaneous
Intramuscular; Subcutaneous
Intramuscular; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intravenous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intramuscular
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Oral
Oral
Oral
Oral
Oral
Oral
Intravenous","100 mg/2mL
100 mg/mL
25 mg/.5mL
25 mg/mL
50 mg/mL
75 mg/1.5mL
75 mg/mL
50 mg
50 mg
50 mg
100 mg
100 mg
100 mg
50 mg
75 mg
10 mg/mL
100 mg
10 mg
25 mg
50 mg
75 mg
50 mg/mL
100 mg/mL
25 mg/mL
50 mg/mL
50 mg/5mL
100 mg/1
150 mg/1
50 mg/1
75 mg/1
10 mg",Used to control moderate to severe pain.
C(C(OC(=O)N1C([H])([H])C([H])([H])C(=C2C3=C(C(=C(Cl)C(=C3[H])[H])[H])C([H])([H])C([H])([H])C3=C2N=C(C(=C3[H])[H])[H])C([H])([H])C1([H])[H])([H])[H])([H])([H])[H],DB00455,79794-75-5,Loratadine,"Loratadina
Loratadinum",small molecule,Humans and other mammals,"Tablet
Tablet
Liquid
Solution
Tablet, chewable
Tablet, multilayer, extended release
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Syrup
Tablet, extended release
Capsule, liquid filled
Tablet, orally disintegrating
Tablet, film coated, extended release
Capsule
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg
10 mg/1
5 mg/5mL
5 mg/5mL
5 mg/1
10 mg
5 mg
5 mg/1
1 mg
10 mg/1
10 mg/1
10 mg
10 mg/1","A self-medication that is used alone or in combination with pseudoephedrine sulfate for the symptomatic relief of seasonal allergic rhinitis. Also used for the symptomatic relief of pruritus, erythema, and urticaria associated with chronic idiopathic urticaria in patients (not for children under 6 unless directed by a clincian)."
C(OC1=C(OC([H])([H])[H])C([H])=C2C(N([H])[H])=NC(=NC2=C1[H])N1C([H])([H])C([H])([H])N(C(=O)C2=C([H])C([H])=C([H])O2)C([H])([H])C1([H])[H])([H])([H])[H],DB00457,19216-56-9,Prazosin,"1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine
2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline
Prazosina
Prazosine
Prazosinum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Capsule
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral
Oral","1 mg
2 mg
5 mg
1 mg/1
2 mg/1
5 mg/1","For treatment of hypertension, symptomatic benign prostatic hyperplasia, and severe congestive heart failure. May also be used alone or in combination with &beta;-blockers in the preoperative management of signs and symptoms of pheochromocytoma. "
C(N(C([H])([H])[H])C(C(C(N1C2=C(C(=C(C(=C2[H])[H])[H])[H])C([H])([H])C([H])([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],"DB00458
DB08002",50-49-7,Imipramine,"10,11-dihydro-N,N-Dimethyl-5H-dibenz[b,F]azepine-5-propanamine
3-(5H-DIBENZO[b,F]azepin-5-yl)-N,N-dimethylpropan-1-amine
5-[3-(dimethylamino)Propyl]-10,11-dihydro-5H-dibenz[b,F]azepine
Antideprin
Imipramin
Imipramine
Imipraminum
Imizine
Irmin
Melipramine
N-(gamma-Dimethylaminopropyl)iminodibenzyl
N-(��-dimethylaminopropyl)iminodibenzyl",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, sugar coated
Tablet, sugar coated
Tablet, sugar coated
Capsule
Capsule
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg
25 mg
50 mg
75 mg
10 mg/1
25 mg/1
50 mg/1
10 mg/1
25 mg/1
50 mg/1
10 mg/1
25 mg/1
50 mg/1
100 mg/1
125 mg/1
150 mg/1
75 mg/1","For the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older [FDA Label]. 
May also be used off-label to manage panic disorders with or without agoraphobia, as a second line agent for ADHD in children and adolescents, to manage bulimia nervosa, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, for the treatment of acute stress disorder and posttraumatic stress disorder, and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy [L1349,L1348,A31900,L1351,L1352,L1353,A31904]. "
C(OC1=C(C([H])([H])[H])C(C([H])([H])[H])=C(C(=C(C(C([H])([H])[H])=C(C(=C(C(C([H])([H])[H])=C(C(O[H])=O)[H])[H])[H])[H])[H])[H])C(C([H])([H])[H])=C1[H])([H])([H])[H],DB00459,55079-83-9,Acitretin,"(all-e)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid
Acetretin
Acitretin
Acitretina
Acitretine
Acitretinum
all-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid
Etretin
Neotigason",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral
Oral","10 mg/1
17.5 mg/1
22.5 mg/1
25 mg/1
10 mg
25 mg",For the treatment of severe psoriasis in adults.
C(OC1=C([H])C([H])=C2C(=C(C(C(C(C([H])([H])[H])=O)([H])[H])([H])[H])C(=C([H])C2=C1[H])[H])[H])([H])([H])[H],DB00461,42924-53-8,Nabumetone,"4-(6-Methoxy-2-naphthalenyl)-2-butanone
4-(6-Methoxy-2-naphthyl)-2-butanone
Nabumeton
Nabumetona
Nabum��tone
Nabumetone
Nabumetonum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral","500 mg/1
750 mg/1
500 mg/1
750 mg/1
500 mg
750 mg",For acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.
C(C(C1(C(C([H])([H])[H])([H])[H])C(=O)N([H])C(=O)N(C([H])([H])[H])C1=O)([H])[H])([H])([H])[H],DB00463,50-11-3,Metharbital,"Metarbital
Metharbital
Metharbitalum",small molecule,Humans and other mammals,,,,Metharbital is used for the treatment of epilepsy.
C(C(C(C(C(C(C([H])([H])[H])([H])[H])(C(C(C(C(C(C([H])([H])[H])(C([H])([H])[H])[H])([H])[H])(OS([O-])(=O)=O)[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00464,139-88-8,Sodium Tetradecyl Sulfate,"7-Ethyl-2-methyl-4-undecanol sulfate sodium salt
7-ethyl-2-methyl-4-undecanolsulfate, sodium salt
Natrii tetradecylis sulfa
Sodium 2-methyl-7-ethylundecanol-4-sulfate
Sodium 7-ethyl-2-methyl-4-undecanol sulfate
Sodium tetradecyl sulphate
Sodium tetradecylsulfate
STS
Tetradecilsulfato sodico
Tetradecyl sodium sulfate
Tetradecyl sulfate de sodium",small molecule,Humans and other mammals,"Solution
Solution
Solution
Solution","Intravenous
Intravenous
Intravenous
Intravenous","10 mg
30 mg
1 %
3 %",For the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.
C(C(N1C([H])=C(C(O[H])=O)C(=O)C2=C(C(F)=C(N=C12)N1C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H])[H])([H])[H])([H])([H])[H],DB00467,74011-58-8,Enoxacin,"1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid
1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid
Enoxacin
Enoxacina
��noxacine
Enoxacino
Enoxacinum",small molecule,Enteric bacteria and other eubacteria,,,,"For the treatment of adults (&ge;18 years of age) with the following infections caused by susceptible strains of the designated microorganisms: (1) uncomplicated urethral or cervical gonorrhea due to <i>Neisseria gonorrhoeae</i>, (2) uncomplicated urinary tract infections (cystitis) due to <i>Escherichia coli</i>, <i>Staphylococcus epidermidis</i>, or <i>Staphylococcus saprophyticus</i>, and (3) complicated urinary tract infections due to <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Proteus mirabilis</i>, <i>Pseudomonas aeruginosa</i>, <i>Staphylococcus epidermidis</i>, or <i>Enterobacter cloacae</i>."
C(N1C(C(=O)N(C2=NC([H])=C([H])C([H])=C2[H])[H])=C(O[H])C2=C(C(=C(S2)[H])[H])S1(=O)=O)([H])([H])[H],DB00469,59804-37-4,Tenoxicam,"Tenoxicam
T��noxicam
Tenoxicamum",small molecule,Humans and other mammals,Tablet,Oral,20 mg,"For the treatment of rheumatoid arthritis, osteoarthritis, backache, and pain."
C(C(C#CC(C([H])([H])[H])(C1(C(C(=C([H])[H])[H])([H])[H])C(=O)N([H])C(=O)N(C([H])([H])[H])C1=O)[H])([H])[H])([H])([H])[H],DB00474,151-83-7,Methohexital,"(+-)-5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid
5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione
5-Allyl-5-(3-hexyn-2-yl)-1-methylbarbituric acid
alpha-DL-1-Methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric acid
Methohexital
Methohexitalum
Methohexitone
Metohexital",small molecule,Humans and other mammals,"Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Powder, for solution","Intramuscular; Intravenous; Rectal
Intramuscular; Intravenous; Rectal
Intravenous","2.5 g/1
500 mg/1
500 mg",Methohexital is indicated for use as an intravenous anaesthetic. It has also been commonly used to induce deep sedation.
C(N(C1=NC2=C(C(=C(Cl)C(=C2[H])[H])[H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])=[N+]([O-])C1([H])[H])[H])([H])([H])[H],DB00475,58-25-3,Chlordiazepoxide,"7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxide
CDP
Chloradiazepoxide
Chlordiazepoxidum
Clopoxide
Methaminodiazepoxide",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Tablet
Tablet, film coated
Capsule
Capsule
Capsule
Capsule, gelatin coated
Capsule, gelatin coated
Capsule, gelatin coated
Capsule","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg
25 mg
5 mg
10 mg/1
25 mg/1
5 mg/1
10 mg/1
25 mg/1
5 mg/1","For the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety."
C(N(C([H])([H])[H])C(C(C(N1C2=C(C(=C(C(=C2[H])[H])[H])[H])SC2=C1C(=C(Cl)C(=C2[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00477,50-53-3,Chlorpromazine,"3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine
3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
Chlorpromazinum
Clorpromazina
CPZ
N-(3-dimethylaminopropyl)-3-chlorophenothiazine",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Solution / drops
Syrup
Tablet, film coated
Tablet, film coated
Liquid
Solution
Injection
Tablet
Tablet
Tablet, film coated
Tablet, sugar coated
Tablet, sugar coated
Tablet, sugar coated
Tablet, sugar coated
Tablet, sugar coated
Liquid
Tablet
Tablet
Liquid
Liquid
Solution
Solution / drops
Suppository
Tablet
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Oral
Rectal
Oral
Oral
Oral
Oral
Oral","111.4 mg
55.7 mg
111.6 mg
27.9 mg
55.8 mg
22.2 mg
44.5 mg
100 mg/1
50 mg/1
25 mg
25 mg
25 mg/mL
200 mg/1
50 mg/1
25 mg/1
10 mg/1
100 mg/1
200 mg/1
25 mg/1
50 mg/1
27.9 mg
25 mg
50 mg
100 mg
25 mg
50 mg
40 mg
100 mg
223.2 mg
11.16 mg
100 mg
25.0 mg
50.0 mg","For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance."
O(C1=C([H])C([H])=C(C2=C(C(=O)C3=C([H])C([H])=C(OC(C(N4C([H])([H])C([H])([H])C([H])([H])C([H])([H])C4([H])[H])([H])[H])([H])[H])C([H])=C3[H])C3=C(C(=C(O[H])C(=C3[H])[H])[H])S2)C([H])=C1[H])[H],DB00481,84449-90-1,Raloxifene,"(2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone
Raloxif��ne
Raloxifeno
Raloxifenum",small molecule,Humans and other mammals,"Tablet
Tablet, film coated
Tablet
Tablet, film coated","Oral
Oral
Oral
Oral","60 mg
60 mg
60 mg/1
60 mg/1","For the prevention and treatment of osteoporosis in post-menopausal women, as well as prevention and treatment of corticosteroid-induced bone loss. Also for the reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis or have a high risk for developing breast cancer."
C(C1=C([H])C([H])=C(C2=C([H])C(C(F)(F)F)=NN2C2=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C2[H])C([H])=C1[H])([H])([H])[H],DB00482,169590-42-5,Celecoxib,"Celecoxib
C��l��coxib
Celecoxibum
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide",small molecule,Humans and other mammals,"Kit
Capsule
Capsule
Capsule
Capsule
Capsule
Capsule
Kit
Capsule","Oral; Topical
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg
200 mg
200 mg/1
100 mg/1
400 mg/1
50 mg/1
400 mg","For relief and management of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis, acute pain, primary dysmenorrhea and oral adjunct to usual care for patients with familial adenomatous polyposis"
C(C([N+](C(C([H])([H])[H])([H])[H])(C(C([H])([H])[H])([H])[H])C(C(OC1=C([H])C([H])=C([H])C(OC(C([N+](C(C([H])([H])[H])([H])[H])(C(C([H])([H])[H])([H])[H])C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])=C1OC(C([N+](C(C([H])([H])[H])([H])[H])(C(C([H])([H])[H])([H])[H])C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00483,65-29-2,Gallamine Triethiodide,"Gallamin triethiodid
Gallamini Triethiodidum
Tri��thiodure de Gallamine
Trietioduro de galamina",small molecule,Humans and other mammals,Liquid,Intravenous,20 mg,For use as adjuncts to anesthesia to induce skeletal muscle relaxation and to facilitate the management of patients undergoing mechanical ventilation
BrC1=C(N(C2=NC([H])([H])C([H])([H])N2[H])[H])C([H])=C([H])C2=NC(=C(N=C12)[H])[H],DB00484,59803-98-4,Brimonidine,"5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline
Brimonidina
Brimonidine
Brimonidinum
Bromoxidine",small molecule,Humans and other mammals,"Liquid
Solution
Solution / drops
Solution / drops
Solution
Solution
Solution / drops
Solution / drops
Solution
Solution / drops
Solution / drops
Gel
Gel
Gel
Solution
Suspension
Suspension / drops","Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Cutaneous
Topical
Topical
Ophthalmic
Ophthalmic
Ophthalmic","0.2 %
0.15 %
1 mg/mL
1.5 mg/mL
1.5 mg/mL
2 mg/mL
2 mg/mg
2 mg/mL
.25 mg/mL
3 mg/g
5 mg/g
0.33 %
0.2 %",The ophthalmic solution is indicated for patients with open-angle glaucoma or ocular hypertension to lower intraocular pressure. The topical gel is indicated for the treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years or older. 
C(C(N1C([H])=C(C(O[H])=O)C(=O)C2=C(C(F)=C(C([H])=C12)N1C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C1([H])[H])[H])([H])[H])([H])([H])[H],DB00487,70458-92-3,Pefloxacin,"Labocton
Pefloxacin
Pefloxacine
Pefloxacino
Pefloxacinum
PFLX",small molecule,Enteric bacteria and other eubacteria,,,,For the treatment of uncomplicated gonococcal urethritis in males and for gram-negative-bacterial infections in the gastrointestinal system and the genitourinary tract.
C(N(C([H])([H])[H])C1=NC(N(C([H])([H])[H])C([H])([H])[H])=NC(N(C([H])([H])[H])C([H])([H])[H])=N1)([H])([H])[H],DB00488,645-05-6,Altretamine,"2,4,6-Tris(dimethylamino)-1,3,5-triazine
2,4,6-Tris(dimethylamino)-S-triazine
Altretamin
Altretamina
Altr��tamine
Altretaminum
Hexamethylmelamine
Hexastat
HMM",small molecule,Humans and other mammals,"Capsule
Capsule","Oral
Oral","50 mg/1
50 mg",For use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.
O=C1C([H])([H])C2(C([H])([H])C([H])([H])C([H])([H])C2([H])[H])C([H])([H])C(=O)N1C(C(C(C(N1C([H])([H])C([H])([H])N(C2=NC([H])=C([H])C([H])=N2)C([H])([H])C1([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB00490,36505-84-7,Buspirone,"8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione
Buspiron
Buspirona
Buspirone
Buspironum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg
10 mg/1
15 mg/1
30 mg/1
5 mg/1
7.5 mg/1
5 mg","For the management of anxiety disorders or the short-term relief of the symptoms of anxiety, and also as an augmention of SSRI-treatment against depression."
C(C(N(C(C([H])([H])[H])([H])[H])C(=O)C(=C(C1=C([H])C([N+]([O-])=O)=C(O[H])C(O[H])=C1[H])[H])C#N)([H])[H])([H])([H])[H],DB00494,130929-57-6,Entacapone,"(e)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
Entacapona
Entacapone
Entacaponum
N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide",small molecule,Humans and other mammals,"Tablet, film coated
Tablet
Tablet, film coated
Tablet
Tablet, film coated
Tablet","Oral
Oral
Oral
Oral
Oral
Oral","200 mg
200 mg
200 mg/1
200 mg/1","Used as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose ""wearing-off""."
O=C1C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])C(=O)C2=C1C(=C(C(=C2[H])[H])[H])[H],DB00498,83-12-5,Phenindione,"2-Phenyl-1,3-diketohydrindene
2-Phenyl-1,3-indandione
2-Phenyl-1,3(2H)-indenedione
Fenindiona
Fenindione
Phenindion
Ph��nindione
Phenindionum
PID",small molecule,Humans and other mammals,,,,"For the treatment of pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, mural thrombosis, and thrombophili. Also used for anticoagulant prophylaxis."
C(C(C([H])([H])[H])(C(=O)N(C1=C([H])C(C(F)(F)F)=C([N+]([O-])=O)C([H])=C1[H])[H])[H])([H])([H])[H],DB00499,13311-84-7,Flutamide,"4'-Nitro-3'-trifluoromethylisobutyranilide
alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide
Flutamid
Flutamida
Flutamide
Flutamidum
FTA
NFBA
Niftolid
Niftolide",small molecule,Humans and other mammals,"Capsule
Tablet","Oral
Oral","125 mg/1
250 mg",For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate
C(N1C(C(C(O[H])=O)([H])[H])=C([H])C([H])=C1C(=O)C1=C([H])C([H])=C(C([H])([H])[H])C([H])=C1[H])([H])([H])[H],DB00500,26171-23-3,Tolmetin,"1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid
1-Methyl-5-P-toluoylpyrrole-2-acetic acid
5-(P-Toluoyl)-1-methylpyrrole-2-acetic acid
Tolmetin
Tolmetina
Tolm��tine
Tolmetino
Tolmetinum",small molecule,Humans and other mammals,"Capsule
Tablet
Tablet
Capsule
Tablet
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral","400 mg
245 mg
600 mg
400 mg/1
200 mg/1
600 mg/1","For the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, including the treatment of acute flares long-term management. Also for treatment of juvenile rheumatoid arthritis."
C(N=C(N(C(C(SC(C1=C(C([H])([H])[H])N([H])C([H])=N1)([H])[H])([H])[H])([H])[H])[H])N(C#N)[H])([H])([H])[H],DB00501,51481-61-9,Cimetidine,"1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine
2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine
Cimetag
Cimetidin
Cimetidina
Cim��tidine
Cimetidinum
N-Cyano-n'-methyl-n''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine
N''-cyano-N-methyl-n'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine
Tagamet hb 200
Ulcerfen",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet
Solution
Tablet
Solution
Tablet
Tablet
Liquid
Liquid
Liquid
Liquid","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Oral
Oral
Intravenous
Intramuscular; Intravenous
Oral
Oral","200 mg
300 mg
600 mg
400 mg/1
200 mg/1
300 mg/1
400 mg/1
800 mg/1
200 mg/1
300 mg/5mL
100 mg
150 mg
400 mg
800 mg
6 mg
150 mg
300 mg
60 mg","For the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion."
O(C1(C([H])([H])C([H])([H])N(C(C(C(C(=O)C2=C([H])C([H])=C(F)C([H])=C2[H])([H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])C1=C([H])C([H])=C(Cl)C([H])=C1[H])[H],DB00502,52-86-8,Haloperidol,"1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine
4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
Haloperidolum
��-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone",small molecule,Humans and other mammals,"Injection
Injection
Injection, solution
Solution
Solution, concentrate
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Injection
Injection
Injection, solution
Injection, solution
Injection, solution
Liquid
Liquid
Solution
Liquid
Tablet
Solution
Tablet
Tablet
Tablet
Tablet
Tablet
Solution
Solution
Tablet","Intramuscular
Intramuscular
Intramuscular
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular
Intramuscular
Intramuscular
Intramuscular
Intramuscular
Intramuscular
Intramuscular
Intramuscular
Intramuscular
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular
Intramuscular
Oral","5 mg/1
5 mg/mL
5 mg/mL
2 mg/mL
2 mg/mL
.5 mg/1
1 mg/1
10 mg/1
2 mg/1
20 mg/1
5 mg/1
100 mg/mL
50 mg/mL
100 mg/mL
50 mg/mL
500 mg/5mL
50 mg
5 mg
5 mg
100 mg
0.5 mg
2 mg
.5 mg
10 mg
1 mg
2 mg
5 mg
100 mg
50 mg
20 mg","For the management of psychotic disorders (eg. schizophrenia) and delirium, as well as to control tics and vocal utterances of Tourette's syndrome (Gilles de la Tourette's syndrome). Also used for the treatment of severe behavioral problems in children with disruptive behavior disorder or ADHD (attention-deficit hyperactivity disorder). Haloperidol has been used in the prevention and control of non-retractable nausea and vomiting."
C(C(=O)OC1=C(C(=O)N(C2=NC([H])=C([N+]([O-])=O)S2)[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB00507,55981-09-4,Nitazoxanide,"Nitaxozanid
Nitaxozanide
Nitazoxanida
Nitazoxanidum",small molecule,"Mycobacterium tuberculosis
Helminthic Microorganisms
Bacteria and protozoa
Escherichia coli","Powder, for suspension
Tablet","Oral
Oral","100 mg/5mL
500 mg/1","For the treatment of diarrhea in adults and children caused by the protozoa <i>Giardia lamblia</i>,  and for the treatment of diarrhea in children caused by the protozoan,  <i>Cryptosporidium parvum</i> [FDA label].
Nitazoxanide has not been shown to be superior to placebo medication for the management of diarrhea caused by Cryptosporidium parvum in patients with HIV/immunodeficiency [FDA label, A31973, A31976]. "
C(N(C([H])([H])[H])C(C(C(N1C2=C(C(=C(C(=C2[H])[H])[H])[H])SC2=C1C(=C(C(=C2[H])[H])C(F)(F)F)[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00508,146-54-3,Triflupromazine,"10-(3-(Dimethylamino)propyl)-2-(trifluoromethyl)phenothiazine
2-(Trifluoromethyl)promazine
2-Trifluoromethyl-10-(gamma-dimethylaminopropyl)phenothiazine
Fluopromazine
Triflupromazin
Triflupromazina
Triflupromazine
Triflupromazinum",small molecule,Humans and other mammals,,,,Used mainly in the management of psychoses. Also used to control nausea and vomiting.
N(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],"DB00513
DB04134",60-32-2,Aminocaproic Acid,"6-Aminocaproic acid
6-aminohexanoic acid
Acide aminocapro��que
��cido aminocapr��ico
acidum aminocaproicum
Aminocaprons��ure
EACA
EACS
Epsilcapramine
Epsilon Aminocaproic Acid
Epsilon-Aminocaproic acid
epsilon-Aminohexanoic acid
omega-Aminocaproic acid
omega-Aminohexanoic acid",small molecule,Humans and other mammals,"Solution
Tablet
Tablet
Syrup
Tablet
Liquid
Injection, solution
Syrup
Paste
Paste
Paste, dentifrice","Oral
Oral
Oral
Oral
Oral
Intravenous
Intravenous
Oral
Topical
Dental
Dental",".25 g/mL
1000 mg/1
500 mg/1
250 mg
500 mg
250 mg
250 mg/mL
.25 g/mL",For use in the treatment of excessive postoperative bleeding.
N([Pt](N([H])[H])(Cl)Cl)([H])[H],DB00515,15663-27-1,Cisplatin,"CDDP
Cis-DDP
cis-diamminedichloroplatinum(II)",small molecule,Humans and other mammals,"Injection
Injection, solution
Injection, solution
Injection, solution
Liquid
Liquid
Solution
Solution
Injection, powder, lyophilized, for solution","Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous","1 mg/mL
1 mg/mL
100 mg/100mL
50 mg/50mL
.5 mg
1 mg
1.0 mg
1 mg
1 mg/mL","For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer."
C(C(C(C(C(C(C([H])([H])[H])([H])[H])([H])[H])(C(=O)OC1(C([H])([H])C2(C(C([H])([H])C([N+]2(C([H])([H])[H])C([H])([H])[H])([H])C1([H])[H])([H])[H])[H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB00517,80-50-2,Anisotropine Methylbromide,"8-Methyl-3-(2-propylpentanoyloxy)tropinium bromide
8-Methyltropinium bromide 2-propylpentanoate
8-Methyltropinium bromide 2-propylvalerate
Anisotropine methobromide
Anisotropine methylbromide
Endo-8,8-dimethyl-3-((1-oxo-2-propylpentyl)oxy)-8-azoniabicyclo(3.2.1)octane bromide
Methylbromure d'octatropine
Methyloctatropine bromide
Metilbromuro de octatropina
Octatropine methylbromide
Octatropini methylbromidum",small molecule,Humans and other mammals,,,,"For use in conjunction with antacids or histamine H<sub>2</sub>-receptor antagonists in the treatment of peptic ulcer, to reduce further gastric acid secretion and delay gastric emptying."
C(C(C(SC1=C([H])C2=C(N=C(N(C(=O)OC([H])([H])[H])[H])N2[H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB00518,54965-21-8,Albendazole,"(5-(propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester
5-(propylthio)-2-carbomethoxyaminobenzimidazole
Albendazol
Albendazole
Albendazolum
Eskazole
O-methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate
Proftril",small molecule,Helminthic Microorganisms,"Tablet, film coated",Oral,200 mg/1,"For the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, <i>Taenia solium</i> and for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, <i>Echinococcus granulosus</i>."
C(N(C(=S)OC1=C([H])C2=C(C(=C(C([H])=C2C([H])=C1[H])[H])[H])[H])C1=C([H])C(C([H])([H])[H])=C([H])C([H])=C1[H])([H])([H])[H],DB00525,2398-96-1,Tolnaftate,"2-Naphthyl N-methyl-N-(3-tolyl)thionocarbamate
m,N-Dimethylthiocarbanilic acid O-2-naphthyl ester
Methyl (3-methylphenyl)carbamothioic acid O-2-naphthalenyl ester
N-Methyl-N-(3-methylphenyl)-1-(naphthalen-2-yloxy)methanethioamide
O-2-Naphthyl m,N-dimethylthiocarbanilate
Separin
Tolnaftato
Tolnaftatum
Tolnaphthate",small molecule,Yeast and other fungi,"Liquid
Powder
Solution
Gel
Cream
Spray
Aerosol
Solution
Cream
Solution / drops
Soap
Oil
Oil
Lotion
Aerosol; powder
Spray
Aerosol, foam
Powder
Spray
Spray
Liquid
Gel
Aerosol, foam
Solution
Spray
Stick
Ointment
Solution
Aerosol, powder
Cream
Kit
Aerosol, spray
Cream
Aerosol, powder
Liquid
Cream
Cream
Oil
Lotion
Spray
Liquid
Liquid
Solution
Liquid
Cream
Liquid
Lotion
Swab
Solution
Cream
Powder
Aerosol
Aerosol
Liquid
Liquid
Aerosol, spray
Cream
Cream
Aerosol, powder
Aerosol, powder
Aerosol, powder
Aerosol, powder
Aerosol, spray
Aerosol, spray
Aerosol, spray
Aerosol, spray
Aerosol, spray
Aerosol, spray
Aerosol, spray
Aerosol, spray
Powder
Spray
Spray
Cream
Cream
Powder","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical",".45 g/45g
1 mg/100mL
1 %
.01 mg/10g
1 g/100g
1 g/100g
1 mL/100mL
.56 g/56.69g
10 mg/mL
1 g/100g
.14 g/14g
.3 g/28g
.3 g/28g
1 %
1 g/150g
1 %
10 mg/g
10 mg/mL
1 %
10 g/1000g
10 mg/g
10 mg/mL
10 mg/mL
10 mg/g
1 g/100g
1 g/100mL
.1 g/10g
.1 g/10g
10 mg/g
10 mg/g
10 mg/g
10 mg/g
.59 g/59g
.01 g/g
.01 mg/mL
100 g/g
1 g/100mL
1 mL/100mL
1 %
1 %
1 g/100g
10 mg/mL
10 mg/mL
1 %
10 mg
10 mg
.72 mg
1 %
10 mg
140 mg/15mL
1.28 g/128g
100 mg/g
.2 mg/20mg
1 g/100g
1.1 g/113.3g
1.3 g/130g
1.3 g/113g
.13 g/130g
.15 g/150g
1.13 g/113g
1.3 g/113g
1.3 g/130g
1.5 g/150.2g
1.5 g/150g
150 g/150g
1 g/100g
1.3 g/130g
1.5 g/150g
1.0 %
1 %
1 %","Tolnaftate topical is used to treat skin infections such as athlete's foot, jock itch, and ringworm infections. Tolnaftate is also used, along with other antifungals, to treat infections of the nails, scalp, palms, and soles of the feet. The powder and powder aerosol may be used to prevent athlete's foot."
C(C(C(C(OC1=NC2=C(C(=C(C([H])=C2C(C(=O)N(C(C(N(C(C([H])([H])[H])([H])[H])C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])[H])=C1[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00527,85-79-0,Cinchocaine,"2-Butoxy-N-(2-(diethylamino)ethyl)cinchoninamide
2-Butoxy-N-(alpha-diethylaminoethyl)cinchoninamide
2-Butoxy-N-(beta-diethylaminoethyl)cinchoninamide
2-Butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide
2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide
2-Butoxyquinoline-4-carboxylic acid diethylaminoethylamide
2-N-Butoxy-N-(2-diethylaminoethyl)cinchoninamide
alpha-Butyloxycinchonic acid-gamma-diethylethylenediamine
alpha-Butyloxycinchoninic acid diethylethylenediamide
CINCHOCAINE
Cinchocainum
Cincocainio
Dibucaine
Dibucaine base
N-(2-(Diethylamino)ethyl)-2-butoxycinchoninamide",small molecule,Humans and other mammals,"Ointment
Cream
Ointment
Ointment
Ointment
Cream
Ointment
Suppository","Topical
Topical
Topical
Topical
Rectal; Topical
Topical
Rectal
Rectal","10 mg/g
10 mg/g
.28 g/28g
1 g/100g
1 %",For production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks.
O(C(=O)P(O[H])(O[H])=O)[H],DB00529,4428-95-9,Foscarnet,"Carboxyphosphonic acid
Foscarmet
Phosphonoformate
Phosphonoformic acid
Phosphonomethanoic acid",small molecule,Human Herpes Virus,"Injection, solution",Intravenous,24 mg/mL,For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
C(OC(C(OC1=C([H])C2=NC(=NC(N(C3=C([H])C(C#C[H])=C([H])C([H])=C3[H])[H])=C2C([H])=C1OC(C(OC([H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB00530,183321-74-6,Erlotinib,"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
Erlotinib
OSI-774",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg
100 mg/1
150 mg
150 mg/1
25 mg/1
25 mg
100 mg
150 mg
25 mg","For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer."
C(S(=O)(=O)C1=C([H])C([H])=C(C2=C(C3=C([H])C([H])=C([H])C([H])=C3[H])C(=O)OC2([H])[H])C([H])=C1[H])([H])([H])[H],DB00533,162011-90-7,Rofecoxib,,small molecule,Humans and other mammals,"Suspension
Tablet
Tablet","Oral
Oral
Oral","12.5 mg
12.5 mg
25 mg","For the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras."
N(C(N([H])[H])=N[H])([H])[H],DB00536,113-00-8,Guanidine,"Aminomethanamidine
Gu
Guanidin
GUANIDINE
H2N-C(=NH)-NH2
Imidourea
Iminourea",small molecule,Humans and other mammals,Tablet,Oral,125 mg/1,For the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis.
O(C(=O)C1=C([H])N(C2(C([H])([H])C2([H])[H])[H])C2=C(C(N3C([H])([H])C([H])([H])N([H])C([H])([H])C3([H])[H])=C(F)C([H])=C2C1=O)[H])[H],DB00537,85721-33-1,Ciprofloxacin,"1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Ciprofloxacine
Ciprofloxacino
Ciprofloxacinum",small molecule,Enteric bacteria and other eubacteria,"Ointment
Ointment
Solution
Kit
Solution, concentrate
Suspension
Liquid
Suspension
Tablet
Tablet, extended release
Tablet, extended release
Suspension / drops
Injection
Injection
Injection, solution
Injection, solution, concentrate
Injection, solution, concentrate
Injection, solution, concentrate
Solution / drops
Solution / drops
Solution / drops
Solution / drops
Solution / drops
Solution / drops
Tablet
Tablet
Tablet
Tablet, coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated, extended release
Solution
Solution
Solution
Solution
Solution / drops
Suspension
Solution
For solution
Tablet, film coated, extended release
Solution
Tablet
Tablet
Tablet","Ophthalmic
Ophthalmic
Ophthalmic
Intravenous
Auricular (otic)
Intravenous
Oral
Oral
Oral
Oral
Auricular (otic)
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Ophthalmic
Ophthalmic
Ophthalmic; Topical
Topical
Topical
Topical
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intravenous
Intravenous
Intravenous
Intravenous
Auricular (otic)
Intratympanic
Auricular (otic)
Auricular (otic)
Oral
Ophthalmic
Oral
Oral
Oral","0.3 %
3 mg/g
3.5 mg/mL
2 mg/mL
10 mg
500 mg
100 mg
1000 mg
500 mg
10 mg/mL
2 mg/mL
2 mg/mL
10 mg/mL
200 mg/20mL
400 mg/40mL
3 mg/mL
3.5 mg/mL
3 mg/mL
3 mg/mL
3.5 mg/mL
3.5 mg/1
250 mg/1
500 mg/1
750 mg/1
500 mg/1
100 mg/1
250 mg/1
500 mg/1
750 mg/1
0.2 %
10 mg
2.0 mg
2 mg
.5 mg/.25mL
6 mg/mL
500 mg/1
0.3 %
250 mg
500 mg
750 mg","For the treatment of the following infections caused by susceptible organisms: urinary tract infections, acute uncomplicated cystitis, chronic bacterial prostatitis, lower respiratory tract infections, acute sinusitis, skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections (used in combination with metronidazole), infectious diarrhea, typhoid fever (enteric fever), uncomplicated cervical and urethral gonorrhea, and inhalational anthrax (post-exposure)."
C(OC(C(N(C(=O)C(N(C(C(N(C(C(N(C(C([O-])=O)([H])[H])C(C(=O)N(C(C(OC([H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])C(C([O-])=O)([H])[H])([H])[H])([H])[H])C(C([O-])=O)([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB00538,131069-91-5,Gadoversetamide,"Gadoversetamid
Gadoversetamida
Gadoversetamide
Gadoversetamidum",small molecule,Humans and other mammals,"Injection, solution
Injection, solution
Solution","Intravenous
Intravenous
Intravenous",".5 mmol/mL
500 micromol/ml
330.9 mg","Gadoversetamide is an MRI contrast agent used for MRI diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors."
C(N(C([H])([H])[H])C(C(OC1=C([H])C([H])=C(C(=C(C(C(Cl)([H])[H])([H])[H])C2=C([H])C([H])=C([H])C([H])=C2[H])C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB00539,89778-26-7,Toremifene,"Toremifeno
Toremifenum",small molecule,Humans and other mammals,"Tablet
Tablet","Oral
Oral","60 mg/1
60 mg",For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.
C(N(C(C(C(=C1C2=C(C(=C(C(=C2[H])[H])[H])[H])C([H])([H])C([H])([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB00540,72-69-5,Nortriptyline,"10,11-dihydro-N-Methyl-5H-dibenzo[a,D]cycloheptene-delta(5,gamma)-propylamine
3-(10,11-dihydro-5H-Dibenzo[a,D]cyclohepten-5-ylidene)-N-methyl-1-propanamine
Ateben
Avantyl
Demethylamitriptyline
Desmethylamitriptyline
Noritren
Nortriptyline
Psychostyl
Sensaval",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule
Capsule
Capsule
Solution","Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg
25 mg
10 mg/1
25 mg/1
50 mg/1
75 mg/1
10 mg/5mL",Primarily indicated for the relief of symptoms of depression.
ClC1=C([H])C2=C(OC3=C(N=C2N2C([H])([H])C([H])([H])N([H])C([H])([H])C2([H])[H])C([H])=C([H])C([H])=C3[H])C([H])=C1[H],DB00543,14028-44-5,Amoxapine,"2-Chloro-11-(1-piperazinyl)dibenz(b,F)(1,4)oxazepine
Amoxapin
Amoxapina
Amoxapinum
Amoxepine
Desmethylloxapin",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg/1
150 mg/1
25 mg/1
50 mg/1
100 mg
25 mg
50 mg",For the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. May also be used to treat depression accompanied by anxiety or agitation.
FC1=C([H])N([H])C(=O)N([H])C1=O,DB00544,51-21-8,Fluorouracil,"5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluracil
5-FU
Fluoro Uracil
Fluorouracil
Fluorouracilo
Fluorouracilum
Fluoruracil
Fluouracil
FU",small molecule,Humans and other mammals,"Solution
Injection, solution
Injection, solution
Liquid
Cream
Cream
Cream
Cream
Cream
Cream
Injection, solution
Solution
Solution
Liquid
Solution
Solution
Cream
Cream","Topical
Intravenous
Intravenous
Intravenous
Topical
Topical
Topical
Topical
Topical
Topical
Intravenous
Topical
Topical
Intravenous
Intravenous
Intravenous
Topical
Topical","2.5 g/50mL
5 g/100mL
500 mg
2 g/40g
5 %
10 mg/g
1 %
5 mg/g
50 mg/g
50 mg/mL
20 mg/mL
50 mg/mL
50 mg
50 mg
5 g
.04 g/g
40 mg/g","For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid."
C(N(C([H])([H])[H])C(=O)OC1=C([H])[N+](C([H])([H])[H])=C([H])C([H])=C1[H])([H])([H])[H],DB00545,155-97-5,Pyridostigmine,"Bromure de Pyridostigmine
Bromuro de piridostigmina
Pyridostigmin bromid
Pyridostigmine
Pyridostigmini Bromidum",small molecule,Humans and other mammals,"Syrup
Tablet
Tablet, extended release
Tablet
Tablet, extended release
Injection, solution
Liquid","Oral
Oral
Oral
Oral
Oral
Intravenous; Parenteral
Intramuscular; Intravenous","60 mg/5mL
60 mg
180 mg
60 mg/1
180 mg/1
5 mg/mL
5 mg",For the treatment of myasthenia gravis.
C(N(C([H])([H])[H])C(C1=NN=C2C(N=C(C3=C([H])C([H])=C([H])C([H])=C3[H])C3=C(N12)C([H])=C([H])C(Cl)=C3[H])([H])[H])([H])[H])([H])([H])[H],DB00546,37115-32-5,Adinazolam,"8-Chloro-1-((dimethylamino)methyl)-6-phenyl-4H-S-triazolo(4,3-a)(1,4)benzodiazepine
Adinazolamum",small molecule,Humans and other mammals,,,,For the treatment of anxiety and status epilepticus.
O(C(=O)C(C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB00548,123-99-9,Azelaic Acid,"1,7-Dicarboxyheptane
1,7-Heptanedicarboxylic acid
1,9-Nonanedioic acid
Acide az��la��que
��cido azelaico
Acidum acelaicum
Acidum azelaicum
Anchoic acid
Azelaic acid
Azelainsaeure
Azelains��ure
Lepargylic acid
N-Nonanedioic acid
Nonandisaeure
Nonandis��ure
Nonanedioic acid
Skinoren",small molecule,Various aerobic and anaerobic microorganisms,"Gel
Cream
Liquid
Gel
Kit
Aerosol, foam
Tablet, coated","Topical
Cutaneous
Topical
Topical
Topical
Oral",".15 g/g
.2 g/g
2.5 mL/50mL
15 %
.15 g/g",For the topical treatment of mild-to-moderate inflammatory acne vulgaris.
C(OC1=C(C(C2=C([H])N(C([H])([H])[H])C3=C2C(=C(N(C(=O)OC2(C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])[H])C(=C3[H])[H])[H])([H])[H])C([H])=C([H])C(C(=O)N(S(=O)(=O)C2=C(C([H])([H])[H])C([H])=C([H])C([H])=C2[H])[H])=C1[H])([H])([H])[H],DB00549,107753-78-6,Zafirlukast,"4-(5-Cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-O-tolylsulfonylbenzamide
Cyclopentyl 3-(2-methoxy-4-((O-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate
ICI-204,219",small molecule,Humans and other mammals,"Tablet, coated
Tablet, coated
Tablet, film coated
Tablet, film coated
Tablet","Oral
Oral
Oral
Oral
Oral","10 mg/1
20 mg/1
10 mg/1
20 mg/1
20 mg",For the prophylaxis and chronic treatment of asthma.
C(C(C(C1=C([H])C(=O)N([H])C(=S)N1[H])([H])[H])([H])[H])([H])([H])[H],DB00550,51-52-5,Propylthiouracil,"2-Mercapto-6-propyl-4-pyrimidone
2-Mercapto-6-propylpyrimid-4-one
2-Thio-4-oxo-6-propyl-1,3-pyrimidine
2-Thio-6-propyl-1,3-pyrimidin-4-one
2,3-dihydro-6-Propyl-2-thioxo-4(1H)-pyrimidinone
4-Propyl-2-thiouracil
6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione
6-Propyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one
6-Propylthiouracil
6-Thio-4-propyluracil
Propiltiouracilo
Propylthiouracil
Propylthiouracile
Propylthiouracilum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet","Oral
Oral
Oral","100 mg
50 mg
50 mg/1",Used to manage hyperthyroidism which is due to an overactive thyroid gland (Grave's disease).
C(C(=O)N(O[H])[H])([H])([H])[H],DB00551,546-88-3,Acetohydroxamic Acid,"Acethydroxamsaeure
Acethydroxamsaure
Acetic acid, oxime
Acetohydroxamate
Acetohydroxamic acid
Acetohydroximic acid
Acetyl hydroxyamino
Acetylhydroxamic acid
Acide acetohydroxamique
Acido acetohidroxamico
Acidum acetohydroxamicum
AHA
Cetohyroxamic acid
Methylhydroxamic acid
N-Acetyl hydroxyacetamide
N-Acetylhydroxylamine
N-Hydroxyacetamide",small molecule,Enteric bacteria and other eubacteria,Tablet,Oral,250 mg/1,"Used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections."
C(OC1=C2OC(=O)C(=C([H])C2=C([H])C2=C1OC(=C2[H])[H])[H])([H])([H])[H],DB00553,298-81-7,Methoxsalen,"6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone
8-Methoxy-[furano-3'.2':6.7-coumarin]
8-Methoxy-2',3',6,7-furocoumarin
8-Methoxy-4',5':6,7-furocoumarin
8-Methoxyfuranocoumarin
8-Methoxypsoralen
8-MP
9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one
Ammoidin
Meladinine
Meloxine
Methoxalen
Methoxsalen
M��thoxsal��ne
O-Methylxanthotoxol
Ultra mop
Xanthotoxin
Xanthotoxine
Xanthoxin
Zanthotoxin",small molecule,Humans and other mammals,"Capsule, gelatin coated
Capsule, liquid filled
Lotion
Lotion
Capsule
Liquid
Injection, solution
Solution","Oral
Oral
Topical
Topical
Oral
Topical
Extracorporeal
Extracorporeal","10 mg/1
10 mg/1
10 mg/mL
10 mg
10 mg
1 %
20 ug/mL
20 mcg",For the treatment of psoriasis and vitiligo
C(N1C(C(=O)N(C2=NC([H])=C([H])C([H])=C2[H])[H])=C(O[H])C2=C(C(=C(C(=C2[H])[H])[H])[H])S1(=O)=O)([H])([H])[H],DB00554,36322-90-4,Piroxicam,"4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid
Piroxicam
Piroxicam betadex
Piroxicamum
Pyroxycam",small molecule,Humans and other mammals,"Capsule
Capsule
Suppository
Suppository
Capsule
Capsule
Tablet
Kit","Oral
Oral
Rectal
Rectal
Oral
Oral
Oral","10 mg
20 mg
10 mg
20 mg
10 mg/1
20 mg/1
10 mg",For treatment of osteoarthritis and rheumatoid arthritis.
N(C1=NN=C(C2=C([H])C([H])=C([H])C(Cl)=C2Cl)C(N([H])[H])=N1)([H])[H],DB00555,84057-84-1,Lamotrigine,"3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
Lamotrigina
Lamotrigine
Lamotriginum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, chewable
Tablet
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Kit
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, chewable
Tablet, chewable
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, for suspension
Tablet, for suspension
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg
150 mg/1
150 mg
2 mg
25 mg
5 mg
2 mg/1
200 mg
100 mg/1
200 mg/1
25 mg/1
50 mg/1
100 mg/1
200 mg/1
25 mg/1
250 mg/1
300 mg/1
50 mg/1
100 mg/1
200 mg/1
25 mg/1
250 mg/1
50 mg/1
25 mg/1
5 mg/1
100 mg/1
200 mg/1
25 mg/1
300 mg/1
50 mg/1
25 mg/1
5 mg/1
300 mg/1","Indicated as adjunctive therapy for the following seizure types in patients ���2 years of age: partial seizures/primary generalized tonic-clonic seizures/generalized seizures of Lennox-Gastaut syndrome [FDA Label].
Indicated for conversion to monotherapy in adults (���16 years of age) with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED)[FDA Label]. 
Indicated for the maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (���18 years of age) treated for acute mood episodes with standard therapy [FDA Label]."
FC(F)(F)C(F)(F)C(F)(F)F,DB00556,76-19-7,Perflutren,"1,1,1,2,2,3,3,3-Octafluoropropane
FC 218
Freon 218
Octafluoropropane
Octafluorpropan
Oktafluorpropan
Perfluoropropane
Perflutren",small molecule,Humans and other mammals,"Injection, suspension
Suspension
Injection, solution
Injection, solution","Intravenous
Intravenous
Intravenous
Intravenous","6.52 mg/mL
150 mcl
150 ��l/ml",Used as an ultrasound contrast imaging in cardiology and radiology.
C(OC1=C(OC2=C(OC(C(O[H])([H])[H])([H])[H])N=C(C3=NC([H])=C([H])C([H])=N3)N=C2N(S(=O)(=O)C2=C([H])C([H])=C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C([H])=C2[H])[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB00559,147536-97-8,Bosentan,"4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide
bosent��n
bosentan
bosentanum
p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide",small molecule,Humans and other mammals,"Tablet
Tablet, film coated
Tablet, film coated
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, for suspension
Tablet, soluble","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","125.0 mg
125 mg
62.5 mg
125 mg
62.5 mg
125 mg/1
62.5 mg/1
32 mg
32 mg/1","Used in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms)."
N(S(=O)(=O)C1=C(Cl)C([H])=C2N(C(C(SC(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])([H])[H])=NS(=O)(=O)C2=C1[H])[H])([H])[H],DB00562,91-33-8,Benzthiazide,"3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine 1,1-dioxide
3-Benzylthiomethyl-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
3-Benzylthiomethyl-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide
6-chloro-1,1-dioxo-3-(Phenylmethylsulfanylmethyl)-4H-benzo[e][1,2,4]thiadiazine-7-sulfonamide
6-chloro-7-Sulfamoyl-3-benzylthiomethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
Benzothiazide
Benzotiazida
Benzthiazid
Benzthiazide
Benzthiazidum
Benztiazide",small molecule,Humans and other mammals,,,,For the treatment of high blood pressure and management of edema.
N(C(=O)N1C2=C(C(=C(C(=C2[H])[H])[H])[H])C([H])=C([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H],DB00564,298-46-4,Carbamazepine,"5-Carbamoyl-5H-dibenz(b,f)azepine
5-Carbamoyl-5H-dibenz[b,F]azepine
5-Carbamoyl-5H-dibenzo(b,F)azepine
5-Carbamyl-5H-dibenzo(b,F)azepine
5H-Dibenz(b,F)azepine-5-carboxamide
Carbamazepen
Carbamazepin
Carbamazepina
Carbamaz��pine
Carbamazepinum
CBZ",small molecule,Humans and other mammals,"Capsule, extended release
Capsule, extended release
Capsule, extended release
Suspension
Suspension
Tablet
Tablet
Tablet, chewable
Tablet, chewable
Injection, powder, for solution
Tablet, chewable
Tablet, chewable
Tablet, extended release
Tablet, extended release
Tablet
Suspension
Tablet, extended release
Tablet, extended release
Tablet, extended release","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg/1
200 mg/1
300 mg/1
100 mg/5mL
200 mg/10mL
100 mg/1
200 mg/1
100 mg/1
200 mg/1
10 mg/mL
100 mg
200 mg
200 mg
400 mg
200 mg
100 mg
100 mg/1
200 mg/1
400 mg/1",For the treatment of epilepsy and pain associated with true trigeminal neuralgia. 
C(C(=C(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H])(N1C([H])([H])C([H])([H])N(C(C2=C([H])C([H])=C([H])C([H])=C2[H])(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])C([H])([H])C1([H])[H])([H])[H],DB00568,298-57-7,Cinnarizine,"1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine
1-Benzhydryl-4-cinnamylpiperazin
1-Cinnamyl-4-(diphenylmethyl)piperazine
Cinarizina
Cinnarizine
Cinnarizinum",small molecule,Humans and other mammals,,,,"For the treatment of vertigo/meniere's disease, nausea and vomiting, motion sickness and also useful for vestibular symptoms of other origins."
ClC1=C([H])C([H])=C([H])C(Cl)=C1N(C1=NC([H])([H])C([H])([H])N1[H])[H],"DB00575
DB07566",4205-90-7,Clonidine,"2-[(2,6-Dichlorophenyl)imino]imidazoline
2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
Chlofazoline
Clonidin
Clonidina
Clonidinum",small molecule,Humans and other mammals,"Injection, solution
Injection, solution
Patch
Patch
Patch
Patch, extended release
Patch, extended release
Patch, extended release
Tablet
Injection, solution
Injection, solution
Tablet
Tablet
Tablet
Tablet, extended release
Tablet
Injection, solution
Injection, solution
Tablet, extended release
Tablet, extended release
For suspension, extended release
Tablet, extended release
Tablet
Tablet
Tablet
Tablet","Epidural
Epidural
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Oral
Intravenous
Intravenous
Oral
Oral
Oral
Oral
Oral
Epidural
Epidural
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 ug/mL
500 ug/mL
.1 mg/d
.2 mg/d
.3 mg/d
.1 mg/24h
.2 mg/24h
.3 mg/24h
.2 mg
100 ug/mL
500 ug/mL
.1 mg/1
.2 mg/1
.3 mg/1
.1 mg/1
.1 mg/mL
.5 mg/mL
.2 mg/1
.17 mg/1
.09 mg/mL
.26 mg/1
.1 mg
0.025 mg
0.1 mg
0.2 mg","May be used as an adjunct in the treatment of hypertension, as an epidural infusion as an adjunct treatment in the management of severe cancer pain that is not relieved by opiate analgesics alone, for differential diagnosis of pheochromocytoma in hypertensive patients, prophylaxis of vascular migraine headaches, treatment of severe dysmenorrhea, management of vasomotor symptoms associated with menopause, rapid detoxification in the management of opiate withdrawal, treatment of alcohol withdrawal used in conjunction with benzodiazepines, management of nicotine dependence, topical use to reduce intraocular pressure in the treatment of open-angle and secondary glaucoma and hemorrhagic glaucoma associated with hypertension, and in the treatment of attention-deficit hyperactivity disorder (ADHD)."
C(C1=NN=C(N(S(=O)(=O)C2=C([H])C([H])=C(N([H])[H])C([H])=C2[H])[H])S1)([H])([H])[H],DB00576,144-82-1,Sulfamethizole,"Rufol
Sulfamethizol
Sulfam��thizol
Sulfamethizole
Sulfamethizolum
Sulfamethylthiadiazole
Sulfametizol",small molecule,Enteric bacteria and other eubacteria,,,,For the treatment of urinary tract infection
C(C1=C(C2=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C2[H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])=NO1)([H])([H])[H],"DB00580
DB07576",181695-72-7,Valdecoxib,,small molecule,Humans and other mammals,,,,For the treatment of osteoarthritis and dysmenorrhoea
C(N(C(N(C(C(SC(C1=C([H])SC(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])=N1)([H])[H])([H])[H])([H])[H])[H])=C([N+]([O-])=O)[H])[H])([H])([H])[H],DB00585,76963-41-2,Nizatidine,"Nizatidina
Nizatidine
Nizatidinum",small molecule,Humans and other mammals,"Tablet, film coated
Capsule
Capsule
Solution
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral
Oral","75 mg/1
150 mg/1
300 mg/1
15 mg/mL
150 mg
300 mg","For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer."
O(C(=O)C(C1=C(N(C2=C(Cl)C([H])=C([H])C([H])=C2Cl)[H])C([H])=C([H])C([H])=C1[H])([H])[H])[H],DB00586,15307-86-5,Diclofenac,"[2-(2,6-dichloroanilino)phenyl]acetic acid
2-((2,6-dichlorophenyl)amino)benzeneacetic acid
Diclofenac Acid
Diclofenaco
Diclofenacum",small molecule,Humans and other mammals,"Patch
Tablet, delayed release
Tablet, delayed release
Tablet, extended release
Solution
Tablet, film coated
Powder, for solution
Powder, for solution
Powder, for solution
Tablet, sugar coated
Tablet
Tablet, film coated
Powder
Aerosol, metered
Gel
Gel
Gel
Solution
Solution
Solution / drops
Solution / drops
Solution / drops
Tablet, delayed release
Cream
Tablet, delayed release
Tablet, delayed release
Tablet, delayed release
Tablet, extended release
Gel
Kit
Injection, solution
Patch
Patch
Kit
Liquid
Solution
Solution
Solution
Suppository
Suppository
Kit
Tablet
Tablet
Tablet, extended release
Cream
Liquid
Gel
Gel
Gel
Tablet
Tablet, film coated, extended release
Capsule, liquid filled
Capsule
Capsule","Topical
Oral
Oral
Oral
Ophthalmic
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Topical
Topical
Topical
Topical
Ophthalmic
Topical
Ophthalmic
Ophthalmic
Transdermal
Oral
Topical
Oral
Oral
Oral
Oral
Topical
Intravenous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Rectal
Rectal
Oral
Oral
Oral
Topical
Ophthalmic
Topical
Topical
Topical
Oral
Oral
Oral
Oral
Oral","1 g/10mL
25 mg
50 mg
100 mg
0.1 %
1 mg/mg
50 mg/1
50 mg
50 mg/1
50 mg/1
50 mg/1
50 mg/1
30 mg/mL
10 mg/1
3 g/100g
30 mg/g
1 mg/mL
16.05 mg/mL
1 mg/mL
3.5 mg/mL
16.05 mg/mL
25 mg/1
300 mg/g
50 mg/1
75 mg/1
100 mg/1
1 g/1
37.5 mg/mL
180 mg/1
180 mg/14g
16.05 mg/mL
1.5 %
15 mg/g
20 mg/g
100 mg
50 mg
25 mg
75 mg
0.1 %
10 mg/g
1.16 %
2.32 %
50 mg
100 mg/1
25 mg/1
18 mg/1
35 mg/1",For the acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.
C(C(C(C(C([H])([H])[H])([H])[H])(C(C(=O)N(C1=C([H])C([H])=C([H])C(C(=C(C2=NC(C3(C([H])([H])C([H])([H])C3([H])[H])[H])=C([H])S2)[H])[H])=C1[H])[H])([H])[H])C(O[H])=O)([H])[H])([H])([H])[H],DB00587,128312-51-6,Cinalukast,"3'-((e)-2-(4-Cyclobutyl-2-thiazolyl)vinyl)-2,2-diethylsuccinanilic acid
Cinalukast",small molecule,Humans and other mammals,,,,For Protection against second- phase inflamation in exercise-induced bronchoconstriction and Asthma.
C1(C([H])([H])N([H])C([H])([H])C([H])([H])N1[H])([H])[H],"DB00592
DB11514",110-85-0,Piperazine,"Diethylenediamine
Piperazidine
Piperazin",small molecule,Parasitic nematodes and other roundworms,"Powder, for solution
Powder
Suspension
Liquid
Liquid
Syrup","Oral
Oral
Oral
Oral
Oral
Oral","2 g
2 g
600 mg
100 mg
110 mg
110 mg","Used as alternative treatment for ascariasis caused by <i>Ascaris lumbricoides</i> (roundworm) and enterobiasis (oxyuriasis) caused by <i>Enterobius vermicularis</i> (pinworm). It is also used to treat partial intestinal obstruction by the common roundworm, a condition primarily occurring in children."
N(C(N([H])[H])=NC(=O)C1=C(N([H])[H])N=C(N([H])[H])C(Cl)=N1)([H])[H],DB00594,2609-46-3,Amiloride,"3,5-Diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide
Amilorid
Amilorida
Amiloridum
Amipramidin
Amipramidine
Amyloride
N-amidino-3,5-diamino-6-chloropyrazinecarboxamide",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral","5 mg/1
5.0 mg
5 mg",For use as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension.
C(C(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])(N(C(C(O[H])(C1=C([H])C(C(N([H])[H])=O)=C(O[H])C([H])=C1[H])[H])([H])[H])[H])[H])([H])([H])[H],DB00598,36894-69-6,Labetalol,"3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol
5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide
Labetalol
Labetalolum
Labetolol",small molecule,Humans and other mammals,"Injection, solution
Injection
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Liquid
Solution
Tablet
Tablet
Tablet","Intravenous
Intravenous
Oral
Oral
Oral
Oral
Oral
Intravenous
Intravenous
Oral
Oral
Oral","5 mg/mL
5 mg/mL
200 mg/1
300 mg/1
100 mg/1
200 mg/1
300 mg/1
5 mg
5 mg
100 mg
100 mg/1
200 mg","For the management of hypertension (alone or in combination with other classes of antihypertensive agents), as well as chronic stable angina pectoris and sympathetic overactivity syndrome associated with severe tetanus. Labetalol is used parenterally for immediate reduction in blood pressure in severe hypertension or in hypertensive crises when considered an emergency, for the control of blood pressure in patients with pheochromocytoma and pregnant women with preeclampsia, and to produce controlled hypotension during anesthesia to reduce bleeding resulting from surgical procedures."
O(C1=C([H])C([H])=C(OC(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])C([H])=C1[H])[H],DB00600,103-16-2,Monobenzone,"4-(Benzyloxy)phenol
4-(Benzyloxyl)phenol
4-(Phenylmethoxy)phenol
4-Benzyloxy-phenol
4-Benzyloxyphenol
Benzyl p-hydroxyphenyl ether
Hydrochinon monobenzylether
Hydroquinone benzyl ether
Hydroquinone monobenzyl ether
Monobenzona
Monobenzone
Monobenzonum
MONOBENZYL ether OF hydroquinone
Monobenzyl hydroquinone
p-(Benzyloxy)phenol
p-Hydroxyphenyl benzyl ether",small molecule,Humans and other mammals,Cream,Topical,20 %,Used topically to treat the loss of skin color (vitiligo).
N(S(=O)(=O)C1=C(Cl)C([H])=C2N(C(N(S(=O)(=O)C2=C1[H])[H])(C1(C([H])([H])C2(C([H])([H])C1(C(=C2[H])[H])[H])[H])[H])[H])[H])([H])[H],DB00606,2259-96-3,Cyclothiazide,"6-chloro-3-(2-Norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
6-chloro-3,4-dihydro-3-(2-Norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
6-chloro-3,4-dihydro-3-(2-Norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide
6-chloro-3,4-dihydro-3-(5-Norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
Ciclotiazida
Ciclotiazide
Cyclothiazide
Cyclothiazidum",small molecule,Humans and other mammals,,,,"Cyclothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension."
C(C(C1=NC([H])=C([H])C(C(N([H])[H])=S)=C1[H])([H])[H])([H])([H])[H],DB00609,536-33-4,Ethionamide,"2-Ethyl-4-thiopyridylamide
2-ethylthioisonicotinamide
ETH
Ethinamide
Ethionamide
Ethionamidum
Ethioniamide
Ethylisothiamide
Ethyonomide
Etionamid
Etionamida
Etionamide
Etioniamid
ETP",small molecule,Mycobacteria,"Tablet, film coated",Oral,250 mg/1,For use in the treatment of pulmonary and extrapulmonary tuberculosis when other antitubercular drugs have failed.
C(C(N(C(C([H])([H])[H])([H])[H])C(C1=C(O[H])C([H])=C([H])C(N(C2=C3C(=C(C(Cl)=C([H])C3=NC([H])=C2[H])[H])[H])[H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB00613,86-42-0,Amodiaquine,"Amodiaquina
Amodiaquine
Amodiaquinum",small molecule,Plasmodium,,,,For treatment of acute malarial attacks in non-immune subjects.
[O-][N+](=O)C1=C([H])C([H])=C(C(=NN2C([H])([H])C([H])([H])OC2=O)[H])O1,DB00614,67-45-8,Furazolidone,"3-(5'-Nitrofurfuralamino)-2-oxazolidone
3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone
3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone
3-[(5-Nitrofurylidene)amino]-2-oxazolidone
3-{[(5-nitro-2-furanyl)methylene]amino}-2-oxazolidinone
5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine
Furazolidona
Furazolidone
Furazolidonum
FZL
N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone
N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one
Nitrofurazolidone
Nitrofurazolidonum",small molecule,"Microbes (bacteria, parasites)",,,,For the specific and symptomatic treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms.
C(N1C([H])([H])C([H])([H])N(C(C2=C([H])C([H])=C(C(=O)N(C3=C([H])C(N(C4=NC(C5=C([H])N=C([H])C([H])=C5[H])=C([H])C([H])=N4)[H])=C(C([H])([H])[H])C([H])=C3[H])[H])C([H])=C2[H])([H])[H])C([H])([H])C1([H])[H])([H])([H])[H],"DB00619
DB03261",152459-95-5,Imatinib,"4-(4-METHYL-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide
alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-P-toluidide
Imatinib
Imatinib Methansulfonate
Imatinibum
STI 571",small molecule,Humans and other mammals,"Capsule
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Capsule
Capsule
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg
100 mg/1
100 mg
400 mg/1
400 mg
100 mg
400 mg
400 mg
50 mg
100 mg/1
400 mg/1","For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST)."
O(C(C(N1C([H])([H])C([H])([H])N(C(C(C(N2C3=C(C(=C(C(=C3[H])[H])[H])[H])SC3=C2C(=C(C(=C3[H])[H])C(F)(F)F)[H])([H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])([H])[H])([H])[H])[H],DB00623,69-23-8,Fluphenazine,"1-(2-Hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine
10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine
10-(3'-(4''-(beta-hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine
2-(4-(3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol
2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine
4-(3-(-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol
4-(3-(2-(Trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol
4-(3-(2-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol
Flufenazina
Fluorfenazine
Fluorophenazine
Fluorphenazine
Fluphenazin
Fluph��nazine
Fluphenazinum
Triflumethazine",small molecule,Humans and other mammals,"Tablet
Liquid
Tablet
Tablet
Injection
Injection, solution
Injection, solution
Elixir
Injection, solution
Solution, concentrate
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Liquid
Liquid
Tablet
Tablet
Elixir
Solution
Solution","Oral
Intramuscular; Subcutaneous
Oral
Oral
Intramuscular; Subcutaneous
Intramuscular; Subcutaneous
Intramuscular; Subcutaneous
Oral
Intramuscular
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular; Subcutaneous
Intramuscular
Oral
Oral
Oral
Intramuscular; Subcutaneous
Intramuscular; Subcutaneous","2.5 mg
25 mg
1 mg
2 mg
25 mg/mL
125 mg/5mL
25 mg/mL
.5 mg/mL
2.5 mg/mL
5 mg/mL
1 mg/1
2.5 mg/1
1 mg/1
10 mg/1
2.5 mg/1
5 mg/1
100 mg
25 mg
10 mg
5 mg
.5 mg
25 mg
100 mg",For management of manifestations of psychotic disorders.
O(C(=O)C1=C([H])N=C([H])C([H])=C1[H])[H],DB00627,59-67-6,Niacin,"3-carboxypyridine
3-Pyridinecarboxylic acid
3-Pyridylcarboxylic acid
Acide Nicotinique
Acido nicotinico
Acidum Nicotinicum
Anti-pellagra vitamin
beta-Pyridinecarboxylic acid
M-Pyridinecarboxylic Acid
Niacin
Nicotinic Acid
Nikotinsaeure
P.P. factor
Pellagra preventive factor
PP Factor
Pyridine-beta-carboxylic acid
pyridine-��-carboxylic acid
Vitamin B3
��-pyridinecarboxylic acid",small molecule,Humans and other mammals,"Tablet, extended release
Tablet, extended release; tablet, multilayer, extended release
Powder
Capsule, liquid filled
Capsule
Tablet
Tablet, film coated
Shampoo
Solution / drops
Liquid
Tablet, chewable
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet
Capsule
Capsule
Solution
Powder
Capsule, extended release
Tablet
Tablet, extended release
Tablet
Tablet
Tablet, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, extended release
Tablet, extended release
Tablet
Kit
Tablet, film coated, extended release
Tablet, coated
Lozenge
Capsule, extended release
Capsule, gelatin coated
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Topical
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","50 mg
2 mg/100mL
1000 mg/1
500 mg/1
750 mg/1
250 mg
250 mg
100 mg
100 mg
800 mg
400 mg
100 mg
475 mg
500 mg
500 mg/1
750 mg
1000 mg/1
750 mg/1
500 mg/1
1000 mg
500 mg
300 mg
10 mg",For the treatment of type IV and V hyperlipidemia. It is indicated as ajunctive therapy.
N(C(N([H])[H])=NN=C(C1=C(Cl)C([H])=C([H])C([H])=C1Cl)[H])([H])[H],DB00629,5051-62-7,Guanabenz,"Guanabenz
Guanabenzo
Guanabenzum",small molecule,Humans and other mammals,,,,For management of High blood pressure
N(C(C(C(C(O[H])(P(O[H])(O[H])=O)P(O[H])(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H],DB00630,66376-36-1,Alendronic acid,"(4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)
(4-amino-1-hydroxybutylidene)bisphosphonic acid
4-amino-1-hydroxybutane-1,1-diphosphonic acid
ABDP
Acide Alendronique
Acido Alendronico
Acidum Alendronicum
Alendronate",small molecule,Humans and other mammals,"Solution
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, effervescent
Solution
Tablet
Tablet
Tablet, coated
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","70 mg/75mL
10 mg/1
35 mg/1
40 mg/1
5 mg/1
70 mg/1
70 mg/1
70 mg
40 mg
70 mg
10 mg/1
10.0 mg
5.0 mg
70.0 mg
10 mg
5 mg",For the treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women.
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00632,661-19-8,Docosanol,"1-Docosanol
Behenic alcohol
Behenyl alcohol
Docosan-1-ol
Docosanol
Docosyl alcohol
N-Docosanol",small molecule,Herpes simplex virus,"Cream
Cream","Topical
Topical","10 %
100 mg/g",For the topical treatment of recurrent oral-facial herpes simplex episodes (cold sores or fever blisters).
C(C(=O)N(S(=O)(=O)C1=C([H])C([H])=C(N([H])[H])C([H])=C1[H])[H])([H])([H])[H],DB00634,144-80-9,Sulfacetamide,"Acetosulfamine
N-((P-Aminophenyl)sulfonyl)acetamide
N-(P-Aminobenzenesulfonyl)acetamide
N-[(P-Aminophenyl)sulfonyl]acetamide
N-Acetyl-4-aminobenzenesulfonamide
N-Acetylsulfanilamide
N-Sulfanilylacetamide
N-Sulphanilylacetamide
N'-acetylsulfanilamide
N(1)-Acetyl-4-aminophenylsulfonamide
N(1)-Acetylsulfanilamide
P-Aminobenzenesulfonacetamide
P-Aminobenzenesulfonoacetamide
Sulfacetamid
Sulfacetamida
Sulfac��tamide
Sulfacetamidum
Sulfanilazetamid
Sulphacetamide
Sulphacetamidum",small molecule,Enteric bacteria and other eubacteria,"Aerosol, foam
Solution / drops
Solution / drops
Ointment
Suspension / drops
Solution / drops
Liquid
Ointment
Ointment
Lotion
Suspension
Solution
Aerosol, foam
Lotion
Cream
Gel
Soap
Liquid
Solution / drops
Gel
Liquid
Shampoo
Solution
Swab
Swab
Cloth
Rinse
Solution
Cream
Emulsion
Gel
Suspension
Lotion
Ointment
Solution
Solution / drops
Solution / drops
Suspension
Solution
Lotion
Liquid
Kit
Liquid","Topical
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Topical
Ophthalmic
Ophthalmic; Topical
Topical
Ophthalmic
Ophthalmic
Topical
Topical
Topical
Topical
Topical
Topical
Ophthalmic
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Topical
Ophthalmic
Topical
Ophthalmic
Ophthalmic","100 mg
10 %
10 %
10 mg/mL
10 %
98 mg/g
98 mg/g
100 mg/g
100 mg/g
100 mg/.95mL
300 mg
100 mg/mL
100 mg/mL
100 mg/mL
100 mg/g
100 mg/mL
100 mg/mL
100 mg/g
100 mg/mL
100 mg/mL
300 mg/mL
100 mg/mL
10 %","For the treatment of bacterial vaginitis, keratitis, acute conjunctivitis, and blepharitis."
C(C(OC(=O)C(C([H])([H])[H])(C([H])([H])[H])OC1=C([H])C([H])=C(Cl)C([H])=C1[H])([H])[H])([H])([H])[H],DB00636,637-07-0,Clofibrate,"2-(4-Chlorophenoxy)-2-methylpropanoic acid ethyl ester
2-(p-Chlorophenoxy)-2-methylpropionic acid ethyl ester
alpha-(p-Chlorophenoxy)isobutyric acid, ethyl ester
alpha-p-Chlorophenoxyisobutyryl ethyl ester
Clofibrate
Clofibrato
Clofibratum
ELPI
EPIB
Ethyl 2-(P-chlorophenoxy)isobutyrate
Ethyl chlorophenoxyisobutyrate
Ethyl clofibrate
Lipofacton
Liprin",small molecule,Humans and other mammals,"Capsule
Capsule","Oral
Oral","1 g
500 mg",For Primary Dysbetalipoproteinemia (Type III hyperlipidemia) that does not respond adequately to diet. This helps control high cholesterol and high triglyceride levels. 
C(OC1=C([H])C([H])=C(C(C(N2C([H])([H])C([H])([H])C(N(C3=NC4=C(C(=C(C(=C4[H])[H])[H])[H])N3C(C3=C([H])C([H])=C(F)C([H])=C3[H])([H])[H])[H])([H])C([H])([H])C2([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB00637,68844-77-9,Astemizole,"1-(P-Fluorobenzyl)-2-((1-(2-(P-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole
1-(P-Fluorobenzyl)-2-((1-(P-methoxyphenethyl)-4-piperidyl)amino)benzimidazole
Astemison
Astemizol
Ast��mizole
Astemizolum",small molecule,Humans and other mammals,"Tablet
Suspension","Oral
Oral","10 mg
2 mg","Astemizole was indicated for use in the relieving allergy symptoms, particularly rhinitis and conjunctivitis. It has been withdrawn from the market however due to concerns of arrhythmias."
C(OC(=O)N(C1=NC2=C(C(=C(C(=C2[H])[H])C(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])[H])N1[H])[H])([H])([H])[H],DB00643,31431-39-7,Mebendazole,"(5-benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester
MBDZ
Mebendazol
M��bendazole
Mebendazolum",small molecule,Helminthic Microorganisms,"Tablet, chewable
Tablet, chewable
Tablet","Oral
Oral
Oral","100 mg/1
500 mg/1
100 mg","For the treatment of <i>Enterobius vermicularis</i> (pinworm), <i>Trichuris trichiura</i> (whipworm), <i>Ascaris lumbricoides</i> (common roundworm), <i>Ancylostoma duodenale</i> (common hookworm), <i>Necator americanus</i> (American hookworm) in single or mixed infections."
C(C(C([H])([H])[H])(C(C(N(C(=O)C(N(C(=O)C(C(C1=C([H])C([H])=C(O[H])C([H])=C1[H])([H])[H])(N(C(=O)C(C(O[H])([H])[H])(N(C(=O)C(C(C1=C([H])N([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])(N(C(=O)C(C(C1=C([H])N=C([H])N1[H])([H])[H])(N(C(=O)C1(C([H])([H])C([H])([H])C(=O)N1[H])[H])[H])[H])[H])[H])[H])[H])[H])[H])[H])([H])[H])[H])(C(=O)N(C(C(C(C(N=C(N([H])[H])N([H])[H])([H])[H])([H])[H])([H])[H])(C(=O)N1C([H])([H])C([H])([H])C([H])([H])C1(C(=O)N(C(C(N([H])[H])=O)([H])[H])[H])[H])[H])[H])[H])([H])[H])[H])([H])([H])[H],DB00644,33515-09-2,Gonadorelin,"GnRH
GnRH-I
Gonadoliberin I
Gonadorelin
Gonadorelin decapeptide
Gonadorelina
Gonador��line
Gonadorelinum
Gonadotropin-releasing hormone",small molecule,Humans and other mammals,"Powder, for solution
Powder, for solution
Powder, for solution
Powder, for solution
Powder, for solution
Liquid; powder, for solution","Intravenous; Subcutaneous
Intravenous; Subcutaneous
Intravenous; Subcutaneous
Intravenous; Subcutaneous
Intravenous; Subcutaneous
Intravenous; Subcutaneous",".5 mg
100 mcg
500 mcg
3.2 mg
0.8 mg",For evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation.
C(C(C(C(OC1=C([H])C([H])=C(C(=O)C(C(N2C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00645,586-60-7,Dyclonine,"1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone
2-(1-Piperidyl)ethyl P-butoxyphenyl ketone
3-Piperidino-4'-butoxypropiophenone
4-Butoxy-beta-piperidinopropiophenone
4-N-Butoxy-beta-(1-piperidyl)propiophenone
4'-Butoxy-3-piperidinopropiophenone
Diclonina
Dyclocaine
Dyclonin
Dyclonine
Dycloninum",small molecule,Humans and other mammals,"Cream
Liquid
Liquid
Spray
Rinse
Lozenge
Lozenge
Lozenge
Lozenge
Lozenge
Lozenge
Aerosol
Lozenge
Gel","Topical
Topical
Oral
Oral
Dental; Oral; Topical; Transmucosal
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Topical","0.1 %
.1 g/100mL
3 mg/1
1.2 mg/1
1.2 mg
2 mg
3 mg
.1 %
2 mg/1","Used to provide topical anesthesia of accessible mucous membranes prior to examination, endoscopy or instrumentation, or other procedures involving the esophagus, larynx, mouth, pharynx or throat, respiratory tract or trachea, urinary tract, or vagina. Also used to suppress the gag reflex and/or other laryngeal and esophageal reflexes to facilitate dental examination or procedures (including oral surgery), endoscopy, or intubation. Also used for relief of canker sores, cold sores or fever blister."
ClC1=C([H])C(N2C([H])([H])C([H])([H])N(C(C(C(N3N=C4C(=C(C(=C([H])N4C3=O)[H])[H])[H])([H])[H])([H])[H])([H])[H])C([H])([H])C2([H])[H])=C([H])C([H])=C1[H],DB00656,19794-93-5,Trazodone,"2-(3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one
Trazodona
Trazodone
Trazodonum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet
Tablet
Kit
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","150 mg
50 mg
300 mg
150 mg/1
150 mg
300 mg
300 mg/1
100 mg
75 mg
100 mg/1
150 mg/1
300 mg/1
50 mg/1
100 mg/1
150 mg/1
50 mg/1
68.25 mg",For the treatment of depression.
C(N(C1(C([H])([H])[H])C2(C(C([H])([H])C(C2([H])[H])([H])C1(C([H])([H])[H])C([H])([H])[H])([H])[H])[H])[H])([H])([H])[H],DB00657,60-40-2,Mecamylamine,Versamine,small molecule,Humans and other mammals,Tablet,Oral,2.5 mg/1,For the treatment of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension
C(C(=O)N(C(C(C(S(O[H])(=O)=O)([H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB00659,77337-76-9,Acamprosate,"3-Acetamido-1-propanesulfonic acid
Acamprosato
Acamprosatum
N-acetyl homotaurine
N-Acetylhomotaurine",small molecule,Humans and other mammals,"Tablet, delayed release
Tablet, delayed release","Oral
Oral","333 mg/1
333 mg",For the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation
C(OC1=C([H])C(C(=O)N(C(C2=C([H])C([H])=C(OC(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])C([H])=C2[H])([H])[H])[H])=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])([H])([H])[H],DB00662,138-56-7,Trimethobenzamide,"N-[[4-(2-Dimethylaminoethoxy)phenyl]methyl]-3,4,5-trimethoxybenzamide
Trimethobenzamidum
Trimetobenzamida",small molecule,Humans and other mammals,"Injection
Injection, solution
Capsule","Intramuscular
Intramuscular
Oral","100 mg/mL
100 mg/mL
300 mg/1",For the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
C(OC1=NC([H])=C([H])N=C1N(S(=O)(=O)C1=C([H])C([H])=C(N([H])[H])C([H])=C1[H])[H])([H])([H])[H],DB00664,152-47-6,Sulfametopyrazine,"Kelfizina
Solfametopirazina
Sulfalene
Sulfaleno
Sulfalenum",small molecule,"Gram negative, positive bacteria and plasmodium",,,,For the treatment of urinary tract infection and chronic bronchitis.
C(C1(C([H])([H])[H])N([H])C(=O)N(C2=C([H])C(C(F)(F)F)=C([N+]([O-])=O)C([H])=C2[H])C1=O)([H])([H])[H],DB00665,63612-50-0,Nilutamide,"5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin
Nilutamida
Nilutamide
Nilutamidum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet","Oral
Oral
Oral","50 mg
100 mg
150 mg/1","For use in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs (Stage D2)."
C(N(S(=O)(=O)C(C1=C([H])C2=C(N(C(=C2C(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])[H])[H])C([H])=C1[H])([H])[H])[H])([H])([H])[H],DB00669,103628-46-2,Sumatriptan,"(3-[2-(dimethylamino)Ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide
1-[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide
3-(2-(dimethylamino)Ethyl)-N-methyl-1H-indole-5-methanesulfonamide
3-[2-(dimethylamino)Ethyl]-N-methylindole-5-methanesulfonamide
NP101
Sumatran
Sumatriptan
Sumatript��n
Sumatriptan Succinate
Sumatriptanum
Sumax
triptan",small molecule,Humans and other mammals,"Injection, solution
Spray
Spray
Liquid
Spray
Spray
Tablet, film coated
Tablet, film coated
Tablet
Tablet
Liquid
Kit
Kit
Tablet
Spray
Spray
Spray
Spray
Tablet
Solution
Injection
Injection, solution
Tablet
Tablet
Tablet, coated
Tablet, coated
Tablet, coated
Tablet, film coated
Tablet
Injection
Solution
Tablet, film coated
Patch, extended release, electrically controlled
Injection, solution","Subcutaneous
Nasal
Nasal
Subcutaneous
Nasal
Nasal
Oral
Oral
Oral
Oral
Subcutaneous
Nasal
Oral
Nasal
Nasal
Nasal
Nasal
Oral
Subcutaneous
Subcutaneous
Subcutaneous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Subcutaneous
Subcutaneous
Oral
Transdermal
Subcutaneous","6 mg/.5mL
20 mg
5 mg
6 mg
20 mg/1
5 mg/1
100 mg/1
50 mg/1
100 mg
50 mg
12 mg
25 mg
20 mg/100uL
20 mg/.1mL
5 mg/.1mL
5 mg/100uL
25 mg/1
12 mg
6 mg/.5mL
4 mg/.5mL
100 mg/1
50 mg/1
100 mg/1
25 mg/1
50 mg/1
25 mg/1
4 mg/.5mL
6 mg
6.5 mg/4h
3 mg/1",For the treatment of migraine attacks with or without aura.
C(N1C([H])([H])C([H])([H])N(C(C(=O)N2C3=C(C(=C(C(=C3[H])[H])[H])[H])C(=O)N([H])C3=C2N=C(C(=C3[H])[H])[H])([H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB00670,28797-61-7,Pirenzepine,"11-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one
Pirenzepin
Pirenzepina
Pirenz��pine
Pirenzepinum",small molecule,Humans and other mammals,Tablet,Oral,50 mg,"For the treatment of peptic ulcer, gastric ulcer, and duodenal ulcer."
C(C(C(N(C(=O)N(S(=O)(=O)C1=C([H])C([H])=C(Cl)C([H])=C1[H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB00672,94-20-2,Chlorpropamide,"1-(P-Chlorobenzenesulfonyl)-3-propylurea
1-(P-Chlorophenylsulfonyl)-3-propylurea
1-Propyl-3-(P-chlorobenzenesulfonyl)urea
4-chloro-N-((Propylamino)carbonyl)benzenesulfonamide
4-chloro-N-[(Propylamino)carbonyl]benzenesulfonamide
Chlorpropamid
Chlorpropamide
Chlorpropamidum
Clorpropamida
N-(4-Chlorophenylsulfonyl)-n'-propylurea
N-(P-Chlorobenzenesulfonyl)-n'-propylurea
N-Propyl-n'-(P-chlorobenzenesulfonyl)urea
N-Propyl-n'-P-chlorophenylsulfonylcarbamide",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral","100 mg
250 mg
100 mg/1
250 mg/1",For treatment of NIDDM in conjunction with diet and exercise. 
C(C(C(=C(C1=C([H])C([H])=C([H])C([H])=C1[H])C1=C([H])C([H])=C(OC(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB00675,10540-29-1,Tamoxifen,"(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Tamoxifen
Tamoxif��ne
Tamoxifene
Tamoxifeno
Tamoxifenum
trans-Tamoxifen",small molecule,Humans and other mammals,"Tablet
Tablet
Liquid
Liquid
Tablet
Tablet
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg
20 mg
10 mg/5mL
20 mg/10mL
10 mg/1
20 mg/1
10 mg/1
20 mg/1",Tamoxifen is indicated for the treatment of metastatic breast cancer in women and men and ductal carcinoma in Situ. 
O=C(OC(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H],"DB00676
DB02775",120-51-4,Benzyl Benzoate,"Acarobenzyl
Benylate
Benzevan
Benzoate de benzyle
Benzoes��urebenzylester
Benzoic acid phenylmethylester
Benzoic acid, benzyl ester
Benzoic acid, phenylmethyl ester
Benzyl benzoat
Benzylis benzoas
Phenylmethyl benzoate",small molecule,Sarcoptes scabiei,,,,Used to kill lice and the mites responsible for the skin condition scabies.
C(C(C([H])([H])[H])(OP(F)(=O)OC(C([H])([H])[H])(C([H])([H])[H])[H])[H])([H])([H])[H],DB00677,55-91-4,Isoflurophate,"DFP
Diisopropoxyphosphoryl Fluoride
Diisopropyl fluorophosphate
Diisopropyl Fluorophosphonate
Diisopropyl Phosphofluoridate
Diisopropyl Phosphorofluoridate
Diisopropylfluorophosphate
Diisopropylfluorophosphoric acid ester
Diisopropylphosphofluoridate
Diisopropylphosphorofluoridate
Fluorodiisopropyl Phosphate
Fluorostigmine
Isofluorphate
Isoflurophate
Isoflurophosphate
Isopropyl fluophosphate
Isopropyl Phosphorofluoridate
Neoglaucit
O,O'-diisopropyl phosphoryl fluoride",small molecule,Humans and other mammals,,,,"For use in the eye to treat certain types of glaucoma and other eye conditions, such as accommodative esotropia."
C(C(C(C(C1=NC(Cl)=C(C(O[H])([H])[H])N1C(C1=C([H])C([H])=C(C2=C(C3=NN([H])N=N3)C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00678,114798-26-4,Losartan,"(2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
2-N-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
DuP 89
Losartan",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","100.0 mg
25.0 mg
50.0 mg
100 mg
25 mg/1
25 mg
50 mg
100 mg/1
50 mg/1
100 mg/1
25 mg/1
50 mg/1","May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors."
C(C(OC(=O)N(C1=C([H])C2=C(SC3=C(N2C(=O)C(C(N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])([H])[H])([H])[H])C([H])=C([H])C([H])=C3[H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB00680,31883-05-3,Moricizine,"[10-(3-Morpholin-4-yl-propionyl)-10H-phenothiazin-2-yl]-carbamic acid ethyl ester
EN-313
Ethmozin
Ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate
Ethyl 10-(beta-N-morpholinylpropionyl)phenothiazine-2-carbamate
Etmozin
Moracizin
Moracizina
Moracizine
Moracizinum
Moricizine",small molecule,Humans and other mammals,,,,Used to treat irregular heartbeats (arrhythmias) and maintain a normal heart rate.
C(C1=NC([H])=C2C(N=C(C3=C(F)C([H])=C([H])C([H])=C3[H])C3=C(N12)C([H])=C([H])C(Cl)=C3[H])([H])[H])([H])([H])[H],DB00683,59467-70-8,Midazolam,"Buccolam
Dormicum
Midazolam
Midazolamum",small molecule,Humans and other mammals,"Liquid
Liquid
Solution
Solution
Solution
Solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection
Injection
Injection
Injection
Injection, solution
Injection, solution
Syrup
Syrup
Solution
Solution","Intramuscular; Intravenous
Intramuscular; Intravenous
Buccal
Buccal
Buccal
Buccal
Intramuscular; Intravenous
Intramuscular; Intravenous
Intravenous
Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Oral
Oral
Intramuscular; Intravenous
Intramuscular; Intravenous","1 mg
5 mg
10 mg
2.5 mg
5 mg
7.5 mg
10 mg/2mL
2 mg/2mL
.5 mg/mL
1 mg/mL
1 mg/mL
10 mg/2mL
2 mg/2mL
5 mg/mL
1 mg/mL
5 mg/mL
10 mg/5mL
2 mg/mL
1 mg
5 mg","The midazolam injection is indicated for preoperative sedation/anziolysis/amnesia. It is also an agent for sedation/anziolysis/amnesia prior to or during diagnostic, therapeutic, or endoscopic procedures. Midazolam can also be given intravenously for induction of general anaesthesia. "
C(OC1=C(C(C(=C(C([H])([H])[H])C(C(C(=O)OC(C(N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])C(O[H])=C2C(=O)OC([H])([H])C2=C1C([H])([H])[H])([H])([H])[H],DB00688,128794-94-5,Mycophenolate mofetil,"2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
MMF
Mycophenolic acid morpholinoethyl ester",small molecule,Humans and other mammals,"Capsule
Capsule
Injection, powder, for solution
Powder, for suspension
Powder, for suspension
Tablet
Powder, for solution
Injection, powder, lyophilized, for solution
Powder, for suspension
Tablet
Tablet, coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Intravenous
Oral
Oral
Oral
Intravenous
Intravenous
Oral
Oral
Oral
Oral
Oral","250 mg/1
250 mg
500 mg
1 g/5ml
200 mg
500 mg
500 mg
500 mg/20mL
200 mg/mL
500 mg/1
500 mg/1
500 mg/1
500 mg","For the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. Mycophenolate mofetil should be used concomitantly with cyclosporine and corticosteroids. "
C(C(N(C(C([H])([H])[H])([H])[H])C(C(N1C2=C(C(=C(Cl)C(=C2[H])[H])[H])C(C2=C(F)C([H])=C([H])C([H])=C2[H])=NC([H])([H])C1=O)([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00690,17617-23-1,Flurazepam,"Flurazepam
Fluraz��pam
Flurazepamum
Insumin",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral","30 mg/1
30 mg
15 mg
15 mg/1
15 mg
30 mg",For short-term and intermittent use in patients with recurring insomnia and poor sleeping habits
C(C1=C([H])C([H])=C(N(C(C2=NC([H])([H])C([H])([H])N2[H])([H])[H])C2=C([H])C([H])=C([H])C(O[H])=C2[H])C([H])=C1[H])([H])([H])[H],DB00692,50-60-2,Phentolamine,"2-(N-(m-Hydroxyphenyl)-P-toluidinomethyl)imidazoline
Fentolamina
Phentolamin
Phentolamine
Phentolamine mesylate
Phentolaminum
Regitina
Vesomax",small molecule,Humans and other mammals,"Injection, solution
Solution
Injection
Injection, powder, for solution
Solution
Solution
Powder, for solution","Submucosal
Submucosal
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous",".235 mg/mL
0.4 mg
5 mg/1
5 mg/mL
5 mg
10 mg
5 mg","Used as an aid for the diagnosis of pheochromocytoma, and may be administered immediately prior to or during pheochromocytomectomy to prevent or control paroxysmal hypertension resulting from anesthesia, stress, or operative manipulation of the tumor. Phentolamine has also been used to treat hypertensive crisis caused by sympathomimetic amines or catecholamine excess by certain foods or drugs in patients taking MAO inhibitors, or by clonidine withdrawal syndrome. Other indications include the prevention of dermal necrosis and sloughing following IV administration or extravasation of norepinephrine, decrease in impedance to left ventricular ejection and the infarct size in patients with MI associated with left ventricular failure, treatment of erectile dysfunction through self-injection of small doses combined with papaverine hydrochloride into the corpus cavernosum, and as an adjunct to the management of cocaine overdose to reverse coronary vasoconstriction following use of oxygen, benzodiazepines,and nitroglycerin. "
O(C1=C([H])C2=C(C3(OC(=O)C4=C3C(=C(C(=C4[H])[H])[H])[H])C3=C(O2)C([H])=C(O[H])C([H])=C3[H])C([H])=C1[H])[H],"DB00693
DB07777",2321-07-5,Fluorescein,"3,6-fluorandiol
3',6'-dihydroxyfluoran
9-(o-carboxyphenyl)-6-hydroxy-3-isoxanthenone
9-(o-carboxyphenyl)-6-hydroxy-3H-xanthen-3-one
C.I. Solvent Yellow 94
D and C Yellow No. 7
D&C Yellow No. 7
Fluoresceine
Fluoreszein
Japan Yellow 201
Resorcinolphthalein
Solvent Yellow 94
Yellow fluorescein",small molecule,Humans and other mammals,"Injection
Injection
Strip
Strip
Strip
Solution
Solution / drops
Injection, solution
Solution
Liquid
Strip
Liquid
Solution
Liquid
Strip
Strip
Solution
Solution / drops
Liquid
Solution","Intravenous
Intravenous
Ophthalmic
Topical
Ophthalmic
Intravenous
Ophthalmic
Ophthalmic
Intravenous
Parenteral
Ophthalmic
Ophthalmic
Ophthalmic
Intravenous
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic; Topical
Intravenous
Intravenous","100 mg/mL
250 mg/mL
1 mg/mg
1 mg
.12 mg/1
25 %
100 mg/mL
10 %
25 %
1 mg
25 %
.6 mg/1
1 mg/1
2 %
250 mg
100 mg",For diagnostic imaging. Primarily indicated in diagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculature.
N(S(=O)(=O)C1=C(Cl)C([H])=C(N(C(C2=C([H])C([H])=C([H])O2)([H])[H])[H])C(C(O[H])=O)=C1[H])([H])[H],"DB00695
DB07799",54-31-9,Furosemide,"2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid
4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid
4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid
Frusemide
Furosemid
Furosemida
Furosemide
Furosemidu
Furosemidum
Lasix (tn)",small molecule,Humans and other mammals,"Tablet
Tablet
Kit
Injection
Injection
Injection
Injection
Injection
Injection
Injection, solution
Injection, solution
Solution
Solution
Solution
Tablet
Tablet
Tablet
Liquid
Solution
Solution
Solution
Liquid
Solution
Tablet
Liquid
Solution
Liquid
Tablet
Liquid","Oral
Oral
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Intravenous
Intramuscular; Intravenous
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Intravenous
Intravenous
Intravenous
Oral
Oral
Oral
Intramuscular; Intravenous
Oral
Intravenous","20 mg
40 mg
10 mg/2mL
10 mg/mL
100 mg/10mL
20 mg/2mL
40 mg/4mL
10 mg/mL
10 mg/mL
10 mg/mL
10 mg/mL
40 mg/4mL
40 mg/5mL
20 mg/1
40 mg/1
80 mg/1
10 mg
10 mg
20 mg
250 mg
250 mg
10 mg
80 mg
10 mg
10 mg
20 mg
500 mg
10 mg","For the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Also for the treatment of hypertension alone or in combination with other antihypertensive agents."
ClC1=C(N(C2=NC([H])([H])C([H])([H])N2[H])[H])C2=NSN=C2C([H])=C1[H],DB00697,51322-75-9,Tizanidine,"5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole
Tizanidin
Tizanidina
Tizanidine
Tizanidinum",small molecule,Humans and other mammals,"Kit
Tablet
Tablet
Tablet
Tablet
Capsule, gelatin coated
Capsule, gelatin coated
Capsule, gelatin coated
Capsule
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","2 mg/1
2 mg
4 mg/1
4 mg
2 mg/1
4 mg/1
6 mg/1
2 mg/1
4 mg/1
6 mg/1",For the management of increased muscle tone associated with spasticity
[O-][N+](=O)C1=C([H])C([H])=C(C(=NN2C([H])([H])C(=O)N([H])C2=O)[H])O1,DB00698,67-20-9,Nitrofurantoin,"1-((5-nitro-2-furanyl)methylene)amino-2,4-imidazolidenedione
1-((5-nitrofurfurylidene)amino)hydantoin
5-Nitrofurantoin
N-(5-Nitrofurfurylidene)-1-aminohydantoin
Nitrofurantoin anhydrous
Nitrofurantoin macrocrystal
Nitrofurantoin macrocrystalline
Nitrofurantoin, macrocrystalline
Nitrofurantoin, macrocrystals
nitrofurantoina
nitrofurantoine
nitrofurantoinum
Nitrofurantoinum anhydrous",small molecule,Gram negative and gram positive bacteria,"Capsule
Capsule
Capsule
Capsule
Suspension
Tablet
Tablet
Capsule
Suspension
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","25 mg
100 mg/1
25 mg/1
50 mg/1
25 mg/5mL
100 mg
50 mg
5 mg
100 mg
50 mg",May be used as an alternative in the treatment of urinary tract infections. May be used by females pericoitally for prophylaxis against recurrent cystitis related to coitus. 
C(N1N=C(S(N([H])[H])(=O)=O)SC1=NC(C([H])([H])[H])=O)([H])([H])[H],DB00703,554-57-4,Methazolamide,"Metazolamida
Methazolamid
M��thazolamide
Methazolamidum
Methenamide
Neptazaneat",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral","50 mg
25 mg/1
50 mg/1
25 mg",For treatment of chronic open-angle glaucoma and acute angle-closure glaucoma
C(C(C([H])([H])[H])(N(C1=C([H])C([H])=C([H])N=C1N1C([H])([H])C([H])([H])N(C(=O)C2=C([H])C3=C(C(=C(C(N(S(C([H])([H])[H])(=O)=O)[H])=C3[H])[H])[H])N2[H])C([H])([H])C1([H])[H])[H])[H])([H])([H])[H],"DB00705
DB08563",136817-59-9,Delavirdine,"(N-[2-[4-[3-(1-Methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide)
1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine
2-(4-(5-Methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine
Delavirdin
Delavirdina
Delavirdine
Delavirdinum
N-(2-(1-(3-(Isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide
N-{2-[4-(3-isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide",small molecule,Human Immunodeficiency Virus,"Tablet
Tablet
Tablet","Oral
Oral
Oral","100 mg
100 mg/1
200 mg/1",For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted
C(C(C(=O)N(C1=C([H])C([H])=C([H])C([H])=C1[H])C1(C(OC([H])([H])[H])([H])[H])C([H])([H])C([H])([H])N(C(C(C2=C([H])C([H])=C([H])S2)([H])[H])([H])[H])C([H])([H])C1([H])[H])([H])[H])([H])([H])[H],"DB00708
DB05563",56030-54-7,Sufentanil,"N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide
N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide
Sufentanil
Sufentanilo
Sufentanilum
Sufentanyl",small molecule,Humans and other mammals,"Liquid
Liquid
Injection
Injection
Injection, solution
Solution
Tablet","Epidural; Intravenous
Intravenous
Epidural; Intravenous
Epidural; Intravenous
Epidural; Intravenous
Epidural; Intravenous
Sublingual","50 mcg
50 mcg
.05 mg/mL
50 ug/mL
50 ug/mL
50 mcg
15 ��g",Used as an analgesic adjunct in anesthesia and as a primary anesthetic drug in procedures requiring assisted ventilation and in the relief of pain.
C(C(C(C(C(N(C([H])([H])[H])C(C(C(O[H])(P(O[H])(O[H])=O)P(O[H])(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],"DB00710
DB04635",114084-78-5,Ibandronate,Ibandronic Acid,small molecule,Humans and other mammals,"Injection, solution
Tablet, film coated
Liquid
Tablet, film coated
Injection, solution, concentrate
Injection, solution, concentrate
Injection, solution, concentrate
Tablet, film coated
Injection
Injection, solution
Tablet","Intravenous
Oral
Intravenous
Oral
Intravenous
Intravenous
Intravenous
Oral
Intravenous
Intravenous
Oral","3 mg
150 mg
1 mg
150 mg/1
1 mg
2 mg
6 mg
50 mg
3 mg/3mL
3 mg/3mL
150 mg/1",For the treatment and prevention of osteoporosis in postmenopausal women.
C(C(N(C(C([H])([H])[H])([H])[H])C(=O)N1C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C1([H])[H])([H])[H])([H])([H])[H],DB00711,90-89-1,Diethylcarbamazine,"Camin
Carbamazine
Diethylcarbamazin
Di��thylcarbamazine
Diethylcarbamazinum
Dietilcarbamazina
N,N-Diethyl-4-methyl-1-piperazinecarboxamide",small molecule,"Humans and other mammals
Parasitic nematodes and other roundworms",Tablet,Oral,50 mg,"Used for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with <i>Wuchereria bancrofti</i>, <i>Brugia malayi</i>, or <i>Brugia timori</i>."
C(C(C(C1=C2N(C(C([H])([H])[H])([H])[H])C(=C(C(=O)C2=C([H])C2=C1OC(=C(C2=O)[H])C(O[H])=O)[H])C(O[H])=O)([H])[H])([H])[H])([H])([H])[H],DB00716,69049-73-6,Nedocromil,"9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)chinolin-2,8-dicarbonsaeure
9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid
Nedocromil
Nedocromilo
Nedocromilum",small molecule,Humans and other mammals,"Liquid
Solution / drops
Aerosol, metered
Aerosol, metered","Ophthalmic
Ophthalmic
Oral
Respiratory (inhalation)","2 %
20 mg/mL
2 mg
2 mg",For the treatment of mild to moderate asthma
C(C(C([H])([H])[H])(C([H])([H])[H])C(=O)OC(OP(=O)(C(OC(C(N1C([H])=NC2=C(N([H])[H])N=C(N=C12)[H])([H])[H])([H])[H])([H])[H])OC(OC(=O)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00718,142340-99-6,Adefovir Dipivoxil,"Adefovir di(pivaloyloxymethyl) ester
Adefovir Pivoxil
bis-POM PMEA",small molecule,Hepatitis B virus,"Tablet
Tablet","Oral
Oral","10 mg/1
10 mg",For the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
C(N1C([H])([H])C([H])([H])C(=C2C3=C(C(=C(C(=C3[H])[H])[H])[H])C([H])([H])C([H])([H])C3=C(C(=C(N=C23)[H])[H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB00719,3964-81-6,Azatadine,"11-(1-Methyl-4-piperidinylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
6,11-Dihydro-11-(1-methyl-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
Azatadin
Azatadina
Azatadine
Azatadinum",small molecule,Humans and other mammals,"Tablet
Tablet, extended release","Oral
Oral",1 mg,"For the relief of the symptoms of upper respiratory mucosal congestion in perennial and allergic rhinitis, and for the relief of nasal congestion and eustachian t.b. congestion."
O(P(O[H])(=O)C(Cl)(Cl)P(O[H])(O[H])=O)[H],DB00720,10596-23-3,Clodronic Acid,"(Dichloro-phosphono-methyl)-phosphonic acid
(Dichloromethylene)bisphosphonic acid
(Dichloromethylene)diphosphonic acid
Acide Clodronique
Acido Clodronico
Acidum Clodronicum
Clodronate
Clodronsaeure
Clodrons��ure
Dichloromethanediphosphonic acid
Dichloromethylene-1,1-bisphosphonic acid
Dichloromethylene-1,1-diphosphonic acid
Dichloromethylidene diphosphonate",small molecule,Humans and other mammals,"Capsule
Solution","Oral
Intravenous","400 mg
60 mg",For the management of hypercalcemia of malignancy and as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors.
C(C(N(C(C([H])([H])[H])([H])[H])C(C(OC(=O)C1=C([H])C([H])=C(N([H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],"DB00721
DB05342",59-46-1,Procaine,"2-Diethylaminoethyl p-aminobenzoate
4-aminobenzoic acid 2-diethylaminoethyl ester
Novocaine
p-Aminobenzoic acid 2-diethylaminoethyl ester
Procaina
Procainum
Vitamin H3
��-(diethylamino)ethyl 4-aminobenzoate
��-(diethylamino)ethyl p-aminobenzoate",small molecule,Humans and other mammals,"Solution
Liquid","Infiltration
Infiltration","2 %
2 %",Used as a local anesthetic primarily in oral surgery
C(OC1=C([H])C(C(O[H])(C(C([H])([H])[H])(N([H])[H])[H])[H])=C(OC([H])([H])[H])C([H])=C1[H])([H])([H])[H],DB00723,390-28-3,Methoxamine,"M��thoxam��drine
Methoxamin
M��thoxamine
Methoxaminum
Metossamina
Metoxamina
Pseudomethoxamine",small molecule,Humans and other mammals,Liquid,Intramuscular; Intravenous,20 mg,Indicated for the treatment and management of hypotension.
C(C(C([H])([H])[H])(C(N1C([H])=NC2=C1C1=C([H])C([H])=C([H])C([H])=C1N=C2N([H])[H])([H])[H])[H])([H])([H])[H],DB00724,99011-02-6,Imiquimod,"1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
Imiquimod
Imiquimodum
R 837
Zartra",small molecule,Humans and other mammals,"Cream
Cream
Cream
Cream
Cream
Cream
Cream
Cream
Cream","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","5 %
12.5 mg/.25g
50 mg/1000mg
50 mg/g
50 mg
3.75 %
2.5 %
2.5 mg/g
37.5 mg/g","For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above."
C([N+]1(C([H])([H])[H])C2(C(C([H])([H])C1(C(C(C2([H])[H])(OC(=O)C(O[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H])([H])[H])[H])([H])[H])[H])([H])([H])[H],DB00725,80-49-9,Homatropine Methylbromide,"3-alpha-Hydroxy-8-methyl-1-alpha-H,5-alpha-H-tropanium bromide mandelate
8-Methylhomatropinium bromide
Homatropine methylbromide
Homatropini methylbromidum
Methylbromure d'homatropine
Methylhomatropine
Methylhomatropine bromide
Methylhomatropinum bromatum
Metilbromuro de homatropina
Omatropina metilbromuro
Tropinium methobromide mandelate",small molecule,Humans and other mammals,"Liquid
Solution
Syrup
Tablet","Oral
Oral
Oral
Oral",,"Used in conjunction with antacids or histamine H2-receptor antagonists in the treatment of peptic ulcers, gastric ulcers and duodenal ulcers, to reduce further gastric acid secretion and delay gastric emptying."
[O-][N+](=O)OC(C(C(O[N+]([O-])=O)([H])[H])(O[N+]([O-])=O)[H])([H])[H],DB00727,55-63-0,Nitroglycerin,"1,2,3-Propanetrioltrinitrate
1,2,3-Propanetriyl nitrate
Glycerin trinitrate
Glycerol trinitrate
Glycerol, nitric acid triester
Glyceroli trinitratis 
Glyceroltrinitrat
Glyceryl trinitrate
Natispray
NG
Nitroglicerina
Nitroglycerin
Nitroglycerine
Nitroglycerol
Nitromed
Propane-1,2,3-triyl trinitrate
Rectogesic
Trinitrine
Trinitroglycerin
Trinitroglycerol",small molecule,Humans and other mammals,"Powder
Patch
Patch
Patch
Patch
Patch
Patch
Patch
Patch
Patch
Patch
Patch
Aerosol, metered
Ointment
Patch
Patch
Patch
Patch
Patch
Patch
Patch, extended release
Patch, extended release
Patch, extended release
Patch, extended release
Capsule
Tablet, extended release
Film, extended release
Film, extended release
Injection, solution
Tablet
Tablet
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Capsule
Capsule
Solution
Injection
Injection
Injection
Injection, solution
Injection, solution
Injection, solution
Liquid
Spray, metered
Patch
Patch
Patch
Patch
Patch, extended release
Patch, extended release
Patch, extended release
Patch, extended release
Solution
Solution
Ointment
Spray
Spray, metered
Spray, metered
Aerosol, metered
Tablet, extended release
Tablet
Tablet
Tablet
Tablet
Tablet
Ointment
Patch, extended release
Patch, extended release
Patch","Sublingual
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Sublingual
Topical
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Oral
Buccal
Transdermal
Transdermal
Intravenous
Sublingual
Sublingual
Sublingual
Sublingual
Sublingual
Oral
Oral
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Sublingual
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Intravenous
Intravenous
Topical
Oral
Oral
Sublingual
Sublingual
Oral
Oral
Oral
Sublingual
Sublingual
Sublingual
Rectal
Transdermal
Transdermal
Transdermal","400 ug/1
0.4 mg
0.6 mg
10 mg/d
15 mg/d
18 mg/1
2.5 mg/d
36 mg/1
5 mg/d
54 mg/1
9 mg/1
72 mg
0.4 mg
20 mg/g
120 mg/1
160 mg/1
20 mg/1
40 mg/1
60 mg/1
80 mg/1
0.2 mg
60 mg
0.6 mg
0.8 mg
9 mg/1
1 mg
20.8 mg/1
37.4 mg/1
5 mg/mL
.3 mg/1
.6 mg/1
.3 mg/1
.4 mg/1
.6 mg/1
2.5 mg/1
6.5 mg/1
10 mg/100mL
20 mg/100mL
40 mg/100mL
100 ug/mL
200 ug/mL
400 ug/mL
5 mg
400 ug/1
.1 mg/h
.2 mg/h
.4 mg/h
.6 mg/h
.1 mg/h
.2 mg/h
.4 mg/h
.6 mg/h
10 mg
50 mg
2 %
400 ug/1
400 ug/1
0.4 mg
400 ug/1
2.6 mg
.3 mg/1
.4 mg/1
.4 mg/1
0.3 mg
0.6 mg
4 mg/g
0.4 mg
100 mg
0.2 mg",For the prevention of angina
C([N+]1(C([H])([H])[H])C([H])([H])C([H])([H])C(=C(C2=C([H])C([H])=C([H])C([H])=C2[H])C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])([H])C1([H])[H])([H])([H])[H],DB00729,62-97-5,Diphemanil Methylsulfate,"4-(Diphenylmethylene)-1,1-dimethylpiperidinium methyl sulfate
Diphemanil methosulfate
Diphemanil methylsulfat
Diphemanil metilsulfate
Diphemanili metilsulfas 
M��tilsulfate de Diph��manil
Metilsulfato de difemanilo
N,N-Dimethyl-4-piperidylidene-1,1-diphenylmethane methylsulfate
P-(alpha-Phenylbenzylidene)-1,1-dimethylpiperidinium methyl sulfate
Vagophemanil",small molecule,Humans and other mammals,,,,"Used in the treatment of peptic ulcer, gastric hyperacidity, and hypermotility in gastritis and pylorospasm, and in the treatment of hyperhidrosis (excessive perspiration)."
N1(C2=C(C(=C(C(=C2[H])[H])[H])[H])N=C1C1=C([H])SC([H])=N1)[H],"DB00730
DB08630",148-79-8,Thiabendazole,"2-(1,3-THIAZOL-4-yl)-1H-benzimidazole
4-(2-Benzimidazolyl)thiazole
Equizole
TBDZ
Thiabendazole
Thibenzole
Tiabendazole",small molecule,"Roundworms, hookworms, and other helminth species",Tablet,Oral,500 mg,"For the treatment of strongyloidiasis (threadworm), cutaneous larva migrans (creeping eruption), visceral larva migrans, and trichinosis."
C(OC1=C([H])C2=C(C(C(C3=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C3[H])([H])[H])([N+](C([H])([H])[H])(C(C(C(=O)OC(C(C(C(C(OC(=O)C(C([N+]3(C([H])([H])[H])C([H])([H])C([H])([H])C4=C(C(=C(OC([H])([H])[H])C(OC([H])([H])[H])=C4[H])[H])C3(C(C3=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C3[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C(C2([H])[H])([H])[H])[H])C([H])=C1OC([H])([H])[H])([H])([H])[H],DB00732,64228-81-5,Atracurium besylate,"1-[(3,4-Dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium
Atracurium besilate
Atracurium dibesylate",small molecule,Humans and other mammals,"Injection, solution
Injection, solution
Injection, solution
Solution
Liquid","Intravenous
Intravenous
Intravenous
Intravenous
Intravenous","10 mg/mL
100 mg/10mL
50 mg/5mL
10 mg
10 mg","For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation."
C([N+]1=C(C(=NO[H])[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB00733,6735-59-7,Pralidoxime,"2-PAM
Pralidoxim
Pralidoxima
Pralidoxime
Pralidoximum",small molecule,Humans and other mammals,"Kit
Injection
Injection, powder, lyophilized, for solution
Powder, for solution","Intramuscular
Intramuscular
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous","600 mg/2mL
1 g/20mL
1 g",For the treatment of poisoning due to those pesticides and chemicals of the organophosphate class which have anticholinesterase activity and in the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis.
C(N(C(C(=C(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H])([H])[H])C(C1=C([H])C([H])=C([H])C2=C(C(=C(C([H])=C12)[H])[H])[H])([H])[H])([H])([H])[H],DB00735,65472-88-0,Naftifine,"Naftifin
Naftifina
Naftifine
Naftifinum",small molecule,Yeast and other fungi,"Cream
Cream
Cream
Cream
Gel
Gel
Cream
Gel","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","1 mg/g
20 mg/g
10 mg/2g
10 mg/g
10 mg/g
2 g/100g
1 %
1 %","For the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms <i>Trichophyton rubrum</i>, <i>Trichophyton mentagrophytes</i>, <i>Trichophyton tonsurans</i> and <i>Epidermophyton floccosum</i>."
N(C(=N[H])C1=C([H])C([H])=C(OC(C(C(C(C(OC2=C([H])C([H])=C(C(N([H])[H])=N[H])C([H])=C2[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H],DB00738,100-33-4,Pentamidine,"1,5-Bis(4-amidinophenoxy)pentane
4,4'-(1,5-Pentanediylbis(oxy))bis-benzenecarboximidamide
4,4'-(Pentamethylenedioxy)dibenzamidine
4,4'-Diamidinodiphenoxypentane
P,P'-(pentamethylenedioxy)dibenzamidine
Pentamidin
Pentamidina
Pentamidindiisetionat
Pentamidine
Pentamidinum",small molecule,Pneumocystis carinii,"Inhalant
Powder, for solution
Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Powder, for solution","Respiratory (inhalation)
Intramuscular; Intravenous; Respiratory (inhalation)
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous","300 mg/6mL
300 mg
300 mg/3mL
300 mg/300mg
300 mg",For the treatment of pneumonia due to <i>Pneumocystis carinii</i>.
N(C1=NC2=C(C(=C(OC(F)(F)F)C(=C2[H])[H])[H])S1)([H])[H],DB00740,1744-22-5,Riluzole,"Riluzol
Riluzole
Riluzolum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral","50 mg
50 mg/1
50 mg
50 mg/1","For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)"
C(C(=O)N(O[H])C(C(C(C(C(N(C(=O)C(C(C(=O)N(O[H])C(C(C(C(C(N(C(=O)C(C(C(=O)N(O[H])C(C(C(C(C(N([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00746,70-51-9,Deferoxamine,"Deferoxamin
Deferoxamina
D��feroxamine
Deferoxaminum
Deferrioxamine
Deferrioxamine b
Desferrioxamine
DFO
DFOA
DFOM",small molecule,Humans and other mammals,"Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Powder, for solution
Injection, powder, lyophilized, for solution
Powder, for solution","Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intraperitoneal; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intraperitoneal; Intravenous; Subcutaneous","95 mg/mL
2 g/1
500 mg/1
2 g
2 g/1
500 mg",Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.
N(C1(C([H])([H])C1(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H])([H])[H],DB00752,155-09-9,Tranylcypromine,"(��)-trans-2-phenylcyclopropylamine
(1R*,2S*)-2-phenylcyclopropan-1-amine
DL-tranylcypromine
Racemic Tranylcypromine
Tranilcipromina
trans-2-phenylcyclopropylamine
trans-DL-2-Phenylcyclopropylamine
Transamine
Tranylcypromin
Tranylcypromine
Tranylcyprominum",small molecule,Humans and other mammals,"Tablet
Tablet, film coated
Tablet","Oral
Oral
Oral","10 mg
10 mg/1
10 mg/1",For the treatment of major depressive episode without melancholia.
O(C1=C(C(C2=C(Cl)C(Cl)=C([H])C(Cl)=C2O[H])([H])[H])C(Cl)=C(Cl)C([H])=C1Cl)[H],DB00756,70-30-4,Hexachlorophene,"2,2'-dihydroxy-3,3',5,5',6,6'-hexachlorodiphenylmethane
2,2'-dihydroxy-3,5,6,3',5',6'-hexachlorodiphenylmethane
2,2'-methanediylbis(3,4,6-trichlorophenol)
2,2'-methylenebis(3,4,6-trichlorophenol)
2,2',3,3',5,5'-hexachloro-6,6'-dihydroxydiphenylmethane
bis(2-hydroxy-3,5,6-trichlorophenyl)methane
bis(3,5,6-trichloro-2-hydroxyphenyl)methane
hexachloroph��ne
Hexachlorophenum
Hexaclorofeno",small molecule,Enteric bacteria and other eubacteria,"Emulsion
Emulsion
Liquid","Topical
Topical
Topical","3 %
30 mg/mL
2 %",For use as a surgical scrub and a bacteriostatic skin cleanser. It may also be used to control an outbreak of gram-positive infection where other infection control procedures have been unsuccessful.
C(N1C([H])=C([H])N([H])C1=S)([H])([H])[H],DB00763,60-56-0,Methimazole,"1-METHYL-1,3-dihydro-2H-imidazole-2-thione
1-Methylimidazole-2(3H)-thione
Danantizol
Favistan
Mercazolyl
Methimazole
Strumazol
Thacapzol
Thiamazol
Thiamazole
Thiamazolum
Tiamazol
USAF el-30",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral","10 mg/1
5 mg/1
10 mg
20 mg
5 mg","For the treatment of hyperthyroidism, goiter, Graves disease and psoriasis."
C(C(N(C(C([H])([H])[H])([H])[H])C(=O)C1(C([H])([H])N2C(C(C3=C(C2([H])C([H])([H])C1(OC(C([H])([H])[H])=O)[H])C([H])=C(OC([H])([H])[H])C(OC([H])([H])[H])=C3[H])([H])[H])([H])[H])[H])([H])[H])([H])([H])[H],DB00767,63-12-7,Benzquinamide,BZQ,small molecule,Humans and other mammals,,,,"Used to prevent and treat nausea and vomiting associated with anesthesia and surgery, administered intramuscularly or intravenously."
C(N(C([H])([H])[H])C(C(C(=C1C2=C(C(=C(C(=C2[H])[H])[H])[H])C([H])([H])OC2=C1C(=C(C(C(O[H])=O)([H])[H])C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB00768,113806-05-6,Olopatadine,"Olopatadin
Olopatadina
Olopatadine
Olopatadinum
Opatanol",small molecule,Humans and other mammals,"Solution
Solution
Solution
Solution / drops
Solution / drops
Spray, metered
Spray
Solution / drops
Spray, metered
Spray, metered
Liquid
Solution
Solution","Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Nasal
Nasal
Ophthalmic
Nasal
Nasal
Ophthalmic
Ophthalmic
Ophthalmic","0.1 %
0.2 %
2 mg/mL
1 mg/mL
1.11 mg/mL
665 ug/100uL
665 ug/1
2 mg/mL
600 ug/1
665 ug/1
0.1 %
0.7 %
7 mg/mL",For the treatment of ocular itching associated with allergic conjunctivitis.
N(S(=O)(=O)C1=C([H])C2=C(N(C(N(S2(=O)=O)[H])([H])[H])[H])C([H])=C1C(F)(F)F)([H])[H],DB00774,135-09-1,Hydroflumethiazide,"Dihydroflumethazide
Hidroflumetiazid
Hidroflumetiazida
Hydroflum��thiazide
Hydroflumethiazide
Hydroflumethiazidum
Idroflumetiazide
Metforylthiadiazin",small molecule,Humans and other mammals,,,,"Used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Also used in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension."
N(C(=O)N1C2=C(C(=C(C(=C2[H])[H])[H])[H])C([H])([H])C(=O)C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H],DB00776,28721-07-5,Oxcarbazepine,"10,11-Dihydro-10-oxo-5H-dibenz(b,F)azepine-5-carboxamide
OCBZ
Oxcarbamazepine
Oxcarbazepina
Oxcarbazepine
Oxcarbazepinum",small molecule,Humans and other mammals,"Suspension
Suspension
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet
Tablet
Tablet
Suspension","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","300 mg/5mL
60 mg/mL
150 mg/1
300 mg/1
600 mg/1
150 mg/1
300 mg/1
600 mg/1
150 mg
300 mg
600 mg
60 mg",For use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults with epilepsy and as adjunctive therapy in the treatment of partial seizures in children ages 4-16 with epilepsy.
C(C(N1C([H])=C(C(O[H])=O)C(=O)C2=C1N=C(C([H])([H])[H])C(=C2[H])[H])([H])[H])([H])([H])[H],DB00779,389-08-2,Nalidixic Acid,"1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure
1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid
1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid
1,4-dihydro-1-Ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one
Acide nalidixique
Acido nalidixico
Acidum Nalidixicum
Nalidixic acid
Nalidixins��ure",small molecule,Enteric bacteria and other eubacteria,Tablet,Oral,500 mg,"For the treatment of urinary tract infections caused by susceptible gram-negative microorganisms, including the majority of <i>E. Coli</i>, <i>Enterobacter</i> species, <i>Klebsiella</i> species, and <i>Proteus</i> species."
N(N(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])[H])([H])[H],DB00780,51-71-8,Phenelzine,"Fenelzina
Phenelzin
Ph��nelzine
Phenelzinum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, film coated","Oral
Oral
Oral","15 mg
15 mg/1
15 mg/1","Phenelzine is indicated for the treatment of nonendogenous, neurotic or atypical depression for patients that do not tolerate other forms of therapy.[L1356] 
Atypical depression has a high prevalence rate, starts in early life, tends to last longer, is more likely to occur in people with bipolar disorder, has a high comorbidity with anxiety disorder and carries more risk of suicidal behavior. It is important to specify the atypical feature to predict the clinical course of depression and hence generate the best treatment and service. The featuring symptoms of the atypical feature include mood reactivity, two or more of this symptoms: 1) increased appetite, 2) increased sleep, 3) leaden paralysis and 4) interpersonal rejection sensitivity and should not have melancholic or catatonic features of depression.[A31917]
Neurotic depression is a depression of an emotionally unstable person. It is a secondary condition to major personality disorder, neuroses and drug use disorders. Likewise, a primary depression with a family history of depression spectrum disease would fit in this category.[A31922]
A nonendogenous depression is characterized by a disturbance in mood and general outlook. The physical symptoms tend to be less severe and it often occurs in response to stressful life events that keep occurring over a large period of time generating a continuous stress in the daily living.[A31924]"
C(C(C(C([H])([H])[H])(C(C(C(C(C(=O)N(C(C(C(N([H])[H])([H])[H])([H])[H])(C(=O)N(C(C(C([H])([H])[H])(O[H])[H])(C(=O)N(C(C(C(N([H])[H])([H])[H])([H])[H])(C(=O)N(C1(C([H])([H])C([H])([H])N([H])C(=O)C(C(C([H])([H])[H])(O[H])[H])([H])N([H])C(=O)C(C(C(N([H])[H])([H])[H])([H])[H])([H])N([H])C(=O)C(C(C(N([H])[H])([H])[H])([H])[H])([H])N([H])C(=O)C(C(C(C([H])([H])[H])(C([H])([H])[H])[H])([H])[H])([H])N([H])C(=O)C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])N([H])C(=O)C(C(C(N([H])[H])([H])[H])([H])[H])([H])N([H])C1=O)[H])[H])[H])[H])[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])([H])[H],DB00781,1405-20-5,Polymyxin B Sulfate,"Polimixina B
Polymyxin B
Polymyxin B Sulphate
Polymyxin-B-Sulfat
Polymyxine B
Polymyxine B (sulfate de)
Polymyxini B sulfas
Polymyxinum B",small molecule,Enteric bacteria and other eubacteria,"Kit
Powder, for solution
Kit
Ointment; swab
Solution
Suspension
Kit
Swab
Ointment
Lozenge
Stick
Liquid
Cream
Solution
Ointment
Suspension
Solution / drops
Suspension
Suspension / drops
Suspension / drops
Solution
Irrigant
Solution
Gel
Liquid
Liquid
Injection
Injection, powder, for solution
Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Injection, solution
Powder, for solution
Solution / drops
Powder
Solution / drops
Ointment
Lozenge
Solution","Intramuscular; Intrathecal; Intravenous; Respiratory (inhalation); Topical
Topical
Auricular (otic)
Topical
Topical
Topical
Topical
Buccal
Topical
Auricular (otic)
Topical
Irrigation
Ophthalmic
Ophthalmic
Auricular (otic)
Auricular (otic)
Auricular (otic)
Ophthalmic
Auricular (otic); Ophthalmic
Irrigation
Urethral
Topical
Ophthalmic
Auricular (otic); Ophthalmic
Intramuscular; Intrathecal; Intravenous
Intramuscular; Intrathecal; Intravenous; Ophthalmic
Intramuscular; Intrathecal; Intravenous; Ophthalmic
Intramuscular; Intrathecal; Intravenous; Ophthalmic
Intramuscular; Intrathecal; Intravenous; Ophthalmic
Intramuscular; Intravenous
Intramuscular; Intrathecal; Intravenous; Ophthalmic
Intramuscular; Intrathecal; Intravenous; Ophthalmic
Ophthalmic
Topical
Auricular (otic); Ophthalmic
Ophthalmic; Topical
Oral
Ophthalmic","500000 unit
500000 1/1
500000 [iU]/1
500000 [USP'U]/1
500000 1/1
500000 [iU]/1
500000 [USP'U]/1
500000 1/1
50 mg","For treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of <i>Pseudomonas aeruginosa</i>."
C(C(C([H])([H])[H])([N+](C([H])([H])[H])(C(C(OC(=O)C1(C2=C(C(=C(C(=C2[H])[H])[H])[H])OC2=C1C(=C(C(=C2[H])[H])[H])[H])[H])([H])[H])([H])[H])C(C([H])([H])[H])(C([H])([H])[H])[H])[H])([H])([H])[H],DB00782,298-50-0,Propantheline,"Propantelina bromuro
Propantelina, bromuro de
Propanthelin bromid
Propantheline
Propanth��line, bromure de
Propanthelini Bromidum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, film coated","Oral
Oral
Oral","15 mg
7.5 mg
15 mg/1","For the treatment of enuresis. It has also been used for hyperhidrosis, and cramps or spasms of the stomach, intestines or bladder."
C(C1=C([H])C([H])=C([H])C(N(C2=C(C(O[H])=O)C([H])=C([H])C([H])=C2[H])[H])=C1C([H])([H])[H])([H])([H])[H],DB00784,61-68-7,Mefenamic acid,"Acide m��f��namique
Acido mefenamico
Acidum mefenamicum
CN 35355
INF 3355
Mefenaminsaeure
Mefenamins��ure
N-(2,3-Xylyl)-2-aminobenzoic acid
N-2,3-Xylylanthranilic acid",small molecule,Humans and other mammals,"Capsule
Capsule","Oral
Oral","250 mg
250 mg/1","For the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever."
N(C1=NC(=O)C2=C(N(C(OC(C(O[H])([H])[H])([H])[H])([H])[H])C(=N2)[H])N1[H])([H])[H],"DB00787
DB05347",59277-89-3,Aciclovir,"Aciclovirum
Acycloguanosine
Acyclovir",small molecule,Human Herpes Virus,"Capsule
Capsule
Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Injection, solution
Ointment
Tablet
Tablet
Injection, solution
Injection, solution
Powder, for solution
Solution
Solution
Tablet
Tablet
Tablet
Tablet
Tablet, delayed release
Cream
Cream
Cream
Ointment
Powder, for solution
Suspension
Suspension
Tablet
Capsule","Oral
Oral
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Topical
Oral
Oral
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Oral
Oral
Oral
Buccal
Buccal
Topical
Topical
Topical
Topical
Intravenous
Oral
Oral
Oral
Oral","200 mg/1
400 mg/1
1 g/1
1000 mg/1
50 mg/mL
500 mg/1
50 mg/mL
50 mg/g
200 mg/1
400 mg/1
1000 mg/20mL
500 mg/10mL
500 mg
25 mg
50 mg
800 mg
200 mg
400 mg
50 mg
50 mg/1
5 %
50 mg/g
5 %
1 g
200 mg/5mL
200 mg
800 mg/1
200 mg","For the treatment and management of herpes zoster (shingles), genital herpes, and chickenpox. "
ClC(C(N(C(C(Cl)([H])[H])([H])[H])C1=C([H])N([H])C(=O)N([H])C1=O)([H])[H])([H])[H],DB00791,66-75-1,Uracil mustard,"5-(Di-2-chloroethyl)aminouracil
5-[Bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione
5-[Di(beta-chloroethyl)amino]uracil
5-Aminouracil mustard
5-N,N-Bis(2-chloroethyl)aminouracil
Aminouracil mustard
Uracil mustard
Uracil nitrogen mustard
Uramustine",small molecule,Humans and other mammals,,,,Used for its antineoplastic properties.
C(N(C([H])([H])[H])C(C(N(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])C1=NC([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB00792,91-81-6,Tripelennamine,"Tripelennamin
Tripelennamina
Trip��lennamine 
Tripelennaminum",small molecule,Humans and other mammals,"Cream
Tablet
Cream
Cream","Topical
Oral
Topical
Vaginal","1.00 %
50 mg
2 %
2 %","Used for the symptomatic relief of hypersensitivity reactions, coughs, and the common cold."
ClC1=C([H])C(Cl)=C(OC(C#CI)([H])[H])C([H])=C1Cl,DB00793,777-11-7,Haloprogin,"Haloprogin
Haloprogina
Haloprogine
Haloproginum",small molecule,"Dermatophytic fungi including Trichophyton, Microsporum and Epidermophyton",,,,"Used to treat fungal (Tinea) skin infections such as athlete's foot, jock itch, ringworm, and tinea versicolor."
C(C(C1(C(=O)N([H])C([H])([H])N([H])C1=O)C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB00794,125-33-7,Primidone,"5-Phenyl-5-ethyl-hexahydropyrimidine-4,6-dione
Desoxyphenobarbital
Primaclone
Primidon
Primidona
Primidone
Primidonum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral","125 mg
250 mg/1
250 mg
50 mg/1",For the treatment of epilepsy
O(C(=O)C1=C(O[H])C([H])=C([H])C(N=NC2=C([H])C([H])=C(S(=O)(=O)N(C3=NC([H])=C([H])C([H])=C3[H])[H])C([H])=C2[H])=C1[H])[H],"DB00795
DB08518",599-79-1,Sulfasalazine,"2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid
2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid
4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene
5-((P-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid
5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid
5-(P-(2-Pyridylsulfamyl)phenylazo)salicylic acid
Azopyrin
Salazosulfapiridina
Salazosulfapyridine
Salazosulfapyridinum
Salicylazosulfapyridine
Sulfasalazin
Sulfasalazina 
Sulfasalazine
Sulfasalazinum",small molecule,Humans and other mammals,"Tablet, delayed release
Suspension
Enema
Tablet
Tablet
Tablet, delayed release","Oral
Rectal
Rectal
Oral
Oral
Oral","500 mg
3 g
3 g
500 mg
500 mg/1
500 mg/1",For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
C(C1=NC([H])([H])C([H])([H])N1[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H],DB00797,59-98-3,Tolazoline,"2-Benzyl-2-imidazoline
2-Benzyl-4,5-imidazoline
2-Benzylimidazoline
4,5-Dihydro-2-(phenylmethyl)-1H-imidazole
Benzazolin
Tolazolin
Tolazolina
Tolazoline
Tolazolinum",small molecule,Humans and other mammals,,,,For the treatment of pulmonary artery anomalies
C(N(C(C([H])([H])[H])(C1(C([H])([H])C([H])([H])C(N([H])[H])([H])C(OC2(C(N([H])[H])([H])C([H])([H])C(N([H])[H])([H])C(OC3(OC([H])([H])C(C([H])([H])[H])(O[H])C(N(C([H])([H])[H])[H])([H])C3(O[H])[H])[H])([H])C2(O[H])[H])[H])([H])O1)[H])[H])[H])([H])([H])[H],DB00798,1403-66-3,Gentamicin,,small molecule,"Enteric bacteria and other eubacteria
Pseudomonas aeruginosa
Yersinia pestis
Francisella tularensis
Serratia marcescens
Proteus vulgaris","Liquid
Liquid
Ointment
Liquid
Ointment
Cream
Solution
Ointment
Ointment
Solution / drops
Solution
Ointment
Solution / drops
Solution / drops
Solution / drops
Injection, solution
Injection, solution
Solution
Solution
Solution
Solution
Cream
Injection, solution, concentrate
Ointment
Solution / drops
Solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Solution
Solution
Solution
Ointment
Solution / drops
Liquid
Ointment
Ointment
Solution
Cream
Suspension / drops
Liquid
Cream
Ointment
Solution
Implant
Cream","Intramuscular; Intravenous
Intramuscular; Intravenous
Topical
Auricular (otic); Ophthalmic
Ophthalmic
Topical
Ophthalmic
Topical
Ophthalmic
Auricular (otic)
Auricular (otic); Ophthalmic
Ophthalmic
Ophthalmic
Auricular (otic)
Ophthalmic
Intramuscular; Intravenous
Intramuscular; Intravenous
Ophthalmic
Ophthalmic
Intramuscular; Intravenous
Intramuscular; Intravenous
Topical
Intravenous
Topical
Ophthalmic
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Ophthalmic
Ophthalmic; Topical
Ophthalmic; Topical
Ophthalmic; Topical
Ophthalmic
Ophthalmic
Topical
Ophthalmic
Ophthalmic
Topical
Topical
Auricular (otic)
Parenteral
Topical","40 mg
10 mg
3 mg/g
.1 %
3 mg/mL
1 mg
0.3 %
3 mg
5 mg
5 mg
3 mg
10 mg/mL
40 mg/mL
.3 %
0.3 %
10 mg
40 mg
1 mg/g
10 mg/mL
1 mg/g
3 mg/mL
.8 mg/mL
.9 mg/mL
1 mg/mL
1.2 mg/mL
1.4 mg/mL
1.6 mg/mL
100 mg/100mL
100 mg/50mL
60 mg/50mL
80 mg/100mL
80 mg/50mL
1 mg
1.2 mg
1.6 mg
3 mg
0.3 %
3 mg
3 mg
5 mg
5 mg
1 mg
3 mg
0.1 %
.1 %
3 mg
4.5 mg","For treatment of serious infections caused by susceptible strains of the following microorganisms: <i>P. aeruginosa</i>, <i>Proteus</i> species (indole-positive and indole-negative), <i>E. coli</i>, <i>Klebsiella-Enterobactor-Serratia</i> species, <i>Citrobacter</i> species and <i>Staphylococcus</i> species (coagulase-positive and coagulase-negative)."
C(C(OC(=O)C1=C([H])N=C(C#CC2=C([H])C3=C(SC(C(C3(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])C([H])=C2[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB00799,118292-40-3,Tazarotene,"Tazarotene
Tazaroteno
Tazarotenum",small molecule,Humans and other mammals,"Aerosol, foam
Cream
Cream
Cream
Cream
Cream
Cream
Gel
Gel
Gel
Gel
Gel","Topical
Topical
Topical
Cutaneous
Cutaneous
Topical
Topical
Cutaneous
Cutaneous
Oral
Topical
Topical","1 mg/g
.5 mg/g
1 mg/g
.5 mg/g
1 mg/g
0.05 %
0.1 %
.5 mg/g
1 mg/g
1 mg/g
0.05 %
0.1 %","Used to treat psoriasis, acne and sun damaged skin (photodamage)."
FC(F)(F)C(N1C2=C(C(=C(Cl)C(=C2[H])[H])[H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])=NC([H])([H])C1=O)([H])[H],DB00801,23092-17-3,Halazepam,"Halaz��pam
Halazepam
Halazepamum",small molecule,Humans and other mammals,,,,"Used to relieve anxiety, nervousness, and tension associated with anxiety disorders."
C(C(N1N=NN(C(C(N2C([H])([H])C([H])([H])C(C(OC([H])([H])[H])([H])[H])(N(C(=O)C(C([H])([H])[H])([H])[H])C3=C([H])C([H])=C([H])C([H])=C3[H])C([H])([H])C2([H])[H])([H])[H])([H])[H])C1=O)([H])[H])([H])([H])[H],DB00802,71195-58-9,Alfentanil,"Alfentanilum
Alfentanyl
N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide",small molecule,Humans and other mammals,"Injection
Injection, solution
Solution","Intravenous
Intravenous
Intravenous","500 ug/mL
500 ug/mL
500 mcg",For the management of postoperative pain and the maintenance of general anesthesia.
C(C(N(C(C([H])([H])[H])([H])[H])C(C(OC(=O)C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00804,77-19-0,Dicyclomine,"2-(Diethylamino)ethyl 1-cyclohexylcyclohexanecarboxylate
Bicyclohexyl-1-carboxylic acid 2-diethylamino-ethyl ester
Dicicloverina
DICYCLOMINE
Dicycloverin
Dicycloverine
Dicycloverinum",small molecule,Humans and other mammals,"Tablet
Syrup
Tablet, extended release
Liquid
Tablet
Tablet
Capsule
Tablet
Capsule
Injection
Injection, solution
Solution
Syrup
Tablet
Solution
Capsule
Tablet","Oral
Oral
Oral
Intramuscular
Oral
Oral
Oral
Oral
Oral
Intramuscular
Intramuscular
Oral
Oral
Oral
Intramuscular
Oral
Oral","20.6 mg/1
10 mg
30 mg
10 mg
10 mg
20 mg
20 mg/1
10 mg/1
10 mg/mL
20 mg/2mL
10 mg/5mL
10 mg/mL
10 mg/1
10 mg
10 mg","For the treatment of functional bowel/irritable bowel syndrome
including Colicky abdominal pain; diverticulitis"
C(C1=C([H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])=NN=C1N(C(C(N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB00805,25905-77-5,Minaprine,"4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholine
4-Methyl-3-(2-morpholinoethylamino)-6-phenylpyridazin
Minaprina
Minaprinum
N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine",small molecule,Humans and other mammals,,,,For the treatment of depression
C(N1C([H])=NC2=C1C(=O)N(C(C(C(C(C(C([H])([H])[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])C(=O)N2C([H])([H])[H])([H])([H])[H],DB00806,6493-05-6,Pentoxifylline,"Oxpentifylline
Pentoxifilina
Pentoxifyllin
Pentoxifylline
Pentoxifyllinum",small molecule,Humans and other mammals,"Kit
Tablet, extended release
Tablet, film coated, extended release
Tablet, extended release","Topical
Oral
Oral
Oral","400 mg/1
400 mg/1
400 mg",For the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs.
C(C(C(OC1=C(N([H])[H])C([H])=C(C(=O)OC(C(N(C(C([H])([H])[H])([H])[H])C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB00807,499-67-2,Proparacaine,"Proximetacaina
Proxymetacaine
Proxymetacainum",small molecule,Humans and other mammals,"Solution / drops
Solution / drops
Solution
Solution
Solution / drops
Liquid
Solution
Solution / drops
Solution / drops","Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic; Topical
Ophthalmic
Ophthalmic; Topical
Ophthalmic
Ophthalmic
Ophthalmic","0.5 %
.5 %
.5 %
0.5 %
5 mg/mL
5 mg/mL
5 mg",Used as a local (ophthalmic) anesthetic.
O(C(C(C(N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])([H])[H])([H])[H])(C1(C([H])([H])C2(C([H])([H])C1(C(=C2[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])[H],DB00810,514-65-8,Biperiden,"1-Bicyclo[2.2.1]hept-5-en-2-yl-1-phenyl-3-piperidin-1-yl-propan-1-ol
alpha-5-Norbornen-2-yl-alpha-phenyl-1-piperidinepropanol
alpha-Bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
Beperiden
Biperidene
Biperideno
Biperidenum",small molecule,Humans and other mammals,Tablet,Oral,2 mg,For use as an adjunct in the therapy of all forms of parkinsonism and control of extrapyramidal disorders secondary to neuroleptic drug therapy.
C(C(C(C(C1(C(=O)N(C2=C([H])C([H])=C([H])C([H])=C2[H])N(C2=C([H])C([H])=C([H])C([H])=C2[H])C1=O)[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],"DB00812
DB08343",50-33-9,Phenylbutazone,"3,5-Dioxo-1,2-diphenyl-4-n-butylpyrazolidine
4-BUTYL-1,2-diphenyl-pyrazolidine-3,5-dione
4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione
Fenilbutazona
Phenbutazone
Phenylbutazon
Phenylbutazone
Phenylbutazonum",small molecule,Humans and other mammals,"Tablet
Tablet","Oral
Oral",100 mg,For the treatment of backache and ankylosing spondylitis
C(C(C(=O)N(C1(C([H])([H])C([H])([H])N(C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],"DB00813
DB05853
DB06055
DB06220
DB05564",437-38-7,Fentanyl,"1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-phenethyl-4-N-propionylanilinopiperidine
Fentanil 
Fentanila
Fentanilo
Fentanyl
Fentanyl CII
Fentanylum
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
Phentanyl",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Patch
Tablet
Tablet
Tablet
Tablet
Tablet
Patch
Patch
Patch
Patch
Patch
Patch
Patch
Patch
Patch
Patch
Patch
Patch
Patch
Patch
Patch, extended release
Patch, extended release
Patch, extended release
Patch, extended release
Patch, extended release
Patch, extended release
Patch, extended release
Patch, extended release
Patch, extended release
Patch, extended release
Patch, extended release
Patch, extended release
Patch, extended release
Patch, extended release
Tablet
Tablet
Tablet
Tablet
Tablet
Injection
Injection
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Lozenge
Lozenge
Lozenge
Lozenge
Lozenge
Lozenge
Lozenge
Lozenge
Lozenge
Lozenge
Solution
Liquid
Injection, solution
Patch
Patch
Patch
Patch
Patch
Patch, extended release
Patch, extended release
Patch, extended release
Patch, extended release
Patch, extended release
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, effervescent
Tablet, effervescent
Tablet, effervescent
Tablet, effervescent
Tablet, effervescent
Liquid
Solution
Solution
Solution
Patch
Patch
Spray
Spray
Spray
Film, soluble
Film, soluble
Film, soluble
Film, soluble
Film, soluble
Patch
Patch
Patch
Patch
Patch
Patch
Spray
Spray
Spray
Spray
Spray
Patch
Patch
Patch
Patch
Patch
Lozenge
Lozenge
Lozenge","Sublingual
Sublingual
Sublingual
Sublingual
Sublingual
Sublingual
Sublingual
Sublingual
Sublingual
Sublingual
Sublingual
Sublingual
Sublingual
Sublingual
Sublingual
Sublingual
Sublingual
Sublingual
Transdermal
Buccal
Buccal
Buccal
Buccal
Buccal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Buccal; Oral; Transmucosal
Buccal; Oral; Transmucosal
Buccal; Oral; Transmucosal
Buccal; Oral; Transmucosal
Buccal; Oral; Transmucosal
Intramuscular; Intravenous
Intravenous
Intramuscular; Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Oral; Transmucosal
Oral; Transmucosal
Oral; Transmucosal
Oral; Transmucosal
Transmucosal
Transmucosal
Transmucosal
Transmucosal
Transmucosal
Transmucosal
Epidural; Intramuscular; Intravenous
Epidural; Intramuscular; Intravenous
Epidural
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Buccal; Sublingual
Buccal; Sublingual
Buccal; Sublingual
Buccal; Sublingual
Buccal; Sublingual
Buccal; Sublingual
Buccal; Sublingual
Buccal; Sublingual
Buccal; Sublingual
Buccal; Sublingual
Intramuscular; Intravenous
Nasal
Nasal
Nasal
Transdermal
Transdermal
Nasal
Nasal
Nasal
Buccal
Buccal
Buccal
Buccal
Buccal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Sublingual
Sublingual
Sublingual
Sublingual
Sublingual
Transdermal
Transdermal
Transdermal
Transdermal
Transdermal
Oral; Transmucosal
Oral; Transmucosal
Oral; Transmucosal","100 ug/1
100 mcg
200 ug/1
200 mcg
300 ug/1
300 mcg
400 ug/1
400 mcg
600 mcg
600 ug/1
800 mcg
800 ug/1
100 ug/1
200 ug/1
300 ug/1
400 ug/1
600 ug/1
800 ug/1
12.5 ug/h
100 micrograms
200 micrograms
400 micrograms
600 micrograms
800 micrograms
1.28 mg/[USP'U]
10.2 mg/[USP'U]
100 ug/h
12 ug/1
12 ug/h
2.55 mg/[USP'U]
25 ug/h
37.5 ug/h
5.1 mg/[USP'U]
50 ug/h
62.5 ug/h
7.65 mg/[USP'U]
75 ug/h
87.5 ug/h
100 ug/h
100 ug/72h
12 ug/h
2.5 mg/72h
25 ug/72h
25 ug/h
37.5 ug/h
5 mg/72h
50 ug/h
50 ug/72h
62.5 ug/h
7.5 mg/72h
75 ug/h
87.5 ug/h
100 ug/1
200 ug/1
400 ug/1
600 ug/1
800 ug/1
50 ug/mL
50 ug/mL
50 ug/mL
10 ug/mL
20 ug/mL
25 ug/mL
5 ug/mL
50 ug/mL
1200 ug/1
1600 ug/1
200 ug/1
800 ug/1
1200 ug/1
1600 ug/1
200 ug/1
400 ug/1
600 ug/1
800 ug/1
50 mcg
50 mcg
100 ug/1
12.5 ug/1
25 ug/1
50 ug/1
75 ug/1
12.5 ug/h
100 mcg
25 mcg
50 mcg
75 mcg
100 ug/1
200 ug/1
400 ug/1
600 ug/1
800 ug/1
100 mcg
200 mcg
400 mcg
600 mcg
800 mcg
100 mcg
200 mcg
50 mcg
40 ug/1
40 ��g/dose
100 ug/1
300 ug/1
400 ug/1
1200 mcg
200 mcg
400 mcg
600 mcg
800 mcg
12.0 mcg
10 mg
2.5 mg
5 mg
7.5 mg
37 mcg
.1 mg/1
.2 mg/1
.4 mg/1
.6 mg/1
.8 mg/1
100 mcg
12 mcg
25 mcg
50 mcg
75 mcg
1200 1/1
400 ug/1
600 ug/1",For the treatment of cancer patients with severe pain that breaks through their regular narcotic therapy.
C(N1C(C(=O)N(C2=NC([H])=C(C([H])([H])[H])S2)[H])=C(O[H])C2=C(C(=C(C(=C2[H])[H])[H])[H])S1(=O)=O)([H])([H])[H],DB00814,71125-38-7,Meloxicam,"M��loxicam
Meloxicam
Meloxicamum
UNII-vg2qf83cgl",small molecule,Humans and other mammals,"Tablet
Kit
Suspension
Tablet
Tablet
Tablet
Tablet
Tablet
Kit
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","15.0 mg
7.5 mg/5mL
7.5 mg/1
15 mg/1
7.5 mg/1
15 mg
7.5 mg
10 mg/1
5 mg/1",For symptomatic treatment of arthritis and osteoarthritis.
C(C(C(C(C(C(C(C(C(C(C(C(OS([O-])(=O)=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00815,151-21-3,Sodium lauryl sulfate,"Laurylsiran sodny
NaDS
Natrium laurylsulfuricum
SDS
SLS
Sodium dodecyl sulfate
Sodium dodecyl sulphate
Sodium dodecylsulfate
Sodium laurilsulfate
Sodium lauryl sulfate
Sodium lauryl sulphate",small molecule,Humans and other mammals,"Paste, dentifrice
Paste, dentifrice
Liquid
Liquid
Cream
Liquid
Paste
Jelly","Oral
Oral
Topical
Topical
Topical
Dental
Dental
Vaginal",".7675 g/100g
1.21 g/160g
25 g/100mL
2 g/100g","SLS is used as a surfactant in shampoos and toothpastes. SLS also has microbicidal activities against both enveloped (Herpes simplex viruses, HIV-1, Semliki Forest virus) and nonenveloped (papillomaviruses, reovirus, rotavirus and poliovirus) viruses, although it has not been approved for this use."
C(C(N1C([H])=C(C(O[H])=O)C(=O)C2=C1C(=C(C(=C2[H])[H])C1=C([H])C([H])=NC([H])=C1[H])[H])([H])[H])([H])([H])[H],DB00817,40034-42-2,Rosoxacin,"Acrosoxacin
ROS
Rosoxacin
Rosoxacine
Rosoxacino
Rosoxacinum
Roxadyl",small molecule,Enteric bacteria and other eubacteria,,,,"For the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients."
C(C(C([H])([H])[H])(C1=C([H])C([H])=C([H])C(C(C([H])([H])[H])(C([H])([H])[H])[H])=C1O[H])[H])([H])([H])[H],"DB00818
DB05893",2078-54-8,Propofol,"2,6-Bis(1-methylethyl)phenol
2,6-Diisopropylphenol
Disoprivan
Disoprofol
Propofol
Propofolum",small molecule,Humans and other mammals,"Kit
Kit
Emulsion
Emulsion
Injection, emulsion","Intravenous
Intravenous
Intravenous","1 %
10 mg
10 mg/mL",Used for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus. 
C(C(=O)N(C1=NN=C(S(N([H])[H])(=O)=O)S1)[H])([H])([H])[H],DB00819,59-66-5,Acetazolamide,"2-acetylamino-1,3,4-thiadiazole-5-sulfonamide
5-acetamido-1,3,4-thiadiazole-2-sulfonamide
5-acetylamino-1,3,4-thiadiazole-2-sulfonamide
Acetazolamid
Acetazolamida 
Ac��tazolamide
Acetazolamidum
N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
N-[5-(aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide",small molecule,Humans and other mammals,"Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Tablet
Tablet
Tablet
Tablet
Powder, for solution
Capsule, extended release
Capsule, extended release","Intravenous
Intravenous
Oral
Oral
Oral
Oral
Intravenous
Oral
Oral","500 mg/5mL
500 mg/1
125 mg/1
250 1/1
250 mg/1
250 mg
500 mg
500 mg/1
500 mg",For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies; chronic simple (open-angle) glaucoma
C(C(N(C(C([H])([H])[H])([H])[H])C(=S)SSC(=S)N(C(C([H])([H])[H])([H])[H])C(C([H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00822,97-77-8,Disulfiram,"1,1'-dithiobis(N,N-diethylthioformamide)
Antabuse (tn)
Bis(diethylthiocarbamoyl) disulfide
Disulfiram
N,N,N',N'-tetraethylthiuram disulfide
Tetraethylthioperoxydicarbonic Diamide
Tetraethylthiuram Disulfide
Tetraethylthiuram Disulphide",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral","250 mg
500 mg
250 mg/1
500 mg/1",For the treatment and management of chronic alcoholism
C(C(C(N1C2=C(N(C(=N2)[H])[H])C(=O)N([H])C1=O)([H])[H])([H])[H])([H])([H])[H],DB00824,41078-02-8,Enprofylline,"3-n-Propylxanthine
3-Propyl-3,7-dihydro-purine-2,6-dione
3-Propylxanthine
3,7-dihydro-3-Propyl-1H-purine-2,6-dione
Enprofilina
Enprofylline
Enprofyllinum",small molecule,Humans and other mammals,,,,"Used in the management of symptoms of asthma. Also used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy."
C(C(N1N=C(C(O[H])=O)C(=O)C2=C1C(=C1OC([H])([H])OC1=C2[H])[H])([H])[H])([H])([H])[H],DB00827,28657-80-9,Cinoxacin,"1-Ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid
5-Ethyl-8-oxo-5,8-dihydro-1,3-dioxa-5,6-diaza-cyclopenta[b]naphthalene-7-carboxylic acid
Cinoxacin
Cinoxacine
Cinoxacino
Cinoxacinum",small molecule,Enteric bacteria and other eubacteria,,,,"For the treatment of initial and recurrent urinary tract infections in adults caused by the following susceptible microorganisms: <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, <i>Proteus vulgaris</i>, <i>Klebsiella</i> species (including <i>K. pneumoniae</i>), and <i>Enterobacter</i> species."
C(N1C2=C(C(=C(Cl)C(=C2[H])[H])[H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])=NC([H])([H])C1=O)([H])([H])[H],"DB00829
DB07699",439-14-5,Diazepam,"7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
Diazepam
Methyl diazepinone",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Gel
Gel
Emulsion
Gel
Gel
Injection
Injection, solution
Injection, solution
Solution
Tablet
Tablet
Tablet
Liquid
Solution
Solution
Solution, concentrate
Kit
Solution
Cream
Liquid","Oral
Oral
Oral
Rectal
Rectal
Intramuscular; Intravenous
Rectal
Rectal
Intramuscular
Intramuscular; Intravenous
Intramuscular; Intravenous
Oral
Oral
Oral
Oral
Intramuscular
Intramuscular; Intravenous
Intramuscular; Intravenous
Oral
Oral
Topical
Intramuscular; Intravenous","10 mg
2 mg
5 mg
2.5 mg/.5mL
5 mg
5 mg
10 mg/2mL
20 mg/4mL
10 mg/2mL
10 mg/2mL
5 mg/mL
5 mg/5mL
10 mg/1
2 mg/1
5 mg/1
10 mg
10 mg
5 mg
5 mg/mL
1 mg
10 mg","Used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome."
C(C1(N([H])C([H])([H])C([H])([H])OC1(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H])([H])([H])[H],DB00830,134-49-6,Phenmetrazine,"2-Phenyl-3-methylmorpholine
Fenmetrazin
Fenmetrazina
Phenmetrazin
Phenmetrazinum",small molecule,Humans and other mammals,,,,Used as an anorectic in the treatment of obesity.
C(N1C([H])([H])C([H])([H])N(C(C(C(N2C3=C(C(=C(C(=C3[H])[H])[H])[H])SC3=C2C(=C(C(=C3[H])[H])C(F)(F)F)[H])([H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])([H])([H])[H],"DB00831
DB08616",117-89-5,Trifluoperazine,"10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine
10-[3-(4-METHYL-piperazin-1-yl)-propyl]-2-trifluoromethyl-10H-phenothiazine
Trifluoperazina
Trifluoperazine
Trifluoperazinum
Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine
Trifluoroperazine
Trifluperazine",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Syrup
Tablet
Syrup
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","1.18 mg
23.6 mg
11.8 mg
2.36 mg
5.9 mg
1 mg
10 mg
1 mg
10 mg
2 mg
20 mg
5 mg
1 mg/1
1 mg/1
10 mg/1
2 mg/1
5 mg/1","For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation."
C(N(C([H])([H])[H])C(=O)C(C(C(N1C([H])([H])C([H])([H])C(O[H])(C2=C([H])C([H])=C(Cl)C([H])=C2[H])C([H])([H])C1([H])[H])([H])[H])([H])[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB00836,53179-11-6,Loperamide,"Loperamid
Loperamida
Lop��ramide
Loperamidum",small molecule,Humans and other mammals,"Solution
Capsule, liquid filled
Solution
Liquid
Tablet, film coated
Solution
Tablet, coated
Solution
Tablet
Tablet, chewable
Capsule
Liquid
Capsule
Liquid
Solution
Suspension
Tablet
Solution
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","1 mg/5mL
2 mg/1
.2 mg
1 mg/5mL
2 mg/1
1 mg/7.5mL
2 mg/1
2 mg
2 mg
.2 mg
2 mg/1
1 mg/7.5mL
2 mg/10mL
1 mg/7.5mL
2 mg
0.2 mg
2 mg/1",For the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease or gastroenteritis. Also used for reducing the volume of discharge from ileostomies.
O(C(=N[H])C(C(C(N=C(C1=C([H])C([H])=C(Cl)C([H])=C1[H])C1=C(O[H])C([H])=C([H])C(F)=C1[H])([H])[H])([H])[H])([H])[H])[H],DB00837,62666-20-0,Progabide,"Halogabide
Progabida
Progabide
Progabidum",small molecule,Humans and other mammals,,,,Indicated for the treatment of epilepsy.
C(C1=C([H])C([H])=C(S(=O)(=O)N(C(=O)N(N2C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB00839,1156-19-0,Tolazamide,"1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea
1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea
4-(p-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide
N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea
Tolazamid
Tolazamida
Tolazamide
Tolazamidum",small molecule,Humans and other mammals,"Tablet
Tablet","Oral
Oral","250 mg/1
500 mg/1",For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.
C(C(C([H])([H])[H])(N=C1C([H])=C2N(C3=C([H])C([H])=C(Cl)C([H])=C3[H])C3=C(N=C2C([H])=C1N(C1=C([H])C([H])=C(Cl)C([H])=C1[H])[H])C([H])=C([H])C([H])=C3[H])[H])([H])([H])[H],DB00845,2030-63-9,Clofazimine,"Clofazimin
Clofazimina
Clofazimine
Clofaziminum
Riminophenazine",small molecule,"Mycobacteria
Mycobacterium leprae",,,,"For the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum."
N(C(C(S[H])([H])[H])([H])[H])([H])[H],DB00847,60-23-1,Cysteamine,"2-Amino-1-ethanethiol
2-AMINO-ethanethiol
2-Aminoethanethiol
beta-Aminoethanethiol
beta-Aminoethylthiol
beta-MEA
beta-Mercaptoethylamine
Cysteamine
MEA
Mercaptamina
Mercaptamine
Mercaptaminum
Thioethanolamine
��-aminoethylthiol
��-MEA",small molecule,Humans and other mammals,"Capsule
Capsule
Solution
Capsule, delayed release
Capsule, delayed release
Capsule, delayed release pellets
Capsule, delayed release pellets","Oral
Oral
Ophthalmic
Oral
Oral
Oral
Oral","150 mg/1
50 mg/1
6.5 mg/mL
25 mg
75 mg
25 mg/1
75 mg/1",Given intravenously or orally to treat radiation sickness. The bitartrate salts (Cystagon�� and Procysbi) have been used for the oral treatment of nephropathic cystinosis and cystinurea. The hydrochloride salt (Cystaran���) is indicated for the treatment of corneal cystine crystal accumulation in cystinosis patients.
O(C(C(N1C([H])([H])C([H])([H])N(C(C(C(N2C3=C(C(=C(C(=C3[H])[H])[H])[H])SC3=C2C(=C(Cl)C(=C3[H])[H])[H])([H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])([H])[H])([H])[H])[H],DB00850,58-39-9,Perphenazine,"2-(4-[3-(2-chloro-10H-Phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol
2-chloro-10-(3-(4-(2-Hydroxyethyl)piperazin-1-yl)propyl)phenothiazine
4-[3-(2-chloro-10H-Phenothiazin-10-yl)propyl]-1-piperazineethanol
4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol
Chlorpiprazine
Etaperazin
Etaperazine
Ethaperazine
gamma-(4-(beta-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine
Perfenazina
Perfenazine
Perphenazin
Perph��nazine
Perphenazinum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, sugar coated
Tablet, sugar coated
Tablet
Tablet, film coated
Liquid
Liquid
Solution
Syrup","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Oral","16 mg
2 mg
4 mg
8 mg/1
8 mg
16 mg/1
2 mg/1
4 mg/1
8 mg/1
2 mg/1
8 mg/1
3.2 mg
16 mg
5 mg
2 mg",For use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.
C(N(C([H])([H])[H])N=NC1=C(C(N([H])[H])=O)N=C([H])N1[H])([H])([H])[H],DB00851,4342-03-4,Dacarbazine,"4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide
4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(dimethyltriazeno)imidazole-5-carboxamide
5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide
5-(3,3-dimethyltriazeno)imidazole-4-carboxamide
5-(dimethyltriazeno)imidazole-4-carboxamide
Biocarbazine
Dacarbazin
Dacarbazina
Dacarbazine
Dacarbazinum
DIC
DTIC
ICDMT",small molecule,Humans and other mammals,"Injection, powder, for solution
Injection, powder, for solution
Powder, for solution
Liquid
Powder, for solution","Intravenous
Intravenous
Intravenous
Intravenous
Intravenous","10 mg/mL
200 mg/20mL
600 mg
200 mg
10 mg","For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents."
C(N1N=NC2=C(N=C([H])N2C1=O)C(N([H])[H])=O)([H])([H])[H],DB00853,85622-93-1,Temozolomide,"3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide
8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
Methazolastone
Temozolodida
Temozolomid
Temozolomida
T��mozolomide
Temozolomidum",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule
Capsule
Capsule
Injection, powder, for solution
Powder, for solution
Capsule
Capsule
Capsule
Capsule
Capsule
Injection, powder, lyophilized, for solution
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral
Oral
Intravenous
Intravenous
Oral
Oral
Oral
Oral
Oral
Intravenous
Oral
Oral","180 mg
100 mg
140 mg
20 mg
250 mg
5 mg
2.5 mg/ml
100 mg
100 mg/1
180 mg/1
20 mg/1
250 mg/1
5 mg/1
2.5 mg/mL
140 mg/1
180 1/1","For the treatment of adult patients diagnosed with anaplastic astrocytoma whose disease has progressed after therapy with nitrosourea and procarbazine, as well as concomitantly with radiation therapy for treatment of newly diagnosed glioblastoma multiforme. Also used as maintenance therapy for glioblastoma multiforme."
N(C(C(=O)C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H],"DB00855
DB05277",106-60-5,Aminolevulinic acid,"5-ALA
5-Aminolevulinic acid
Aminolevulinic acid
dALA
��-ALA
��-aminolevulinic acid",small molecule,Humans and other mammals,"Gel
Gel
Powder, for solution
Powder, for solution
Kit
Powder, for solution","Cutaneous
Topical
Oral
Oral
Topical","78 mg/g
100 mg/g
1500 mg/1
30 mg/ml
20 %",Aminolevulinic acid plus blue light illumination using a blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.
C(N(C(C(=C(C#CC(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])[H])[H])([H])[H])C(C1=C([H])C([H])=C([H])C2=C(C(=C(C([H])=C12)[H])[H])[H])([H])[H])([H])([H])[H],DB00857,91161-71-6,Terbinafine,"(e)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine
(e)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine
Terbinafina
Terbinafinum",small molecule,Fungi,"Tablet
Cream
Granule
Granule
Spray
Aerosol, spray
Cream
Spray
Gel
Liquid
Cream
Gel
Tablet
Spray
Solution
Tablet
Tablet","Oral
Topical
Oral
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Oral
Oral","125 mg
1 g/100g
125 mg/1
187.5 mg/1
1.25 mL/125mL
.84 g/125mL
10 mg/g
1 mL/100mL
10 mg/g
1.25 mL/125mL
1 %
10 mg
250 mg
1 %
250 1/1
250 mg/1",For the treatment of dermatophyte infections of the toenail or fingernail caused by susceptible fungi. Also for the treatment of tinea capitis (scalp ringworm) and tinea corporis (body ringworm) or tinea cruris (jock itch).
O(C(=O)C1=C(O[H])C([H])=C([H])C(C2=C(F)C([H])=C(F)C([H])=C2[H])=C1[H])[H],"DB00861
DB06895",22494-42-4,Diflunisal,"2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid
2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid
5-(2,4-Difluorophenyl)salicylic acid
Diflunisal
Diflunisalum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet, film coated","Oral
Oral
Oral
Oral","250 mg
500 mg/1
500 mg
500 mg/1","For symptomatic treatment of mild to moderate pain accompanied by inflammation (e.g. musculoskeletal trauma, post-dental extraction, post-episiotomy), osteoarthritis, and rheumatoid arthritis."
C(C(C(C1=NC(C([H])([H])[H])=C2N1N(C(=NC2=O)C1=C(OC(C([H])([H])[H])([H])[H])C([H])=C([H])C(S(=O)(=O)N2C([H])([H])C([H])([H])N(C(C([H])([H])[H])([H])[H])C([H])([H])C2([H])[H])=C1[H])[H])([H])[H])([H])[H])([H])([H])[H],DB00862,224785-90-4,Vardenafil,"2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-F][1,2,4]triazin-4(1H)-one
Vard��nafil
Vardenafil
Vardenafilum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg
20 mg
5 mg
10 mg
10 mg/1
2.5 mg/1
20 mg
20 mg/1
5 mg/1
5 mg
10 mg
10 mg/1
11.85 mg/1",Used for the treatment of erectile dysfunction
C(N(C(N(C(C(SC(C1=C([H])C([H])=C(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])O1)([H])[H])([H])[H])([H])[H])[H])=C([N+]([O-])=O)[H])[H])([H])([H])[H],DB00863,66357-35-5,Ranitidine,"RAN
Ranitidina
Ranitidinum",small molecule,Humans and other mammals,"Tablet
Tablet
Kit
Kit
Tablet, film coated
Tablet, coated
Tablet
Solution
Solution
Syrup
Syrup
Tablet
Tablet, coated
Tablet, film coated
Tablet, film coated
Capsule
Capsule
Injection
Solution
Solution
Tablet
Tablet
Tablet
Solution
Solution
Tablet
Injection, solution
Liquid
Solution
Solution
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Topical
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Oral
Oral
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Oral
Oral
Oral","75.0 mg
150 mg/1
150 mg/1
150 mg/1
400 mg
15 mg/mL
150 mg/mL
15 mg/mL
15 mg/mL
300 mg/1
75 mg/1
300 mg/1
75 mg/1
150 mg/1
300 mg/1
25 mg/mL
150 mg/10mL
75 mg/5mL
75 mg
150 mg
300 mg
25 mg
75 mg
75 mg/1
25 mg/mL
25 mg
50 mg
15 mg
150 mg
300 mg","Used in the treatment of peptic ulcer disease (PUD), dyspepsia, stress ulcer prophylaxis, and gastroesophageal reflux disease (GERD)."
C(C(C(C(N(C1=C([H])C([H])=C(C(=O)OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00868,104-31-4,Benzonatate,"2-[2-[2-[2-[2-[2-[2-[2-(2-Methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-butylaminobenzoate
2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-yl P-(butylamino)benzoate
3,6,9,12,15,18,21,24,27-Nonaoxaoctacosyl 4-butylaminobenzoate
4-(Butylamino)benzoic acid 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester
Benzonatat
Benzonatate
Benzonatato
Benzonatatum
Benzononatine
Nonaethyleneglycol monomethyl ether P-N-butylaminobenzoate
P-Butylaminobenzoic acid omega-O-methylnonaethyleneglycol ester",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule, gelatin coated
Capsule, liquid filled
Capsule, liquid filled
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg/1
150 mg/1
200 mg/1
200 mg/1
100 mg/1
200 mg/1
100 mg/1",For the symptomatic relief of cough. Has also been applied locally in the oral cavity in adults by releasing the drug from the liquid-filled capsules to provide oropharyngeal anesthesia for conscious intubation.
C(C1=NC2=C(C(C(N(C(=O)C3=C([H])C([H])=C(N(C(=O)C4=C(C5=C([H])C([H])=C([H])C([H])=C5[H])C([H])=C([H])C([H])=C4[H])[H])C([H])=C3[H])C3=C2C([H])=C([H])C([H])=C3[H])([H])[H])([H])[H])N1[H])([H])([H])[H],DB00872,210101-16-9,Conivaptan,"4'-((4,5-dihydro-2-Methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide
Conivaptan",small molecule,Humans and other mammals,"Injection, solution",Intravenous,20 mg/100mL,"For the treatment of euvolemic or hypervolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients."
O(C(C(N1C([H])([H])C([H])([H])N(C(C(C(=C2C3=C(C(=C(C(=C3[H])[H])[H])[H])SC3=C2C(=C(C(=C3[H])[H])C(F)(F)F)[H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])([H])[H])([H])[H])[H],DB00875,2709-56-0,Flupentixol,"Flupenthixol
Flupenthixole
Flupentixol
Flupentixolo
Flupentixolum",small molecule,Humans and other mammals,"Tablet
Tablet
Solution
Solution
Liquid
Liquid","Oral
Oral
Intramuscular
Intramuscular
Intramuscular
Intramuscular","0.5 mg
3 mg
100 mg
20 mg
100 mg
20 mg",For use in the treatment of schizophrenia and depression
C(C(C(C(C1=NC([H])=C(C(=C(C(C2=C([H])C([H])=C([H])S2)([H])[H])C(O[H])=O)[H])N1C(C1=C([H])C([H])=C(C(O[H])=O)C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00876,133040-01-4,Eprosartan,"(e)-2-Butyl-1-(P-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid
(e)-3-[2-N-Butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid
(e)-Alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid
��prosartan
Eprosartan
Eprosartanum",small molecule,Humans and other mammals,"Tablet, film coated
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral","600 mg/1
400 mg/1
400 mg
600 mg
600 mg/1
300 mg","For the management of hypertension alone or in combination with other classes of antihypertensive agents. Also used as a first-line agent in the treatment of diabetic nephropathy, as well as a second-line agent in the treatment of congestive heart failure (only in those intolerant of ACE inhibitors)."
ClC1=C([H])C([H])=C(N(C(=N[H])N(C(=N[H])N(C(C(C(C(C(C(N(C(=N[H])N(C(=N[H])N(C2=C([H])C([H])=C(Cl)C([H])=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])[H])[H])C([H])=C1[H],DB00878,55-56-1,Chlorhexidine,"1,1'-Hexamethylene bis(5-(P-chlorophenyl)biguanide)
Chlorhexidin
Chlorhexidine
Chlorhexidinum
Cloresidina
Clorhexidina
N,N'-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide",small molecule,Bacteria,"Sponge
Liquid
Lotion
Lotion
Cloth
Swab
Solution
Solution
Liquid
Lotion
Dressing
Sponge
Solution
Solution
Solution
Spray
Liquid
Solution
Cloth
Gel
Rinse
Rinse
Liquid
Liquid; mouthwash
Mouthwash
Solution
Solution
Liquid
Kit
Lotion
Liquid
Liquid
Liquid
Cloth
Cream
Liquid
Gel
Gel
Mouthwash
Cloth
Liquid
Gel
Aerosol
Solution
Concentrate
Cream
Swab
Kit
Rinse
Ointment
Liquid; mouthwash
Insert, extended release
Mouthwash
Rinse
Solution
Liquid
Solution
Solution
Kit; solution
Liquid
Lotion
Solution
Solution
Solution
Liquid
Solution
Solution
Liquid
Solution
Solution
Soap
Lotion
Soap
Soap
Kit
Lotion
Liquid; sponge
Sponge
Aerosol
Solution
Sponge
Sponge
Solution; sponge
Swab
Shampoo
Aerosol
Spray
Liquid
Spray
Liquid","Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Oral
Buccal
Oral
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Ophthalmic
Topical
Topical
Topical
Topical
Topical
Buccal
Topical
Topical
Topical
Topical
Topical
Irrigation
Topical
Topical
Dental
Topical
Buccal
Periodontal
Buccal; Oral
Buccal
Buccal
Topical
Ophthalmic
Topical
Dental
Buccal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","1.2 mg/mL
.0045 g/.9g
.07075 g/14.15g
2 %
.0002 mg/mg
4 g/100mL
2 g/100g
0.12 %
.5 %
40 mg/mL
.5 %
40 g/1000mL
.04 mg/mL
2 g/100mL
4 %
500 mg/1
4 g/100mL
.12 mg/mL
1.2 mg/mL
1.2 [iU]/mL
0.12 %
0.12 %
0.05 %
20 %
.05 %
4 %
4.0 %
2 %
2 g/100g
4 g/100mL
2 %
0.12 %
4 %
213 g/1000mL
2.36 mL/236mL
2 %
2 %
1.2 mg/mL
1 %
0.12 %
2.5 mg/1
0.12 %
1.2 mg/mL
0.12 %
.12 %
1 mg/25mL
10 %
0.12 %
2 %
.75 mg/100mL
4 mg/100mL
4 mg/100mL
2 g/100mL
2 mg/100mL
4 %
20 mg/mL
40 mg/mL
2.0 %
24 mg/3g
48 mg/3g
2.25 %
4 %
4 %
4 %
2 %
2 %
0.05 %
0.5 %
0.5 %
.5 %
2 %
20 %","For reduction of pocket depth in patients with adult periodontitis, used as an adjunct to scaling and root planing procedures. Also for prevention of dental caries, oropharyngeal decontamination in critically ill patients, hand hygiene in health-care personnel, general skin cleanser, and catheter site preparation and care."
N(S(=O)(=O)C1=C(Cl)C([H])=C2N(C(=NS(=O)(=O)C2=C1[H])[H])[H])([H])[H],DB00880,58-94-6,Chlorothiazide,"6-Chloro-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide
6-chloro-7-Sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
Chlorothiazid
Chlorothiazide
Chlorothiazidum
Chlorthiazide
Clorotiazida
Mechlozid
Uroflux",small molecule,Humans and other mammals,"Tablet
Tablet
Injection
Injection, powder, lyophilized, for solution
Suspension
Injection
Tablet","Oral
Oral
Intravenous
Intravenous
Oral
Intravenous
Oral","250 mg/1
500 mg/1
500 mg/1
500 mg/18mL
250 mg/5mL
.5 mg/18mL","Chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension."
O(C(C(C1=C([H])N=C([H])C([H])=C1[H])([H])[H])(P(O[H])(O[H])=O)P(O[H])(O[H])=O)[H],"DB00884
DB02782",105462-24-6,Risedronate,"Acide ris��droniqe
Acido risedronico
Acidum risedronicum
Ridron
Risedronate
Risedronic acid
Risedrons��ure",small molecule,Humans and other mammals,"Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, delayed release
Granule, effervescent; kit; tablet
Tablet
Tablet
Tablet, delayed release
Tablet, delayed release
Tablet, film coated
Tablet, film coated
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","75 mg
150 mg/1
35 mg/1
5 mg/1
35 mg
150 mg
35 mg/1
30 mg/1
75 mg/1
30 mg
35 mg
5 mg","For the treatment of Paget's disease of the bone (osteitis deformans), postmenopausal and glucocorticoid-induced osteoporosis"
C(C1=C([H])C([H])=C([H])N2C(=O)C(=C(N=C12)[H])C1=NN([H])N=N1)([H])([H])[H],DB00885,69372-19-6,Pemirolast,"Pemirolast
Pemirolastum
Pemirox",small molecule,Humans and other mammals,,,,"For the prevention of itching of the eyes caused by allergies such as hay fever, and allergic conjunctivitis"
C(C(C(C(N(C1=C([H])C(C(O[H])=O)=C([H])C(S(N([H])[H])(=O)=O)=C1OC1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00887,28395-03-1,Bumetanide,"3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid
3-Butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid
3-Butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
3-Butylamino-4-phenoxy-5-sulfamoylbenzoic acid
Bumetanida
Bumetanidum",small molecule,Humans and other mammals,"Injection
Injection, solution
Injection, solution
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet","Intramuscular; Intravenous
Intramuscular; Intravenous
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral",".25 mg/mL
.25 mg/mL
.25 mg/mL
.5 mg/1
1 mg/1
2 mg/1
2 mg
1 mg
5 mg","For the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome."
C(N(C(C(Cl)([H])[H])([H])[H])C(C(Cl)([H])[H])([H])[H])([H])([H])[H],DB00888,51-75-2,Mechlorethamine,"2,2'-dichloro-N-methyldiethylamine
beta,Beta'-dichlorodiethyl-N-methylamine
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl)methylamine
Chlormethine
Mechlorethamine
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Mustine
N-methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
Nitrogen mustard
��,��'-dichlorodiethyl-N-methylamine",small molecule,Humans and other mammals,"Powder, for solution
Powder, for solution
Gel","Intracavitary; Intravenous
Intravenous
Topical","10 mg/10mL
10 mg
.012 g/60g","For the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma. Also for the palliative treatment of metastatic carcinoma resulting in effusion."
C(C(=C(C(=C(C([H])([H])[H])[H])C1=C([H])C([H])=C(O[H])C([H])=C1[H])C1=C([H])C([H])=C(O[H])C([H])=C1[H])[H])([H])([H])[H],DB00890,13029-44-2,Dienestrol,"alpha-dienestrol diacetate
Cycladiene
Dehydrostilbestrol
Dienestrol
Di��nestrol
Dienestrolum
DV",small molecule,Humans and other mammals,Cream,Vaginal,.01 %,For use in the treatment of atrophic vaginitis and kraurosis vulvae.
N(C1=C([H])C([H])=C(S(=O)(=O)N(C2=NC([H])=C([H])C([H])=C2[H])[H])C([H])=C1[H])([H])[H],DB00891,144-83-2,Sulfapyridine,"2-(P-Aminobenzenesulphonamido)pyridine
2-Sulfanilamidopyridin
2-Sulfanilamidopyridine
2-Sulfanilylaminopyridine
2-Sulfapyridine
4-(2-Pyridinylsulfonyl)aniline
4-[(2-Pyridylamino)sulfonyl]aniline
4-Amino-N-pyridin-2-yl-benzenesulfonamide
4-Amino-N,2-pyridinylbenzenesulfonamide
N-2-Pyridylsulfanilamide
N(1)-2-Pyridylsulfanilamide
N(1)-Pyridylsulfanilamide
Solfapiridina
Streptosilpyridine
Sulfapiridina
Sulfapyridin
Sulfapyridine
Sulfapyridinum
Sulphapyridine",small molecule,Humans and other mammals,Tablet,Oral,500 mg,"For the treatment of dermatitis herpetiformis, benign mucous membrane pemphigoid and pyoderma gangrenosum"
C(C(C(C(OC1=C(N([H])[H])C([H])=C([H])C(C(=O)OC(C(N(C(C([H])([H])[H])([H])[H])C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])=C1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00892,99-43-4,Oxybuprocaine,"4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid
4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester
4-Amino-3-N-butoxy-benzoesaeure-diaethylaminoaethylester
Benoxil
Benoxinate
BNX
Butoxyaminobenzoyldiethylaminoethanol
Oxibuprocaina
Oxybucaine
Oxybuprocainum
Oxyriprocaine",small molecule,Humans and other mammals,"Solution / drops
Liquid
Solution
Solution / drops","Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic; Topical",.4 %,Used to temporarily numb the front surface of the eye so that the eye pressure can be measured or a foreign body removed.
C(C1=NN=C2C(N=C(C3=C(Cl)C([H])=C([H])C([H])=C3[H])C3=C(N12)C([H])=C([H])C(Cl)=C3[H])([H])[H])([H])([H])[H],DB00897,28911-01-5,Triazolam,"Triazolam
Triazolamum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral","0.125 mg
.125 mg
.25 mg
.125 mg/1
.25 mg/1
0.25 mg",For the short-term treatment of insomnia.
C(C(O[H])([H])[H])([H])([H])[H],DB00898,64-17-5,Ethanol,"1-Hydroxyethane
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
Alcohol et��lico
Alcohol, denatured
Alcool ��thylique
Alkohol
��thanol
��thylalkohol
Dehydrated ethanol
etanol
��thanol
Ethyl Alcohol
Grain alcohol
Hydroxyethane
Methylcarbinol
Spiritus vini",small molecule,Humans and other mammals,"Gel
Gel
Liquid
Kit
Liquid
Liquid
Gel
Gel
Liquid
Gel
Gel
Lotion
Aerosol, spray
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Kit
Liquid
Solution
Liquid
Swab
Solution
Swab
Swab
Swab
Swab
Cloth
Liquid
Liquid
Liquid
Liquid
Spray
Liquid
Liquid
Soap
Gel
Gel
Gel
Gel
Spray
Kit
Gel
Liquid
Gel
Gel
Solution
Spray
Spray
Swab
Liquid
Liquid
Liquid
Liquid
Patch
Liquid
Gel
Gel
Spray
Spray
Lotion
Cloth
Cloth
Liquid
Liquid
Spray
Gel
Lotion
Jelly
Stick
Gel
Cloth
Gel
Gel
Liquid
Solution
Cloth
Gel, dentifrice
Lotion
Cream
Gel
Liquid
Gel
Liquid
Aerosol, foam
Lipstick
Spray
Liquid
Syrup
Cloth
Liquid
Gel
Liquid
Gel
Gel
Gel
Cloth
Liquid
Solution
Solution
Spray
Liquid
Mouthwash
Gel
Liquid
Liquid
Gel
Spray
Liquid
Liquid
Liquid
Liquid
Solution
Injection
Injection, solution
Solution
Liquid
Liquid
Aerosol, foam
Gel
Spray
Liquid
Liquid
Aerosol, foam
Solution
Aerosol, foam
Liquid
Liquid
Gel
Gel
Spray
Solution
Solution
Solution
Gel
Solution
Cloth
Spray
Liquid
Liquid
Liquid
Gel
Aerosol, foam
Cloth
Gel
Gel
Gel
Solution
Liquid
Liquid
Cloth
Gel
Liquid
Liquid
Liquid
Liquid
Soap
Gel
Gel
Liquid
Lotion
Aerosol, foam
Soap
Cream
Soap
Gel
Lotion
Lotion
Solution
Gel
Liquid
Gel
Mouthwash
Lotion
Gel
Gel
Gel
Liquid
Liquid
Gel
Liquid
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Lotion
Lotion
Lotion
Spray
Swab
Gel
Swab
Gel
Liquid
Gel
Liquid
Gel
Liquid
Spray
Spray
Spray
Gel
Cloth
Liquid
Gel
Gel
Cloth
Cloth
Liquid
Spray
Gel
Liquid
Liquid
Solution
Soap
Solution
Gel
Gel
Gel
Gel
Gel
Solution
Gel
Aerosol
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Liquid
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Gel
Liquid
Solution
Gel
Gel
Liquid
Gel
Gel
Liquid
Gel
Gel
Spray
Gel
Cloth
Gel
Gel
Spray
Lotion
Gel
Liquid
Solution
Solution
Liquid
Spray
Tincture
Gel
Cloth
Gel
Liquid
Gel
Gel
Lotion
Gel
Gel
Spray
Gel
Liquid
Lotion
Gel
Gel
Gel
Gel
Gel
Gel, dentifrice
Cloth
Spray
Swab
Liquid
Solution
Soap
Cloth
Stick
Cloth
Cloth
Liquid
Solution
Kit
Gel
Spray
Gel
Liquid
Solution
Gel
Aerosol, foam
Liquid
Swab
Gel
Liquid
Liquid
Gel
Liquid
Swab
Aerosol, foam
Cloth
Gel
Solution
Solution
Gel
Spray
Solution
Solution
Solution
Solution
Gel
Liquid
Liquid
Liquid
Liquid
Gel
Liquid
Gel
Gel
Liquid
Liquid
Aerosol, foam
Solution
Aerosol, foam
Gel
Swab
Solution
Soap
Spray
Spray
Cloth
Solution
Gel
Spray
Liquid
Gel
Gel
Liquid
Aerosol, foam
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Gel
Lotion
Lotion
Swab
Liquid
Gel
Liquid
Liquid
Swab
Liquid
Liquid
Gel
Soap
Solution
Kit
Gel
Liquid
Liquid
Gel
Gel
Lotion; swab
Gel
Cloth
Kit
Elixir
Liquid
Gel
Liquid
Lotion
Liquid
Lotion
Lotion
Solution
Gel
Swab
Gel
Gel
Gel
Gel
Gel
Lotion
Gas
Gel
Gel
Liquid
Spray, suspension
Gel
Liquid
Lotion
Gel
Liquid
Liquid
Liquid
Liquid
Gel
Liquid
Aerosol, spray
Gel","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral; Topical
Topical
Topical
Topical
Topical
Intravenous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Respiratory (inhalation)
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Dental
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Dental
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Intraspinal
Intraspinal
Intraspinal
Intraspinal
Intramuscular; Subcutaneous
Intravenous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Percutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Percutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Dental
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Intramuscular; Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","62 mL/1
36.7 mL/59.2mL
62 mL/1
496 mg/mL
548 mg/mL
577.7 mg/mL
70 mL/1
70 mL/1
21.024 mL/30mL
266.304 mL/380mL
.79 mL/mL
62 mL/mL
616 mg/mL
70 kg/100L
616 mg/100mL
616 mL/mL
70 mL/100mL
700 mg/mL
62 g/53mL
60 mL/100mL
80 mL/100mL
62 mg/mL
1.31 g/1
700 mg/g
70 mL/1
70 mL/100mL
.7 mL/mL
.31 mL/mL
1 mL/mL
720 g/L
700 mL/1000mL
710 g/1000mL
800 mg/mL
600 mL/L
377.5 mL/500mL
630 mg/mL
18.335 mL/29.574mL
60 mL/100mL
72 mL/100mL
620 g/kg
620 g/L
65 mg/100mL
77 mL/100mL
.62 mL/mL
620 mg/mL
4.96 mL/8mL
.62 mL/1
1.313 mg/mL
62 mL/100mL
665 mg/L
700 mL/L
65.9 g/100g
65.9 g/100g
19.66 mL/29.57mL
39.33 mL/59.14mL
2.79 mL/4.5mL
5.58 mL/9mL
62 mL/100mL
.6 g/1
665 mL/L
665 mL/L
75 g/100g
600 mL/L
69 %
530.7 mg/mL
60.14 %
60.14 %
.7 L/L
42 mg/25mL
.29326 L/.473L
600 mg/mL
65.9 mL/100mL
500 mg/g
62 dL/100dL
70 mL/100mL
.65 mg/100mL
82 mL/100mL
.26 g/26g
26.36 g/44mL
.625 mg/mg
65 mL/100mL
1.42 g/30mL
710 g/L
70 %
70 %
37 mL/60mL
65.2 mL/100mL
150.97 g/266mL
39.184 g/70mL
36.58 g/59mL
3.32 g/1
63 mg/mL
67 mL/100mL
71 mL/100mL
.62 g/g
338.82 g/L
65 g/100mL
585 g/mL
.48 mL/mL
58.1 mg/g
56 mg/g
72 mL/100mL
70 L/100L
.8 mL/mL
.45 mL/mL
9.8 mg/mL
.98 mL/mL
.98 mL/mL
.98 mL/mL
0.995 ml
100 %
65 mL/100mL
81.11 mL/100mL
66 %
62.5 g/100g
70 mL/100mL
62 g/100g
38.7 g
7 mL/10mL
800 mg/1.2mL
800 mg/1.2mL
540.02 mg/mL
589.4 mg/mL
598.5 mg/mL
620 mg/g
7 mL/10mL
.7 1/1
7 mL/10mL
22.5 mL/30mL
.67 mL/100mL
.7 mL/100mL
.5634 g/mL
62 mL/100mL
65 mL/1
61.9937 mL/100mL
.62 mL/mL
.7 g/g
.67 mL/mL
70 mL/100mL
610 mg/mL
62 mL/100mL
600 mL/1000mL
128.21 g/1
48 g/100mL
70 g/100mL
75 mL/100mL
.072 mg/mL
36.58 mL/59mL
66 g/100g
65 mL/100mL
185 mL/295mL
.62 g/g
.07 mg/mL
620 mg/g
.67 mL/mL
69.5 g/100g
63 %
62 %
630 g/1000g
620 mL/1000mL
46.5 mL/75mL
70 mL/100mL
15.67 mg/30mL
130.65 mg/250mL
16.41 mg/30mL
35.15 g/60mL
.71 L/L
.7 mg/mL
.62 mL/mL
62 mL/100mL
.62 g/g
.65 kg/100L
146.3 mL/236mL
184.6 mL/355mL
53.5 g/100mL
540.26 g/L
545 mg/mL
567 mg/mL
578 mg/mL
585 mg/mL
62 mL/mL
65 mL/100L
650 mL/mL
700 mL/100mL
837 mg/mL
.879 mg/mL
36.58 mL/59mL
53.3 g/100mL
616 mg/mL
62 kg/100L
620 mL/1000mL
630 mL/1000mL
71 mL/100mL
.073 mL/100L
558 mg/mL
567 mg/mL
.63 mL/mL
63 mL/100mL
5 mL/8mL
65 mL/100mL
62 %
62 g/100mL
9.3 mL/60mL
60 %
62 mg/117.6mL
63 mL/100mL
4.58 mL/7.39mL
62 g/100g
65 g/100g
62 g/100mL
620 mg/g
65 mL/mL
70 g/100mL
62 mg/mL
62 1/1001
620 mg/mL
62 mL/100L
4.65 mL/7.5mL
62 g/100g
60 g/100g
.3 mL/mL
65 mL/100mL
.62 mL/mL
42 mg/25mL
6 g/200g
2 g/200g
6 mL/200mL
5.4 mg/180mL
1.8 mg/180mL
1.8 mg/180mL
4 mg/50mL
600 mL/L
.6329 mL/.9242mL
10.35 mL/14.78mL
315 mL/450mL
42 mL/60mL
69.8 mL/100mL
21 g/30mL
56.525 g/100mL
63 mL/100mL
.6 g/1
.6 g/.9g
.6 g/mL
.7 g/mL
6 mL/10mL
60 g/mL
65 kg/100L
665 mg/L
665 mL/L
665 mL/1000mL
665 mL/g
700 mg/L
700 mg/1000mL
75 mL/100mL
64.5 mL/100mL
62 mL/100mL
33 mL/53mL
146 mL/236mL
146 mL/236mL
.665 g/mL
18.6 mL/30mL
65 g/100g
62 mL/100mL
62 mg/100mL
62 mL/100mL
65 mL/100mL
.68 mL/mL
680 mg/mL
70 mL/100mL
613.8 mg/mL
14.88 g/30mL
62 mg/100mL
.7 L/L
42 mg/25mL
670 mg/mL
650 mg/mL
17.98 mL/29mL
62 mg/1
72 L/100L
.5 g/10mL
64.5 mL/100mL
60.25 %
.8 L/L
554 mL/554mL
.7 mL/mL
68 mL/100mL
620 mg/g
.62 mL/mL
153.34 mL/237mL
60 g/100g
558 mg/mL
60 %
19.428 mL/30mL
50 g/100g
1 ug/mL
64 mL/100mL
75 mL/100mL
.67 mL/mL
70 mg/mL
.7 mL/mL
.7 mL/mL
.7 mL/mL
.659 mL/1
.659 mL/mL
17.57 g/30mL
.7 mL/mL
62 mL/62mL
340.56 mL/470mL
70 g/100g
75 g/100mL
75.85 mL/100mL
620 mg/mL
40 mg/mL
68 mg/mL
65.9 g/100g
70 mg/100mL
62 mL/100mL
62 %
.7 mL/mL
.7 mL/mL
.62 mL/mL
.625 mL/mL
.62 mL/mL
70.0 %
60 mL/100mL
650 mg/mL
.62 mL/mL
539.4 mg/mL
539.71 mg/mL
620 mg/mL
54.7 g/100g
62.5 mL/100mL
68 mL/100mL
62.0 %
620 mg/mL
700 mg/mL
63 1/100g
95 %
.625 mL/mL
64 g/100mL
56.07 1/56.071
650 mg/mL
.67 g/mL
.659 mL/mL
620 mg/g
620 mL/L
.659 mL/mL
534 mg/mL
650 mL/L
650 mL/L
60 mL/100mL
.7 mL/.7mL
62.5 mL/100mL
.734 g/mL
65 mL/100mL
60 L/100L
62 g/59g
1 g/100mL
700 g/L
620 mg/mL
74.4 mL/120mL
146.94 mL/237mL
652.2 g/1000mL
672 g/1000mL
693 g/1000mL
710 g/1000mL
62 L/100L
76 L/100L
67.6 mL/100mL
67.6 L/100L
670 mL/1000mL
18.6 mL/30mL
18 mL/30mL
1.82 mL/1
.8 g/mL
85 mL/100mL
85 mL/100mL
80 mL/100mL
850 mg/mL
70 g/100g
.6 mL/mL
62 mL/100mL
.75 mL/mL
147 mL/237mL
65 g/100mL
62 g/100g
62.5 g/100mL
80.4 mL/120mL
70 %
28 g/1
.72 mL/mL
76 mL/100mL
67 mL/100mL
60 %
64.6 g/100mL
250 mL/295mL
.7 mL/mL
.61 g/g
62 g/29mL
70 g/100g
146.32 mL/236mL
215.14 mL/347mL
496 mL/800mL
618.1 mL/947mL
74.4 mL/120mL
154 mL/236mL
62 mL/100mL
.62 kg/100L
.65 mL/100L
70 mL/100mL
650 mL/L
18 mL/30mL
75 1/100mL
60.1 L/100L
146 g/236g
37 g/60g
67.63 %
6.2 mL/10mL
6 mL/10mL
44.9 mL/59.1mL
.76 mL/mL
224 g/400g
143 g/238g","For therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (tic douloureux), in patients for whom neurosurgical procedures are contraindicated."
C(C(C(=O)N(C1=C([H])C([H])=C([H])C([H])=C1[H])C1(C([H])([H])C([H])([H])N(C(C(C(=O)OC([H])([H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])C(=O)OC([H])([H])[H])([H])[H])([H])([H])[H],DB00899,132875-61-7,Remifentanil,"REMIFENTANIL
Remifentanyl",small molecule,Humans and other mammals,"Powder, for solution
Powder, for solution
Injection, powder, lyophilized, for solution
Powder, for solution","Intravenous
Intravenous
Intravenous
Intravenous","1 mg
2 mg
1 mg/mL
5 mg",For use during the induction and maintenance of general anesthesia.
C(C(C(=C([H])[H])C(=O)C1=C([H])C([H])=C(OC(C(O[H])=O)([H])[H])C(Cl)=C1Cl)([H])[H])([H])([H])[H],DB00903,58-54-8,Etacrynic acid,"(2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid
acide ��tacrynique
��cido etacr��nico
acidum etacrynicum
Etacrinic acid
Etakrinic acid
Ethacryinic Acid
Ethacrynate
Ethacrynic acid
Methylenebutyrylphenoxyacetic acid",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Injection, powder, for solution
Injection, powder, lyophilized, for solution
Powder, for solution
Powder, for solution","Oral
Oral
Oral
Intravenous
Intravenous
Intravenous
Intravenous","25 mg
25 mg/1
50 mg
50 mg/50mL
50 mg/50mL
50 mg/50mL
50 mg","For the treatment of high blood pressure and edema caused by diseases like congestive heart failure, liver failure, and kidney failure."
N(S(=O)(=O)C(C1=NOC2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H],DB00909,68291-97-4,Zonisamide,"1,2-Benzisoxazole-3-methanesulfonamide
3-(Sulfamoylmethyl)-1,2-benzisoxazole
Benzo[d]isoxazol-3-yl-methanesulfonamide
Zonisamida
Zonisamidum",small molecule,Humans and other mammals,"Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Capsule
Capsule
Capsule
Capsule
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg
25 mg
300 mg
50 mg
100 mg/1
25 mg/1
50 mg/1
100 mg
25 mg
50 mg",For use as adjunctive treatment of partial seizures in adults with epilepsy.
C(C(S(=O)(=O)C(C(N1C(C([H])([H])[H])=NC([H])=C1[N+]([O-])=O)([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00911,19387-91-8,Tinidazole,Timidazole,small molecule,"Trichomonas vaginalis, Giardia duodenalis, and Entamoeba histolytica","Tablet, film coated
Tablet
Tablet
Tablet, film coated","Oral
Oral
Oral
Oral","500 mg/1
250 mg/1
500 mg/1
250 mg/1",For the treatment of trichomoniasis caused by <i>T. vaginalis</i> in both female and male patients. Also for the treatment of giardiasis caused by <i>G. duodenalis</i> in both adults and pediatric patients older than three years of age and for the treatment of intestinal amebiasis and amebic liver abscess caused by <i>E. histolytica</i> in both adults and pediatric patients older than three years of age.
C(C(OC(=O)C1(C([H])([H])C([H])([H])N(C(C(C2=C([H])C([H])=C(N([H])[H])C([H])=C2[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB00913,144-14-9,Anileridine,"1-[2-(4-Aminophenyl)ethyl]-4-phenyl-4-piperidinecarboxlic acid ethyl ester
Anileridina
Anileridinum
Ethyl 1-(2-(4-aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylate
ethyl 1-(4-aminophenethyl)-4-phenylisonipecotate
Ethyl 1-(P-aminophenethyl)-4-phenylisonipecotate
N-(beta-(P-Aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidine
N-beta-(P-Aminophenyl)ethylnormeperidine
N-��-(p-aminophenyl)ethylnormeperidine",small molecule,Humans and other mammals,"Liquid
Tablet","Intramuscular; Intravenous; Subcutaneous
Oral","25 mg
25 mg",For treatment and management of pain (systemic) and for use as an anesthesia adjunct.
N(C(=N[H])N(C(=N[H])N(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])[H])[H])([H])[H],DB00914,114-86-3,Phenformin,"DBI
Fenformin
Fenformina
Phenformine
Phenforminum
��-Phenethybiguanide",small molecule,Humans and other mammals,,,,For the reatment of type II diabetes mellitus.
N(C12C([H])([H])C3(C([H])([H])C(C(C(C3([H])[H])(C1([H])[H])[H])([H])[H])([H])C2([H])[H])[H])([H])[H],DB00915,768-94-5,Amantadine,"1-adamantanamine
1-adamantylamine
1-aminoadamantane
Amantadina
Amantadine
Amantadinum
Amantidine
Aminoadamantane
Tricyclo[3.3.1.1(3,7)]decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-ylamine
Tricyclo[3.3.1.1(3,7)]decane-1-amine
Viregyt
Virosol",small molecule,"Humans and other mammals
Various viruses","Capsule, liquid filled
Capsule
Capsule, gelatin coated
Solution
Syrup
Tablet
Tablet, film coated
Kit
Capsule, coated pellets
Capsule, coated pellets
Capsule
Syrup","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Topical
Oral
Oral
Oral
Oral","100 mg/1
100 mg/1
100 mg/1
50 mg/5mL
50 mg/5mL
100 mg/1
100 mg/1
137 mg/1
68.5 mg/1
100 mg
10 mg","For the chemoprophylaxis, prophylaxis, and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Also for the treatment of parkinsonism and drug-induced extrapyramidal reactions."
C(C1=NC([H])=C([N+]([O-])=O)N1C(C(O[H])([H])[H])([H])[H])([H])([H])[H],DB00916,443-48-1,Metronidazole,"1-(2-hydroxy-1-ethyl)-2-methyl-5-nitroimidazole
1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(beta-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Oxyethyl)-2-methyl-5-nitroimidazole
1-(��-ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(��-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(��-oxyethyl)-2-methyl-5-nitroimidazole
2-methyl-1-(2-hydroxyethyl)-5-nitroimidazole
2-methyl-3-(2-hydroxyethyl)-4-nitroimidazole
2-methyl-5-nitroimidazole-1-ethanol
Metronidazol
Metronidazolum",small molecule,"Bacteria and protozoa
Helicobacter pylori
Peptoclostridium difficile","Suppository
Cream
Cream
Suppository
Tablet, extended release
Cream
Gel
Gel
Lotion
Capsule
Capsule
Gel
Gel
Gel
Injection, solution
Lotion
Lotion
Solution
Tablet
Tablet
Tablet
Tablet, film coated, extended release
Tablet, film coated
Tablet, film coated
Liquid
Solution
Gel
Cream
Cream
Cream
Gel
Gel
Capsule
Kit
Cream
Cream","Vaginal
Vaginal
Vaginal
Vaginal
Oral
Topical
Topical
Topical
Topical
Oral
Oral
Topical
Topical
Vaginal
Intravenous
Topical
Topical
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Intravenous
Intravenous
Vaginal
Topical
Topical
Topical
Topical
Vaginal
Oral
Topical
Topical","500 mg
10 %
750 mg
.75 %
0.75 %
1 %
0.75 %
375 mg/1
500 mg
10 mg/g
7.5 mg/g
7.5 mg/g
500 mg/100mL
7.5 mg/mL
7.5 mg/g
500 mg/100mL
250 mg
250 mg/1
500 mg/1
750 mg/1
250 mg/1
500 mg/1
5 mg
5 mg
0.75 %
1 %
10 mg/g
10 mg/60g
65 mg/5g
65 mg/5g
7.5 mg/g","For the treatment of anaerobic infections and mixed infections, surgical prophylaxis requiring anaerobic coverage, Clostridium difficile-associated diarrhea and colitis, Helicobacter pylori infection and duodenal ulcer disease, bacterial vaginosis, Giardia lamblia gastro-enteritis, amebiasis caused by Entamoeba histolytica, acne rosacea (topical treatment), and Trichomonas infections."
C(N(C([H])([H])[H])C(C(C1=C([H])N([H])C2=C1C(=C(C(S(=O)(=O)N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H])([H])[H])C(=C2[H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB00918,154323-57-6,Almotriptan,1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine,small molecule,Humans and other mammals,"Tablet, film coated
Tablet, film coated
Tablet, coated
Tablet, coated
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral","12.5 mg/1
6.25 mg/1
12.5 mg/1
6.25 mg/1
12.5 mg
6.25 mg",For the treatment of acute migraine headache in adults
C(N1C([H])([H])C([H])([H])C(=C2C3=C(SC(=C3[H])[H])C(=O)C([H])([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB00920,34580-13-7,Ketotifen,"Ketotifene
Ketotifeno
Ketotifenum",small molecule,Humans and other mammals,"Kit
Solution / drops
Solution / drops
Solution
Solution
Solution
Solution / drops
Syrup
Tablet
Solution / drops
Solution","Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Oral
Oral
Oral
Ophthalmic",".25 mg/mL
.35 mg/mL
.25 g/mL
.25 mg/mL
.35 mg/mL
.345 mg/mL
1 mg
1 mg
1 mg
0.25 mg",Indicated as an add-on or prophylactic oral medication in the chronic treatment of mild atopic asthmatic children. Also used as self-medication for the temporary relief of itching of the eye due to allergic conjunctivitis (ophthalmic).
C(N(C([H])([H])[H])C(C(C(=C1C2=C(C(=C(C(=C2[H])[H])[H])[H])C([H])=C([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB00924,303-53-7,Cyclobenzaprine,"(3-Dibenzo[a,d]cyclohepten-5-ylidene-propyl)-dimethyl-amine
Ciclobenzaprina
Cyclobenzaprine
Cyclobenzaprinum
N,N-Dimethyl-5H-dibenzo(a,D)cycloheptene-delta(5,gamma)-propylamine
N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-��5,��-propylamine",small molecule,Humans and other mammals,"Capsule, extended release
Capsule, extended release
Kit
Capsule, film coated, extended release
Capsule, film coated, extended release
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Kit
Kit
Tablet
Kit","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Topical
Oral
Oral","15 mg/1
30 mg/1
10 mg/1
5 mg/1
10 mg/1
10 mg/10mg
5 mg/1
7.5 mg/1
10 mg/301
10 mg/1
5 mg/1
7.5 mg/1
10 mg","For use as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions."
C(C(OC(=O)C(=C(C([H])([H])[H])C(=C(C(=C(C([H])([H])[H])C(=C(C1=C(C([H])([H])[H])C(C([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])[H])[H])[H])[H])[H])[H])[H])([H])[H])([H])([H])[H],DB00926,54350-48-0,Etretinate,,small molecule,Humans and other mammals,,,,For the treatment of severe psoriasis in adults.
N(C(N([H])[H])=NC1=NC(C(SC(C(C(N([H])[H])=NS(N([H])[H])(=O)=O)([H])[H])([H])[H])([H])[H])=C([H])S1)([H])[H],DB00927,76824-35-6,Famotidine,"(1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide
3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide
3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine
Famotidina
Famotidinum
N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide",small molecule,Humans and other mammals,"Tablet, chewable
Tablet, coated
For suspension
Injection
Injection, solution
Injection, solution
Injection, solution
Powder, for solution
Powder, for suspension
Tablet
Tablet
Tablet, film coated
Tablet, film coated, extended release
Solution
Tablet
Tablet
Tablet, chewable
Tablet, film coated
Tablet, film coated
Tablet
Tablet
Tablet, coated","Oral
Oral
Oral
Intravenous
Intravenous
Intravenous
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","40 mg/5mL
10 mg/mL
10 mg/mL
2 mg/mL
20 mg/50mL
40 mg/5mL
40 mg/5mL
10 mg/1
40 mg/1
40 mg/1
10 mg/1
10 mg
20 mg/1
10 mg
20 mg/1
20 mg/1
10 mg/1
20 mg
40 mg
10 mg/1",For the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD).
C(N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1(C(C(N1C2=C(C(=C(C(=C2[H])[H])[H])[H])SC2=C1C(=C(C(=C2[H])[H])S(C([H])([H])[H])=O)[H])([H])[H])([H])[H])[H])([H])([H])[H],DB00933,5588-33-0,Mesoridazine,"10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine
10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine
2-Methanesulfinyl-10-[2-(1-methyl-piperidin-2-yl)-ethyl]-10H-phenothiazine
Mesoridazina
Mesoridazine
Mesoridazinum
Thioridazine Thiomethyl Sulfoxide
thioridazine-2-sulfoxide
TPS-23",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet","Oral
Oral
Oral","10 mg
25 mg
50 mg","Used in the treatment of schizophrenia, organic brain disorders, alcoholism and psychoneuroses."
C(N(C(C(C(C12C([H])([H])C([H])([H])C(C3=C1C([H])=C([H])C([H])=C3[H])([H])C1=C2C(=C(C(=C1[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB00934,10262-69-8,Maprotiline,"Maprotilina
Maprotilinum
Maprotylina",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral","25 mg
50 mg
75 mg
25 mg/1
50 mg/1
75 mg/1
10 mg","For treatment of depression, including the depressed phase of bipolar depression, psychotic depression, and involutional melancholia, and may also be helpful in treating certain patients suffering severe depressive neurosis."
C(C1=C([H])C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=C(O[H])C(C([H])([H])[H])=C1C(C1=NC([H])([H])C([H])([H])N1[H])([H])[H])([H])([H])[H],DB00935,1491-59-4,Oxymetazoline,"2-(4-Tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline
3-[(4,5-dihydro-1H-Imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol
6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
6-Tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
Oximetazolinum
Oxymetazolina
Oxymetazolinum
Oxymethazoline
Oxymetozoline",small molecule,Humans and other mammals,"Liquid
Spray
Spray
Spray, metered
Spray, metered
Spray
Spray
Spray
Spray
Spray
Spray
Spray
Spray
Liquid
Spray
Solution
Solution
Solution
Solution / drops; spray
Spray
Spray
Liquid
Spray, metered
Solution / drops
Spray, metered
Spray
Spray, metered
Spray, metered
Cream
Spray
Spray
Spray
Spray
Spray
Spray
Liquid
Spray
Liquid
Liquid
Solution / drops
Spray
Solution","Nasal
Topical
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Topical
Nasal
Ophthalmic
Nasal
Oral
Nasal
Nasal
Topical
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Ophthalmic
Ophthalmic
Ophthalmic
Nasal
Nasal","50 mg/100mL
.5 mg/mL
0.05 mg
.05 g/100mL
.05 mg/mL
.05 g/100mL
.05 mg/100mL
.2 mg/.4mL
.5 mg/mL
0.5 %
.0005 g/mL
.05 mg/100mg
0.05 %
0.05 %
.5 mg/mL
.05 g/100mL
.05 mg/100mL
.025 %
5 g/100mL
.05 mg/mL
.05 g/100mL
.0005 mL/100mL
.25 mg
0.05 %
.5 mg/mL
.2 mg/.4mL
.5 mg/mL
10 mg/g
7.5 mg/15mL
50 mg/100mL
.512 mg/mL
.0005055 g/mL
.000512 g/mL
.0005095 g/mL
.05 %
.05 g/mL
.25 mg/mL
.025 %
0.025 %
.005 g/100mL
0.05 %",For treatment of nasal congestion and redness associated with minor irritations of the eye
O(C(=O)C1=C(O[H])C([H])=C([H])C([H])=C1[H])[H],"DB00936
DB01398",69-72-7,Salicylic acid,"2-Carboxyphenol
2-Hydroxybenzoic acid
O-carboxyphenol
O-hydroxybenzoic acid",small molecule,Humans and other mammals,"Gel
Cream
Liquid
Gel
Solution
Cream
Liquid
Cream
Gel
Gel
Liquid
Liquid
Gel
Liquid
Gel
Gel
Gel
Gel
Cream
Solution
Liquid
Soap
Lotion
Cream
Gel
Liquid
Cream
Gel
Liquid
Cream
Patch
Kit; liquid; lotion
Liquid
Swab
Swab
Swab
Swab
Lotion
Cloth
Spray
Solution
Lotion
Gel
Lotion
Cream
Cream
Patch
Plaster
Plaster
Aerosol, foam
Cloth
Cloth
Cloth
Shampoo
Gel
Powder
Liquid
Liquid
Powder
Strip
Liquid; swab
Liquid
Liquid
Lotion
Shampoo
Cream
Cream
Cream
Shampoo
Liquid
Gel
Swab
Jelly
Rinse
Shampoo
Disc
Stick
Lotion
Cream
Shampoo
Spray
Lotion
Lotion
Cloth
Cloth
Cream
Lotion
Soap
Soap
Cloth
Soap
Soap
Lotion
Jelly
Stick
Stick
Lotion
Liquid
Swab
Emulsion
Emulsion
Liquid
Ointment
Solution
Kit
Lotion
Shampoo
Spray
Ointment
Gel
Cream
Gel
Gel
Gel
Liquid
Liquid
Gel
Gel
Liquid
Liquid
Gel
Rinse
Lotion
Lotion
Lotion
Lotion
Lotion
Lotion
Cloth
Strip
Gel
Gel
Gel
Powder
Gel
Ointment
Patch
Patch
Shampoo
Plaster
Lotion
Liquid
Cream
Liquid
Cream
Cream
Liquid
Liquid
Paste
Spray
Liquid
Solution
Gel
Gel
Lotion
Cream
Liquid
Gel
Lotion
Kit
Cream
Liquid
Cloth
Lotion
Lotion
Cloth
Gel
Lotion
Lotion
Liquid
Gel
Solution
Salve
Liquid
Lotion
Lotion
Swab
Solution
Solution
Solution
Lotion
Solution
Liquid
Cloth
Cloth
Lotion
Solution
Gel
Cream
Gel
Cream
Liquid
Paste
Lotion
Liquid
Cream
Gel
Liquid
Cream
Gel
Lotion
Gel
Gel
Liquid
Liquid
Solution
Stick
Spray
Liquid
Cream
Gel
Powder
Gel
Liquid
Liquid
Plaster
Liquid
Cream
Emulsion
Emulsion
Plaster
Ointment
Cream
Gel
Stick
Gel
Cream
Liquid
Patch
Soap
Liquid
Liquid
Tablet
Cream
Solution
Lotion
Liquid
Liquid
Lotion
Liquid
Ointment
Lotion
Liquid
Lotion
Gel
Gel
Cream
Liquid
Liquid
Lotion
Shampoo
Shampoo
Soap
Ointment
Liquid
Tablet
Tablet
Gel
Cream
Spray
Cream
Gel
Liquid
Liquid
Solution
Disc
Solution
Disc
Lotion
Liquid
Liquid
Liquid
Cream
Cream
Gel
Liquid
Patch
Powder
Paste
Liquid
Stick
Lotion
Gel
Liquid, extended release
Paste
Swab
Liquid
Liquid
Gel
Gel
Patch
Liquid
Liquid
Soap
Cream
Liquid
Liquid
Liquid
Oil
Gel
Shampoo
Solution
Solution
Spray
Solution
Aerosol, foam
Liquid
Gel
Lotion
Liquid
Cream
Aerosol, foam
Gel
Solution
Lotion / shampoo
Shampoo
Liquid
Gel
Lotion
Liquid
Liquid
Liquid
Lotion
Liquid
Soap
Cream
Gel
Cream
Liquid
Liquid
Gel
Shampoo
Cream
Jelly
Cream
Gel
Shampoo
Shampoo
Gel
Gel
Cream
Cream
Gel
Cream
Solution
Lotion
Paste
Cream; suspension
Spray
Cloth
Gel
Gel
Paste
Stick
Solution
Liquid
Plaster
Liquid
Swab
Gel
Disc
Shampoo
Plaster
Patch
Plaster
Plaster
Plaster
Shampoo
Shampoo
Cream
Lotion
Solution
Cloth
Shampoo
Ointment
Solution
Liquid
Shampoo
Emulsion
Liquid
Cream
Liquid
Lotion
Shampoo
Swab
Gel
Aerosol, foam
Cream
Suspension
Kit
Aerosol, foam
Liquid
Gel
Cloth
Lotion
Lotion
Liquid
Cream
Gel
Cream
Powder
Shampoo
Ointment
Gel
Gel
Soap
Cloth
Cloth
Lotion
Gel
Solution, gel forming / drops
Shampoo
Liquid
Cloth
Liquid
Lotion
Gel
Gel
Cream
Gel
Gel
Patch
Soap
Soap
Swab
Swab
Suspension
Gel
Lotion
Swab
Swab
Patch
Cream
Gel
Lotion
Plaster
Kit; lotion; solution
Shampoo
Patch
Plaster
Strip
Cream
Rinse
Liquid
Cream
Concentrate
Solution
Liquid
Cream
Liquid
Gel
Gel
Cream
Gel
Lotion
Spray
Cloth
Cream
Lotion
Gel
Soap
Solution
Liquid
Gel
Lotion
Lotion / shampoo
Soap
Gel
Cream
Liquid
Lotion
Swab
Gel
Cream
Cream
Soap
Shampoo
Cream
Cream
Liquid
Cream
Liquid
Swab
Spray
Patch
Stick
Liquid
Shampoo
Cream
Lotion
Lotion
Gel
Aerosol, foam
Cream
Cream
Cream
Gel
Gel
Gel
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Lotion
Lotion
Lotion
Lotion
Patch
Patch
Patch
Patch
Patch
Patch
Plaster
Plaster
Plaster
Plaster
Shampoo
Shampoo
Strip
Gel
Soap
Liquid
Liquid
Gel
Aerosol, foam
Soap
Liquid
Liquid
Liquid
Gel
Gel
Paste
Liquid; shampoo
Shampoo
Shampoo
Liquid
Cream
Gel
Cream
Liquid
Liquid
Liquid
Rinse
Liquid
Liquid
Liquid
Lotion
Liquid
Liquid
Ointment
Kit
Gel
Cloth
Liquid
Solution
Shampoo
Soap
Cream
Liquid
Cream
Emulsion
Soap
Emulsion
Emulsion
Emulsion
Emulsion
Liquid
Soap
Soap
Soap
Liquid
Liquid
Liquid
Liquid
Cream
Shampoo
Suspension
Shampoo
Ointment
Stick
Stick
Lotion
Lotion
Ointment
Spray
Shampoo
Solution
Liquid
Plaster
Cream
Solution
Tape
Gel
Patch
Liquid
Liquid
Cream
Lotion
Gel
Gel
Liquid
Solution
Disc
Liquid
Liquid
Spray
Emulsion
Plaster
Gel
Liquid
Liquid
Gel
Swab
Swab
Soap
Solution
Shampoo
Gel
Plaster
Plaster
Plaster
Liquid
Cloth
Stick
Gel
Cream
Solution
Cream
Cream
Liquid
Liquid
Gel
Gel
Liquid
Stick","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Transdermal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Dental
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Intravenous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical; Transdermal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical",".6 g/120mL
.001 mg/10mL
.1 mg/100mL
.000001 g/10mL
22.5 mg/15mL
14 g/100g
1.2 g/240mL
.5 g/100g
7 mg/354mg
.02158 g/100mL
.02 g/1
29.2 mg/1
2 g/100g
.75 mg/150mL
0.5 %
1.5 g/100mL
21 mg/mL
.01 g/g
.5 mg/mL
.2 g/40g
1.5 mL/100mL
2 g/100g
1 mL/100mL
1 mL/100mL
.5 mL/100mL
.5 g/.5mL
.5 g/100mL
.005 mg/g
.018 mg/mg
2 g/mL
2 g/100mL
2 g/200mL
.5 g/100mL
.5 g/100g
5 mg/1000mg
5 mg/mL
.02 mL/mL
5 mg/1
2.84 g/142g
20 mg/1
10 mg/mL
.6 g/30mL
1 mg/mL
1.5 %
.3 mL/15mL
2 mg/100mg
.4 1/1001
40 1/1
1.5 g/100g
2 g/1
2 g/101
2 g/301
60 mg/mL
.5 %
.6 mg/mL
.01 g/mL
1 mg/mL
0.6 %
1.4 %
.5 %
.5 %
1 g/200mL
250 g/5g
200 g/6g
50 g/g
.08 g/20mL
5 mg/g
.2 g/100mL
.1 g/100mL
15 uL/mL
10 uL/mL
1 %
2 g/397g
2 g/414g
20 mg/1
2 g/100g
1 mg/100mL
5 mL/100mL
20 mg/mL
5 mg/mL
.75 mg/150mL
11 mg/mL
20 mg/mL
.5 g/100g
.5 mL/100mL
2 mL/100mL
0.50 %
.5 g/100g
6 mg/1
.5 %
5 mg/g
0.7 %
2 %
1.5 %
1.5 %
40 %
20 mg/mL
10 mg/g
2.1 g/100mL
30 mg/g
.5 g/100mL
1 %
.24 mg/355mL
2 mg/355mL
2.8 g/140g
1.8 %
2 mL/100mL
2 mL/100mL
1.27 g/127g
2.5 g/127g
4.3 g/200mL
4.56 g/236mL
2 g/200mL
1.3 g/127g
2.8 g/141g
2.54 g/127g
19.4 mg/g
.2 mg/100mg
.587 g/118mL
2 g/120mL
1.5 g/15mL
.6 g/200mL
.6 g/100mL
2 g/40mL
10 mg/1
.03 mg/1
.02 g/g
25 mg/mL
1.25 g/250mL
.4 g/20g
5 g/g
.19 mg/1
11.9 mg/21
.3 g/100mL
40 %
.5 g/59g
20.6 mg/mL
10 mg/mL
.156 g/8.9mL
.28 g/14g
.623 g/130mL
.691 g/133mL
5 mg/g
2 g/118mL
28.8 mg/mL
10 mg/mL
2 g/151mL
30 mg/mL
50 mg/mL
50 mg/mL
1 g/100g
.5 g/100mL
.6 mL/60mL
2.4 mL/240mL
283.5 mg/56.7g
.0053 g/100mL
.0091 g/100mL
.5 mg/90mL
.5 mg/118mL
2 mg/15mL
.5 mg/50mL
2.00 %
2 %
2 g/100g
20 mg/mL
3.57 mg/mL
.01 g/g
7 mg/mL
2 g/100mL
.03 g/1
.01 g/1
.015 g/1
1 g/100mL
1 g/100mL
2 %
.02 g/1
.03 g/1
150 mL/mL
.02 g/1
10 g/.2g
50 g/.5g
18.4 mg/mL
10 mg/g
5 mL/250mL
5 mg/mL
.6 mL/30mL
300 mg/30g
1.5 mL/75mL
.022 mL/1.1mL
5 mg/mL
1 mL/50mL
.375 mL/75mL
5 mg/mL
5 mg/mL
.3 mL/15mL
.25 g/50mL
20 mg/mL
20 mg/mL
2 g/2mL
2 %
1 %
1 %
1 %
.5 g/100g
17 %
150 mg/mL
20 %
4 mg/1
30 %
2 1/100g
.24 mg/29.6mg
1.89 mg/237mg
40 mg/1
15 %
1 g/100g
.3 mg/30mL
.025 g/2.5g
.1425 g/30mL
1 mg/100mL
2 mg/30mg
40 mg/1
20 mg/g
3 g/100mL
20.5 mg/mL
5.05 mg/mL
2.4 mL/120mL
.015 g/g
17.64 mg/mL
18 mg/mL
.5 %
20 mg/g
20 mg/g
10 uL/mL
7.08 mL/236mL
2.36 mL/118mL
3 %
3.54 mL/118mL
3 g/100g
.5 g/100g
50.5 mg/2.5mL
30 mg/1.5mL
3.0 %
.035 g/g
4.8 g/240g
25 g/100mL
325 mg
500 mg
1 g/50mL
.01 g/15mL
.14 g/140mL
1.5 g/50mL
.1 g/100mL
.3 g/10mL
12.64 %
150 mg/mL
4 mg/1
1.7 mg/mL
.4 g/1
20 mg/g
.48 g/100mL
.48 mL/100mL
.5 mg/100mg
.5 mg/100mg
.00001 g/100mL
11 %
150.28 mg/mL
3 mg/30mL
1 g/100g
2 g/100g
1 g/100g
2 g/100mL
1 mg/g
20 g/1000mL
2 mg/100mL
20 mg/mL
21 mg/1
170 mL/mL
40 mg/1
50 mg/mL
.5 g/100mL
40 mg/100mg
17 g/100mL
2 %
2 %
2.16 mg/120mL
158.4 mg/mL
.2 g/100mL
.01 mL/mL
2000 mg/g
11.52 mL/384mL
30 mg/mL
15 mg/mL
20 mg/mL
4.8 g/240mL
.5 mL/100mL
4 mL/200mL
21.2 mg/100mL
3 g/100g
3 g/100g
2 g/100g
.7 mg/mL
2.0 %
1 mg/200mL
18.5 mg/mL
.1 1/300mL
3 %
1.184 mL/59.2mL
.003 mL/mL
.003 g/mL
.0001 mL/mL
2.15 g/110mL
1.2 g/120mL
1.35 g/135g
3 %
2 mg/2mL
.5 mg/.5mL
20 mL/L
.02 mL/mL
.02 mL/mL
.5 g/100mL
0.5 %
.5 %
.5 %
6 g/100g
5 g/100mL
6 g/92.6mL
3 g/100g
6 %
.15105 g/15mL
.025 mg/5mL
5 mg/g
2 mCi/100mL
5 mg/mL
.45 mL/30mL
0.5 %
4.72 mL/118mL
.6 mL/60mL
.75 mL/50mL
.425 mL/25mL
.75 mL/150mL
36 mg/1.8g
2 g/100mL
.75 %
.4 g/g
17 mg/100mg
.02 mL/1
19.8 mg/g
40 %
1.8 g/100mL
40 g/100g
.056 mg/1
2.068 mg/1
3.175 mg/1
5.51 mg/1
2 g
.03 g/g
2.016 g/112g
30 mg/mL
.15 mg/30mL
1 g/100g
.2 1/300g
40 %
.1 g/25mL
.06 g/mL
.06 g/mL
1 g/100g
.75 g/100g
30 mL/100mL
1 mL/100mL
.5 mg/mL
.01 g/100mL
2 mL/100mL
1 mg/g
20 mg/g
1 mg/g
20 mg/mL
5 mg/g
1.8 %
20 mg/mL
20 mg/1
20 mg/mL
2.0 %
5 mg/g
5.5 mg/g
1.5 %
1.0 %
5 mg/g
30 mg/mL
2 g/100g
3 mg/15mL
.1 g/20mL
.01 g/g
.02 g/g
.05 mg/100mg
5 g/1000mL
5 g/1000mL
20 mg/mL
9 mg/500g
170 mg
20.5 mg/mL
2.5 g/125g
20.6 mg/mL
3 g/150g
4 mg/177mg
.5 mL/50mL
1.15 mL/115mL
.06 mL/15mL
.4 g/g
.27 g/55g
.4 g/80g
20 mg/1
5 mg/1
0.5 %
10 mg/mL
2 %
2 %
.5 %
5 mg/1
20 mg/g
20 mg/g
2 g/100mL
.4 g/1
4 mg/1
.4 1/1
4.42 mg/1
1 mg/20mg
2 g/100g
.025 g/1
15 mg/mL
2 g/100mL
.013 mg/2.5mL
.7 %
.02 g/mL
1 mL/100mL
1 g/100mL
29 mL/100mL
.008776 g/mL
1.8 mg/180mg
2 mg/100mL
.036 g/1
.02 g/1000mL
2 mg/100mL
5 mg/1000mL
1 mg/100g
5 mg/1000mL
2 mg/100mL
.2 g/100mL
.5 mg/100mL
.02 g/1000mL
1 g/100g
.5 mg/100mL
1.5 g/100g
0.5 %
0.5 %
0.5 %
1.77 g/59mL
2.26 g/113g
1.1 g/56.7g
3 g/100g
3 g/100g
2.5 g/100g
3 g/100mL
1.8 g/100mL
17 g/100g
2 mg/mL
20 mg/mL
4.8 mL/240mL
.04 g/40mL
1 %
2 mL/100mL
.25 g/100mL
24 g/400g
24.84 mg/414mL
60 mg/mL
1.2 g/60g
6 g/100g
27.24 g/g
6 g/100g
60 mg/g
.17 g/7g
.21 g/1.25g
60 mg/g
.17 g/g
.17 mg/9.8mL
.17 g/9.8mL
.17 mg/15mL
.17 mg/9mL
.17 g/9.8g
.17 mg/151mL
.17 mg/9.8g
.17 g/9mL
2 g/100g
2.1 g/14.7mL
260 mg/mL
275 mg/mL
.5 g/60mL
6 g/100mL
6 mg/100mL
60 mg/g
40 mg/91
40 mg/241
40 mg/141
40 mg/181
40 mg/41
40 mg/61
.4 g/181
.4 g/1411
.4 g/141
40 mg/141
2 g/100g
6 mg/100mL
40 mg/1
.75 mg/150mL
3.5 %
.02 mg/mL
570 mg
15 mg/mL
3.88 g/70g
12 g/100mL
30 mg/g
17 %
2 g/100mL
8 g/100g
1 g/100g
.02 g/mL
.03 g/mL
.5 mL/100mL
20 mg/mL
154 mg/30mL
1.8 %
.6 g/100mL
1.5 mg/100mL
.5 mL/100mL
20 g/2mL
5 g/2mL
.5 mg/mL
15 mg/mL
4 g/100g
.2 g/g
1.8 g/50g
.5 g/100g
2 g/100g
20 mg/1
17 %
18 mg/L
20 mg/mL
2.0 %
.009506 g/100mL
.065 mg/13mL
.02 g/g
.02 g/mL
.01 g/mL
.02 mL/mL
.02 g/mL
.01 mL/mL
2.2 %
.01 mL/mL
.02 mL/mL
.02 g/g
1 g/100mL
2 g/100mL
.1 g/1
.5 g/100mL
2 %
2 %
3 %
3 g/100g
12 g/100g
15 g/100g
1 g/100g
2 g/100g
.14 g/28g
18 mg/mL
.0024 mg/.12mg
15 %
2 g/100mL
285 mg/mL
4 mg/1
17 g/100g
.4 g/100g
170 mg/mL
17 mL/10mL
5 mg/mL
.5 mL/50mL
1 mL/200mL
.625 mL/125mL
1 mL/200mL
275 mg/mL
17.67 mg/1
.25 g/100mL
.15 g/100mL
15 mg/mL
1.2 g/120mL
40 mL/1
.17 g/g
2.51 mL/14.78mL
.02 g/g
4 g/200g
1 g/100g
2 g/100g
.001 g/.1g
280 mg/g
10 g/325g
5 mg/237mg
40 g/1
156 mg/1
5.3 g/265mL
5 mg/mL
1 g/100g
1 mg/100mL
10 mg/mL
2 mg/100mL
.47 g/100mL
.47 mL/100mL
.47 g/100mL
.47 mL/100mL
.47 g/100mL
.47 mL/100mL
.4 g/100mL
20 mg/g","Key additive in many skin-care products for the treatment of acne, psoriasis, callouses, corns, keratosis pilaris and warts."
C(C1=C([H])C([H])=C(Cl)C(N(C2=C(C(O[H])=O)C([H])=C([H])C([H])=C2[H])[H])=C1Cl)([H])([H])[H],DB00939,644-62-2,Meclofenamic acid,"Acide meclofenamique
Acido meclofenamico
Acidum meclofenamicum
Meclofenamate
N-(2,6-Dichloro-3-methylphenyl)anthranilic acid
N-(2,6-Dichloro-m-tolyl)anthranilic acid
N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid",small molecule,Humans and other mammals,"Capsule
Capsule","Oral
Oral","100 mg/1
50 mg/1","For the relief of mild to moderate pain, for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss. Also for relief of the signs and symptoms of acute and chronic rheumatoid arthritis and osteoarthritis."
C(C([N+](C([H])([H])[H])(C(C([H])([H])[H])([H])[H])C(C(OC(=O)C1(C2=C(C(=C(C(=C2[H])[H])[H])[H])OC2=C1C(=C(C(=C2[H])[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00940,5818-17-7,Methantheline,"Methantheline
Methanthelinium
Methanthelinum",small molecule,Humans and other mammals,,,,"For the treatment of peptic ulcer disease, irritable bowel syndrome, pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, and reflex neurogenic bladder in children."
C([N+](C([H])([H])[H])(C(C(C(C(C(C([N+](C([H])([H])[H])(C([H])([H])[H])C1(C2=C(C(=C(C(=C2[H])[H])[H])[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C1(C2=C(C(=C(C(=C2[H])[H])[H])[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])[H])([H])([H])[H],DB00941,4844-10-4,Hexafluronium,"Hexafluorenium
Hexafluorenium cation
Hexafluorenium ion
Hexamethylenebis(fluoren-9-yldimethylammonium)",small molecule,Humans and other mammals,,,,Used as an adjunct with succinylcholine (or suxamethonium chloride) to prolong muscle relaxation and to prevent succinylcholine-induced muscle fasciculations.
C(N(C(C(C(C(C(C(C(C(C(C(N(C([H])([H])[H])C(=O)OC1=C([H])C([N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C(=O)OC1=C([H])C([N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=C([H])C([H])=C1[H])([H])([H])[H],DB00944,,Demecarium,Demecarium,small molecule,Humans and other mammals,,,,For the topical treatment of chronic open-angle glaucoma.
C(C(=O)OC1=C(C(O[H])=O)C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB00945,50-78-2,Acetylsalicylic acid,"2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoic acid
Acetylsalicylate
Acetylsalicyls��ure
acide 2-(ac��tyloxy)benzo��que
acide ac��tylsalicylique
��cido acetilsalic��lico
Acidum acetylsalicylicum
ASA
Aspirin
Azetylsalizyls��ure
o-acetoxybenzoic acid
O-acetylsalicylic acid
o-carboxyphenyl acetate
Polopiryna
salicylic acid acetate",small molecule,Humans and other mammals,"Tablet
Tablet
Kit; tablet, delayed release; tablet, extended release
Tablet
Capsule, extended release
Capsule; capsule, extended release
Tablet, effervescent
Kit
Granule, effervescent
Tablet, delayed release
Suppository
Suppository
Tablet, chewable
Tablet, delayed release
Tablet, film coated
Tablet, film coated
Gum, chewing
Suppository
Suppository
Tablet
Tablet, coated
Tablet, extended release
Tablet, delayed release; tablet, extended release
Tablet, delayed release; tablet, extended release
Tablet, delayed release
Granule
Tablet, coated
Tablet, chewable
Tablet, coated
Tablet
Tablet, coated
Powder
Tablet, coated
Tablet
Kit
Powder
Kit
Paste
Tablet, film coated
Capsule, extended release
Kit
Tablet, delayed release
Tablet, delayed release
Tablet, delayed release
Tablet, delayed release
Tablet, chewable
Tablet, delayed release
Tablet, delayed release
Tablet, delayed release
Tablet, chewable
Capsule, gelatin coated
Tablet, coated
Tablet, orally disintegrating
Tablet, film coated
Kit
Tablet, delayed release
Capsule, coated
Tablet
Powder
Tablet, multilayer
Kit; tablet; tablet, delayed release
Capsule
Tablet
Tablet
Tablet, delayed release
Tablet
Tablet
Tablet
Strip
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Rectal
Rectal
Oral
Oral
Oral
Oral
Oral
Rectal
Rectal
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Topical
Dental
Oral
Oral
Oral; Topical
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Topical
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","500 mg
300 mg
325 1/1
600 mg
150 mg
650 mg
80 mg
162 mg
500 mg/1
325 mg/1
325 mg
300 mg/1
600 mg/1
325 g/1
325 ng/1
81 mg/1
325 mg
500 mg
81 mg/811
500 mg
500 mg/5001
81 mg/1
81 mg/1
500 mg/1
325 mg/1
500 mg/1
500 mg/1
81 mg/1
325 mg/1
162.5 mg/1
325 mg/1
325 mg/3251
325 mg
650 mg
81 mg
500 mg
975 mg
81 mg
325 mg
81 mg/1
81 mg/1
81 mg/1
325 mg
81 mg
80 mg
80 mg
325 mg/1
81 mg/1
81 mg/81mg
325 mg/325mg","For use in the temporary relief of various forms of pain, inflammation associated with various conditions (including rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and ankylosing spondylitis), and is also used to reduce the risk of death and/or nonfatal myocardial infarction in patients with a previous infarction or unstable angina pectoris."
N(C(=O)OC(C(C(OC(N([H])[H])=O)([H])[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H])([H])[H],DB00949,25451-15-4,Felbamate,"2-Phenyl-1,3-propanediol dicarbamate
Carbamic acid 2-phenyltrimethylene ester
Carbamic acid 3-carbamoyloxy-2-phenyl-propyl ester
Felbamate
Felbamato
Felbamatum",small molecule,Humans and other mammals,"Suspension
Tablet
Tablet","Oral
Oral
Oral","600 mg/5mL
400 mg/1
600 mg/1",For use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.
N(N(C(=O)C1=C([H])C([H])=NC([H])=C1[H])[H])([H])[H],DB00951,54-85-3,Isoniazid,"4-pyridinecarbohydrazide
INH
Isoniazid
Isonicotinic acid hydrazide
Isonicotinic hydrazide
Isonicotinohydrazide
Isonicotinoylhydrazide
Isonicotinsaeurehydrazid
Isonicotinylhydrazine
Pyridine-4-carboxylic acid hydrazide",small molecule,"Mycobacteria
Mycobacterium tuberculosis","Capsule
Injection, solution
Solution
Syrup
Tablet
Tablet
Syrup
Tablet
Powder
Syrup
Solution
Tablet
Tablet
Tablet
Tablet, sugar coated","Oral
Intramuscular
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg/mL
50 mg/5mL
50 mg/5mL
100 mg/1
300 mg/1
50 mg
50 mg
500 g
10 mg
50 mg
100 mg
300 mg",For the treatment of all forms of tuberculosis in which organisms are susceptible.
C(N(S(=O)(=O)C(C(C1=C([H])C2=C(N(C(=C2C2(C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C2([H])[H])[H])[H])[H])C([H])=C1[H])([H])[H])([H])[H])[H])([H])([H])[H],DB00952,121679-13-8,Naratriptan,"N-Methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide
N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
Naratriptanum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet, coated
Tablet, coated
Tablet, film coated
Tablet, film coated
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","1 mg
1 mg/1
2.5 mg/1
1 mg/1
2.5 mg/1
1 mg/1
2.5 mg/1
2.5 mg",For the acute treatment of migraine attacks with or without aura in adults.
C(N(C([H])([H])[H])C(C(C1=C([H])N([H])C2=C1C(=C(C(N1C([H])=NC([H])=N1)([H])[H])C(=C2[H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB00953,144034-80-0,Rizatriptan,"N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine
N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine
Risatriptan
Rizatript��n
Rizatriptan
Rizatriptanum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet, orally disintegrating
Tablet, orally disintegrating
Film, soluble
Film, soluble
Tablet, film coated
Tablet, film coated
Tablet
Tablet, orally disintegrating
Tablet, orally disintegrating","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","5 mg
10 mg/1
10 mg
10 mg
5 mg
10 1/1
5 1/1
10 mg/1
5 mg/1
5 mg/1
10 mg/1
5 mg/1",For treatment of acute migraine attacks with or without aura.
O=C1O[Pt]OC(=O)C21C([H])([H])C([H])([H])C2([H])[H],DB00958,41575-94-4,Carboplatin,"Carboplatin
CBDCA
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)",small molecule,Humans and other mammals,"Injection
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Solution
Solution
Solution
Liquid
Solution
Powder, for solution","Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous","10 mg/mL
10 mg/mL
150 mg/15mL
450 mg/45mL
50 mg/5mL
600 mg/60mL
150 mg/5mL
450 mg/5mL
50 mg/5mL
10 mg
10 mg
150 mg","For the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of PARAPLATIN and cyclophosphamide. It is also indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. "
C(C(N(C(C([H])([H])[H])=O)C1=C([H])C(C2=C([H])C([H])=NC3=C(C(=NN23)[H])C#N)=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB00962,151319-34-5,Zaleplon,"3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule
Capsule, gelatin coated
Capsule, gelatin coated","Oral
Oral
Oral
Oral
Oral
Oral","10 mg
5 mg
10 mg/1
5 mg/1
10 mg/1
5 mg/1",For the treatment of short-term treatment of insomnia in adults.
N(C1=C(C(=O)C2=C([H])C([H])=C(Br)C([H])=C2[H])C([H])=C([H])C([H])=C1C(C(O[H])=O)([H])[H])([H])[H],DB00963,91714-94-2,Bromfenac,"[2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid
2-amino-3-(4-Bromobenzoyl)benzeneacetic acid
Bromfenaco
Bromfenacum",small molecule,Humans and other mammals,"Solution / drops
Solution / drops
Solution / drops
Suspension / drops
Solution
Solution / drops
Solution / drops","Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic",".9 mg/mL
1.035 mg/mL
.76 mg/mL
0.07 %
.7 mg/mL
0.9 mg/ml",For the treatment of postoperative inflammation in patients who have undergone cataract extraction.
N(C1=C([H])C(Cl)=C(N(C2=NC([H])([H])C([H])([H])N2[H])[H])C(Cl)=C1[H])([H])[H],DB00964,66711-21-5,Apraclonidine,"4-Aminoclonidine
Apraclonidina
Apraclonidinum",small molecule,Humans and other mammals,"Solution
Solution / drops
Solution
Solution
Solution
Solution / drops","Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic","5.75 mg/mL
5 mg/mL
0.5 %
1 %
5 mg/mL
10 mg/mL",For prevention or reduction of intraoperative and postoperative increases in intraocular pressure (IOP) before and after ocular laser surgery when used prophylactically. Also used as a short-term adjunctive therapy in patients with open-angle glaucoma who are on maximally tolerated medical therapy requiring additional IOP reduction.
C(C(C(C1=NC2=C(C(=C(C(=C2C([H])([H])[H])[H])C2=NC3=C(C(=C(C(=C3[H])[H])[H])[H])N2C([H])([H])[H])[H])N1C(C1=C([H])C([H])=C(C2=C(C(O[H])=O)C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00966,144701-48-4,Telmisartan,"4'-((1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid
4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid
4'-[(1,4'-Dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid
4'-[(1,7'-Dimethyl-2'-propyl-1H,3'h-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
BIBR 277
Telmisartan",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, multilayer","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","20 mg
40 mg/1
80 mg/1
40 mg
80 mg
20 mg/1","Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors)."
ClC1=C([H])C2=C(C(=C3C([H])([H])C([H])([H])N([H])C([H])([H])C3([H])[H])C3=C(C(C2([H])[H])([H])[H])C([H])=C([H])C([H])=N3)C([H])=C1[H],DB00967,100643-71-8,Desloratadine,"8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
8-chloro-6,11-dihydro-11-(4-Piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
Descarboethoxyloratadine
DESLORATADINE",small molecule,Humans and other mammals,"Syrup
Tablet, multilayer, extended release
Tablet
Tablet, extended release
Tablet, film coated
Solution
Tablet
Tablet, film coated
Tablet, orally disintegrating
Tablet, orally disintegrating
Solution
Tablet, orally disintegrating
Tablet, orally disintegrating","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","0.5 mg
5 mg
5 mg
.5 mg/mL
5 mg/1
5 mg/1
2.5 mg/1
5 mg/1
0.5 mg/ml
2.5 mg
5 mg","For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria."
C(N1C2=C(C(=O)N(C(C3=C(C([H])([H])[H])N([H])C([H])=N3)([H])[H])C(C2([H])[H])([H])[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])([H])[H],DB00969,122852-42-0,Alosetron,"2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one",small molecule,Humans and other mammals,"Tablet, film coated
Tablet, film coated
Tablet
Tablet","Oral
Oral
Oral
Oral",".5 mg/1
1 mg/1
.5 mg/1
1 mg/1",Only for the treatment of symptoms of severe diarrhea-predominant irritable bowel syndrome (IBS) in women with chronic symptoms (generally lasting greater than 6 months) who does not present with anatomic or biochemical GI abnormalities and have not responded to conventional therapy.
S=[Se]=S,DB00971,7488-56-4,Selenium Sulfide,"Selenii disulfidum
Selenium disulfide
Selenium disulphide
Selenium sulfide, micronized
Selenium sulphide
Selenium sulphide, micronized
Selenium(IV) disulfide
Selenium(IV) disulphide
Selenium(IV) sulfide
Selenium(IV) sulphide",small molecule,"Humans and other mammals
Fungi
Bacteria","Cloth
Shampoo
Lotion / shampoo
Shampoo
Shampoo
Liquid
Liquid
Shampoo
Lotion
Lotion
Lotion
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Aerosol, foam","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","10 mg/mL
1 g/100mL
1 kg/100L
.6 g/100mL
10 mg/mL
1 mL/100mL
1 mL/100mL
2.5 mg/100mL
2.5 g/100mL
25 mg/mL
22.5 mg/mL
23 mg/mL
1 g/100mL
1 %
1.0 %
.025 g/mL
1.44 g/70g","For treatment of tinea versicolor, tinea capitis, dandruff and seborrheic dermatitis of the scalp."
O(C(=O)C(N(C(C(N(C(C(O[H])=O)([H])[H])C(C(O[H])=O)([H])[H])([H])[H])([H])[H])C(C(O[H])=O)([H])[H])([H])[H])[H],DB00974,60-00-4,Edetic Acid,"(ethylenedinitrilo)tetraacetic acid, ion(4���)
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate
acide edetique
Acide ethylenediaminetetracetique
Acido edetico
Acidum edeticum
EDTA
EDTA, ion(4-)
Ethylenediaminetetraacetate
Ethylenediaminetetraacetic acid
N,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine)",small molecule,Humans and other mammals,"Injection
Injection
Liquid
Liquid
Liquid
Liquid","Intramuscular
Intramuscular; Intravenous
Intramuscular; Intravenous; Subcutaneous
Topical
Dental
Ophthalmic","200 mg/mL
200 mg/mL
200 mg","For the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults."
O(C(C(N(C(C(O[H])([H])[H])([H])[H])C1=NC(N2C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])=C2N=C(N=C(N3C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])C2=N1)N(C(C(O[H])([H])[H])([H])[H])C(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB00975,58-32-2,Dipyridamole,"Cleridium 150
Curantyl
Dipiridamol
Dipyridamine
Dipyridamolum
Dipyudamine
Dypyridamol
Persantin",small molecule,Humans and other mammals,"Capsule, extended release
Capsule; capsule, extended release
Tablet
Capsule
Injection
Solution
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Liquid
Tablet
Solution
Tablet, coated
Tablet, coated
Tablet, coated
Tablet
Tablet","Oral
Oral
Oral
Oral
Intravenous
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Intravenous
Oral
Intravenous
Oral
Oral
Oral
Oral
Oral","50 mg
5 mg/mL
5 mg/mL
25 mg/1
50 mg/1
75 mg/1
25 mg/1
50 mg/1
75 mg/1
5 mg
100 mg
5 mg
25 mg/1
50 mg/1
75 mg/1
25 mg
75 mg",For as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.
C(OC1=C([H])C([H])=C(C(C(C([H])([H])[H])(N(C(C(O[H])(C2=C([H])C(N(C(=O)[H])[H])=C(O[H])C([H])=C2[H])[H])([H])[H])[H])[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB00983,73573-87-2,Formoterol,"2'-Hydroxy-5'-(1-hydroxy-2-((P-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide
2'-Hydroxy-5'-{1-hydroxy-2-[(P-methoxy-alpha-methylphenethyl)amino]ethyl}formanilide
Formoterolum
N-[2-Hydroxy-5-(1-hydroxy-2-{[2-(4-methoxyphenyl)-1-methylethyl]amino}ethyl)phenyl]formamide",small molecule,Humans and other mammals,"Aerosol, metered
Aerosol
Capsule
Capsule
Powder
Powder
Solution
Powder","Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)","12 ug/1
12 mcg
12 mcg
6 mcg
20 ug/2mL","For use as long-term maintenance treatment of asthma in patients 6 years of age and older with reversible obstructive airways disease, including patients with symptoms of nocturnal asthma, who are using optimal corticosteroid treatment and experiencing regular or frequent breakthrough symptoms requiring use of a short-acting bronchodilator. Not indicated for asthma that can be successfully managed with occasional use of an inhaled, short-acting beta2-adrenergic agonist. Also used for the prevention of exercise-induced bronchospasm, as well as long-term treatment of bronchospasm associated with COPD."
N(C(C(C1=C([H])C(O[H])=C(O[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H],DB00988,51-61-6,Dopamine,"2-(3,4-dihydroxyphenyl)ethylamine
3-Hydroxytyramine
3,4-Dihydroxyphenethylamine
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
Dopamina
Dopamine
Dopaminum
Oxytyramine",small molecule,Humans and other mammals,"Injection, solution
Injection, solution
Solution
Liquid
Injection, solution
Injection, solution, concentrate
Injection, solution, concentrate
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Solution","Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous","80 mg/mL
160 mg/mL
40 mg
40 mg/mL
40 mg/mL
80 mg/mL
.8 mg/mL
1.6 mg/mL
160 mg/100mL
3.2 mg/mL
320 mg/100mL
80 mg/100mL
40 mg","For the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure"
O(C(=O)C(C(C1=NC(C2=C([H])C([H])=C([H])C([H])=C2[H])=C(C2=C([H])C([H])=C([H])C([H])=C2[H])O1)([H])[H])([H])[H])[H],DB00991,21256-18-8,Oxaprozin,"Danoprox
Dayrun
Deflam
Duraprox
Oxaprozina
Oxaprozine
Oxaprozinum
Walix",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, film coated","Oral
Oral
Oral","600 mg
600 mg/1
600 mg/1","Used to relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis."
C(OC(=O)C(C(C(=O)C(N([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB00992,33320-16-0,Methyl aminolevulinate,"5-Aminolevulinic acid methyl ester
Aminolevulinic acid methyl ester
Methyl aminolevulinate
Methyl delta-aminolevulinate",small molecule,Humans and other mammals,Cream,Topical,168 mg,"For topical use, in combination with 570 to 670 nm wavelength red light illumination, in the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette)."
C(N1C([H])=NC([N+]([O-])=O)=C1SC1=NC([H])=NC2=C1N(C(=N2)[H])[H])([H])([H])[H],DB00993,446-86-6,Azathioprine,"6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
Imuran (tn)",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Injection, powder, lyophilized, for solution
Powder, for solution
Powder, for solution
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intravenous
Intravenous
Intravenous
Oral","100 mg/1
75 mg/1
100 1/1
25 1/1
50 mg/1
50 1/1
75 1/1
100 mg/10mL
50 mg
100 mg
50 mg","For use in rheumatoid arthritis, preventing renal transplant rejection, Crohn's disease, and colitis."
N(C(C1(C(C(O[H])=O)([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])([H])[H])([H])[H],DB00996,60142-96-3,Gabapentin,"1-(Aminomethyl)cyclohexaneacetic acid
Gabapentin GR
Gabapentina
Gabapentine
Gabapentino
Gabapentinum
Gabapetin",small molecule,Humans and other mammals,"Kit
Capsule
Capsule
Capsule
Capsule
Capsule
Solution
Suspension
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Kit
Tablet, multilayer, extended release
Tablet, multilayer, extended release
Kit
Tablet
Tablet
Capsule
Capsule
Capsule
Kit
Kit
Cream","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Topical
Oral
Oral
Oral
Oral
Oral
Oral; Topical
Topical","100 mg/1
300 mg/300mg
300 mg/1
400 mg/1
600 mg/1
250 mg/5mL
250 mg/5mL
600 mg/1
800 mg/1
800 mg/800mg
100 mg/1
300 mg/1
400 mg/1
600 mg/1001
600 mg/1
800 mg/1
600 mg
800 mg
600 mg
800 mg
100 mg
300 mg
400 mg",For the management of postherpetic neuralgia in adults and as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy.
N(S(=O)(=O)C1=C(Cl)C([H])=C2N(C(N(S(=O)(=O)C2=C1[H])[H])([H])[H])[H])([H])[H],DB00999,58-93-5,Hydrochlorothiazide,HCTZ,small molecule,Humans and other mammals,"Tablet, film coated
Tablet
Tablet
Tablet, coated
Capsule
Capsule, gelatin coated
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Capsule","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","50 mg
12.5 mg
12.5 mg/1
12.5 mg/1
12.5 mg/1
25 mg/25mg
25 mg/1
50 mg/1
50 mg/50mg
25 mg
100 mg",For the treatment of high blood pressure and management of edema.
O(C(C(OC1=C([H])C([H])=C([H])C2=C1C(=O)C(=C(O2)C(O[H])=O)[H])([H])[H])(C(OC1=C2C(=O)C(=C(OC2=C([H])C([H])=C1[H])C(O[H])=O)[H])([H])[H])[H])[H],DB01003,16110-51-3,Cromoglicic acid,"5-[3-(2-carboxy-4-oxo-4H-5-chromenyloxy)-2-hydroxypropoxy]-4-oxo-4H-2-chromenecarboxylic acid
Acide Cromoglicique
Acido Cromoglicico
Acidum Cromoglicicum
Cromoglicate
Cromoglicic acid
Cromoglycate
Cromoglycic acid
Cromolyn",small molecule,Humans and other mammals,"Solution; spray
Solution
Solution
Solution
Solution / drops
Solution, concentrate
Solution, concentrate
Spray, metered
Liquid
Liquid
Aerosol, metered; solution
Aerosol, metered
Powder
Capsule
Spray, metered
Solution
Liquid; spray
Solution
Liquid
Solution
Spray, metered
Aerosol, metered
Ointment","Nasal
Ophthalmic
Intrabronchial
Oral
Ophthalmic
Oral
Oral
Nasal
Oral
Respiratory (inhalation)
Nasal
Respiratory (inhalation)
Respiratory (inhalation)
Oral
Nasal
Respiratory (inhalation)
Nasal
Respiratory (inhalation)
Ophthalmic
Oral; Respiratory (inhalation)
Nasal
Nasal
Ophthalmic","2 %
2 %
20 mg/2mL
20 mg/mL
40 mg/mL
100 mg/5mL
20 mg/mL
5.2 mg/mL
20 mg/mL
1 %
2 %
1 mg
20 mg
100 mg
5.2 mg/1
1 %
2 %
10 mg
2 %
1 %
2 %
2 %
40 mg","For the management of patients with bronchial asthma. Also used in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis."
N(C1=NC2=C(N=C(N2C(OC(C(O[H])([H])[H])(C(O[H])([H])[H])[H])([H])[H])[H])C(=O)N1[H])([H])[H],DB01004,82410-32-0,Ganciclovir,"2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one
2-amino-9-(2-Hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine
9-[(1,3-dihydroxy-2-propoxy)methyl]guanine
GA2
Ganciclovir
Ganciclovirum
Gancyclovir",small molecule,Human Herpes Virus,"Capsule
Powder, for solution
Injection, powder, lyophilized, for solution
Capsule
Capsule
Capsule
Injection, solution
Injection, solution
Injection, solution
Implant
Gel","Oral
Intravenous
Intravenous
Oral
Oral
Oral
Intravenous
Intravenous
Intravenous
Intravitreal
Ophthalmic","250 mg
500 mg
500 mg/10mL
500 mg
250 mg/1
500 mg/1
2 mg/mL
50 mg/mL
500 mg/10mL
4.5 mg
1.5 mg/g","For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients."
N(C(=O)N(O[H])[H])([H])[H],DB01005,127-07-1,Hydroxyurea,"Carbamohydroxamic Acid
Carbamohydroximic Acid
Carbamoyl Oxime
Carbamyl Hydroxamate
Hidroxicarbamida
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamidum
Hydroxyharnstoff
Hydroxyurea
N-Carbamoylhydroxylamine
N-Hydroxyurea
Oxyurea",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule
Capsule
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","200 mg/1
300 mg/1
400 mg/1
500 mg
500 mg/1
100 mg/1
100 mg
1000 mg/1
1000 mg","For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia."
N#CC1=C([H])C([H])=C(C(N2C([H])=NC([H])=N2)(C2=C([H])C([H])=C(C#N)C([H])=C2[H])[H])C([H])=C1[H],DB01006,112809-51-5,Letrozole,Letrozol,small molecule,Humans and other mammals,"Tablet
Kit
Tablet
Tablet, film coated","Oral
Oral
Oral","2.5 mg
2.5 mg/1
2.5 mg/1",For the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. Also for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
C(S(=O)(=O)OC(C(C(C(OS(C([H])([H])[H])(=O)=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01008,55-98-1,Busulfan,"1,4-Bis(methanesulfonoxy)butane
1,4-Butanediol dimethanesulfonate
1,4-Dimesyloxybutane
1,4-Dimethanesulfonoxybutane
Bisulfex
Busulfan
Busulfano
Busulfanum
Leucosulfan
Mablin
Mielucin
Misulban
Mitostan
Myeloleukon
Tetramethylene bis(methanesulfonate)",small molecule,Humans and other mammals,"Injection, solution, concentrate
Injection
Solution
Tablet
Tablet, film coated","Intravenous
Intravenous
Intravenous
Oral
Oral","6 mg/mL
6 mg/mL
60 mg
2 mg
2 mg/1","For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous  (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases."
C(C([N+](C([H])([H])[H])(C([H])([H])[H])C1=C([H])C([H])=C([H])C(O[H])=C1[H])([H])[H])([H])([H])[H],DB01010,,Edrophonium,"(3-Hydroxyphenyl)dimethylethylammonium
3-hydroxy-N,N-dimethyl-N-ethylanilinium
EDR
Edrophonium
Edrophonium Ion
Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium
N-ethyl-3-hydroxy-N,N-dimethylanilinium
N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium",small molecule,Humans and other mammals,"Injection, solution
Liquid
Injection, solution
Liquid","Intramuscular; Intravenous
Intravenous
Intravenous
Intramuscular; Intravenous","10 mg/mL
10 mg
10 mg",For the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises.
C(C(C([H])([H])[H])(C(=O)C1=C([H])N=C([H])C([H])=C1[H])C1=C([H])N=C([H])C([H])=C1[H])([H])([H])[H],DB01011,54-36-4,Metyrapone,"Metirapona
Metopiron
Metyrapone
Metyraponum",small molecule,Humans and other mammals,"Capsule, gelatin coated",Oral,250 mg/1,Used as a diagnostic drug for testing hypothalamic-pituitary ACTH function. Occasionally used in Cushing's syndrome.
O(C(=O)C(C(N(C(=O)C1=C([H])C([H])=C(N=NC2=C([H])C(C(O[H])=O)=C(O[H])C([H])=C2[H])C([H])=C1[H])[H])([H])[H])([H])[H])[H],DB01014,80573-04-2,Balsalazide,"(e)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid
(e)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid
3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid
5-[4-(2-Carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid
Balsalazida
Balsalazido
Balsalazidum",small molecule,Humans and other mammals,"Capsule
Tablet
Tablet, film coated","Oral
Oral
Oral","750 mg/1
1.1 g/1
1.1 g/1",For the treatment of mildly to moderately active ulcerative colitis.
C(C1=C([H])C(N(S(=O)(=O)C2=C([H])C([H])=C(N([H])[H])C([H])=C2[H])[H])=NO1)([H])([H])[H],DB01015,723-46-6,Sulfamethoxazole,"3-(p-Aminophenylsulfonamido)-5-methylisoxazole
3-Sulfanilamido-5-methylisoxazole
4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide
Gantanol (tn)
SMX
Sulfamethoxazole",small molecule,"Gram negative and gram positive bacteria
Listeria monocytogenes
Escherichia coli","Liquid
Solution
Injection
Injection, solution, concentrate
Suspension
Tablet
Tablet
Tablet","Intravenous
Intravenous
Intravenous
Intravenous
Oral
Oral
Oral
Oral","800 mg/1
500 mg","For the treatment bacterial infections causing bronchitis, prostatitis and urinary tract infections."
C(OC1=C(C(=O)N(C(C(C2=C([H])C([H])=C(S(=O)(=O)N(C(=O)N(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])[H])[H])C([H])=C2[H])([H])[H])([H])[H])[H])C([H])=C(Cl)C([H])=C1[H])([H])([H])[H],DB01016,10238-21-8,Glyburide,"1-((p-(2-(5-chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea
1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea
5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide
Glibenclamida
Glibenclamide
Glibenclamidum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","2.5 mg
5 mg
1.25 mg/1
1.5 mg/1
2.5 mg/1
3 mg/1
5 mg/1
6 mg/1",Indicated as an adjunct to diet to lower the blood glucose in patients with NIDDM whose hyperglycemia cannot be satisfactorily controlled by diet alone.
N(C(=N[H])N(C(=O)C(C1=C(Cl)C([H])=C([H])C([H])=C1Cl)([H])[H])[H])([H])[H],DB01018,29110-47-2,Guanfacine,"Estulic
Guanfacina
Guanfacinum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Kit
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","1 mg/1
2 mg/1
1 mg/1
2 mg/1
3 mg/1
4 mg/1
1 mg/1
2 mg/1
3 mg/1
4 mg/1
1 mg
2 mg
3 mg
4 mg",For use alone or in combination with other classes of antihypertensive agents in the management of hypertension. Has also been used for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients.
C(OC1=C(C(C(=C(C([H])([H])[H])C(C(C(O[H])=O)([H])[H])([H])[H])[H])([H])[H])C(O[H])=C2C(=O)OC([H])([H])C2=C1C([H])([H])[H])([H])([H])[H],DB01024,24280-93-1,Mycophenolic acid,"(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
Micofenolico acido
Mycophenolate
Mycophenols��ure",small molecule,Humans and other mammals,"Tablet, delayed release
Tablet, delayed release
Tablet, delayed release
Tablet, delayed release","Oral
Oral
Oral
Oral","180 mg
360 mg
180 mg/1
360 mg/1","For the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids."
C(C(C([H])([H])[H])(C1=C([H])C2=C(OC3=C(C2=O)C([H])=C(C(O[H])=O)C(N([H])[H])=N3)C([H])=C1[H])[H])([H])([H])[H],DB01025,68302-57-8,Amlexanox,"2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid
Amlexanox
Amlexanoxo
Amlexanoxum
Amoxanox",small molecule,Humans and other mammals,Paste,Oral,5 %,Used as a paste in the mouth to treat aphthous ulcers (canker sores). 
C(C(=O)N1C([H])([H])C([H])([H])N(C2=C([H])C([H])=C(OC(C3(C([H])([H])OC(C(N4C([H])=C([H])N=C4[H])([H])[H])(C4=C(Cl)C([H])=C(Cl)C([H])=C4[H])O3)[H])([H])[H])C([H])=C2[H])C([H])([H])C1([H])[H])([H])([H])[H],DB01026,65277-42-1,Ketoconazole,"Ketoconazol
Ketoconazole
Ketoconazolum
Ketozole",small molecule,Fungi,"Aerosol, foam
Aerosol, foam
Cream
Cream
Shampoo, suspension
Shampoo, suspension
Tablet
Kit
Cream
Shampoo
Shampoo
Shampoo
Suspension
Tablet
Gel
Gel","Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Oral
Oral
Topical
Topical","20 mg/g
2 g/100g
20 mg/g
20 mg/1
20 mg/mL
20.5 mg/mL
200 mg/1
2 %
20 mg/mL
2 %
10 mg/mL
20 mg
200 mg
2 %
20 mg/g","For the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis."
C(OC(F)(F)C(Cl)(Cl)[H])([H])([H])[H],DB01028,76-38-0,Methoxyflurane,"Methoflurane
Methoxyfluoran
Methoxyfluran
Methoxyfluranum
Methyl 1,1-difluoro-2,2-dichloroethyl ether
Metoxiflurano",small molecule,Humans and other mammals,,,,For use in the induction and maintenance of general anesthesia
C(C(C(C(C1=NC2(C([H])([H])C([H])([H])C([H])([H])C2([H])[H])C(=O)N1C(C1=C([H])C([H])=C(C2=C(C3=NN([H])N=N3)C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01029,138402-11-6,Irbesartan,"2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
Irbesartan",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, coated
Tablet, coated
Tablet, coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","150 mg/1
150 mg
300 mg/1
300 mg
75 mg
150 mg/150mg
300 mg/300mg
75 mg/75mg
75 mg/1
150 mg/1
300 mg/1
75 mg/1
150 mg/1
300 mg/1
75 mg/1
150 mg
300 mg
75 mg","For the treatment of hypertension, as well as diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. Irbesartan is also used as a second line agent in the treatment of congestive heart failure."
N(C(=O)OC1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])C#C[H])([H])[H],DB01031,126-52-3,Ethinamate,"1-Ethynylcyclohexanol carbamate
Aethinyl-cyclohexyl-carbamat
Ethinamate
Ethinamatum
Etinamato",small molecule,Humans and other mammals,,,,"Used for the short-term treatment of insomnia, however, it generally has been replaced by other sedative-hypnotic agents."
C(C(C(N(C(C(C([H])([H])[H])([H])[H])([H])[H])S(=O)(=O)C1=C([H])C([H])=C(C(O[H])=O)C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB01032,57-66-9,Probenecid,"4-((Dipropylamino)sulfonyl)benzoic acid
4-(Di-N-propylsulfamoyl)benzoesaeure
4-(N,N-Dipropylsulfamoyl)benzoesaeure
P-(Dipropylsulfamoyl)benzoic acid
Probenecid acid
Probenecida
Probenecide
Probenecidum",small molecule,Humans and other mammals,"Tablet
Capsule; tablet
Tablet
Tablet, film coated
Tablet","Oral
Oral
Oral
Oral
Oral","500 mg
500 mg/1
500 mg/1",For the reduction of serum uric acid concentrations in chronic gouty arthritis and tophaceous gout in patients with frequent disabling gout attacks. Has also been effectively used to promote uric acid excretion in hyperuricemia secondary to the administration of thiazide and related diuretics. 
S=C1N=C([H])N([H])C2=C1N(C(=N2)[H])[H],DB01033,50-44-2,Mercaptopurine,"6 MP
6-Mercaptopurine
6-MP
6-Thiohypoxanthine
6-Thioxopurine
Mercaptopurina
Mercaptopurine anhydrous
mercaptopurinum
Mercapurin",small molecule,Humans and other mammals,"Tablet
Tablet
Suspension","Oral
Oral
Oral","50 mg/1
50 mg
20 mg/mL",For remission induction and maintenance therapy of acute lymphatic leukemia.
C(C(N(C(C([H])([H])[H])([H])[H])C(C(N(C(=O)C1=C([H])C([H])=C(N([H])[H])C([H])=C1[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01035,51-06-9,Procainamide,"Biocoryl
p-Amino-N-(2-diethylaminoethyl)benzamide
p-Aminobenzoic diethylaminoethylamide
Procainamida
Procainamide
Procainamidum",small molecule,Humans and other mammals,"Capsule
Injection
Injection
Injection, solution
Injection, solution
Solution
Capsule
Tablet, extended release
Tablet, extended release
Tablet, extended release
Capsule
Capsule
Liquid","Oral
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous","375 g
100 mg/mL
1000 mg/1
100 mg/mL
500 mg/mL
100 mg
250 mg
250 mg
500 mg
750 mg
375 mg
500 mg
100 mg",For the treatment of life-threatening ventricular arrhythmias.
C(C(C(=O)C1=C([H])C2=C(SC3=C(N2C(C(C(N2C([H])([H])C([H])([H])N(C(C(O[H])([H])[H])([H])[H])C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C([H])C([H])=C3[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB01038,2622-30-2,Carphenazine,"carfenazina
carf��nazine
Carfenazine
carfenazinum",small molecule,Humans and other mammals,,,,Used in the treatment of acute or chronic schizophrenic reactions in hospitalized patients.
C(C(C([H])([H])[H])(OC(=O)C(C([H])([H])[H])(C([H])([H])[H])OC1=C([H])C([H])=C(C(=O)C2=C([H])C([H])=C(Cl)C([H])=C2[H])C([H])=C1[H])[H])([H])([H])[H],"DB01039
DB09545",49562-28-9,Fenofibrate,"2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester
Fenofibrato
Fenofibratum
Finofibrate
FNF
Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate
Procetofen",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule
Capsule
Capsule
Tablet
Tablet
Tablet
Capsule
Tablet, film coated
Capsule
Capsule
Capsule
Capsule
Capsule
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, coated
Tablet, coated
Tablet, coated
Tablet, coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet
Tablet
Capsule
Tablet
Tablet, film coated
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","130 mg/1
30 mg/1
43 mg/1
90 mg/1
200 mg
67 mg
100 mg
160 mg
200 mg
100 mg
134 mg/1
150 mg/1
200 mg/1
50 mg/1
67 mg/1
145 mg/301
160 mg/301
160 mg/1
48 mg/1
54 mg/1
145 mg/1
160 mg/1
48 mg/1
54 mg/1
145 mg/1
160 mg/1
48 mg/1
120 mg/1
40 mg/1
160 mg
48 mg
54 mg/1
145 mg
145.0 mg
48.0 mg
145 mg/1","For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)"
N(C(=N[H])C1=C([H])C([H])=C(C(=C(C2=C(O[H])C([H])=C(C(N([H])[H])=N[H])C([H])=C2[H])[H])[H])C([H])=C1[H])([H])[H],DB01040,533-22-2,Hydroxystilbamidine Isethionate,"2-hydroxy-4,4'-stilbenedicarboxamidine bis(2-hydroxyethanesulphonate) (salt)
HSB
Hydroxystilbamidine isetionate",small molecule,"Yeast, Molds, Trypanosomes",,,,Used in the treatment of nonprogressive blastomycosis of the skin and other mycoses.
C(C12C([H])([H])C3(C(C(C([H])([H])[H])(C1([H])[H])C([H])([H])C(N([H])[H])(C3([H])[H])C2([H])[H])([H])[H])[H])([H])([H])[H],DB01043,19982-08-2,Memantine,"1-Amino-3,5-dimethyladamantane
1,3-Dimethyl-5-adamantanamine
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
Memantina
Memantine
Memantinum",small molecule,Humans and other mammals,"Tablet
Tablet, film coated
Tablet, film coated
Solution
Tablet
Capsule, extended release
Capsule, extended release
Kit
Liquid
Solution
Tablet
Tablet
Tablet, coated
Tablet, coated
Tablet, film coated
Tablet, film coated
Solution
Capsule, extended release
Capsule, extended release
Capsule, extended release
Kit
Capsule
Kit
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","5 mg
10 mg
20 mg
5 mg/Pump actuation
10 mg
21 mg/1
2 mg/mL
2 mg/mL
10 mg/1
5 mg/1
10 mg/1
5 mg/1
10 mg/1
5 mg/1
5 mg / pump actuation
14 mg/1
28 mg/1
7 mg/1
5.0 mg",For the treatment of moderate to severe dementia of the Alzheimer's type.
C(C(OP(=O)(OC(C([H])([H])[H])([H])[H])SC(C([N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01057,6736-03-4,Echothiophate,"2-(Diethoxyphosphorylsulfanyl)ethyl-N,N,N-trimethylazanium iodide
Echothiophate
Ecothiopate
Ecothiopatum
Phospholine",small molecule,Humans and other mammals,"Liquid; powder, for solution
Powder, for solution
Powder, for solution
Kit
Powder, for solution","Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic","3 mg
12.5 mg
3 mg
6.25 mg",For use in the treatment of subacute or chronic angle-closure glaucoma after iridectomy or where surgery is refused or contraindicated.
C(C(N1C([H])=C(C(O[H])=O)C(=O)C2=C(C(F)=C(C([H])=C12)N1C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H])[H])([H])[H])([H])([H])[H],DB01059,70458-96-7,Norfloxacin,"1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure
1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
NFLX
Norfloxacine
Norfloxacino
Norfloxacinum",small molecule,Enteric bacteria and other eubacteria,"Tablet
Solution","Oral
Ophthalmic","400 mg
3 mg",For the treatment of urinary tract infection
C(C(=O)C1=C([H])C2=C(SC3=C(N2C(C(C(N2C([H])([H])C([H])([H])N(C(C(O[H])([H])[H])([H])[H])C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C([H])C([H])=C3[H])C([H])=C1[H])([H])([H])[H],DB01063,2751-68-0,Acetophenazine,Acetophenazine,small molecule,Humans and other mammals,,,,For the treatment of disorganized and psychotic thinking. Also used to help treat false perceptions (e.g. hallucinations or delusions.)
C(OC1=C([H])C2=C(N(C(=C2C(C(N(C(C([H])([H])[H])=O)[H])([H])[H])([H])[H])[H])[H])C([H])=C1[H])([H])([H])[H],"DB01065
DB08189",73-31-4,Melatonin,"5-methoxy-N-acetyltryptamine
Melatonin
Melatonine
N-[2-(5-methoxyindol-3-yl)ethyl]acetamide
N-Acetyl-5-methoxytryptamine",small molecule,Humans and other mammals,"Tablet, extended release
Tablet","Oral
Oral",2 mg,"Used orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind (evidence for efficacy), and benzodiazepine and nicotine withdrawal. Evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults. It has received FDA orphan drug status as an oral medication for this use. A number of studies have shown that melatonin may be effective for treating sleep-wake cycle disturbances in children and adolescents with mental retardation, autism, and other central nervous system disorders. It appears to decrease the time to fall asleep in children with developmental disabilities, such as cerebral palsy, autism, and mental retardation. It may also improve secondary insomnia associated with various sleep-wake cycle disturbances. Other possible uses for which there is some evidence for include: benzodiazepine withdrawal, cluster headache, delayed sleep phase syndrome (DSPS), primary insomnia, jet lag, nicotine withdrawal, preoperative anxiety and sedation, prostate cancer, solid tumors (when combined with IL-2 therapy in certain cancers), sunburn prevention (topical use), tardive dyskinesia, thrombocytopenia associated with cancer, chemotherapy and other disorders. "
C(C1=C([H])N=C(C(=O)N(C(C(C2=C([H])C([H])=C(S(=O)(=O)N(C(=O)N(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])[H])[H])C([H])=C2[H])([H])[H])([H])[H])[H])C([H])=N1)([H])([H])[H],DB01067,29094-61-9,Glipizide,"1-cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)urea
Glipizida
Glipizide
Glipizidum
N-{4-[��-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylurea",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, film coated
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg/1
5 mg/1
10 mg/1
2.5 mg/1
5 mg/1
10 mg/1
2.5 mg/1
5 mg/1","For use as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory."
[O-][N+](=O)C1=C([H])C2=C(N(C(=O)C(N=C2C2=C(Cl)C([H])=C([H])C([H])=C2[H])([H])[H])[H])C([H])=C1[H],DB01068,1622-61-3,Clonazepam,"1,3-dihydro-7-Nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one
5-(2-Chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one
5-(2-Chlorophenyl)-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one
5-(O-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
CLONAZEPAM
Clonazepamum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","1.0 mg
2.0 mg
.5 mg
.5 mg/1
1 mg/1
2 mg/1
.125 mg/1
.25 mg/1
.5 mg/1
1 mg/1
2 mg/1
0.5 mg
1 mg
2 mg
0.25 mg","Clonazepam is used as an anticonvulsant in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. It can also be used for the treatment of panic disorders. "
C(C(O[H])(P(O[H])(O[H])=O)P(O[H])(O[H])=O)([H])([H])[H],DB01077,2809-21-4,Etidronic acid,"(1-hydroxy-ethylidene)diphosphonic acid
(1-Hydroxyethylene)diphosphonic acid
(1-Hydroxyethylidene)bis(phosphonic acid)
(1-Hydroxyethylidene)bisphosphonic acid
(1-Hydroxyethylidene)diphosphonic acid
(Hydroxyethylidene)diphosphonic acid
1-Hydroxy-1,1-diphosphonoethane
1-hydroxyethane 1,1-diphosphonic acid
1-Hydroxyethane-1,1-bisphosphonic acid
1-Hydroxyethane-1,1-diphosphonate
1-Hydroxyethane-1,1-diphosphonic acid
1-Hydroxyethanediphosphonic acid
1-Hydroxyethylidene-1,1-bisphosphonate
1-Hydroxyethylidene-1,1-diphosphonic acid
1,1,1-Ethanetriol diphosphonate
Acetodiphosphonic acid
acide ��tidronique
��cido etidr��nico
acidum etidronicum
EHDP
Ethane-1-hydroxy-1,1-bisphosphonic acid
Ethane-1-hydroxy-1,1-diphosphonate
Ethane-1-hydroxy-1,1-diphosphonic acid
Etidronate
Etidrons��ure
HEDP
Hydroxyethanediphosphonic acid
Oxyethylidenediphosphonic acid",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Solution
Tablet
Tablet
Kit; tablet","Oral
Oral
Oral
Intravenous
Oral
Oral
Oral","200 mg
400 mg
50 mg
200 mg/1
400 mg/1",For the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury.
C(C(C(C(C(N(C(=N[H])N(N=C(C1=C([H])N([H])C2=C1C(=C(OC([H])([H])[H])C(=C2[H])[H])[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01079,145158-71-0,Tegaserod,"1-(((5-Methoxyindol-3-yl)methylene)amino)-3-pentylguanidine
t��gas��rod
tegaserodum",small molecule,Humans and other mammals,,,,Provides relief from the symptoms of irritable bowel syndrome including chronic idiopathic constipation.
C(C(OC(=O)C1(C([H])([H])C([H])([H])N(C(C(C(C#N)(C2=C([H])C([H])=C([H])C([H])=C2[H])C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB01081,915-30-0,Diphenoxylate,"1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-isonipecotic acid ethyl ester
2,2-Diphenyl-4-(4-carbethoxy-4-phenylpiperidino)butyronitrile
4-Ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile
Difenossilato
Difenoxilato
Diphenoxylatum
Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylate
Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate",small molecule,Humans and other mammals,"Solution
Tablet","Oral
Oral",,For as adjunctive therapy in the management of diarrhea
C(C(OC(C(N1C(N2C([H])([H])C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C2([H])[H])=NC2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01084,87233-61-2,Emedastine,"1-(2-Ethoxy-ethyl)-2-(4-methyl-[1,4]diazepan-1-yl)-1H-benzoimidazole
1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzimidazole
1-[2-(Ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole
Emedastina
Emedastinum",small molecule,Humans and other mammals,"Liquid
Solution / drops","Ophthalmic
Ophthalmic","0.05 %
.5 mg/mL",For the temporary relief of the signs and symptoms of allergic conjunctivitis.
C(C(OC(=O)C1=C([H])C([H])=C(N([H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB01086,94-09-7,Benzocaine,"4-aminobenzoic acid ethyl ester
Amben ethyl ester
Benzocaina
Benzocaine
Benzocainum
Ethyl Aminobenzoate
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
p-(Ethoxycarbonyl)aniline
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline",small molecule,Humans and other mammals,"Strip
Kit
Kit
Kit
Stick
Cream
Aerosol, spray
Ointment
Stick
Gel
Gel
Gel
Liquid
Solution
Solution
Gel
Liquid
Solution
Liquid
Gel
Solution / drops
Gel
Lozenge
Gel
Spray
Spray
Gel
Gel
Swab
Swab
Cream
Liquid
Spray
Cream
Ointment
Cream
Ointment
Cream
Cream
Cream
Gel
Gel
Lotion
Liquid
Cream
Spray
Tablet, orally disintegrating
Lozenge
Lozenge
Swab
Aerosol
Ointment
Gel
Sponge
Paste, dentifrice
Paste
Gel
Lotion
Ointment
Gel, dentifrice
Gel, dentifrice
Gel, dentifrice
Liquid
Gel
Ointment
Gel
Ointment
Lotion
Gel
Gel
Gel
Spray
Aerosol, metered
Liquid
Liquid
Liquid
Liquid
Spray
Spray
Patch
Patch
Gel
Spray, metered
Gel
Gel
Liquid
Liquid
Aerosol, spray
Kit
Cream
Gel
Solution
Suppository
Cream
Spray
Liquid
Gel
Spray
Gel
Liquid
Aerosol
Solution
Gel
Liquid
Liquid
Cream
Liquid
Liquid
Gel
Cream
Gel
Lozenge
Gel
Granule
Liquid
Liquid
Gel
Gel
Swab
Swab
Cloth
Spray
Liquid
Gel
Liquid
Cream
Powder, for solution
Gel
Gel
Gel
Spray, metered
Paste, dentifrice
Liquid
Gel
Liquid
Swab
Gel
Liquid
Gel
Swab
Gel
Kit
Liquid
Paste
Gel
Gel
Gel
Ointment
Solution
Liquid
Liquid
Cream
Swab
Gel
Solution / drops
Tablet
Gel
Liquid
Gel
Gel
Gel
Cream
Ointment
Ointment
Liquid
Gel
Gel, dentifrice
Gel, dentifrice
Liquid
Swab
Powder, for solution
Cloth
Kit
Aerosol, spray
Gel
Gel
Syrup
Gum, chewing
Lozenge
Gel
Swab
Swab
Swab
Liquid
Ointment
Liquid
Spray, metered
Gel
Gel
Gel, dentifrice
Gel
Gel
Gel
Enema
Gel, dentifrice
Paste, dentifrice
Liquid
Spray, metered
Aerosol
Gel
Swab
Gel
Gel","Dental
Oral; Topical
Topical
Oral; Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Buccal
Topical
Topical
Oral
Topical
Auricular (otic)
Topical
Oral
Auricular (otic)
Topical
Oral
Topical
Topical
Topical
Dental
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Oral
Topical
Oral
Oral
Oral
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Dental
Oral
Topical
Topical
Dental
Dental
Dental
Dental; Topical
Dental
Dental
Buccal; Topical
Topical
Topical
Topical
Topical
Topical
Buccal; Oral
Topical
Rectal
Topical
Oral
Oral
Oral
Topical
Topical
Topical
Dental
Dental
Dental
Dental; Oral; Periodontal
Dental
Dental; Oral; Periodontal
Topical
Topical
Dental
Oral
Rectal
Topical
Dental; Periodontal
Topical
Dental; Periodontal
Dental; Oral; Periodontal
Dental; Oral; Periodontal
Dental; Oral; Periodontal
Dental; Topical
Topical
Dental; Oral
Topical
Dental
Topical
Buccal; Topical
Buccal
Oral
Dental
Topical
Buccal
Oral
Oral
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Oral
Dental; Topical
Buccal
Dental; Oral
Dental; Oral; Topical
Dental
Dental
Dental
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Oral; Topical
Auricular (otic)
Oral
Topical
Topical
Dental
Dental; Topical
Topical
Topical
Rectal
Topical
Topical
Oral
Oral
Oral
Dental
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Dental
Oral
Oral
Topical
Topical
Topical
Oral
Oral
Topical
Oral
Periodontal
Oral; Topical
Oral; Topical
Dental
Dental
Dental
Dental
Rectal
Oral
Topical
Oral
Topical
Oral
Topical
Topical
Topical
Dental","10 mg/1
100 mg/mL
7.5 g/100g
11.4 g/57g
5.6 g/28g
20 %
7.5 %
20 %
100 mg/g
200 mg/mL
100 mg/mL
.2 g/100g
.2 mg/2mL
20 g/100mL
10 g/100g
10 g/100g
15 mg/1
210 mg/g
11.8 g/59mL
20 mL/100mL
230 mg/mL
200 mg/mL
.12 mL/1
60 mg/mL
.2 g/g
5 g/100g
5 g/100g
5 g/100mL
5 g/28g
20 %
71.9395789 mg/mL
73.9395789 mg/mL
4.25 g/85.05g
9 mg/mL
.2 g/g
20 g/100mL
10 g/100g
6 mg/1
3 mg/1
4 mg/1
.06 mL/mL
10 g/100g
.075 g/g
200 mg/g
75 mg/g
50 mg/mL
20 g/100g
20 g/100g
10 g/100g
200 mg/mL
.2 g/mL
1.27 g/100g
.05 g/g
7.5 %
2410 mg/50mL
50 mg/mL
20 %
1417 mg/30mL
7.5 mg/100mg
7.5 mg/100mL
6 g/100g
6 g/30g
11.4 g/57g
20 %
200 mg/1
20 %
200 mg/1
200 mg/g
4.5 g/100g
183 mg/g
20 %
200 mg/g
200 mg/g
200 mg/g
200 mg/g
21.9 %
150 mg/mL
6.4 g/100g
6 g/100g
5 %
200 mg/mL
7 g/100mL
20 g/100g
6 mg/1
50 mg/mL
200 mg/mL
3 g/100mL
2.13 g/28.35g
.12 g/g
.12 g/.6mL
11.4 g/57g
200 mg/g
7.5 g/100g
2.1 mg/30mL
200 mg/mL
90 mg/1
6.4 g/32g
12 g/60g
19.8 mg/g
205 mg
200 mg
.2 mL/mL
200 mg/g
200 mg/g
.075 mL/mL
75 mg/g
.2 mL/mL
.2 mL/mL
20 g/100g
200 mg/g
5 mg/g
.009 mg/mL
18.6 g/100mL
20 mg/100mg
200 mg/mL
5 g/100mL
4 g/100mL
221 mg/g
20 %
20 1/100g
4.2 g/56g
200 mg/g
200 mg/mL
200 mg/mL
20 g/100g
20 g/100g
15 %
150 mg/3000mg
.0543 g/1
1.125 g/15g
5.06 g/67.5g
5.07 g/67.5g
1.8 %
2833 mg/60mL
6 g/100mL
.06 mg/1
20 %
1.3 mg/13mL
3.5 g/100g
50 mg/mL
220 mg/g
20 %
200 mg
220 mg/g
220 mg/g
6.96 g/30mL
231 mg/mL
7.5 g/100g
20 g/100g
20 g/100g
10 %
20 %
.1 g/g
20 g/100g","For general use as a lubricant and topical anesthetic on esophagus, larynx, mouth, nasal cavity, rectum, respiratory tract or trachea, urinary tract, vagina. It is also used to suppress gag reflex."
C([N+]1(C(C(C(C(C([N+]2(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])([H])([H])[H],DB01090,144-44-5,Pentolinium,"Pentolineum
Pentolonium
Pentolonum",small molecule,Humans and other mammals,,,,Used to produce controlled hypotension during surgical procedures and in hypertensive crises.
C(N(C(C1=C([H])C([H])=C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C([H])=C1[H])([H])[H])C(C1=C([H])C([H])=C([H])C2=C(C(=C(C([H])=C12)[H])[H])[H])([H])[H])([H])([H])[H],DB01091,101828-21-1,Butenafine,"(4-Tert-butyl-benzyl)-methyl-naphthalen-1-ylmethyl-amine
(4-Tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine
4-Tert-butylbenzyl(methyl)(1-naphthalenemethyl)amine
Butenafina
Butenafine
Butenafinum
N-(P-Tert-butylbenzyl)-N-methyl-1-naphthalenemethylamine",small molecule,Fungi,"Cream
Cream
Cream","Topical
Topical
Topical","1 %
10 mg/g
1 g/100g","For the topical treatment of the following dermatologic infections: tinea (pityriasis) versicolor due to <i>M. furfur</i>, interdigital tinea pedis (athlete&rsquo;s foot), tinea corporis (ringworm) and tinea cruris (jock itch) due to <i>E. floccosum</i>, <i>T. mentagrophytes</i>, <i>T. rubrum</i>, and <i>T. tonsurans</i>."
C(S(C([H])([H])[H])=O)([H])([H])[H],DB01093,67-68-5,Dimethyl sulfoxide,"(CH3)2SO
Dimethyl sulfoxide
Dimethyl sulfur oxide
Dimethyl sulphoxide
Dimethyli sulfoxidum
Dimethylsulfoxid
Dimethylsulfoxyde
Dimetil sulfoxido
DMSO
Methylsulfinylmethane
S(O)Me2
Sulfinylbis(methane)",small molecule,Humans and other mammals,"Solution
Irrigant
Solution","Topical
Intravesical
Intravesical","70 %
.54 g/mL
500 mg",For the symptomatic relief of patients with interstitial cystitis.
C(C1=C(C(=O)N(C2=C([H])C([H])=C(C(F)(F)F)C([H])=C2[H])[H])C([H])=NO1)([H])([H])[H],DB01097,75706-12-6,Leflunomide,"5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide
5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-P-toluidide
Leflunomida
Leflunomide
Leflunomidum
Lefunomide",small molecule,Humans and other mammals,"Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg
100 mg/1
100 mg
20 mg
100 mg
10 mg
20 mg
10 mg/1
20 mg/1
10 mg/1
20 mg/1
15 mg",For the management of the signs and symptoms of active rheumatoid arthritis (RA) to improve physical function and to slow the progression of structural damage associated with the disease. Has also been used for the prevention of acute and chronic rejection in recipients of solid organ trasnplants and is designated by the FDA as an orphan drug for this use.
N(C1=C(F)C([H])=NC(=O)N1[H])([H])[H],DB01099,2022-85-7,Flucytosine,"5-FC
5-Fluorocystosine
5-Fluorocytosin
5-Fluorocytosine
5-Flurocytosine
Ancobon (tn)
Flucytosin
Flucytosine
Fluocytosine
Fluorcytosine",small molecule,Yeast and other fungi,"Capsule
Capsule","Oral
Oral","500 mg/1
250 mg/1","For the treatment (in combination with amphotericin B) of serious infections caused by susceptible strains of Candida (septicemia, endocarditis and urinary system infections) and/or Cryptococcus (meningitis and pulmonary infections)."
FC1=C([H])C([H])=C(C(C(C(C(N2C([H])([H])C([H])([H])C(N3C(=O)N([H])C4=C3C(=C(C(=C4[H])[H])[H])[H])([H])C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])(C2=C([H])C([H])=C(F)C([H])=C2[H])[H])C([H])=C1[H],DB01100,2062-78-4,Pimozide,"Pimozida
Pimozide
Pimozidum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral","1 mg/1
2 mg/1
10 mg
2 mg
4 mg",Used for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.
C(C(C(C([H])([H])[H])(C(C(C(C(C(=O)N(C(C(C(N(C(S([O-])(=O)=O)([H])[H])[H])([H])[H])([H])[H])(C(=O)N(C(C(C([H])([H])[H])(O[H])[H])(C(=O)N(C(C(C(N(C(S([O-])(=O)=O)([H])[H])[H])([H])[H])([H])[H])(C(=O)N(C1(C([H])([H])C([H])([H])N([H])C(=O)C(C(C([H])([H])[H])(O[H])[H])([H])N([H])C(=O)C(C(C(N(C(S([O-])(=O)=O)([H])[H])[H])([H])[H])([H])[H])([H])N([H])C(=O)C(C(C(N(C(S([O-])(=O)=O)([H])[H])[H])([H])[H])([H])[H])([H])N([H])C(=O)C(C(C(C([H])([H])[H])(C([H])([H])[H])[H])([H])[H])([H])N([H])C(=O)C(C(C(C([H])([H])[H])(C([H])([H])[H])[H])([H])[H])([H])N([H])C(=O)C(C(C(N(C(S([O-])(=O)=O)([H])[H])[H])([H])[H])([H])[H])([H])N([H])C1=O)[H])[H])[H])[H])[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])([H])[H],DB01111,12705-41-8,Colistimethate,"Colistin methanesulfonic acid
Colistin sulfomethate
Colistinmethanesulfonic acid",small molecule,Gram-negative bacilli,"Injection
Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Capsule","Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Respiratory (inhalation)","150 mg/2mL
150 mg/2mL
150 mg/4mL
1662500 IU","For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly <i>Pseudomonas aeruginosa</i>."
C(OC1=C([H])C2=C(C(=NC(C(C3=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C3[H])([H])[H])=C2C([H])=C1OC([H])([H])[H])[H])[H])([H])([H])[H],"DB01113
DB07725",58-74-2,Papaverine,Mesotina,small molecule,Humans and other mammals,"Injection, solution
Liquid","Intravenous
Intramuscular; Intravenous; Subcutaneous","30 mg/mL
65 mg",For the treatment of impotence and vasospasms.
C(OC(=O)C1=C(C([H])([H])[H])N([H])C(C([H])([H])[H])=C(C(=O)OC([H])([H])[H])C1(C1=C([N+]([O-])=O)C([H])=C([H])C([H])=C1[H])[H])([H])([H])[H],DB01115,21829-25-4,Nifedipine,"4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsaeuredimethylester
Adapine
Nifecard
Nifecor
Nifedipine
Nifedipino
Nifedipinum
Nifedipres",small molecule,Humans and other mammals,"Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet
Tablet
Tablet, extended release
Tablet, extended release
Tablet, extended release
Kit; tablet, delayed release; tablet, extended release
Tablet, extended release
Capsule
Capsule
Capsule
Capsule
Capsule, liquid filled
Capsule, liquid filled
Tablet
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","30 mg/1
60 mg/1
90 mg/1
10 mg
20 mg
20 mg
30 mg
60 mg
60 mg/60mg
10 mg
10 mg/1
20 mg/1
5 mg
10 mg/1
20 mg/1
30 mg/1
30 mg/1
60 mg/1
90 mg/1
10 mg
30 mg/1
60 mg/1
90 mg/1","For the management of vasospastic angina, chronic stable angina, hypertension, and Raynaud's phenomenon. May be used as a first line agent for left ventricular hypertrophy and isolated systolic hypertension (long-acting agents). "
O=C1N(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])C2(C([S+]3C([H])([H])C([H])([H])C([H])([H])C3([H])C2([H])N1C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])[H],DB01116,7187-66-8,Trimethaphan,"Thimethaphan
Trimetaphan
Trimetaphanum
Trimethaphan",small molecule,Humans and other mammals,,,,For the controlled reduction of blood pressure during surgery and in the treatment of hypertensive emergencies.
C(C(C(C(C1=C(C(=O)C2=C([H])C(I)=C(OC(C(N(C(C([H])([H])[H])([H])[H])C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])C(I)=C2[H])C2=C(C(=C(C(=C2[H])[H])[H])[H])O1)([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01118,1951-25-3,Amiodarone,"2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran
2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone
2-N-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
Amiodarona
Amiodarone
Amiodaronum",small molecule,Humans and other mammals,"Injection, solution
Injection
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution, concentrate
Tablet
Tablet
Tablet
Tablet
Liquid
Solution
Injection, solution
Tablet
Tablet","Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Oral
Oral
Oral
Oral
Intravenous
Intravenous
Intravenous
Oral
Oral","1.8 mg/mL
50 mg/mL
150 mg/3mL
450 mg/9mL
50 mg/mL
900 mg/18mL
50 mg/mL
100 mg/1
200 mg/1
300 mg/1
400 mg/1
50 mg
50 mg
1.5 mg/mL
100 mg
200 mg","Intravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia."
C(C1=NS(=O)(=O)C2=C(C(=C(C(Cl)=C2[H])[H])[H])N1[H])([H])([H])[H],DB01119,364-98-7,Diazoxide,"Diazossido
Diazoxide
Diazoxido
Diazoxidum
Eudemine",small molecule,Humans and other mammals,"Liquid
Capsule
Suspension
Suspension","Intravenous
Oral
Oral
Oral","15 mg
100 mg
50 mg/mL
50 mg",Used parentally to treat hypertensive emergencies. Also used to treat hypoglycemia secondary to insulinoma.
C(C1=C([H])C([H])=C(S(=O)(=O)N(C(=O)N(N2C([H])([H])C3(C(C(C([H])([H])C3([H])C2([H])[H])([H])[H])([H])[H])[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB01120,21187-98-4,Gliclazide,"1-(3-Azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea
1-(Hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea
Gliclazida
Gliclazidum
N-(4-Methylbenzenesulfonyl)-N'-(3-azabicyclo(3.3.0)oct-3-yl)urea",small molecule,Humans and other mammals,"Tablet, extended release
Tablet, extended release
Tablet","Oral
Oral
Oral","60 mg
30 mg
80 mg",For the treatment of NIDDM in conjunction with diet and exercise. 
N(C(=O)N(C(=O)C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H])([H])[H],DB01121,63-98-9,Phenacemide,,small molecule,Humans and other mammals,,,,Used to control certain seizures in the treatment of epilepsy.
C(C([N+](C(C([H])([H])[H])([H])[H])(C(C(N(C(=O)C(=O)N(C(C([N+](C(C([H])([H])[H])([H])[H])(C(C([H])([H])[H])([H])[H])C(C1=C(Cl)C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])[H])C(C1=C(Cl)C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB01122,7648-98-8,Ambenonium,"Ambenonium
Ambenonium base
Ambenonum",small molecule,Humans and other mammals,,,,Ambenonium is used to treat muscle weakness due to muscle disease (myasthenia gravis).
N(C1=C([H])C2=NC3=C([H])C(N([H])[H])=C([H])C([H])=C3C([H])=C2C([H])=C1[H])([H])[H],DB01123,92-62-6,Proflavine,"2,8-Diaminoacridine
3,6-acridinediamine
3,6-diaminoacridine
Diaminoacridine
Proflavin
Proflavina
Proflavine
Proflavinum",small molecule,Enteric bacteria and other eubacteria,"Swab
Solution
Liquid","Topical
Topical
Topical",,Topical antiseptic used mainly in wound dressings.
C(C(C(C(N(C(=O)N(S(=O)(=O)C1=C([H])C([H])=C(C([H])([H])[H])C([H])=C1[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01124,64-77-7,Tolbutamide,"1-Butyl-3-(P-methylphenylsulfonyl)urea
1-Butyl-3-(P-tolylsulfonyl)urea
1-Butyl-3-tosylurea
1-P-Toluenesulfonyl-3-butylurea
3-(P-Tolyl-4-sulfonyl)-1-butylurea
N-(4-Methylbenzenesulfonyl)-n'-butylurea
N-(4-Methylphenylsulfonyl)-n'-butylurea
N-(P-Methylbenzenesulfonyl)-n'-butylurea
N-(Sulfonyl-P-methylbenzene)-n'-N-butylurea
N-Butyl-n'-(4-methylphenylsulfonyl)urea
N-Butyl-N'-(p-tolylsulfonyl)urea
N-Butyl-n'-P-toluenesulfonylurea
N-N-Butyl-n'-tosylurea
Orinase (tn)
Tolbutamida
Tolbutamide
Tolbutamidum
Tolylsulfonylbutylurea",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet","Oral
Oral
Oral","1 g
500 mg
500 mg/1",For treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.
C(OC1=C([H])C([H])=C(C2(C(=O)C3=C(C(=C(C(=C3[H])[H])[H])[H])C2=O)[H])C([H])=C1[H])([H])([H])[H],DB01125,117-37-3,Anisindione,"2-(4-Methoxyphenyl)-1H-indene-1,3(2H)-dione
2-(4-Methoxyphenyl)indan-1,3-dione
2-(P-Methoxyphenyl)-1,3-indandione
2-(P-Methoxyphenyl)indane-1,3-dione
2-P-Anisyl-1,3-indandione
2-Para-anisyl-1,3-indandione
Anisin indandione
Anisindiona
Anisindionum",small molecule,Humans and other mammals,,,,"For the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrillation with embolization, the prophylaxis and treatment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion."
C(C(C([H])([H])[H])(N=C(N([H])[H])N=C(N([H])[H])N(C1=C([H])C([H])=C(Cl)C([H])=C1[H])[H])[H])([H])([H])[H],DB01131,500-92-5,Proguanil," N-(4-Chlorophenyl)-n'-(isopropyl)-imidodicarbonimidic diamide
1-(P-Chlorophenyl)-5-isopropylbiguanide
Chlorguanide
Chloroguanide
N-(4-Chlorophenyl)-n'-(isopropyl)-imidodicarbonimidic diamide
Proguanilum",small molecule,Plasmodium,"Tablet
Tablet, film coated
Tablet","Oral
Oral
Oral",100 mg,For the causal prevention and suppression of malaria caused by susceptible strains of <i>P. falciparum</i> and other species of Plasmodium found in some geographical areas of the world.
O(P(O[H])(=O)C(SC1=C([H])C([H])=C(Cl)C([H])=C1[H])(P(O[H])(O[H])=O)[H])[H],DB01133,89987-06-4,Tiludronic acid,"Acide tiludronique
Acido tiludronico
Acidum tiludronicum
Tiludronate",small molecule,Humans and other mammals,,,,For treatment of Paget's disease of bone (osteitis deformans).
C(N(C([H])([H])[H])C(C(C(=C1C2=C(C(=C(C(=C2[H])[H])[H])[H])C([H])([H])OC2=C1C(=C(C(=C2[H])[H])[H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB01142,1668-19-5,Doxepin,"Cidoxepin
Doxepin",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule
Capsule
Capsule
Solution
Solution, concentrate
Capsule
Tablet
Tablet
Tablet
Tablet
Capsule
Capsule
Capsule
Capsule
Capsule
Cream
Cream","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Topical
Topical","10 mg/1
100 mg/1
150 mg/1
25 mg/1
50 mg/1
75 mg/1
10 mg/mL
10 mg/mL
150 mg
3 mg/1
3.00 mg
6 mg/1
6.00 mg
100 mg
10 mg
25 mg
50 mg
75 mg
50 mg/g
5 %","**Oral: **
- Indicated for the treatment of depression and/or anxiety [FDA Label]. 
- Indicated for the treatment of depression and/or anxiety associated with different conditions, including alcoholism, organic disease and manic-depressive disorders [FDA Label].
- Indicated for the treatment of insomnia characterized by difficulties with sleep maintenance [L1347].
Topical: 
- Indicated for the short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus [L1344]."
N(C(C(C(N(C(C(SP(O[H])(O[H])=O)([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB01143,20537-88-6,Amifostine,"Amifostina
Amifostinum
Aminopropylaminoethyl thiophosphate",small molecule,Humans and other mammals,"Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Powder, for solution","Intravenous
Intravenous
Intravenous","50 mg/mL
500 mg/10mL
500 mg",For reduction in the cumulative renal toxicity in patients with ovarian cancer (using cisplatin) and moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.
N(S(=O)(=O)C1=C([H])C(Cl)=C(Cl)C(S(N([H])[H])(=O)=O)=C1[H])([H])[H],"DB01144
DB07948",120-97-8,Diclofenamide,"1,3-disulfamoyl-4,5-dichlorobenzene
1,3-Disulfamyl-4,5-dichlorobenzene
3,4-Dichloro-5-sulfamylbenzenesulfonamide
4,5-Dichloro-1,3-benzenedisulfonamide
4,5-dichloro-1,3-disulfamoylbenzene
4,5-Dichloro-benzene-1,3-disulfonic acid diamide
4,5-dichloro-m-benzenedisulfonamide
4,5-DICHLOROBENZENE-1,3-disulfonamide
Dichlofenamide
Dichlorophenamide
Dichlorphenamide
Diclofenamida
Diclofenamide
Diclofenamidum",small molecule,Humans and other mammals,Tablet,Oral,50 mg/1,"For adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure"
O(S(=O)C(N(C1=C([H])C([H])=C(S(=O)(=O)C2=C([H])C([H])=C(N(C(S(O[H])=O)([H])[H])[H])C([H])=C2[H])C([H])=C1[H])[H])([H])[H])[H],DB01145,144-76-3,Sulfoxone,"Aldesulfone
Aldesulphone",small molecule,Enteric bacteria and other eubacteria,,,,For the treatment of leprosy and dermatitis herpetiformis
C(N1C([H])([H])C([H])([H])C(OC(C2=C([H])C([H])=C([H])C([H])=C2[H])(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])([H])C([H])([H])C1([H])[H])([H])([H])[H],DB01146,147-20-6,Diphenylpyraline,"1-Methyl-4-hydroxypiperidine benzhydryl ether
1-Methyl-4-piperidyl benzhydryl ether
4-(Benzhydryloxy)-1-methylpiperidine
4-(Benzhydryloxy)-N-methylpiperidine
Difenilpiralina
Diphenylpyralamine
Diphenylpyralinum",small molecule,Humans and other mammals,"Liquid
Suppository
Ointment
Syrup
Tablet","Oral
Rectal
Topical
Oral
Oral",,"For use in the treatment of allergic rhinitis, hay fever, and allergic skin disorders."
C(C1=C(C2=C([H])C([H])=C([H])C([H])=C2[H])OC2=C(C(=C(C(=C2C(=O)OC(C(N2C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])([H])[H])([H])[H])[H])[H])[H])C1=O)([H])([H])[H],DB01148,15301-69-6,Flavoxate,"2-(1-Piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate
2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate
2-Piperidinoethyl 3-methylflavone-8-carboxylate
beta-Piperidinoethyl 3-methylflavone-8-carboxylate
Flavoxate
Flavoxate HCI
Flavoxato
Flavoxatum",small molecule,Humans and other mammals,"Tablet
Tablet, film coated
Tablet","Oral
Oral
Oral","100 mg/1
100 mg/1
200 mg","For symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis."
C(C(C1=NN(C(C(C(N2C([H])([H])C([H])([H])N(C3=C([H])C([H])=C([H])C(Cl)=C3[H])C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])C(=O)N1C(C(OC1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01149,83366-66-9,Nefazodone,"1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one
Nefazodona
Nefazodone
Nefazodonum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg/1
150 mg/1
200 mg/1
250 mg/1
50 mg/1
100 mg
150 mg
200 mg
50 mg",For the treatment of depression.
C(N(C(C(C(N1C2=C(C(=C(C(=C2[H])[H])[H])[H])C([H])([H])C([H])([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])[H])([H])([H])[H],"DB01151
DB07682",50-47-5,Desipramine,"3-(10,11-DIHYDRO-5H-dibenzo[b,F]azepin-5-yl)-N-methylpropan-1-amine
5-(gamma-Methylaminopropyl)iminodibenzyl
5-(��-methylaminopropyl)iminodibenzyl
D��m��thylimipramine
Desipramin
Desipramina
Desipramine
Desipraminum
Desmethylimipramine
DMI
Monodemethylimipramine
N-(3-methylaminopropyl)iminobibenzyl
Norimipramine",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, sugar coated
Tablet, sugar coated
Tablet, sugar coated
Tablet, sugar coated
Tablet, sugar coated
Tablet, sugar coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg
100 mg
25 mg
50 mg
75 mg
10 mg/1
100 mg/1
150 mg/1
25 mg/1
50 mg/1
75 mg/1
10 mg/1
100 mg/1
150 mg/1
25 mg/1
50 mg/1
75 mg/1
10 mg/1
100 mg/1
150 mg/1
25 mg/1
50 mg/1
75 mg/1","For relief of symptoms in various depressive syndromes, especially endogenous depression. It has also been used to manage chronic peripheral neuropathic pain, as a second line agent for the management of anxiety disorders (e.g. panic disorder, generalized anxiety disorder), and as a second or third line agent in the ADHD management. "
C(OC1=C([H])C(N(C(C2=C(C([H])([H])[H])C3=C(N([H])[H])N=C(N([H])[H])N=C3C([H])=C2[H])([H])[H])[H])=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])([H])([H])[H],DB01157,52128-35-5,Trimetrexate,"Trimetrexato
Trimetrexatum",small molecule,"Humans and other mammals
Pneumocystis carinii
Bacteria and protozoa","Powder, for solution",Intravenous,25 mg,"For use, with concurrent leucovorin administration (leucovorin protection), as an alternative therapy for the treatment of moderate-to-severe <i>Pneumocystis carinii</i> pneumonia (PCP) in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS). Also used to treat several types of cancer including colon cancer."
C(C([N+](C([H])([H])[H])(C([H])([H])[H])C(C1=C(Br)C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB01158,59-41-6,Bretylium,"(2-Bromobenzyl)ethyldimethylaminium
2-Bromo-N-ethyl-N,N-dimethylbenzenemethanaminium
N-Ethyl-N,N-dimethyl-2-bromobenzenemethanaminium",small molecule,Humans and other mammals,"Liquid
Solution
Solution","Intramuscular; Intravenous
Intravenous
Intramuscular; Intravenous","50 mg
50 mg","For use in the prophylaxis and therapy of ventricular fibrillation. Also used in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia, that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine."
C(C(N(C(C([H])([H])[H])([H])[H])C(C(OC(=O)C1=C(Cl)C([H])=C(N([H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01161,133-16-4,Chloroprocaine,"2-Chloroprocaine
4-amino-2-Chlorobenzoic acid 2-(diethylamino)ethyl ester
Chloroprocain
Chloroprocaine
Chloroprocainum
Chlorprocaine
Cloroprocaina",small molecule,Humans and other mammals,"Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Solution
Solution
Injection, solution
Injection, solution","Epidural; Infiltration
Epidural; Infiltration
Intrathecal
Infiltration; Perineural
Infiltration; Perineural
Epidural; Intracaudal
Epidural; Intracaudal
Epidural; Infiltration; Intracaudal; Perineural
Epidural; Infiltration; Intracaudal; Perineural","20 mg/mL
30 mg/mL
10 mg/mL
10 mg/mL
20 mg/mL
20 mg
30 mg
20 mg/mL
30 mg/mL",For the production of local anesthesia by infiltration and peripheral nerve block. They are not to be used for lumbar or caudal epidural anesthesia.
O=C1C([H])([H])C([H])([H])C2=C(C(=C(C(OC(C(C(C(C3=NN=NN3C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])=C2[H])[H])[H])N1[H],DB01166,73963-72-1,Cilostazol,"3,4-dihydro-6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
Cilostazole
Cilostazolum",small molecule,Humans and other mammals,"Tablet
Tablet","Oral
Oral","100 mg/1
50 mg/1",For the reduction of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).
C(N(N(C(C1=C([H])C([H])=C(C(=O)N(C(C([H])([H])[H])(C([H])([H])[H])[H])[H])C([H])=C1[H])([H])[H])[H])[H])([H])([H])[H],DB01168,671-16-9,Procarbazine,"1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine
2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine
4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide
N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide
N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine
N-isopropyl-4-[(2-methylhydrazino)methyl]benzamide
N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide
N-Isopropyl-��-(2-methylhydrazino)-p-toluamide
p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide
Procarbazin
Procarbazina
Procarbazinum",small molecule,Humans and other mammals,"Capsule
Capsule","Oral
Oral","50 mg/1
50 mg",For use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin's disease.
O=[As]O[As]=O,DB01169,1327-53-3,Arsenic trioxide,"Acide Arsenieux
Anhydride Arsenieux
Arsenic Blanc
Arsenic oxide
Arsenic(III) oxide
Arsenigen Saure
Arsenolite
Arsenous oxide
Arsenous oxide anhydride
Diarsenic oxide
Diarsenic trioxide
White arsenic",small molecule,Humans and other mammals,"Injection, solution
Injection, solution
Solution","Intravenous
Intravenous
Intravenous","1 mg/mL
2 mg/mL
10 mg","For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression"
N(C(N([H])[H])=NC(C(N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])([H])[H])([H])[H])([H])[H],DB01170,55-65-2,Guanethidine,"(2-(hexahydro-1(2h)-azocinyl)ethyl)guanidine
(2-(Octahydro-1-azocinyl)ethyl)guanidine
2-(1-N,N-Heptamethyleneimino)ethylguanidine
2-(1'-Azacyclooctyl)ethylguanidine
Azocine, 1-(2-guanidinoethyl)octahydro-
guan��thidine
guanethidinum
guanetidina
Guanidine, (2-(hexahydro-1(2H)-azocinyl)ethyl)-
Heptamethylenimine, 1-(2-guanidinoethyl)-
N-(2-Perhydroazocin-1-ylethyl)guanidine",small molecule,Humans and other mammals,"Tablet
Tablet","Oral
Oral","10 mg
25 mg","For the treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension."
ClC1=C([H])C([H])=C(C(=O)N(C(C(N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])([H])[H])([H])[H])[H])C([H])=C1[H],DB01171,71320-77-9,Moclobemide,"4-Chlor-N-(2-morpholinoethyl)benzamid
4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide
4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide
Aurorix
Moclaime
Moclamide
Moclamine
Moclobemid
Moclobemida
Moclobemide
Moclobemidum
p-Chloro-N-(2-morpholinoethyl)benzamide",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet","Oral
Oral
Oral","100 mg
150 mg
300 mg",For the treatment of major depressive disorder and bipolar disorder [A31901].
C(C(C1(C(=O)N([H])C(=O)N([H])C1=O)C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB01174,50-06-6,Phenobarbital,"5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione
5-Ethyl-5-phenylbarbituric acid
5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione
5-Phenyl-5-ethylbarbituric acid
Phenobarbital
Phenobarbitol
Phenobarbitone
Phenobarbituric Acid
Phenylaethylbarbitursaeure
Phenylethylbarbiturate
Phenylethylbarbituric Acid
Phenylethylbarbitursaeure
PHENYLETHYLMALONYLUREA",small molecule,Humans and other mammals,"Elixir
Tablet
Tablet, extended release
Tablet, film coated, extended release
Capsule
Tablet
Tablet
Tablet
Tablet
Elixir
Elixir
Liquid
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Injection
Injection
Solution
Solution
Solution
Elixir","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous
Intramuscular; Intravenous
Oral","4 mg
100 mg
15 mg
30 mg
60 mg
5 mg
20 mg/5mL
20 mg/5mL
100 mg/1
15 mg/1
16.2 mg/1
30 mg/1
32.4 mg/1
60 mg/1
64.8 mg/1
97.2 mg/1
130 mg/mL
65 mg/mL
30 mg
120 mg
30 mg",For the treatment of all types of seizures except absence seizures.
C(N1C([H])([H])C([H])([H])N(C(C2=C([H])C([H])=C([H])C([H])=C2[H])(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB01176,82-92-8,Cyclizine,"(+-)-1-Diphenylmethyl-4-methylpiperazine
(��)-1-diphenylmethyl-4-methylpiperazine
(N-Benzhydryl)(n'-methyl)diethylenediamine
1-(Diphenylmethyl)-4-methylpiperazine
1-Benzhydryl-4-methylpiperazin
Ciclizina
Cyclizine
Cyclizinum
N-Benzhydryl-N'-methylpiperazine
N-methyl-N'-benzhydrylpiperazine",small molecule,Humans and other mammals,"Tablet
Liquid
Tablet","Oral
Intramuscular; Intravenous
Oral","25 mg/25mg
50 mg","For prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness, and vertigo (dizziness caused by other medical problems)."
ClC1=C([H])C2=C(N(C3(C([H])([H])C([H])([H])N(C(C(C(N4C(=O)N([H])C5=C4C(=C(C(=C5[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])C([H])([H])C3([H])[H])[H])C(=O)N2[H])C([H])=C1[H],DB01184,57808-66-9,Domperidone,"1-(3-(4-(5-chloro-2-oxo-2,3-Dihydrobenzo[D]imidazol-1-yl)piperidin-1-yl)propyl)-1H-benzo[D]imidazol-2(3H)-one
5-chloro-1-(1-(3-(2-oxo-1-Benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone
5-chloro-1-(1-(3-(2-oxo-2,3-Dihydrobenzo[D]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[D]imidazol-2(3H)-one
5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one
Domperidona
Domperidonum",small molecule,Humans and other mammals,Tablet,Oral,10 mg,"For management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting."
C(C1=C([H])C(=O)N(O[H])C(C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])=C1[H])([H])([H])[H],DB01188,29342-05-0,Ciclopirox,"6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone
Ciclopiroxum",small molecule,"Humans and other mammals
Yeast and other fungi","Cream
Gel
Kit
Lotion
Shampoo
Shampoo
Solution
Solution
Solution
Solution
Suspension
Suspension
Solution
Cream
Cream
Lotion
Lotion
Kit
Solution
Shampoo
Solution","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","7.7 mg/g
7.7 mg/g
7.7 mg/mL
1 g/100mL
10 mg/.96mL
71.3 mg/mL
8 g/100mL
80 mg/g
80 mg/mL
7.7 mg/mL
7.7 mg/100mL
2.28 g/mL
1 %
10 mg
1 %
10 mg
8 %
1.5 %","Used as a topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to <i>Trichophyton rubrum</i>."
O(C(C(N(C(C(N(C1=C([H])C([H])=C(N(C(C(N(C(C(O[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])C2=C1C(=O)C1=C(C2=O)C(O[H])=C([H])C([H])=C1O[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H],DB01204,65271-80-9,Mitoxantrone,"1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione
Mitoxantrona
Mitoxantrone
Mitoxantronum",small molecule,Humans and other mammals,"Injection, solution
Injection, solution, concentrate
Solution
Liquid","Intravenous
Intravenous
Intravenous
Intravenous","2 mg/mL
2 mg/mL
2 mg
2 mg","For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis"
C(C(OC(=O)C1=C2C(N(C([H])([H])[H])C(=O)C3=C(N2C([H])=N1)C([H])=C([H])C(F)=C3[H])([H])[H])([H])[H])([H])([H])[H],DB01205,78755-81-4,Flumazenil,"Flumazenilo
Flumazenilum
Flumazepil",small molecule,Humans and other mammals,"Injection
Injection
Injection
Injection, solution
Solution","Intravenous
Intravenous
Intravenous
Intravenous
Intravenous",".1 mg/mL
.5 mg/5mL
1 mg/10mL
.1 mg/mL
0.1 mg","For the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, and where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures. Also for the management of benzodiazepine overdose as an adjunct for appropriate supportive and symptomatic measures."
ClC(C(N(N=O)C(=O)N(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])[H])([H])[H])([H])[H],DB01206,13010-47-4,Lomustine,"1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
1-(2-Chloroethyl)-3-cyclohexylnitrosourea
Belustine
Cecenu
Chloroethylcyclohexylnitrosourea
CINU
Cyclohexyl chloroethyl nitrosourea
Lomustina
Lomustinum
N-(2-Chloroethyl)-n'-cyclohexyl-N-nitrosourea",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule, gelatin coated
Capsule, gelatin coated
Capsule, gelatin coated
Capsule, gelatin coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg
100 mg
40 mg
10 mg/1
40 mg/1
5 mg/1
100 mg/1",For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.
O(C(=O)C(C(C(C(ON=C(C1=C([H])N=C([H])C([H])=C1[H])C1=C([H])C([H])=C([H])C(C(F)(F)F)=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB01207,110140-89-1,Ridogrel,"R-68070
Ridogrel
Ridogrelum",small molecule,Humans and other mammals,,,,Used as an adjunctive therapy to induce thrombolysis in patients suffering acute myocardial infarction.
C(C1=C([H])N([H])N=C1[H])([H])([H])[H],DB01213,7554-65-6,Fomepizole,"4-Methylpyrazol
4-methylpyrazole
Fomepizol
Fomepizole
Fomepizolum",small molecule,Humans and other mammals,"Injection
Liquid
Injection, solution
Solution","Intravenous
Intravenous
Intravenous
Intravenous","1 g/mL
1 g
1 g/mL
1 g","Antizol is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis"
ClC1=C([H])C2=C(N3C([H])=NN=C3C(N=C2C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])C([H])=C1[H],DB01215,29975-16-4,Estazolam,"8-chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine
Estazolamum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral","1 mg/1
2 mg/1
1 mg
2 mg","For the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings."
C(C(C([H])([H])[H])(C#N)C1=C([H])C(C(C([H])([H])[H])(C([H])([H])[H])C#N)=C([H])C(C(N2C([H])=NC([H])=N2)([H])[H])=C1[H])([H])([H])[H],DB01217,120511-73-1,Anastrozole,"alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
Anastrozol",small molecule,Humans and other mammals,"Tablet
Tablet, coated
Tablet, film coated
Tablet","Oral
Oral
Oral
Oral","1 mg/1
1 mg/1
1 mg/1
1 mg","For adjuvant treatment of hormone receptor positive breast cancer , as well as hormonal treatment of advanced breast cancer in post-menopausal women. Has also been used to treat pubertal gynecomastia and McCune-Albright syndrome; however, manufacturer states that efficacy for these indications have not been established."
[O-][N+](=O)C1=C([H])C([H])=C(C2=C([H])C([H])=C(C(=NN3C([H])([H])C(=O)N([H])C3=O)[H])O2)C([H])=C1[H],DB01219,7261-97-4,Dantrolene,"Dantamacrin
Dantrolene
Dantroleno
Dantrolenum
F-368",small molecule,Humans and other mammals,"Capsule
Capsule
Injection
Capsule
Capsule
Powder, for solution
Injection, powder, for solution
Capsule
Injection, powder, lyophilized, for solution
Injection, suspension","Oral
Oral
Intravenous
Oral
Oral
Intravenous
Intravenous
Oral
Intravenous
Intravenous","100 mg/1
50 mg/1
20 mg/60mL
100 mg
25 mg
20 mg
20 mg/1
25 mg/1
20 mg/60mL
250 mg/5mL","For use, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Also used preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible."
O(C(C(OC(C(N1C([H])([H])C([H])([H])N(C2=NC3=C(C(=C(C(=C3[H])[H])[H])[H])SC3=C2C(=C(C(=C3[H])[H])[H])[H])C([H])([H])C1([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB01224,111974-69-7,Quetiapine,"2-[2-(4-Dibenzo[b,F][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol
Quetiapina
Quetiapine
Quetiapine fumarate
Quetiapine hemifumarate
Quetiapinum",small molecule,Humans and other mammals,"Tablet, multilayer, extended release
Tablet, multilayer, extended release
Tablet, multilayer, extended release
Tablet, multilayer, extended release
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet, film coated, extended release
Tablet
Tablet
Tablet
Tablet
Kit
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet, extended release
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg
200 mg
25 mg
300 mg
50 mg
100 mg/1
150 mg/1
200 mg/1
25 mg/1
300 mg/1
400 mg/1
50 mg/1
100 mg/1
150 mg/1
200 mg/1
25 mg/1
300 mg/1
400 mg/1
50 mg/1
150 mg/1
200 mg/1
300 mg/1
400 mg/1
50 mg/1
300 mg
100 mg
200 mg
25 mg
150 mg
150 mg/1
200 mg
200 mg/1
300 mg/1
300 mg
400 mg/1
400 mg
50 mg/1
50 mg
150 mg",For the treatment of schizophrenia and related psychotic disorders.
O(C(C(C(C(N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])([H])[H])([H])[H])([H])[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C1=C([H])C([H])=C([H])C([H])=C1[H])[H],DB01231,972-02-1,Diphenidol,"alpha,alpha-Diphenyl-1-piperidinebutanol
Difenidol
Difenidolo
Difenidolum
Diphenidol
Diphenyl(3-(1-piperidyl)propyl)carbinol",small molecule,Humans and other mammals,,,,"For use in the prevention and symptomatic treatment of peripheral (labyrinthine) vertigo and associated nausea and vomiting that occur in such conditions as Meniere's disease and surgery of the middle and inner ear. Also for the control of nausea and vomiting associated with postoperative states, malignant neoplasms, labyrinthine disturbances, antineoplastic agent therapy, radiation sickness, and infectious diseases."
C(C(N(C(C([H])([H])[H])([H])[H])C(C(N(C(=O)C1=C([H])C(Cl)=C(N([H])[H])C([H])=C1OC([H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01233,364-62-5,Metoclopramide,"2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide
2-methoxy-5-chloroprocainamide
4-amino-5-chloro-2-methoxy-N-(��-diethylaminoethyl)benzamide
4-amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide
Metoclopramida
Metoclopramidum",small molecule,Humans and other mammals,"Liquid
Injection
Injection, solution
Injection, solution
Solution
Solution
Tablet
Tablet
Injection, solution
Tablet, orally disintegrating
Tablet, orally disintegrating
Liquid
Liquid
Solution
Tablet
Tablet
Syrup","Oral
Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous
Oral
Oral
Oral
Oral
Intravenous
Oral
Oral
Intramuscular; Intravenous
Intravenous
Oral
Oral
Oral
Oral","1 mg
5 mg/mL
10 mg/2mL
5 mg/mL
10 mg/10mL
5 mg/5mL
10 mg/1
5 mg/1
5 mg/mL
10 mg/1
5 mg/1
5 mg
5 mg
5 mg
10 mg
5 mg
1 mg","For the treatment of gastroesophageal reflux disease (GERD). It is also used in treating nausea and vomiting, and to increase gastric emptying."
FC(OC(C(F)(F)F)(C(F)(F)F)[H])([H])[H],DB01236,28523-86-6,Sevoflurane,"1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
Sevofluran
Sevoflurane
Sevoflurano
Sevofluranum",small molecule,Humans and other mammals,"Liquid
Liquid
Liquid","Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)","99.97 %
1 mL/mL
250 mL/250mL",Used for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.
ClC1=C(Cl)C(N2C([H])([H])C([H])([H])N(C(C(C(C(OC3=C([H])C4=C(C(C(C(=O)N4[H])([H])[H])([H])[H])C([H])=C3[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])([H])C2([H])[H])=C([H])C([H])=C1[H],DB01238,129722-12-9,Aripiprazole,"Abilitat
Aripiprazol
Aripiprazole
Aripiprazolum
OPC 31",small molecule,Humans and other mammals,"Injection, solution
Solution
Tablet
Tablet
Tablet
Tablet
Injection, powder, for suspension, extended release
Injection, powder, for suspension, extended release
Injection, powder, for suspension, extended release; kit
Injection, powder, for suspension, extended release; kit
Kit
Tablet
Tablet
Tablet
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, orally disintegrating
Tablet, orally disintegrating
Tablet, orally disintegrating
Injection, suspension, extended release
Injection, suspension, extended release
Injection, suspension, extended release
Injection, suspension, extended release","Intramuscular
Oral
Oral
Oral
Oral
Oral
Intramuscular
Intramuscular
Intramuscular
Intramuscular
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular
Intramuscular
Intramuscular
Intramuscular","9.75 mg/1.3mL
1 mg/mL
2 mg
2 mg/1
30 mg/1
5 mg/1
300 mg
400 mg
300 mg
400 mg
10 mg/1
15 mg/1
20 mg/1
10 mg/1
15 mg/1
10 mg
15 mg
30 mg
5 mg
20 mg
10 mg
15 mg
30 mg
1064 mg/3.9mL
441 mg/1.6mL
662 mg/2.4mL
882 mg/3.2mL",For the treatment of schizophrenia and related psychotic disorders.
C(N(C([H])([H])[H])C(C(C(=C1C2=C(C(=C(C(=C2[H])[H])[H])[H])SC2=C1C(=C(Cl)C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB01239,113-59-7,Chlorprothixene,"Alpha-Chlorprothixene
Chlorprothixen
Chlorprothixine
Chlorprotixen
Chlorprotixene
Chlorprotixine
Chlothixen",small molecule,Humans and other mammals,,,,For treatment of psychotic disorders (e.g. schizophrenia) and of acute mania occuring as part of bipolar disorders.
C(C1=C([H])C(OC(C(C(C(C([H])([H])[H])(C([H])([H])[H])C(O[H])=O)([H])[H])([H])[H])([H])[H])=C(C([H])([H])[H])C([H])=C1[H])([H])([H])[H],DB01241,25812-30-0,Gemfibrozil,"2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure
2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure
2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid
Gemfibrozil
Gemfibrozilo
Gemfibrozilum",small molecule,Humans and other mammals,"Tablet
Tablet, coated
Tablet, film coated
Capsule
Tablet","Oral
Oral
Oral
Oral
Oral","600 mg/1
600 mg/1
600 mg/1
300 mg
600 mg",For treatment of adult patients with very high elevations of serum triglyceride levels (types IV and V hyperlipidemia) who are at risk of developing pancreatitis (inflammation of the pancreas) and who do not respond adequately to a strict diet.
C(N(C([H])([H])[H])C(C(C(N1C2=C(C(=C(C(=C2[H])[H])[H])[H])C([H])([H])C([H])([H])C2=C1C(=C(Cl)C(=C2[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],"DB01242
DB07600",303-49-1,Clomipramine,"3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine
3-(3-chloro-5H-dibenzo[b,F]azepin-5-yl)-N,N-dimethylpropan-1-amine
3-Chloroimipramine
Chlorimipramine
Clomipramina
Clomipraminum
Monochlorimipramine",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral","25 mg/1
50 mg/1
75 mg/1
10 mg
25 mg
50 mg","May be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette���s disorder).
Unlabeled indications include: depression, panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy (limited evidence), autistic disorder (limited evidence), trichotillomania (limited evidence), onchophagia (limited evidence), stuttering (limited evidence), premature ejaculation, and premenstrual syndrome. "
O(C1=C(Cl)C([H])=C(Cl)C2=C(C(=C(N=C12)[H])[H])[H])[H],DB01243,773-76-2,Chloroxine,"5,7-Dichlor-8-hydroxychinolin
5,7-Dichloro-8-hydroxyquinoline
5,7-Dichloro-8-oxyquinoline
5,7-Dichloro-8-quinolinol
5,7-Dichlorooxine
5,7-Dichloroxine
Chlorquinol
CHQ",small molecule,Humans and other mammals,,,,Used in the treatment of dandruff and mild to moderately severe seborrheic dermatitis of the scalp.
C([N+](C([H])([H])[H])(C([H])([H])[H])C(C(C(C(C(C(C(C(C(C([N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01245,156-74-1,Decamethonium,"Decamethonium
DECAMETHONIUM ion
Decamethonum
Decamethylenebis(trimethylammonium)
N,N,N,N',n',n'-hexamethyl-1,10-decanediaminium",small molecule,Humans and other mammals,,,,For use as a skeletal muscle relaxant
C(C1=C([H])C(C(=O)N(N(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])[H])[H])=NO1)([H])([H])[H],DB01247,59-63-2,Isocarboxazid,"Isocarboxazida
Isocarboxazide
Isocarboxazidum",small molecule,Humans and other mammals,Tablet,Oral,10 mg/1,"Isocarboxazid is indicated for the treatment of the enduring and debilitating symptoms of depression that have not responded to other antidepressant drugs.[L1372] Depression is a common but serious mood disorder. The patient will present changes in its feelings, thoughts, and ability to handle everyday activities. For a mood disorder to be considered as depression, the symptoms should be present for at least two weeks.[L1375]"
C(C(=O)N(C(C(O[H])(C(N(C(C([H])([H])[H])=O)C1=C(I)C(C(=O)N(C(C(O[H])(C(O[H])([H])[H])[H])([H])[H])[H])=C(I)C(C(=O)N(C(C(O[H])(C(O[H])([H])[H])[H])([H])[H])[H])=C1I)([H])[H])[H])([H])[H])C1=C(I)C(C(=O)N(C(C(O[H])(C(O[H])([H])[H])[H])([H])[H])[H])=C(I)C(C(=O)N(C(C(O[H])(C(O[H])([H])[H])[H])([H])[H])[H])=C1I)([H])([H])[H],DB01249,92339-11-2,Iodixanol,"5,5'-((2-Hydroxytrimethylene)bis(acetylimino))bis(N,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide)
Indixanol
Iodixanolum",small molecule,Humans and other mammals,"Injection, solution
Injection, solution
Solution
Solution","Intravascular
Intravascular
Intra-arterial; Intravenous
Intra-arterial; Intravenous","270 mg/mL
320 mg/mL
550 mg
652 mg",Iodixanol is a contrast agent during coronary angiography.
O(C(=O)C1=C(O[H])C([H])=C([H])C(N=NC2=C([H])C(C(O[H])=O)=C(O[H])C([H])=C2[H])=C1[H])[H],DB01250,15722-48-2,Olsalazine,,small molecule,Humans and other mammals,"Capsule
Capsule, gelatin coated","Oral
Oral","250 mg
250 mg/1",For the treatment of Inflammatory Bowel Disease and Ulcerative Colitis.
C(OC1=C([H])C2=C(C(C([H])([H])[H])(C([H])([H])[H])C(=O)N(C(C(C3=C([H])C([H])=C(S(=O)(=O)N(C(=O)N(C4(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C4([H])[H])[H])[H])[H])C([H])=C3[H])([H])[H])([H])[H])C2=O)C([H])=C1[H])([H])([H])[H],DB01251,33342-05-1,Gliquidone,Glurenorm,small molecule,Humans and other mammals,,,,Used in the treatment of diabetes mellitus type 2.
C(C1=NC(N2C([H])([H])C([H])([H])N(C(C(O[H])([H])[H])([H])[H])C([H])([H])C2([H])[H])=C([H])C(N(C2=NC([H])=C(C(=O)N(C3=C(Cl)C([H])=C([H])C([H])=C3C([H])([H])[H])[H])S2)[H])=N1)([H])([H])[H],DB01254,302962-49-8,Dasatinib,"anh. dasatinib
Anhydrous dasatinib
BMS dasatinib
Dasatinib
Dasatinib (anh.)
dasatinib (anhydrous)
Dasatinibum
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg/1
100 mg
140 mg/1
140 mg
20 mg/1
20 mg
50 mg/1
50 mg
70 mg/1
70 mg
80 mg
80 mg/1
100 mg
140 mg
20 mg
50 mg
70 mg
80 mg","For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy."
C(S(=O)(=O)C(C(N(C(C1=C([H])C([H])=C(C2=C([H])C([H])=C3N=C(N=C(N(C4=C([H])C(Cl)=C(OC(C5=C([H])C(F)=C([H])C([H])=C5[H])([H])[H])C([H])=C4[H])[H])C3=C2[H])[H])O1)([H])[H])[H])([H])[H])([H])[H])([H])([H])[H],"DB01259
DB02584",231277-92-2,Lapatinib,"FMM
GW 572016
Lapatinib tosilate hydrate
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, film coated","Oral
Oral
Oral","250 mg
250 mg/1
250 mg","Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma."
C(C(N(C(C([H])([H])[H])([H])[H])C(C(N(C(=O)C1=C(C([H])([H])[H])N([H])C(C(=C2C(=O)N([H])C3=C2C(=C(F)C(=C3[H])[H])[H])[H])=C1C([H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],"DB01268
DB07417",557795-19-4,Sunitinib,Sunitinibum,small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule
Capsule
Capsule
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","12.5 mg
12.5 mg/1
25 mg/1
25 mg
37.5 mg
37.5 mg/1
50 mg/1
50 mg",For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.
N(N(C1=NN=C([H])C2=C(C(=C(C([H])=C12)[H])[H])[H])[H])([H])[H],DB01275,86-54-4,Hydralazine,"(1Z)-1(2H)-Phthalazinone hydrazone
(2H)-Phthalazinone hydrazone
1-Hydrazinophthalazine
1-Phthalazinylhydrazine
6-Hydralazine
Hidralazina
Hydralazin
Hydralazinum
Hydrallazine
Hydrazinophthalazine
Hydrazone 1(2H)-phthalazinone
Hypophthalin
Idralazina
Phthalazin-1-ylhydrazine",small molecule,Humans and other mammals,"Solution
Tablet, film coated
Injection
Injection, solution
Injection, solution
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet
Tablet
Tablet
Tablet","Intravenous
Oral
Intramuscular; Intravenous
Intramuscular; Intravascular
Intramuscular; Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","20 mg
20 mg/mL
20 mg/mL
20 mg/mL
10 mg/1
100 mg/1
25 mg/1
50 mg/1
10 mg/1
100 mg/1
25 mg/1
50 mg/1
10 mg
25 mg
50 mg","For the treatment of essential hypertension, alone or as an adjunct. Also for the management of severe hypertension when the drug cannot be given orally or when blood pressure must be lowered immediately, congestive heart failure (in combination with cardiac glycosides and diuretics and/or with isosorbide dinitrate), and hypertension secondary to pre-eclampsia/eclampsia."
C(C1=C([H])C(C(C(O[H])=O)([H])[H])=C(N(C2=C(Cl)C([H])=C([H])C([H])=C2F)[H])C([H])=C1[H])([H])([H])[H],DB01283,220991-20-8,Lumiracoxib,"2-((2-chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid
Lumiracoxibum",small molecule,Humans and other mammals,,,,For the acute and chronic treatment of the signs and symptoms of osteoarthritis of the knee in adults.
C(C(C(C1=C([H])C([H])=C(O[H])C([H])=C1[H])([H])[H])(N(C(C(O[H])(C1=C([H])C(O[H])=C([H])C(O[H])=C1[H])[H])([H])[H])[H])[H])([H])([H])[H],DB01288,13392-18-2,Fenoterol,"1-(3,5-Dihydroxyphenyl)-1-hydroxy-2-((4-hydroxyphenyl)isopropylamino)ethane
1-(P-Hydroxyphenyl)-2-((beta-hydroxy-beta-(3',5'-dihydroxyphenyl))ethyl)aminopropane
3,5-Dihydroxy-alpha-(((P-hydroxy-alpha-methylphenethyl)amino)methyl)benzyl alcohol
5-{1-hydroxy-2-[2-(4-hydroxy-phenyl)-1-methyl-ethylamino]-ethyl}-benzene-1,3-diol
Fenoterolum
Phenoterol",small molecule,Humans and other mammals,"Solution
Aerosol, metered
Aerosol, metered
Tablet
Solution
Solution
Solution","Respiratory (inhalation)
Oral; Respiratory (inhalation)
Oral; Respiratory (inhalation)
Oral
Oral; Respiratory (inhalation)
Oral; Respiratory (inhalation)
Oral; Respiratory (inhalation)","1 mg
100 mcg
0.2 mg
2.5 mg
0.25 mg
0.625 mg",Fenoterol is used for the treatment of asthma.
C(C1=C([H])C(C(=O)N(C(C(C2=C([H])C([H])=C(S(=O)(=O)N(C(=O)N(N3C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])[H])C([H])=C2[H])([H])[H])([H])[H])[H])=NO1)([H])([H])[H],DB01289,25046-79-1,Glisoxepide,,small molecule,,,,,For the treatment of diabetes mellitus type 2.
O([Bi]1OC(=O)C2=C(C(=C(C(=C2[H])[H])[H])[H])O1)[H],"DB01294
DB01402",14882-18-9,Bismuth Subsalicylate,"2-Hydroxy-benzo[1,3,2]dioxabismin-4-one
Basic bismuth salicylate
Bismuth oxide salicylate
Bismuth oxysalicylate
Bismuth subsalicylate
pink bismuth
Wismutsubsalicylat",small molecule,,"Liquid
Tablet
Liquid
Suspension
Tablet
Liquid
Suspension
Tablet, chewable
Liquid
Powder
Liquid
Suspension
Suspension
Tablet
Liquid
Liquid
Liquid
Tablet, chewable
Suspension
Suspension
Suspension
Kit
Tablet
Tablet
Liquid
Tablet
Tablet, chewable
Liquid
Suspension
Liquid
Liquid
Liquid
Tablet, chewable
Suspension
Liquid
Powder
Liquid","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","17.66 mg
262 mg/434mg
17.6 mg
17.5 mg
262 mg
17.5 mg
35.2 mg
262 mg/15mL
262 mg/1
35 mg
35 mg
525 mg/30mL
262 mg/1
35 mg/mL
17.47 mg/mL
525 mg/15mL
524 mg
17.5 mg/mL
262 mg/15mL
525 mg/15mL
525 mg/21
35.2 mg
525 mg/1
262 mg
1050 mg/10mL
17.6 mg
1.7 %
1050 mg/30mL
262 mg/30mL
262 mg/1
1050 mg/30mL
525 mg/30mL
525 mg/1","Used to treat nausea, heartburn, indigestion, upset stomach, diarrhea, and other temporary discomforts of the stomach and gastrointestinal tract."
C(C(N1C([H])=C([H])C(N(S(=O)(=O)C2=C([H])C([H])=C(N([H])[H])C([H])=C2[H])[H])=NC1=O)([H])[H])([H])([H])[H],DB01298,17784-12-2,Sulfacytine,"1-ethyl N4-sulfanilylcytosin
1-ethyl-N-sulfanilylcytosine
N-sulfanilyl-l-ethylcytosine
Renoquid
Sulfacitina
Sulfacitine
Sulfacitinum",small molecule,Bacteria,,,,Used orally in the treatment of acute urinary tract infections.
C(OC1=C(OC([H])([H])[H])C(N(S(=O)(=O)C2=C([H])C([H])=C(N([H])[H])C([H])=C2[H])[H])=NC([H])=N1)([H])([H])[H],DB01299,2447-57-6,Sulfadoxine,"4-Sulfanilamido-5,6-dimethoxypyrimidine
Sulfadoxina
Sulfadoxine
Sulfadoxinum
Sulforthomidine
Sulphadoxine
Sulphormethoxine",small molecule,,Tablet,Oral,,"Sulfadoxine is used in combination with pyrimethamine for the treatment or prevention of malaria. It can also be used to treat various infections in livestock as well.
Sulfadoxine and pyrimethamine is indicated for the treatment of Plasmodium falciparum malaria in those patients in whom chloroquine resistance is suspected. "
C(N1C2=C([N-]C(=N2)[H])C(=O)N(C([H])([H])[H])C1=O)([H])([H])[H],DB01303,4499-40-5,Oxtriphylline,"Choline theophyllinate
Choline theophylline
Oxtriphylline
Theocolin
Theophyline - choline mixt",small molecule,Humans and other mammals,"Elixir
Elixir
Syrup
Tablet, extended release
Tablet, extended release
Tablet
Syrup
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg
50 mg
400 mg
600 mg
300 mg
10 mg
100 mg
200 mg","Used to treat the symptoms of asthma, bronchitis, COPD, and emphysema."
O(P(O[H])(=O)OC(N1C(=O)N([H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])(C2=C([H])C([H])=C([H])C([H])=C2[H])C1=O)([H])[H])[H],DB01320,93390-81-9,Fosphenytoin,"(3-Phosphoryloxymethyl)phenytoin
Fosfenitoina
Fosphenytoin
Fosphenytoine
Fosphenytoinum",small molecule,Humans and other mammals,"Liquid
Injection
Injection, solution","Intramuscular; Intravenous
Intramuscular; Intravenous
Intramuscular; Intravenous","75 mg
50 mg/mL
50 mg/mL","For the control of generalized convulsive status epilepticus and prevention and treatment of seizures occurring during neurosurgery. It can also be substituted, short-term, for oral phenytoin."
C(C(C(C(C1=NN(C(C2=C([H])N=C(C3=C(C4=NN([H])N=N4)C([H])=C([H])C([H])=C3[H])C([H])=C2[H])([H])[H])C(C(C(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])=N1)([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01342,145216-43-9,Forasartan,,small molecule,Humans and other mammals,,,,For the treatment of hypertension.
[K][H],DB01345,7440-09-7,Potassium,"K
Kalium",small molecule,,"Injection, solution
Capsule
Tablet
Tablet, extended release
Powder
Powder, for solution
Tablet, effervescent
Tablet, effervescent
Solution
Liquid
Granule, effervescent
Injection, solution, concentrate
Powder
Solution
Capsule
Injection, solution
Injection, solution, concentrate
Injection, solution, concentrate
Injection, solution, concentrate
Solution
Liquid
Solution
Liquid
Tablet
Tablet
Liquid
Liquid
Kit
Solution, concentrate
Liquid
Powder, for solution","Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intravenous
Intravenous
Oral
Intravenous
Oral
Oral
Oral
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Oral
Oral
Oral
Topical
Oral
Oral
Oral
Oral","1.86 g
975 mg
1.193 g
398 mg
250 mg
196 mg/mL
196.3 mg/mL
3.93 g/20mL
392 mg/mL
2 meq
392 mg
392 mg
39.2 %
92 mg
99 mg
780 mg",Potassium is used to regulate hypokalemia as a primary condition or secondary to other medical conditions. 
C(OC1=C([H])C2=C(C(=C(N=C2C([H])=C1[H])[H])[H])C(O[H])(C1(C([H])([H])C2(C(C([H])([H])N1C(C2(C(=C([H])[H])[H])[H])([H])[H])([H])[H])[H])[H])[H])([H])([H])[H],DB01346,,Quinidine barbiturate,,small molecule,,,,,
C(C(C1=NC(C2(C([H])([H])C2([H])[H])[H])=C(C(N([H])[H])=O)N1C(C1=C([H])C2=C(OC(=C2Br)C2=C(N(S(=O)(=O)C(F)(F)F)[H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB01347,146623-69-0,Saprisartan,,small molecule,Humans and other mammals,,,,Saprisartan is used in the treatment of hypertension and heart failure.
C(C1=NC(C([H])([H])[H])=C2C(C(C(=O)N(C(C3=C([H])C([H])=C(C4=C(C5=NN([H])N=N5)C([H])=C([H])C([H])=C4[H])C([H])=C3[H])([H])[H])C2=N1)([H])[H])([H])[H])([H])([H])[H],DB01349,145733-36-4,Tasosartan,"Tasosartan
WAY-ana-756",small molecule,,,,,Tasosartan is infrequently in the treatment of hypertension and heart failure.
C(C(C1(C(C(C(C([H])([H])[H])(C([H])([H])[H])[H])([H])[H])([H])[H])C(=O)N([H])C(=O)N([H])C1=O)([H])[H])([H])([H])[H],DB01351,57-43-2,Amobarbital,"5-Ethyl-5-(3-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Ethyl-5-(3-methylbutyl)barbituric acid
5-Ethyl-5-isoamylbarbituric acid
5-Ethyl-5-isopentylbarbituric acid
Amobarbital
Amylobarbitone
Barbamil
Barbamyl",small molecule,,"Injection, powder, lyophilized, for solution
Powder, for solution
Capsule
Capsule
Capsule","Intramuscular; Intravenous
Intramuscular; Intravenous
Oral
Oral
Oral",".5 g/5mL
500 mg
60 mg
200 mg",
C(C(C([H])([H])[H])(C1(C(C(=C([H])[H])[H])([H])[H])C(=O)N([H])C(=O)N([H])C1=O)[H])([H])([H])[H],DB01352,77-02-1,Aprobarbital,"5-(1-Methylethyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Allyl-5-isopropylbarbituric acid
5-Allyl-5-isopropylpyrimidine-2,4,6(1H,3H,5H)-trione
5-Isopropyl-5-allylbarbituric acid
Allypropymal
Alurate
Aprobarbital",small molecule,,,,,
C(C(C(C(C1(C(C([H])([H])[H])([H])[H])C(=O)N([H])C(=O)N([H])C1=O)([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01353,77-28-1,Butethal,"Butethal
Butobarbital
Butobarbitone
Neonal",small molecule,Humans and other mammals,,,,For the treatment of insomnia.
C(C(C1(C(=O)N([H])C(=O)N([H])C1=O)C1=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])([H])[H])([H])([H])[H],DB01354,509-86-4,Heptabarbital,"Heptabarb
Heptabarbital
Heptabarbitone
Heptabarbum
Heptadorm
Heptamal
Heptamalum
Heptbarbital
Medapan
Medomine",small molecule,Humans and other mammals,,,,Used mainly for sedation and hypnosis.
[Li+],DB01356,7439-93-2,Lithium,"Li(+)
Lithium cation
Lithium ion
Lithium, ion
Lithium, ion (li1+)",small molecule,,"Capsule
Capsule
Capsule
Solution
Capsule
Capsule
Capsule
Capsule, gelatin coated
Capsule, gelatin coated
Capsule, gelatin coated
Tablet
Tablet, extended release
Tablet, extended release
Tablet, film coated, extended release
Tablet
Tablet, extended release
Syrup","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","300 mg
600 mg
150 mg
8 meq/5mL
150 mg/1
300 mg/1
600 mg/1
150 mg/1
300 mg/1
600 mg/1
300 mg/1
300 mg/1
450 mg/1
300 mg/1
450 mg/1
300 mg
8 mmol","Lithium is used as a mood stabilizer, and is used for treatment of depression and mania. It is often used in bipolar disorder treatment."
C(C(=O)N(C(C(O[H])(C(O[H])([H])[H])[H])([H])[H])C1=C(I)C(C(=O)N(C(C(O[H])(C(O[H])([H])[H])[H])([H])[H])[H])=C(I)C(C(=O)N(C(C(O[H])(C(O[H])([H])[H])[H])([H])[H])[H])=C1I)([H])([H])[H],DB01362,66108-95-0,Iohexol,"Iohexolum
N,N'-Bis(2,3-dihydroxypropyl)-5-(N-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide",small molecule,Humans and other mammals,"Injection
Injection
Injection
Injection, solution
Injection, solution
Solution
Solution
Solution
Solution
For solution","Intrathecal; Intravascular; Intravenous; Oral
Intravenous
Intravenous
Intravenous
Intravenous
Subarachnoid
Intravascular; Subarachnoid
Intravascular; Subarachnoid
Intravascular
Oral","518 mg/mL
140 mg/mL
180 mg/mL
300 mg/mL
350 mg/mL
388 mg
518 mg
647 mg
755 mg
4.5 g/1","Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures."
C(N(C(C([H])([H])[H])(C([H])([H])[H])C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H])([H])([H])[H],DB01365,100-92-5,Mephentermine,Mephentermine,small molecule,Humans and other mammals,Liquid,Intramuscular; Intravenous,30 mg,Used to maintain blood pressure in hypotensive states.
[Al],"DB01370
DB11314",7429-90-5,Aluminium,"13Al
Al
Aluminio
Aluminium
Aluminium atom
Aluminum",small molecule,,"Gel
Solution
Gel
Gel
Suspension
Gel
Liquid
Powder, for solution
Solution
Gel
Powder","Topical
Auricular (otic)
Topical
Oral
Oral
Oral
Topical
Topical
Topical
Topical
Topical",".008 mg/4mL
5 mg/mL
61.9 g/100g
530 mg/mL
615 mg/1
3 mg/mL
2 mg/mL
4866 mg/4.866g",
[Ca]([H])[H],DB01373,7440-70-2,Calcium,,small molecule,Humans and other mammals,"Capsule
Powder
Granule, effervescent; kit; tablet
Capsule; liquid
Tablet
Powder
Powder
Tablet
Tablet
Wafer
Capsule
Tablet
Tablet
Capsule
Capsule
Tablet
Capsule
Tablet
Tablet
Capsule
Tablet
Tablet
Liquid
Syrup
Syrup
Tablet
Tablet
Tablet
Powder
Capsule
Liquid
Powder, for solution
Tablet
Capsule, gelatin coated
Capsule
Tablet
Tablet
Tablet
Liquid
Liquid
Liquid; tablet
Granule, effervescent
Kit; tablet
Tablet
Tablet
Tablet, film coated
Tablet, chewable
Tablet, effervescent
Tablet
Tablet, extended release
Solution
Solution
Tablet
Liquid
Capsule
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral",".99 1/1
63.4 mg
336 mg
100 mg
30 mg
150 mg
600 mg
650 mg
400 mg
246 mg
160.0 mg
60 mg
120 mg
100 mg
84.5 mg
84 mg
100 mg
100 mg
110 mg
150 mg
125 mg
266.7 mg
216.7 mg
500 mg
803.8 mg/1000mL
300 mg
45 mg
.99 1/1
84.2 mg
42.1 mg
10 mg
350 mg
250 mg
200 mg
1.458 mg
1.667 mg
400 mg
400 mg
600 mg
500 mg","Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. It is vital in cell signaling, muscular contractions, bone health, and signalling cascades."
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(=O)O[Al](O[H])O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01375,7047-84-9,Aluminium monostearate,"Aluminium, dihydroxide stearate
Aluminum monostearate
Aluminum stearate 300
Dibasic aluminium stearate
Dibasic aluminum stearate
Dihydroxy(stearato)aluminium
Dihydroxy(stearato)aluminum
Dihydroxyaluminum stearate",small molecule,,,,,
O=[Mg],DB01377,1309-48-4,Magnesium oxide,Magmitt,small molecule,,"Tablet
Liquid
Kit
Tablet, film coated
Capsule
Liquid
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Powder, for solution
Tablet, coated
Powder, metered
Solution
Liquid
Tablet, chewable
Capsule, gelatin coated
Capsule, liquid filled","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Irrigation
Irrigation
Oral
Oral
Oral","1.75 g
253 mg/1
400 mg/1
420 mg/1
250 mg
420 mg
410 mg","Magnesium hydroxide is used as a laxative to relieve occasional constipation (irregularity) and as an antacid to relieve indigestion, sour stomach, and heartburn."
C(OC(C(OC1=C([H])N=C(N(S(=O)(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])[H])N=C1[H])([H])[H])([H])[H])([H])([H])[H],DB01382,339-44-6,Glycodiazine,"Glidiazine
Glymidine",small molecule,Humans and other mammals,,,,Glycodiazine is used concomitantly with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus. 
C(C(C([H])([H])[H])(OC1=C([H])C([H])=C(C(C(N(C(=O)C2=C([H])C([H])=C(Cl)C([H])=C2[H])[H])([H])[H])([H])[H])C([H])=C1[H])C(O[H])=O)([H])([H])[H],"DB01393
DB08380",41859-67-0,Bezafibrate,"2-(P-(2-(P-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid
Befizal
Bezafibrat
Bezafibrato
Bezafibratum
Bezalip
Bezatol sr (tn)
Cedur",small molecule,Humans and other mammals,"Tablet, extended release
Tablet","Oral
Oral","400 mg
200 mg","For the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. Also for the treatment of secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus)."
O(C(=O)C1=C(OC(=O)C2=C(O[H])C([H])=C([H])C([H])=C2[H])C([H])=C([H])C([H])=C1[H])[H],DB01399,552-94-3,Salsalate,"2-Carboxyphenyl salicylate
Disalicylic acid
Disalicylsaeure
O-Salicylcylsalicylsaeure
O-Salicylsalicylic acid
Salicylic acid bimolecular ester
Salicyloxysalicylic acid
Salicyloylsalicylic acid
salicylsalicylic acid
Salsalato
Salsalatum
Sasapyrin
Sasapyrine
Sasapyrinum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral","500 mg
750 mg
500 mg/1
750 mg/1
500 mg/1
750 mg/1","For relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorders."
C(N(C([H])([H])[H])C(=O)OC1=C([H])C([N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=C([H])C([H])=C1[H])([H])([H])[H],DB01400,59-99-4,Neostigmine,"(m-Hydroxyphenyl)trimethylammonium dimethylcarbamate
3-Trimethylammoniumphenyl N,N-dimethylcarbamate
Eustigmin
Eustigmine
m-Trimethylammoniumphenyldimethylcarbamate",small molecule,Humans and other mammals,"Injection
Injection
Injection
Injection
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Injection, solution
Solution
Solution
Liquid
Liquid
Liquid
Tablet","Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intravenous
Intravenous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intravenous
Intravenous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Intramuscular; Intravenous; Subcutaneous
Oral",".5 mg/mL
1 mg/mL
.5 mg/mL
1 mg/mL
.5 mg/mL
1 mg/mL
5 mg/mL
.5 mg/mL
1 mg/mL
0.5 mg
2.5 mg
0.5 mg
1 mg
.5 mg
15 mg",Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.
O=C(N(C1=C([H])C([H])=C([H])C2=C1OC(=C(C2=O)[H])C1=NN([H])N=N1)[H])C1=C([H])C([H])=C(OC(C(C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H],DB01411,103177-37-3,Pranlukast,ONO-RS 411,small molecule,Humans and other mammals,,,,Used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists. 
C(N1C([H])=NC2=C1C(=O)N(C(=O)N2C([H])([H])[H])[H])([H])([H])[H],DB01412,83-67-0,Theobromine,"3,7-dihydro-3,7-Dimethyl-1H-purine-2,6-dione
3,7-Dimethylpurine-2,6-dione
3,7-Dimethylxanthine
Theobromin
Theobromine",small molecule,,,,,"theobromine is used as a vasodilator, a diuretic, and heart stimulant. And similar to caffeine, it may be useful in management of fatigue and orthostatic hypotension."
FC(F)(F)C1=C([H])C2=NC(=C(C(N(C3=C(C(=O)OC(C(N4C([H])([H])C([H])([H])N(C5=C([H])C(C(F)(F)F)=C([H])C([H])=C5[H])C([H])([H])C4([H])[H])([H])[H])([H])[H])C([H])=C([H])C([H])=C3[H])[H])=C2C([H])=C1[H])[H])[H],DB01419,55300-29-3,Antrafenine,,small molecule,,,,,Antrafenine is used as an anti-inflammatory and analgesic agent for the relief of mild to moderate pain.
O(C1=C([H])C([H])=C([N+]([O-])=O)C2=C(C(=C(N=C12)[H])[H])[H])[H],DB01422,4008-48-4,Nitroxoline,"5-Nitro-8-hydroxyquinoline
5-Nitro-8-oxyquinoline
5-Nitro-8-quinolinol
5-Nitrox
5-NOK
5NOK
8-Hydroxy-5-nitroquinoline
Nitroxolina
Nitroxolinum",small molecule,,,,,Nitroxoline is an antibiotic agent.
C(N(C([H])([H])[H])C1=C(C([H])([H])[H])N(C([H])([H])[H])N(C2=C([H])C([H])=C([H])C([H])=C2[H])C1=O)([H])([H])[H],DB01424,58-15-1,Aminophenazone,"(Dimethylamino)phenazone
1-Phenyl-2,3-dimethyl-4-(dimethylamino)-5-pyrazolone
1-Phenyl-2,3-dimethyl-4-dimethylaminopyrazol-5-one
1,5-Dimethyl-4-dimethylamino-2-phenyl-3-pyrazolone
2,3-Dimethyl-4-dimethylamino-1-phenyl-5-pyrazolone
3-Keto-1,5-dimethyl-4-dimethylamino-2-phenyl-2,3-dihydropyrazole
4-(Dimethylamino)-1,2-dihydro-1,5-dimethyl-2-phenyl-3H-pyrazol-3-one
4-(Dimethylamino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one
4-(Dimethylamino)antipyrine
4-Dimethylamino-1-phenyl-2,3-dimethylpyrazolone
4-Dimethylamino-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one
4-Dimethylamino-2,3-dimethyl-1-phenyl-5-pyrazolone
4-Dimethylaminoantipyrine
4-Dimethylaminophenazone
Aminofenazona
Aminofenazone
Aminophenazon
Aminophenazonum
Aminopyrine
Dimethylaminoantipyrine
Dimethylaminoazophene
Dimethylaminophenazon
Dimethylaminophenazone
Dimethylaminophenyldimethylpyrazolone
Dipyrine",small molecule,Humans and other mammals,,,,"Formerly widely used as an antipyretic and analgesic in rheumatism, neuritis, and common colds. Currently used to measure total body water."
N(C1=C([H])C(C2=C([H])C([H])=NC([H])=C2[H])=C([H])N([H])C1=O)([H])[H],DB01427,60719-84-8,Amrinone,"Amrinona
Amrinonum
Inamrinone",small molecule,Humans and other mammals,Liquid,Intravenous,5 mg,Used in the treatment of congestive heart failure.
C(OC1=C([H])C(O[H])=C(C(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])([H])[H],DB01428,131-57-7,Oxybenzone,"(2-Hydroxy-4-methoxyphenyl)phenylmethanone
2-Benzoyl-5-methoxyphenol
2-Hydroxy-4-methoxybenzophenone
4-Methoxy-2-hydroxybenzophenone
4-Methoxy-2-hydroxybenzophenone butyric acid
Benzophenone-3
Oxibenzona
Oxybenzonum",small molecule,Humans and other mammals,"Cream
Lotion
Salve
Kit
Paste
Gel
Cloth; cream
Liquid
Spray
Stick
Gel; kit; lotion
Oil
Emulsion
Liquid; lotion
Jelly
Cream, augmented
Lotion / shampoo
Kit
Solution
Aerosol, foam
Suspension
Aerosol, spray
Kit
Lotion
Cloth
Aerosol
Ointment
Spray, suspension
Stick
Spray
Liquid; spray
Lotion; spray
Lipstick
Powder
Liquid","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Topical",.05 g/100g,Used as an ingredient in sunscreen and other cosmetics.
C(C(N(C(C([H])([H])[H])([H])[H])C(C(C(N(C1(C([H])([H])C2=C(C(=C(C(=C2[H])[H])[H])[H])C1([H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01429,37640-71-4,Aprindine,"Aprindina
Aprindine
Aprindinum
Compound 99170",small molecule,,,,,
FC1=C([H])C([H])=C(C(N2C([H])([H])C([H])([H])N(C3=NC(N(C(C(=C([H])[H])[H])([H])[H])[H])=NC(N(C(C(=C([H])[H])[H])([H])[H])[H])=N3)C([H])([H])C2([H])[H])(C2=C([H])C([H])=C(F)C([H])=C2[H])[H])C([H])=C1[H],DB01430,27469-53-0,Almitrine,"2,4-Bis(allylamino)-6-(4-(bis(P-fluorophenyl)methyl)-1-piperazinyl)-S-triazine
Almitrina
Almitrinum",small molecule,Humans and other mammals,,,,For the treatment of chronic obstructive pulmonary disease.
C(C(C(OC(C([H])([H])[H])=O)(C(C(C(C([H])([H])[H])(N(C([H])([H])[H])C([H])([H])[H])[H])([H])[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB01433,509-74-0,Methadyl Acetate,"Acetilmetadol
Acetylmethadol
Acetylmethadolum
Betamethadol",small molecule,Humans and other mammals,,,,Used mainly in the treatment of narcotic dependence.
N(C1=C([H])C([H])=C(N=NC2=C([H])C([H])=C([H])C([H])=C2[H])C(N([H])[H])=N1)([H])[H],DB01438,94-78-0,Phenazopyridine,"3-(Phenylazo)-2,6-pyridinediamine
Fenazopiridina",small molecule,Humans and other mammals,"Tablet
Kit
Tablet
Tablet
Tablet
Tablet
Tablet, coated
Tablet, coated
Tablet, film coated
Tablet, film coated
Tablet
Tablet
Tablet
Tablet, film coated
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","95 mg/1
100 mg/mg
200 mg/mg
100 mg/1
200 mg/1
100 mg/1
200 mg/1
100 mg/1
200 mg/1
100 mg
200 mg
97.5 mg/1
99.5 mg/1
99.5 mg/1","For the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters."
C(C(C(=O)N(C1(C([H])([H])C([H])([H])N(C(C(C2=C([H])C([H])=C([H])S2)([H])[H])([H])[H])C([H])([H])C1(C([H])([H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB01439,86052-04-2,3-Methylthiofentanyl,3-Methyl-thiofentanyl,small molecule,Humans and other mammals,,,,
C(OC1=C([H])C2=C(N(C(=C2C(C(N(C(C([H])([H])[H])(C([H])([H])[H])[H])C(C([H])([H])[H])(C([H])([H])[H])[H])([H])[H])([H])[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB01441,4021-34-5,"5-Methoxy-N,N-diisopropyltryptamine","5-MeO-DIPT
5-methoxy-N,N-bis(1-methylethyl)-1H-Indole-3-ethanamine
Foxy
Foxy methoxy",small molecule,Humans and other mammals,,,,
C(N(C([H])([H])[H])C(C(C1=C([H])N([H])C2=C1C(=C(O[H])C(=C2[H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB01445,487-93-4,Bufotenine,"3-[2-(dimethylamino)ethyl]-5-indolol
3-[2-(dimethylamino)ethyl]indol-5-ol
3-[��-(dimethylamino)ethyl]-5-hydroxyindole
5-hydroxy-N,N-dimethyltryptamine
Bufotenin
DM5-HT
N,N-dimethylserotonin",small molecule,Humans and other mammals,,,,
C(C1(N=C(N([H])[H])OC1(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H])([H])([H])[H],DB01447,3568-94-3,4-Methylaminorex,,small molecule,,,,,
C(C(C(SC1=C(OC([H])([H])[H])C([H])=C(C(C(N([H])[H])([H])[H])([H])[H])C(OC([H])([H])[H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB01458,207740-26-9,"2,5-Dimethoxy-4-(n)-propylthiophenethylamine","2,5-dimethoxy-4-propylthiophenethylamine",small molecule,,,,,
C(C(C(=O)N1C(=O)N(C2(C([H])([H])C([H])([H])N(C(C(C(C#N)(C3=C([H])C([H])=C([H])C([H])=C3[H])C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])([H])[H])C([H])([H])C2([H])[H])[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])([H])[H],DB01459,15301-48-1,Bezitramide,"1-[1-(3-Cyano-3,3-diphenylpropyl)-4-piperidinyl]-1,3-dihydro-3-(1-oxopropyl)-2H-benzimidazol-2-one",small molecule,,,,,A narcotic analgesic once used for the treatment of severe chronic pain. [1] 
C(C(N(C(C([H])([H])[H])([H])[H])C(C(C1=C([H])N([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01460,61-51-8,Diethyltryptamine,"3-(2-Diethylaminoethyl)indole
N,N-Diethyl-2-(1H-indol-3-yl)ethanamine",small molecule,,,,,
C(C(OC(C(=O)OC(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB01461,509-78-4,Dimenoxadol,"dimenoxadole 
estocin",small molecule,,,,,
C(C(OC1=C([H])C([H])=C(C(C2=NC3=C(C(=C(C(=C3[H])[N+]([O-])=O)[H])[H])N2C(C(N(C(C([H])([H])[H])([H])[H])C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB01462,911-65-9,Etonitazene,,small molecule,,,,,
C(C(N(C1(C2(C(C([H])([H])C(C2([H])[H])([H])C1(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H])[H])[H])[H])([H])[H])([H])([H])[H],DB01463,1209-98-9,Fencamfamine,"Fencamfamin
Fencamfamine
Fencamfaminum
Fencanfamina",small molecule,Humans and other mammals,,,,"For the the treatment of depressive fatigue in convalescence and other debilitated states as well as in the treatment of depressive day-time fatigue, lack of concentration and lethargy."
C(C(OC(=O)C(C(C(N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H])([H])[H])([H])[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB01475,467-86-7,Dioxaphetyl butyrate,,small molecule,,,,,
C(C(C(=O)OC1(C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C1([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB01478,13147-09-6,Desmethylprodine,"1-Methyl-4-phenyl-4-piperidinol propionate
1-Methyl-4-phenyl-4-propionoxypiperidine
3-Demethylprodine
MPPP",small molecule,,,,,
C(C(C1(C(C([H])([H])[H])([H])[H])C(=O)N([H])C(=O)N([H])C1=O)([H])[H])([H])([H])[H],DB01483,57-44-3,Barbital,,small molecule,,,,,
C(C(C(C(C([H])([H])[H])([H])[H])(C(N(C(=O)C(C(C(O[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],"DB01487
DB11402",15687-14-6,Embutramide,Embutramid,small molecule,,,,,
C(N(C([H])([H])[H])C(C(C1=C([H])N([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB01488,61-50-7,Dimethyltryptamine,,small molecule,,,,,Some people use this compound as a psychedelic inducing agent.
FC(F)(F)C1=C(C2=C([H])C([H])=C(C(C3(C(=O)N([H])C(=S)N([H])C3=O)[H])([H])[H])O2)C([H])=C([H])C([H])=C1[H],DB01496,,Barbituric acid derivative,,small molecule,,,,,
C(C(OC(=O)C1(C([H])([H])C([H])([H])N(C(C(OC(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB01505,469-82-9,Etoxeridine,,small molecule,,,,,
N(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H],DB01506,2201-24-3,1-Phenylcyclohexylamine,,small molecule,,,,,
ClC1=C([H])C2=C(N(C(=O)C(N=C2C2=C(Cl)C([H])=C([H])C([H])=C2[H])([H])[H])[H])C([H])=C1[H],DB01511,2894-67-9,Delorazepam,"CDDZ
Chlordesmethyldiazepam
Dadumir",small molecule,,,,,"Mainly used as an anti-anxiety agent. Studies have found delorazepam to be more effective in the first 4 weeks of use than antidepressants; however, after 4 weeks, antidepressants showed superior anti-anxiety effects. [Wikipedia] Anti-anxiety effects also appear to be weaker in elderly patients. [1]
Effectiveness has also been observed in the treatment of alcohol withdrawal. Delorazapam was reported to be a manageable drug in that it did not exhibit severe side effects and did not require further therapies to control symptoms of withdrawal. [3]"
C(C(OC(=O)C1(C([H])([H])C([H])([H])N(C(C(OC(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB01518,3691-78-9,Benzethidine,,small molecule,,,,,
C1(C([H])([H])C([H])([H])N(C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])C2=C([H])C([H])=C([H])S2)C([H])([H])C1([H])[H])([H])[H],DB01520,21500-98-1,Tenocyclidine,TCP,small molecule,Humans and other mammals,,,,"Because of its high affinity for the phencyclidine binding site on the NMDA receptor, the 3H radiolabelled form of tenocyclidine is widely used in research into NMDA receptors."
C(C(N(C(C([H])([H])[H])([H])[H])C(C(N1C(C(C2=C([H])C([H])=C(Cl)C([H])=C2[H])([H])[H])=NC2=C1C(=C(C(=C2[H])[N+]([O-])=O)[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01523,3861-76-5,Clonitazene,,small molecule,,,,,
C(C(C([H])([H])[H])(N([H])[H])C(C1=C(Cl)C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB01527,10389-73-8,Clortermine,,small molecule,,,,,
C(C(C(C(C([H])([H])[H])(C([H])([H])[H])O[H])([H])[H])(OC(O[H])(C(Cl)(Cl)Cl)[H])[H])([H])([H])[H],DB01534,3563-58-4,Chlorhexadol,"2-methyl-4-(2,2,2-trichloro-1-hydroxy-ethoxy)pentan-2-ol
2-Methyl-4-(2,2,2-trichloro-1-hydroxyethoxy)-2-pentanol
2-methyl-4-(2,2,2-trichloro-1-hydroxyethoxy)pentan-2-ol
2-Pentanol
Cloralodol
Lora
Mecoral
Medodorm
Merchloral",small molecule,,,,,
C(C(C(=O)N(C1=C([H])C([H])=C([H])C([H])=C1[H])C1(C([H])([H])C([H])([H])N(C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])C(=O)OC([H])([H])[H])([H])[H])([H])([H])[H],DB01535,59708-52-0,Carfentanil,Carfentanyl,small molecule,,,,,Carfentanil is similar (but more potent) to the opioid analgesic fentanyl. It is used as a tranquilizer for large animals.
C(OC1=C([H])C(Br)=C(OC([H])([H])[H])C([H])=C1C(C(N([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01537,66142-81-2,"4-Bromo-2,5-dimethoxyphenethylamine",2C-B,small molecule,,,,,
N#CC1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H],DB01539,3867-15-0,1-Piperidinocyclohexanecarbonitrile,,small molecule,,,,,
C(C(C(=O)OC1(C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C1(C(C(=C([H])[H])[H])([H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB01542,25384-17-2,Allylprodine,,small molecule,,,,,
C(N1C2=C(C(=C(C(=C2[H])[H])[N+]([O-])=O)[H])C(C2=C(F)C([H])=C([H])C([H])=C2[H])=NC([H])([H])C1=O)([H])([H])[H],DB01544,1622-62-4,Flunitrazepam,"Flunitrazepamum
Rohypnol",small molecule,Humans and other mammals,,,,"For short-term treatment of severe insomnias, that are not responsive to other hypnotics."
C1(C([H])([H])C([H])([H])N(C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])C2=C([H])C([H])=C([H])C([H])=C2[H])C1([H])[H])([H])[H],DB01549,2201-39-0,Rolicyclidine,"1-(1-phenylcyclohexyl)pyrrolidine
PCPy
Pyrrolidine analog of phencyclidine
Roliciclidina
Rolicyclidinum",small molecule,Humans and other mammals,,,,Rolicyclidine has anesthetic properties and can induce a sedative effect. 
C(C(C([H])([H])[H])(N([H])[H])C(C1=C([H])C([H])=C(Cl)C([H])=C1[H])([H])[H])([H])([H])[H],DB01556,461-78-9,Chlorphentermine,"4-Chloro-a,a-dimethylbenzeneethanamine
4-Chloro-a,a-dimethylphenethylamine
a,a-Dimethyl-p-chlorophenethylamine
Chlorphenterminum
Clorfentermina",small molecule,,,,,Used as an appetite suppressant.
BrC1=C([H])C2=C(N(C(=O)C(N=C2C2=NC([H])=C([H])C([H])=C2[H])([H])[H])[H])C([H])=C1[H],DB01558,1812-30-2,Bromazepam,"Bromazepamum
Lectopam",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet","Oral
Oral
Oral","1.5 mg
3 mg
6 mg","For the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal."
C(C(C1=C([H])C2=C(N(C([H])([H])[H])C(=O)C(N=C2C2=C(Cl)C([H])=C([H])C([H])=C2[H])([H])[H])S1)([H])[H])([H])([H])[H],DB01559,33671-46-4,Clotiazepam,"Clotiazepamum
Rize",small molecule,Humans and other mammals,,,,For the treatment of anxiety disorders.
C(C(=O)OC1(C([H])([H])C([H])([H])N(C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB01562,64-52-8,1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine,"1-(2-Phenethyl)-4-phenyl-4-acetoxypiperidine
1-phenethyl-4-phenyl-4-piperidinol acetate
PEPAP",small molecule,Humans and other mammals,,,,
O(C(O[H])(C(Cl)(Cl)Cl)[H])[H],DB01563,302-17-0,Chloral hydrate,"1,1,1-trichloro-2,2-dihydroxyethane
1,1,1-trichloro-2,2-ethanediol
2,2,2-trichloro-1,1-ethanediol
chloral monohydrate
Chloralhydrat
Trichloracetaldehyd-hydrat
trichloroacetaldehyde hydrate",small molecule,,"Ointment
Capsule
Syrup","Topical
Oral
Oral","500 mg
100 mg","Mainly used as a hyponotic in the treatment of insomnia; however, it is only effective as a hypnotic for short-term use. May be used as a routine sedative preoperatively to decrease anxiety and cause sedation and/or sleep with respiration depression or cough reflex. "
C(N1C2=C(C(=C(Cl)C(=C2[H])[H])[H])C(C2=C(F)C([H])=C([H])C([H])=C2[H])=NC([H])([H])C1=O)([H])([H])[H],DB01567,3900-31-0,Fludiazepam,"7-chloro-5-(O-Fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one
Erispan
Fludiazepamum",small molecule,Humans and other mammals,,,,Used for the short-term treatment of anxiety disorders.
C(C(C(=O)N(C1(C([H])([H])C([H])([H])N(C(C(O[H])(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])([H])[H])C([H])([H])C1(C([H])([H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB01570,78995-14-9,Ohmefentanyl,"Beta-hydroxy-3-methylfentanyl
OMF
��-hydroxy-3-methylfentanyl",small molecule,,,,,
C(C(C(=O)N(C1(C([H])([H])C([H])([H])N(C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])C([H])([H])C1(C([H])([H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB01571,42045-86-3,3-Methylfentanyl,"3-MF
mefentanyl",small molecule,Humans and other mammals,,,,
[O-][Si]([O-])([O-])O[Si]([O-])([O-])[O-],DB01575,1332-58-7,Kaolin,"Kaolin, light",small molecule,,"Gel
Suspension
Cream
Cream
Powder
Liquid
Ointment
Paste
Patch
Cream
Patch
Patch
Cream
Cream","Topical
Oral
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","8 g/100mL
4 g/100g
4.5 g/30mL
.002 g/.2g
3.5 g/14g
2.8 g/14g
45.5 g/130g
15 g/100mL","Used for upset stomach and diarrhea, a traditional medicine used in China, South America and Africa. Kaolin is also used to treat AIDs-related diarrhea. Kaolin based bandages are also under investigation. "
C(C1=C([H])C([H])=NC(N(S(=O)(=O)C2=C([H])C([H])=C(N([H])[H])C([H])=C2[H])[H])=N1)([H])([H])[H],DB01581,127-79-7,Sulfamerazine,"(P-Aminobenzolsulfonyl)-2-amino-4-methylpyrimidin
2-(4-Aminobenzenesulfonamido)-4-methylpyrimidine
2-(P-Aminobenzolsulfonamido)-4-methylpyrimidine
2-(Sulfanilamido)-4-methylpyrimidine
2-Sulfa-4-methylpyrimidine
4-Amino-N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide
N-(4-Methyl-2-pyrimidyl)sulfanilamide
N(1)-(4-Methyl-2-pyrimidinyl)sulfanilamide
Sulfamerazina
Sulfamerazinum
Sulfamethyldiazine
Sulphamerazine",small molecule,,"Suspension
Tablet","Oral
Oral",,"A sulfanilamide that is used as an antibacterial agent. It can be used to treat bronchitis, prostatitis and urinary tract infections."
C(C1=C([H])C(C([H])([H])[H])=NC(N(S(=O)(=O)C2=C([H])C([H])=C(N([H])[H])C([H])=C2[H])[H])=N1)([H])([H])[H],DB01582,57-68-1,Sulfamethazine,"(P-Aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin
2-(4-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine
2-(P-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine
2-Sulfanilamido-4,6-dimethylpyrimidine
4-Amino-N-(2,6-dimethyl-4-pyrimidinyl)benzenesulfonamide
4-Amino-N-(4,6-dimethyl-pyrimidin-2-yl)-benzenesulfonamide
4-amino-N-(4,6-Dimethylpyrimidin-2-yl)benzenesulfonamide
4,6-Dimethyl-2-sulfanilamidopyrimidine
6-(4'-Aminobenzol-sulfonamido)-2,4-dimethylpyrimidin
N-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide
N(1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide
N(1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide
SMZ
Sulfadimethyldiazine
Sulfadimethylpyrimidine
Sulfadimidina
Sulfadimidine
Sulfadimidinum
Sulfametazina
Sulfametazyny
Sulfamezathine
Sulphadimethylpyrimidine
Sulphamethazine",small molecule,,"Suspension
Tablet","Oral
Oral",,"For the treatment bacterial infections causing bronchitis, prostatitis and urinary tract infections."
ClC1=C([H])C2=C(N(C(C3(C([H])([H])C3([H])[H])[H])([H])[H])C(=O)C(N=C2C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])C([H])=C1[H],DB01588,2955-38-6,Prazepam,Prazepamum,small molecule,Humans and other mammals,,,,For the treatment of anxiety disorders.
FC1=C(C2=NC([H])([H])C(=S)N(C(C(F)(F)F)([H])[H])C3=C2C(=C(Cl)C(=C3[H])[H])[H])C([H])=C([H])C([H])=C1[H],DB01589,36735-22-5,Quazepam,Quazepamum,small molecule,Humans and other mammals,Tablet,Oral,15 mg/1,Used to treat insomnia.
[Fe],DB01592,7439-89-6,Iron,"Carbonyl iron
Eisen
Electrolytic iron
Fe
fer
Ferrum
Ferrum metallicum
Hierro
Iron powder
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, reduced
Reduced iron",small molecule,Humans and other mammals,"Capsule; liquid
Capsule
Tablet
Tablet
Capsule, liquid filled
Capsule
Liquid
Tablet, chewable
Lotion
Tablet
Liquid
Solution / drops
Tablet
Tablet, extended release
Tablet, extended release
Tablet
Elixir
Tablet
Tablet
Tablet, film coated
Tablet
Syrup
Syrup
Kit
Capsule, extended release
Capsule
Capsule
Tablet
Tablet, extended release
Tablet
Capsule
Tablet, extended release
Tablet, chewable
Tablet
Tablet, effervescent
Tablet
Liquid; tablet
Liquid
Solution / drops
Tablet, delayed release
Tablet
Tablet
Tablet, film coated
Kit
Powder
Capsule
Capsule, gelatin coated
Tablet, delayed release
Liquid
Tablet, coated","Oral
Oral
Oral
Oral
Oral
Oral
Intramuscular; Intravenous
Oral
Topical
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intravenous
Oral","33 mg
25 mg
18 mg
50 mg
28 mg
16.7 mg
125 mg
65 mg
105 mg
200 mg
220 mg/5mL
325 mg/1
65 mg/1
325 mg/1
325 mg
35 mg
30 mg
150 mg/1
40 mg
30 mg
35 mg
37 mg
50 mg
50 mg
15 mg/1
35 mg
6 mg
300 mg
300 mg
100 mg
60 mg
20 mg",Used in preventing and treating iron-deficiency anemia.
[Zn],DB01593,7440-66-6,Zinc,"30Zn
Cinc
Zinc
Zincum
Zink
Zn
Zn(ii)
Zn2+",small molecule,,"Powder, for suspension
Cream
Cream
Cream
Granule, effervescent
Capsule
Lotion
Tablet
Tablet
Tablet, extended release
Ointment
Gel, dentifrice
Spray
Spray
Liquid
Soap
Wafer
Tablet, effervescent
Tablet, chewable
Capsule, gelatin coated
Capsule, liquid filled
Spray
Capsule
Capsule
Aerosol, spray
Solution
Spray
Lozenge
Lozenge
Aerosol
Syrup
Gel
Liquid
Liquid
Cream
Capsule
Liquid
Solution
Solution
Spray, metered
Tablet
Gel
Gel
Solution
Solution
Tablet
Liquid
Capsule
Gel, dentifrice
Spray
Powder
Cream
Lipstick
Liquid
Solution
Tablet, coated
Lozenge
Tablet
Injection, solution
Tablet
Capsule
Tablet
Tablet
Tablet
Capsule
Tablet
Liquid
Lozenge
Lozenge
Liquid
Tablet
Lozenge","Topical
Topical
Topical
Topical
Oral
Oral
Topical
Oral
Oral
Oral
Topical
Dental
Topical
Topical
Topical
Topical
Oral
Oral
Oral
Oral
Oral
Oropharyngeal
Oral
Oral
Topical
Oral
Oral
Oral
Oral
Topical
Oral
Oral
Oral
Topical
Topical
Oral
Intravenous
Intravenous
Intravenous
Oral
Oral
Topical
Dental; Topical
Topical
Dental
Oral
Dental
Oral
Oral
Topical
Oral
Topical
Topical
Topical
Intravenous
Oral
Oral
Oral
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral",".001 mg/mL
1 g/50g
15 g/150g
.15 g/75g
75 mg
25 mg
.1 g/100g
.531 g/118mL
1 mg
.0025 mg/mg
25 mg/1
50 mg/1
5.5 mg
5 mg
5 mg
1 mg
5 mg
25.0 mg
1 %
.15 %
2.5 mg
1.5 g/75g
.001 mg/mL
13.3 mg
90 mg
1 mg/mL
10 mg
50 mg
50 mg
15 mg
30 mg
30 mg
1.37 mg
15 mg
9.9 mg
10 mg
5 mg
20 mg",
[O-][N+](=O)C1=C([H])C2=C(N(C(=O)C(N=C2C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])[H])C([H])=C1[H],DB01595,146-22-5,Nitrazepam,"1,3-dihydro-7-Nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
2,3-dihydro-7-Nitro-5-phenyl-1H-1,4-benzodiazepin-2-one
7-Nitro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one
7-Nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
Apodorm
Atempol
Benzalin
Calsmin
Eatan
Eunoctin
Gerson
Hipnax
Hipsal
Ibrovek
Imeson
Imesont
N-Desmethylnimetazepam
Nelbon
Nelmat
Neozepam
Neuchlonic
Nitrazepamum
Paxisyn
Pelson
Persopit
Radedorm
Relact
Somitran
Sonebon
Sonnolin
Trazenin",small molecule,Humans and other mammals,"Tablet
Tablet","Oral
Oral","10 mg
5 mg","Used to treat short-term sleeping problems (insomnia), such as difficulty falling asleep, frequent awakenings during the night, and early-morning awakening."
C(C(C([H])([H])[H])(SC1=C([H])C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=C(O[H])C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=C1[H])SC1=C([H])C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=C(O[H])C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=C1[H])([H])([H])[H],DB01599,23288-49-5,Probucol,"4,4'- (Isopropylidenedithio)bis(2,6-di-tert-butylphenol)
Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole
Biphenabid
Bisbid
Bisphenabid
Probucol
Probucolum",small molecule,Humans and other mammals,Tablet,Oral,250 mg,Used to lower LDL and HDL cholesterol.
O(C1(C([H])([H])C([H])([H])N(C(C(C(N2C3=C(C(=C(C(=C3[H])[H])[H])[H])SC3=C2C(=C(C(=C3[H])[H])C#N)[H])([H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])[H])[H],DB01608,2622-26-6,Propericiazine,"10-(3-(4-Hydroxypiperidino)propyl)phenothiazine-2-carbonitrile
2-Cyano-10-(3-(4-hydroxy-1-piperidyl)propyl)phenothiazine
2-Cyano-10-(3-(4-hydroxypiperidino)propyl)phenothiazine
Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazine
Periciazina
Periciazine
Periciazinum
Pericyazine
Piperocyanomazine
Propericiazine",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Solution / drops","Oral
Oral
Oral
Oral","10 mg
20 mg
5 mg
10 mg","For use as adjunctive medication in some psychotic patients. Propericiazine (Pericyazine)is used for the control of residual prevailing hostility, impulsiveness and aggressiveness. "
O(C(=O)C1=C([H])C([H])=C(N2N=C(C3=C(O[H])C([H])=C([H])C([H])=C3[H])N=C2C2=C(O[H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])[H],DB01609,201530-41-8,Deferasirox,"Deferasiroxum
ICL 670
ICL 670a",small molecule,Humans and other mammals,"Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, for suspension
Tablet, for suspension
Tablet, for suspension
Tablet, for suspension
Tablet, for suspension
Tablet, for suspension
Granule
Granule
Granule
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","180 mg
360 mg
90 mg
125 mg
125 mg/1
250 mg
250 mg/1
500 mg/1
500 mg
180 mg/1
360 mg/1
90 mg/1
180 mg
360 mg
90 mg
180 mg/1
360 mg/1
90 mg/1",For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
C(C(C(C(C(ON=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01612,8017-89-8,Amyl Nitrite,"1-nitropentane
n-Amyl nitrite
n-pentyl nitrite
Nitramyl
pentyl nitrite",small molecule,Humans and other mammals,"Inhalant
Liquid
Liquid","Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)",".3 g/.3mL
0.33 ml
.3 ml",For the rapid relief of angina pectoris.
C(N(C([H])([H])[H])C(C(C(N1C2=C(C(=C(C(=C2[H])[H])[H])[H])SC2=C1C(=C(C(=C2[H])[H])C(C([H])([H])[H])=O)[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01614,61-00-7,Acepromazine,"1-[10-(3-DIMETHYLAMINO-propyl)-10H-phenothiazin-2-yl]-ethanone
10-(3-dimethylaminopropyl)phenothiazin-3-yl methyl ketone
10-(3-dimethylaminopropyl)phenothiazine-3-ethylone
Acetazine
Acetopromazine
Acetylpromazine",small molecule,Humans and other mammals,,,,Acepromazine was first used in humans in the 1950s as an antipsychotic agent. It is now rarely used in humans. Acepromazine is frequently used in animals as a sedative and antiemetic. Its principal value is in quietening and calming anxious animals.
C(C(N(C(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])C(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01616,150-59-4,Alverine,"Alverina
Alverinum
Bis(gamma-phenylpropyl)ethylamine
Di(phenylpropyl)ethylamine
N-Ethyl-3-phenyl-N-(3-phenylpropyl)-1-propanamine
N-Ethyl-3,3'-diphenyldipropylamine
N-Ethyl-N-(3-phenylpropyl)benzenepropanamine
N,N-Bis(3-phenylpropyl)ethylamine
Phenopropamine
Phenpropamine",small molecule,Humans and other mammals,,,,Used to relieve cramps or spasms of the stomach and intestines. It is also useful in treating irritable bowel syndrome (IBS) and similar conditions. It can also be used to help relieve period pain. Alverine citrate is also under investigation to increase the cytotoxic effects of the proteasome inhibitor MG132 on breast cancer cells. 
C(N(C([H])([H])[H])S(=O)(=O)C1=C([H])C2=C(SC3=C(N2C(C(C(N2C([H])([H])C([H])([H])C(C(C(O[H])([H])[H])([H])[H])([H])C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C([H])C([H])=C3[H])C([H])=C1[H])([H])([H])[H],DB01621,39860-99-6,Pipotiazine,"Piportil
Pipothiazine
Pipotiazina
Pipotiazinum",small molecule,Humans and other mammals,"Solution
Solution","Intramuscular
Intramuscular","25 mg
50 mg",For the maintenance treatment of chronic non-agitated schizophrenic patients.
C(N(C([H])([H])[H])S(=O)(=O)C1=C([H])C2=C(SC3=C(N2C(C(C(N2C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C([H])C([H])=C3[H])C([H])=C1[H])([H])([H])[H],DB01622,316-81-4,Thioproperazine,"(Thioproperazine)-2-dimethylsulfamido-(10-(3-1-methylpiperazinyl-4)propyl)-phenothiazine
2-Dimethylsulfamido-(10-(3-1-methylpiperazinyl-4)propyl)-phenothiazine
N,N-Dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]-10H-phenothiazine-2-sulfonamide
N,N-Dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine-2-sulfonamide
Thioperazine
Thioproperazin
Thioproperazinum
Tioproferazina
Tioproperazina",small molecule,Humans and other mammals,Tablet,Oral,10 mg,"For the treatment of all types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes."
C(N(C([H])([H])[H])S(=O)(=O)C1=C([H])C2=C(SC3=C(C2=C(C(C(N2C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C2([H])[H])([H])[H])([H])[H])[H])C([H])=C([H])C([H])=C3[H])C([H])=C1[H])([H])([H])[H],DB01623,3313-26-6,Thiothixene,"(e)-thiothixene
cis-thiothixene
Thiothixine
Tiotixene
Tiotixeno
Tiotixenum",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule
Capsule
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral
Oral
Oral","2 mg
5 mg
10 mg
1 mg/1
10 mg/1
2 mg/1
5 mg/1",For the management of schizophrenia.
O(C(C(N1C([H])([H])C([H])([H])N(C(C(C(=C2C3=C(C(=C(C(=C3[H])[H])[H])[H])SC3=C2C(=C(Cl)C(=C3[H])[H])[H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])([H])[H])([H])[H])[H],"DB01624
DB08919
DB08920",53772-83-1,Zuclopenthixol,"cis-Clopenthixol
Zuclopenthixol
Zuclopenthixolum
Zuclopentixol",small molecule,Humans and other mammals,"Tablet
Liquid
Liquid
Liquid
Solution
Tablet
Tablet
Solution","Oral
Intramuscular
Intramuscular
Intramuscular
Intramuscular
Oral
Oral
Intramuscular","40 mg
50 mg
200 mg
500 mg
200 mg
10 mg
25 mg
50 mg","Used in the management of acute psychoses such as mania or schizophrenia. However, the use of zuclopenthixol acetate in psychiatric emergencies as an alternative to standard treatments (haloperidol, clotiapine, etc.) should be cautioned, since well executed and documented trials of zuclopenthixol acetate for this use have yet to be conducted. Zuclopenthixol acetate is not intended for long-term use."
C(C(C([H])([H])[H])([N+](C([H])([H])[H])(C(C(C(C(N([H])[H])=O)(C1=C([H])C([H])=C([H])C([H])=C1[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])C(C([H])([H])[H])(C([H])([H])[H])[H])[H])([H])([H])[H],DB01625,7492-32-2,Isopropamide,Isopropamide,small molecule,Humans and other mammals,Tablet,Oral,,"For the treatment of a wide range of gastrointestinal disorders, including such conditions as peptic ulcer, gastritis, hyperchlorhydria, functional diarrhea, irritable or spastic colon, pyloroduodenal irritability, pylorospasm, acute nonspecific gastroenteritis, biliary dyskinesia and chronic cholelithiasis, duodenitis, gastrointestinal spasm; it may also be used to treat genitourinary spasm."
C(N(C(C#C[H])([H])[H])C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB01626,555-57-7,Pargyline,"Eutonyl
Eutron
Pargyline",small molecule,Humans and other mammals,,,,For the treatment of moderate to severe hypertension.
C(C1=NC([H])=C(C2=NC([H])=C(Cl)C([H])=C2C2=C([H])C([H])=C(S(C([H])([H])[H])(=O)=O)C([H])=C2[H])C([H])=C1[H])([H])([H])[H],"DB01628
DB07166",202409-33-4,Etoricoxib,"5-chloro-2-(6-Methylpyridin-3-yl)-3-(4-(methylsulfonyl)phenyl)pyridine
5-Chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl
5-chloro-6'-Methyl-3-(P-(methylsulfonyl)phenyl)-2,3'-bipyridine
ETORICOXIB
Etoricoxibum
L791456",small molecule,Humans and other mammals,,,,"For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout."
C(C(C(C(C(C(C(C(C(=O)OC([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01631,,Methyl Nonanoate (Ester),,small molecule,,,,,
C(C1=C(C(C(C(O[H])=O)([H])[H])([H])[H])C2N3[Fe]45N6C(C=2[H])=C(C(C(C(O[H])=O)([H])[H])([H])[H])C(C([H])([H])[H])=C6C([H])=C2N4C(C(C([H])([H])[H])=C2C(=C([H])[H])[H])=C([H])C2N5C(=C(C=2C(=O)[H])C([H])([H])[H])C([H])=C13)([H])([H])[H],DB01636,,Clorocruoro Hem,,small molecule,,,,,
C(C1=C(O[H])C(C(=O)[H])=C(C(OP(O[H])(O[H])=O)([H])[H])C([H])=[N+]1C([H])([H])[H])([H])([H])[H],DB01639,,N-Methyl-Pyridoxal-5'-Phosphate,,small molecule,,,,,
O(C(=O)C(C(C1(C2=C(C(=C(O[H])C(=C2[H])[H])[H])OC2=C1C(=C(C(O[H])=C2[H])[H])[H])[H])([H])[H])([H])[H])[H],DB01644,,"3,6-Dihydroxy-Xanthene-9-Propionic Acid",,small molecule,,,,,
O(C1=C([H])C([H])=C(C2=C([H])OC3=C(C(O[H])=C(C(O[H])=C3[H])[H])C2=O)C([H])=C1[H])[H],DB01645,446-72-0,Genistein,"4',5, 7-Trihydroxyisoflavone
5,7,4'-Trihydroxyisoflavone
Genisteol
Genisterin",small molecule,"Humans and other mammals
Helminthic Microorganisms
Parasitic nematodes and other roundworms",,,,Currently Genistein is being studied in clinical trials as a treatment for prostate cancer.  
O(C(=O)C(=C(C1=C(O[H])C([H])=C([H])C([H])=C1[H])[H])[H])[H],DB01650,614-60-8,trans-2-hydroxycinnamic acid,"(2E)-3-(2-Hydroxyphenyl)-2-propenoic acid
(2E)-3-(2-HYDROXYPHENYL)ACRYLIC ACID
(2E)-3-(2-hydroxyphenyl)prop-2-enoic acid
(E)-3-(2-Hydroxyphenyl)-2-propenoic acid
(e)-o-hydroxycinnamic acid
2-Coumarate
2-Coumaric acid
2-Hydroxycinnamate
2-Hydroxycinnamic acid
3-(2-hydroxyphenyl)acrylic acid
3-(2-hydroxyphenyl)prop-2-enoic acid
O-Coumaric Acid
O-hydroxy-trans-cinnamic acid
O-hydroxycinnamic acid
Ortho-hydroxycinnamic acid
trans-2-Hydroxycinnamate
Trans-o-coumaric acid
Trans-o-hydroxycinnamic acid",small molecule,,,,,
FC(F)(OC1=C(OC(C2(C([H])([H])C2([H])[H])[H])([H])[H])C([H])=C(C(=O)N(C2=C(Cl)C([H])=NC([H])=C2Cl)[H])C([H])=C1[H])[H],DB01656,162401-32-3,Roflumilast,"ROF
Roflumilastum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet, film coated","Oral
Oral
Oral
Oral","250 ug/1
500 ug/1
500 mcg
500 ��g",Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm.
N(C(C(C1(C([H])([H])C(=NC2(C([H])([H])C2(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])[H])C(O[H])=C([H])C1=O)[H])([H])[H])(C(O[H])=O)[H])([H])[H],DB01657,,"2-Amino-3-[4-Hydroxy-6-Oxo-3-(2-Phenyl-Cyclopropylimino)-Cyclohexa-1,4-Dienyl]-Propionic Acid",,small molecule,,,,,
N(C1(N=C2C(=C(C(=C([H])C2=N1)[H])[H])[H])[H])([H])[H],DB01665,,ZK-800270,2H-BENZOIMIDAZOL-2-YLAMINE,small molecule,Humans and other mammals,,,,
N(C1=NC2=C(N(N=N2)[H])C(O[H])=N1)([H])[H],DB01667,134-58-7,8-azaguanine,"Azaguanine
Azaguanine-8
Guanazol
Pathocidin
Pathocidine",small molecule,,,,,
C(C(C(OC(C([H])([H])[H])=O)([H])[H])([H])[H])([H])([H])[H],DB01670,109-60-4,Propyl Acetate,,small molecule,,,,,
O([Hg]C1=C([H])C([H])=C(C(O[H])=O)C([H])=C1[H])[H],DB01671,,4-(Hydroxymercury)Benzoic Acid,,small molecule,,,,,
O(C(=O)C1=C(O[H])C(O[H])=C([H])C([H])=C1[H])[H],DB01672,303-38-8,"2,3-Dihydroxy-Benzoic Acid",,small molecule,,,,,
C(C1=C([N+]([O-])=O)C([H])=C([N+]([O-])=O)C([H])=C1[N+]([O-])=O)([H])([H])[H],DB01676,118-96-7,Trinitrotoluene,"2,4,6-TNT
2,4,6-trinitrotoluene
2,4,6-Trinitrotoluol
TNT
��-TNT",small molecule,,,,,
O(C(=O)C1=C(C(O[H])=O)C(C(O[H])=O)=C(C(O[H])=O)C(C(O[H])=O)=C1C(O[H])=O)[H],DB01681,517-60-2,Benzene Hexacarboxylic Acid,,small molecule,,,,,
N#CC1=NC([H])=C([H])C(C2=NN([H])C(C3=C([H])C([H])=NC([H])=C3[H])=N2)=C1[H],DB01685,577778-58-6,Topiroxostat,"4-(5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl)pyridine-2-carbonitrile",small molecule,,,,,Indicated for the treatment of gout and hyperurcemia in Japan.
C(C1=C([H])C([H])=C(O[H])C([H])=C1[H])([H])([H])[H],DB01688,106-44-5,P-Cresol,,small molecule,,,,,
C(C1=C([H])C(N(C(=O)C(C2=C(C([H])([H])[H])C([H])=C([H])C([H])=C2[H])([H])[H])[H])=C([H])C(C([H])([H])[H])=C1S(=O)(=O)N(C(C(O[H])=O)([H])[H])[H])([H])([H])[H],DB01689,,Inhibitor Idd 384,,small molecule,,,,,
C(N(C(C1=C([H])N(C([H])([H])[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])C(=O)C(=C(C1=C([H])N=C2N(C(=O)C(C([H])([H])C2=C1[H])([H])[H])[H])[H])[H])([H])([H])[H],DB01691,,Indole Naphthyridinone,,small molecule,,,,,
O(N(C(=O)C(C(C(P([O-])([O-])=O)([H])[H])([H])[H])([H])[H])[H])[H],DB01695,146086-80-8,N-Hydroxy-4-Phosphono-Butanamide,,small molecule,,,,,
C(C(=C(N([H])[H])C(C(C(O[H])=O)([H])[H])([H])[H])[H])([H])([H])[H],DB01699,,(4e)-4-Aminohex-4-Enoic Acid,,small molecule,,,,,
O(C(=O)C(C1=C([H])C(O[H])=C(O[H])C([H])=C1[H])([H])[H])[H],DB01702,102-32-9,"2-(3,4-Dihydroxyphenyl)Acetic Acid",,small molecule,,,,,
N1(C(=O)C([H])=C([H])C1=O)C(C(C12C3([H])[Fe]4567891(C3([H])C4([H])C25[H])C1([H])C6(C7(C8(C91[H])[H])[H])[H])([H])[H])([H])[H],DB01703,,N-(2-Ferrocenylethyl)Maleimide,,small molecule,,,,,
O(C(=O)C(=C(C1=C(O[H])C([H])=C(O[H])C([H])=C1[H])[H])[H])[H],DB01704,614-86-8,"2,4-Dihydroxy-Trans Cinnamic Acid",,small molecule,,,,,
N(C(=[N+]([H])[H])C1=C([H])C2=C(N=C(C(C3=NC4=C(C(=C(C(=C4[H])[H])C([N+]([H])([H])[H])=[N+]([H])[H])[H])N3[H])([H])[H])N2[H])C([H])=C1[H])([H])[H],DB01705,,Bis(5-Amidino-Benzimidazolyl)Methane,,small molecule,,,,,
ClC1=C2N=C(N=C2N([H])C(Br)=N1)[H],DB01706,,2-Bromo-6-Chloro-Purine,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(=O)OC(C(O[H])(C(OP(O[H])(=O)OC(C([N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01707,,"L-Alfa-Lysophosphatidylcholine, Lauroyl",,small molecule,,,,,
C1(=C([H])C2N3[Fe]45N6C(C=2[H])=C(C([H])=C6C([H])=C2N4C(C(=C2[H])[H])=C([H])C2=C(C(=C(C([H])=C13)N52)[H])[H])[H])[H],DB01710,,Porphyrin Fe(III),,small molecule,,,,,
O(C(C1=C(F)C(F)=C(F)C(F)=C1F)([H])[H])[H],DB01711,440-60-8,"2,3,4,5,6-Pentafluorobenzyl Alcohol",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C([N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],"DB01718
DB13159",6899-10-1,Cetrimonium,"Cetrimonium cation
Cetrimonium ion
Cetyl-Trimethyl-Ammonium
Cetyltrimethylammonium
Cetyltrimethylammonium cation
Cetyltrimethylammonium ion
Hexadecyltrimethylammonium
Hexadecyltrimethylammonium cation
Hexadecyltrimethylammonium ion
N,N,N-Trimethyl-1-hexadecanaminium
Trimethylhexadecylammonium",small molecule,,"Lotion
Liquid
Cream
Tincture
Liquid
Liquid
Liquid; shampoo
Cream
Solution
Aerosol, metered; spray
Gel
Aerosol","Topical
Topical
Topical
Topical
Topical
Dental
Topical
Topical
Topical
Topical
Topical
Topical","1 %
.5 %
.5 %
1 %",
O(C(=O)C(N(C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H])[H])=C(C1=C([H])C([H])=C(OC2=C(Br)C([H])=C([H])C([H])=C2[H])C([H])=C1[H])[H])[H],DB01720,,(2z)-2-(Benzoylamino)-3-[4-(2-Bromophenoxy)Phenyl]-2-Propenoic Acid,,small molecule,,,,,
N(C(=N[H])C1=C([H])C2=C(N(C(=N2)C2=C([H])C([H])=C([H])C(C3=C([H])C([H])=C([H])C([H])=C3[H])=C2O[H])[H])C([H])=C1[H])([H])[H],"DB01725
DB06854",,"2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1H-1,3-benzodiazole-5-carboximidamide","2-(2-HYDROXY-BIPHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE
3-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-1,1'-BIPHENYL-2-OLATE",small molecule,,,,,
N(C1=C(O[H])C([H])=C([H])C([H])=C1[H])([H])[H],DB01726,95-55-6,2-Aminophenol,,small molecule,,,,,
O(C(=O)C(=O)N(C1=C([H])C2=C(C(=C(C([H])=C2C([H])=C1C(O[H])=O)[H])[H])[H])[H])[H],DB01734,,3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(=O)N(C(C(C([N+](C([H])([H])[H])(C([H])([H])[H])[O-])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01736,,[3-(Dodecanoylamino)Propyl](Hydroxy)Dimethylammonium,,small molecule,,,,,
N(C(C(OP(O[H])(O[H])=O)([H])[H])([H])[H])([H])[H],"DB01738
DB04403",1071-23-4,Phosphorylcolamine,"2-aminoethyl dihydrogen phosphate
Colamine phosphate
Colamine phosphoric acid
O-Phosphoethanolamine
Phosphorylethanolamine",small molecule,,,,,
C(C(C(C(C1=C(C(C(C([H])([H])[H])([H])[H])([H])[H])[Se]C(=N[H])N1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01740,,2-Amino-4-Butyl-5-Propylselenazole,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(C(=O)N(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])[H])C([H])=C1[H])([H])[H],DB01748,,N-Benzyl-4-Sulfamoyl-Benzamide,,small molecule,,,,,
C(OC(C(OC([H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01749,110-71-4,"1,2-Dimethoxyethane",,small molecule,,,,,
O(C(=O)C(C1=C([H])C([H])=C([H])C2=C(C(=C(C([H])=C12)[H])[H])[H])([H])[H])[H],DB01750,86-87-3,1-naphthaleneacetic acid,"1-Naphthylacetic acid
NAA
naphthalen-1-yl-acetic acid
naphthalene-1-acetic acid
��-NAA
��-naphthaleneacetic acid",small molecule,,,,,
O(C(=O)C(C1=C([H])C(I)=C(OC2=C([H])C(I)=C(O[H])C(I)=C2[H])C(I)=C1[H])([H])[H])[H],DB01751,,"3,3',5,5'-Tetraiodothyroacetic Acid",,small molecule,,,,,
C(N1C(=O)C(O[H])=C(O[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])([H])[H],DB01754,,"3,4-Dihydroxy-1-Methylquinolin-2(1h)-One",,small molecule,,,,,
O(C(C1=C([H])C(=O)C(O[H])=C([H])O1)([H])[H])[H],DB01759,501-30-4,Kojic acid,"5-hydroxy-2-(hydroxymethyl)-4-pyrone
5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one",small molecule,,,,,
C(OC1=NC([H])=C([H])N=C1C(C([H])([H])[H])(C([H])([H])[H])[H])([H])([H])[H],DB01760,25773-40-4,2-Methoxy-3-Isopropylpyrazine,,small molecule,,,,,
C(C(=O)C(C(O[H])=O)([H])[H])([H])([H])[H],"DB01762
DB04025",541-50-4,Acetoacetic Acid,,small molecule,,,,,
O(C(=O)C(C1=C2N(C(=O)C3=C(N2C2=C1C(=C(C(=C2[H])[H])[H])[H])C([H])=C([H])C([H])=C3[H])[H])([H])[H])[H],DB01765,,"(5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid",,small molecule,,,,,
N(C(=N[H])C1=C([H])C2=C(N(C(C(C3=NC4=C(C(=C(C(=C4[H])[H])[H])[H])N3[H])([H])[H])=N2)[H])C([H])=C1[H])([H])[H],DB01767,,Hemi-Babim,,small molecule,,,,,
N(C(=N[H])C1=C(Cl)C([H])=C2N(C(=C([H])C2=C1[H])C1=C(O[H])C(OC2(C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])=C([H])C([H])=C1[H])[H])([H])[H],DB01771,,CRA_10991,,small molecule,,,,,
O(C(C(=O)C(O[H])([H])[H])([H])[H])[H],DB01775,96-26-4,Dihydroxyacetone,,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C(O[H])=C1[H])([H])([H])[H],DB01776,108-39-4,M-Cresol,,small molecule,,,,,
C(N1C2=C(N(C(=N[H])N2[H])[H])C(=O)N(C([H])([H])[H])C1=O)([H])([H])[H],DB01778,,"8-Amino-1,3-Dimethyl-3,7-Dihydropurine-2,6-Dione",,small molecule,,,,,
O(C(C(C(O[H])([H])[H])(OP(O[H])(O[H])=O)[H])([H])[H])[H],DB01779,,Glycerol-2-Phosphate,,small molecule,,,,,
O=C1C2=C3C(N(N=C3C3=C1C(=C(C(=C3[H])[H])[H])[H])[H])=C(C(=C2[H])[H])[H],DB01782,,"2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One",,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(F)C([H])=C1[H])([H])[H],DB01784,,4-Flourobenzenesulfonamide,,small molecule,,,,,
C(C1=NC(=N[H])C(=C([H])[H])C([H])=N1)([H])([H])[H],DB01788,,4-Imino-5-Methidyl-2-Methylpyrimidine,,small molecule,,,,,
C(OC1=C(OC2(C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])C([H])=C(C(=O)N(C2=C(Cl)C([H])=NC([H])=C2Cl)[H])C([H])=C1[H])([H])([H])[H],DB01791,144035-83-6,Piclamilast,RP 73-401,small molecule,Humans and other mammals,,,,
O(C(=O)C1=C(Cl)C([H])=C([H])C(N(C2=C(C3=C([H])C(Cl)=C([H])C([H])=C3[H])C(=O)N([H])C2=O)[H])=C1[H])[H],DB01793,,SB-409513,I-5,small molecule,,,,,
N(C1=NC2=C(N(C3(C(N2[H])([H])OC(C(OP([O-])([O-])=O)([H])[H])([H])C2=C3S[W]3(S2)SC2=C(C4(N([H])C5=C(N=C(N([H])[H])N(C5=O)[H])N([H])C4(OC2(C(OP([O-])([O-])=O)([H])[H])[H])[H])[H])S3)[H])[H])C(=O)N1[H])([H])[H],DB01794,,bis(molybdopterin)tungsten cofactor,"tungsten-molybdopterin
W-molybdopterin cofactor",small molecule,,,,,
O(B(O[H])C1=C([H])C([H])=C([H])C([H])=C1[H])[H],DB01795,,Phenyl Boronic Acid,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C([H])N=C1C(O[H])=O)[H],DB01796,89-00-9,Quinolinic Acid,,small molecule,,,,,
O(C1=C(OS(O[H])(=O)=O)C([H])=C([N+]([O-])=O)C([H])=C1[H])[H],DB01800,,"N,4-Dihydroxy-N-Oxo-3-(Sulfooxy)Benzenaminium",,small molecule,,,,,
C([N+](C([H])([H])[H])(C([H])([H])[H])C(C(S[H])([H])[H])([H])[H])([H])([H])[H],DB01803,,2-(Trimethylammonium)Ethyl Thiol,,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C1=C([H])C(=NC(=O)N(C2=C([H])C([H])=C(Cl)C([H])=C2[H])[H])N(C2=C([H])C([H])=C([H])C([H])=C2[H])N1[H])([H])([H])[H],DB01807,,"N-[(3z)-5-Tert-Butyl-2-Phenyl-1,2-Dihydro-3h-Pyrazol-3-Ylidene]-N'-(4-Chlorophenyl)Urea",,small molecule,,,,,
C(C1=C([H])C([H])=C(C2=NN(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C3=C2C(N([H])[H])=NC(=N3)[H])C([H])=C1[H])([H])([H])[H],DB01809,,"1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine",,small molecule,,,,,
O(C1=C(O[H])C([H])=C2C(=C(N([H])C2=C1[H])[H])[H])[H],DB01811,3131-52-0,"3h-Indole-5,6-Diol",,small molecule,,,,,
O(C(=O)C(=C([H])[H])OP(O[H])(O[H])=O)[H],DB01819,138-08-9,Phosphoenolpyruvate,,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C2=C1N(C(N([H])[H])=NC2=O)[H])([H])([H])[H],DB01825,,2-Amino-8-Methylquinazolin-4(3h)-One,,small molecule,,,,,
C(C(C(C([N+]#[C-])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01826,2769-64-4,N-Butyl Isocyanide,,small molecule,,,,,
C(OC1=C(F)C(F)=C(C(N([H])[H])=O)C(F)=C1F)([H])([H])[H],DB01827,,"2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide",,small molecule,,,,,
C(N([H])[H])([H])([H])[H],DB01828,74-89-5,Methylamine,,small molecule,,,,,
ClC1=C([H])C2=C(C(=C(C([H])=C2C([H])=C1[H])S(=O)(=O)N1C([H])([H])C([H])([H])N(C(=O)C2(C([H])([H])C([H])([H])N(C3=C([H])C([H])=NC([H])=C3[H])C([H])([H])C2([H])[H])[H])C([H])([H])C1([H])[H])[H])[H],DB01836,,"[4-(6-Chloro-Naphthalene-2-Sulfonyl)-Piperazin-1-Yl]-(3,4,5,6-Tetrahydro-2h-[1,4']Bipyridinyl-4-Yl)-Methanone",,small molecule,,,,,
C(C1=C(C2=C([H])C(Br)=C(O[H])C(Br)=C2[H])OC2=C(C(=C(O[H])C(=C2[H])[H])[H])C1=O)([H])([H])[H],DB01838,,"6,4'-Dihydroxy-3-Methyl-3',5'-Dibromoflavone",,small molecule,,,,,
C(N(C([H])([H])[H])C(=O)[H])([H])([H])[H],DB01844,68-12-2,"N,N-dimethylformamide","Dimethylformamide
N-Formyldimethylamine
N,N-Dimethylmethanamide",small molecule,,,,,
O=C1C([H])([H])C([H])([H])N([H])C(=O)N1[H],DB01849,,"3,4-Dihydrouracil",,small molecule,,,,,
C(C(C(C([N+](C(C(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])(C(C(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])C(C(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01851,2052-49-5,Tetrabutylammonium Ion,,small molecule,,,,,
O(C1=C([H])C([H])=C(C2=C(O[H])C(=O)C3=C(C(=C(O[H])C(=C3O[H])[H])[H])O2)C([H])=C1[H])[H],DB01852,520-18-3,Kaempherol,,small molecule,,,,,
N(C(=O)C1=C([H])C(Br)=C([H])N=C1[H])([H])[H],DB01854,28733-43-9,5-Bromonicotinamide,,small molecule,,,,,
O(C(=O)C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB01856,111-16-0,Pimelic Acid,,small molecule,,,,,
C(N(C(C1=C([H])C2=C(C(=C(C(=C2[H])[H])[H])[H])N1C([H])([H])[H])([H])[H])C(=O)C(=C(C1=C([H])N=C(N([H])[H])C([H])=C1[H])[H])[H])([H])([H])[H],DB01865,,3-(6-Aminopyridin-3-Yl)-N-Methyl-N-[(1-Methyl-1h-Indol-2-Yl)Methyl]Acrylamide,,small molecule,,,,,
O(C1=NC(O[H])=C2N=NN([H])C2=N1)[H],DB01875,1468-26-4,8-Azaxanthine,,small molecule,,,,,
N(C(=N[H])C1=C([H])C2=C(N=C(N2[H])C(=O)C2=NC3=C(C(=C(C(=C3[H])C(N([H])[H])=N[H])[H])[H])N2[H])C([H])=C1[H])([H])[H],DB01876,,Bis(5-Amidino-2-Benzimidazolyl)Methanone,,small molecule,,,,,
O=C(C1=C([H])C([H])=C([H])C([H])=C1[H])C1=C([H])C([H])=C([H])C([H])=C1[H],DB01878,119-61-9,Benzophenone,"Benzoylbenzene
Diphenyl ketone
Diphenylmethanone
Phenyl ketone",small molecule,,"Cream
Gel
Lotion
Liquid","Topical
Topical
Topical
Topical",,
O(C(=O)C(=C(C1=C([H])C(O[H])=C(O[H])C([H])=C1[H])[H])[H])[H],DB01880,331-39-5,"3,4-Dihydroxycinnamic Acid",,small molecule,,,,,
N(C1=C([H])C([H])=C([H])C(B(O[H])O[H])=C1[H])([H])[H],DB01896,,M-Aminophenylboronic Acid,,small molecule,,,,,
O=C1N([H])N([H])C(=O)C2=C1C(=C(C(=C2[H])[N+]1=NC(C(=C(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])[H])=NN1C1=NC2=C(C(=C(C(=C2[H])[H])[H])[H])S1)[H])[H],DB01897,,2-(2f-Benzothiazolyl)-5-Styryl-3-(4f-Phthalhydrazidyl)Tetrazolium Chloride,,small molecule,,,,,
C(C(N1C(=O)C([H])([H])C([H])([H])C1=O)([H])[H])([H])([H])[H],DB01902,,"1-Ethyl-Pyrrolidine-2,5-Dione",,small molecule,,,,,
C(OC1=C([H])C(C2=NC3=C(C(=C(C(=C3[H])C(N([H])[H])=[N+]([H])[H])[H])[H])N2[H])=C(O[H])C([H])=C1[H])([H])([H])[H],DB01905,,2-(2-Hydroxy-5-Methoxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine,,small molecule,,,,,
N(C1=NC2=NN(N=C2C(O[H])=N1)C1=C([H])C([H])=C([H])C(C(O[H])=O)=C1[H])([H])[H],DB01906,,"3-(5-Amino-7-Hydroxy-[1,2,3]Triazolo[4,5-D]Pyrimidin-2-Yl)-Benzoic Acid",,small molecule,,,,,
C(C(C1=C(C([H])([H])[H])C2=C(C3=C(C(C([H])([H])[H])([H])[H])C(C([H])([H])[H])=C(C(=C4N=C(C(=C5N([H])C(=C([H])C1=N2)C(C([H])([H])[H])=C5C(C(C(O[H])=O)([H])[H])([H])[H])[H])C(C(C(C(O[H])=O)([H])[H])([H])[H])=C4C([H])([H])[H])[H])N3C([H])([H])[H])[H])([H])[H])([H])([H])[H],DB01911,142234-85-3,N-Methylmesoporphyrin,,small molecule,,,,,
C1(=C([H])N=C(C2=C([H])C([H])=C([H])C(C3=NC([H])=C([H])C([H])=C3[H])=N2)C([H])=C1[H])[H],DB01912,,"2,2':6',2''-Terpyridine Platinum(Ii)",,small molecule,,,,,
N(C(C(C(C(N([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB01917,110-60-1,Putrescine,,small molecule,,,,,
C([Te]C(C([O-])=O)([H])[H])([H])([H])[H],DB01918,,[Methyltelluro]Acetate,,small molecule,,,,,
C(C(C(C(C(=O)[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB01919,110-62-3,Pentanal,,small molecule,,,,,
O(N(C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H],DB01924,495-18-1,Benzhydroxamic Acid,,small molecule,,,,,
O(C1=C([H])C([H])=C([H])C(C2=C(Cl)C([H])=C([H])C([H])=C2[H])=C1O[H])[H],DB01925,,"2'-Chloro-Biphenyl-2,3-Diol",,small molecule,,,,,
C(C1=C(C([H])([H])[H])C(=O)C(C([H])([H])[H])=C(C([H])([H])[H])C1=O)([H])([H])[H],DB01927,527-17-3,Duroquinone,,small molecule,,,,,
O(C(=O)C1=C([H])C(O[H])=C2C(Cl)=C(C(Cl)=C([H])C2=N1)[H])[H],DB01931,,"Dcka, 5,7-Dichlorokynurenic Acid",,small molecule,,,,,
C(C1=C([H])N([H])C([H])=C1[H])([H])([H])[H],DB01932,616-43-3,5-Methylpyrrole,,small molecule,,,,,
N(C(=[N+]([H])[H])C1=C([H])C2=C(N=C(N2[H])[H])C([H])=C1[H])([H])[H],DB01939,,5-Amidino-Benzimidazole,,small molecule,,,,,
C(C1=C(C2(C([H])([H])C2([H])[H])C2=NC([H])=C(C(O[H])=O)C([H])=C2[H])C([H])=C2C(C(C([H])([H])[H])(C([H])([H])[H])C(C(C2(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])=C1[H])([H])([H])[H],DB01941,,"6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-Tetrahydronaphthalen-2-Yl)Cyclopropyl]Pyridine-3-Carboxylic Acid",,small molecule,,,,,
O(C(=O)[H])[H],DB01942,64-18-6,Formic Acid,"Acide formique
Ameisens��ure
Aminic acid
bilorin
Formate
Formylic acid
Hydrogen carboxylic acid
Methanoic acid",small molecule,,"Capsule, gelatin coated
Tablet, coated","Oral
Oral",,
C(N1C([H])=C(C2=C(C3=C([H])N(C(C(C(N([H])[H])([H])[H])([H])[H])([H])[H])C4=C3C(=C(C(=C4[H])[H])[H])[H])C(=O)N([H])C2=O)C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])([H])[H],DB01946,,"3-[1-(3-Aminopropyl)-1h-Indol-3-Yl]-4-(1-Methyl-1h-Indol-3-Yl)-1h-Pyrrole-2,5-Dione",,small molecule,,,,,
O(P(O[H])(=O)OC1=C(C(=O)[H])C([H])=C([H])C([H])=C1[H])[H],DB01947,,RU78262,,small molecule,,,,,
FC1=C([H])C(F)=C(C2=C([H])C(C3(C([H])([H])C([H])([H])N([H])C([H])([H])C3([H])[H])[H])=C([H])C3=C2C(C(C(=O)N3C2=C(Cl)C([H])=C([H])C([H])=C2Cl)([H])[H])([H])[H])C([H])=C1[H],DB01948,,"1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One",,small molecule,,,,,
C(OC1=C([H])C([H])=C(C(N(C(=O)N(C2=NC([H])=C([N+]([O-])=O)S2)[H])[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB01950,,"N-(4-Methoxybenzyl)-N'-(5-Nitro-1,3-Thiazol-2-Yl)Urea",,small molecule,,,,,
N1(C([H])=NC2=C1N=C(N1C([H])=C([H])N=C12)[H])[H],DB01952,13875-63-3,"1,N6-Ethenoadenine",,small molecule,,,,,
C(C(C1=C([H])C([H])=NC([H])=C1[H])([H])[H])(C1=C([H])N([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H],DB01953,,Inhibitor of P38 Kinase,,small molecule,,,,,
O(C(C(C(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB01955,110-63-4,"1,4-Butanediol",,small molecule,,,,,
N(C(C(S(O[H])(=O)=O)([H])[H])([H])[H])([H])[H],"DB01956
DB11103",107-35-7,Taurine,"Aminoethylsulfonic acid
Taurineold",small molecule,Humans and other mammals,"Solution
Injection, solution
Liquid
Emulsion
Capsule, gelatin coated","Intravenous
Intravenous
Intravenous
Intravenous
Oral",,"The use of diet supplements containing taurine is indicated for the nutritional support of infants and young pediatric patients requiring total parenteral nutrition via central or peripheral routes. The usage of diet supplements containing taurine prevents nitrogen and weight loss or to treat negative nitrogen balance in pediatric patients where the alimentary tract cannot be done through oral, gastrostomy or jejunostomy administration, there is impaired gastrointestinal absorption or protein requirements are substantially increased.[FDA label]"
O(C1=C([H])C([H])=C([H])C(Cl)=C1[H])[H],DB01957,108-43-0,3-Chlorophenol,,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C1=C([H])C([H])=C(SC2=C([H])C([H])=C([H])C3=NC(N([H])[H])=NC(N([H])[H])=C23)C([H])=C1[H])([H])([H])[H],DB01958,,"5-[4-Tert-Butylphenylsulfanyl]-2,4-Quinazolinediamine",,small molecule,,,,,
C(C(OC(=O)C1=C(C([H])([H])[H])N(C2=C([H])C([H])=C([H])C([N+]([O-])=O)=C2[H])N=C1C([H])([H])[H])([H])[H])([H])([H])[H],DB01959,,"3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester",,small molecule,,,,,
O(B(O[H])C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])[H],DB01963,34420-17-2,Phenylethane Boronic Acid,,small molecule,,,,,
N(C(=C(S[H])[H])[H])([H])[H],DB01968,,2-Thioethenamine,,small molecule,,,,,
O(C(=O)C(=C(C1=C([H])N([H])C([H])=N1)[H])[H])[H],DB01971,3465-72-3,trans-urocanic acid,"(2E)-3-(1H-imidazol-4-yl)acrylic acid
(E)-3-(1H-imidazol-4-yl)-2-propenoic acid
Urocanic acid",small molecule,,,,,
N(C1=C([H])C([H])=C([H])C2=C(C3=C([H])C([H])=C([H])C([H])=C3C([H])=C12)[H])([H])[H],DB01976,62813-37-0,Aminoanthracene,,small molecule,,,,,
N(C(=N[H])C1=C([H])C([H])=C2C(=C(C(=C([H])C2=C1[H])[H])C(=O)N(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H])([H])[H],DB01977,,6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine,,small molecule,,,,,
C(C1=C(F)C([H])=C([H])C([H])=C1N([H])[H])([H])([H])[H],DB01986,,3-Fluoro-2-Methyl-Aniline,,small molecule,,,,,
O(C(C(N(C1=NC([H])=NC2=C1N=C1C([H])=C([H])C([H])=C([H])N12)[H])([H])[H])([H])[H])[H],DB01994,,"2-(Pyrido[1,2-E]Purin-4-Yl)Amino-Ethanol",,small molecule,,,,,
C(C1=C([H])C([H])=C([H])N=C1[H])([H])([H])[H],DB01996,108-99-6,3-Methylpyridine,,small molecule,,,,,
[O-][N+](=O)C1=C([H])C([H])=C([H])C2=C1N(N=C2Br)[H],DB01997,,3-Bromo-7-Nitroindazole,,small molecule,,,,,
O(S(O[H])(O[H])C1=C([H])C([H])=C(C2=C3C(=C([H])C(=N3)C(C3=C([H])C([H])=C(S(O[H])(O[H])[O-])C([H])=C3[H])=C3N([H])C(C(=C3[H])[H])=C(C3=C([H])C([H])=C(S([O-])([O-])[O-])C([H])=C3[H])C3=NC(C(=C3[H])[H])=C(C3=C([H])C([H])=C(S(O[H])(O[H])O[H])C([H])=C3[H])C3=C(C([H])=C2N3[H])[H])[H])C([H])=C1[H])[H],DB01999,,"5,10,15,20-Tetrakis(4-Sulpfonatophenyl)-21h,23h-Porphine",,small molecule,,,,,
N(C1=NC(N([H])[H])=C2C(SC3=C([H])C([H])=C(N4C([H])([H])C([H])([H])OC([H])([H])C4([H])[H])C([H])=C3[H])=C(C(=C([H])C2=N1)[H])[H])([H])[H],DB02001,,"5-(4-Morpholin-4-Yl-Phenylsulfanyl)-2,4-Quinazolinediamine",,small molecule,,,,,
N(C(=C([H])[H])C(N([H])[H])=O)([H])[H],DB02002,,2-Aminoprop-2-Enamide,,small molecule,,,,,
C(OC1=C([H])C(C2=NC(N([H])[H])=C(C(N([H])[H])([H])[H])C(C3=C(Cl)C([H])=C(Cl)C([H])=C3[H])=N2)=C([H])C(OC([H])([H])[H])=C1[H])([H])([H])[H],DB02004,,"5-(Aminomethyl)-6-(2,4-Dichlorophenyl)-2-(3,5-Dimethoxyphenyl)Pyrimidin-4-Amine",,small molecule,,,,,
C(C(=C(C(=O)C(O[H])=O)[H])[H])([H])([H])[H],DB02005,,2-Oxo-3-Pentenoic Acid,,small molecule,,,,,
C(C(C(C(N1C2=C(N(C(C(C3=C([H])C([H])=C(N(C(C([H])([H])[H])=O)[H])C([H])=C3[H])([H])[H])=N2)[H])C(=O)N(C(C2=C(F)C([H])=C([H])C([H])=C2[H])([H])[H])C1=O)([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02008,,1-(2-Fluorobenzyl)-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine,,small molecule,,,,,
[Fe]O[Fe]N=[N+]=[N-],DB02013,,Monoazido-Mu-Oxo-Diiron,,small molecule,,,,,
C(OC(=O)C1=C(OC(C(=C(C2=C([H])C(C3=C([H])C(C(O[H])=O)=NO3)=C(F)C([H])=C2[H])[H])[H])([H])[H])C([H])=C([H])C([H])=C1O[H])([H])([H])[H],DB02014,,Compound 9,5-{2-fluoro-5-[3-(3-hydroxy-2-methoxycarbonyl-phenoxy)-propenyl]-phenyl}-isoxazole-3-carboxylic acid,small molecule,,,,,
C(N(C(C(C(C(C(C(OC1=C([H])C(F)=C(C(=O)C2=C([H])C([H])=C(Br)C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C(C(=C([H])[H])[H])([H])[H])([H])([H])[H],DB02016,161582-11-2,R048-8071,,small molecule,,,,,
N(C(=N[H])C1=C([H])C([H])=C(C(C(=O)C(O[H])=O)([H])[H])C([H])=C1[H])([H])[H],DB02018,,Amido Phenyl Pyruvic Acid,,small molecule,,,,,
O(C(=O)C(C1=C([H])C([H])=C2C(C3=C([H])C([H])=C([H])C(O[H])=C3C(=O)C2=C1O[H])([H])[H])([H])[H])[H],DB02019,,Acetyl Dithranol,,small molecule,,,,,
O(C(=O)C(N1C(=O)C2C3C(C(=C(C=2[H])[H])[H])=C(C(=C([H])C=3C1=O)[H])[H])([H])[H])[H],DB02020,51411-04-2,Alrestatin,,small molecule,,,,,
C(C1=NC(N([H])[H])=C(C(O[H])([H])[H])C([H])=N1)([H])([H])[H],DB02022,73-67-6,4-Amino-5-Hydroxymethyl-2-Methylpyrimidine,,small molecule,,,,,
O(C(=O)C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])[H],DB02024,501-52-0,3-phenylpropionic acid,"3-Phenyl-propionic acid
3-Phenylpropanoic acid
3PP
beta-Phenylpropionic acid
Hydrocinnamic acid
Phenylpropanoate",small molecule,,,,,
IC1=C([H])C([H])=C(N(C(=O)N(C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])[H])[H])C([H])=C1[H],DB02029,,N-Cyclohexyl-N'-(4-Iodophenyl)Urea,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(S(F)(=O)=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02035,,1-Hexadecylsulfonyl Fluoride,,small molecule,,,,,
N(C1=NC(O[H])=C(N([H])[H])C(O[H])=N1)([H])[H],DB02037,,"2,4-Diamino-4,6-Dihydroxypyrimidine",,small molecule,,,,,
N(C1=C([H])C2=C(C(=O)N(N(C2=O)[H])[H])C([H])=C1[H])([H])[H],DB02041,,Isoluminol,4-aminophthalhydrazide,small molecule,,,,,
C(OC(C(OC(C(OC(C(OC(C(OC(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02042,,2-(2-{2-[2-(2-Methoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(=O)OC(C(C(OP(O[H])(=O)OC(C(O[H])(C(O[H])([H])[H])[H])([H])[H])([H])[H])(OC(=O)C(C(C(C(C(C(C(C(C(C(C(C(C(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02043,,"1,2-Dipalmitoyl-Phosphatidyl-Glycerole",,small molecule,,,,,
C(C(=N[H])N(C(C1=C([H])C(C(N([H])[H])([H])[H])=C([H])C([H])=C1[H])([H])[H])[H])([H])([H])[H],DB02044,,N-(3-(Aminomethyl)Benzyl)Acetamidine,,small molecule,,,,,
C(C(C(C(C(N([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02045,110-58-7,Amylamine,,small molecule,,,,,
N(C(=[N+]([H])[H])N1C([H])=NC([H])=N1)([H])[H],DB02048,,"1,2,4-Triazole-Carboxamidine",,small molecule,,,,,
O(N(C(=O)C(C1(C([H])([H])C([H])([H])OC([H])([H])C1([H])[H])S(=O)(=O)C1=C([H])C([H])=C(OC2=C([H])C([H])=C(Cl)C([H])=C2[H])C([H])=C1[H])([H])[H])[H])[H],DB02049,,2-{4-[4-(4-Chloro-Phenoxy)-Benzenesulfonyl]-Tetrahydro-Pyran-4-Yl}-N-Hydroxy-Acetamide,,small molecule,,,,,
O(N=C1C(=C2C(=O)N([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])N([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])[H],DB02052,,Indirubin-3'-Monoxime,,small molecule,,,,,
N(C1=C([H])C([H])=C([H])C(C(O[H])=O)=C1[H])([H])[H],DB02054,87980-11-8,Gabaculine,,small molecule,,,,,
C(C(C(C(N(S(=O)(=O)C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02055,3622-84-2,N-Butyl-Benzenesulfonamide,,small molecule,,,,,
O=C1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H],DB02060,108-94-1,Cyclohexanone,,small molecule,,,,,
[N+](C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02068,,Delta-Amino Valeric Acid,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(C(=O)N(C(C2=C(F)C([H])=C([H])C([H])=C2[H])([H])[H])[H])C([H])=C1[H])([H])[H],DB02069,,N-(2-Flouro-Benzyl)-4-Sulfamoyl-Benzamide,,small molecule,,,,,
C(OC1=C([H])C([H])=C(S(=O)(=O)N(C(C2=C([H])N=C([H])C([H])=C2[H])([H])[H])C2=C(C(=O)N(O[H])[H])C([H])=C([H])C([H])=C2C([H])([H])[H])C([H])=C1[H])([H])([H])[H],DB02071,,WAY-151693,n-hydroxy-2-[(4-methoxy-benzenesulfonyl)-pyridin-3-ylmethyl-amino]-3-methyl-benzamide,small molecule,Humans and other mammals,,,,
O(C(=O)C(=O)N(C1=C(C(O[H])=O)C2=C(C(SC(C2([H])[H])([H])[H])([H])[H])S1)[H])[H],DB02072,,"2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid",,small molecule,,,,,
C(C1=C(C(=C([H])[H])[H])C(=C(C2=C(C([H])([H])[H])C(C(C(C(O[H])=O)([H])[H])([H])[H])=C(C(=C3N=C(C(=C4N([H])C(=O)C(C(=C([H])[H])[H])=C4C([H])([H])[H])[H])C(C([H])([H])[H])=C3C(C(C(O[H])=O)([H])[H])([H])[H])[H])N2[H])[H])N([H])C1=O)([H])([H])[H],DB02073,114-25-0,Biliverdine IX Alpha,,small molecule,,,,,
C(C(=C(C(O[H])=O)[H])[H])([H])([H])[H],DB02074,107-93-7,Butenoic Acid,,small molecule,,,,,
C(OC(C(OC(C(OC(C(OC([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02078,112-49-2,Triglyme,"1-methoxy-2-[2-(2-methoxyethoxy)ethoxy]ethane
1,2-bis(2-methoxyethoxy)ethane
dimethyl ether of triethylene glycol
Glyme 4",small molecule,,,,,
N(OC(C(O[H])=O)([H])[H])([H])[H],DB02079,645-88-5,Aminooxyacetic acid,"(aminooxy)acetic acid
aminoxyacetic acid
AOAA
carboxymethoxyamine
Carboxymethoxylamine",small molecule,,,,,
C(OC(C(OC(C(OC(C(OC1=C([H])C([H])=C(C(C([H])([H])[H])(C([H])([H])[H])C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02080,,"1-{2-[2-(2-Methoxyethoxy)Ethoxy]Ethoxy}-4-(1,1,3,3-Tetramethylbutyl)Benzene",,small molecule,,,,,
C(N(C([H])([H])[H])C(C(O[H])=O)([H])[H])([H])([H])[H],DB02083,1118-68-9,"N,N-dimethylglycine","(dimethylamino)acetic acid
2-(Dimethylamino)acetic acid
Dimethylglycine
N-Methylsarcosine
N,N-Dimethylaminoacetic acid",small molecule,,,,,
N(C1(C([H])([H])C1([H])[H])C(O[H])=O)([H])[H],DB02085,22059-21-8,1-Aminocyclopropanecarboxylic Acid,,small molecule,,,,,
O(C1=C(O[H])C([H])=C([As+](C2=C([H])C([H])=C([H])C([H])=C2[H])(C2=C([H])C([H])=C([H])C([H])=C2[H])C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])[H],DB02086,,"(3,4-Dihydroxy-Phenyl)-Triphenyl-Arsonium",,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C(F)=C([H])C(F)=C1[H])([H])[H],DB02087,,"3,5-Difluorobenzenesulfonamide",,small molecule,,,,,
ClC1=C([H])C2=C(N(C(=C2[H])C(=O)N(C(C(OC(C(OC(C(N(C(=O)C2=C([H])C3=C(C(=C(C(Cl)=C3[H])[H])[H])N2[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])[H])C([H])=C1[H],DB02089,,CP-526423,"1,2-bis(2-(5-chloroindole-2-carbonylamino)ethoxy)ethane
bis[5-chloro-1h-indol-2-yl-carbonyl-aminoethyl]-ethylene glycol",small molecule,,,,,
C(C1=NC(C([H])([H])[H])=C(C2=NC(N([H])[H])=NC([H])=C2[H])S1)([H])([H])[H],DB02091,,"4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine",,small molecule,,,,,
O(B(O[H])C(N(C(=O)C(C1=C([H])C([H])=C([H])S1)([H])[H])[H])([H])[H])[H],DB02094,,N-2-Thiophen-2-Yl-Acetamide Boronic Acid,,small molecule,,,,,
O=C1N([H])C2=C(C(=C(C(=C2[H])[H])[H])[H])C1=O,DB02095,91-56-5,Isatin,"1H-indole-2,3-dione",small molecule,,,,,
C(OC1=C([H])C(N(C([H])([H])[H])C(C2=C(C([H])([H])[H])C3=C(N([H])[H])N=C(N([H])[H])N=C3N=C2[H])([H])[H])=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])([H])([H])[H],DB02104,,"2,4-Diamino-5-Methyl-6-[(3,4,5-Trimethoxy-N-Methylanilino)Methyl]Pyrido[2,3-D]Pyrimidine",,small molecule,,,,,
O(C1=C([H])C([N+]([O-])=O)=C([H])C([N+]([O-])=O)=C1O[H])[H],DB02105,,"3,5-Dinitrocatechol",,small molecule,,,,,
N(C(C(=N[H])[H])([H])[H])([H])[H],DB02108,,2-Aminoethanimidic Acid,,small molecule,,,,,
O(N(C(C(O[H])=O)([H])[H])C(=O)[H])[H],DB02109,,Hadacidin,,small molecule,,,,,
C(C1=C(C(C(C(O[H])=O)([H])[H])([H])[H])C2N3[Co]45N6C(C=2[H])=C(C(C(C(O[H])=O)([H])[H])([H])[H])C(C([H])([H])[H])=C6C([H])=C2N4C(C(C([H])([H])[H])=C2C(=C([H])[H])[H])=C([H])C2N5C(=C(C=2C(=C([H])[H])[H])C([H])([H])[H])C([H])=C13)([H])([H])[H],DB02110,,Protoporphyrin Ix Containing Co,,small molecule,,,,,
O(C(=O)C1=C([H])ON=C1O[H])[H],DB02111,,3-Hydroxyisoxazole-4-Carboxylic Acid,,small molecule,,,,,
C(C(=N[H])N1C([H])([H])C([H])([H])C(OC2=C([H])C3=C(C4=C(N3C(C3=C([H])C5=C(C(=C(C([H])=C5C([H])=C3[H])[H])C(N([H])[H])=N[H])[H])([H])[H])C([H])=C([H])C([H])=C4[H])C([H])=C2[H])([H])C([H])([H])C1([H])[H])([H])([H])[H],DB02112,,Zk-806450,,small molecule,,,,,
C(C1=NC([H])=NC2=C1N(C(=N2)[H])[H])([H])([H])[H],DB02113,2004-03-7,6-Methylpurine,,small molecule,,,,,
C(C(C([H])([H])[H])(C1=C([H])C([H])=C(N([H])[H])C([H])=C1[H])[H])([H])([H])[H],DB02114,,Para-Isopropylaniline,,small molecule,,,,,
C(N1C([H])=NC2=C(N(C(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])[H])N=C(N(C(C(O[H])([H])[H])([H])[H])[H])N=C12)([H])([H])[H],DB02116,101622-51-9,Olomoucine,,small molecule,,,,,
N(C1=NC2=C(N=C(C(O[H])([H])[H])C(N2[H])([H])[H])C(=O)N1[H])([H])[H],DB02119,3672-03-5,"6-Hydroxymethyl-7,8-Dihydropterin",,small molecule,,,,,
C(C(C(C(N([H])[H])=O)([H])[H])([H])[H])([H])([H])[H],DB02121,541-35-5,Butyramide,,small molecule,,,,,
O(B(O[H])C1=C([H])C([H])=C([H])C(N(C(=O)C(I)([H])[H])[H])=C1[H])[H],DB02122,,4-iodo-acetamido phenylboronic acid,,small molecule,,,,,
O(C(=O)C(=C(C1=C([H])C([H])=C(C(O[H])=O)C([H])=C1[H])[H])[H])[H],DB02126,,4-Carboxycinnamic Acid,,small molecule,,,,,
C(C(C([H])([H])[H])(OP(C([H])([H])[H])(=O)OC(C([H])([H])[H])(C([H])([H])[H])[H])[H])([H])([H])[H],DB02127,,Methylphosphonic Acid Diisopropyl Ester,,small molecule,,,,,
C(OC1=C(O[H])C([H])=C([H])C(C([O-])=O)=C1[H])([H])([H])[H],DB02130,121-34-6,Vanillic acid,"4-Hydroxy-3-methoxybenzoic acid
VA",small molecule,,,,,
O(C(=O)C(N1C(=O)N(C(C2=C(F)C([H])=C(Br)C([H])=C2[H])([H])[H])C(=O)C2=C1C(=C(Cl)C(=C2[H])[H])[H])([H])[H])[H],"DB02132
DB06424",112733-06-9,Zenarestat,,small molecule,,,,,Investigated for use/treatment in neuropathy (diabetic).
O=C1N([H])C2=C(N(C(=N2)[H])[H])C(=O)N1[H],DB02134,69-89-6,Xanthine,,small molecule,,,,,
C(C(OP(=O)(C(C1=C([H])C([H])=C(C([H])([H])[H])C([H])=C1[H])([H])[H])OC(C([H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02138,3762-25-2,Diethyl 4-Methylbenzylphosphonate,,small molecule,,,,,
C(N(C(C(=C([H])[H])[H])([H])[H])C(C(=C(C(OC1=C([H])C2=C(C(=NN2C([H])([H])[H])C2=C([H])C([H])=C(Br)C([H])=C2[H])C([H])=C1F)([H])[H])[H])[H])([H])[H])([H])([H])[H],DB02139,,(2e)-N-Allyl-4-{[3-(4-Bromophenyl)-5-Fluoro-1-Methyl-1h-Indazol-6-Yl]Oxy}-N-Methyl-2-Buten-1-Amine,,small molecule,,,,,
N(C(=N[H])SC(C(C1=C([H])C([H])=C(C(C(SC(N([H])[H])=N[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H],DB02141,,"S,S'-(1,4-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea",,small molecule,,,,,
C(C1=C(O[H])C(C(N([H])[H])([H])[H])=C(C(OP(O[H])(O[H])=O)([H])[H])C([H])=N1)([H])([H])[H],DB02142,529-96-4,Pyridoxamine-5'-Phosphate,Pyridoxamine phosphate,small molecule,,,,,
C(C(C([H])([H])[H])(N(C(=N[H])N(O[H])[H])[H])[H])([H])([H])[H],DB02143,,N-Isopropyl-N'-Hydroxyguanidine,,small molecule,,,,,
C(C(C(C(O[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02145,71-36-3,Butyl alcohol,"Butan-1-ol
N-butyl alcohol",small molecule,,,,,
[O-][V]1(=O)O[V]([O-])(=O)O[V]([O-])(=O)O[V]([O-])(=O)O1,DB02147,,Cyclo-Tetrametavanadate,,small molecule,,,,,
O(C(=O)C(=O)C(S(O[H])(=O)=O)([H])[H])[H],DB02156,98022-26-5,Sulfopyruvate,,small molecule,,,,,
C(C1=C([H])C(N([H])[H])=C(C([H])([H])[H])C([H])=C1[H])([H])([H])[H],DB02163,95-78-3,"2,5-Xylidine",,small molecule,,,,,
O([Zn-](O[H])O[H])[H],DB02165,,Zinc Trihydroxide,,small molecule,,,,,
C(C([N+](C([H])([H])[H])(C(C([H])([H])[H])([H])[H])C(C(C([N+]1=C(C2=C([H])C([H])=C([H])C([H])=C2[H])C2=C(C(N([H])[H])=C(C([H])=C2C2=C(C(=C(N([H])[H])C([H])=C12)[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02166,36015-30-2,Propidium,,small molecule,,,,,
BrC1=C2N=C(N=C2N([H])C([H])=N1)[H],DB02168,767-69-1,Bromopurine,,small molecule,,,,,
O(C1=C([H])C([H])=C([H])C2=C1C(=O)C1=C(O[H])C([H])=C([H])C([N+]([O-])=O)=C1O2)[H],DB02170,,"1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One",,small molecule,,,,,
C(C1=C([H])C2=C(C3=NC(=C(C4=C(C([H])([H])[H])C(C(C(C([O-])=O)([H])[H])([H])[H])=C(C(=C5N=C(C([H])=C1[N-]2)C(C([H])([H])[H])=C5C(C(C(O[H])=O)([H])[H])([H])[H])[H])N4[H])[H])C([H])=C3C([H])([H])[H])[H])([H])([H])[H],DB02173,,Co(III)-(Deuteroporphyrin IX),,small molecule,,,,,
O(C(=O)C(C(O[H])=O)([H])[H])[H],DB02175,141-82-2,Malonic acid,"Malonate
Propanedioic acid",small molecule,,,,,
C(C(=O)O[Hg+])([H])([H])[H],DB02176,,Mercury Acetate Ion,,small molecule,,,,,
C(C(OC1=C(SC2=C([N+]([O-])=O)C([H])=C(C3=C([H])C(N4C([H])([H])C([H])([H])N(C(C([H])([H])[H])=O)C([H])([H])C4([H])[H])=NC([H])=C3[H])C([H])=C2[H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB02177,,1-Acetyl-4-(4-{4-[(2-Ethoxyphenyl)Thio]-3-Nitrophenyl}Pyridin-2-Yl)Piperazine,,small molecule,,,,,
O=C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H],DB02178,122-78-1,Phenylacetaldehyde,,small molecule,,,,,
O(C(=O)C1=C(N(C2=C(C(F)(F)F)C([H])=C([H])C([H])=C2[H])[H])C([H])=C([H])C([H])=C1[H])[H],DB02179,,O-Trifluoromethylphenyl Anthranilic Acid,,small molecule,,,,,
C(C(C1=C2N3[Fe]45N6C(C(C(=C([H])[H])[H])=C(C6=C2[H])C([H])([H])[H])=C([H])C2N4C(=C(C=2C([H])([H])[H])C(C(C(O[H])=O)([H])[H])([H])[H])C([H])=C2N5C(=C([H])C3=C1C([H])([H])[H])C(C([H])([H])[H])=C2C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02182,,Hybrid Between B and C Type Hemes (Protoporphyrin Ixcontaining Fe),,small molecule,,,,,
O(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])[H],DB02192,60-12-8,Phenylethyl alcohol,"2-phenylethanol
Benzeneethanol
Phenethyl alcohol
Phenylethanol",small molecule,,,,,
O(N1C2=C(C(=C(N=C2C(C2=C([H])C([H])=C(F)C([H])=C2[H])=C1C1=C([H])C([H])=NC([H])=C1[H])[H])[H])[H])[H],DB02195,,"3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine",,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(N(C2=NC(C3=C([H])N=C4C(=C(C(=C([H])N34)[H])[H])[H])=C([H])C([H])=N2)[H])C([H])=C1[H])([H])[H],DB02197,,"4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide",,small molecule,,,,,
O(C(=O)C(Br)([H])[H])[H],DB02198,79-08-3,2-Bromoacetyl Group,,small molecule,,,,,
C(C1=C(C(C(C(O[H])=O)([H])[H])([H])[H])C2N3[Fe]45N6C(C=2[H])=C(C(C(C(O[H])=O)([H])[H])([H])[H])C(C([H])([H])[H])=C6C([H])=C2N4C(C(C(=C([H])[H])[H])=C2C(=C([H])[H])[H])=C([H])C2N5C(=C(C=2C(=C([H])[H])[H])C(=C([H])[H])[H])C([H])=C13)([H])([H])[H],DB02199,,"1,3-Dedimethyl-1,3-Divinyl Heme",,small molecule,,,,,
[O-]C(=O)C(C([O-])=O)([H])[H],DB02201,,Malonate Ion,,small molecule,,,,,
C(C(C([H])([H])[H])(O[H])C#N)([H])([H])[H],DB02203,75-86-5,Acetone Cyanohydrin,,small molecule,,,,,
[O-][N+](=O)C1=C([H])C([H])=C([H])C2=C(N(N=C12)[H])[H],DB02207,2942-42-9,7-Nitroindazole,,small molecule,,,,,
C(C1=C(O[H])C(C(O[H])([H])[H])=C(C(OP(O[H])(O[H])=O)([H])[H])C([H])=N1)([H])([H])[H],DB02209,447-05-2,Pyridoxine phosphate,Pyridoxine 5-phosphate,small molecule,,,,,
O(C(C(C(C(C(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB02210,629-11-8,"Hexane-1,6-Diol",,small molecule,,,,,
O(S(=O)(=O)C(C(C(N(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])[H])([H])[H])([H])[H])([H])[H])[H],DB02219,,3-Cyclohexyl-1-Propylsulfonic Acid,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(C(=O)N(C(C2=C(F)C([H])=C(F)C([H])=C2F)([H])[H])[H])C([H])=C1[H])([H])[H],DB02221,,"4-(Aminosulfonyl)-N-[(2,4,6-Trifluorophenyl)Methyl]-Benzamide",,small molecule,,,,,
N(C1=C([H])C([H])=C2C3=C([H])C([H])=C(N([H])[H])C([H])=C3[N+](C(C(C(C(C(C(C3=C([H])N(C(C(N(C4=C5C(C(C(C([H])([H])C5=NC5=C(C(=C(C([H])=C45)[H])[H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])N=N3)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])=C(C3=C([H])C([H])=C([H])C([H])=C3[H])C2=C1[H])([H])[H],DB02226,,"3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-4-Yl]Hexyl]-Phenanthridinium",,small molecule,,,,,
O(C1=C(O[H])C([H])=C([H])C([H])=C1[H])[H],DB02232,120-80-9,"1,2-Dihydroxybenzene",,small molecule,,,,,
C(C(SC(N([H])[H])=N[H])([H])[H])([H])([H])[H],"DB02234
DB02539",2986-20-1,S-Ethylisothiourea,"2-Ethyl-2-thiopseudourea
Ethyron
Etiron",small molecule,,,,,
C(SC(C(C(=O)C(O[H])=O)([H])[H])([H])[H])([H])([H])[H],DB02238,,4-(Methylsulfanyl)-2-Oxobutanoic Acid,,small molecule,,,,,
C(C(=O)C(C(C(O[H])=O)([H])[H])([H])[H])([H])([H])[H],DB02239,123-76-2,Laevulinic Acid,,small molecule,,,,,
O(C(=O)C(C(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])([H])[H])([H])[H])[H],DB02242,,Cyclohexane Propionic Acid,,small molecule,,,,,
N(C1=NC2=C(C(C(=N2)[H])([H])[H])C(=O)N1[H])([H])[H],DB02245,7355-55-7,7-Deazaguanine,,small molecule,,,,,
C(C(OC(C(O[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02249,110-80-5,2-Ethoxyethanol,,small molecule,,,,,
O(C(=O)C(C(C(=O)C1=C(C(O[H])=O)C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])[H],DB02251,27415-09-4,O-Succinylbenzoate,,small molecule,,,,,
IC1=C([H])C([H])=C([H])C([H])=C1[H],DB02252,,Iodophenyl,,small molecule,,,,,
C(C1=C(C(C(OP([O-])([O-])=O)([H])[H])([H])[H])SC([H])=[N+]1C(C1=C(N([H])[H])N=C(C(F)(F)F)N=C1[H])([H])[H])([H])([H])[H],DB02254,,Trifluoro-thiamin phosphate,FTP,small molecule,,,,,
C(C(=O)N(Br)C(C(OP(O[H])(O[H])=O)([H])[H])([H])[H])([H])([H])[H],DB02257,,N-Bromoacetyl-Aminoethyl Phosphate,,small molecule,,,,,
C(C1(C([H])([H])[H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C2=C1C(=C(C(=C2[H])C(=NO[H])C1=C([H])C([H])=C2C(=C(C(=C([H])C2=C1[H])[H])C(O[H])=O)[H])[H])[H])([H])([H])[H],DB02258,,SR11254,,small molecule,,,,,
C(C(C1=C(C(=O)C2=C([H])C(Br)=C(O[H])C(Br)=C2[H])C2=C(C(=C(C(=C2[H])[H])S(=O)(=O)N(C2=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C2[H])[H])[H])O1)([H])[H])([H])([H])[H],DB02259,,"3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide",,small molecule,,,,,
O(C(=O)C(C(C(C(C(C(=O)C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB02260,,4-Oxosebacic Acid,,small molecule,,,,,
O(C(=O)C1=C([H])C(=O)N([H])C(=O)N1[H])[H],DB02262,65-86-1,Orotic Acid,,small molecule,,,,,
C(C([Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])([H])[H],DB02265,3439-38-1,Ethyl-Trimethyl-Silane,,small molecule,,,,,
O(C(=O)C1=C(N(C2=C([H])C([H])=C([H])C(C(F)(F)F)=C2[H])[H])C([H])=C([H])C([H])=C1[H])[H],DB02266,530-78-9,Flufenamic Acid,,small molecule,,,,,
C(C(=O)N(C1=C(N([H])[H])C([H])=C(C(O[H])=O)C([H])=C1[H])[H])([H])([H])[H],DB02268,,4-(Acetylamino)-3-Amino Benzoic Acid,,small molecule,,,,,
C([N+](C([H])([H])[H])(C([H])([H])[H])C1=C([H])C([H])=C(C(N(C(=O)C2=C([H])C3=C(C(=C(C(OC(C4=C([H])C([H])=C([H])C([H])=C4[H])([H])[H])=C3[H])[H])[H])N2C(C2=C([H])C(C(N([H])[H])=N[H])=C([H])C([H])=C2[H])([H])[H])[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB02269,,[4-({[5-Benzyloxy-1-(3-Carbamimidoyl-Benzyl)-1h-Indole-2-Carbonyl]-Amino}-Methyl)-Phenyl]-Trimethyl-Ammonium,,small molecule,,,,,
N(C(C1=C(C(C(O[H])=O)([H])[H])C(C(C(C(O[H])=O)([H])[H])([H])[H])=C([H])N1[H])([H])[H])([H])[H],DB02272,487-90-1,Porphobilinogen,"2-aminomethylpyrrol-3-acetic acid 4-propionic acid
5-(Aminomethyl)-4-(carboxymethyl)-1H-pyrrole-3-propionic acid
PBG",small molecule,,,,,
C(N1N=C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C([H])=C1N(C(=O)N(C1=C([H])C([H])=C(Cl)C([H])=C1[H])[H])[H])([H])([H])[H],DB02277,,1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea,,small molecule,,,,,
C(C1(C([H])([H])[H])N([H])C2=C(C(=O)N(C(N([H])[H])=N2)[H])N=C1O[H])([H])([H])[H],DB02278,,"7,8-Dihydro-7,7-Dimethyl-6-Hydroxypterin",,small molecule,,,,,
O(C(=O)C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H])[H],DB02279,611-73-4,Benzoylformic Acid,,small molecule,,,,,
O(S(=O)(=O)C(C(N(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H])([H])[H])[H],DB02283,,2-Phenylamino-Ethanesulfonic Acid,,small molecule,,,,,
C(C1=C(C(C(C(O[H])=O)([H])[H])([H])[H])C2=C(C3=NC(=C(C4=C(C([H])([H])[H])C(C(=C([H])[H])[H])=C(C(=C5N=C(C([H])=C1N2[H])C(C(=C([H])[H])[H])=C5C([H])([H])[H])[H])N4[H])[H])C(C([H])([H])[H])=C3C(C(C(O[H])=O)([H])[H])([H])[H])[H])([H])([H])[H],DB02285,553-12-8,Protoporphyrin,Protoporphyrin IX,small molecule,,,,,
N(C(=[N+]([H])[H])C1=C([H])C2=C(N=C(N2[H])C2=C(O[H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H],"DB02287
DB02193",,2-(2-Hydroxy-Phenyl)-3h-Benzoimidazole-5-Carboxamidine,,small molecule,,,,,
C(C1=C([H])C(Br)=C(O[H])C(C2=NC3=C(C(=C(C(=C3[H])C(N([H])[H])=N[H])[H])[H])N2[H])=C1[H])([H])([H])[H],DB02288,,CRA_9334,,small molecule,,,,,
N(C(C(O[H])=O)(C(O[H])=O)[H])([H])[H],DB02289,1068-84-4,2-Aminopropanedioic Acid,,small molecule,,,,,
N(S(=O)(=O)OC1=C([H])C2=C(C3=C(C(=O)O2)C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])C([H])=C1[H])([H])[H],"DB02292
DB12437",288628-05-7,Irosustat,"6-Oxo-8,9,10,11-Tetrahydro-7h-Cyclohepta[C][1]Benzopyran-3-O-Sulfamate",small molecule,,,,,
C(C(C([H])([H])[H])(C1=C(C(=O)N(C(C(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])([H])[H])[H])N=C(N(C(=O)C2=C([H])C(N(C(=O)C3=C([H])C(N(C(=O)[H])[H])=C([H])N3C([H])([H])[H])[H])=C([H])N2C([H])([H])[H])[H])S1)[H])([H])([H])[H],DB02295,,"N-[3-(Dimethylamino)Propyl]-2-({[4-({[4-(Formylamino)-1-Methyl-1h-Pyrrol-2-Yl]Carbonyl}Amino)-1-Methyl-1h-Pyrrol-2-Yl]Carbonyl}Amino)-5-Isopropyl-1,3-Thiazole-4-Carboxamide",,small molecule,,,,,
C(C(C([H])([H])[H])(C(C(O[H])([H])[H])([H])[H])[H])([H])([H])[H],DB02296,,1-Hydroxy-3-Methylbutane,,small molecule,,,,,
N(C1=C([H])N=C([H])C(Cl)=N1)([H])[H],DB02297,,2-Amino-6-Chloropyrazine,,small molecule,,,,,
[N+](C(C(C(C(OB1OC([H])([H])C([H])([H])O1)([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02308,,"4-(1,3,2-Dioxaborolan-2-Yloxy)Butan-1-Aminium",,small molecule,,,,,
C(C1=C([H])C2=C(C([H])([H])[H])C(C([H])([H])[H])=C3C([H])=C(C([H])([H])[H])C([H])=[N+](C([H])([H])[H])C3=C2N=C1[H])([H])([H])[H],DB02310,,"3,5,6,8-Tetramethyl-N-Methyl Phenanthrolinium",,small molecule,,,,,
O(C(=O)C(C(C(C(C(N1C(C(O[H])=O)=C([H])C2=C1C(=C(C(OC(C1=C(Cl)C([H])=C([H])C([H])=C1Cl)([H])[H])=C2[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB02316,,"1-(5-Carboxypentyl)-5-[(2,6-Dichlorobenzyl)Oxy]-1 H-Indole-2-Carboxylic Acid",,small molecule,,,,,
C(C(C([H])([H])[H])(O[H])[H])([H])([H])[H],"DB02325
DB04402",67-63-0,Isopropyl Alcohol,Isopropanol,small molecule,Humans and other mammals,"Sponge
Spray
Solution
Liquid
Cream
Kit
Kit
Liquid
Gel
Liquid
Patch
Swab
Swab
Swab
Swab
Gel
Swab
Cloth
Swab
Sponge
Swab
Swab
Swab
Cloth
Swab
Liquid
Swab
Gel
Lotion
Liquid
Liquid
Jelly
Liquid
Liquid
Gel
Solution / drops
Patch
Swab
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Cloth
Kit
Liquid
Cloth
Kit
Liquid
Liquid
Liquid
Solution
Liquid
Liquid
Liquid
Aerosol, foam
Solution
Solution
Patch
Patch
Kit
Solution
Kit
Liquid
Spray
Solution
Liquid
Solution / drops
Spray
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Solution
Solution
Solution
Spray
Spray
Swab
Swab
Swab
Liquid
Swab
Liquid
Solution
Sponge
Liquid
Solution
Solution
Solution
Liquid
Solution
Kit
Spray
Liquid
Kit
Cloth
Cloth
Liquid
Liquid
Aerosol, spray
Solution
Stick
Swab
Liquid
Swab
Gel
Liquid
Gel
Kit
Liquid
Soap
Gel
Cloth
Solution; sponge
Cloth
Solution
Liquid
Liquid
Liquid
Stick
Solution
Liquid
Solution
Cloth
Liquid
Gel","Topical
Topical
Topical
Topical
Topical
Intramuscular; Subcutaneous; Topical
Intramuscular; Intraocular; Subcutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Auricular (otic)
Topical
Topical
Auricular (otic)
Topical
Topical
Topical
Topical
Topical
Topical
Auricular (otic)
Topical
Topical
Auricular (otic)
Topical
Epidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Intravenous; Soft tissue; Subcutaneous; Topical
Auricular (otic)
Auricular (otic)
Auricular (otic)
Topical
Auricular (otic)
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical; Vaginal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Infiltration; Intramuscular; Intravenous; Topical
Topical
Topical
Epidural; Infiltration; Topical
Topical
Topical
Topical
Topical
Topical
Auricular (otic)
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Auricular (otic)
Topical
Topical
Topical
Topical
Topical","700 mg/mL
.7 mg/mL
500 mg/mL
62.0 %
62 mL/100mL
.99 mL/mL
700 mg/g
.7 g/g
7 mL/10mL
70 mL/100mL
700 mg/g
700 mL/1000mL
.7 mL/1
.7 mL/.7mL
1.4 mL/1
7 mL/10mL
.7 mL/mL
.7 mg/mg
700 mg/1
70 mg/1
70 1/1
70 %
.7 g/mL
70 %
70 %
21 ml
760 g/1000mL
50 %
.56118 g/mL
715 mL/L
70 mL/100mL
.7 mL/mL
70 g/100g
28 mL/29mL
30 mg/30mL
60 %
63 %
63 mL/100mL
.7 mL/mL
70 mg/100mg
950 mg/mL
.7 g/g
.76 g/mL
70 %
94.998 1/100mL
95 g/100mL
75 mL/100mL
.95 g/100g
.7 L/100L
13 g/100g
.14 g/.2mL
1.4 g/2mL
70 g/100g
700 g/1000g
70 g/100g
75 kg/100kg
.57 1/1
.95 g/100mL
70 mL/100mL
924 mg/mL
.7 mg/mL
.91 mg/mL
.91 L/100L
50 mL/100mL
613 mg/mL
70 mL/100mL
70.14 g/100mL
700 mL/L
91 mg/mL
91 kg/100L
910 mg/mL
.105 mL/.15mL
462 mg/mL
91 mL/100mL
550.2 g/L
700 mL/L
.238 mL/1
.75 g/1
70 mL/1
91 mL/100mL
.7 1/1
99 %
.7 mL/mL
.07 mL/mL
350 mL/500mL
.7 L/L
70 mL/100mL
700 mg/mL
30 mg/mL
90 mL/100mL
15 g/100g
.7 mL/1
.7 g/1
630 mg/g
97.79 %
.95 g/mL
70 %
1 mL/1
700 mg/mL
49 %
700 mg/mL
.45 mg/g
700 g/kg
.7 mL/mL
.8 g/mL
70 L/100L
95 ml
70 1/1001
950 mg/mL
99 mL/100mL
.13 g/mL
70 g/100g
90 mL/100mL
65 %",
O(C(C(OC(C(OC(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB02327,112-27-6,Triethylene glycol,,small molecule,,,,,
C(C1=C(O[H])C(C(N=C(C(=C(C(P(O[H])(O[H])=O)([H])[H])[H])[H])C(O[H])=O)([H])[H])=C(C(OP(O[H])(O[H])=O)([H])[H])C([H])=N1)([H])([H])[H],DB02328,,2-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Imino]-5-Phosphono-Pent-3-Enoic Acid,,small molecule,,,,,
N(C1=NC([H])([H])C([H])([H])S1)([H])[H],DB02335,1779-81-3,2-Aminothiazoline,,small molecule,,,,,
C(N(C(C(C(C(C(C(OC1=C([H])C2=C(C(=C(O2)[H])C2=C([H])C([H])=C(Br)C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C(C(=C([H])[H])[H])([H])[H])([H])([H])[H],DB02339,,Allyl-{6-[3-(4-Bromo-Phenyl)-Benzofuran-6-Yloxy]-Hexyl-}-Methyl-Amin,,small molecule,,,,,
C(C(OC(C(OC(C(OC(C(OC(C(OC(C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02343,4353-28-0,"3,6,9,12,15-Pentaoxaheptadecane",,small molecule,,,,,
[O-]P([O-])(F)=O,DB02348,10163-15-2,Fluoro-Phosphite Ion,,small molecule,,,,,
N(C1=C(OC(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])C([H])=C([H])C([H])=N1)([H])[H],DB02352,,3-(Benzyloxy)Pyridin-2-Amine,,small molecule,,,,,
C(N1C(C(N(C2=C([H])C([H])=C(C(N([H])[H])=N[H])C([H])=C2[H])[H])([H])[H])=NC2=C1C(=C(C(C(N1C(C([H])([H])[H])=NC3=C1C(=C(C(=C3[H])[H])[H])[H])([H])[H])=C2[H])[H])[H])([H])([H])[H],DB02354,,4-{[1-Methyl-5-(2-Methyl-Benzoimidazol-1-Ylmethyl)-1h-Benzoimidazol-2-Ylmethyl]-Amino}-Benzamidine,,small molecule,,,,,
C(C(C(C(N1C(C(C2=C(OC([H])([H])[H])C([H])=C([H])C(OC([H])([H])[H])=C2[H])([H])[H])=NC2=C1N=C(N=C2N([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02359,,"9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine",,small molecule,,,,,
N(C1=C([H])C([H])=C(C(O[H])=O)C([H])=C1[H])([H])[H],DB02362,150-13-0,Aminobenzoic acid,4-aminobenzoic acid,small molecule,,"Capsule
Lotion","Oral
Topical",,
C1(=C([H])C2=C(C(=C3C([H])=C([H])C([H])=NC3=C2N=C1[H])[H])[H])[H],DB02365,66-71-7,"1,10-Phenanthroline",,small molecule,,,,,
N(C(=N[H])C1=C(Cl)C([H])=C2N(C(=NC2=C1[H])C1=C(O[H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])=C([H])C([H])=C1[H])[H])([H])[H],DB02366,,CRA_10762,,small molecule,,,,,
O(C(C(C(O[H])([H])[H])(C(O[H])([H])[H])N(C(C(S(O[H])(=O)=O)([H])[H])([H])[H])[H])([H])[H])[H],DB02371,7365-44-8,"2-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Ethanesulfonic Acid",,small molecule,,,,,
C(C1=C([H])N=C(C([H])([H])[H])N=C1N([H])[H])([H])([H])[H],DB02372,,"2,5-Dimethylpyrimidin-4-Amine",,small molecule,,,,,
O(C1=C([H])C2=C(C(=O)C(O[H])=C(O2)C2=C([H])C(O[H])=C(O[H])C(O[H])=C2[H])C(O[H])=C1[H])[H],DB02375,529-44-2,Myricetin,"3,3',4,4',5',7-Hexahydro-2-phenyl-4H-chromen-4-one
3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one
3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one
3,5,7,3',4',5'-Hexahydroxyflavone
Cannabiscetin
MYC
Myricetol
Myricitin",small molecule,,,,,
N(C1=NC(=O)C2=C(N=C(N2[H])[H])N1[H])([H])[H],DB02377,73-40-5,Guanine,,small molecule,,,,,
C(OC1=C([H])C([H])=C2C(=C(C(=C([H])C2=C1C(F)(F)F)[H])[H])C(=S)N(C([H])([H])[H])C(C(O[H])=O)([H])[H])([H])([H])[H],DB02383,82964-04-3,Tolrestat,,small molecule,Humans and other mammals,,,,For the pharmacological control of certain diabetic complications.
O(C(=O)C(F)=C(C1=C([H])C([H])=C([O-])C([H])=C1[H])[H])[H],DB02384,,(E)-2-Fluoro-P-Hydroxycinnamate,,small molecule,,,,,
C(C(C(N1C(C2(C([H])([H])C([H])([H])N([H])C([H])([H])C2([H])[H])[H])=NC(C2=C([H])C(Cl)=C(Cl)C([H])=C2[H])=C1C1=NC(N(C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])[H])=NC([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB02388,,"Cyclohexyl-{4-[5-(3,4-Dichlorophenyl)-2-Piperidin-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine",,small molecule,,,,,
C([N+](C([H])([H])[H])(C(C(N(C(=O)C1=C2[N+](=C3C(Br)=C([H])C([H])=C([H])C3=C(N([H])[H])C2=C([H])C([H])=C1[H])[H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB02390,,5-Bromo-N[2-(Dimethylamino)Ethyl]-9-Aminoacridine-4-Carboxamide,,small molecule,,,,,
N(C1=NC2=C(N(C(C(N(C(C(O[H])([H])[H])(C(O[H])([H])[H])[H])[H])([H])[H])([H])[H])C(=N2)[H])C(=O)N1[H])([H])[H],DB02391,,"2-Amino-7-[2-(2-Hydroxy-1-Hydroxymethyl-Ethylamino)-Ethyl]-1,7-Dihydro-Purin-6-One",,small molecule,,,,,
C(N1C(C(C(C(O[H])([H])[H])([H])[H])([H])[H])=C(C(O[H])([H])[H])C2=C1C(=O)C(=C(N1C([H])([H])C1([H])[H])C2=O)[H])([H])([H])[H],DB02395,,"3-Hydroxymethyl-5-Aziridinyl-1methyl-2-[1h-Indole-4,7-Dione]-Propanol",,small molecule,,,,,
C(C(N(C([H])([H])[H])[H])([H])[H])([H])([H])[H],DB02396,624-78-2,Methylethylamine,,small molecule,,,,,
N(C(C1=C([H])C([H])=C(N(C(=O)C2=C([H])C3=C(C(=C(C([H])=C3C([H])=C2[H])C(N([H])[H])=N[H])[H])[H])[H])C([H])=C1[H])([H])[H])([H])[H],DB02398,,6-[N-(4-(Aminomethyl)Phenyl)Carbamyl]-2-Naphthalenecarboxamidine,,small molecule,,,,,
C(OC1=C([H])C(=O)C2=C(C(C(OC3=C([H])C([H])=C([N+]([O-])=O)C([H])=C3[H])([H])[H])=C(C([H])([H])[H])N2C([H])([H])[H])C1=O)([H])([H])[H],DB02400,,"5-Methoxy-1,2-Dimethyl-3-(4-Nitrophenoxymethyl)Indole-4,7-Dione",,small molecule,,,,,
O(C(=O)C1=NON=C1O[H])[H],DB02401,,"4-Hydroxy-1,2,5-Oxadiazole-3-Carboxylic Acid",,small molecule,,,,,
C(OC1=C([H])C([H])=C(OC2=C([H])C([H])=C([H])C3=NC(N([H])[H])=NC(N([H])[H])=C23)C([H])=C1[H])([H])([H])[H],DB02402,,"5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine",,small molecule,,,,,
N(C1=C(F)C([H])=C([H])C([H])=C1[H])([H])[H],DB02403,348-54-9,2-Fluoroaniline,,small molecule,,,,,
O(C(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(S[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB02404,,1-Deoxy-1-Thio-Heptaethylene Glycol,,small molecule,,,,,
O(C(=O)C(C(C(C(C(C(C(C(C(C(C(Br)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB02405,73367-80-3,12-Bromododecanoic Acid,,small molecule,,,,,
C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])([H])[H],"DB02406
DB04344",109-52-4,N-Valeric Acid,,small molecule,,,,,
N(C1=NC2=C(N=C(N2[H])[H])C(OC(C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])([H])[H])=N1)([H])[H],DB02407,,6-O-Cyclohexylmethyl Guanine,,small molecule,,,,,
C1(C([H])([H])C([H])([H])OC([H])([H])C1([H])[H])([H])[H],DB02412,142-68-7,Tetrahydropyran,,small molecule,,,,,
O(C1=C(Br)C([H])=C(Br)C([H])=C1Br)[H],DB02417,118-79-6,"2,4,6-Tribromophenol",,small molecule,,,,,
C(C(OC(=O)C(=O)N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])([H])[H])([H])([H])[H],DB02419,53074-96-7,Ethyl Oxo(Piperidin-1-Yl)Acetate,,small molecule,,,,,
N(C(C1=C([H])C([H])=C(N(C(=O)C(O[H])=O)[H])C([H])=C1[H])([H])[H])([H])[H],DB02420,,"[[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(OC(=O)C(C(C(C(C(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02425,29710-31-4,Hexadecyl Octanoate,"Caprylic acid, cetyl ester
Cetyl caprylate
Cetyl octanoate
Hexadecyl caprylate
Hexadecyl N-octanoate",small molecule,,,,,
C(OC1=C([H])C(C(N(C([H])([H])[H])C2=C([H])C3=C(N([H])[H])N=C(N([H])[H])N=C3C([H])=C2[H])([H])[H])=C(OC([H])([H])[H])C([H])=C1[H])([H])([H])[H],DB02427,,"2,4-Diamino-6-[N-(2',5'-Dimethoxybenzyl)-N-Methylamino]Quinazoline",,small molecule,,,,,
O(C(=O)C1=NC2=C(C(=C(C([H])=C2C([H])=C1[H])[H])[H])[H])[H],"DB02428
DB08452",93-10-7,Quinaldic Acid,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(C(=O)N(C(C2=C([H])C([H])=C(F)C([H])=C2[H])([H])[H])[H])C([H])=C1[H])([H])[H],DB02429,,4-(Aminosulfonyl)-N-[(4-Fluorophenyl)Methyl]-Benzamide,,small molecule,,,,,
O(C(=O)C(C(C(C1=C([H])C([H])=C([H])S1)([H])[H])([H])[H])([H])[H])[H],DB02434,4653-11-6,4-(2-Thienyl)Butyric Acid,,small molecule,,,,,
[N+](C(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])([H])[H])([H])([H])[H],DB02435,3218-02-8,Aminomethylcyclohexane,,small molecule,,,,,
C(C(C(C(C1=NC2=C(C(=O)N(N(C2=O)[H])[H])N1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02441,,"2-Butyl-5,6-Dihydro-1h-Imidazo[4,5-D]Pyridazine-4,7-Dione",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02448,638-53-9,N-Tridecanoic Acid,,small molecule,,,,,
O([Sb](O[H])O[H])[H],DB02453,,Trihydroxyantimonite(Iii),,small molecule,,,,,
C(C(N=C(S[H])N(C1=C([H])C(C(O[H])=O)=C(C2=C3C(=C(C(=O)C([H])=C3OC3=C2C(=C(C(O[H])=C3[H])[H])[H])[H])[H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB02455,,Fluoresceinylthioureido,,small molecule,,,,,
N(C(=N[H])N(C1=C([H])C([H])=C(C(O[H])=O)C([H])=C1[H])[H])([H])[H],DB02459,,4-Guanidinobenzoic Acid,,small molecule,,,,,
C(N(C([H])([H])[H])C(C(C(OC1=C([H])C(=O)SC2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02462,,Thiocoumarin,,small molecule,,,,,
N(C(=[N+]([H])[H])C1=C([H])C2=C(N(C(=C2[H])C2=C(O[H])C([H])=C([H])C([H])=C2[H])[H])C([H])=C1[H])([H])[H],DB02463,,2-(2-Hydroxy-Phenyl)-1h-Indole-5-Carboxamidine,,small molecule,,,,,
N(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H],DB02464,100-46-9,Benzylamine,,small molecule,,,,,
C(C1(C([H])([H])[H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C2=C1C(=C(C(=C2[H])C(=O)C(=C(C1=C([H])C([H])=C(C(O[H])=O)C([H])=C1[H])[H])[H])[H])[H])([H])([H])[H],DB02466,,"4-[3-Oxo-3-(5,5,8,8-Tetramethyl-5,6,7,8-Tetrahydro-Naphthalen-2-Yl)-Propenyl]-Benzoic Acid",,small molecule,,,,,
C(C1(C(C(=C([H])[H])[H])([H])C2=C(C3=C(C([H])([H])[H])C(C(C(C(O[H])=O)([H])[H])([H])[H])=C4C(=C5N6[Fe+2]7(N34)N2C1=C(C1=C(C(=C([H])[H])[H])C(C([H])([H])[H])=C(N17)C([H])=C6C(C([H])([H])[H])=C5C(C(C(O[H])=O)([H])[H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H])[H])([H])([H])[H],DB02468,,12-Phenylheme,,small molecule,,,,,
C(C(C([H])([H])[H])(C1=NC([H])([H])C([H])([H])C2=C1C(=C(N(C(=O)C1=C([H])C3=C(C(=C(C([H])=C3C([H])=C1[H])C(N([H])[H])=N[H])[H])[H])[H])C(=C2[H])[H])[H])[H])([H])([H])[H],DB02473,,"6-[N-(1-Isopropyl-3,4-Dihydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine",,small molecule,,,,,
O=C(N(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H])[H],DB02481,6343-54-0,N-Benzylformamide,,small molecule,,,,,
O(C(C(SSC(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB02486,1892-29-1,2-Hydroxyethyl Disulfide,,small molecule,,,,,
C(N1C([H])=NC2=C1N=C(N([H])[H])N=C2O[H])([H])([H])[H],DB02489,5502-78-3,9-Methylguanine,,small molecule,,,,,
C(N(C(C(O[H])=O)([H])[H])C(N([H])[H])(N([H])[H])[H])([H])([H])[H],DB02490,,(Diaminomethyl-Methyl-Amino)-Acetic Acid,,small molecule,,,,,
C(C(C([H])([H])[H])(N([H])[H])C1=C([H])C([H])=C(C2=C(Cl)C([H])=NC(N(C3=C([H])C([H])=C(C(C(N4C([H])([H])C([H])([H])OC([H])([H])C4([H])[H])([H])[H])([H])[H])C([H])=C3[H])[H])=N2)C([H])=C1[H])([H])([H])[H],DB02491,,4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine,,small molecule,,,,,
O(C(C(C(C(N1C([H])=NC2=C1N=C(N(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])N(C2=O)[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB02495,,9-(4-hydroxybutyl)-N2-phenylguanine,HBPG,small molecule,,,,,
C(C1=C(C(C(C(O[H])([H])[H])(C(O[H])([H])[H])[H])([H])[H])N([H])C(=O)N([H])C1=O)([H])([H])[H],DB02500,,6-(Dihydroxy-Isobutyl)-Thymine,,small molecule,,,,,
O(B(O[H])C1=C([H])C([H])=C(C(=C(C(O[H])=O)[H])[H])C([H])=C1[H])[H],DB02503,,4-(Carboxyvin-2-Yl)Phenylboronic Acid,,small molecule,,,,,
C(C1=C(C(C(N([H])[H])=O)([H])[H])C2=C(C(=C(C(OC(C(C(P(O[H])(O[H])=O)([H])[H])([H])[H])([H])[H])=C2[H])[H])[H])N1C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB02504,,[3-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Propyl-]-Phosphonic Acid,,small molecule,,,,,
C(C(C(C(C(C1=C([H])C([H])=C(C(=O)N(C(C2=C([H])C([H])=C(C3=C([H])C([H])=C(C(C(=O)OC([H])([H])[H])([H])[H])C([H])=C3[H])C([H])=C2[H])([H])[H])C2(C([H])([H])C([H])([H])N(C(C3=NC([H])=C([H])N3[H])([H])[H])C([H])([H])C2([H])[H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02505,,N-(R-Carboxy-Ethyl)-Alpha-(S)-(2-Phenylethyl),,small molecule,,,,,
C(C(C([H])([H])[H])=C(C(C(C(C([H])([H])[H])=C(C(C(C(C([H])([H])[H])=C(C(O[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB02509,4602-84-0,Farnesol,,small molecule,,,,,
C(C(C([H])([H])[H])(C1=C(O[H])C([H])=C(C([H])([H])[H])C([H])=C1[H])[H])([H])([H])[H],DB02513,89-83-8,Thymol,"2-isopropyl-5-methylphenol
5-Methyl-2-(1-Methylethyl)Phenol
IPMP",small molecule,,"Oil
Oil
Liquid
Rinse
Mouthwash
Liquid
Spray
Lotion
Spray
Powder
Ointment
Oil
Soap
Spray
Cloth
Mouthwash
Soap
Liquid
Oil
Gel
Mouthwash
Mouthwash
Jelly
Liquid
Soap
Lozenge
Plaster
Patch
Mouthwash
Liquid","Topical
Topical
Dental
Oral
Buccal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Buccal; Oral
Topical
Oral
Topical
Topical
Dental; Oral
Oral
Nasal
Topical
Topical
Oral
Topical
Cutaneous; Topical; Transdermal
Dental
Respiratory (inhalation)",".7 g/50g
1.5 g/50g
.5 mL/L
.06 mL/120mL
.5 g/50g
.0004 1/kg
.0005 kg/kg
.0005 kg/kg
.0004 kg/kg
1.7 g/50g
.0024 kg/kg",
[O-]C(=O)C(=C(OP(=O)=O)[H])C1=C([H])C([H])=C([H])C([H])=C1[H],DB02514,2007-07-0,(2Z)-3-{[Oxido(oxo)phosphoranyl]oxy}-2-phenylacrylate,,small molecule,,,,,
O(S(=O)(=O)C1=C([H])C2=C(N(C(=O)C2=C2N([H])C3=C(C(=C(C(=C3[H])[H])[H])[H])C2=O)[H])C([H])=C1[H])[H],DB02519,,Indirubin-5-Sulphonate,,small molecule,,,,,
C(C(N(C(C([H])([H])[H])([H])[H])C(S[H])=S)([H])[H])([H])([H])[H],DB02520,147-84-2,Ditiocarb,"diethyl dithiocarbamate
diethylcarbamodithioic acid
diethyldithiocarbamate
diethyldithiocarbamic acid",small molecule,,,,,
O(C1=C([H])C2=C(C(=O)C(=C(O[H])C2=O)[H])C(O[H])=C1[H])[H],DB02521,479-05-0,"2,5,7-Trihydroxynaphthoquinone",,small molecule,,,,,
O(C(=O)C(=O)C(P(O[H])(O[H])=O)([H])[H])[H],DB02522,,Phosphonopyruvate,,small molecule,,,,,
N(C(=N[H])C1=C([H])C2=C(N(C(=N2)C2=C([H])C([H])=C([H])C(OC3(C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])=C2O[H])[H])C([H])=C1[H])([H])[H],DB02526,,CRA_10655,,small molecule,,,,,
N(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H],"DB02530
DB08850",56-12-2,gamma-Aminobutyric acid,"4-aminobutanoic acid
4-aminobutyric acid
4Abu
GABA
gamma-Aminobutyric acid
piperidic acid
piperidinic acid
��-amino-n-butyric acid
��-aminobutanoic acid
��-Aminobutters��ure
��-aminobutyric acid
��-aminobutyric acid",small molecule,,"Cream
Tablet
Kit
Kit","Topical
Oral
Oral",.022 mL/100mL,
C(C(C([H])([H])[H])(C(O[H])=O)[H])([H])([H])[H],"DB02531
DB04305",79-31-2,Isobutyric Acid,2-Methyl-propionic acid,small molecule,,,,,
N(C1=C([H])C([H])=C2N=C(N([H])[H])N=C(N([H])[H])C2=C1[H])([H])[H],DB02532,,"2,4,6-Triaminoquinazoline",,small molecule,,,,,
O(C1=C(C(C(=C([H])[H])[H])([H])[H])C([H])=C([H])C([H])=C1[H])[H],DB02534,1745-81-9,2-Allylphenol,,small molecule,,,,,
N(C(C(OC(C(OC(C(N(C(=O)C1=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C1[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB02535,,Aminodi(Ethyloxy)Ethylaminocarbonylbenzenesulfonamide,,small molecule,,,,,
C(C(=O)N(C1=NC(C2=C(C([H])([H])[H])N=C3C(=C(C(=C([H])N23)[H])[H])[H])=C([H])C([H])=N1)[H])([H])([H])[H],DB02538,,"N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide",,small molecule,,,,,
[N+](C(C(C(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02541,,4-Hydroxybutan-1-Aminium,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C([H])N1[H])[H],DB02543,,Pyrrole-2-Carboxylate,,small molecule,,,,,
C(N(C(C(C(C(C(C(OC1=C([H])C2=C(C(=NS2)C2=C([H])C([H])=C(Br)C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C(C(=C([H])[H])[H])([H])[H])([H])([H])[H],DB02544,,"N-(6-{[3-(4-Bromophenyl)-1,2-Benzisothiazol-6-Yl]Oxy}Hexyl)-N-Methylprop-2-En-1-Amine",,small molecule,,,,,
C(OC(=O)C(=C(C1=C([H])C(N(C(C2=C([H])C([H])=C(C3=C([H])C([H])=C(N(C([H])([H])[H])C([H])([H])[H])C([H])=C3[H])C([H])=C2[H])([H])[H])C(=O)C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])=C([H])C([H])=C1[H])[H])[H])([H])([H])[H],DB02545,574013-66-4,Fexaramine,,small molecule,,,,,
O(N(C(=O)C(C(C(C(C(C(C(=O)N(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])[H],DB02546,149647-78-9,Vorinostat,"Octanedioic acid hydroxyamide phenylamide
SAHA
SHH
Suberanilohydroxamic acid
Suberoylanilide hydroxamic acid
Vorinostatum",small molecule,Humans and other mammals,"Capsule
Capsule","Oral
Oral","100 mg
100 mg/1","For the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies."
C(OC1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(Cl)C(C(C2=NC3=C(N=C(F)N=C3N([H])[H])N2C(C(C(C#C[H])([H])[H])([H])[H])([H])[H])([H])[H])=C1[H])([H])([H])[H],DB02550,,"8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine",,small molecule,,,,,
C(N(C([H])([H])[H])C1=C([H])C([H])=C(C(=O)N(C(C(C(C(C(C(C(O[H])=NO[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])C([H])=C1[H])([H])([H])[H],DB02565,,4-Dimethylamino-N-(6-Hydroxycarbamoyethyl)Benzamide-N-Hydroxy-7-(4-Dimethyla Minobenzoyl)Aminoheptanamide,,small molecule,,,,,
C(SC1=C([H])C([H])=C([H])C(N(C2=NC3=C(C(=C(C(=O)N3C([H])([H])[H])C3=C(Cl)C([H])=C([H])C([H])=C3Cl)[H])C([H])=N2)[H])=C1[H])([H])([H])[H],DB02567,,PD173955,"6-(2,6-dichlorophenyl)-8-methyl-2-{[3-(methylthio)phenyl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one",small molecule,,,,,
N(C1=NC(=O)C2=C(C(C(C3=C([H])N=C([H])C([H])=C3[H])([H])[H])=C(N2[H])[H])N1[H])([H])[H],"DB02568
DB07442",,Peldesine,"2-Amino-3,5-dihydro-7-(3-pyridylmethyl)-4H-pyrrolo(3,2-d)pyrimidin-4-one
4H-Pyrrolo(3,2-d)pyrimidin-4-one, 2-amino-3,5-dihydro-7-(3-pyridinylmethyl)-
Peldesine",small molecule,,,,,
C(C1=C(C(C(C(O[H])=O)([H])[H])([H])[H])C2N3[Fe+2]45N6C(C=2[H])=C(C(C(C(O[H])=O)([H])[H])([H])[H])C(C([H])([H])[H])=C6C([H])=C2N4C(C(C([H])([H])[H])=C2C(=C([H])[H])[H])=C([H])C2N5C(=C(C=2C(=C([H])[H])[H])C([H])([H])[H])C([H])=C13)([H])([H])[H],DB02577,,Mesoheme,,small molecule,,,,,
O(C(=O)C(=C([H])[H])[H])[H],DB02579,79-10-7,Acrylic Acid,"2-Propenoic acid
acroleic acid
Acrylate
ethylenecarboxylic acid
Propenoate
Propenoic acid
Vinylformic acid",small molecule,,,,,
C(OC(C(OC(C(OC(C(OC(C(OC(C(OC([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02580,1191-87-3,Pentaglyme,pentaethyleneglycol dimethyl ether,small molecule,,,,,
C(OC1=C([H])C(C(N(C([H])([H])[H])C2=C([H])C3=C(N([H])[H])N=C(N([H])[H])N=C3N=C2[H])([H])[H])=C(OC([H])([H])[H])C([H])=C1[H])([H])([H])[H],DB02583,175354-76-4,"N6-(2,5-Dimethoxy-Benzyl)-N6-Methyl-Pyrido[2,3-D]Pyrimidine-2,4,6-Triamine",,small molecule,,,,,
N(C(=N[H])C1=C([H])C([H])=C(C(O[H])([H])[H])C([H])=C1[H])([H])[H],DB02585,,4-(Hydroxymethyl)Benzamidine,,small molecule,,,,,
C(C1=C([H])C([H])=NC2=C3N=C([H])C([H])=C(C([H])([H])[H])C3=C(C([H])=C12)[H])([H])([H])[H],DB02586,3248-05-3,"4,7-Dimethyl-[1,10]Phenanthroline",,small molecule,,,,,
C(C([Se]C(N([H])[H])=N[H])([H])[H])([H])([H])[H],DB02589,,Se-Ethyl-Isoselenourea,,small molecule,,,,,
C(C1=C([H])C2=C(N=C(N2[H])[H])C([H])=C1C([H])([H])[H])([H])([H])[H],DB02591,582-60-5,"5,6-Dimethylbenzimidazole",,small molecule,,,,,
C(C(C(SC(C1=C2N=C(N([H])[H])N(C(=O)C2=C([H])C(N([H])[H])=C1[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02599,,"2,6-Diamino-8-Propylsulfanylmethyl-3h-Quinazoline-4-One",,small molecule,,,,,
C(OC1=C([H])C([H])=C([H])C(N2C([H])([H])C([H])([H])C3=C(SC(=C3[H])S(N([H])[H])(=O)=O)S2(=O)=O)=C1[H])([H])([H])[H],DB02602,,AL7182,,small molecule,,,,,
N(C1=C([H])C2=C(N=C(N2[H])[H])C(OC(C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])([H])[H])=N1)([H])[H],DB02603,,1-Amino-6-Cyclohex-3-Enylmethyloxypurine,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(C(=O)N(C(C2=C(F)C(F)=C(F)C(F)=C2F)([H])[H])[H])C([H])=C1[H])([H])[H],DB02610,,"N-(2,3,4,5,6-Pentaflouro-Benzyl)-4-Sulfamoyl-Benzamide",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C([N+](C([H])([H])[H])(C([H])([H])[H])[O-])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02613,,"Decylamine-N,N-Dimethyl-N-Oxide",,small molecule,,,,,
N(C(N([H])[H])=NC1=NC(C2=C([H])C([H])=C(C(N(C3=NC4=C(C(=C(C(=C4[H])[H])[H])[H])N3[H])[H])([H])[H])S2)=C([H])S1)([H])[H],DB02616,,FR117016,,small molecule,,,,,
C(C([N+](C([H])([H])[H])(C([H])([H])[H])C(C(C(S([O-])(=O)=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02618,,Ethyl Dimethyl Ammonio Propane Sulfonate,,small molecule,,,,,
O(C(C(C(C(C(C(C(C(C(C(C(C(Br)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB02619,,Bromo-Dodecanol,,small molecule,,,,,
O(C(=O)C(=O)N(C1=C(C(O[H])=O)C([H])=C([H])C([H])=C1[H])[H])[H],DB02622,,2-(Oxalyl-Amino)-Benzoic Acid,,small molecule,,,,,
O(B(O[H])C1=C([H])C([H])=C(C2=C([H])C([H])=C(B(O[H])O[H])C([H])=C2[H])C([H])=C1[H])[H],DB02627,,"4,4'-Biphenyldiboronic Acid",,small molecule,,,,,
N(C1=C2C(=O)C3=C(C(=O)C2=C(N(C2=C([H])C(S(O[H])(=O)=O)=C(N(C4=NC(N(C5=C(S(O[H])(=O)=O)C([H])=C([H])C([H])=C5[H])[H])=NC(Cl)=N4)[H])C([H])=C2[H])[H])C([H])=C1S(O[H])(=O)=O)C([H])=C([H])C([H])=C3[H])([H])[H],DB02633,84166-13-2,Cibacron Blue,,small molecule,,,,,
C(OC1=C2C(=C(C3=C(C(O[H])=O)C([H])=C4OC(OC4=C3C2=C([H])C([H])=C1O[H])([H])[H])[N+]([O-])=O)[H])([H])([H])[H],DB02636,,"9-Hydroxy-8-Methoxy-6-Nitro-Phenanthrol[3,4-D][1,3]Dioxole-5-Carboxylic Acid",,small molecule,,,,,
O(C(=O)C(=O)C(C([O-])=O)([H])[H])[H],DB02637,,Oxaloacetate Ion,,small molecule,,,,,
C(C(C(C(C(C(C(N([H])[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02641,628-62-6,Heptanamide,,small molecule,,,,,
O(P(O[H])(=O)C(N(C(=O)OC(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H])([H])[H])[H],DB02642,,[[N-(Benzyloxycarbonyl)Amino]Methyl]Phosphate,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C([N+](C([H])([H])[H])(C([H])([H])[H])C(C(C(S(O[H])(=O)=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02643,,"N-Dodecyl-N,N-Dimethyl-3-Ammonio-1-Propanesulfonate",,small molecule,,,,,
C(C(N=O)([H])[H])([H])([H])[H],DB02646,925-91-7,Nitrosoethane,,small molecule,,,,,
O=C(N(C1=C([H])C(C2(C([H])([H])C2([H])[H])[H])=NN1[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H],DB02647,,N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide,,small molecule,,,,,
N(C(=O)C(C(O[H])=O)([H])[H])([H])[H],DB02649,2345-56-4,3-Amino-3-Oxopropanoic Acid,,small molecule,,,,,
ClC(Cl)(Cl)C(=O)[H],DB02650,,Tri-Chloro-Acetaldehyde,,small molecule,,,,,
O(P(O[H])(=O)C(F)(F)C1=C([H])C([H])=C(C(C(C(C2=C([H])C([H])=C(C(F)(F)P(O[H])(O[H])=O)C([H])=C2[H])([H])[H])(N2N=NC3=C2C(=C(C(=C3[H])[H])[H])[H])C2=C([H])C(F)=C(F)C([H])=C2[H])([H])[H])C([H])=C1[H])[H],DB02651,,"{[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid)",,small molecule,,,,,
O=C1C([H])=C(N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])OC2=C1C(=C(C(=C2C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H])[H],DB02656,154447-36-6,LY-294002,2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one,small molecule,,,,,
C(OC1=C(OC2(C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])C([H])=C(C(C([H])([H])[H])=NOC(N([H])[H])=O)C([H])=C1[H])([H])([H])[H],DB02660,141184-34-1,Filaminast,,small molecule,,,,,
O(C(=O)C(=O)N(C1=C(C(O[H])=O)C([H])=C(I)C([H])=C1[H])[H])[H],DB02662,,Novo Nordisk a/S Compound,,small molecule,,,,,
C(C(C(C(B(O[H])O[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02664,,1-Butane Boronic Acid,,small molecule,,,,,
C(N1C([H])=C([H])[N+]([H])=C1[H])([H])([H])[H],DB02671,616-47-7,1-Methylimidazole,,small molecule,,,,,
O(C(C(C(O[H])([H])[H])(C(O[H])([H])[H])N(C(C(C(N(C(C(O[H])([H])[H])(C(O[H])([H])[H])C(O[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])[H],DB02676,,"2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol",,small molecule,,,,,
N(C#N)([H])[H],DB02679,420-04-2,Cyanamide,,small molecule,,,,,
[O-][N+](=O)C1=C([H])C([N+]([O-])=O)=C([H])C([H])=C1[H],DB02680,,Dinitrophenylene,,small molecule,,,,,
[O-][V](=O)[O+]([V](=O)O[V](=O)(=O)O[V](=O)(=O)[O+]([V]([O-])=O)[V](=O)(=O)=O)[V](=O)(=O)=O,DB02681,,Meta Vanadate,,small molecule,,,,,
N(C(=C([H])[H])C(O[H])=O)([H])[H],DB02688,1948-56-7,"2,3-Didehydroalanine",,small molecule,,,,,
C(C1=NC2=C(C(=C(C(=C2O[H])[H])[H])[H])C(=O)N1[H])([H])([H])[H],DB02690,90417-38-2,NU1025,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C([H])C2=C1OC1=C(N2C2=C([H])C([H])=C([H])C(C(F)(F)F)=C2[H])C([H])=C([H])C([H])=C1C(O[H])=O)[H],DB02698,,"N-(M-Trifluoromethylphenyl) Phenoxazine-4,6-Dicarboxylic Acid",,small molecule,,,,,
C(C(=C(C(O[H])([H])[H])[H])C(=C(C(=C(C([H])([H])[H])C(=C(C1=C(C([H])([H])[H])C(=O)C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H])[H])[H])[H])[H])[H])([H])([H])[H],DB02699,62702-55-0,4-Oxoretinol,,small molecule,,,,,
N(C(=O)C1=C([H])N=C([H])C([H])=C1[H])([H])[H],DB02701,98-92-0,Nicotinamide,"Niacinamide
Nicotinic amide",small molecule,,"Cream
Cream
Liquid
Patch
Cream
Liquid
Liquid
Liquid
Cream
Patch
Elixir
Tablet, extended release
Injection
Injection, solution
Cream
Cream
Cream
Powder, for solution
Powder, for solution
Liquid
Granule
Patch
Liquid
Liquid
Powder
Emulsion
Liquid
Patch
Gel
Solution
Cream
Liquid
Emulsion
Solution
Patch
Shampoo
Shampoo
Liquid
Patch
Solution
Shampoo
Kit
Cream
Kit
Cream
Patch
Tablet, effervescent
Kit
Capsule, gelatin coated
Liquid
Liquid
Patch
Cream
Emulsion
Solution / drops
Liquid
Cream
Solution
Patch
Patch
Gel
Solution / drops
Injection, solution
Lotion
Gel
Cream
Liquid
Liquid
Patch
Tablet, chewable
Lotion
Kit
Liquid
Injection, powder, lyophilized, for solution
Patch
Cream
Cream
Cream
Cream
Cream
Cream
Cream
Emulsion
Liquid
Patch
Liquid; tablet
Gel
Liquid
Injection, solution, concentrate
Solution
Solution
Solution
Spray
Gel
Tablet
Tablet, extended release
Liquid
Tablet
Tablet
Tablet
Cream
Syrup
Capsule, liquid filled
Shampoo
Tablet, film coated
Tablet, coated
Emulsion
Gel
Oil
Solution
Solution
Cream
Patch
Liquid
Cream
Patch
Cream
Cream
Cream
Lotion
Gel
Liquid
Kit
Capsule, extended release
Capsule
Cream
Capsule; liquid
Shampoo
Liquid
Pellet
Cream
Cream
Cream
Cream
Cream
Cream
Cream
Lozenge
Liquid
Capsule
Powder
Injection
Injection
Cream
Liquid
Gel
Liquid
Cream
Cream
Liquid","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Oral
Intramuscular
Intramuscular; Intravenous
Topical
Topical
Topical
Intramuscular; Intravenous
Intravenous
Topical
Oral
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Oral
Topical
Intramuscular; Intravenous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Intravenous
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Intravenous
Intravenous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Oral
Intravenous
Intravenous
Oral
Intramuscular; Intravenous
Topical
Topical
Oral
Oral
Intramuscular; Intravenous
Oral
Oral
Oral
Topical
Oral
Oral
Topical
Oral
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Oral
Oral
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Oral
Topical
Intramuscular; Intravenous
Intravenous
Topical
Topical
Topical
Topical
Topical
Topical
Topical","1 g/50mL
.6 g/30mL
2.4 g/120mL
.54 g/27mL
.6 g/50mL
.6 g/30g
60 mg/30mL
2 g/100mL
1.1 g/55g
.4 g/20g
3.5 g/50mL
.02 g/55mL
2 mL/100mL
2 mg/100mL
.5 mg/25mL
2 g/50mL
.3 g/100mL
3 g/150mL
3 g/150mL
.46 g/31
.3 g/21
.05 g/51
.4 g/20mL
3.2 g/160mL
2.8 g/140mL
.1 g/5mL
.46 g/23mL
1.08 g/360g
1.2 mg/400mL
2 g/100g
.6 mg/51
.1 mg/201
.51 mg/510mL
2.14 g/100g
2 g/100mL
.5 g/25g
3.6 g/180mL
.44 g/22g
1.2 g/60mL
2.4 mg/120mL
2.4 mg/120mL
2 g/50g
2.85 mg/150mL
.59 g/27g
.5 g/25mL
2.4 g/120g
2 g/mL
2 g/mL
4 mg/200mL
.03 g/1.5mL
.002 g/25mL
.2 mg/10g
4.6 mg/23mL
.06 g/3g
.6 g/30g
.012 g/30g
2.8 g/140mL
1.4 g/70g
2.6 g/130mL
2.6 g/130mL
.6 g/101
5 mg/100mL
.16 g/160g
500 mg
500 mg
100 mg
100 mg
50 mg
.54 g/27g
.02 1/120mL
.4 mg/20mL
.5 mg/25mL
2.1 g/100g
.3 mg/15mL
.2 g/10g
2 g/100g
.1 g/100g
2 g/100g
2 g/100g
.02 mL/mL
1.1 g/55mL
.3 mL/100mL
.3 mL/100mL
.3 g/100g
1 g/50g
1.2 g/60g
1 mg/50mL
.7 g/35mL
2.4 g/120mL
.4 mg/20mL
.9 mg/45mL
.4 mg/20mL
500 mg
1.5 g/75g
1 g/50mL
2 g/100mL
2.8 g/140mL
3 g/150mL
2 g/40mL
3 g/100mL",
O(C1=C([H])C([H])=C(C(=C(C2=C([H])C(O[H])=C([H])C(O[H])=C2[H])[H])[H])C([H])=C1[H])[H],DB02709,501-36-0,Resveratrol,"(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
(E)-resveratrol
3,4',5-trihydroxy-trans-stilbene
3,4',5-trihydroxystilbene
3,5,4'-trihydroxystilbene
5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol
trans-resveratrol",small molecule,Humans and other mammals,Capsule,Oral,,Being investigated for the treatment of Herpes labialis infections (cold sores).
C(C(=O)N(C(C(O[H])=O)([H])[H])[H])([H])([H])[H],DB02713,543-24-8,Acetylamino-Acetic Acid,,small molecule,,,,,
IC1=C([H])N([H])N=C1[H],DB02721,3469-69-0,4-Iodopyrazole,,small molecule,,,,,
O(C(=O)C(OP(O[H])(O[H])=O)([H])[H])[H],"DB02726
DB02389",13147-57-4,2-Phosphoglycolic Acid,,small molecule,,,,,
C(C(C(C(N(C(=N[H])N(O[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02727,,N-Butyl-N'-Hydroxyguanidine,,small molecule,,,,,
C(C(OC(=O)C1=C([H])C2=C(C(=C(O[H])C(=C2[H])[H])[H])OC1=O)([H])[H])([H])([H])[H],DB02728,,7-Hydroxy-2-Oxo-Chromene-3-Carboxylic Acid Ethyl Ester,,small molecule,,,,,
C(C([Hg]SC1=C(C(O[H])=O)C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB02731,148-61-8,Ethylmercurithiosalicylic acid,"[(o-carboxyphenyl)thio]ethylmercury
2-(ethylmercuri-thio)-benzoic acid
2-(ethylmercuriothio)benzoic acid",small molecule,,,,,
C(C(N([H])[H])=O)([H])([H])[H],DB02736,60-35-5,Acetamide,,small molecule,,,,,
O(C(=O)C(C(C(C1=C([H])N([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])[H],DB02740,133-32-4,3-Indolebutyric Acid,,small molecule,,,,,
C(C1(C([H])([H])[H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C2=C1C(=C(C(=C2[H])C(=O)C1=C([H])C([H])=C2C(=C(C(=C([H])C2=C1[H])[H])C(O[H])=O)[H])[H])[H])([H])([H])[H],DB02741,,CD564,,small molecule,,,,,
O(C(=O)C1=C(C(O[H])=O)C([H])=C([H])C([H])=C1[H])[H],DB02746,88-99-3,Phthalic Acid,,small molecule,,,,,
O(C(=O)C1=C([H])C(C(O[H])=O)=C(C(O[H])=O)C([H])=C1C(O[H])=O)[H],DB02749,89-05-4,Pyromellitic Acid,,small molecule,,,,,
N(C(=N[H])N(C(C(O[H])=O)([H])[H])[H])([H])[H],DB02751,352-97-6,Glycocyamine,"Amidinoglycine
Betacyamine
Guanidineacetic acid
Guanidoacetic acid
Guanyl glycine
N-(aminoiminomethyl)glycine
N-amidinoglycine",small molecule,,,,,
C(C(C(C(N1C(C(C2=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C(OC([H])([H])[H])=C2[H])([H])[H])=NC2=C1N=C(N=C2N([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02754,,"9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine",,small molecule,,,,,
O=C1C([H])([H])C([H])([H])C2=C3C(=C(C(=C2[H])[H])[H])C(C([H])([H])N13)([H])[H],DB02756,,"1,2,5,6-Tetrahydro-4h-Pyrrolo(3,2,1-Ij)Quinolin-4-One",,small molecule,,,,,
N1(C([H])=C([H])C([H])=N1)[H],DB02757,288-13-1,Pyrazole,"1,2-Diazole",small molecule,,,,,
O(C(=O)C(C(C1=C([H])N([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])[H],DB02758,,Indolylpropionic Acid,,small molecule,,,,,
O(P(O[H])(=O)OC1=C([H])C([H])=C([H])C2=C(C(=C(N=C12)C#N)[H])[H])[H],DB02762,,RU79072,,small molecule,,,,,
O(C(=O)C1=C([N+]([O-])=O)C([H])=C([H])C(S[H])=C1[H])[H],DB02763,15139-21-6,5-Mercapto-2-Nitro-Benzoic Acid,,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])OC(=O)[H])([H])([H])[H],DB02768,,Tert-Butyloxycarbonyl Group,,small molecule,,,,,
C(C(C(OC1=C(Cl)C([H])=C(C(C(O[H])=O)([H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB02773,,(3-Chloro-4-Propoxy-Phenyl)-Acetic Acid,,small molecule,,,,,
O(C(C(C(O[H])([H])[H])([H])[H])([H])[H])[H],DB02774,,"1,3-Propandiol",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(S(O[H])(=O)=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02776,15015-81-3,1-Hexadecanosulfonic Acid,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C([N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02779,,Dodecane-Trimethylamine,,small molecule,,,,,
C(SC(C(C(=O)C1=NC(=C(C2=C([H])C([H])=C([O-])C([H])=C2[H])[H])C(=O)N1C(C(=O)[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02781,,"4-{(Z)-[2-[3-(Methylsulfanyl)Propanoyl]-5-Oxo-1-(2-Oxoethyl)-1,5-Dihydro-4h-Imidazol-4-Ylidene]Methyl}Benzenolate",,small molecule,,,,,
C(C1=C(O[H])C(C(N(OC(C(O[H])=O)([H])[H])[H])([H])[H])=C(C(OP(O[H])(O[H])=O)([H])[H])C([H])=N1)([H])([H])[H],DB02783,,4'-Deoxy-4'-Acetylyamino-Pyridoxal-5'-Phosphate,,small molecule,,,,,
C(OC1=C([H])C([H])=C(C(O[H])=O)C([H])=C1[H])([H])([H])[H],DB02795,100-09-4,P-Anisic Acid,,small molecule,,,,,
O(B(O[H])C1=C([H])C([H])=C([H])C([N+]([O-])=O)=C1[H])[H],DB02797,13331-27-6,3-Nitrophenylboronic Acid,,small molecule,,,,,
C(C(N(C(C([H])([H])[H])([H])[H])C1=C([H])C2=C(C(=C(C(=O)N(C(=C(N3C(=O)C([H])([H])C([H])([H])C3=O)[H])[H])[H])C(=O)O2)[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB02799,,N-[2-(1-Maleimidyl)Ethyl]-7-Diethylaminocoumarin-3-Carboxamide,,small molecule,,,,,
C(OC(C(O[H])([H])[H])([H])[H])([H])([H])[H],DB02806,109-86-4,2-Methoxyethanol,,small molecule,,,,,
N(C(=O)C(N(C(C(O[H])=O)([H])[H])C(C(O[H])=O)([H])[H])([H])[H])([H])[H],DB02810,26239-55-4,N-(2-Acetamido)Iminodiacetic Acid,,small molecule,,,,,
C(C(OP(=O)(OC(C([H])([H])[H])([H])[H])[H])([H])[H])([H])([H])[H],DB02811,,Diethylphosphono Group,,small molecule,,,,,
O(C(C1=C([H])C([H])=C(Br)C([H])=C1[H])([H])[H])[H],DB02822,873-75-6,Para-Bromobenzyl Alcohol,,small molecule,,,,,
O(C(=O)C(P(O[H])(O[H])=O)([H])[H])[H],DB02823,4408-78-0,Phosphonoacetic Acid,,small molecule,,,,,
C(C1=C(O[H])C(C(N(C(C(O[H])=O)([H])[H])[H])([H])[H])=C(C(OP(O[H])(O[H])=O)([H])[H])C([H])=N1)([H])([H])[H],DB02824,,N-Pyridoxyl-Glycine-5-Monophosphate,,small molecule,,,,,
O(C(=O)C(C(C(=O)C(F)([H])[H])([H])[H])([H])[H])[H],DB02828,76385-49-4,5-Fluorolevulinic Acid,,small molecule,,,,,
C(C(=O)N(C1=C(N(C(=O)C([N+]([H])([H])[H])([H])[H])[H])C([H])=C(C(O[H])=O)C([H])=C1[H])[H])([H])([H])[H],DB02829,,4-(Acetylamino)-3-[(Aminoacetyl)Amino]Benzoic Acid,,small molecule,,,,,
C(C1=C(C2=NC(N(C3=C([H])C([N+]([O-])=O)=C([H])C([H])=C3[H])[H])=NC([H])=C2[H])SC(N([H])[H])=N1)([H])([H])[H],DB02833,,[4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine,,small molecule,,,,,
O(C(=O)C(OC1=C(C(=O)N(C(C2=NC3=C(F)C(F)=C(C(F)=C3S2)[H])([H])[H])[H])C([H])=C([H])C(F)=C1[H])([H])[H])[H],DB02834,,IDD552,,small molecule,,,,,
O(C(=O)C1=NC([H])([H])C([H])([H])C1([H])[H])[H],DB02838,,"3,4-Dihydro-2h-Pyrrolium-5-Carboxylate",,small molecule,,,,,
O(C(=O)C1=C(O[H])C([H])=C(O[H])C([H])=C1[H])[H],DB02839,89-86-1,"2,4-Dihydroxybenzoic Acid",,small molecule,,,,,
C(C(C1=C([H])C(C2=NN([H])C(C(O[H])=O)=C2C2=C([H])C3=C(OC(O3)([H])[H])C([H])=C2[H])=C(O[H])C([H])=C1O[H])([H])[H])([H])([H])[H],DB02840,,"4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid",,small molecule,,,,,
C(C(OC1=C(C(=O)N(C(B(O[H])O[H])([H])[H])[H])C2=C(C(=C(C([H])=C2C([H])=C1[H])[H])[H])[H])([H])[H])([H])([H])[H],DB02841,,[(2-Ethoxy-1-Naphthoyl)Amino]Methylboronic Acid,,small molecule,,,,,
C(N(C([H])([H])[H])C(C(C(N(C(=O)C1=C([H])C([H])=C([H])C2=C(N([H])[H])C3=C([H])C([H])=C([H])C([H])=C3N=C12)[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02842,,9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide,9-amino-N-(3-dimethylaminopropyl)acridine-4-carboxamide,small molecule,,,,,
C(C(OC1=C(OC(C([H])([H])[H])([H])[H])C([H])=C2C(N(C3=C([H])C([H])=C([H])C(C4=C([H])SC(C(O[H])([H])[H])=N4)=C3[H])[H])=NC(=NC2=C1[H])[H])([H])[H])([H])([H])[H],DB02848,,"{4-[3-(6,7-Diethoxy-Quinazolin-4-Ylamino)-Phenyl]-Thiazol-2-Yl}-Methanol",,small molecule,,,,,
C(C1=C(O[H])C(C(N(C2(C([H])([H])C2([H])[H])C(O[H])=O)[H])([H])[H])=C(C(OP(O[H])(O[H])=O)([H])[H])C([H])=N1)([H])([H])[H],DB02849,,N-Pyridoxyl-1-Amino-Cyclopropanecarboxylic Acid-5-Monophosphate,,small molecule,,,,,
C(OC1=C([H])C([H])=C(C2=C(S(C([H])([H])[H])(=O)=O)C([H])=C([H])C(C(=O)C3=C(O[H])N(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])N=C3[H])=C2C([H])([H])[H])C([H])=C1[H])([H])([H])[H],DB02850,,(1-Tert-Butyl-5-Hydroxy-1h-Pyrazol-4-Yl)-(6-Methanesulfonyl-4'-Methoxy-2-Methyl-Biphenyl-3-Yl)-Methanone,,small molecule,,,,,
C(C(OC(=O)N(C([H])([H])[H])[H])([H])[H])([H])([H])[H],DB02856,,Methyl-Carbamic Acid Ethyl Ester,,small molecule,,,,,
O(B(O[H])C1=C([H])C([H])=C([H])C(N(S(=O)(=O)C2=C([H])C(S(=O)(=O)C3=C([H])C([H])=C([H])C([H])=C3[H])=C([H])S2)[H])=C1[H])[H],DB02858,,3-(4-Benzenesulfonyl-Thiophene-2-Sulfonylamino)-Phenylboronic Acid,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(C(=O)N(C(C2=C([H])C(F)=C(F)C(F)=C2[H])([H])[H])[H])C([H])=C1[H])([H])[H],DB02861,,"4-(Aminosulfonyl)-N-[(3,4,5-Trifluorophenyl)Methyl]-Benzamide",,small molecule,,,,,
C(C1=C(C(=C([H])[H])[H])C(=C(C2=NC(=O)C(C(C(C(O[H])=O)([H])[H])([H])[H])=C2C([H])([H])[H])[H])N([H])C1=C(C1=C(C(=C([H])[H])[H])C(C([H])([H])[H])=C(C(=C2N=C(O[H])C(C(C(C(O[H])=O)([H])[H])([H])[H])=C2C([H])([H])[H])[H])N1[H])[H])([H])([H])[H],DB02864,,Biliverdin Ix Gamma Chromophore,,small molecule,,,,,
C(N(C([H])([H])[H])C1=C2C(=C(C(=C(S(N([H])[H])(=O)=O)C2=C([H])C([H])=C1[H])[H])[H])[H])([H])([H])[H],DB02866,,Dansylamide,,small molecule,,,,,
C(=C(C(N(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H])[H])([H])[H],DB02870,,N-Allyl-Aniline,,small molecule,,,,,
FC1=C([H])C(F)=C(C2=C([H])C(N3C([H])([H])C([H])([H])N([H])C([H])([H])C3([H])[H])=C([H])C3=C2C(N(C(=O)N3C2=C(Cl)C([H])=C([H])C([H])=C2Cl)[H])([H])[H])C([H])=C1[H],DB02873,,"1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One",,small molecule,,,,,
N(C(=N[H])C1=C([H])C2=C(N(C(=N2)C2=C(O[H])C([H])=C([H])C(F)=C2[H])[H])C([H])=C1[H])([H])[H],DB02875,,CRA_1802,,small molecule,,,,,
O(C(=N[H])C(=C(C(C(S(=O)(=O)[H])([H])[H])=C(N(C1=C(C(=O)[H])C([H])=C2C(=C(C(=C([H])N12)[H])[H])[H])[H])C(O[H])=O)[H])[H])[H],DB02876,,"3-(4-Carbamoyl-1-Carboxy-2-Methylsulfonyl-Buta-1,3-Dienylamino)-Indolizine-2-Carboxylic Acid",,small molecule,,,,,
C(C(=C(C1=C([H])C([H])=C(C(O[H])=O)C([H])=C1[H])[H])C1=C([H])C2=C(C(C([H])([H])[H])(C([H])([H])[H])C(C(C2(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB02877,71441-28-6,Arotinoid acid,"(E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylenyl)-1 -propenyl] benzoic acid
TTNPB",small molecule,Humans and other mammals,,,,
C(C(C([H])([H])[H])(C1=C(O[H])C([H])=C([H])C(SC2=C([H])C(C(C([H])([H])[H])(C([H])([H])[H])[H])=C(O[H])C([H])=C2[H])=C1[H])[H])([H])([H])[H],DB02881,,4-(4-Hydroxy-3-Isopropylphenylthio)-2-Isopropylphenol,,small molecule,,,,,
N(C(C1=C(N=C(C(=C(C2=C([H])C([H])=C([H])C([H])=C2[H])C2=C([H])C([H])=C([H])C([H])=C2[H])[H])[H])C2=C(C(=C(C([H])=C2N=N1)[H])[H])[H])([H])[H])([H])[H],DB02882,,Cyanocinnoline,,small molecule,,,,,
FC(F)(F)C1=NC(=N[H])C(=C([H])[H])C([H])=N1,DB02885,,4-Imino-5-Methidyl-2-Trifluoromethylpyrimidine,,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C2=C1N1C([H])=NN=C1S2)([H])([H])[H],DB02891,41814-78-2,Tricyclazole,"2,7,8,9-tricyclazole
5-methyl-1,2,4-triazolo(3,4-b)(1,3)benzothiazole
5-methyl-1,2,4-triazolo(3,4-b)benzothiazole
Beam
Tricyclazone",small molecule,,,,,
C(C(=O)OP(O[H])(O[H])=O)([H])([H])[H],DB02897,,Acetylphosphate,,small molecule,,,,,
N(C(=C(OP(O[H])(O[H])=O)[H])[H])([H])[H],DB02907,,2-Amino-Vinyl-Phosphate,,small molecule,,,,,
O(P(O[H])(=O)C(C1=C([H])C([H])=C([H])C([H])=C1[H])(P(O[H])(O[H])=O)[H])[H],DB02908,,RU78783,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C(C2=C(Cl)C([H])=C([H])C([H])=C2[H])O1)[H],DB02909,,5-(2-Chlorophenyl)Furan-2-Carboxylic Acid,,small molecule,,,,,
C(C(C(=C([H])[H])[H])=C(C(=C(C(C([H])([H])[H])=C(C(=C1C(C([H])([H])[H])=C([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H])[H])[H])[H])[H])[H])([H])([H])[H],DB02914,,"(6e)-6-[(2e,4e,6e)-3,7-Dimethylnona-2,4,6,8-Tetraenylidene]-1,5,5-Trimethylcyclohexene",,small molecule,,,,,
C(C1=NC(C([H])([H])[H])=C(C2=NC(N(C3=C([H])C([H])=C(C(F)(F)F)C([H])=C3[H])[H])=NC([H])=C2[H])S1)([H])([H])[H],DB02915,,"4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine",,small molecule,,,,,
C(N(C1=C([H])C([H])=C(C(=O)N(O[H])[H])C([H])=C1[H])S(=O)(=O)C1=C([H])C([H])=C(C2=NC([H])=C([H])C([H])=C2[H])S1)([H])([H])[H],DB02917,,N-Hydroxy-4-(Methyl{[5-(2-Pyridinyl)-2-Thienyl]Sulfonyl}Amino)Benzamide,,small molecule,,,,,
C(OC1=C(OC(F)(F)[H])C([H])=C([H])C(C2=NN([H])C(=O)C([H])=C2[H])=C1[H])([H])([H])[H],DB02918,,6-(4-Difluoromethoxy-3-Methoxy-Phenyl)-2h-Pyridazin-3-One,,small molecule,,,,,
C(OC1=C([H])C(C(N(C([H])([H])[H])C2=C([H])C3=C(N([H])[H])N=C(N([H])[H])N=C3N=C2[H])([H])[H])=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])([H])([H])[H],DB02919,,"2,4-Diamino-6-[N-(3',4',5'-Trimethoxybenzyl)-N-Methylamino]Pyrido[2,3-D]Pyrimidine",,small molecule,,,,,
C(C1=C(C(C(C(O[H])=O)([H])[H])([H])[H])C2N3[Zn]45N6C(C=2[H])=C(C(C(C(O[H])=O)([H])[H])([H])[H])C(C([H])([H])[H])=C6C(O[H])=C2C(C([H])([H])[H])=C(C(=C(C6=C(C([H])([H])[H])C(C(=C([H])[H])[H])=C(C([H])=C13)N64)[H])N52)C(=C([H])[H])[H])([H])([H])[H],DB02920,,Zn(Ii)-(20-Oxo-Protoporphyrin Ix),,small molecule,,,,,
O(C(O[H])(C(F)(F)F)C(F)(F)F)[H],DB02922,,Hexafluoroacetone Hydrate,,small molecule,,,,,
O(C1=C(O[H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])=C([H])C([H])=C1[H])[H],DB02923,1133-63-7,"Biphenyl-2,3-Diol",,small molecule,,,,,
N(S(=O)(=O)C1=C(OC2=C([H])C([H])=C([H])C([H])=C2[H])C(N2C([H])([H])C([H])([H])C([H])([H])C2([H])[H])=C([H])C(C(O[H])=O)=C1[H])([H])[H],DB02925,55837-27-9,Piretanide,,small molecule,,,,,
C(OC1=C([H])C2=C(SC(C(N(C2([H])[H])C(=O)C(C(N2C([H])([H])C([H])([H])C(C(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])([H])C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB02929,,K201,,small molecule,,,,,
C(OC(C(OC(C(OC([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02935,111-96-6,Diglyme,"2,2'-oxybis(1-methoxyethane)
2,2'-oxybis[1-(methyloxy)ethane]
2,5,8-trioxanonane
bis(2-methoxyethyl) ether
di(2-methoxyethyl) ether
diethylene glycol dimethyl ether",small molecule,,,,,
C(C1=C(C(C(N([H])[H])=O)([H])[H])C2=C(C(=C(C(OC(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])=C2[H])[H])[H])N1C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB02936,,4-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Butyric Acid,,small molecule,,,,,
C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02938,,Heptanoic Acid,,small molecule,,,,,
O(N(C(C(C(P(O[H])(O[H])=O)([H])[H])([H])[H])([H])[H])C(=O)[H])[H],DB02948,,Fosmidomycin,,small molecule,,,,,
O(C(C(=O)C(O[H])=O)([H])[H])[H],DB02951,1113-60-6,3-Hydroxypyruvic Acid,,small molecule,,,,,
C(C(C([H])([H])[H])(N([H])[H])C(O[H])=O)([H])([H])[H],DB02952,,Alpha-Aminoisobutyric Acid,,small molecule,,,,,
O(N(C(C(O[H])=O)([H])[H])C(O[H])=O)[H],DB02954,,(Carboxyhydroxyamino)Ethanoic Acid,,small molecule,,,,,
[S-]SSS[S-],DB02956,,Pentasulfide-Sulfur,,small molecule,,,,,
[N+](C(C1=C([H])C([H])=C(C(N(C(C(C(O[H])=O)([H])[H])([H])[H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB02960,,1-Carboxyethylaminomethyl-4-Aminomethylbenzene,,small molecule,,,,,
N1(C([H])=NC2=C1C(=C(C(=C2[H])[H])[H])[H])[H],DB02962,51-17-2,Benzimidazole,,small molecule,,,,,
C(S(=O)(=O)C1=C([H])C([H])=C(N(C2=C([H])C(Cl)=NC3=C(C(=NN23)[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB02963,,"(5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine",,small molecule,,,,,
C(C(N1C(=O)C([H])=C([H])C1=O)([H])[H])([H])([H])[H],DB02967,128-53-0,N-Ethylmaleimide,,small molecule,,,,,
C(C1=C(C(C(O[H])([H])[H])([H])[H])SC([H])=N1)([H])([H])[H],DB02969,,4-Methyl-5-Hydroxyethylthiazole,,small molecule,,,,,
C(C(C(C1=C(N([H])[H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB02970,,2-Propyl-Aniline,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(N=NC2=C3C(=C(Br)C(=C([H])C3=NC2=O)[H])[H])C([H])=C1[H])([H])[H],DB02973,,4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide,,small molecule,,,,,
ClC1=C([H])C([H])=C(C2=C([H])N=C([H])N2[H])C([H])=C1[H],DB02974,,4-(4-Chlorophenyl)Imidazole,,small molecule,,,,,
C(SC(N([H])[H])=NC(C(C(C(C(C(C(C(C(C(C(C(C(C(N=C(N([H])[H])SC([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02979,,"N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane",,small molecule,,,,,
C(C(C(C(=C(C(=C(C(C(C(C(C(C(C(C(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])[H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB02982,,Bombykol,,small molecule,,,,,
O(S(=O)(=O)C1=C([H])C([H])=C([Hg])C([H])=C1[H])[H],DB02983,,Para-Mercury-Benzenesulfonic Acid,,small molecule,,,,,
C(OC1=C(OC([H])([H])[H])C([H])=C2C(N(C3=C([H])C([H])=C([H])C(SC([H])([H])[H])=C3[H])[H])=NC(=NC2=C1[H])[H])([H])([H])[H],DB02984,,"4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline",,small molecule,,,,,
O(C1=NC(=N[H])N([H])C2=C1N=C(I)N2[H])[H],DB02985,,8-Iodo-Guanine,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(S(=O)(=O)N(C(C2=C([H])C([H])=C([H])S2)([H])[H])[H])S1)([H])[H],DB02986,,"N-(2-Thienylmethyl)-2,5-Thiophenedisulfonamide",,small molecule,,,,,
O(C(=O)C(=N[H])C(C1=C([H])N([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])[H],DB02988,,Imino-Tryptophan,,small molecule,,,,,
C(C(C([H])([H])[H])(C(OC1=C([H])C([H])=C([H])C(C2=NC3=C(C(C(N([H])[H])=N[H])=C(Cl)C([H])=C3N2[H])[H])=C1O[H])([H])[H])[H])([H])([H])[H],DB02989,,CRA_10972,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(=O)SC(C(N(C(C([H])([H])[H])=O)[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB02990,,C16-Fatty-Acyl-Substrate-Mimic,,small molecule,,,,,
C(C(SC(N([H])[H])=NC1=C([H])C([H])=C(C(F)(F)F)C([H])=C1[H])([H])[H])([H])([H])[H],DB02991,,S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea,,small molecule,,,,,
C(C1=NC2=C(N=C(N([H])[H])N(C2=O)[H])O1)([H])([H])[H],DB02993,,8-Methyl-9-Oxoguanine,,small molecule,,,,,
C([As](C([H])([H])[H])(O[H])=O)([H])([H])[H],DB02994,75-60-5,Cacodylic acid,"Dimethylarsenic acid
Dimethylarsinic acid
Hydroxydimethylarsine oxide",small molecule,,,,,
[N+](C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])([H])([H])[H],DB02995,,Cyclohexylammonium Ion,,small molecule,,,,,
O(C1=C([H])C([H])=C(I)C([H])=C1[H])[H],DB03002,540-38-5,p-Iodophenol,4-iodophenol,small molecule,,,,,
N(C1=C([H])C([H])=C2C3=C([H])C([H])=C(N([H])[H])C([H])=C3[N+](C(C(C(C(C(C(C3=C([H])N=NN3C(C(N(C3=C4C(C(C(C([H])([H])C4=NC4=C(C(=C(C([H])=C34)[H])[H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])=C(C3=C([H])C([H])=C([H])C([H])=C3[H])C2=C1[H])([H])[H],DB03005,,"3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-5-Yl]Hexyl]-Phenanthridinium",,small molecule,,,,,
N(C1=C([H])C([H])=C([As](O[H])(O[H])=O)C([H])=C1[H])([H])[H],DB03006,98-50-0,Arsanilic acid,"(p-aminophenyl)arsonic acid
4-aminobenzenearsonic acid
4-Aminophenylarsonic acid
4-Aminophenylarsons��ure
4-arsanilic acid
Arsanils��ure
atoxylic acid
p-arsanilic acid",small molecule,,,,,
O(C1=C([H])C(C(F)(F)F)=NC(SC(C(=O)N2C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])([H])[H])=N1)[H],DB03009,,2-[(2-Oxo-2-Piperidin-1-Ylethyl)Thio]-6-(Trifluoromethyl)Pyrimidin-4(1h)-One,,small molecule,,,,,
N(C(=N[H])C1=C([H])C2=C(N=C(N2[H])C2=C(O[H])C([H])=C([H])C([H])=N2)C([H])=C1[H])([H])[H],DB03016,,CRA_1801,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03017,143-07-7,Lauric Acid,"1-Undecanecarboxylic acid
ABL
C12 fatty acid
C12:0
Coconut oil fatty acids
DAO
Dodecanoate
Dodecanoic acid
Dodecoic acid
Dodecylcarboxylate
Dodecylic acid
Duodecyclic acid
Duodecylic acid
Laurins��ure
Laurostearic acid
N-dodecanoate
N-dodecanoic acid
Undecane-1-carboxylic acid
Vulvic acid",small molecule,,"Capsule, liquid filled",Oral,,
C(C1=C(C([H])([H])[H])C([H])=C(N([H])[H])C([H])=C1[H])([H])([H])[H],DB03018,,"3,4-Dimethylaniline",,small molecule,,,,,
N(C1=NC([H])=C([H])C(C2=C(Cl)SC(Cl)=C2[H])=N1)([H])[H],DB03019,,"4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine",,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])N1[N+]([H])=C(C2=C([H])C([H])=C(Cl)C([H])=C2[H])C2=C(N([H])[H])N=C(N=C12)[H])([H])([H])[H],DB03023,,"1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine",,small molecule,,,,,
O(N(C(=O)C(OP(O[H])(O[H])=O)([H])[H])[H])[H],DB03026,51528-59-7,Phosphoglycolohydroxamic Acid,,small molecule,,,,,
O(C(=O)C1=NC2=C(C(=C(C(=C2[H])[H])[H])[H])N1[H])[H],DB03028,,1h-Benoximidazole-2-Carboxylic Acid,,small molecule,,,,,
C(C1=C([H])C([H])=C(C(N2C([H])=NC(C3=C([H])C([H])=C([H])S3)=C2[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB03030,,4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole,,small molecule,,,,,
C(OC1=C([H])C([H])=C(S(=O)(=O)[H])C([H])=C1[H])([H])([H])[H],DB03033,,1-Methyloxy-4-Sulfone-Benzene,,small molecule,,,,,
O(C1=C([H])C([H])=C([H])C2=C1C(=O)C1=C(O[H])C([H])=C([H])C([N+]([O-])=O)=C1C2=O)[H],DB03035,,"1,8-Di-Hydroxy-4-Nitro-Anthraquinone",,small molecule,,,,,
O(C(=O)C(C1=C([H])C([H])=C2C(=O)C3=C([H])C([H])=C([H])C(O[H])=C3C(=O)C2=C1O[H])([H])[H])[H],DB03037,,Oxidized Acetyl Dithranol,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(C(=O)N(C(C2=C(F)C([H])=C([H])C(F)=C2[H])([H])[H])[H])C([H])=C1[H])([H])[H],DB03039,,"4-(Aminosulfonyl)-N-[(2,5-Difluorophenyl)Methyl]-Benzamide",,small molecule,,,,,
O(C(=O)C(N(C(C(O[H])=O)([H])[H])C(C(O[H])=O)([H])[H])([H])[H])[H],DB03040,,Nitrilotriacetic Acid,,small molecule,,,,,
C(C1=C([H])C([H])=C(N2N=C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C([H])=C2N(C(=O)N(C2=C([H])C([H])=C(OC(C(N3C([H])([H])C([H])([H])OC([H])([H])C3([H])[H])([H])[H])([H])[H])C3=C(C(=C(C([H])=C23)[H])[H])[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB03044,,1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea,,small molecule,,,,,
C(OC1=C(C2=C([H])N(S(C([H])([H])[H])(=O)=O)N=C2[H])C2=C(C(=C(C([H])=C2C([H])=C1[H])[H])C(N([H])[H])=N[H])[H])([H])([H])[H],DB03046,,7-Methoxy-8-[1-(Methylsulfonyl)-1h-Pyrazol-4-Yl]Naphthalene-2-Carboximidamide,,small molecule,,,,,
O(C(=O)C(C1=C([H])C(=O)N([H])C(=O)N1[H])([H])[H])[H],DB03048,,6-Carboxymethyluracil,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C(OC(C(N2C([H])=C([H])N=C2[H])([H])[H])([H])[H])C([H])=C1[H])[H],DB03052,,Dazoxiben,"Benzoic acid, 4-(2-(1H-imidazol-1-yl)ethoxy)-
Dazoxiben
Dazoxibene
Dazoxibenum",small molecule,,,,,
BrC(Br)(Br)[H],DB03054,75-25-2,Bromoform,"Tribrommethan
Tribromomethane",small molecule,,,,,
C1(C([H])([H])C([H])([H])N(C2(C([H])([H])C([H])([H])N([H])C([H])([H])C2([H])[H])[H])C([H])([H])C1([H])[H])([H])[H],DB03056,,4-Piperidino-Piperidine,,small molecule,,,,,
O=C(C(C(=O)[H])([H])[H])[H],DB03057,,Malonaldehyde,,small molecule,,,,,
N(C1=C(C(O[H])([H])[H])C([H])=C([H])C([H])=C1[H])([H])[H],DB03058,5344-90-1,2-Aminobenzyl alcohol,"2-Aminobenzenemethanol
2-Aminobenzyl alcohol
o-(Hydroxymethyl)aniline
o-Aminobenzyl alcohol
o-Aminobenzylic alcohol",small molecule,,,,,
C(OC1=C([H])C(C(=C(C2=C(C([H])([H])[H])C3=C(N([H])[H])N=C(N([H])[H])N=C3N=C2[H])[H])[H])=C(OC([H])([H])[H])C([H])=C1[H])([H])([H])[H],DB03060,,Sri-9662,,small molecule,,,,,
C(N1C([H])=C([H])N=C1C(=O)C1=C(C([H])([H])[H])C2=C(C(=C(C(=C2OC(C(C(N(C(C2=C([H])N=C([H])C([H])=C2[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])[H])[H])[H])O1)([H])([H])[H],DB03062,,(1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C1=C(O[H])C(=O)N([H])C1=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03064,,"3-Decyl-2,5-Dioxo-4-Hydroxy-3-Pyrroline",,small molecule,,,,,
N(C(=N[H])N1C([H])=C2C(=C(C(=C([N+]([O-])=O)C2=N1)[H])[H])[H])([H])[H],DB03065,,7-Nitroindazole-2-Carboxamidine,,small molecule,,,,,
O(C(=O)C1=C(C(O[H])=O)C([H])=C(OC2=C(N(C(=O)C3=C([H])C([H])=C([H])C([N+]([O-])=O)=C3[H])[H])C([H])=C(N(C(=O)C3=C([H])C([N+]([O-])=O)=C([H])C([H])=C3[H])[H])C([H])=C2[H])C([H])=C1[H])[H],DB03067,,"4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid",,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C2=C1N=C(C(C(C(N1C([H])([H])C([H])([H])C(C3=C([H])C([H])=C(F)C([H])=C3[H])=C([H])C1([H])[H])([H])[H])([H])[H])([H])[H])N(C2=O)[H])([H])([H])[H],DB03072,,"2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone",,small molecule,,,,,
C(OC1=C([H])C([H])=C([H])C(C(N([H])[H])=O)=C1[H])([H])([H])[H],DB03073,,3-Methoxybenzamide,,small molecule,,,,,
O(C1=NC(=N[H])N([H])C2=C1C(=C(N2[H])[H])C#N)[H],DB03074,,7-Deaza-7-Cyano-Guanine,,small molecule,,,,,
C(C(C(OC(C(OC(C(OC(C(C(N(C1=C(N([H])[H])C(=O)C1=O)[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03077,,"3-Amino-4-{3-[2-(2-Propoxy-Ethoxy)-Ethoxy]-Propylamino}-Cyclobut-3-Ene-1,2-Dione",,small molecule,,,,,
N(C(C1=C([H])C([H])=C(N(C(=O)C2=C([H])C3=C(C(=C(C([H])=C3C(N(C3=NC([H])=C([H])C([H])=N3)[H])=C2[H])C(N([H])[H])=N[H])[H])[H])[H])C([H])=C1[H])([H])[H])([H])[H],DB03082,,6-[(Z)-Amino(Imino)Methyl]-N-[4-(Aminomethyl)Phenyl]-4-(Pyrimidin-2-Ylamino)-2-Naphthamide,,small molecule,,,,,
C(OC1=C([H])C(OC([H])([H])[H])=C(C(=C2C(=O)N([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])[H])C(OC([H])([H])[H])=C1[H])([H])([H])[H],DB03083,,IC261,,small molecule,,,,,
C(C(C(N1C(C2(C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C2([H])[H])[H])=NC(C2=C([H])C(Cl)=C(Cl)C([H])=C2[H])=C1C1=NC(N(C2(C([H])([H])C2([H])[H])[H])[H])=NC([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB03084,,"Cyclopropyl-{4-[5-(3,4-Dichlorophenyl)-2-[(1-Methyl)-Piperidin]-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine",,small molecule,,,,,
O(C(C(O[H])=O)([H])[H])[H],"DB03085
DB11307",79-14-1,Glycolic acid,"2-Hydroxyacetic acid
2-Hydroxyethanoic acid
alpha-Hydroxyacetic acid
Glycollic acid
Hydroxyacetic Acid
Hydroxyethanoic Acid
��-hydroxyacetic acid",small molecule,,"Liquid
Liquid","Topical
Topical",3 g/30mL,
C(OC1=C([H])C(C(C2=NC3=NC(F)=NC(N([H])[H])=C3N2[H])([H])[H])=C(OC([H])([H])[H])C([H])=C1[H])([H])([H])[H],DB03093,,"8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine",,small molecule,,,,,
C([N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])([H])([H])[H],DB03095,,Tetramethylammonium Ion,,small molecule,,,,,
N(C(C(N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H])([H])[H])([H])[H])([H])[H],DB03096,,N-Aminoethylmorpholine,,small molecule,,,,,
C(C1=C(O[H])C(C(N(C2=C([H])ON=C2O[H])[H])([H])[H])=C(C(OP(O[H])(O[H])=O)([H])[H])C([H])=N1)([H])([H])[H],DB03097,,"Pmp-Hydroxyisoxazole, Pyridoxamine-5-Phosphate-Hydroxyisoxazole",,small molecule,,,,,
C([Se]C(C([O-])=O)([H])[H])([H])([H])[H],DB03098,,[Methylseleno]Acetate,,small molecule,,,,,
N(C1=C([N+]([O-])=O)N([H])C(=O)N([H])C1=O)([H])[H],DB03099,,5-Amino 6-Nitro Uracil,,small molecule,,,,,
[O-][N+](=O)C1=C([H])C2=NN(C([H])=C2C([H])=C1[H])[H],DB03100,,6-Nitroindazole,,small molecule,,,,,
O(C(=O)C(=O)N(C1=C(C(O[H])=O)C2=C(C(OC(C2([H])[H])([H])[H])([H])[H])S1)[H])[H],DB03102,,"2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid",,small molecule,,,,,
N(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H],DB03107,107-95-9,Beta-Alanine,,small molecule,,,,,
O(C1=C(Cl)C([H])=C([H])C([H])=C1[H])[H],DB03110,,2-Chlorophenol,,small molecule,,,,,
O(C(=C(C(=O)C1=C([H])N([H])C2=C1C(=C(Cl)C(=C2[H])[H])[H])[H])C1=NN([H])N=N1)[H],DB03118,,1-(5-Chloroindol-3-Yl)-3-Hydroxy-3-(2h-Tetrazol-5-Yl)-Propenone,,small molecule,,,,,
C(C1=C([H])C([H])=C(S(O[H])(=O)=O)C([H])=C1[H])([H])([H])[H],DB03120,,Para-Toluene Sulfonate,,small molecule,,,,,
C(OC1=C([H])C2=C(N(C(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])C(C([H])([H])[H])=C2C(C(O[H])=O)([H])[H])C([H])=C1[H])([H])([H])[H],DB03121,59283-35-1,(1-Benzyl-5-methoxy-2-methyl-1H-indol-3-yl)acetic acid,,small molecule,,,,,
C(OC1=C([H])C(C(C2=C(N([H])[H])N=C(N([H])[H])[N+]([H])=C2[H])([H])[H])=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])([H])([H])[H],DB03125,,"2,4-Diamino-5-(3,4,5-Trimethoxy-Benzyl)-Pyrimidin-1-Ium",,small molecule,,,,,
N(C(=[N+]([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H],DB03127,618-39-3,Benzamidine,,small molecule,,,,,
C(C(=O)OC(C([N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03128,51-84-3,Acetylcholine,Acetylcholine Chloride,small molecule,,"Kit
Powder, for solution
Powder, for solution","Ophthalmic
Intraocular","10 mg
20 mg","Used to obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid miosis may be required."
N(C(=[N+]([H])[H])N(C(C(C(OB1OC([H])([H])C([H])([H])O1)([H])[H])([H])[H])([H])[H])[H])([H])[H],DB03129,,"[3-(1,3,2-Dioxaborolan-2-Yloxy)Propyl]Guanidine",,small molecule,,,,,
O(S(=O)(=O)C(C(C(SC1=NC2=C(C(=C(C(=C2[H])[H])[H])[H])S1)([H])[H])([H])[H])([H])[H])[H],DB03132,,3-(2-Benzothiazolylthio)-1-Propanesulfonic Acid,,small molecule,,,,,
O(N(C(C(P(O[H])(O[H])=O)([H])[H])([H])[H])C(=O)[H])[H],DB03135,,[2(Formyl-Hydroxy-Amino)-Ethyl]-Phosphonic Acid,,small molecule,,,,,
N(C(=[N+]([H])[H])C1=C([H])C2=C(I)C(=C(C([H])=C2S1)[H])[H])([H])[H],DB03136,,4-Iodobenzo[B]Thiophene-2-Carboxamidine,,small molecule,,,,,
C(OC1=C([H])C(C(C2=NC3=C(N([H])[H])N=C(F)N=C3N2C(C(C(C#C[H])([H])[H])([H])[H])([H])[H])([H])[H])=C(OC([H])([H])[H])C([H])=C1[H])([H])([H])[H],DB03137,,"8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine",,small molecule,,,,,
O(B(O[H])C1=C([H])C([H])=C(C(O[H])=O)C([H])=C1[H])[H],DB03140,,4-Carboxyphenylboronic Acid,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03143,28473-21-4,Nonan-1-Ol,,small molecule,,,,,
C(C1=C(C(C(OP(O[H])(O[H])=O)([H])[H])([H])[H])SC([H])=N1)([H])([H])[H],DB03145,,4-Methyl-5-Hydroxyethylthiazole Phosphate,,small molecule,,,,,
[Cu]12S34[Cu]5[Cu]13[Cu]245,DB03151,,(Mu-4-Sulfido)-Tetra-Nuclear Copper Ion,,small molecule,,,,,
O(C1=NC([H])=NC2=C1N=NC2([H])[H])[H],DB03153,,"3h-Pyrazolo[4,3-D]Pyrimidin-7-Ol",,small molecule,,,,,
O(P(O[H])(=O)C(F)(F)C1=C([H])C2=C(C(=C(C([H])=C2C([H])=C1[H])[H])C(F)(F)P(O[H])(O[H])=O)[H])[H],DB03154,,{[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid,,small molecule,,,,,
N(C(=N[H])C1=C([H])C2=C(N(C(=C2[H])C2=C([H])C([H])=C([H])C(C3=C([H])C([H])=C([H])C([H])=C3[H])=C2O[H])[H])C([H])=C1[H])([H])[H],DB03159,,CRA_8696,,small molecule,,,,,
O(C(=O)C1=NSN=C1O[H])[H],DB03162,,"4-Hydroxy-1,2,5-Thiadiazole-3-Carboxylic Acid",,small molecule,,,,,
C(C(=O)C(SC(C(S(O[H])(=O)=O)([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03163,,2-oxopropyl-CoM,"2-(2-Oxopropylthio)ethanesulfonate
2-[(2-Oxopropyl)sulfanyl]ethanesulfonic acid
2-ketopropyl-CoM",small molecule,,,,,
C([N+]1=C([H])N([H])C2=NC(=NC2=C1N([H])[H])[H])([H])([H])[H],DB03164,,6-Amino-1-Methylpurine,,small molecule,,,,,
C(C(O[H])=O)([H])([H])[H],"DB03166
DB04184",64-19-7,Acetic acid,"Acetic acid, glacial
Aceticum acidum
acide ac��tique
Essigs��ure
Ethanoat
Ethanoate
Ethanoic acid
Ethoic acid
Ethylic acid
Glacial acetic acid
HOAc
Methanecarboxylic acid
Vinegar",small molecule,Bacteria,"Irrigant
Irrigant
Solution
Solution
Solution
Solution
Liquid
Solution / drops
Jelly
Solution
Solution
Gel
Tablet, coated
Kit","Irrigation
Irrigation
Auricular (otic)
Auricular (otic)
Auricular (otic)
Auricular (otic)
Hemodialysis
Auricular (otic)
Vaginal
Auricular (otic)
Hemodialysis
Topical
Oral",".25 g/100mL
250 mg/100mL
.02 mg/mL
20 mg/mL
20.65 mg/mL
25 mg/mL
2 mg/mL",Used to treat infections in the ear canal.
O(C1=C(Br)C(Br)=C(Br)C(Br)=C1Br)[H],DB03167,,Pentabromophenol,,small molecule,,,,,
O(P(O[H])(=O)OC(C(C(C1=C([H])N([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])[H],DB03171,,Indole-3-Propanol Phosphate,,small molecule,,,,,
N(C(=N[H])C1=C([H])C2=C(N(C(=C2[H])C2=C([H])C([H])=C([H])C(OC3(C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])=C2O[H])[H])C([H])=C1[H])([H])[H],DB03173,,CRA_10433,,small molecule,,,,,
O(P(O[H])(=O)C(C(=O)[H])([H])[H])[H],DB03174,,Phosphonoacetaldehyde,,small molecule,,,,,
C(C(C(O[H])([H])[H])([H])[H])([H])([H])[H],DB03175,71-23-8,Propyl alcohol,"1-propanol
1-proponol
N-propanol
N-propyl alcohol
Propanol",small molecule,,Solution,Topical,,
C(C(C([H])([H])[H])(C1=C(O[H])C([H])=C([H])C(OC2=C(Cl)C([H])=C(C(C(O[H])=O)([H])[H])C([H])=C2Cl)=C1[H])[H])([H])([H])[H],DB03176,219691-94-8,KB-141,"3,5-dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid",small molecule,,,,,
C(C1=C([H])C2=C(N=C(N2[H])[H])C([H])=C1[H])([H])([H])[H],DB03177,614-97-1,5-methylbenzimidazole,"5-methyl-1H-benzimidazole
6-methyl-1H-benzimidazole
ethyl 4-cyanophenylalaninate",small molecule,Mycobacterium,,,,
C(C1=C([H])C(N([H])[H])=C(N([H])[H])C([H])=C1C([H])([H])[H])([H])([H])[H],DB03180,,"4,5-Dimethyl-1,2-Phenylenediamine",,small molecule,,,,,
C(C(C([H])([H])[H])(C1=C(O[H])C([H])=C([H])C(OC2=C(C([H])([H])[H])C([H])=C(N3N=C([H])C(=O)N([H])C3=O)C([H])=C2C([H])([H])[H])=C1[H])[H])([H])([H])[H],DB03181,,"2-[4-(4-Hydroxy-3-Isopropyl-Phenoxy)-3,5-Dimethyl-Phenyl]-2h-[1,2,4]Triazine-3,5-Dione",,small molecule,,,,,
C(C(OC(=O)C1=C(C([H])([H])[H])N(C2=C([H])C([H])=C(N([H])[H])C([H])=C2[H])N=C1C([H])([H])[H])([H])[H])([H])([H])[H],DB03183,,"1-(4-Aminophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester",,small molecule,,,,,
C1(C([H])([H])N([H])C([H])([H])C([H])([H])N([H])C([H])([H])C([H])([H])C([H])([H])N([H])C([H])([H])C([H])([H])N([H])C1([H])[H])([H])[H],DB03189,,Cu-Cyclam,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03193,57-11-4,Stearic acid,"1-Heptadecanecarboxylic acid
Cetylacetic acid
Fatty acids C16-18
Isooctadecanoic acid
Isostearic acid
N-octadecanoic acidd
Octadecanoic acid
Octadecansaeure
Octadecoic acid
OLA
Stearate
Stearinsaeure",small molecule,Humans and other mammals,"Cream
Cream
Cream
Cream
Cream
Cream
Cream
Liquid
Soap
Soap
Cream
Ointment
Gel","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","16 g/100mL
1.5 g/100mL
15 g/10mL
20 g/100mL
8 g/100mL
25 g/100mL
120 mg/g
12 g/100g
1 g/100mL
.4 g/20mL",
N(C1=NC2=NC(=C(C(O[H])([H])[H])N=C2C(=O)N1[H])[H])([H])[H],DB03197,,6-Hydroxymethylpterin,,small molecule,,,,,
C(C1=NC([H])=C(C(N([H])[H])([H])[H])C(N([H])[H])=N1)([H])([H])[H],DB03204,,5-(Aminomethyl)-2-Methylpyrimidin-4-Amine,,small molecule,,,,,
O(C(=O)C1=C([H])C2=C(C3=C(C(O[H])=O)C([H])=C(C(O[H])=O)N=C3C(=O)C2=O)N1[H])[H],DB03205,72909-34-3,Pyrroloquinoline Quinone,,small molecule,,,,,
O(C(=O)C1=NC(=O)N([H])C(=O)N1[H])[H],DB03209,937-13-3,Oteracil,"5-azaorotic acid
Allantoxanic acid
Oxonate
Oxonic Acid",small molecule,,Capsule,Oral,,"Oteracil is used as an adjunct to antineoplastic therapy. When used within the product Teysuno, oteracil is indicated for the treatment of adults with advanced gastric (stomach) cancer when given in combination with cisplatin."
N(C1=C([H])C([H])=C(C(C(C(O[H])=O)([H])[H])([H])[H])C([H])=C1[H])([H])[H],DB03210,,4-Aminohydrocinnamic Acid,,small molecule,,,,,
O(P(O[H])(=O)C(C(C(=C([H])[H])C(=O)[H])([H])[H])([H])[H])[H],DB03211,,(3-Formyl-but-3-Enyl)-Phosphonic Acid,,small molecule,,,,,
N(C(=N[H])C1=C([H])C2=C(N=C(N2[H])C(=O)C2=NC3=C(C(=C(C(=C3[H])C([N+]([H])([H])[H])=[N+]([H])[H])[H])[H])N2[H])C([H])=C1[H])([H])[H],DB03213,,Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone,,small molecule,,,,,
O(C(C(F)(F)F)([H])[H])[H],DB03226,,Trifluoroethanol,,small molecule,,,,,
N(C(=O)C1=C([H])C(N(C(C(Cl)([H])[H])([H])[H])C(C(Cl)([H])[H])([H])[H])=C([N+]([O-])=O)C([H])=C1[N+]([O-])=O)([H])[H],DB03228,,"5-[Bis-2(Chloro-Ethyl)-Amino]-2,4-Dintro-Benzamide",,small molecule,,,,,
C(C(C([H])([H])[H])(C(C(=O)C(O[H])=O)([H])[H])[H])([H])([H])[H],DB03229,,2-Oxo-4-Methylpentanoic Acid,,small molecule,,,,,
N(C1=NC(=O)C2=NN(N([H])C2=N1)C1=C([H])C([H])=C([H])C(C(=O)N(C(C2=C(SC3=C(C(O[H])([H])[H])C([H])=C([H])C([H])=C3[H])C([H])=C([H])C([H])=C2[H])([H])[H])[H])=C1[H])([H])[H],DB03231,,"3-(5-Amino-7-oxo-3,7-dihydro-2H-[1,2,3]triazolo[4,5-d]pyrimidin-2-yl)-N-(2-{[2-(hydroxymethyl)phenyl]sulfanyl}benzyl)benzamide",,small molecule,,,,,
C(C(C([H])([H])[H])=C(C(C(C(C([H])([H])[H])=C(C(C(C(C([H])([H])[H])=C(C(C(C(C([H])([H])[H])=C(C(C(C(C([H])([H])[H])=C(C(C(C(C([H])([H])[H])=C(C(C(C(C([H])([H])[H])=C(C(C(C(C([H])([H])[H])=C(C(C1=C(O[H])C([H])=C([H])C([H])=C1[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB03232,,"2-[(2e,6e,10e,14e,18e,22e,26e)-3,7,11,15,19,23,27,31-Octamethyldotriaconta-2,6,10,14,18,22,26,30-Octaenyl]Phenol",,small molecule,,,,,
C(N(C(C(=C([H])[H])[H])([H])[H])C(C1=C([H])C([H])=C(C2=C([H])C([H])=C(C(=O)C3=C([H])C([H])=C(Br)C([H])=C3[H])C([H])=C2[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB03234,,"(4'-{[Allyl(Methyl)Amino]Methyl}-1,1'-Biphenyl-4-Yl)(4-Bromophenyl)Methanone",,small molecule,,,,,
N(C1=C([H])C(F)=C([H])C(F)=C1[H])([H])[H],DB03238,,"3,5-Difluoroaniline",,small molecule,,,,,
[N+](C(C1=C([H])C([H])=C(F)C([H])=C1[H])([H])[H])([H])([H])[H],DB03243,,4-Fluorobenzylamine,,small molecule,,,,,
N1(C([H])=NC([H])=C1C1=C([H])C([H])=C([H])C([H])=C1[H])[H],DB03254,,4-Phenyl-1h-Imidazole,,small molecule,,,,,
O(C1=C([H])C([H])=C([H])C([H])=C1[H])[H],DB03255,108-95-2,Phenol,"Acide carbolique
Acide phenique
Benzenol
Carbolic acid
Carbolsaeure
Hydroxybenzene
Karbolsaeure
Monohydroxybenzene
Oxybenzene
Phenic Acid
Phenol
Phenyl alcohol
Phenyl hydroxide
Phenylic Acid
Phenylic alcohol
PHOH",small molecule,Humans and other mammals,"Gel
Liquid
Liquid
Liquid
Stick
Ointment
Paste
Cream
Lotion
Liquid
Lozenge
Lozenge
Spray
Sponge
Spray
Injection, solution
Liquid
Liquid
Stick
Liquid
Spray
Liquid
Powder
Salve
Spray
Solution
Liquid
Spray
Solution
Liquid
Liquid
Gel
Spray
Spray
Liquid
Spray
Liquid
Spray
Spray
Injection, solution
Injection, solution
Plaster","Oral
Buccal
Oral
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Oral
Oral
Topical
Oral
Percutaneous; Subcutaneous
Intradermal; Percutaneous; Subcutaneous
Subcutaneous
Topical
Topical
Oral
Topical
Oral
Topical
Oral
Topical
Topical
Oral
Other
Intradermal; Subcutaneous
Oral
Topical
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intradermal; Subcutaneous
Intradermal; Subcutaneous
Topical","1 mg/mL
15 mg/mL
14.5 mg/1
29 mg/1
3.5 mg/.7mL
.68 g/7g
1.5 g/100mL
1.4 mL/100mL
.8 g/100g
1.4 g/177mL
1.4 %
1.4 mg/mL
6 %
.25 mg/100mL
1.4 mg/100mL
1.5 g/100mL
1.5 g/100mL
1.4 g/100mL
1.4 g/100mL
10.268 mg/100mL
10.628 mg/100mL
.004 mL/mL","Phenol is primarily indicated for minor sore throat pain, sore mouth, minor mouth irritation, and pain associated with canker sores. Additionally, phenol is indicated in the treatment of focal spasticity. "
O(C1=C([H])C([H])=C([H])C(C2=C(Cl)C([H])=C([H])C([H])=C2Cl)=C1O[H])[H],DB03259,,"2',6'-Dichloro-Biphenyl-2,6-Diol",,small molecule,,,,,
N(C(C(C(C(C(C(N([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB03260,,"1,6-Diaminohexane",,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C2=C(S(=O)(=O)N(C(C(N3C([H])([H])C([H])([H])OC([H])([H])C3([H])[H])([H])[H])=C2[H])C2=C([H])C(O[H])=C([H])C([H])=C2[H])S1)([H])[H],DB03262,,"Al-6619, [2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide,2-(3-Hydroxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide]",,small molecule,,,,,
O=C(C(C(C(C(=O)[H])([H])[H])([H])[H])([H])[H])[H],DB03266,111-30-8,Glutaral,Pentanedial,small molecule,,,,,
C(C(C(C(N1C2=C(N(C(C(C3=C([H])C([H])=C(N(C(C([H])([H])[H])=O)[H])C([H])=C3[H])([H])[H])=N2)[H])C(=O)N(C(C(=C([H])[H])[H])([H])[H])C1=O)([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03267,,1-Allyl-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine,,small molecule,,,,,
N(S(=O)(=O)C1=C(F)C([H])=C([H])C([H])=C1F)([H])[H],DB03270,,"2,6-Difluorobenzenesulfonamide",,small molecule,,,,,
C(N1N=C(C2=C(F)C([H])=C(Cl)C(C(O[H])=O)=C2[H])C(Br)=C1C(F)(F)F)([H])([H])[H],DB03272,,4-Bromo-3-(5'-Carboxy-4'-Chloro-2'-Fluorophenyl)-1-Methyl-5-Trifluoromethyl-Pyrazol,,small molecule,,,,,
O(C1=C([H])C([H])=C(C(=C(C(=O)C2=C(O[H])C([H])=C(O[H])C([H])=C2[H])[H])[H])C([H])=C1[H])[H],DB03285,,"2',4,4'-Trihydroxychalcone",,small molecule,,,,,
C(C1=C(O[H])C(C(N=C(C(=C(OC(C(N([H])[H])([H])[H])([H])[H])[H])[H])C(O[H])=O)([H])[H])=C(C(OP(O[H])(O[H])=O)([H])[H])C([H])=N1)([H])([H])[H],DB03287,,4-(2-Amino-Ethoxy)-2-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Amino]-but-3-Enoic Acid,,small molecule,,,,,
C(N1C(=O)N([H])C2=C1N(C(=O)N(C2=O)[H])[H])([H])([H])[H],DB03293,,9-Methyl Uric Acid,,small molecule,,,,,
C(N1SC(=O)C2=C1C(=C(C(=C2[H])S(N([H])[H])(=O)=O)[H])[H])([H])([H])[H],DB03294,,"1-Methyl-3-Oxo-1,3-Dihydro-Benzo[C]Isothiazole-5-Sulfonic Acid Amide",,small molecule,,,,,
O(S(=O)(=O)C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H],DB03297,,Benzylsulfinic Acid,,small molecule,,,,,
O(P(O[H])(=O)OC1=C([H])C([H])=C([H])C([H])=C1[H])[H],DB03298,,Phenylphosphate,,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C(C(C(=C([H])[H])[H])([H])[H])=C1O[H])([H])([H])[H],DB03301,,2-Allyl-6-Methyl-Phenol,,small molecule,,,,,
ClC1=C2C(OC(=O)C2=C(Cl)C(Cl)=C1Cl)([H])[H],DB03302,,"4,5,6,7-Tetrachloro-3h-Isobenzofuran-1-One",,small molecule,,,,,
N(C(C1=C([H])N([H])C2=C1C(=O)N(C(N([H])[H])=N2)[H])([H])[H])([H])[H],DB03304,,7-Deaza-7-Aminomethyl-Guanine,,small molecule,,,,,
C(OC1=C(OP(O[H])(O[H])=O)C(C(=O)[H])=C([H])C([H])=C1[H])([H])([H])[H],DB03306,,RU78300,,small molecule,,,,,
N(C1=C([H])C(N(C2=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C2[H])[H])=NC([H])=N1)([H])[H],DB03307,,4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide,,small molecule,,,,,
O(S(=O)(=O)C(C(N(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])[H])([H])[H])([H])[H])[H],DB03309,,N-Cyclohexyltaurine,CHES,small molecule,,,,,
C(C(C1=C(C(=O)C2=C([H])C(Br)=C(O[H])C(Br)=C2[H])C2=C(C(=C(C(=C2[H])[H])S(=O)(=O)N(C2=C([H])C([H])=C(S(=O)(=O)N(C3=NC([H])=C([H])S3)[H])C([H])=C2[H])[H])[H])O1)([H])[H])([H])([H])[H],DB03311,,"3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide",,small molecule,,,,,
C1(C([H])([H])OC([H])([H])C([H])([H])O1)([H])[H],DB03316,,"1,4-Diethylene Dioxide",,small molecule,,,,,
C(C(S[H])(C1=C2N3[Fe-2]45[N+]6C(=C2[H])C(C([H])([H])[H])=C(C(C([H])([H])[H])(S[H])[H])C=6C([H])=C2C(C([H])([H])[H])=C(C(C(C(O[H])=O)([H])[H])([H])[H])C(N42)=C([H])C2=[N+]5C(=C([H])C3=C1C([H])([H])[H])C(C([H])([H])[H])=C2C(C(C(O[H])=O)([H])[H])([H])[H])[H])([H])([H])[H],DB03317,,Heme C,,small molecule,,,,,
S([Mo](=O)=O)[H],DB03328,,dioxothiomolybdenum(VI) ion,,small molecule,,,,,
S(C1=NC([H])=C([H])C([H])=C1[H])[H],DB03329,,2-Pyridinethiol,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(N(C(=S)OC(C(C2=C([H])SC([H])=C2[H])([H])[H])([H])[H])[H])C([H])=C1[H])([H])[H],DB03333,,(4-sulfamoyl-phenyl)-thiocarbamic acid O-(2-thiophen-3-yl-ethyl) ester,,small molecule,,,,,
O(C1=C(O[H])C([N+]([O-])=O)=C([H])C(C(=O)C(C(N2C([H])([H])C([H])([H])N(C3=C([H])C([H])=C([H])C(C(F)(F)F)=C3[H])C([H])([H])C2([H])[H])([H])[H])([H])[H])=C1[H])[H],DB03336,,BIA,,small molecule,,,,,
N(C(=N[H])C1=C([H])C([H])=C(N(C(=O)N(C2=C([H])C([H])=C(OC3=C([H])C([H])=C([H])C([H])=C3[H])C([H])=C2[H])[H])[H])C([H])=C1[H])([H])[H],DB03337,,1-(2-Amidinophenyl)-3-(Phenoxyphenyl)Urea,,small molecule,,,,,
O(C(C1=C([H])C([H])=C([H])C(I)=C1[H])([H])[H])[H],DB03339,,3-Iodo-Benzyl Alcohol,,small molecule,,,,,
C(C(=O)N(C1=C(N(C(N([H])[H])(N([H])[H])[H])[H])C([H])=C(C(O[H])=O)C([H])=C1[H])[H])([H])([H])[H],DB03342,,4-(Acetylamino)-3-Guanidinobenzoic Acid,,small molecule,,,,,
O(C(C(S[H])([H])[H])([H])[H])[H],"DB03345
DB03131",60-24-2,Beta-Mercaptoethanol,2-Sulfhydryl-Ethanol,small molecule,,,,,
O(C1=C(Cl)C([H])=C(C2=C([H])C(Cl)=C(O[H])C(Cl)=C2[H])C([H])=C1Cl)[H],DB03346,,"3,5,3',5'-Tetrachloro-Biphenyl-4,4'-Diol",,small molecule,,,,,
C(C(OP(=O)(OC(C([H])([H])[H])([H])[H])OC(C([H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03347,,Triethyl Phosphate,,small molecule,,,,,
[N+]([Co-3]([N+]([H])([H])[H])([N+]([H])([H])[H])([N+]([H])([H])[H])([N+]([H])([H])[H])[N+]([H])([H])[H])([H])([H])[H],DB03350,,Cobalt Hexammine Ion,"Cobalt Hexammine(III)
hexaamminecobalt(3+)",small molecule,,,,,
C(C1=C2C(N([H])[H])=NC(N([H])[H])=NC2=NC([H])=C1C(N(C1=C([H])C([H])=C([H])C2=NC(=C(C([H])=C12)[H])[H])[H])([H])[H])([H])([H])[H],DB03351,,Sri-9439,,small molecule,,,,,
C([N+](C([H])([H])[H])(C([H])([H])[H])C1=C([H])C([H])=C([H])C(C(O[H])(O[H])C(F)(F)F)=C1[H])([H])([H])[H],DB03359,,"M-(N,N,N-Trimethylammonio)-2,2,2-Trifluoro-1,1-Dihydroxyethylbenzene",,small molecule,,,,,
C(OC1=C([H])C2=NC(=NC(N(C3=C([H])C(O[H])=C([H])C([H])=C3[H])[H])=C2C([H])=C1OC([H])([H])[H])[H])([H])([H])[H],DB03365,,"4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline",,small molecule,,,,,
N1(C([H])=C([H])N=C1[H])[H],DB03366,288-32-4,Imidazole,,small molecule,,,,,
C(C1(C(=O)N([H])C(=O)N([H])C1=O)C1=C([H])C([H])=C(OC2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])([H])[H],DB03368,,"5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione",,small molecule,,,,,
N(C1=C([H])C2=C(C(=C(C([H])=C2C2=C(C(=C(C([H])=C12)[H])[H])[H])[H])[H])[H])([H])[H],DB03369,,9-Aminophenanthrene,,small molecule,,,,,
S(C(C(C(=O)N1C([H])([H])C([H])([H])C2=C(N(C3=C2C([H])=C([H])C([H])=C3[H])[H])C1([H])[H])([H])[H])([H])[H])[H],DB03372,,"3-Mercapto-1-(1,3,4,9-Tetrahydro-B-Carbolin-2-Yl)-Propan-1-One",,small molecule,,,,,
C(C(=N[H])N1C([H])([H])C([H])([H])C(OC2=C([H])C3=C(N=C(C([H])([H])[H])N3C(C3=C([H])C4=C(C(=C(C([H])=C4C([H])=C3[H])[H])C(N([H])[H])=[N+]([H])[H])[H])([H])[H])C([H])=C2[H])([H])C([H])([H])C1([H])[H])([H])([H])[H],DB03373,,ZK-806711,,small molecule,,,,,
O(C(=O)C(C(P(O[H])(O[H])=O)([H])[H])([H])[H])[H],DB03379,,2-Carboxyethylphosphonic Acid,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(=O)[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03381,629-80-1,Hexadecanal,"16-Hexadecanal
N-hexadecanal
Palmitaldehyde
Palmitoyl
Palmitoyl aldehyde
PLM
PLY",small molecule,,,,,
FC1=C([H])C2=C(N(C(=C2[H])C(=O)N(C(C(S[H])([H])[H])([H])[H])[H])[H])C([H])=C1[H],DB03384,,Fica,,small molecule,,,,,
C(C1=C([H])N=C([H])N1[H])([H])([H])[H],DB03385,,4-Methylimidazole,,small molecule,,,,,
C(C(C([H])([H])[H])(N(O[H])C(=O)C(O[H])=O)[H])([H])([H])[H],DB03387,,N-Hydroxy-N-Isopropyloxamic Acid,,small molecule,,,,,
C(C(C([H])([H])[H])(N(C(=O)C1=C(Cl)C([H])=C(Cl)C([H])=C1[H])C1=C(C(O[H])=O)SC(C2=C([H])C([H])=C([H])C([H])=C2[H])=C1[H])[H])([H])([H])[H],DB03388,,"3-[(2,4-Dichlorobenzoyl)(Isopropyl)Amino]-5-Phenylthiophene-2-Carboxylic Acid",,small molecule,,,,,
C(C([N+]#C[H])([H])[H])([H])([H])[H],DB03399,,Ethyl Isocyanide,,small molecule,,,,,
C(C1=C([H])C([H])=C(C(C(C(O[H])=O)([H])[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB03400,,3-(P-Tolyl)Propionic Acid,,small molecule,,,,,
O(C1=C(O[H])C([H])=C([N+]([O-])=O)C([H])=C1[H])[H],DB03407,3316-09-4,4-Nitrocatechol,,small molecule,,,,,
O(C1=C([H])C(=O)OC2=C1C(=C(C(=C2[H])[H])[H])[H])[H],DB03410,1076-38-6,4-hydroxycoumarin,"4-coumarinol
4-Hydroxy-1-Benzopyran-2-One
4-hydroxy-2H-1-benzopyran-2-one
4-hydroxychromen-2-one
benzotetronic acid",small molecule,,,,,
C(C(=O)C1=C(C([H])([H])[H])C2N3[Fe]45N6C(C(=C(C6=C(C6=C(C(C(C(O[H])=O)([H])[H])([H])[H])C(C([H])([H])[H])=C(C([H])=C13)N64)[H])C(C(C(O[H])=O)([H])[H])([H])[H])C([H])([H])[H])=C([H])C1=C(C(=C(C=2[H])N51)C(O[H])=C([H])[H])C([H])([H])[H])([H])([H])[H],DB03418,,Diacetyldeuteroheme,,small molecule,,,,,
O=C1N([H])C([H])=C([H])C(=O)N1[H],DB03419,66-22-8,Uracil,,small molecule,,,,,
O=C1N([H])N(C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])C(=O)C2=C1C(=C(C(=C2[H])[H])[H])[H],DB03421,,"2-Phenethyl-2,3-Dihydro-Phthalazine-1,4-Dione",,small molecule,,,,,
O(C(=O)C1=C([H])SC([H])=N1)[H],DB03422,,"1,3-Thiazole-4-Carboxylic Acid",,small molecule,,,,,
C(OC1=C([H])C2=C(N(C(=O)C2=C(C2=C([H])N=C([H])N2[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB03428,,SU9516,,small molecule,,,,,
O(S(=O)(=O)C(C(C(N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H])([H])[H])([H])[H])([H])[H])[H],DB03434,,3[N-Morpholino]Propane Sulfonic Acid,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(=O)N(C(C(O[H])=O)([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03440,,N-Hexadecanoylglycine,,small molecule,,,,,
C(C1=NN(C2=C(C([H])([H])[H])C([H])=C(S(O[H])(=O)=O)C([H])=C2[H])C(O[H])=C1N=NC1=C(C(O[H])=O)C([H])=C([H])C(S(O[H])(=O)=O)=C1[H])([H])([H])[H],DB03442,,2-[5-Hydroxy-3-Methyl-1-(2-Methyl-4-Sulfo-Phenyl)-1h-Pyrazol-4-Ylazo]-4-Sulfo-Benzoic Acid,,small molecule,,,,,
N(C(N([H])[H])(C1=C([H])C2=C([N+]3=C(N2[H])C(=O)C2=[N+](C4=C(N2[H])C([H])=C(C(N([H])[H])(N([H])[H])[H])C([H])=C4[H])[Zn]3)C([H])=C1[H])[H])([H])[H],DB03443,,Bis(5-Amidino-Benzimidazolyl)Methanone Zinc,,small molecule,,,,,
O(N=C1C(=C2C(=O)N([H])C3=C2C(=C(C(Br)=C3[H])[H])[H])N([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])[H],DB03444,,"(3e)-6'-Bromo-2,3'-Biindole-2',3(1h,1'h)-Dione 3-Oxime",,small molecule,,,,,
ClC1=C([H])C(C(N(C(C(C2=C([H])C([H])=C(N(C(=N[H])C3=C([H])C([H])=C([H])S3)[H])C([H])=C2[H])([H])[H])([H])[H])[H])([H])[H])=C([H])C([H])=C1[H],DB03449,,N-(4-(2-((3-Chlorophenylmethyl)Amino)Ethyl)Phenyl)-2-Thiophecarboxamidine,,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C(O[H])=C1O[H])([H])([H])[H],DB03454,488-17-5,"3-methyl-benzene-1,2-diol",,small molecule,,,,,
C(C1=C([H])N([H])C(=O)N([H])C1=O)([H])([H])[H],DB03462,65-71-4,Thymine,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C2=C(C(C(N(C2([H])[H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H],DB03468,,"1,2,3,4-Tetrahydro-Isoquinoline-7-Sulfonic Acid Amide",,small molecule,,,,,
N(C1=NC(N(C2=C3C(O[H])=C(N=NC4=C(S(O[H])(=O)=O)C([H])=C([H])C([H])=C4[H])C(=C([H])C3=C([H])C(S(O[H])(=O)=O)=C2[H])S(O[H])(=O)=O)[H])=NC(N([H])[H])=N1)([H])[H],DB03474,,Reactive Red 1 Dye,,small molecule,,,,,
C(C(C(C(C([H])([H])[H])([H])[H])(N(C1=C(N2C(=O)C([H])([H])C([H])([H])C2(C(O[H])([H])[H])C(O[H])([H])[H])C([H])=C([H])C(C(O[H])=O)=C1[H])[H])[H])([H])[H])([H])([H])[H],DB03475,,"1-[4-Carboxy-2-(3-Pentylamino)Phenyl]-5,5'-Di(Hydroxymethyl)Pyrrolidin-2-One",,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(N2N=C(C(F)(F)F)C([H])=C2C2=C([H])C([H])=C(Br)C([H])=C2[H])C([H])=C1[H])([H])[H],DB03477,,1-Phenylsulfonamide-3-Trifluoromethyl-5-Parabromophenylpyrazole,,small molecule,,,,,
C(C1=C(C2=C([H])C([H])=C(C3=C([H])C([H])=C([H])C([H])=C3[H])C([H])=C2[H])N=C2C(=C(C(F)=C([H])C2=C1C(O[H])=O)[H])[H])([H])([H])[H],DB03480,,Brequinar Analog,,small molecule,,,,,
C1(C2=C(C(=C(C(=C2[H])[H])[H])[H])C2=NN(C(C3=C([H])C([H])=NC([H])=C3[H])=C12)[H])([H])[H],DB03490,,"3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole",,small molecule,,,,,
C1(C([H])=C([H])N2C(C3=C([H])C([H])([H])C([H])=C([H])N3[Os+2]32(N2C([H])=C([H])N=C2[H])N2C(=C(C(C([H])=C2C2=C(C(C(=C([H])N32)[H])([H])[H])[H])([H])[H])[H])[H])=C1[H])([H])[H],"DB03492
DB04550",,"lambda-bis(2,2'-bipyridine)imidazole osmium (II)","delta-bis(2,2'-bipyridine)imidazole osmium (II)",small molecule,,,,,
[O-]P([O-])(=O)C(S[H])([H])[H],DB03498,,Mercaptomethyl Phosphonate,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03500,,Tricosanoic Acid,,small molecule,,,,,
C(C(C(C(N1C(C(C2=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C(OC([H])([H])[H])=C2Cl)([H])[H])=NC2=C1N=C(N=C2N([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03504,,"9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine",,small molecule,,,,,
N(C1=C([H])C([H])=C2N=C(N([H])[H])N=C(O[H])C2=C1[H])([H])[H],DB03505,,"2,6-Diaminoquinazolin-4(3h)-One",,small molecule,,,,,
N(=C1N([H])C([H])=NC2=C1N(C(=C2[H])[H])[H])[H],DB03506,,9-Deazaadenine,,small molecule,,,,,
[O-][N+](=O)C1=C([H])C([H])=C([H])C(C2=C([H])C3=C(C(=C4N3C(=S)N(C(C(C(N3C([H])([H])C([H])([H])OC([H])([H])C3([H])[H])([H])[H])([H])[H])([H])[H])C4=O)[H])S2)=C1[H],DB03507,,"6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One",,small molecule,,,,,
C(C(OC(C(OC(C(OC([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03508,,1-Ethoxy-2-(2-Methoxyethoxy)Ethane,,small molecule,,,,,
N(C(=O)C1=C2N=C(C(=NC2=C([H])C([H])=C1[H])[H])C1=C([H])C([H])=C(Cl)C([H])=C1[H])([H])[H],DB03509,,2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide,,small molecule,,,,,
C(OC1=C(O[H])C([H])=C([H])C(C(=C([H])[H])[H])=C1[H])([H])([H])[H],DB03514,,2-Methoxy-4-Vinyl-Phenol,,small molecule,,,,,
O=C1N([H])C([H])=C(C#C[H])C(=O)N1[H],DB03516,59989-18-3,Eniluracil,"5-ethynyl-2,4(1H,3H)-Pyrimidinedione
5-Ethynyluracil
Compound 776C",small molecule,Humans and other mammals,,,,For the treatment of cancer in combination with 5-fluorouracil.
C(SC(C([O-])=O)([H])[H])([H])([H])[H],DB03517,,[Methylthio]Acetate,,small molecule,,,,,
FC1=NC(Cl)=C2N=C(N=C2N1[H])[H],DB03520,,6-Chloro-2-Fluoropurine,,small molecule,,,,,
C(C1=C(C(O[H])=O)C2=C(C(F)=C(C([H])=C2N=C1C1=C([H])C([H])=C(C2=C(F)C([H])=C([H])C([H])=C2[H])C([H])=C1[H])[H])[H])([H])([H])[H],DB03523,96187-53-0,Brequinar,,small molecule,,,,,
O(P(O[H])(=O)OC1=C2N(C(C(C([H])([H])C2=C([H])C([H])=C1[H])([H])[H])([H])[H])[H])[H],DB03525,,RU79073,,small molecule,,,,,
C(OC1=C([H])C([H])=C(C(N(S(=O)(=O)C2=C([H])C([H])=C(S(N([H])[H])(=O)=O)S2)[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB03526,,AL5927,,small molecule,,,,,
C(N(C(C1=C(N([H])[H])C([H])=C([H])C(C(=O)N(C([H])([H])[H])C(C2=C([H])C3=C(C(=C(C(=C3[H])[H])[H])[H])N2C([H])([H])[H])([H])[H])=C1[H])([H])[H])C(C([H])([H])[H])=O)([H])([H])[H],DB03534,,3-[(Acetyl-Methyl-Amino)-Methyl]-4-Amino-N-Methyl-N-(1-Methyl-1h-Indol-2-Ylmethyl)-Benzamide,,small molecule,,,,,
O(C(=O)C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])[H],DB03553,110-94-1,Glutaric Acid,,small molecule,,,,,
IC1=C([H])N([H])C(=O)N([H])C1=O,DB03554,,5-Iodouracil,,small molecule,,,,,
C(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03556,,"2-(2-{2-[2-(2-{2-[2-(2-Ethoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol, Polyethyleneglycol Peg400",,small molecule,,,,,
O=C(N(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])[H])[H],DB03559,,Cyclohexylformamide,,small molecule,,,,,
O(C1=C([H])C([H])=C(C(=O)[H])C([H])=C1[H])[H],DB03560,123-08-0,P-Hydroxybenzaldehyde,,small molecule,,,,,
N(C(C(C(C(N(C(C(C(N([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB03566,124-20-9,Spermidine,"1,5,10-Triazadecane
1,8-Diamino-4-azaoctane
4-Azaoctane-1,8-diamine
N-(3-Aminopropyl)-1,4-butane-diamine
N-(3-Aminopropyl)-1,4-butanediamine
N-(3-Aminopropyl)-1,4-diaminobutane
N-(3-aminopropyl)butane-1,4-diamine
Spermidin",small molecule,,,,,
C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])([H])[H],DB03568,107-92-6,Butyric Acid,"1-propanecarboxylic acid
Butanoic acid
Butyrate
Butyricum acidum
Ethylacetic acid
N-butanoic acid
N-butyric acid
Propylformic acid",small molecule,,,,,
C([N+](C(O[H])([H])[H])(C(O[H])([H])[H])C(O[H])([H])[H])([H])([H])[H],DB03570,,Tris-Hydroxymethyl-Methyl-Ammonium,,small molecule,,,,,
N(C1=NC2=NN(N=C2C(O[H])=N1)C1=C([H])C([H])=C([H])C(C(=O)N(C(C2=C([H])C(Cl)=C([H])C(Cl)=C2[H])([H])[H])[H])=C1[H])([H])[H],DB03571,,"3-(5-Amino-7-Hydroxy-[1,2,3]Triazolo[4,5-D]Pyrimidin-2-Yl)-N-(3,5-Dichlorobenzyl)-Benzamide",,small molecule,,,,,
C1(C([H])([H])C([H])([H])N(C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])([H])C1([H])[H])([H])[H],DB03575,77-10-1,Phencyclidine,"1-(1-Phenylcyclohexyl)piperidine
PCP",small molecule,Humans and other mammals,,,,
C(C(O[H])(C(N(C(C1=C(C(OP(O[H])(O[H])=O)([H])[H])C([H])=NC(C([H])([H])[H])=C1O[H])([H])[H])[H])(C(O[H])=O)[H])[H])([H])([H])[H],DB03576,,N-Pyridoxyl-Threonine-5-Monophosphate,,small molecule,,,,,
C(C(=O)C(N([H])[H])=O)([H])([H])[H],DB03578,,Pyruvamide,,small molecule,,,,,
C(C(=O)C(=O)[H])([H])([H])[H],DB03587,78-98-8,Pyruvaldehyde,"2-ketopropionaldehyde
2-oxopropanal
Acetyl formaldehyde
Acetylformyl
alpha-ketopropionaldehyde
Methyl glyoxal
Methylglyoxal
Pyruvic aldehyde",small molecule,,,,,
O(C(=O)C(C1=C([H])C([H])=C([H])C([H])=C1[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H],DB03588,,Diphenylacetic Acid,,small molecule,,,,,
O(C(=O)C(=O)C(O[H])=O)[H],DB03589,,Alpha-Ketomalonic Acid,,small molecule,,,,,
N(C1=NC2=C(N=C(C(OP(O[H])(O[H])=O)([H])[H])C(=N2)[H])C(=O)N1[H])([H])[H],DB03592,,Pterin-6-Yl-Methyl-Monophosphate,,small molecule,,,,,
N1(C([H])=NC([H])=N1)[H],DB03594,63598-71-0,"1,2,4-Triazole",,small molecule,,,,,
N(C(=N[H])C1=C([H])C2=C(N(C(=N2)C2=C(O[H])C([H])=C([H])C(OC(F)(F)F)=C2[H])[H])C([H])=C1[H])([H])[H],DB03595,,CRA_9785,,small molecule,,,,,
C(OC1=C([H])C([H])=C([H])C(N2C(C(N3C([H])([H])C([H])([H])OC([H])([H])C3([H])[H])([H])[H])=C([H])C3=C(SC(=C3[H])S(N([H])[H])(=O)=O)S2(=O)=O)=C1[H])([H])([H])[H],DB03598,,"Al-6629, [2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide,2-(3-Methoxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide]",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],"DB03600
DB03838",334-48-5,Capric acid,"1-nonanecarboxylic acid
Decanoic acid
N-capric acid
N-decanoic acid",small molecule,,,,,
O(C(=O)C(C1=C([H])C(I)=C(OC2=C([H])C(I)=C(O[H])C([H])=C2[H])C(I)=C1[H])([H])[H])[H],"DB03604
DB12922",51-24-1,Tiratricol,"3',3,5-Triiodothyroacetic acid
Tiratricolum
Triacana
Triiodothyroacetic acid",small molecule,,,,,
N(C(=N[H])C1=C([H])C([H])=C(N(N=NC2=C([H])C([H])=C(C(N([H])[H])=N[H])C([H])=C2[H])[H])C([H])=C1[H])([H])[H],DB03608,536-71-0,Diminazene,"1,3-TRIS-(4'AMIDINOPHENYL)TRIAZINE
4,4'-(1-Triazene-1,3-diyl)bis-benzenecarboximidamide
4,4'-(Diazoamino)benzamidine
Diminazene aceturate
Diminazine
Diminazine aceturate",small molecule,,,,,
O(C1=C([H])C([H])=C(C(F)(F)F)C([H])=C1[H])[H],DB03610,,"Alpha,Alpha,Alpha-Trifluoro-P-Cresol",,small molecule,,,,,
O(C1=C([H])C([H])=C(C2=C([H])C3=C4C([H])=NC([H])=C([H])C4=C(C([H])=C3N=C2[H])[H])C([H])=C1[H])[H],DB03623,,"9-(4-Hydroxyphenyl)-2,7-Phenanthroline",,small molecule,,,,,
C(OC1=C([H])C(=O)C2=C(C(C(OC3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])=C(C([H])([H])[H])N2C([H])([H])[H])C1=O)([H])([H])[H],DB03626,,"5-Methoxy-1,2-Dimethyl-3-(Phenoxymethyl)Indole-4,7-Dione",,small molecule,,,,,
C1(C2(C([H])([H])C3(C(C(C2([H])[H])(C([H])([H])C1(C3([H])[H])[H])[H])([H])[H])[H])[H])([H])[H],DB03627,,Adamantane,,small molecule,,,,,
C(C(C1=C([H])C([H])=C(N(C(=O)P(O[H])(O[H])=O)[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB03628,,ISO24,,small molecule,,,,,
C(C1=C(O[H])C(C(=O)[H])=C(C(OP(O[H])(O[H])=O)([H])[H])C([H])=[N+]1[O-])([H])([H])[H],DB03629,,Pyridoxal-5'-Phosphate-N-Oxide,,small molecule,,,,,
S(C(C1=C(I)C([H])=C([H])C([H])=C1[H])([H])[H])[H],DB03630,,2-Iodobenzylthio Group,,small molecule,,,,,
C(C(S(O[H])(=O)=O)([H])[H])([H])([H])[H],DB03635,,Ethanesulfonic Acid,,small molecule,,,,,
N(C(C(N([H])[H])=O)([H])[H])([H])[H],DB03636,,Glycinamid,,small molecule,,,,,
N(C(=[N+]([H])[H])N(C(C(C(O[H])([H])[H])([H])[H])([H])[H])[H])([H])[H],DB03637,,Guanidine-3-Propanol,,small molecule,,,,,
N(C(C(C(C(C(C(C(N(C(N([H])[H])(N([H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB03639,,1-Guanidinium-7-Aminoheptane,,small molecule,,,,,
N(C(=N[H])C1=C([H])C2=C(N(C(=N2)C2=C(O[H])C([H])=C([H])C([H])=C2[H])[H])C([H])=C1[H])([H])[H],DB03643,,CRA_1144,,small molecule,,,,,
N(C1=C(C(O[H])=O)C([H])=C([H])C([H])=C1O[H])([H])[H],DB03644,548-93-6,3-Hydroxyanthranilic Acid,"2-Amino-3-hydroxy-benzoic acid
2-Amino-3-Hydroxybenzoic Acid
3-HYDROXY-ANTHRANILATE
3-Hydroxy-anthranilsaeure
3-hydroxyanthranilate
3-Oxyanthranilic acid",small molecule,,,,,
O(N(C(=O)C(P(O[H])(O[H])=O)([H])[H])[H])[H],DB03645,,Phosphonoacetohydroxamic Acid,,small molecule,,,,,
C(C(C([H])([H])[H])(N(C(=O)C1=C([H])C([H])=C(C([H])([H])[H])C([H])=C1[H])C1=C(C(O[H])=O)SC(C2=C([H])C([H])=C([H])C([H])=C2[H])=C1[H])[H])([H])([H])[H],DB03647,,3-[Isopropyl(4-Methylbenzoyl)Amino]-5-Phenylthiophene-2-Carboxylic Acid,,small molecule,,,,,
O(P(O[H])(=O)C(N(C1=NC([H])=C(Cl)C([H])=C1[H])[H])(P(O[H])(O[H])=O)[H])[H],DB03649,,"[{(5-Chloro-2-Pyridinyl)Amino} Methylene]-1,1-Bisphosphonate",,small molecule,,,,,
O(C1=C([H])C([H])=C(N=C2C(=O)N([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])C([H])=C1[H])[H],DB03650,,(3e)-3-[(4-Hydroxyphenyl)Imino]-1h-Indol-2(3h)-One,,small molecule,,,,,
O(C1=C([N+]([O-])=O)C([H])=C([N+]([O-])=O)C([H])=C1[N+]([O-])=O)[H],DB03651,88-89-1,Picric acid,"Picricum acidum
Trinitrophenol",small molecule,,"Aerosol, spray",Topical,,
C(C(N(C([H])([H])[H])C(C1=C([H])N=C(C([H])([H])[H])N=C1N([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03653,,"5-{[Ethyl(Methyl)Amino]Methyl}-2-Methyl-5,6-Dihydropyrimidin-4-Amine",,small molecule,,,,,
C(OC(=O)C1=C(S(=O)(=O)N(C(=O)N(C([H])([H])[H])C2=NC(OC([H])([H])[H])=NC(C([H])([H])[H])=N2)[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB03656,101200-48-0,Tribenuron Methyl,"Sulfmethmeton-methyl
Tribenuron methyl ester
Tribenuron-methyl",small molecule,,,,,
C(C(C(C(N([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03659,109-73-9,Butylamine,"1-aminobutane
1-butanamine
n-butylamine",small molecule,,,,,
C(C(C([H])([H])[H])(C(=O)C(OC1=NC(N([H])[H])=NC2=C1N(C(=N2)[H])[H])([H])[H])[H])([H])([H])[H],DB03663,,"1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol",,small molecule,,,,,
C(C(=O)ON(C(=O)C1=C(O[H])C([H])=C([H])C([H])=C1[H])[H])([H])([H])[H],DB03667,,Acetic Acid Salicyloyl-Amino-Ester,,small molecule,,,,,
O(C(C(C1=C([H])C([H])=C(F)C([H])=C1[H])([H])[H])([H])[H])[H],DB03669,,4-Fluorophenethyl Alcohol,,small molecule,,,,,
O(C(=O)C(=O)N(C1=C(C(O[H])=O)C2=C(C(N(C(C2([H])[H])([H])[H])[H])([H])[H])S1)[H])[H],DB03670,,"2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid",,small molecule,,,,,
C(N(C1=C2C(C(C(C([H])([H])C2=NC2=C(C(=C(C([H])=C12)[H])[H])[H])([H])[H])([H])[H])([H])[H])[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H],DB03672,,9-N-Phenylmethylamino-Tacrine,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(N(C(=O)N(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03677,,N-Cyclohexyl-N'-Decylurea,,small molecule,,,,,
O(C(C([O-])=O)(C([O-])=O)[H])[H],DB03680,,Tartronate,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C([H])C2=C1OC1=C(C(O[H])=O)C([H])=C([H])C([H])=C12)[H],DB03682,,"Dibenzofuran-4,6-Dicarboxylic Acid",,small molecule,,,,,
O(C(C(C(O[H])=O)([H])[H])([H])[H])[H],DB03688,,3-Hydroxy-Propanoic Acid,,small molecule,,,,,
N(C(C(N(S(=O)(=O)C1=C([H])C([H])=C(Cl)C2=C(C(=NC([H])=C12)[H])[H])[H])([H])[H])([H])[H])([H])[H],DB03693,,N-(2-Aminoethyl)-5-Chloroisoquinoline-8-Sulfonamide,,small molecule,,,,,
N(C(=S)N(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H],DB03694,,N-Phenylthiourea,,small molecule,,,,,
C(OC1=C([H])C(C(C2=C(C([H])([H])[H])C3=C(N([H])[H])N=C(N([H])[H])N=C3N=C2[H])([H])[H])=C(OC([H])([H])[H])C([H])=C1[H])([H])([H])[H],"DB03695
DB12918",72732-56-0,Piritrexim,,small molecule,,,,,
N(C(C(C(C(N(C(=O)C1=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C1[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB03697,,4-Sulfonamide-[1-(4-Aminobutane)]Benzamide,,small molecule,,,,,
FC1=C([H])C([H])=C(C(OC(C(N2C([H])([H])C([H])([H])N(C(C(C(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])([H])[H])([H])[H])C([H])([H])C2([H])[H])([H])[H])([H])[H])(C2=C([H])C([H])=C(F)C([H])=C2[H])[H])C([H])=C1[H],DB03701,67469-69-6,Vanoxerine,1-(2-(bis(p-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine,small molecule,,,,,
O(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])[H],DB03703,108-93-0,Cyclohexanol,,small molecule,,,,,
O(C(C(C(C(C(C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB03704,505-95-3,12-Hydroxydodecanoic Acid,,small molecule,,,,,
C(N(C1=C([N+]([O-])=O)C(=O)N([H])C(N([H])[H])=N1)[H])([H])([H])[H],DB03705,,6-Methylamino-5-Nitroisocytosine,,small molecule,,,,,
C(C(SC(N([H])[H])=NC1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB03707,,S-Ethyl-N-Phenyl-Isothiourea,,small molecule,,,,,
O(C(C(N(C(C(O[H])([H])[H])([H])[H])C(C(O[H])=O)([H])[H])([H])[H])([H])[H])[H],DB03709,,Bicine,,small molecule,,,,,
C(C(C(=O)C(C(C(C([H])([H])[H])(C([H])([H])[H])O[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03711,,6-Hydroxy-6-Methyl-Heptan-3-One,,small molecule,,,,,
C(C(=C(N([H])[H])C(O[H])=O)[H])([H])([H])[H],DB03720,,Z-Dehydrobutyrine,,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C2=C1C(C(N(C2=O)[H])([H])[H])([H])[H])([H])([H])[H],DB03722,,"3,4-Dihydro-5-Methyl-Isoquinolinone",,small molecule,,,,,
C(C1=C(C(C(C(O[H])=O)([H])[H])([H])[H])C2=C(C3=NC(=C(C4=C(C([H])([H])[H])C(C(C(C(O[H])=O)([H])[H])([H])[H])=C(C(=C5N=C(C([H])=C1N2[H])C(C(C(C(O[H])=O)([H])[H])([H])[H])=C5C([H])([H])[H])[H])N4[H])[H])C(C(C(C(O[H])=O)([H])[H])([H])[H])=C3C([H])([H])[H])[H])([H])([H])[H],DB03727,,Coproporphyrin I,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C(Cl)C([H])=C1[H])[H],DB03728,74-11-3,p-Chlorobenzoic acid,"4-chlorobenzoic acid
Chlorodracylic acid",small molecule,,,,,
O(C1=C([H])C2=C(N(C(=N[H])N2[H])[H])C([H])=C1[H])[H],DB03729,,2-Amino-5-Hydroxy-Benzimidazole,,small molecule,,,,,
C(N1C([H])=NC2=C(N([H])[H])N=C([N+](C([H])([H])[H])=C12)[H])([H])([H])[H],DB03730,,"3,9-Dimethyladenine",,small molecule,,,,,
ClC(C(Cl)([H])[H])([H])[H],DB03733,107-06-2,Ethylene Dichloride,,small molecule,,,,,
C(C(C1=C([H])C(C2=NN([H])C([H])=C2C2=C([H])N([H])C([H])=N2)=C(O[H])C([H])=C1O[H])([H])[H])([H])([H])[H],DB03749,,"4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole",,small molecule,,,,,
C(C(C([H])([H])[H])(C(C(O[H])=O)([H])[H])[H])([H])([H])[H],DB03750,503-74-2,Isovaleric Acid,,small molecule,,,,,
N(C(C(O[H])([H])[H])(C(O[H])([H])[H])C(O[H])([H])[H])([H])[H],DB03754,77-86-1,Tromethamine,"1,1,1-tris(hydroxymethyl)methanamine
2-Amino-2-(hydroxymethyl)-1,3-propanediol
aminotris(hydroxymethyl)methane
THAM
Tris
Tris(hydroxymethyl)aminomethane
Trometamol",small molecule,,"Cream
Injection, solution
Solution","Topical
Intravenous
Intravenous","3.6 g/100mL
36 mg",For the prevention and correction of metabolic acidosis.
C(C(C(=C(C(C(=C(C(C(=C(C(C(=C(C(C(=C(C(C(=C(C(C(C(O[H])=O)([H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])([H])([H])[H],"DB03756
DB11070",6217-54-5,Doconexent,"(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid
22:6-4, 7,10,13,16,19
22:6(n-3)
4,7,10,13,16,19-docosahexaenoic acid
4,7,10,13,16,19-Docosahexaenoic acid
all-cis-4,7,10,13,16,19-docosahexaenoic acid
all-cis-DHA
cervonic acid
DHA
docosa-4,7,10,13,16,19-hexaenoic acid
Docosahexaenoic acid",small molecule,,"Capsule
Kit
Tablet, film coated
Capsule, liquid filled
Kit
Tablet
Capsule, gelatin coated","Oral
Oral
Oral
Oral
Oral
Oral",,Used as a high-docosahexaenoic acid (DHA) oral supplement. 
[O-][N+](=O)C1=C([N+]([O-])=O)C([H])=C2N(C(=O)C(=O)N([H])C2=C1[H])[H],DB03759,2379-57-9,FG-9041,"2,3-quinoxalinedione, 1,4-dihydro-6,7-dinitro-
6,7-dinitro-1,4-dihydroquinoxaline-2,3-dione
6,7-dinitroquinoxaline-2,3-dione
DNQX",small molecule,,,,,
C(OC1=C(O[H])C([H])=C([H])C(OO[H])=C1[H])([H])([H])[H],DB03764,,4-Hydroperoxy-2-Methoxy-Phenol,,small molecule,,,,,
C(C(C(O[H])=O)([H])[H])([H])([H])[H],DB03766,79-09-4,Propanoic Acid,Propionic acid,small molecule,,,,,
N(C(=N[H])N(O[H])[H])([H])[H],DB03770,,N-Hydroxyguanidine,,small molecule,,,,,
C(N(C(C(=C([H])[H])[H])([H])[H])C(C(=C(C(OC1=C([H])C2=C(C(=C(O2)[H])C2=C([H])C([H])=C(Br)C([H])=C2[H])C([H])=C1[H])([H])[H])[H])[H])([H])[H])([H])([H])[H],DB03771,,Allyl-{4-[3-(4-Bromo-Phenyl)-Benzofuran-6-Yloxy]-but-2-Enyl}-Methyl-Amine,,small molecule,,,,,
C(N(C([H])([H])[H])C(C(C(N1C([H])=C(C2=C(C3=C([H])N([H])C4=C3C(=C(C(=C4[H])[H])[H])[H])C(=O)N([H])C2=O)C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03777,,Rbt205 Inhibitor,,small molecule,,,,,
N(C1=NC2=C(C(=C(C(=C2[H])[H])[H])[H])C(=O)N1[H])([H])[H],DB03780,,2-Aminoquinazolin-4(3h)-One,,small molecule,,,,,
C(C(OC1=C([H])C([H])=C(N(C(C([H])([H])[H])=O)[H])C([H])=C1[H])([H])[H])([H])([H])[H],"DB03783
DB08243",62-44-2,Phenacetin,"Acetophenetidin
Acetophenetidine
Acetophenetin
Acetphenetidin",small molecule,Humans and other mammals,,,,Used principally as an analgesic.
C(C(C(C(C(C(C(C(C(=C(C(C(C(C(C(C(C(C(N([H])[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03784,,Elaidoylamide,,small molecule,,,,,
C(C1=C(O[H])C(C(N=C2C([H])([H])ON=C2O[H])([H])[H])=C(C(OP(O[H])(O[H])=O)([H])[H])C([H])=N1)([H])([H])[H],DB03787,,"[5-hydroxy-6-methyl-4-({[(4E)-3-oxo-1,2-oxazolidin-4-ylidene]amino}methyl)pyridin-3-yl]methyl dihydrogen phosphate",,small molecule,,,,,
C(C1=C([H])C(OC(C(O[H])=O)([H])[H])=C([H])C(C([H])([H])[H])=C1C(C1=C([H])C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])=C(O[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB03788,,GC-24,,small molecule,,,,,
C(N1C([H])=C([H])[N+]([H])=C1C([H])([H])[H])([H])([H])[H],DB03789,,"2,3-Dimethylimidazolium Ion",,small molecule,,,,,
O(C(=O)C(C1=C([H])C([H])=C([H])C(OC(C(C(N(C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])([H])[H])C(C2=C([H])C([H])=C([H])C(C(F)(F)F)=C2Cl)([H])[H])([H])[H])([H])[H])([H])[H])=C1[H])([H])[H])[H],DB03791,,"(3-{3-[[2-Chloro-3-(Trifluoromethyl)Benzyl](2,2-Diphenylethyl)Amino]Propoxy}Phenyl)Acetic Acid",,small molecule,,,,,
N(C1=C([H])N([H])C(=O)N([H])C1=O)([H])[H],DB03792,,"5-Amino-1h-Pyrimidine-2,4-Dione",,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H])[H],DB03793,65-85-0,Benzoic Acid,,small molecule,,"Injection, solution, concentrate
Tincture
Lozenge
Liquid
Liquid
Tablet","Intravenous
Oral
Oral
Topical
Dental
Oral",,
C(C(C([H])([H])[H])(C(O[H])([H])[H])C(=O)C(O[H])=O)([H])([H])[H],DB03795,,2-Dehydropantoate,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03796,57-10-3,Palmitic Acid,"1-Hexyldecanoic Acid
1-Pentadecanecarboxylic acid
FAT
Hexadecanoate
Hexadecanoic acid
Hexadecoic acid
Hexadecylic acid
Hexaectylic acid
Palmitate
Palmitinic acid
Palmitinsaeure",small molecule,,"Powder, for solution
Ointment
Suspension","Intravenous
Topical
Endotracheal",,
C(C(OC(=O)C1=C(C([H])([H])[H])N(C2=C(Cl)C([H])=C([H])C([H])=C2[H])N=C1C([H])([H])[H])([H])[H])([H])([H])[H],DB03807,,"1-(2-Chlorophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester",,small molecule,,,,,
N(C(=N[H])C1=C([H])C([H])=C(OC(C(C(C(C(C(OC2=C([H])C([H])=C(C(N([H])[H])=N[H])C([H])=C2[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H],DB03808,3811-75-4,Hexamidine,,small molecule,,,,,
C(C(C(C(N1C(C(C2=C([H])C([H])=C([H])C(OC([H])([H])[H])=C2[H])([H])[H])=NC2=C1N=C(N=C2N([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03809,,9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine,,small molecule,,,,,
C(C(C(C(C(C(C(C(=C(C(=O)SC(C(N(C(C([H])([H])[H])=O)[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03813,,2-Decenoyl N-Acetyl Cysteamine,,small molecule,,,,,
O(S(=O)(=O)C(C(N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H])([H])[H])([H])[H])[H],DB03814,,2-(N-Morpholino)-Ethanesulfonic Acid,,small molecule,,,,,
O(N(C(=O)C1=C(O[H])C([H])=C([H])C([H])=C1[H])[H])[H],DB03819,89-73-6,Salicylhydroxamic Acid,,small molecule,,,,,
C(C(OP(O[H])(O[H])=O)([H])[H])([H])([H])[H],DB03822,,Ethyl Dihydrogen Phosphate,,small molecule,,,,,
IC1=C([H])C2=C(C(C(N(C2([H])[H])[H])([H])[H])([H])[H])C([H])=C1[H],DB03824,,"7-Iodo-1,2,3,4-Tetrahydro-Isoquinoline",,small molecule,,,,,
C(C(N(C1=C([H])C2=[O+]C3=C([H])C(N(C(C([H])([H])[H])([H])[H])[H])=C(C([H])([H])[H])C([H])=C3C(C3=C(C(=O)OC(C([H])([H])[H])([H])[H])C([H])=C([H])C([H])=C3[H])=C2C([H])=C1C([H])([H])[H])[H])([H])[H])([H])([H])[H],DB03825,989-38-8,Rhodamine 6G,"Basic red 1
Calcozine rhodamine 6GX
CI basic red 1
R6G",small molecule,,,,,
N(C1=C(N([H])[H])C(=O)N([H])C(=O)N1[H])([H])[H],DB03826,,"5,6-Diaminouracil",,small molecule,,,,,
C(C1=C([H])C(C(=O)[H])=C(OP(O[H])(O[H])=O)C(C(=O)[H])=C1[H])([H])([H])[H],DB03828,,RU78299,,small molecule,,,,,
N(C1=NC2=C(N=C(C(N(C3=C([H])C([H])=C(C(=O)OP(O[H])(O[H])=O)C([H])=C3[H])[H])([H])[H])C(=N2)[H])C(=O)N1[H])([H])[H],DB03830,,Phosphorylated Dihydropteroate,,small molecule,,,,,
ClC1=C([H])C(Cl)=C([H])C(Cl)=C1[H],DB03836,,"1,3,5-Trichloro-Benzene",,small molecule,,,,,
[N-]1C([H])=C([H])N=C1[H],DB03840,,Tetra(Imidazole)Diaquacopper (Ii),,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C(OC1=C(C#N)C([H])=C(N2C([H])=C(C(O[H])=O)C([H])=N2)C([H])=C1[H])([H])[H])([H])([H])[H],DB03841,,Y-700,,small molecule,,,,,
C(=O)([H])[H],DB03843,50-00-0,Formaldehyde,"Formaldehyde solution
Formalin
Formol
Methanal
Methyl aldehyde
Methylene oxide
Oxomethane
Oxomethylene
Oxymethylene
Paraform
Paraformaldehyde",small molecule,,"Powder
Tablet
Liquid
Liquid
Solution
Liquid","Topical
Dental
Topical
Topical
Topical
Dental",".2 mL/59mL
.1 mL/59mL
100 mg/mL",Use for drying skin before or after surgical removal of warts or where dryness is required. 
N(S(=O)(=O)C1=C([H])C([H])=C(C(=O)N(C(C2=C(F)C([H])=C([H])C([H])=C2F)([H])[H])[H])C([H])=C1[H])([H])[H],DB03844,,"N-(2,6-Diflouro-Benzyl)-4-Sulfamoyl-Benzamide",,small molecule,,,,,
O(C(=O)C(C(C(N1C2=C(C(=C(C(=C2[H])[H])[H])[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])[H],DB03851,,Carbazole Butanoic Acid,,small molecule,,,,,
O(C1=C(N=NC2=C(S(O[H])(=O)=O)C([H])=C3C(C(=C(C(N(C4=NC(N(C5=C(S(O[H])(=O)=O)C6=C(C(=C(N=NC7=C(O[H])C([H])=C([H])C(S(O[H])(=O)=O)=C7[H])C(O[H])=C6C([H])=C5[H])S(O[H])(=O)=O)[H])[H])=NC([H])=N4)[H])=C3S(O[H])(=O)=O)[H])[H])=C2O[H])C([H])=C(S(O[H])(=O)=O)C([H])=C1[H])[H],DB03853,,Reactive Red 6 hapten,"azo-dye hapten
RR6 azo-dye hapten",small molecule,,,,,
N(C(C(C(C(C(N([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB03854,,"Pentane-1,5-Diamine",,small molecule,,,,,
N(C(=[N+]([H])[H])C1=C(Cl)C([H])=C2N(C(=C([H])C2=C1[H])C1=C(O[H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])=C([H])C([H])=C1[H])[H])([H])[H],DB03865,,6-Chloro-2-(2-Hydroxy-Biphenyl-3-Yl)-1h-Indole-5-Carboxamidine,,small molecule,,,,,
C1(C([H])=C([H])N2C(C3=C([H])C([H])([H])C([H])=C([H])N3[Ru+2]32(N2C([H])=C([H])N=C2[H])N2C(=C(C(C([H])=C2C2=C(C(C(=C([H])N32)[H])([H])[H])[H])([H])[H])[H])[H])=C1[H])([H])[H],"DB03871
DB02003",,"lambda-bis(2,2'-bipyridine)imidazole ruthenium (II)","delta-bis(2,2'-bipyridine)imidazole ruthenium (II)",small molecule,,,,,
C(N(C([H])([H])[H])C(C(C(C(C([H])([H])[H])=C(C(C(C(C([H])([H])[H])=C(C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C([H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03874,,"(4e,8e,12z,16z)-N,N,4,8,13,17,21-Heptamethyldocosa-4,8,12,16,20-Pentaen-1-Amine",,small molecule,,,,,
N(C(=[N+]([H])[H])C1=C([H])C2=C(C(=C(N=C2S1)[H])[H])[H])([H])[H],DB03876,,"Thieno[2,3-B]Pyridine-2-Carboxamidine",,small molecule,,,,,
C(C1=C(N(C2=NC(C3=C([H])N=C([H])C([H])=C3[H])=C([H])C([H])=N2)[H])C([H])=C(N(C(=O)C2=C([H])N=C([H])C([H])=C2[H])[H])C([H])=C1[H])([H])([H])[H],DB03878,,N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide,,small molecule,,,,,
O(C(=O)C(=O)C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H],DB03884,156-06-9,Phenylpyruvic acid,,small molecule,,,,,
C(N(C(C(C(C(C(C(OC1=C([H])C2=C(C(=NN2C([H])([H])[H])C2=C([H])C([H])=C(Br)C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C(C(=C([H])[H])[H])([H])[H])([H])([H])[H],DB03888,,N-Allyl-6-{[3-(4-bromophenyl)-1-methyl-1H-indazol-6-yl]oxy}-N-methyl-1-hexanamine,,small molecule,,,,,
C(N(C([H])([H])[H])C1=C([H])C([H])=C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])=C2C([H])=C([H])C(=[N+](C([H])([H])[H])C([H])([H])[H])C([H])=C2[H])C([H])=C1[H])([H])([H])[H],DB03895,10309-95-2,Malachite Green,"malachite green cation
malachite green(1+)",small molecule,,,,,
O(P(O[H])(=O)OP(O[H])(=O)OP(O[H])(O[H])=O)[H],DB03896,10380-08-2,Triphosphoric acid,"acide triphosphorique
catena-triphosphoric acid
Inorganic triphosphate
Triphosphors��ure
tripolyphosphoric acid",small molecule,,,,,
O(C(=O)C(C(C1=C([H])C([H])=C(O[H])C([H])=C1[H])([H])[H])([H])[H])[H],DB03897,,Hydroxyphenyl Propionic Acid,,small molecule,,,,,
C(C(C(C(N1C(C(C2=C([H])C([H])=C(OC([H])([H])[H])C([H])=C2[H])([H])[H])=NC2=C1N=C(N=C2N([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03899,,9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine,,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])O[H])([H])([H])[H],DB03900,,2-Methyl-2-Propanol,,small molecule,,,,,
O(C(=O)C(O[H])=O)[H],"DB03902
DB02737",144-62-7,Oxalic Acid,,small molecule,,,,,
C(N(C([H])([H])[H])C1=C([H])C([H])([H])C2=C(C3=C(OC2=C1[H])C([H])=C(N(C([H])([H])[H])C([H])([H])[H])C([H])=C3[H])C1=C(C(O[H])=O)C([H])=C(N2C(=O)C([H])=C([H])C2=O)C([H])=C1[H])([H])([H])[H],DB03903,,Tmr,,small molecule,,,,,
C(C1=C(C(=C([H])[H])[H])C2=C(C3=[N+]4[Fe]56N2C1=C(C1=[N+]5C(=C(C2=C(C(C(C(O[H])=O)([H])[H])([H])[H])C(C([H])([H])[H])=C(N26)C([H])=C4C(C(=C([H])[H])[H])=C3C([H])([H])[H])C2=C([H])C([H])=C([H])C([H])=C2[H])C(C(C(C(O[H])=O)([H])[H])([H])[H])=C1C([H])([H])[H])[H])[H])([H])([H])[H],DB03906,,2-Phenylheme,,small molecule,,,,,
N(C(=N[H])SC(C(C1=C([H])C(C(C(SC(N([H])[H])=N[H])([H])[H])([H])[H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H],DB03910,,"S,S'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea",,small molecule,,,,,
C(C1=C(Cl)C([H])=C(N(C2=NC(C3=C([H])C(N4C([H])([H])C([H])([H])N(C(C(N([H])[H])([H])[H])([H])[H])C([H])([H])C4([H])[H])=NC([H])=C3[H])=C([H])C([H])=N2)[H])C([H])=C1[H])([H])([H])[H],DB03916,,4-{2-[4-(2-Aminoethyl)Piperazin-1-Yl]Pyridin-4-Yl}-N-(3-Chloro-4-Methylphenyl)Pyrimidin-2-Amine,,small molecule,,,,,
C(C(N(C(=O)C(=C(C([H])([H])[H])C(=C(C(=C(C([H])([H])[H])C(=C(C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H])[H])[H])[H])[H])[H])[H])[H])([H])[H])([H])([H])[H],DB03917,,N-Ethyl Retinamide,,small molecule,,,,,
C(C(N(C(=O)OC([H])([H])[H])[H])([H])[H])([H])([H])[H],DB03919,,Ethyl-Carbamic Acid Methyl Ester,,small molecule,,,,,
C(N(C(=C([H])[H])C(O[H])=O)[H])([H])([H])[H],DB03920,,N-Methyl-Alpha-Beta-Dehydroalanine,,small molecule,,,,,
N1(C([H])=C(C2=C([H])C([H])=NC3=C(C(=C(C([H])=C23)[H])[H])[H])C(C2=NC([H])=C([H])C([H])=C2[H])=N1)[H],DB03921,,4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline,,small molecule,,,,,
N(C1=C([H])C([H])=C(N([H])[H])C2=C1C(=O)C1=C(C2=O)C(O[H])=C([H])C([H])=C1O[H])([H])[H],DB03924,,"5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone",,small molecule,,,,,
O(C(=O)C(SC1=NC(C2=C([H])C([H])=C([H])C(Cl)=C2[H])=NO1)([H])[H])[H],DB03928,,"Carboxymethylthio-3-(3-Chlorophenyl)-1,2,4-Oxadiazol",,small molecule,,,,,
N(C(=O)C(O[H])=O)([H])[H],DB03940,471-47-6,Oxamic Acid,,small molecule,,,,,
C(C(C(C(C(C(C(C1=C([H])C([H])=C(O[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03941,,Heptanyl-P-Phenol,,small molecule,,,,,
C([N+](C([H])([H])[H])(C([H])([H])[H])C(C(OP(O[H])(O[H])=O)([H])[H])([H])[H])([H])([H])[H],DB03945,3616-04-4,"N,N,N-Trimethyl-2-(phosphonooxy)ethanaminium","Choline, dihydrogen phosphate (ester) (8CI)
Ethanaminium, N,N,N-trimethyl-2-(phosphonooxy)-
Phosphocholine cation",small molecule,,,,,
O(C(=O)C1=C([H])C(O[H])=C(O[H])C([H])=C1[H])[H],DB03946,99-50-3,"3,4-Dihydroxybenzoic Acid",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(OS(O[H])(=O)=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03967,,Dodecyl Sulfate,,small molecule,,,,,
C(N1C(=O)C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H])([H])([H])[H],DB03968,,"1-Methyl-2-Oxy-5,5-Dimethyl Pyrrolidine",,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C([Hg])C([H])=C1[H])[H],DB03975,,Mercuribenzoic Acid,,small molecule,,,,,
C(C(C([H])([H])[H])(OP(O[H])(O[H])=O)[H])([H])([H])[H],"DB03976
DB04251",,Phosphorylisopropane,,small molecule,,,,,
N(C1=NC([H])=C([H])C(C2=C(C3=C([H])C([H])=C(F)C([H])=C3[H])N=C([H])N2C(C2(C([H])([H])C2([H])[H])[H])([H])[H])=N1)([H])[H],DB03980,,4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole,,small molecule,,,,,
O(C(=O)C(=O)N(C1=C([H])C([H])=C([H])C2=C(C(=C(C([H])=C12)[H])[H])[H])C1=C(C(O[H])=O)C([H])=C([H])C([H])=C1[H])[H],DB03982,,"Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid",,small molecule,,,,,
C(OC1=C([H])C(OC([H])([H])[H])=C([H])C(C(N(C([H])([H])[H])C2=C([H])C3=C(N([H])[H])N=C(N([H])[H])N=C3N=C2[H])([H])[H])=C1[H])([H])([H])[H],DB03987,,"2,4-Diamino-6-[N-(3',5'-Dimethoxybenzyl)-N-Methylamino]Pyrido[2,3-D]Pyrimidine",,small molecule,,,,,
C(C(C([H])([H])[H])(C(C(C(O[H])=O)([H])[H])([H])[H])[H])([H])([H])[H],DB03993,,4-Methyl Valeric Acid,,small molecule,,,,,
N(C(C(O[H])([H])[H])([H])[H])([H])[H],DB03994,141-43-5,Ethanolamine,,small molecule,,,,,
N(C(C1=NC(=C(C2=C([H])C([H])=C(O[H])C([H])=C2[H])[H])C(=O)N1C(C(O[H])=O)([H])[H])([H])[H])([H])[H],DB03998,,"[2-(Methyleneamine)-4-(4-Hydroxy-Benzylidine)-5-Oxo-4,5-Dihydro-Imidazol-1-Yl]-Acetaldehyde",,small molecule,,,,,
C(C(C(C(P(O[H])(O[H])=O)([H])[H])([H])[H])([H])[H])([H])([H])[H],DB03999,,Butylphosphonate,,small molecule,,,,,
O(C(=O)C(=O)N(C1=C(C(O[H])=O)C([H])=C2C(=C(N([H])C2=C1[H])[H])[H])[H])[H],DB04001,,6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(C(=O)N(C(C(C(C(N(C(S[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])C([H])=C1[H])([H])[H],DB04002,,4-Sulfonamide-[4-(Thiomethylaminobutane)]Benzamide,,small molecule,,,,,
C(N(C([H])([H])[H])C(C(SC(C1=C2N=C(N([H])[H])N(C(=O)C2=C([H])C(N([H])[H])=C1[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04004,,"2,6-Diamino-8-(2-Dimethylaminoethylsulfanylmethyl)-3h-Quinazolin-4-One",,small molecule,,,,,
N(C1=C(C(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])N2C(=C(C(=C([H])C2=N1)[H])C(=O)C1=C(F)C([H])=C([H])C([H])=C1F)[H])([H])[H],DB04006,,"[2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone",,small molecule,,,,,
C(C1(C([H])([H])[H])N=C(N([H])[H])N=C(N([H])[H])N1OC(C(C(OC1=C([H])C([H])=C(Br)C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04007,,Bromo-WR99210,,small molecule,,,,,
N(C(=N[H])C1=C([H])C2=C(N3[Zn]N4C(=[N+](C5=C4C([H])=C([H])C(C(N([H])[H])=N[H])=C5[H])[H])C([H])([H])C3=[N+]2[H])C([H])=C1[H])([H])[H],DB04008,,Bis(5-Amidino-Benzimidazolyl)Methane Zinc,,small molecule,,,,,
C(OC(=O)C(C(C1=C(C([H])([H])[H])C2N3[Fe]45N6C(C(=C(C6=C(C6=C(C([H])([H])[H])C(C(C(C(=O)OC([H])([H])[H])([H])[H])([H])[H])=C(C([H])=C13)N64)[H])C([H])([H])[H])C(=C([H])[H])[H])=C([H])C1=C(C(=C(C=2[H])N51)C(=C([H])[H])[H])C([H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04009,,Dimethyl Propionate Ester Heme,,small molecule,,,,,
C(OC1=C([H])C([H])=C([H])C(C2=NC3=C(C(=C(C([H])=C3N2[H])[H])[H])C(N([H])[H])=O)=C1[H])([H])([H])[H],DB04010,,2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide,,small molecule,,,,,
C(N(C([H])([H])[H])C1=C([H])C([H])=C(C2=NC3=C(C(=C(C(=C3[H])C3=NC4=C(C(=C(C(=C4[H])[H])N4C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C4([H])[H])[H])N3[H])[H])[H])N2[H])C([H])=C1[H])([H])([H])[H],DB04011,,"2'-(4-Dimethylaminophenyl)-5-(4-Methyl-1-Piperazinyl)-2,5'-Bi-Benzimidazole",,small molecule,,,,,
[O-][N+](=O)C1=C([H])C2=C(N(C3=C2C([H])([H])C(=O)N([H])C2=C3C(=C(C(=C2[H])[H])[H])[H])[H])C([H])=C1[H],DB04014,,Alsterpaullone,,small molecule,,,,,
C(N(C(C(C(OC1=C(Cl)C([H])=C(Cl)C([H])=C1[H])([H])[H])([H])[H])([H])[H])C(C#C[H])([H])[H])([H])([H])[H],DB04017,,"N-Methyl-N-Propargyl-3-(2,4-Dichlorophenoxy)Propylamine",,small molecule,,,,,
C(C(C([H])([H])[H])(SC(N([H])[H])=N[H])[H])([H])([H])[H],DB04018,,S-Isopropyl-Isothiourea,,small molecule,,,,,
O(C1=C([H])C([H])=C(C(C(N(C2=NC(SC(C(C(C3=C([H])C([H])=C(Cl)C([H])=C3[H])([H])[H])([H])[H])([H])[H])=NC(N3C([H])([H])C([H])([H])N([H])C([H])([H])C3([H])[H])=N2)[H])([H])[H])([H])[H])C([H])=C1[H])[H],DB04020,,"4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol",,small molecule,,,,,
O(C1=C([H])C([H])=C(C(N2C3=C(C(C(N(C3([H])[H])C(=O)C3=C([H])C([H])=C(O[H])C([H])=C3[H])([H])[H])([H])[H])C3=C2C(=C(C(=C3[H])[H])[H])[H])([H])[H])C([H])=C1[H])[H],DB04030,,"1,3,4,9-Tetrahydro-2-(Hydroxybenzoyl)-9-[(4-Hydroxyphenyl)Methyl]-6-Methoxy-2h-Pyrido[3,4-B]Indole",,small molecule,,,,,
C(C(C([H])([H])[H])(ON=C(C(=O)N(C(B(O[H])O[H])([H])[H])[H])C1=C([H])SC(N([H])[H])=N1)C(O[H])=O)([H])([H])[H],DB04035,,Pinacol[[2-Amino-Alpha-(1-Carboxy-1-Methylethoxyimino)-4-Thiazoleacetyl]Amino]Methaneboronate,,small molecule,,,,,
ClC1=C([H])C([H])=C(C(N(C(C2=C([H])C([H])=C(Cl)C([H])=C2[H])([H])[H])C2=NN([H])N=N2)([H])[H])C([H])=C1[H],DB04037,,"N,N-Bis(4-Chlorobenzyl)-1h-1,2,3,4-Tetraazol-5-Amine",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(C(=O)C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04039,,3-Oxo-Pentadecanoic Acid,,small molecule,,,,,
O(C(=O)C1=C(C(O[H])=O)C([H])=C(OC2=C(N(C(=O)C3=C([H])C([H])=C([H])C([N+]([O-])=O)=C3[H])[H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])[H],DB04044,,4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid,,small molecule,,,,,
O(C1=C([H])C([H])=C(C(C(=O)N(C2=NC([H])=C(C3=C([H])C([H])=C(O[H])C([H])=C3[H])N=C2C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])[H])([H])[H])C([H])=C1[H])[H],DB04049,,Coelenteramide,,small molecule,,,,,
C(C(C([N+]#[C-])([H])[H])([H])[H])([H])([H])[H],DB04050,,N-Propyl Isocyanide,,small molecule,,,,,
O(C(=O)C(C(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB04051,,5-Phenylvaleric Acid,,small molecule,,,,,
C(C1=C(C([H])([H])[H])C([H])=C(O[H])C([H])=C1[H])([H])([H])[H],DB04052,,"3,4-Dimethylphenol",,small molecule,,,,,
[O-]P=O,DB04053,,Hypophosphite,,small molecule,,,,,
C(C(C(C(N1C(C(C2=C(OC([H])([H])[H])C([H])=C([H])C(OC([H])([H])[H])=C2[H])([H])[H])=NC2=C(N([H])[H])N=C(F)N=C12)([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04054,,"9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine",,small molecule,,,,,
N(C(=N[H])C1=C([H])C([H])=C2C(=C(C(=C(N(C3=NC([H])=C([H])C([H])=N3)[H])C2=C1[H])[H])[H])[H])([H])[H],DB04059,,8-(Pyrimidin-2-Ylamino)Naphthalene-2-Carboximidamide,,small molecule,,,,,
C(OC(=O)C1=C(C([H])([H])[H])C([H])([H])C(=O)C2=C1C(=C1C(=O)C3=C(C(=C(C(O[H])=C3C(=O)C1=C2O[H])[H])[H])[H])[H])([H])([H])[H],DB04064,,Nogalaviketone,,small molecule,,,,,
O=C(N(C1(C([H])([H])C([H])([H])C1([H])[H])[H])C1(C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])[H],DB04065,,N-Cyclopentyl-N-Cyclobutylformamide,,small molecule,,,,,
O(C(=O)C(=C(C1=C([H])C([H])=C(O[H])C([H])=C1[H])[H])[H])[H],DB04066,,para-Coumaric Acid,"4-coumaric acid
p-Coumaric acid",small molecule,,,,,
N(C1=C([H])C2=C(C3=C(C(C2([H])[H])([H])[H])C([H])=C([H])C([H])=C3[H])N=N1)([H])[H],DB04069,,"5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine",,small molecule,,,,,
C(C(C([H])([H])[H])(C(=O)C(O[H])=O)[H])([H])([H])[H],DB04074,759-05-7,Alpha-ketoisovalerate,"2-Keto-3-methylbutyric acid
2-Ketovaline
2-Oxo-3-methylbutanoate
2-Oxoisopentanoate
2-Oxoisovalerate
3-Methyl-2-oxobutanoate
3-Methyl-2-oxobutanoic acid
3-Methyl-2-oxobutyric acid
alpha-Ketovaline",small molecule,,,,,
O(C1=NC([H])=NC2=C1N(C(=N2)[H])[H])[H],DB04076,68-94-0,Hypoxanthine,,small molecule,,,,,
O(C(=O)C(C(O[H])=O)(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H],DB04080,,RU78191,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(OC(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04082,,Decyloxy-Methanol,,small molecule,,,,,
O=C1C([H])=C([H])C(=O)N1C(OC(N1C(=O)C([H])=C([H])C1=O)([H])[H])([H])[H],DB04085,,"1-[Pyrrol-1-Yl-2,5-Dione-Methoxymethyl]-Pyrrole-2,5-Dione",,small molecule,,,,,
C(C1=C(N2C([H])([H])C2([H])[H])C(=O)C(C(O[H])([H])[H])=C(N2C([H])([H])C2([H])[H])C1=O)([H])([H])[H],"DB04090
DB12103",221635-42-3,RH-1,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(=O)[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04093,,Undecanal,,small molecule,,,,,
C(C(=O)C(C(O[H])([H])[H])([H])[H])([H])([H])[H],DB04094,,4-Hydroxy-2-Butanone,,small molecule,,,,,
O(C1=NC([H])=NC2=C1N(C(=C2[H])[H])[H])[H],DB04095,,9-Deazahypoxanthine,,small molecule,,,,,
C(C1=NC(C([H])([H])[H])=C(C2=NC(N(C(=NO[H])[H])[H])=NC([H])=C2[H])S1)([H])([H])[H],DB04101,,"N-[4-(2,4-Dimethyl-1,3-Thiazol-5-Yl)Pyrimidin-2-Yl]-N'-Hydroxyimidoformamide",,small molecule,,,,,
C([N+]1=C(N([H])[H])C([H])=C([H])N([H])C1=O)([H])([H])[H],DB04103,,3-Methylcytosine,,small molecule,,,,,
C(N1C([H])=NC(N([H])[H])=C2N=C(N=C12)[H])([H])([H])[H],DB04104,,3-Methyladenine,,small molecule,,,,,
C(C(C(C(C(C(C(N(C(=O)[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04105,,N-Heptylformamide,,small molecule,,,,,
C(C(OC(=O)C(ON=C(C1=NC([H])=C([H])C([H])=C1[H])C1(C([H])([H])C1([H])[H])C1=C([H])C2=C(N(C([H])([H])[H])C(C(N(C3=C([H])C([H])=C(C(N([H])[H])=N[H])C([H])=C3[H])[H])([H])[H])=N2)C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB04107,,[(1-{2[(4-Carbamimidoyl-Phenylamino)-Methyl]-1-Methyl-1h-Benzoimidazol-5-Yl}-Cyclopropyl)-Pyridin-2-Yl-Methyleneaminooxy]-Acetic Acid Ethyl Ester,,small molecule,,,,,
N(C(=[N+]([H])[H])C1=C([H])C([H])=C(C(OB2OC([H])([H])C([H])([H])O2)([H])[H])C([H])=C1[H])([H])[H],DB04109,,"[4-(1,3,2-Dioxaborolan-2-Yloxy)Methyl]Benzamidine",,small molecule,,,,,
C(C1=C([H])C([N+]([O-])=O)=C(O[H])C([H])=C1[H])([H])([H])[H],DB04110,,2-Nitro-P-Cresol,,small molecule,,,,,
O=C(N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H],DB04113,,N-Formylpiperidine,,small molecule,,,,,
C(OC1=C([H])C([H])=C2C(=C3C4=C(C5=C(C([H])=C4C([H])([H])C([H])([H])[N+]3=C([H])C2=C1OC([H])([H])[H])OC([H])([H])O5)[H])[H])([H])([H])[H],DB04115,2086-83-1,Berberine,,small molecule,,,,,
Br[H],DB04119,,Hexatantalum Dodecabromide,,small molecule,,,,,
C(C1=C([H])C(O[H])=C(O[H])C([H])=C1[H])([H])([H])[H],DB04120,452-86-8,"4-Methyl-1,2-Benzenediol",,small molecule,,,,,
C(OC1=C([H])C2=C(N=C(N2[H])[H])C([H])=C1[H])([H])([H])[H],DB04130,,5-Methoxybenzimidazole,,small molecule,,,,,
O(C(=NC(C(=O)C(=O)[H])([H])[H])C1=C([H])C(N(C(C(Br)([H])[H])([H])[H])C(C(Br)([H])[H])([H])[H])=C([N+]([O-])=O)C([H])=C1[N+]([O-])=O)[H],DB04138,,"2,4-Dinitro,5-[Bis(2-Bromoethyl)Amino]-N-(2',3'-Dioxopropyl)Benzamide",,small molecule,,,,,
C(C1=C(C(C(C(O[H])([H])[H])([H])[H])([H])[H])N([H])C(=O)N([H])C1=O)([H])([H])[H],DB04139,,6-Hydroxypropylthymine,,small molecule,,,,,
C(C(C1=C(C(=O)C2=C([H])C(Br)=C(O[H])C(Br)=C2[H])C2=C(C(=C(C(=C2[H])[H])S(=O)(=O)N(C([H])([H])[H])C([H])([H])[H])[H])O1)([H])[H])([H])([H])[H],DB04142,,"3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide",,small molecule,,,,,
O(C(C1=C([H])N=C([H])C([H])=C1[H])([H])[H])[H],DB04145,100-55-0,Nicotinyl alcohol,"3-pyridinemethanol
beta-pyridylcarbinol
Nicotinic alcohol
Pyridylcarbinol
Pyridylmethanol",small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C([N+](C([H])([H])[H])(C([H])([H])[H])[O-])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04147,,Lauryl Dimethylamine-N-Oxide,,small molecule,,,,,
C(N(C(C([H])([H])[H])=O)C1=C([H])C(C2=NN=C3C(=C(C(=NN23)C2=C([H])C([H])=C([H])C([H])=C2[H])[H])[H])=C([H])C([H])=C1[H])([H])([H])[H],DB04154,,"N-Methyl-N-[3-(6-Phenyl[1,2,4]Triazolo[4,3-B]Pyridazin-3-Yl)Phenyl]Acetamide",,small molecule,,,,,
N(OC(=O)N(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H],DB04157,,N-[(Aminooxy)Carbonyl]Aniline,,small molecule,,,,,
O(P(O[H])(=O)OP(O[H])(O[H])=O)[H],"DB04160
DB11055",2466-09-3,Pyrophosphoric acid,"acide diphosphorique
Diphosphoric acid
Diphosphors��ure
Pyrophosphors��ure",small molecule,,"Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution","Intravenous
Intravenous",27.6 mg/1,
C(C(C(N([H])[H])=O)([H])[H])([H])([H])[H],DB04161,,Propionamide,,small molecule,,,,,
N(C1=NC(N([H])[H])=C2C(SC3=C([H])C([H])=C([H])C([H])=C3[H])=C(C(=C([H])C2=N1)[H])[H])([H])[H],DB04163,,"5-Phenylsulfanyl-2,4-Quinazolinediamine",,small molecule,,,,,
C(C(C(C(C(C(C([H])([H])[H])([H])[H])([H])[H])(C(N([H])[H])=O)[H])([H])[H])([H])[H])([H])([H])[H],DB04165,,Valpromide,,small molecule,,,,,
N(C1=C(C(O[H])=O)C([H])=C([H])C([H])=C1[H])([H])[H],"DB04166
DB04056",118-92-3,Anthranilic acid,"2-Aminobenzoes��ure
2-aminobenzoic acid
2-carboxyaniline
o-Aminobenzoes��ure
o-Aminobenzoic acid
o-carboxyaniline
Vitamin L1",small molecule,,,,,
N(C1=NC(O[H])=C(Br)C(C2=C([H])C([H])=C([H])C([H])=C2[H])=N1)([H])[H],DB04168,,2-Amino-5-Bromo-6-Phenylpyrimidin-4-Ol,,small molecule,,,,,
N(C1=C([H])C(N([H])[H])=C2C(=O)N(N(C(=O)C2=C1[H])[H])[H])([H])[H],DB04169,,"3,5-Diaminophthalhydrazide",,small molecule,,,,,
O(C(=O)C(C(C1=C(C(O[H])=O)N([H])C2=C(C(Cl)=C(C(Cl)=C12)[H])[H])([H])[H])([H])[H])[H],DB04175,101861-63-6,Mdl-29951,,small molecule,,,,,
O1C([H])=C([H])C2=C1C(=C(C(=C2[H])[H])[H])[H],DB04179,,Benzofuran,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(C(=O)N(C(C2=C(F)C([H])=C(F)C([H])=C2[H])([H])[H])[H])C([H])=C1[H])([H])[H],DB04180,,"4-(Aminosulfonyl)-N-[(2,4-Difluorophenyl)Methyl]-Benzamide",,small molecule,,,,,
C(C(C(O[H])=O)(C(O[H])=O)[H])([H])([H])[H],DB04183,516-05-2,Methylmalonic Acid,,small molecule,,,,,
C(=C=C(C(N(C(C(C(C(N(C(C(=C=C([H])[H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])[H])([H])[H],DB04188,,MDL72527,,small molecule,,,,,
N(C1=NC(O[H])=C2N=C(C(N(C3=C([H])C([H])=C(C(O[H])=O)C([H])=C3[H])[H])([H])[H])C(=NC2=N1)[H])([H])[H],DB04196,119-24-4,Pteroic Acid,,small molecule,,,,,
N(C(N(O[H])[H])=NC(C(C([N+]([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB04197,,Descarboxy-nor-N(Omega)-Hydroxy-L-Arginine,,small molecule,,,,,
C(OC1=C([H])C2=C(C(=O)C(=C(O2)[H])C2=C([H])C([H])=C(O[H])C([H])=C2[H])C([H])=C1[H])([H])([H])[H],DB04202,,Isoformononetin,,small molecule,,,,,
N(C1=C([Hg])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C1[H])([H])[H],DB04203,,3-Mercuri-4-Aminobenzenesulfonamide,,small molecule,,,,,
O(P(O[H])(=O)C(F)(F)C1=C([H])C([H])=C(C(C(C(C(C2=C([H])C([H])=C(C(F)(F)P(O[H])(O[H])=O)C([H])=C2[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])[H],DB04204,,[(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid,,small molecule,,,,,
C(OC1=C(OC([H])([H])[H])C([H])=C(C(C(C(O[H])=O)([H])[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB04208,,"3-(3,4-Dimethoxyphenyl)Propionic Acid",,small molecule,,,,,
C(C1=[N+](C(C(C(C(C(C(C(C(C(C([N+]2=C(C([H])([H])[H])C([H])=C(N([H])[H])C3=C(C(=C(C([H])=C23)[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C2=C(C(=C(C([H])=C2C(N([H])[H])=C1[H])[H])[H])[H])([H])([H])[H],"DB04209
DB11615",6707-58-0,Dequalinium,"1,1'-(1,10-Decanediyl)bis(4-amino-2-methylquinolinium) dichloride
1,1'-Decamethylenebis(4-aminoquinaldinium chloride)
Decamethylenebis(4-aminoquinaldinium chloride)",small molecule,"Candida albicans and other yeasts
Trichomonas vaginalis, Giardia duodenalis, and Entamoeba histolytica
Bacteria and protozoa
Bacteroides
Peptostreptococcus","Lozenge
Lozenge
Liquid
Liquid","Oral
Oral
Oral
Oral","0.25 mg
.25 mg
0.5 %
.5 %","Effective local treatment as vaginal tablets for infections such as fluor vaginalis, bacterial vaginosis, aerobic vaginitis, vulvo-vaginal candidiasis and trichomoniasis. Used as a topical antimicrobial agent. "
C(C(=N[H])C(O[H])=O)([H])([H])[H],DB04212,,2-Iminiopropanoate,,small molecule,,,,,
O=C(N(C(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])[H])N(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])[H],DB04213,,N-Cyclohexyl-N'-(Propyl)Phenyl Urea,,small molecule,,,,,
O(P(O[H])(=O)OC1=C([H])C([H])=C([N+]([O-])=O)C([H])=C1[H])[H],DB04214,330-13-2,4-Nitrophenyl Phosphate,,small molecule,,,,,
C(C1=C([H])C(Br)=C(O[H])C(C2=C([H])C3=C(C(=C(C(=C3[H])C(N([H])[H])=N[H])[H])[H])N2[H])=C1[H])([H])([H])[H],DB04215,,CRA_9076,,small molecule,,,,,
O(C1=C([H])C2=C(C(=O)C(O[H])=C(O2)C2=C([H])C(O[H])=C(O[H])C([H])=C2[H])C(O[H])=C1[H])[H],DB04216,117-39-5,Quercetin,"3,5,7,3',4'-Pentahydroxyflavone",small molecule,,,,,
O([V](=O)(O[V]([O-])=O)O[V](=O)=O)[H],DB04219,,Trivanadate,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C([N+](C([H])([H])[H])(C([H])([H])[H])C(C(C(C(C(C(C(C(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],"DB04221
DB11287",20256-56-8,Didecyldimethylammonium,"Didecyl-dimethyl-ammonium
Didecyldimethylammonium cation
Didecyldimethylammonium ion
Didecyldimonium",small molecule,,"Liquid
Cloth
Lotion
Spray
Soap","Topical
Topical
Topical
Topical",,
C(N(C(=C(C([H])([H])[H])[H])C(O[H])=O)[H])([H])([H])[H],DB04225,,N-Methyldehydrobutyrine,,small molecule,,,,,
O(C(=O)C(N(C(C(N(C(C(O[H])=O)([H])[H])C(C(=O)N(C(C(S[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])C(C(N(C(C(O[H])=O)([H])[H])C(C(=O)N(C(C(S[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB04229,,"7,10,13-Tri(Carboxymethyl)-5,15-Dioxo-4,7,10,13,16-Pentaaza-1,19-Dithianonadecane",,small molecule,,,,,
C(C(C(C(C(C(C(C(OC(C(OC(C(OC(C(OC(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04233,,(Hydroxyethyloxy)Tri(Ethyloxy)Octane,,small molecule,,,,,
N(C(C(C(O[H])([H])[H])([H])[H])(C(C(O[H])([H])[H])([H])[H])C(C(O[H])([H])[H])([H])[H])([H])[H],DB04237,,Tris(Hydroxyethyl)Aminomethane,,small molecule,,,,,
N(C(C1=C([H])C(C(SC2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])=C2N=C(N([H])[H])N(C(=O)C2=C1[H])[H])([H])[H])([H])[H],DB04239,,2-Amino-6-Aminomethyl-8-Phenylsulfanylmethyl-3h-Quinazolin-4-One,,small molecule,,,,,
C(C1=C(O[H])C(C(N(C(C([H])([H])[H])(C([H])([H])[H])C(O[H])=O)[H])([H])[H])=C(C(OP(O[H])(O[H])=O)([H])[H])C([H])=N1)([H])([H])[H],DB04241,,N-Pyridoxyl-2-Methylalanine-5-Phosphate,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C(O[H])C([H])=C1[H])[H],DB04242,,P-Hydroxybenzoic Acid,,small molecule,,,,,
N(C(=N[H])C1=C([H])C2=C(N=C(N2[H])C2=C([H])C(C(C([N+]([H])([H])[H])([H])[H])([H])[H])=C([H])C(C3=C([H])C([H])=C([H])C([H])=C3[H])=C2O[H])C([H])=C1[H])([H])[H],DB04246,,CRA_23653,,small molecule,,,,,
C(C(=C1C(C([H])([H])[H])=C2[N-]C1=C(C1=C(C([H])([H])[H])C(=C(C([H])([H])[H])[H])C(=C(C3=C(C([H])([H])[H])C(C(C(C(O[H])=O)([H])[H])([H])[H])=C(C(=C4[N-]C(=C2[H])C(C([H])([H])[H])=C4C(C(C(O[H])=O)([H])[H])([H])[H])[H])[N-]3)[H])[N-]1)[H])[H])([H])([H])[H],DB04249,,Zinc Substituted Heme C,,small molecule,,,,,
C(C(C(C(=O)SC(C([N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04250,,Butyrylthiocholine,,small molecule,,,,,
N(C(=O)C1=C([H])C(N2C([H])([H])C2([H])[H])=C([N+]([O-])=O)C([H])=C1[N+]([O-])=O)([H])[H],"DB04253
DB12772",21919-05-1,Tretazicar,,small molecule,,,,,
C(C(C(C(N1C(C(C2=C([H])C3=C(OC(O3)([H])[H])C([H])=C2[H])([H])[H])=NC2=C(N([H])[H])N=C(F)N=C12)([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04254,,"8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine",,small molecule,,,,,
C(C(C(C(C(C(C(=C(C(C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04257,373-49-9,Palmitoleic Acid,"(9Z)-hexadecenoic acid
(Z)-9-hexadecenoic acid
(Z)-hexadec-9-enoic acid
9-cis-hexadecenoic acid
cis-9-Hexadecenoic acid
palmitolinoleic acid
zoomaric acid",small molecule,,,,,
N(C1=NC2=C(N=C(N2C(C(C(C(C(F)(F)P(O[H])(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])[H])C(=O)N1[H])([H])[H],DB04260,,"9-(5,5-Difluoro-5-Phosphonopentyl)Guanine",,small molecule,,,,,
N(C(O[H])=O)([H])[H],DB04261,463-77-4,Carbamic Acid,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C([H])C(C(O[H])=O)=N1)[H],DB04267,,Dipicolinic Acid,,small molecule,,,,,
C(C(OC(=O)C1=C(C([H])([H])[H])N([H])N=C1C([H])([H])[H])([H])[H])([H])([H])[H],DB04271,,"3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester",,small molecule,,,,,
O(C(=O)C(C(O[H])(C(C(O[H])=O)([H])[H])C(O[H])=O)([H])[H])[H],DB04272,77-92-9,Citric Acid,"2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Citric Acid, Anhydrous
Citronens��ure",small molecule,Humans and other mammals,"Liquid
Solution
Kit
Tablet, effervescent
Tablet
Aerosol, spray
Injection, solution
Solution
Injection, solution
Liquid
Powder, for solution
Granule
Solution
Granule, effervescent
Solution
Capsule, delayed release pellets
Solution
Liquid
Liquid
Kit
Kit
Kit
Liquid
Powder
Granule, for solution
Powder, metered
Powder, for solution
Solution
Solution
Spray
Spray
Liquid
Liquid","Intravenous
Intravenous
Oral
Oral
Topical
Extracorporeal
Unknown
Intravenous
Topical
Oral
Intravenous
Oral
Hemodialysis
Oral
Intravenous
Oral
Extracorporeal
Topical
Topical
Oral
Intravenous
Oral
Oral
Oral
Oral
Irrigation; Topical
Irrigation
Oral
Topical
Topical
Irrigation
Topical","8 mg/mL
1.5 g/30mL
.3 g/100g
.7 mg/100mL
7 mg/mL
.007 g/mL",
ClC1=C(Cl)C2=C(C(C(C(N(C2([H])[H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H],DB04273,,"8,9-Dichloro-2,3,4,5-Tetrahydro-1h-Benzo[C]Azepine",,small molecule,,,,,
C(C(=O)N(C(C(C1=C([H])N([H])C2=C1C(=C(O[H])C(=C2[H])[H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB04275,,N-Acetyl Serotonin,,small molecule,,,,,
C(C(C([H])([H])[H])(C(C(O[H])(C(O[H])=O)[H])(C(O[H])=O)[H])[H])([H])([H])[H],DB04279,,3-Isopropylmalic Acid,,small molecule,,,,,
O(C1=C2N=C(N([H])C2=NC(Br)=N1)[H])[H],DB04283,,2-Bromo-6-Hydroxy-Purine,,small molecule,,,,,
O=C(N1C([H])([H])C([H])([H])N(C2(C3=C(C(=C(C(=C3[H])[H])[H])[H])C3=C2C(=C(C(=C3[H])[H])[H])[H])[H])C([H])([H])C1([H])[H])C1=C([H])C2=C(N(C(=C2[H])[H])[H])C([H])=C1[H],DB04289,,Genz-10850,,small molecule,,,,,
N(C(=N[H])C1=C([H])C2=C(N=C(N2[H])C(O[H])(O[H])C2=NC3=C(C(=C(C(=C3[H])[H])C([N+]([H])([H])[H])=[N+]([H])[H])[H])N2[H])C([H])=C1[H])([H])[H],DB04301,,Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone Hydrate,,small molecule,,,,,
C(C1=C([H])C([H])=C(SC2=C([H])C([H])=C([H])C3=NC(N([H])[H])=NC(N([H])[H])=C23)C([H])=C1[H])([H])([H])[H],DB04306,,"5-[(4-Methylphenyl)Sulfanyl]-2,4-Quinazolinediamine",,small molecule,,,,,
N(C(C(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB04311,,4-Phenylbutylamine,,small molecule,,,,,
O(C(C1=C([H])C([H])=C([H])C(F)=C1F)([H])[H])[H],DB04312,,"2,3-Difluorobenzyl Alcohol",,small molecule,,,,,
C(N1C([H])=C([H])C(N([H])[H])=NC1=O)([H])([H])[H],DB04314,,1-Methylcytosine,,small molecule,,,,,
O(C(=O)C(C(P(O[H])(O[H])=O)([H])[H])=C(Cl)Cl)[H],DB04317,,"3,3-Dichloro-2-Phosphonomethyl-Acrylic Acid",,small molecule,,,,,
O(C(C(Br)=C([H])[H])([H])[H])[H],DB04320,,2-Bromo-2-Propene-1-Ol,,small molecule,,,,,
N(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H],DB04325,64-04-0,Phenethylamine,"2-phenylethylamine
benzeneethanamine
beta-Phenylethylamine
Phenylethylamine
��-aminoethylbenzene
��-phenethylamine",small molecule,,,,,
O(C(C(=O)C(OP(O[H])(O[H])=O)([H])[H])([H])[H])[H],"DB04326
DB12496",57-04-5,Dihydroxyacetone phosphate,"1-hydroxy-3-(phosphonooxy)-2-Propanone
1-Hydroxy-3-(phosphonooxy)acetone
1,3-Dihydroxy-2-propanone monodihydrogen phosphate
1,3-Dihydroxy-2-propanone phosphate
1,3-Dihydroxyacetone 1-phosphate
3-hydroxy-2-oxopropyl phosphate
DHAP
Dihydroxyacetone monophosphate
Glycerone monophosphate
Glycerone phosphate",small molecule,,,,,
C1(=C([H])C([H])=C2C(=NC(=C([H])C2=C1[H])[H])[H])[H],DB04329,119-65-3,Isoquinoline,,small molecule,,,,,
C(OC(C(OC(C(OC(C(OC(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04332,,2-{2-[2-2-(Methoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethanol,,small molecule,,,,,
N(C(C(C(C(C(C(C(C(N([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB04333,373-44-4,Octamethylenediamine,"1,8-Diaminooctane
1,8-Octamethylenediamine
1,8-Octanediamine
1,8-Octylenediamine",small molecule,,,,,
N(C(=N[H])C1=C([H])C([H])=C(N(C(=O)N(C2=C([H])C([H])=C(Cl)C([H])=C2[H])[H])[H])C([H])=C1[H])([H])[H],DB04336,,1-(4-Amidinophenyl)-3-(4-Chlorophenyl)Urea,,small molecule,,,,,
C([N+]#[C-])([H])([H])[H],DB04337,,Methyl Isocyanide,,small molecule,,,,,
N(C1=NC([H])=C([H])C(C2=C(C3=C([H])C([H])=C(F)C([H])=C3[H])N=C([H])N2C2(C([H])([H])C([H])([H])N([H])C([H])([H])C2([H])[H])[H])=N1)([H])[H],DB04338,,SB220025,,small molecule,,,,,
O(C(=O)C(=O)[H])[H],DB04343,298-12-4,Glyoxylic acid,,small molecule,,,,,
C(C1=C(C([H])([H])[H])C([H])=C2N=C3C(=O)N([H])C(=O)N([H])C3=NC2=C1[H])([H])([H])[H],DB04345,1086-80-2,"7,8-dimethylalloxazine","6,7-Dimethylalloxazine
7,8-dimethylbenzo[g]pteridine-2,4(1H,3H)-dione
7,8-dimethylisoalloxazine
lumichrome
Riboflavin lumichrome",small molecule,,,,,
[O-]C(=O)C(C(=C(C([O-])=O)[H])C([O-])=O)([H])[H],DB04351,,Aconitate Ion,,small molecule,,,,,
O(C1=NC(=N[H])N([H])C2=C1N(C(=C2[H])[H])[H])[H],DB04356,,9-Deazaguanine,,small molecule,,,,,
N(C1=NC(O[H])=C2N=C(C(N(C3=C([H])C([H])=C(C(O[H])=O)C([H])=C3[H])[H])([H])[H])C(=NC2=[N+]1[H])[H])([H])[H],DB04357,,Pteric Acid,,small molecule,,,,,
O(S(=O)(=O)C(=C([H])[H])[H])[H],DB04359,,Vinylsulphonic Acid,,small molecule,,,,,
O(B(O[H])C1=C([H])C2=C(C(=C(C(=C2[H])[H])[H])[H])S1)[H],DB04360,,Benzo[B]Thiophene-2-Boronic Acid,,small molecule,,,,,
C(N=N[H])([H])([H])[H],DB04361,26981-93-1,Methyldiazene,"Diazene, methyl- (9CI)
Methyldiimide",small molecule,,,,,
C(C(C1=C(C([H])([H])[H])C(O[H])=NC1=C(C1=C(C(C(C(O[H])=O)([H])[H])([H])[H])C(C([H])([H])[H])=C(C(=C2N=C(C(=C3N=C(O[H])C(C([H])([H])[H])=C3C(C([H])([H])[H])([H])[H])[H])C(C(C(C(O[H])=O)([H])[H])([H])[H])=C2C([H])([H])[H])[H])N1[H])[H])([H])[H])([H])([H])[H],DB04363,,Mesobiliverdin Iv Alpha,,small molecule,,,,,
C(OC(=O)C1=C([H])C([H])([H])C([H])([H])N(C([H])([H])[H])C1([H])[H])([H])([H])[H],DB04365,63-75-2,Arecoline,,small molecule,,,,,
O(C1=NC(=N[H])N([H])C1=C1C([H])([H])C([H])([H])N=C(O[H])C2=C1C(=C(N2[H])[H])[H])[H],DB04367,,Debromohymenialdisine,,small molecule,,,,,
O(B1OC([H])([H])C([H])([H])O1)[H],DB04369,,"1,3,2-Dioxaborolan-2-Ol",,small molecule,,,,,
C(OC1=C([H])C([H])=C([H])C(N2C([H])=C([H])C3=C(SC(=C3[H])S(N([H])[H])(=O)=O)S2(=O)=O)=C1[H])([H])([H])[H],DB04371,,AL6528,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])(SC1=C(C(O[H])=O)N=NN1[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04374,,"4-Carboxy-5-(1-Pentyl)Hexylsulfanyl-1,2,3-Triazole",,small molecule,,,,,
C(C(O[H])(C(C(O[H])=O)([H])[H])C(C(O[H])=O)([H])[H])([H])([H])[H],DB04377,,3-Hydroxy-3-Methyl-Glutaric Acid,,small molecule,,,,,
N(C(=O)N(C(N(C(N([H])[H])=O)[H])(C([O-])=O)[H])[H])([H])[H],DB04380,,Diureido-Acetate,,small molecule,,,,,
C(C(=C(C(=O)[H])[H])[H])([H])([H])[H],DB04381,,Crotonaldehyde,,small molecule,,,,,
O(C1=C(OC2=C([H])C([H])=C(Cl)C([H])=C2[H])C([H])=C([H])C(Cl)=C1[H])[H],DB04393,3380-30-1,Soneclosan,"5-chloro-2-(p-chlorophenoxy)phenol
Hydroxydichlorodiphenyl ether",small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([N+]([O-])=O)=C(N2C([H])([H])C([H])([H])C([H])([H])C2=O)C([H])=C1[H])([H])[H],DB04394,,3-Nitro-4-(2-Oxo-Pyrrolidin-1-Yl)-Benzenesulfonamide,,small molecule,,,,,
C([N+](C([H])([H])[H])(C([H])([H])[H])C(C(=O)[H])([H])[H])([H])([H])[H],DB04401,,"[Formylmethyl]Trimethyl-Ammonium, N,N,N-Trimethylammonium Acetaldehyde",,small molecule,,,,,
O(C(=O)C1=C(C(P(O[H])(O[H])=O)([H])[H])C([H])=C([H])C([H])=N1)[H],DB04406,,3-(Phosphonomethyl)Pyridine-2-Carboxylic Acid,,small molecule,,,,,
C(N(C1=NC(C([H])([H])[H])=C(C2=NC(N(C3=C([H])C([H])=C(O[H])C([H])=C3[H])[H])=NC([H])=C2[H])S1)[H])([H])([H])[H],DB04407,,4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol,,small molecule,,,,,
[O-]S(=O)(=O)C1=C([H])C([H])=C2C(C(=C(C(=C2S([O-])(=O)=O)[H])S([O-])(=O)=O)[H])=C1[H],DB04409,,Naphthalene Trisulfonate,,small molecule,,,,,
N(C(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H],DB04410,2038-57-5,3-Phenylpropylamine,"3-phenyl-1-aminopropane
3-phenyl-1-propylamine
3-phenyl-N-propylamine
3-phenylpropanamine
benzenepropanamine
gamma-phenyl-n-propylamine
gamma-phenylpropylamine
hydrocinnamylamine",small molecule,,,,,
O(C1=C([H])C([H])=C([N+]([O-])=O)C([H])=C1[H])[H],DB04417,100-02-7,P-Nitrophenol,,small molecule,,,,,
C(C1=C(C(C(C(O[H])=O)([H])[H])([H])[H])C2N3[Co]45N6C(C(=C(C6=C(C6=C(C([H])([H])[H])C(C(C(C(O[H])=O)([H])[H])([H])[H])=C(C([H])=C13)N64)[H])C(C(C(O[H])=O)([H])[H])([H])[H])C([H])([H])[H])=C([H])C1=C(C(=C(C=2[H])N51)C([H])([H])[H])C(C(C(O[H])=O)([H])[H])([H])[H])([H])([H])[H],DB04423,,Coproporphyrin I Containing Co(Iii),,small molecule,,,,,
N#CC(=C(N(C1=C([H])C([H])=C(N(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])C([H])=C1[H])[H])[H])C1=NN([H])N=N1,DB04430,,3-(4-Phenylamino-Phenylamino)-2-(1h-Tetrazol-5-Yl)-Acrylonitrile,,small molecule,,,,,
C(C1=C(F)C(OC2=C([H])C(C(N([H])[H])=N[H])=C([H])C([H])=C2[H])=[N+]([H])C(OC2=C([H])C(C(N([H])[H])=N[H])=C([H])C([H])=C2[H])=C1F)([H])([H])[H],DB04432,,ZK-805623,,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C(C2=C(C3=NC4=C(C(=C(N=C4C([H])=C3[H])[H])[H])[H])C([H])([H])N([H])N2[H])=N1)([H])([H])[H],DB04434,,Naphthyridine Inhibitor,,small molecule,,,,,
N(C(=[N+]([H])[H])C1=C([H])C2=C(N(C(=N2)C2=C([H])C([H])=C([H])N=C2O[H])[H])C([H])=C1[H])([H])[H],DB04442,,"2-(2-Oxo-1,2-Dihydro-Pyridin-3-Yl)-1h-Benzoimidazole-5-Carboxamidine",,small molecule,,,,,
F[Al-](F)(F)F,DB04444,21340-02-3,Tetrafluoroaluminate Ion,"Tetrafluoroaluminate anion
tetrafluoroaluminate(1���)",small molecule,,,,,
I[Hg]I,"DB04445
DB11214",7774-29-0,Mercuric iodide,"Hydrargyrum bijodatum
Mercuric iodide red
Mercuric iodide, red
Mercury Diiodide
Red mercuric iodide",small molecule,,,,,
N(C(=[N+]([H])[H])C1=C([H])C2=C(C(=C(C(=C2[H])[H])[H])[H])S1)([H])[H],DB04446,,Benzo[B]Thiophene-2-Carboxamidine,,small molecule,,,,,
O(C(C1=C(F)C([H])=C(F)C([H])=C1[H])([H])[H])[H],DB04448,,"2,4-Difluorobenzyl Alcohol 2,4-Difluoro-1-(Hydroxymethyl)Benzene",,small molecule,,,,,
C(OC1=C(O[H])C(O[H])=C([H])C(C(=C(C(O[H])(O[H])[H])[H])[H])=C1[H])([H])([H])[H],DB04449,,"5-(3,3-Dihydroxypropeny)-3-Methoxy-Benzene-1,2-Diol",,small molecule,,,,,
C(N1C([H])([H])C([H])([H])N(C(O[H])=O)C([H])([H])C1([H])[H])([H])([H])[H],DB04451,,4-Methylpiperazin-1-Yl Carbonyl Group,,small molecule,,,,,
C(C1=C([H])C(N([H])[H])=C2C(=C(N(C(=O)N(C3=C([H])C4=C(N([H])[H])C(=C(C([H])([H])[H])N=C4C([H])=C3[H])[H])[H])[H])C(=C([H])C2=N1)[H])[H])([H])([H])[H],DB04452,3811-56-1,Aminoquinuride,,small molecule,,,,,
C([N+](C([H])([H])[H])(C([H])([H])[H])C(C(O[H])=O)([H])[H])([H])([H])[H],DB04455,,"N,N,N-trimethylglycinium",,small molecule,,,,,
O([As](O[H])O[H])[H],DB04456,13464-58-9,Arsenous acid,"arsenic trihydroxide
arsenous acid
arsorous acid
trihydroxyarsenite(III)",small molecule,,,,,
ClC1=C(Cl)C2=C(C(=C(C(=C2[H])[H])[H])[H])C(=O)O1,DB04459,,"3,4-Dichloroisocoumarin",,small molecule,,,,,
C(C1=C2C(C3=C(C([H])([H])[H])C(C(C(C(O[H])=O)([H])[H])([H])[H])=C(C(C4=C(C(C(C(O[H])=O)([H])[H])([H])[H])C(C([H])([H])[H])=C(C(C5=C(C(C(C(O[H])=O)([H])[H])([H])[H])C(C([H])([H])[H])=C(C([H])([H])C(N2[H])=C1C(C(C(O[H])=O)([H])[H])([H])[H])N5[H])([H])[H])N4[H])([H])[H])N3[H])([H])[H])([H])([H])[H],DB04461,2624-63-7,Coproporphyrinogen III,"3,8,13,17-tetramethyl-5,10,15,20,22,24-hexahydroporphyrin-2,7,12,18-tetrapropionic acid
5,10,15,20,22,24-hexahydro-3,8,13,17-tetramethyl-21H,23H-porphine-2,7,12,18-tetrapropanoic acid",small molecule,,,,,
BrC1=C(Br)C(Br)=C(Br)C2=NN(N=C12)[H],DB04462,,Tetrabromo-2-Benzotriazole,,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])N1N=C(C2=C([H])C([H])=C([H])C(O[H])=C2[H])C2=C(N([H])[H])N=C(N=C12)[H])([H])([H])[H],DB04463,,"3-(4-Amino-1-Tert-Butyl-1h-Pyrazolo[3,4-D]Pyrimidin-3-Yl)Phenol",,small molecule,,,,,
C(C(OP(=O)(OC(C([H])([H])[H])([H])[H])C(=C(C1=C([H])C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=C(O[H])C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=C1[H])[H])P(=O)(OC(C([H])([H])[H])([H])[H])OC(C([H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04466,126411-39-0,SR12813,,small molecule,,,,,
C(C(C(=C(C1=C([H])C([H])=C(O[H])C([H])=C1[H])C1=C([H])C([H])=C(OC(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB04468,68392-35-8,Afimoxifene,"4-hydroxytamoxifen
4-monohydroxytamoxifen
4-OHT",small molecule,Humans and other mammals,,,,"For the potential treatment of menstrual-cycle related mastalgia, fibrocystic breast disease, breast disease, gynecomastia and Keloid scarring."
C(C(OC(=O)C1=C(C([H])([H])[H])N(C2=C([H])C([H])=C(OC([H])([H])[H])C([H])=C2[H])N=C1C([H])([H])[H])([H])[H])([H])([H])[H],DB04469,,"1-(4-Methoxyphenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester",,small molecule,,,,,
C(C(C([H])([H])[H])(C(OC1=C(O[H])C(C2=NC3=C(C(=C(C(=C3[H])C(N([H])[H])=N[H])[H])[H])N2[H])=C([H])C([H])=C1[H])([H])[H])[H])([H])([H])[H],DB04470,,CRA_10656,,small molecule,,,,,
O(S(=O)(=O)C1=C([H])C([H])=C([H])C2=C(C(=C(C(N(C3=C([H])C([H])=C([H])C([H])=C3[H])[H])=C12)[H])[H])[H])[H],DB04474,,1-Anilino-8-Naphthalene Sulfonate,,small molecule,,,,,
N(C(=O)C1=C(O[H])C(O[H])=C([H])C([H])=C1[H])([H])[H],DB04476,,"Trencam-3,2-Hopo",,small molecule,,,,,
C(N(C([H])([H])[H])S(=O)(=O)N1C([H])([H])C([H])([H])N(C2=NC(C(O[H])([H])[H])=NC([H])=C2[H])C([H])([H])C1([H])[H])([H])([H])[H],DB04478,,"Cp-166572, 2-Hydroxymethyl-4-(4-N,N-Dimethylaminosulfonyl-1-Piperazino)-Pyrimidine",,small molecule,,,,,
[O-][N+](=O)C1=C2C(=C(C(=O)C2=C([H])C([H])=C1[H])[H])[H],DB04479,,4-Nitro-Inden-1-One,,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C(C2=NN3C(C(C([H])([H])C3=C2C2=C([H])C([H])=C(F)C([H])=C2[H])([H])[H])([H])[H])=N1)([H])([H])[H],DB04480,,"3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole",,small molecule,,,,,
S(C(C1=C([H])N=C([H])C([H])=C1[H])([H])[H])[H],DB04490,,3-(Mercaptomethylene)Pyridine,,small molecule,,,,,
C(C(C([H])([H])[H])(OP(=O)(OC(C([H])([H])[H])(C([H])([H])[H])[H])[H])[H])([H])([H])[H],DB04491,,Diisopropylphosphono Group,,small molecule,,,,,
O([Mo+6](O[H])=O)[H],DB04494,,Dihydroxy(oxo)molybdenum(6+),OMO,small molecule,,,,,
C(C(=O)N(C1=C([H])C([H])=C(C(O[H])=O)C([H])=C1[H])[H])([H])([H])[H],DB04500,556-08-1,4-acetamidobenzoic acid,"4-(Acetylamino)benzoic acid
4-Acetylaminobenzoic acid
4-Carboxyacetanilide
4'-Carboxyacetanilide
Acedoben
Acedobene
Acedobenum
N-Acetyl-p-aminobenzoic acid
N-Acetyl-PABA
p-Acetamidobenzoic acid
p-Acetaminobenzoic acid
p-Acetoaminobenzoic acid
p-Acetylaminobenzoic acid
PAAB
PAcBA
Para acetamido benzoic acid",small molecule,,,,,
C(OC1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(Cl)C(C(C2=NC3=C(N=C(N=C3N([H])[H])[H])N2C(C(C(C#C[H])([H])[H])([H])[H])([H])[H])([H])[H])=C1[H])([H])([H])[H],DB04505,,"8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine",,small molecule,,,,,
C(OC1=NC([H])=C([H])N=C1C(C(C([H])([H])[H])(C([H])([H])[H])[H])([H])[H])([H])([H])[H],DB04512,,2-Isobutyl-3-Methoxypyrazine,,small molecule,,,,,
N(C(C(C(C(C(C(N(S(=O)(=O)C1=C2C(=C(C(=C(Cl)C2=C([H])C([H])=C1[H])[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB04513,,N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide,,small molecule,,,,,
C(C1=C(C(C(O[H])=O)([H])[H])C(C(C(C(O[H])=O)([H])[H])([H])[H])=C(C(C2=C(C(C(O[H])=O)([H])[H])C(C(C(C(O[H])=O)([H])[H])([H])[H])=C([H])N2[H])([H])[H])N1[H])([H])([H])[H],DB04517,,Dipyrromethane Cofactor,,small molecule,,,,,
C(C1=NC(C([H])([H])[H])=C(C2=NC(N(C3=C([H])C(O[H])=C([H])C([H])=C3[H])[H])=NC([H])=C2[H])S1)([H])([H])[H],DB04518,,"3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol",,small molecule,,,,,
C(C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04519,124-07-2,Caprylic acid,"capryloate
Caprylsaeure
Enantic acid
Kaprylsaeure
n-caprylic acid
n-octanoic acid
n-Octoic acid
n-octylic acid
neo-fat 8
octanoate
octanoic acid
Octic acid
octoic acid
Octylic acid",small molecule,,"Injection, emulsion",Intravenous,,
O(C1=C([N+]([O-])=O)C([H])=C([N+]([O-])=O)C([H])=C1[H])[H],DB04528,51-28-5,"2,4-Dinitrophenol",Dinitrophenol,small molecule,,,,,
N1(C([H])=C([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])[H],DB04532,120-72-9,Indole,,small molecule,,,,,
C(C1=C([H])C(N([H])[H])=C(O[H])C([H])=C1[H])([H])([H])[H],DB04533,,2-Amino-P-Cresol,,small molecule,,,,,
[O-][N+](=O)C1=C([H])C2=C(N(N=C2[H])[H])C([H])=C1[H],DB04534,,5-Nitroindazole,,small molecule,,,,,
O(C(=O)C([N+](C(P(O[H])(O[H])=O)([H])[H])([H])[H])([H])[H])[H],DB04539,1071-83-6,Glyphosate,,small molecule,,,,,
N(C1=NC2=C(C(SC3=NC([H])=C([H])N3[H])([H])[H])C(=C(N([H])[H])C([H])=C2C(=O)N1[H])[H])([H])[H],DB04543,,"2,6-Diamino-8-(1h-Imidazol-2-Ylsulfanylmethyl)-3h-Quinazoline-4-One",,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(C(=O)N(C(C2=C(F)C(F)=C(F)C([H])=C2[H])([H])[H])[H])C([H])=C1[H])([H])[H],DB04549,,"4-(Aminosulfonyl)-N-[(2,3,4-Trifluorophenyl)Methyl]-Benzamide",,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C([H])N=C1N(C1=C([H])C([H])=C([H])C(C(F)(F)F)=C1[H])[H])[H],DB04552,4394-00-7,Niflumic Acid,"Acide niflumique
Acido niflumico
Acidum niflumicum
NFA
Niflugel",small molecule,Humans and other mammals,,,,Used in the treatment of rheumatoid arthritis.
C(C(C(=O)C(O[H])=O)([H])[H])([H])([H])[H],DB04553,600-18-0,2-Oxobutanoic Acid,,small molecule,,,,,
C(C(C(C(C(C(=C(C(C(=C(C(C(=C(C(C(=C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04557,506-32-1,Arachidonic Acid,,small molecule,,,,,
O(N(C(=N[H])N(C1=C([H])C([H])=C(Cl)C([H])=C1[H])[H])[H])[H],DB04559,,N-(Chlorophenyl)-N'-Hydroxyguanidine,,small molecule,,,,,
O(C(=O)C(C(C(=O)C(C(C(=O)C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB04560,,"4,7-Dioxosebacic Acid",,small molecule,,,,,
O(C(=O)C(C(C(C(O[H])=O)([H])[H])(C(O[H])=O)[H])([H])[H])[H],DB04562,,Tricarballylic Acid,,small molecule,,,,,
N(C(=N[H])C1=C([H])C2=C(N(C(=C2[H])C2=C([H])C(C(C([O-])=O)([H])[H])=C([H])C(Br)=C2O[H])[H])C([H])=C1[H])([H])[H],DB04563,,CRA_9678,,small molecule,,,,,
C(C(=O)N(C1=C(N(C(=O)C(O[H])([H])[H])[H])C([H])=C(C(O[H])=O)C([H])=C1[H])[H])([H])([H])[H],DB04565,,4-(Acetylamino)-3-[(Hydroxyacetyl)Amino]Benzoic Acid,,small molecule,,,,,
O=C(OC(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H],DB04569,,Formic Acid Benzyl Ester,,small molecule,,,,,
C(C1=C([H])C2=C(C3=C(C(C([H])([H])[H])=C2O1)OC(=O)C([H])=C3C([H])([H])[H])[H])([H])([H])[H],DB04571,3902-71-4,Trioxsalen,"2',4,8-Trimethylpsoralen
4,5',8-Trimethylpsoralen
4,8,5'-Trimethylpsoralen
6-Hydroxy-beta,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone
trimethylpsoralen
Trioxisaleno
Trioxsalen
trioxysalen
Trioxysalene
Trioxysalenum
trisoralen",small molecule,,Tablet,Oral,5 mg,Trioxsalen is a pigmenting photosensitizing agent used in conjunction with ultraviolet light in the treatment of vitiligo.
S=P(N1C([H])([H])C1([H])[H])(N1C([H])([H])C1([H])[H])N1C([H])([H])C1([H])[H],DB04572,52-24-4,Thiotepa,,small molecule,Humans and other mammals,"Injection, powder, for solution
Injection, powder, for solution
Powder, for solution
Powder, for solution
Powder, for solution
Injection, powder, lyophilized, for solution
Powder, for solution","Intracavitary; Intravenous; Intravesical
Intracavitary; Intravenous; Intravesical
Intravenous
Intravenous
Oral; Rectal; Vaginal
Intracavitary; Intravenous; Intravesical
Intracavitary; Intravenous; Intravesical","100 mg/1
15 mg/1
100 mg
15 mg
15 mg
15 mg/1.5mL
15 mg","ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients."
C(N1C([H])([H])C([H])([H])N(C2=C(F)C3=C(C(=O)C(=C(N3C(C(F)([H])[H])([H])[H])[H])C(O[H])=O)C([H])=C2F)C([H])([H])C1([H])[H])([H])([H])[H],DB04576,79660-72-3,Fleroxacin,"Fleroxacin
Fleroxacine
Fleroxacino
Fleroxacinum
Fleroxicin
FLRX
Megalocin
Megalocin (TN)
Megalone
Megalone (TN)
Megalosin
Quinodis",small molecule,,,,,Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone.
N(C(C1(C([H])([H])C([H])([H])C([H])([H])C1([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H],DB04577,17511-89-6,1-(1-phenylcyclopentyl)methylamine,"1-(1-PHENYLCYCLOPENTYL)METHANAMINE
1-Phenylcyclopentanemethylamine
C-(1-Phenyl-cyclopentyl)-methylamine",small molecule,Humans and other mammals,,,,
C(N1C(=O)C([H])=C([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])([H])[H],DB04580,606-43-9,1-Methyl-2-quinolone,,small molecule,,,,,
C(N1C([H])=C([H])N=C1[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H],DB04581,4238-71-5,1-benzylimidazole,"1-Benzyl-1H-imidazole
N-Benzylimidazole",small molecule,Humans and other mammals,,,,
N(C(=O)C1=C([H])C(C(O[H])=O)=C([H])C(C2=C([H])C([H])=C(C3=C([H])C([H])=C([H])C([H])=C3[H])C([H])=C2[H])=C1[H])([H])[H],DB04583,,"5-Carbamoyl-1,1':4',1''-terphenyl-3-carboxylic acid",,small molecule,,,,,
N(C(=C(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])C(O[H])=O)([H])[H],DB04584,7060-39-1,Phenyldehydroalanine,"2,3-Didehydrophenylalanine
alpha-Aminocinnamate",small molecule,,,,,
O(C1=C(Br)C([H])=C([H])C([H])=C1[H])[H],DB04586,95-56-7,2-bromophenol,"2-Bromfenol
Bromophenol
o-bromo-phenol
o-bromophenol",small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(C(N(C(=O)C2=C(C3=C([H])C(Cl)=C(O[H])C([H])=C3O[H])N([H])N=C2[H])[H])([H])[H])C([H])=C1[H])([H])[H],DB04588,,"N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE",,small molecule,,,,,
O(C(C(C(Br)=C([H])[H])([H])[H])([H])[H])[H],DB04592,76334-36-6,3-Bromo-3-buten-1-ol,,small molecule,,,,,
O(C(C(C(O[H])=O)([H])[H])(C(C(O[H])=O)([H])[H])[H])[H],DB04594,638-18-6,3-hydroxyglutaric acid,,small molecule,,,,,
N(C1=C(C(O[H])=O)C([H])=C([H])C(Cl)=C1O[H])([H])[H],DB04598,,2-AMINO-4-CHLORO-3-HYDROXYBENZOIC ACID,,small molecule,,,,,
C(OC1=C([H])C([H])=C(C(=O)N2C([H])([H])C([H])([H])C([H])([H])C2=O)C([H])=C1[H])([H])([H])[H],DB04599,72432-10-1,Aniracetam,1-P-ANISOYL-2-PYRROLIDINONE,small molecule,Humans and other mammals,,,,
N(S(=O)(=O)OC1=C(Br)C([H])=C(C(N(N2C([H])=NN=C2[H])C2=C([H])C([H])=C(C#N)C([H])=C2[H])([H])[H])C([H])=C1[H])([H])[H],DB04600,,"4-[(3-BROMO-4-O-SULFAMOYLBENZYL)(4-CYANOPHENYL)AMINO]-4H-[1,2,4]-TRIAZOLE",,small molecule,,,,,
N(S(=O)(=O)OC1=C([H])C([H])=C(C(N(N2C([H])=NN=C2[H])C2=C([H])C([H])=C(C#N)C([H])=C2[H])([H])[H])C([H])=C1[H])([H])[H],DB04601,,"4-[(4-O-SULFAMOYLBENZYL)(4-CYANOPHENYL)AMINO]-4H-[1,2,4]-TRIAZOLE",,small molecule,,,,,
N(C1=C2C(=C(N=C([H])C2=C([H])C([H])=C1[H])[H])[H])([H])[H],DB04605,1125-60-6,5-Aminoisoquinoline,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(N(C2=C([H])N3C(=C(C(=C([H])C3=N2)[H])C(=O)C2=C(Cl)C([H])=C([H])C([H])=C2Cl)[H])[H])C([H])=C1[H])([H])[H],DB04607,,"PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE",,small molecule,,,,,
O(C1=C([H])C2=C(N(C3=C([H])C(C4=C([H])C([H])=C([H])C([H])=C4[H])=C4C(=O)N(C(=O)C4=C32)[H])[H])C([H])=C1[H])[H],DB04608,,"9-HYDROXY-4-PHENYL-6H-PYRROLO[3,4-C]CARBAZOLE-1,3-DIONE",,small molecule,,,,,
C(C(C(C(C(N(C1=C2C(C(C(C([H])([H])C2=NC2=C(C(=C(C([H])=C12)[H])[H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])(C(C(C(N(C1=C([H])C([H])=NC2=C(C(=C(C([H])=C12)[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB04616,,TACRINE(8)-4-AMINOQUINOLINE,,small molecule,,,,,
[N+](C(C(C(C(C(C(C(C(N(C1=C2C(C(C(C([H])([H])C2=[N+]([H])C2=C(C(=C(C([H])=C12)[H])[H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04617,,"(9S)-9-[(8-AMMONIOOCTYL)AMINO]-1,2,3,4,9,10-HEXAHYDROACRIDINIUM",,small molecule,,,,,
C(C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB04619,,ACETOPHENONE,,small molecule,,,,,
N(C1(C([H])([H])C([H])([H])C([H])([H])C1([H])[H])C(O[H])=O)([H])[H],DB04620,52-52-8,Cycloleucine,"1-Amino-1-cyclopentanecarboxylic acid
1-Amino-cyclopentanecarboxylic acid
1-Aminocyclopentane-1-carboxylic acid
1-Aminocyclopentanecarboxylate
1-Aminocyclopentanecarboxylic acid
Amino-1-cyclopentanecarboxylic acid
Cyclo-leucine
Cycloleucin",small molecule,Humans and other mammals,,,,
C(C(=O)N(C(C(C1=C([H])N=C([H])N1[H])([H])[H])([H])[H])[H])([H])([H])[H],DB04622,,N-ACETYLHISTAMINE,,small molecule,,,,,
O(C1=C(C(N(C2(C([H])([H])C([H])([H])N(S(=O)(=O)N(C3=C([H])C(OC4=C([H])C([H])=C(F)C([H])=C4[H])=C([H])C([H])=C3[H])[H])C([H])([H])C2([H])[H])[H])[H])([H])[H])C([H])=C([H])C([H])=C1[H])[H],DB04632,,4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE,,small molecule,,,,,
C(C(C(N(C(C(C(N(C(C(C(N(C(C([H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB04633,,"N-ethyl-N-[3-(propylamino)propyl]propane-1,3-diamine",BE3,small molecule,Humans and other mammals,,,,
O(C(C(C(C(C(C(Br)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB04637,4286-55-9,6-Bromo-1-hexanol,,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C1=C([H])C(O[H])=C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C([H])=C1O[H])([H])([H])[H],DB04638,,"2,5-DI-(TERT-BUTYL)-1,4,BENZOHYDROQUINONE",,small molecule,,,,,
O(S(=O)(=O)C1=C([H])C2=C(C(=C(C([H])=C2C([H])=C1[H])S(O[H])(=O)=O)[H])[H])[H],DB04640,581-75-9,"Naphthalene-2,6-disulfonic acid","2,6-naphthalenedisulfonic acid
Ebert-Merz beta-acid
naphthalene-2,6-disulphonic acid",small molecule,,,,,
O(C(=O)C1=C([H])C2=C(C(O[H])=C(C([H])=C2C([H])=C1O[H])[H])[H])[H],DB04641,,"3,7-DIHYDROXYNAPHTHALENE-2-CARBOXYLIC ACID",,small molecule,,,,,
O(C(=O)C(C(C(C(C(C(OC1=C(Cl)C([H])=C(N(C(=O)N(C(=O)C2=C(Cl)C([H])=C([H])C([H])=C2[H])[H])[H])C([H])=C1Cl)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB04642,,"7-{2,6-DICHLORO-4-[3-(2-CHLORO-BENZOYL)-UREIDO]-PHENOXY}-HEPTANOIC ACID",,small molecule,,,,,
O(C(=O)C(C(C(OC1=C([H])C(Cl)=C(N(C(=O)N(C(=O)C2=C(Cl)C([H])=C(Cl)C([H])=C2[H])[H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])[H],DB04643,,"4-{3-CHLORO-4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-PHENOXY}-BUTYRIC ACID",,small molecule,,,,,
C(C1=C(N(C(=O)N(C(=O)C2=C(Cl)C([H])=C(Cl)C([H])=C2[H])[H])[H])C([H])=C([H])C(OC(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])=C1C([H])([H])[H])([H])([H])[H],DB04644,,"4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID",,small molecule,,,,,
C(C1=C(N(C(=O)N(C(=O)C2=C(Cl)C([H])=C(Cl)C([H])=C2[H])[H])[H])C([H])=C([H])C([H])=C1OC(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04645,,"5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID",,small molecule,,,,,
C(C(C([H])([H])[H])(C1=C(Br)C(=O)C(C([H])([H])[H])=C(Br)C1=O)[H])([H])([H])[H],DB04646,29096-93-3,Dibromothymoquinone,"2,5-DIBROMO-3-ISOPROPYL-6-METHYLBENZO-1,4-QUINONE
2,5-Dibromo-3-isopropyl-6-methylbenzoquinone
2,5-Dibromo-3-methyl-6-isopropyl-p-benzoquinone
2,5-Dibromo-6-isopropyl-3-methyl-1,4-benzoquinone
DBMIB",small molecule,,,,,
O=C(C(C(C(C1(C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H])[H])([H])[H])([H])[H])([H])[H])[H],DB04654,,4-PIPERIDIN-4-YLBUTANAL,,small molecule,,,,,
C(C1=NC(N([H])[H])=NC(N([H])[H])=C1C1=C([H])C(Cl)=C(Cl)C([H])=C1[H])([H])([H])[H],DB04655,7761-45-7,Metoprine,,small molecule,,,,,
C(C1=C(C(=O)N(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])SC([H])([H])C([H])([H])O1)([H])([H])[H],DB04657,5234-68-4,Carboxin,"2,3-Dihydro-5-carboxanilido-6-methyl-1,4-oxathiin
2,3-Dihydro-6-methyl-5-phenylcarbamoyl-1,4-oxathiin
Carbathiin
Carbathiine
Carboxine
CBX",small molecule,,,,,
O=C1OC2=C(C(=C(C(=C2[H])[H])[H])[H])C([H])=C1[H],DB04665,91-64-5,Coumarin,"1,2-benzopyrone
2H-1-benzopyran-2-one
2H-benzo(b)pyran-2-one
Coumarinic lactone
Cumarin",small molecule,,,,,
O(C(=O)C(C(C(=N[H])C1=NC(=C(C2=C([H])C([H])=C(O[H])C([H])=C2[H])[H])C(=O)N1C(C(O[H])=O)([H])[H])([H])[H])([H])[H])[H],DB04668,,CHROMOPHORE (GLU-TYR-GLY),,small molecule,,,,,
BrC1=C([H])C(C2=NC3=[N+](N(C(=N3)[H])[H])C(N(C(C3=C([H])C([H])=NC([H])=C3[H])([H])[H])[H])=C2[H])=C([H])C([H])=C1[H],DB04669,,TRIAZOLOPYRIMIDINE,,small molecule,,,,,
O(C(=O)C1=C([H])C(I)=C([H])C(I)=C1O[H])[H],DB04674,,"2-HYDROXY-3,5-DIIODOBENZOIC ACID",,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C(C(C([H])([H])[H])(C([H])([H])[H])C1=C([H])C([H])=C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB04682,9036-19-5,Octylphenoxy polyethoxyethanol,"alkylphenol-hydroxypolyoxyetheylene
Anapoe-305",small molecule,,,,,
N(C(C(C(C(C(C(N(C(C(C(C(C(C(N([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB04684,,BIS(HEXAMETHYLENE)TRIAMINE,,small molecule,,,,,
C(OP(O[H])(=S)OC([H])([H])[H])([H])([H])[H],DB04687,,DIMETHYL THIOPHOSPHATE,,small molecule,,,,,
C(C(C(C1=C2C(=C(C(=C([H])C2=C([H])C([H])=C1OC(C(C(OC1=C([H])C2=C(N(C(C(O[H])=O)([H])[H])C(=C2[H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB04689,,2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID,,small molecule,,,,,
O(C1=C(Br)C([H])=C(C2(OC(=O)C3=C4C(C(=C(C([H])=C24)[H])[H])=C(Cl)C(=C3[H])[H])C2=C([H])C(Br)=C(O[H])C([H])=C2[H])C([H])=C1[H])[H],DB04696,,"4-CHLORO-3',3''-DIBROMOPHENOL-1,8-NAPHTHALEIN",,small molecule,,,,,
O=C1C2=C(C(=C(C(=C2[H])[H])[H])[H])OC2=C1C(=C(C(=C2[H])[H])S(=O)(=O)N=C1N([H])N=NN1[H])[H],DB04698,,"N-(1,4-DIHYDRO-5H-TETRAZOL-5-YLIDENE)-9-OXO-9H-XANTHENE-2-SULFONAMIDE",,small molecule,,,,,
O=C1C([H])([H])C([H])([H])C([H])([H])O1,DB04699,96-48-0,gamma-butyrolactone,"1,4-Lactone
4-Butyrolactone
4-Hydroxybutyric acid lactone
butyrolactone
dihydrofuran-2(3h)-one
��-butyrolactone",small molecule,,,,,
O(C1=C2C(=C(C(=C(S(=O)(=O)N3C([H])([H])C([H])([H])C([H])([H])N([H])C([H])([H])C3([H])[H])C2=C([H])C([H])=N1)[H])[H])[H])[H],DB04707,105628-72-6,Hydroxyfasudil,Hydroxy-Fasudil,small molecule,,,,,
O(C(=O)C1=C(I)C([H])=C(I)C(N(C(=O)C(C(C(C(C(=O)N(C2=C(I)C(C(O[H])=O)=C(I)C([H])=C2I)[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])=C1I)[H],DB04711,606-17-7,Iodipamide,"3,3'-(adipoyldiimino)bis(2,4,6-triiodobenzoic acid)
Adipiodona
Adipiodone
Adipiodonum",small molecule,Humans and other mammals,"Liquid
Injection, solution
Liquid","Intravenous
Intrauterine
Intrauterine",52 %,Iodipamide is used as a contrast agent for cholecystography and intravenous cholangiography.
C(C(=O)C1=C([H])C(C2=C([H])N=C3C(=C(C(N(C(C4(C([H])([H])C4([H])[H])[H])([H])[H])[H])=NN23)[H])[H])=C([H])C([H])=C1[H])([H])([H])[H],DB04715,,IMIDAZOPYRIDAZIN 1,,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C1=NC2=C3C([H])=C([H])C(F)=C([H])C3=C3C(=O)N([H])C([H])=C([H])C3=C2N1[H])([H])([H])[H],DB04716,,"2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE",,small molecule,,,,,
C(N(C([H])([H])[H])C1=NC2=C(Br)C(Br)=C(Br)C(Br)=C2N1[H])([H])([H])[H],DB04719,,"DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE",,small molecule,,,,,
C(SC1=NC2=C(Br)C(Br)=C(Br)C(Br)=C2N1[H])([H])([H])[H],DB04720,,"S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE",,small molecule,,,,,
C(N1C([H])([H])C([H])([H])N2C1=NC1=C(Br)C(Br)=C(Br)C(Br)=C12)([H])([H])[H],DB04721,,"N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE",,small molecule,,,,,
C(C1(C([H])([H])[H])C([H])([H])N2C(C(C(O[H])=O)([H])[H])=C(C(C3=C([H])C([H])=C([H])C([H])=C3[H])=C2C1([H])[H])C1=C([H])C([H])=C(Cl)C([H])=C1[H])([H])([H])[H],DB04725,156897-06-2,Licofelone,"LCF
ML3000",small molecule,Humans and other mammals,,,,For the management of osteoarthritis.
C(N1C2=C(C(=C(C([H])([H])[H])C(C([H])([H])[H])=C2[H])[H])N=C2C(=O)N(C(=O)N=C12)[H])([H])([H])[H],DB04726,,"7,8,10-TRIMETHYLBENZO[G]PTERIDINE-2,4(3H,10H)-DIONE",,small molecule,,,,,
C(OC1=C([H])C([H])=C(C2=C(C3=C([H])C([H])=C(N(C(O[H])=NC4=C(F)C([H])=C([H])C(C(F)(F)F)=C4[H])[H])C([H])=C3[H])C3=C(N([H])[H])N=C(N=C3O2)[H])C([H])=C1[H])([H])([H])[H],DB04727,,"N-(4-{4-AMINO-6-[4-(METHYLOXY)PHENYL]FURO[2,3-D]PYRIMIDIN-5-YL}PHENYL)-N'-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]UREA",,small molecule,,,,,
C(C(=C(C(O[H])=O)[H])C(O[H])=O)([H])([H])[H],DB04734,498-23-7,Citraconic acid,"(Z)-2-Methyl-2-butenedioic acid
2-Methyl-2-butenedioic acid
2-methylmaleic acid
cis-2-methylbutenedioic acid
cis-Methylbutenedioic acid
Citracons��ure
Methyl-maleins��ure
Methylmaleic acid
��-methylmaleic acid",small molecule,,,,,
C(N1C([H])([H])C([H])([H])N(C(C2=C([H])C([H])=C(C(=O)N(C3=C([H])C(N(C4=NC(C5=C([H])N=C([H])C([H])=C5[H])=C([H])C([H])=N4)[H])=C([H])C([H])=C3[H])[H])C([H])=C2[H])([H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB04739,,4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE,,small molecule,,,,,
C(S(=O)(=O)N(C1=C(OC2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C([N+]([O-])=O)C([H])=C1[H])[H])([H])([H])[H],DB04743,51803-78-2,Nimesulide,,small molecule,Humans and other mammals,,,,"For the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old."
O(C1=C([H])C(=O)C2=C(C(=C(C(=C2[H])[H])[H])[H])C1=O)[H],DB04744,,"2-HYDROXY-1,4-NAPHTHOQUINONE",,small molecule,,,,,
O=C1N([H])C2=C(C(=C(C(=C2[H])[H])[H])[H])C([H])=C1[H],DB04745,,2-OXOQUINOLINE,,small molecule,,,,,
C(C(C(C(C(C(=C(C(=C(C(C(C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04746,,"(10E,12Z)-octadeca-10,12-dienoic acid","10-TRANS-12-CIS-OCTADECADIENOIC ACID
10E,12Z-octadecadienoic acid
10E,Z12-CLA",small molecule,,,,,
C(C(C(=C(C(=C(C(=C(C(C(C(C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])[H])[H])[H])[H])[H])([H])[H])([H])([H])[H],DB04747,,11-TRANS-13-TRANS-15-CIS-OCTADECATRIENOIC ACID,,small molecule,,,,,
[S-]C(C(C(=O)SC(C(C(=O)[H])([H])[H])([H])[H])([H])[H])([H])[H],DB04749,,2-(3-OXO-PROPYLSULFANYLCARBONYL)-ETHANETHIOLATE,,small molecule,,,,,
O(C(=O)C1=C([H])C(C(O[H])=O)=C(C2=C3C(=C(F)C(=O)C([H])=C3OC3=C2C(=C(F)C(O[H])=C3[H])[H])[H])C([H])=C1[H])[H],DB04750,,OREGON GREEN 488 CARBOXYLATE,,small molecule,,,,,
[O-]C(C(C(OP(=O)=O)([H])[H])([H])[H])([H])[H],DB04755,,PROPYL-1-PHOSPHATE,,small molecule,,,,,
O(OOC1=C(Cl)C([H])=C(N(C2=C(C(O[H])=O)C([H])=C([H])C([H])=C2[H])[H])C([H])=C1Cl)[H],DB04756,,"2-[(3,5-Dichloro-4-trioxidanylphenyl)amino]benzoic acid",,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C(C(N(C(=O)C2=C([H])C(C(=O)N(C(C3=C([H])C(C([H])([H])[H])=C([H])C([H])=C3[H])([H])[H])[H])=NC([H])=N2)[H])([H])[H])=C1[H])([H])([H])[H],DB04759,,"PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-(3-METHYL-BENZYLAMIDE)",,small molecule,,,,,
C(C1=C(F)C([H])=C([H])C(C(N(C(=O)C2=C([H])C(C(=O)N(C(C3=C([H])C(C([H])([H])[H])=C(F)C([H])=C3[H])([H])[H])[H])=NC([H])=N2)[H])([H])[H])=C1[H])([H])([H])[H],DB04760,,"PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-(4-FLUORO-3-METHYL-BENZYLAMIDE)",,small molecule,,,,,
O=C(N(C(C1=C([H])N=C([H])C([H])=C1[H])([H])[H])[H])C1=C([H])C(C(=O)N(C(C2=C([H])N=C([H])C([H])=C2[H])([H])[H])[H])=NC([H])=N1,DB04761,,"PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-[(PYRIDIN-3-YLMETHYL)-AMIDE]",,small molecule,,,,,
C(C1=C([H])C(C([H])([H])[H])=[N+](C(C(C2=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C2[H])([H])[H])([H])[H])C(C([H])([H])[H])=C1[H])([H])([H])[H],DB04763,,"1-N-(4-SULFAMOYLPHENYL-ETHYL)-2,4,6-TRIMETHYLPYRIDINIUM",,small molecule,,,,,
N(C(C1=C([H])C([H])=C([H])C(C2(C([H])([H])C([H])([H])N(C(=O)C3=C([H])N=C([H])C(C(C(C4=C([H])C([H])=C([H])C([H])=C4[H])([H])[H])([H])[H])=C3[H])C([H])([H])C2([H])[H])[H])=C1[H])([H])[H])([H])[H],DB04764,,[4-(3-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-(5-PHENETHYL- PYRIDIN-3-YL)-METHANONE,,small molecule,,,,,
O=C1N([H])C(=O)C(=C(C2=C([H])C3=NC(=C(N=C3C([H])=C2[H])[H])[H])[H])S1,DB04769,,"5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE",,small molecule,,,,,
C(C(SC(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])=NOS(O[H])(=O)=O)([H])[H])([H])([H])[H],DB04779,,ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE,,small molecule,,,,,
O(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])[H],DB04781,13392-69-3,5-hydroxyvaleric acid,"5-hydroxy valeric acid
5-hydroxy-pentanoic acid
5-Hydroxypentanoate
5-hydroxypentanoic acid
5-Hydroxyvalerate
delta-Hydroxypentanoic acid
delta-hydroxyvaleric acid",small molecule,,,,,
C(C1=C(N(C(=O)C2=C([H])C(N(C(=O)N(C3=C([H])C(C(=O)N(C4=C(C([H])([H])[H])C([H])=C([H])C(C(=O)N(C5=C([H])C([H])=C(S(O[H])(=O)=O)C6=C(C(=C(C(S(O[H])(=O)=O)=C56)[H])S(O[H])(=O)=O)[H])[H])=C4[H])[H])=C([H])C([H])=C3[H])[H])[H])=C([H])C([H])=C2[H])[H])C([H])=C(C(=O)N(C2=C3C(C(=C(C(=C3S(O[H])(=O)=O)[H])S(O[H])(=O)=O)[H])=C(S(O[H])(=O)=O)C([H])=C2[H])[H])C([H])=C1[H])([H])([H])[H],DB04786,145-63-1,Suramin,"8,8'-[CARBONYLBIS[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfonic acid
Belganyl
Naganol
Naphuride
Suramin
Suramine",small molecule,"Yeast, Molds, Trypanosomes",,,,"For treatment of human sleeping sickness, onchocerciasis and other diseases caused by trypanosomes and worms."
C(N1C(C#N)=C([H])C([H])=C1C1=C([H])C2=C(N(C(=S)OC2(C([H])([H])[H])C([H])([H])[H])[H])C([H])=C1[H])([H])([H])[H],DB04787,304853-42-7,Tanaproget,,small molecule,,,,,
FC(F)(F)C(=O)C(C(=O)C1=C([H])C([H])=C([H])S1)([H])[H],DB04795,326-91-0,Thenoyltrifluoroacetone,".alpha.-Thenoyltrifluoroacetone
1-Thenoyl-3,3,3-trifluoroacetone
1,1,1-Trifluoro-3-(2-thenoyl)acetone
2-Thenoyltrifluoroacetone
alpha-Thenoyltrifluoroacetone
Perfluoroacetyl(2-thenoyl)methane
TTFA",small molecule,Humans and other mammals,,,,
C(C(C([H])([H])[H])(C1=NN=C2C(=C(C(=C([H])N12)C1=C(C2=C([H])C([H])=C(F)C([H])=C2[H])N=C([H])O1)[H])[H])[H])([H])([H])[H],DB04797,,Triazolopyridine,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C1=C(O[H])C(=O)C2=C(N=C(S2)[H])C1=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04799,43152-58-5,"5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole","3-undecyl-2-hydroxydioxobenzothiazol
6-hydroxy-5-undecyl-1,3-benzothiazole-4,7-dione
6-Hydroxy-5-undecyl-4,7-benzothiazoledione
UHDBT",small molecule,,,,,
C(N1N=C(C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1N(S(O[H])(=O)=O)[H])([H])([H])[H],DB04800,,1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID,,small molecule,,,,,
C(C(C(C(C(C(C(=C(C(C(C(C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04801,,(11E)-OCTADEC-11-ENOIC ACID,,small molecule,,,,,
C(C1=C([H])C2N3[Fe]45[N+]6C(C(C([H])([H])[H])=C(C=6C=2[H])C(C(C(O[H])=O)([H])[H])([H])[H])=C([H])C2=C(C(=C([H])[H])[H])C(C([H])([H])[H])=C(N42)OC2N5C(=C(C=2C(=C([H])[H])[H])C([H])([H])[H])C([H])=C13)([H])([H])[H],DB04803,,Verdoheme,,small molecule,,,,,
O(C(=O)C(C(C1=C([H])C(N=C(C2=C([O-])C([H])=C([H])C([H])=C2[H])[H])=C(N=C(C2=C([O-])C([H])=C([H])C([H])=C2[H])[H])C([H])=C1[H])([H])[H])([H])[H])[H],DB04809,,SALOPHEN-10-PROPIONATE IRON CHELATE,,small molecule,,,,,
O(C(=O)C1=C([H])C(N=C(C2=C([O-])C([H])=C([H])C([H])=C2[H])[H])=C(N=C(C2=C([O-])C([H])=C([H])C([H])=C2[H])[H])C([H])=C1[H])[H],DB04810,,Salophen-10-carboxylate iron chelate,,small molecule,,,,,
[O-]C1=C(C(=NC2=C(N=C(C3=C([O-])C([H])=C([H])C([H])=C3[H])[H])C([H])=C([H])C([H])=C2[H])[H])C([H])=C([H])C([H])=C1[H],DB04811,,Salophen iron chelate,,small molecule,,,,,
O(C1=C(Cl)C([H])=C(Cl)C([H])=C1SC1=C(O[H])C(Cl)=C([H])C(Cl)=C1[H])[H],DB04813,97-18-7,Bithionol,"2-Hydroxy-3,5-dichlorophenyl sulfide
2-Hydroxy-3,5-dichlorophenyl sulphide
2,2'-Dihydroxy-3,3',5,5'-tetrachlorodiphenyl sulfide
2,2'-Dihydroxy-3,3',5,5'-tetrachlorodiphenylsulfide
2,2'-sulfanediylbis(4,6-dichlorophenol)
2,2'-Thiobis (4,6-dichlorophenol)
2,2'-Thiobis-(4,6-dichlorophenol)
2,2'-Thiobis(4,6-dichlorophenol)
2,2'-Thiobis[4,6-dichlorophenol]
Bis(2-hydroxy-3,5-dichlorophenyl) sulfide
Bis(3,5-dichloro-2-hydroxyphenyl) sulfide
Bithional
Bithionol sulfide
Bithionolate
Bithionolum
Bitionol",small molecule,,,,,
C(C(C(C(=O)N(C1=C(I)C(C(=C(C(C([H])([H])[H])([H])[H])C(O[H])=O)[H])=C(I)C([H])=C1I)[H])([H])[H])([H])[H])([H])([H])[H],DB04814,1233-53-0,Bunamiodyl,"2-(3-Butyramido-3,4,6-triiodophenylmethylene)butyric acid
Bunamiodilo
Bunamiodylum",small molecule,,,,,
O(C1=C(I)C([H])=C(Cl)C2=C(C(=C(N=C12)[H])[H])[H])[H],DB04815,130-26-7,Clioquinol,"5-Chlor-7-jod-8-hydroxy-chinolin
5-Chloro-7-iodo-8-hydroxyquinoline
5-Chloro-7-iodo-8-quinolinol
5-chloro-7-iodoquinolin-8-ol
5-Chloro-8-hydroxy-7-iodoquinoline
7-Iodo-5-chloro-8-hydroxyquinoline
7-Iodo-5-chloroxine
Chloroiodoquin
Clioquinolum
Iodochlorhydroxyquin
Iodochlorhydroxyquinoline
Iodochlorohydroxyquin
Iodochloroxyquinoline",small molecule,,"Cream
Ointment
Solution / drops
Tablet
Cream
Ointment","Topical
Topical
Auricular (otic)
Vaginal
Topical
Topical","3 %
3 %",Used as a topical antifungal treatment.
O(C1=C2C(=O)C3=C(O[H])C([H])=C([H])C([H])=C3C(=O)C2=C([H])C([H])=C1[H])[H],DB04816,117-10-2,Danthron,"1,8-dihydroxy-9,10-anthracenedione
1,8-dihydroxy-9,10-anthraquinone
1,8-dihydroxyanthra-9,10-quinone
1,8-Dihydroxyanthrachinon
1,8-Dihydroxyanthraquinone
Chrysazin
Dantron",small molecule,,"Tablet
Capsule","Oral
Oral",,
C(N(C(S([O-])(=O)=O)([H])[H])C1=C(C([H])([H])[H])N(C([H])([H])[H])N(C2=C([H])C([H])=C([H])C([H])=C2[H])C1=O)([H])([H])[H],DB04817,50567-35-6,Metamizole,,small molecule,Humans and other mammals,,,,Used in the past as a powerful painkiller and fever reducer.
C(C(C([H])([H])[H])(N(N(C(=O)C1=C([H])C([H])=NC([H])=C1[H])[H])[H])[H])([H])([H])[H],DB04818,54-92-2,Iproniazid,,small molecule,Humans and other mammals,,,,For the treatment of depression (originally intended to treat tuberculosis).
C(N(C([H])([H])[H])C(C(N(C(C1=C([H])C([H])=C([H])S1)([H])[H])C1=NC([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB04819,91-80-5,Methapyrilene,"2-[[2-(Dimethylamino)ethyl]-2-thenylamino]pyridine
Methypyrilene
N,N-Dimethyl-N'-pyrid-2-yl-N'-2-thenylethylenediamine
Thenylpyramine",small molecule,Humans and other mammals,,,,
O=C(C(C(N(N(C(=O)C1=C([H])C([H])=NC([H])=C1[H])[H])[H])([H])[H])([H])[H])N(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H],DB04820,51-12-7,Nialamide,"1-(2-(Benzylcarbamoyl)ethyl)-2-isonicotinoylhydrazine
1-[2-(Benzylcarbamoyl)ethyl]-2-isonicotinoylhydrazine
2-(2-(Benzylcarbamoyl)ethyl)hydrazide isonicotinic acid
2-(2-(Benzylcarbamoyl)ethyl)hydrazide, isonicotinic acid
2-(2-(Benzylcarbamyl)ethyl)hydrazide isonicotinic acid
2-[2-(Benzylcarbamoyl)ethyl]hydrazide isonicotinic acid
BEIH
Isonicitinic acid 2-[(2-benzylcarbamoyl)ethyl]hydrazide
Isonicotinic acid 2-((2-benzylcarbamoyl)ethyl)hydrazide
Isonicotinic acid, {2-[2-(benzylcarbamoyl)ethyl]hydrazide}
Isonicotinic acid, {2-[2-(benzylcarbamoylethyl]hydrazide}
Isonicotinic acid, 2-(2-(benzylcarbamoyl)ethyl)hydrazide
Isonicotinic acid, 2-[2- (benzylcarbamoyl)ethyl]hydrazide
Isonicotinic acid, 2-[2-(benzylcarbamoyl)ethyl]hydrazide
Isonicotinic acid, 2-[2-(benzylcarbamoylethyl]hydrazide
N-(2-(Benzylcarbamyl)ethylamino)isonicotinamide
N-Benzyl-3-(2-isonicotinoylhydrazino)propanamide
N-benzyl-beta-(isonicotinoylhydrazine)propionamide
N-benzyl-beta-(isonicotinylhydrazino)propionamide
N-isonicotinoyl-n'(beta-n-benzylcarboxamidoethyl)hydrazine
N-isonicotinyl hydrazide
Nialamida
Nialamidum
Pyridine-4-carboxylic 2-[2-(benzylcarbamoyl)ethyl]hydrazide",small molecule,Humans and other mammals,,,,
C(C(N(C(C([H])([H])[H])([H])[H])C(C(OC(C(OC(=O)C(C(C([H])([H])[H])([H])[H])(C(C([H])([H])[H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04822,468-61-1,Oxeladin,"2-(2-Diethylaminoethoxy)ethyl 2-ethyl-2-phenylbutyrate
Oxeladina
Oxeladine
Oxeladinum",small molecule,Humans and other mammals,,,,
O(C1=C([H])C([H])=C(C2(C(=O)N([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])C2=C([H])C([H])=C(O[H])C([H])=C2[H])C([H])=C1[H])[H],DB04823,125-13-3,Oxyphenisatin,"1,3-Dihydro-3,3-bis(4-hydroxyphenyl)-2H-indol-2-one
3,3-Bis(4-hydroxyphenyl)-oxindole
3,3-Bis(4-hydroxyphenyl)oxindole
3,3-Bis(p-hydroxyphenyl)-2-indolinone
3,3-Bis(p-hydroxyphenyl)oxindole
4,4'-Dihydroxydiphenylisatin
Dihydroxyphenoloxindol
Oxifenisatina
Oxiphenisatinum
Oxyphenisatine
Oxyphenisatinum",small molecule,,,,,
O(C1=C([H])C([H])=C(C2(OC(=O)C3=C2C(=C(C(=C3[H])[H])[H])[H])C2=C([H])C([H])=C(O[H])C([H])=C2[H])C([H])=C1[H])[H],DB04824,77-09-8,Phenolphthalein,"3,3-Bis(4-hydroxyphenyl)phthalide
Fenolftalein
Fenolftaleina
Phenolphtaleine
Phenolphthaleinum
Phthalimetten
phthalin
Yellow phenolphthalein",small molecule,Humans and other mammals,"Emulsion
Tablet
Tablet
Tablet
Liquid
Tablet
Tablet
Tablet
Jelly
Capsule","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","60 mg
95 mg
100 mg
90 mg
94 mg
100 mg",Used for over a century as a laxative.
C(N1C([H])([H])C([H])([H])C(N(C(C2=C([H])C([H])=C([H])S2)([H])[H])C2=C([H])C([H])=C([H])C([H])=C2[H])([H])C([H])([H])C1([H])[H])([H])([H])[H],DB04826,86-12-4,Thenalidine,"1-Methyl-4-amino-N-phenyl-N-(2-thenyl)piperidine
1-Methyl-4-N-2-thenylanilinopiperidine
Tenalidina
Thenaldine
Thenalidinum
Thenophenopiperidine",small molecule,,,,,
C(C(OC(N([H])[H])=O)([H])[H])([H])([H])[H],DB04827,51-79-6,Ethyl carbamate,"Aethylcarbamat
Aethylurethan
Carbamic acid ethyl ester
Carbamidsaeure-aethylester
Estane 5703
Ethyl ester of carbamic acid
Ethyl urethan
Ethyl urethane
Ethylcarbamate
Ethylester kyseliny karbaminove
Ethylurethan
Ethylurethane
O-ethyl urethane
O-ethylurethane
Uretan
Uretan etylowy
Uretano
Urethan
Urethane
Urethanum",small molecule,Humans and other mammals,,,,
C(N1C(C(C(O[H])=O)([H])[H])=C([H])C(C([H])([H])[H])=C1C(=O)C1=C([H])C([H])=C(Cl)C([H])=C1[H])([H])([H])[H],DB04828,33369-31-2,Zomepirac,"5-(4-Chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-2-acetic acid
Zomepiracum",small molecule,Humans and other mammals,,,,Zomepirac was indicated for the management of mild to severe pain.
C(C(C(C(N=C(N([H])[H])N=C(N([H])[H])N([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04830,692-13-7,Buformin,"1-Butylbiguanide
Buformina
Buformine
Buforminum",small molecule,Humans and other mammals,,,,
O(C(=O)C(OC1=C([H])C([H])=C(C(=O)C2=C([H])C([H])=C([H])S2)C(Cl)=C1Cl)([H])[H])[H],DB04831,40180-04-9,Ticrynafen,"(2,3-Dichloro-4-(2-thenoyl)phenoxy)acetic acid
(2,3-Dichloro-4-(2-thienylcarbonyl)phenoxy)acetic acid
(2,3-Dichloro-4-(2-thiophenecarbonyl)phenoxy)acetic acid
4-(2-Theonyl)-2,3-dichlorphenoxyessigsaeure
4-(2-Thienylketo)-2,3-dichlorophenoxyacetic acid
Acide tienilique
Acido tienilico
Acidum tienilicum
Thienylic acid
Tienilic acid
Tienilico acido",small molecule,Humans and other mammals,,,,For the treatment of hypertension.
C(N(C([H])([H])[H])C(C(=C(C1=C([H])C([H])=C(Br)C([H])=C1[H])C1=C([H])N=C([H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB04832,56775-88-3,Zimelidine,"(Z)-3-(4'-Bromophenyl)-3-(3''-pyridyl)dimethylallylamine
(Z)-3-[1-(p-Bromophenyl)-3-(dimethylamino)propenyl]pyridine
(z)-zimelidine
Cis-zimelidine
Zimeldine",small molecule,Humans and other mammals,,,,For the treatment of depression.
C(C1=C(N2C(C([H])([H])[H])=NC3=C(C(=C(C(=C3[H])[H])[H])[H])C2=O)C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB04833,72-44-6,Methaqualone,,small molecule,Humans and other mammals,,,,"For the treatment of insomnia, and as a sedative and muscle relaxant."
O(C(=O)C(C(C(C(C(C(N(C1(C2=C(C(=C(C(=C2[H])[H])[H])[H])C([H])([H])C([H])([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB04836,57574-09-1,Amineptine,,small molecule,Humans and other mammals,,,,For the treatment of depression.
C(C1(C([H])([H])C(OC(=O)C(O[H])(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C1([H])[H])[H])([H])([H])[H],DB04838,456-59-7,Cyclandelate,"3,3,5-Trimethylcyclohexyl mandelate
3,5,5-Trimethylcyclohexyl amygdalate
Ciclandelato
Cyclandelatum",small molecule,Humans and other mammals,Tablet,Oral,200 mg,"Used in the treatment of various blood vessel diseases (e.g., claudication, arteriosclerosis and Raynaud's disease) and nighttime leg cramps."
N(C(=N[H])N1C([H])([H])C([H])([H])C2=C(C(=C(C(=C2[H])[H])[H])[H])C1([H])[H])([H])[H],DB04840,1131-64-2,Debrisoquin,"Debrisochinum
Debrisoquin
Debrisoquina
Debrisoquine
Debrisoquinum
Isocaramidine",small molecule,Humans and other mammals,,,,"For the treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension."
FC1=C([H])C([H])=C(C(N2C([H])([H])C([H])([H])N(C(C(=C(C3=C([H])C([H])=C([H])C([H])=C3[H])[H])[H])([H])[H])C([H])([H])C2([H])[H])(C2=C([H])C([H])=C(F)C([H])=C2[H])[H])C([H])=C1[H],DB04841,52468-60-7,Flunarizine,"1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine
Flunarizina
Flunarizinum",small molecule,Humans and other mammals,Capsule,Oral,5 mg,"Used in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy."
FC1=C([H])C([H])=C(C(C(C(C(N2C([H])([H])C([H])([H])C3(N(C4=C([H])C([H])=C([H])C([H])=C4[H])C([H])([H])N([H])C3=O)C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])(C2=C([H])C([H])=C(F)C([H])=C2[H])[H])C([H])=C1[H],DB04842,1841-19-6,Fluspirilene,"Fluspirileno
Fluspirilenum
Imap",small molecule,Humans and other mammals,"Suspension
Suspension","Intramuscular
Intramuscular","10 mg
2 mg",Used for the treatment of schizophrenia.
C(OC1=C([H])C2=C(C3(C([H])([H])C(=O)C(C(C(C([H])([H])[H])(C([H])([H])[H])[H])([H])[H])([H])C([H])([H])N3C(C2([H])[H])([H])[H])[H])C([H])=C1OC([H])([H])[H])([H])([H])[H],DB04844,58-46-8,Tetrabenazine,"1,2,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one
2-oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine
2-oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-benzoquinolizine
Tetrabenazina
Tetrabenazinum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet, coated
Tablet, coated","Oral
Oral
Oral
Oral
Oral","25 mg
12.5 mg/1
25 mg/1
12.5 mg/1
25 mg/1","Treatment of hyperkinetic movement disorders like chorea in Huntington's disease, hemiballismus, senile chorea, Tourette syndrome and other tic disorders, and tardive dyskinesia "
C(C1=NC(C(=O)N(C(C(O[H])=O)([H])[H])[H])=C(O[H])C2=C(C(=C(OC3=C([H])C([H])=C([H])C([H])=C3[H])C([H])=C12)[H])[H])([H])([H])[H],DB04847,,Roxadustat,,small molecule,Humans and other mammals,,,,In clinical development for the treatment of anemia of chronic inflammatory disease.
C(OC1=C(OC(C(C(N2C([H])([H])C([H])([H])C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C2N=C(N=C(OC3=C(F)C4=C(N(C(C([H])([H])[H])=C4[H])[H])C([H])=C3[H])C2=C1[H])[H])([H])([H])[H],"DB04849
DB12033",288383-20-0,Cediranib,,small molecule,Humans and other mammals,,,,"For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors."
C(C(C([H])([H])[H])(C(OC1=C(C#N)C([H])=C(C2=NC(C([H])([H])[H])=C(C(O[H])=O)S2)C([H])=C1[H])([H])[H])[H])([H])([H])[H],"DB04854
DB03786",144060-53-7,Febuxostat,"2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acid
F��buxostat
Febuxostat
Febuxostatum",small molecule,Humans and other mammals,"Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral","120 mg
80 mg
40 mg/1
80 mg/1
40 mg/1
80 mg/1
80 mg",For the treatment of hyperuricemia in patients with gout.
C(C(C(C(N(C(C(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])C(C(C(OC1=C([H])C([H])=C(C(=O)C2=C(C(C(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])OC3=C2C(=C(N(S(C([H])([H])[H])(=O)=O)[H])C(=C3[H])[H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04855,141626-36-0,Dronedarone,"N-(2-Butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide
N-(2-Butyl-3-(P-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide
SR 33589
SR 33589b",small molecule,Humans and other mammals,"Tablet
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral","400 mg
400 mg/1
400 mg",Management of paroxysmal or persistent atrial fibrillation via restoration of normal sinus rhythm. 
N(C1=[N+]([O-])C2=C(C(=C(C([H])=C2[N+]([O-])=N1)[H])[H])[H])([H])[H],DB04858,27314-97-2,Tirapazamine,"1,2,4-benzotriazin-3-amine, 1,4-dioxide
3-Amino-1,2,4-benzotriazine 1,4-dioxide",small molecule,Humans and other mammals,,,,For the treatment of head and neck cancer.
O=C(C(C(C1(C([H])([H])C([H])([H])N(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])C([H])([H])C1([H])[H])[H])([H])[H])([H])[H])C1=C([H])C2=C(C(C(C(C(N2[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H],DB04859,142852-50-4,Zanapezil,Zanepezil,small molecule,Humans and other mammals,,,,For the treatment of dementia in subjects with Alzheimer���s disease.
O(C(C(N(C(C(O[H])(C1(C([H])([H])C([H])([H])C2=C(C(=C(C(F)=C2[H])[H])[H])O1)[H])[H])([H])[H])[H])([H])[H])(C1(C([H])([H])C([H])([H])C2=C(C(=C(C(F)=C2[H])[H])[H])O1)[H])[H])[H],DB04861,118457-14-0,Nebivolol,"1,1'-[Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)]-2,2'-iminodiethanol
1,1'-Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2,2'-iminodiethanol
alpha,alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
alpha,alpha'-(iminodimethylene)bis-(6-fluoro-2-chromanmethanol)
Narbivolol
Nebivololum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","10.0 mg
2.5 mg
20.0 mg
5.0 mg
10 mg/1
2.5 mg/1
20 mg/1
5 mg/1",For the treatment of essential hypertension.
O(C(=O)C(N1C(C(=O)N(C2=NC(C3=C(Cl)C([H])=C([H])C([H])=C3[H])=C([H])S2)[H])=C([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])[H],DB04867,136381-85-6,Lintitript,,small molecule,Humans and other mammals,,,,For the treatment of pancreatic cancer and appetite disorders.
C(C1=C([H])N(C2=C([H])C(N(C(=O)C3=C([H])C(N(C4=NC(C5=C([H])N=C([H])C([H])=C5[H])=C([H])C([H])=N4)[H])=C(C([H])([H])[H])C([H])=C3[H])[H])=C([H])C(C(F)(F)F)=C2[H])C([H])=N1)([H])([H])[H],DB04868,641571-10-0,Nilotinib,Nilotinibum,small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral","150 mg/1
150 mg
200 mg
200 mg/1
50 mg/1","For the potential treatment of various leukemias, including chronic myeloid leukemia (CML)."
C(C(C(C(N1C([H])([H])C([H])([H])C(C(N(C(=O)C2=C3OC(C(C([H])([H])N3C3=C2C(=C(C(=C3[H])[H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])C([H])([H])C1([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04873,152811-62-6,Piboserod,,small molecule,Humans and other mammals,,,,For the treatment of atrial fibrillation and irritable bowel syndrome (IBS).
C(C1=NC([H])=C([H])C([H])=C1[H])([H])([H])[H],DB04874,181630-15-9,Picoplatin,(SP-4-3)-Amminedichloro(2-methylpyridine)platinium,small molecule,Humans and other mammals,,,,For the treatment of patients with solid tumors.
ClC1=C([H])C([H])=C(N(C2=NN=C(C(C3=C([H])C([H])=NC([H])=C3[H])([H])[H])C3=C(C(=C(C([H])=C23)[H])[H])[H])[H])C([H])=C1[H],DB04879,212141-54-3,Vatalanib,"1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate
PTK 787
PTK/ZK",small molecule,Humans and other mammals,,,,Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).
C(SC1=C([H])C([H])=C(C(=O)C2=C(C([H])([H])[H])N([H])C(=O)N2[H])C([H])=C1[H])([H])([H])[H],DB04880,77671-31-9,Enoximone,Perfan,small molecule,Humans and other mammals,,,,For the treatment of congestive heart failure.
C(OC1=C([H])C2=C(C(N(C(C(C3=C([H])C([H])=C(N(C(=O)C4=C([H])C([H])=C([H])C5=C4N(C4=C(C5=O)C([H])=C([H])C([H])=C4OC([H])([H])[H])[H])[H])C([H])=C3[H])([H])[H])([H])[H])C(C2([H])[H])([H])[H])([H])[H])C([H])=C1OC([H])([H])[H])([H])([H])[H],DB04881,143664-11-3,Elacridar,,small molecule,Humans and other mammals,,,,For the treatment of solid tumors.
O=C1N([H])C2=C(C(=C(C(=C2[H])[H])[H])N2C([H])([H])C([H])([H])N(C(C3=C([H])C(C4=C([H])C([H])=C([H])C([H])=C4[H])=C([H])C([H])=C3[H])([H])[H])C([H])([H])C2([H])[H])O1,DB04888,350992-10-8,Bifeprunox,"Bifeprunox mesilate
Bifeprunoxum",small molecule,Humans and other mammals,,,,"Bifeprunox is being evaluated for the treatment of schizophrenia, psychosis, and Parkinson's disease."
C(C1=C([H])C([H])=C(C23C([H])([H])C2([H])C([H])([H])N([H])C3([H])[H])C([H])=C1[H])([H])([H])[H],DB04889,71195-57-8,Bicifadine,,small molecule,Humans and other mammals,,,,For the treatment of pain.
C(C(N(C(C([H])([H])[H])([H])[H])C(C(OC1=C([H])C([H])=C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04905,98774-23-3,Tesmilifene,"Depmpe
DPPE
N,N-diethyl-2-((4-phenylmethyl)phenoxy)ethanamine",small molecule,Humans and other mammals,,,,Intended for the treatment of various forms of cancer.
FC(F)(F)C1=C([H])C(N2C([H])([H])C([H])([H])N(C(C(N3C(=O)N([H])C4=C3C(=C(C(=C4[H])[H])[H])[H])([H])[H])([H])[H])C([H])([H])C2([H])[H])=C([H])C([H])=C1[H],DB04908,167933-07-5,Flibanserin,"BIMT-17
BIMT-17-BS",small molecule,Humans and other mammals,"Tablet
Tablet, film coated","Oral
Oral","100 mg
100 mg/1",For the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. 
C(C(N(C(C([H])([H])[H])([H])[H])C(C(C(C(C(C(N(C1=C([H])C(OC([H])([H])[H])=C([H])C2=C(C([H])([H])[H])C(=C(N=C12)[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04909,57695-04-2,Sitamaquine,"8-aminoquinoline
WR-6026",small molecule,Plasmodium,,,,Investigated for use/treatment in infectious and parasitic disease (unspecified).
C(C(C(OC1=C([H])C2=C(N=C(N(C(=O)OC([H])([H])[H])[H])N2[H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB04910,20559-55-1,Oxibendazole,"(5-Propoxy-1H-benzimidazol-2-yl)carbamic acid methyl ester
5-Propoxy-2-benzimidazolecarbamic acid methyl ester
Methyl (5-propoxy-1H-benzimidazol-2-yl)carbamate
methyl 5-[n-propoxy]benzimidazole-2-carbamate
Methyl 5-n-propoxy-2-benzimidazole carbamate
Methyl 5-propoxy-2-benzimidazolecarbamate
OBZ
Oxibendazolo
Oxibendazolum
Oxybendazole",small molecule,Helminthic Microorganisms,,,,Investigated for use/treatment in infectious and parasitic disease (unspecified) and pediatric indications.
C(C(C1=C2[N-]C(C(=C3N=C(C(=C4[N-]C(=C(C5=NC(=C2[H])C(C([H])([H])[H])=C5C(C([H])([H])[H])([H])[H])[H])C(C([H])([H])[H])=C4C(C(C(O[H])=O)([H])[H])([H])[H])[H])C(C(C(C(O[H])=O)([H])[H])([H])[H])=C3C([H])([H])[H])[H])=C1C([H])([H])[H])([H])[H])([H])([H])[H],DB04912,106344-20-1,Stannsoporfin,"SnMP
Tin (IV) mesoporphyrin IX dichloride
tin-mesoporphyrin",small molecule,Humans and other mammals,,,,"Investigated for use/treatment in liver disease, metabolic disease, and pediatric indications."
O(C1=C([H])C([H])=C(C2=C([H])C3=C(C(=C(O[H])C(=C3[H])[H])[H])OC2([H])[H])C([H])=C1[H])[H],DB04915,81267-65-4,Idronoxil,"3-(4-hydroxyphenyl)-2H-chromen-7-ol
Dehydroequol
Haginin E
Phenoxodiol",small molecule,Humans and other mammals,,,,Intended for the treatment of various forms of cancer.
C(OC1=C(Cl)C(N([H])[H])=C([H])C([H])=C1C(=O)N(C1(C([H])([H])C([H])([H])N2C(C(C([H])([H])C1(C2([H])[H])[H])([H])[H])([H])[H])[H])[H])([H])([H])[H],DB04917,112727-80-7,Renzapride,,small molecule,Humans and other mammals,,,,For the treatment of constipation-predominant irritable bowel syndrome (IBS-C).
C(OC1=C(OC([H])([H])[H])C([H])=C(C(=O)N(C(C2=C([H])C([H])=C(OC(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])C([H])=C2[H])([H])[H])[H])C([H])=C1[H])([H])([H])[H],DB04924,122898-67-3,Itopride,N-(p-(2-(Dimethylamino)ethoxy)benzyl)veratramide,small molecule,Humans and other mammals,,,,Investigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous).
C(C1(C([H])([H])[H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(C([H])([H])[H])(N([H])[H])C1([H])[H])([H])([H])[H],DB04926,219810-59-0,Neramexane,,small molecule,Humans and other mammals,,,,"Investigated for use/treatment in alzheimer's disease, hearing loss, and pain (acute or chronic)."
C(C1(C([H])([H])[H])C(C(=C(Cl)Cl)[H])([H])C1(C(=O)OC(C1=C([H])C(OC2=C([H])C([H])=C([H])C([H])=C2[H])=C([H])C([H])=C1[H])([H])[H])[H])([H])([H])[H],DB04930,52645-53-1,Permethrin,"(3-Phenoxyphenyl)methyl (+-)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate
3-(2,2-Dichloroethenyl)-2,2-dimethylcyclopropane carboxylic acid, (3-phenoxyphenyl) methyl ester
Permethrin",small molecule,Scabies (Sarcoptes scabei) and other insects,"Cream
Liquid
Lotion
Lotion
Shampoo
Kit
Cream
Cream
Cream","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","50 mg/100g
1.0 %
5 %
1 mg/100mL
560 mg/59mL
1 %
5 %
50 mg/g",For the treatment of infestation with <i>Sarcoptes scabiei</i> (scabies).
O(C(C(OC1=C([H])C([H])=C(C(=C(C(C(Cl)([H])[H])([H])[H])C2=C([H])C([H])=C([H])C([H])=C2[H])C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])[H],DB04938,128607-22-7,Ospemifene,"2-(4-(4-Chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol
2-(P-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol
Deamino-hydroxytoremifene",small molecule,Humans and other mammals,"Tablet, film coated",Oral,60 mg/1,"Ospemifene is used for the treatment of moderate to dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause."
C(C1(C([H])([H])[H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C2=C1C(=C(C(N(C(=O)C1=C([H])C([H])=C(C(O[H])=O)C([H])=C1[H])[H])=C2[H])[H])[H])([H])([H])[H],"DB04942
DB03873",94497-51-5,Tamibarotene,retinobenzoic acid,small molecule,Humans and other mammals,,,,Investigated for use/treatment in leukemia (unspecified).
C(OC1=C(OC(C(C(N2C([H])([H])C([H])([H])C(C3=NOC4=C3C(=C(C(F)=C4[H])[H])[H])([H])C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C([H])C(C(C([H])([H])[H])=O)=C1[H])([H])([H])[H],DB04946,133454-47-4,Iloperidone,"1-[4-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1- piperidinyl]propoxy]-3-methoxyphenyl]ethanone
4'-(3-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone
Fanapta
Iloperidona
Iloperidonum
Zomaril",small molecule,Humans and other mammals,"Kit
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","1 mg/1
10 mg/1
12 mg/1
2 mg/1
4 mg/1
6 mg/1
8 mg/1",Treatment of acute schizophrenia. 
C(C1=C([H])N(C2=C([H])C([H])=C([H])C([H])=C2[H])C(=O)C([H])=C1[H])([H])([H])[H],DB04951,53179-13-8,Pirfenidone,,small molecule,Humans and other mammals,"Capsule
Capsule
Tablet
Tablet
Tablet, coated
Tablet, coated","Oral
Oral
Oral
Oral
Oral
Oral","267 mg/1
267 mg
267 mg
801 mg
267 mg/1
801 mg/1",For the treatment of idiopathic pulmonary fibrosis (IPF).
C(C(OC(=O)N(C1=C(N([H])[H])C([H])=C(N(C(C2=C([H])C([H])=C(F)C([H])=C2[H])([H])[H])[H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB04953,150812-12-7,Ezogabine,"Ethyl {2-amino-4-[(4-fluorobenzyl)amino]phenyl}carbamate
Ethyl 2-amino-4-((P-fluorobenzyl)amino)carbanilate
EZG
N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester
N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester
Retigabine
RTG",small molecule,Humans and other mammals,"Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","200 mg/1
300 mg/1
400 mg/1
50 mg/1
100 mg
200 mg
300 mg
400 mg
50 mg",Adjuvant treatment of partial-onset seizures. 
C(N1C([H])([H])C([H])([H])N(C(C(C(C(N2C(=O)C([H])([H])N(N=C(C3=C([H])C([H])=C(C4=C([H])C([H])=C(Cl)C([H])=C4[H])O3)[H])C2=O)([H])[H])([H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB04957,149908-53-2,Azimilide,,small molecule,Humans and other mammals,,,,Investigated for use/treatment in arrhythmia and atrial fibrillation.
C(C(N(C(C([H])([H])[H])([H])[H])C(C(N(C1=C([H])C([H])=C(C([H])([H])[H])C2=C1C(=O)C1=C(S2)C([H])=C([H])C([H])=C1[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB04967,479-50-5,Lucanthone,"1-((2-(Diethylamino)ethyl)amino)-4-methylthioxanthen-9-one
1-{[2-(diethylamino)ethyl]amino}-4-methylthioxanthen-9-one
1-diethylaminoethylethylamino-4-methyl-thioxanthenone
Lucanthone
Lucanthonum
Lucantona",small molecule,Humans and other mammals,,,,Intended for use as a radiation sensitizer in the treatment of brain cancer.
ClC1=C([H])N(C(C(C(C(N2C([H])([H])C([H])([H])N(C3=NC([H])=C([H])C([H])=N3)C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])N=C1[H],DB04970,132449-46-8,Lesopitron,Lesopitran,small molecule,Humans and other mammals,,,,Intended for the treatment of anxiety disorders.
C([N+](C([H])([H])[H])([O-])C(C(N(C1=C([H])C([H])=C(N(C(C([N+](C([H])([H])[H])(C([H])([H])[H])[O-])([H])[H])([H])[H])[H])C2=C1C(=O)C1=C(C2=O)C(O[H])=C([H])C([H])=C1O[H])[H])([H])[H])([H])[H])([H])([H])[H],DB04975,136470-65-0,Banoxantrone,AQ4N,small molecule,Humans and other mammals,,,,For the treatment of various forms of cancer.
N(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])([H])[H],DB04996,129580-63-8,Satraplatin,,small molecule,Humans and other mammals,,,,"Investigated for use/treatment in lung cancer, prostate cancer, and solid tumors."
O(N(C(=O)C(=C(C1=C([H])C([H])=C([H])C(S(=O)(=O)N(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])=C1[H])[H])[H])[H])[H],DB05015,866323-14-0,Belinostat,,small molecule,Humans and other mammals,"Injection, powder, lyophilized, for solution",Intravenous,500 mg/10mL,Belinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with manageable safety profile. It is a potential alternative therapy for patients who did not experience adequate response to first-line drugs for PTCL. It can be used in patients with baseline thrombocytopenia [A19161]. 
O(C(=O)C1=C([H])C([H])=C([H])C(C2=NOC(C3=C(F)C([H])=C([H])C([H])=C3[H])=N2)=C1[H])[H],DB05016,775304-57-9,Ataluren,"3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
EC-000.2051",small molecule,Humans and other mammals,"Granule
Granule
Granule","Oral
Oral
Oral","1000 mg
125 mg
250 mg","Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. More specifically, ataluren is used in the small group of patients whose disease is caused by a specific genetic defect (called a ���nonsense mutation���) in the dystrophin gene."
C(N(C([H])([H])[H])C(C(N1C(=O)C2C3C(C(=C(C=2[H])N([H])[H])[H])=C(C(=C([H])C=3C1=O)[H])[H])([H])[H])([H])[H])([H])([H])[H],DB05022,69408-81-7,Amonafide,,small molecule,,,,,"Investigated for use/treatment in breast cancer, ovarian cancer, and prostate cancer."
C(C(C([H])([H])[H])(C1=C(O[H])C([H])=C([H])C(OC2=C(Br)C([H])=C(N(C(=O)C(C(O[H])=O)([H])[H])[H])C([H])=C2Br)=C1[H])[H])([H])([H])[H],DB05035,,Eprotirome,,small molecule,,,,,"Investigated for use/treatment in hyperlipidemia, metabolic disease, and obesity."
C(C(OC(=O)C(C([H])([H])[H])(C([H])([H])[H])N(P(=O)(N(C(C([H])([H])[H])(C([H])([H])[H])C(=O)OC(C([H])([H])[H])([H])[H])[H])C1=C([H])C([H])=C(C2=C(C(=O)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])SC(N([H])[H])=N2)O1)[H])([H])[H])([H])([H])[H],DB05053,,MB-07803,,small molecule,,,,,Investigated for use/treatment in diabetes mellitus type 2.
C(C1=C([H])C(C2=C(Cl)C([H])=C([H])C(OC(=O)C3=C([H])C([H])=C([H])C([H])=C3[H])=C2[H])=C([H])C2=NN=C(N(C3=C([H])C([H])=C(OC(C(N4C([H])([H])C([H])([H])C([H])([H])C4([H])[H])([H])[H])([H])[H])C([H])=C3[H])[H])N=C12)([H])([H])[H],DB05075,,TG-100801,,small molecule,,,,,Investigated for use/treatment in macular degeneration.
C(C(C(=C(C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H])[H])[H])=C(C(=C(C(C([H])([H])[H])=C(C(=O)N(C1=C([H])C([H])=C(O[H])C([H])=C1[H])[H])[H])[H])[H])[H])([H])([H])[H],"DB05076
DB03922",65646-68-6,Fenretinide,"4-HPR
4-hydroxy(phenyl)retinamide
N-(4-Hydroxyphenyl)All-Trans Retinamide",small molecule,,,,,Investigated for use/treatment in macular degeneration.
S=[Mo]=S,DB05088,16330-92-0,Tiomolibdate ion,ATN-224,small molecule,,,,,Investigated for use/treatment in liver disease and pulmonary fibrosis.
C(OC1=C(F)C([H])=C(C2=C(Cl)N=C([H])N2C2=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C2[H])C([H])=C1[H])([H])([H])[H],DB05095,265114-23-6,Cimicoxib,,small molecule,Humans and other mammals,,,,Investigated for use/treatment in depression.
C(C(C(C(=O)OC(OC(=O)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB05103,122110-53-6,AN-9,"Pivaloyloxymethyl butyrate
Pivaloyloxymethylbutyrate
Pivanex",small molecule,,,,,"Investigated for use/treatment in liver cancer, lung cancer, melanoma, and leukemia (lymphoid)."
C(C1=NOC(C(C(C(OC2=C(C([H])([H])[H])C([H])=C(C3=NOC(C(F)(F)F)=N3)C([H])=C2C([H])([H])[H])([H])[H])([H])[H])([H])[H])=C1[H])([H])([H])[H],"DB05105
DB08716",153168-05-9,Pleconaril,,small molecule,,,,,Investigated for use/treatment in upper respiratory infection.
C(OC(C(N1C([H])([H])C([H])([H])C(N(C(C2=C([H])C([H])=C(C3=C([H])C([H])=C(C(F)(F)F)C([H])=C3[H])C([H])=C2[H])([H])[H])C(=O)C(N2C(SC(C3=C(F)C(F)=C([H])C([H])=C3[H])([H])[H])=C([H])C(=O)C3=C2C(=C(C(=C3[H])[H])[H])[H])([H])[H])([H])C([H])([H])C1([H])[H])([H])[H])([H])[H])([H])([H])[H],"DB05119
DB05256",412950-08-4,Rilapladib,,small molecule,,,,,Investigated for use/treatment in atherosclerosis and cardiovascular disorders.
C(C(C([H])([H])[H])(C(C(C(C(OC(C(C(C(C(C([H])([H])[H])(C([H])([H])[H])C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C(O[H])=O)([H])([H])[H],DB05123,183293-82-5,Gemcabene,,small molecule,,,,,"Investigated for use/treatment in atherosclerosis, cardiovascular disorders, and hyperlipidemia."
C(OC1=C([H])C([H])=C(C(=C(C2=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C(OC([H])([H])[H])=C2[H])[H])[H])C(OP(O[H])(O[H])=O)=C1OP(O[H])(O[H])=O)([H])([H])[H],DB05143,288847-35-8,OXI-4503,"CA1P
Combretastatin A-1 bis(phosphate)
Combretastatin A1 diphosphate
OXI4503",small molecule,,,,,Investigated for use/treatment in cancer/tumors (unspecified).
C(C(C([H])([H])[H])=C(C(C(C(C([H])([H])[H])=C(C(N(C(C(N(C1(C2(C([H])([H])C3(C(C(C2([H])[H])(C([H])([H])C1(C3([H])[H])[H])[H])([H])[H])[H])[H])[H])[H])([H])[H])([H])[H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB05186,502487-67-4,SQ-109,,small molecule,,,,,"Investigated for use/treatment in bacterial infection, infectious and parasitic disease (unspecified), and tuberculosis."
C(SC1=C([H])C([H])=C(C(=O)C(=C(C2=C([H])C(C([H])([H])[H])=C(OC(C([H])([H])[H])(C([H])([H])[H])C(O[H])=O)C(C([H])([H])[H])=C2[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB05187,923978-27-2,Elafibranor,,small molecule,,,,,Investigated for use/treatment in atherosclerosis and diabetes mellitus type 2.
C(C(C([H])([H])[H])=C(C(OC1=C([H])C([H])=C(C(=C(C(=O)C2=C(OC(C(O[H])=O)([H])[H])C([H])=C(OC(C(=C(C([H])([H])[H])C([H])([H])[H])[H])([H])[H])C([H])=C2[H])[H])[H])C([H])=C1[H])([H])[H])[H])([H])([H])[H],DB05197,64506-49-6,Sofalcone,,small molecule,,,,,Investigated for use/treatment in gastroenteritis and ulcers.
O(B1OC([H])([H])C2=C1C(=C(C(OC1=C([H])C([H])=C(C#N)C([H])=C1[H])=C2[H])[H])[H])[H],DB05219,906673-24-3,Crisaborole,,small molecule,Humans and other mammals,Ointment,Topical,20 mg/g,Intended for the topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.
C(OC1=C([H])C([H])=C([H])C(F)=C1C1=NC([H])([H])C2=C(N=C(N(C3=C([H])C(OC([H])([H])[H])=C(C(O[H])=O)C([H])=C3[H])[H])N=C2C2=C1C(=C(Cl)C(=C2[H])[H])[H])[H])([H])([H])[H],DB05220,,Alisertib,,small molecule,Humans and other mammals,,,,For the treatment of various forms of cancer.
C(C(C(C(C1=NC2=C(C(=C(C(C(=C(C(=O)N(O[H])[H])[H])[H])=C2[H])[H])[H])N1C(C(N(C(C([H])([H])[H])([H])[H])C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB05223,,Pracinostat,,small molecule,Humans and other mammals,,,,For the treatment of various forms of cancer.
N(C1=C([H])C([H])=C(S(=O)(=O)[N-]C2=NC([H])=C([H])C([H])=N2)C([H])=C1[H])([H])[H],DB05245,22199-08-2,Silver sulfadiazine,"Silver sulfadiazinate
Silver sulfadiazine
Silver sulphadiazine
Sulfadiazine silver
Sulfadiazine silver salt",small molecule,"Yeast and other fungi
Candida albicans and other yeasts
Various gram-negative and gram-positive eubacteria
Pseudomonas aeruginosa
Staphylococcus aureus","Cream
Cream
Gel
Cream
Cream","Topical
Topical
Topical
Topical
Topical","1 %
1 kg/kg
10 g/1000g
10 mg/g",Indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.
O=C1N([H])C(=O)C2=C(N(N([H])C2=N1)[H])[H],DB05262,2465-59-0,Oxypurinol,"1H-Pyrazolo[3,4-d]pyrimidine-4,6-diol
1H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
6-hydroxy allopurinol
Alloxanthin
Alloxanthine
DHPP
metabolite of allopurinol
Oxipurinol
Oxipurinolum
Oxoallopurinol
Oxyprim",small molecule,Humans and other mammals,,,,Intended for the treatment of congestive heart failure and hyperuricemia.
C(C(C([H])([H])[H])(C(=O)C1=C2C(=C(C(=C([H])N2N=C1C(C([H])([H])[H])(C([H])([H])[H])[H])[H])[H])[H])[H])([H])([H])[H],"DB05266
DB05066",50847-11-5,Ibudilast,Ibudilastum,small molecule,Humans and other mammals,,,,"For the treatment of multiple sclerosis, asthma, and cerebrovascular disease."
O(P(O[H])(=O)C(N(C(C(N(C(P(O[H])([O-])=O)([H])[H])C(P(O[H])([O-])=O)([H])[H])([H])[H])([H])[H])C(P(O[H])([O-])=O)([H])[H])([H])[H])[H],DB05273,122575-21-7,Samarium (153Sm) lexidronam,"153SM-EDTMP
Samarium (153 Sm) lexidronam
Samarium Sm-153 lexidronam
Samarium-153 lexidronam
Samarium-153-EDTMP",small molecule,,,,,"Investigated for use/treatment in bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis."
C(OC1=C(OC(C2(C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C2([H])[H])[H])([H])[H])C([H])=C2N=C(N=C(N(C3=C(F)C([H])=C(Br)C([H])=C3[H])[H])C2=C1[H])[H])([H])([H])[H],"DB05294
DB08764",443913-73-3,Vandetanib,"N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine
N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral","100 mg
300 mg
100 mg
300 mg
100 mg/1
300 mg/1","Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure. "
C(C(OC1=C(OC(C([H])([H])[H])([H])[H])C([H])=C(C2=NC(C3=NC(C(O[H])=O)=C([H])C([H])=C3[H])=C([H])S2)C([H])=C1[H])([H])[H])([H])([H])[H],"DB05298
DB12166",145739-56-6,Tetomilast,,small molecule,,,,,Investigated for use/treatment in ulcerative colitis.
C(C(C([H])([H])[H])(C(OC1=C([H])C([H])=C(C(N(C(=O)N(C(C2=C([H])C([H])=C(F)C([H])=C2[H])([H])[H])C2(C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C2([H])[H])[H])[H])([H])[H])C([H])=C1[H])([H])[H])[H])([H])([H])[H],DB05316,706779-91-1,Pimavanserin,,small molecule,Humans and other mammals,"Tablet, coated",Oral,17 mg/1,"Investigated for use/treatment in neurologic disorders, parkinson's disease, psychosis, schizophrenia and schizoaffective disorders, and sleep disorders."
C(C12C([H])([H])C(O[H])([H])C3([H])C(C(C(C4=C([H])C(=O)C([H])=C([H])C43C([H])([H])[H])([H])[H])([H])[H])([H])C1([H])C([H])([H])C([H])([H])C2(O[H])C(=O)C(OC(=O)C1=C([H])C([H])=C([H])C(S([O-])(=O)=O)=C1[H])([H])[H])([H])([H])[H],DB05340,,ATL-2502,,small molecule,,,,,Investigated for use/treatment in inflammatory bowel disease and ulcerative colitis.
ClC1=C([H])C([H])=C(OS(=O)(=O)C2=C([H])C([H])=C(Cl)C([H])=C2[H])C([H])=C1[H],DB05377,80-33-1,Chlorfenson,"4-Chlorophenyl 4-chlorobenzenesulfonate
Ester sulfonate",small molecule,,,,,Investigated for use/treatment in fungal infections.
O(P(O[H])(=O)C(N1C([H])([H])C([H])([H])N(C(P(O[H])(O[H])=O)([H])[H])C([H])([H])C([H])([H])N(C(P([O-])([O-])=O)([H])[H])C([H])([H])C([H])([H])N(C(P(O[H])(O[H])=O)([H])[H])C([H])([H])C1([H])[H])([H])[H])[H],DB05380,633308-23-3,DOTMP HO-166,"166Ho-DOTMP
Holmium Ho-166 DOTMP",small molecule,,,,,Investigated for use/treatment in multiple myeloma.
N(C(C(C1=C([H])N([H])C([H])=N1)([H])[H])([H])[H])([H])[H],"DB05381
DB05891
DB11320
DB00667",51-45-6,Histamine,"1H-Imidazole-4-ethanamine
2-(4-imidazolyl)ethylamine
4-imidazoleethylamine
5-imidazoleethylamine
beta-aminoethylglyoxaline
beta-aminoethylimidazole",small molecule,Humans and other mammals,"Stick
Liquid
Cream
Cream
Spray
Injection, solution
Cream
Cream
Liquid
Injection, solution
Solution
Solution
Solution
Lotion
Cream
Injection
Liquid","Topical
Topical
Topical
Topical
Topical
Subcutaneous
Topical
Topical
Subcutaneous
Intradermal
Percutaneous
Intradermal
Percutaneous
Topical
Topical
Percutaneous
Percutaneous",".05 g/100g
.25 mg/g
0.5 mg/0.5ml
.025 g/100g
.25 mg/mL
1 mg
.275 mg/mL
2.75 mg/mL
0.275 mg
2.75 mg
.6 mg/mL
6 mg/mL
6 mg",Histamine phosphate is indicated as a diagnostic aid for evaluation of gastric acid secretory function.
II,"DB05382
DB05247",7553-56-2,Iodine,"diiodine
I2
Jod
molecular iodine",small molecule,,"Solution
Kit
Tablet
Solution
Solution
Liquid
Capsule, gelatin coated
Kit
Liquid
Liquid
Capsule
Strip
Tincture
Tablet
Tablet
Solution / drops
Spray
Solution / drops
Tablet
Tablet
Tincture
Liquid
Liquid
Solution
Capsule
Liquid; ointment
Liquid
Liquid
Liquid
Liquid
Liquid
Solution
Solution
Liquid
Aerosol, spray
Aerosol
Suppository
Liquid
Liquid
Kit
Tablet
Liquid
Liquid
Liquid
Tablet, coated
Capsule, liquid filled","Topical
Oral
Topical
Topical
Topical
Oral
Intra-amniotic
Topical
Oral
Oral
Topical
Topical
Oral
Oral
Topical
Topical
Topical
Oral
Oral
Topical
Oral
Topical
Topical
Oral
Subcutaneous; Topical
Subarachnoid
Intravenous; Subarachnoid
Intravenous; Subarachnoid
Intravenous
Intravascular
Intrathecal
Intrathecal
Epidural; Intravenous
Topical
Topical
Vaginal
Intravenous
Oral
Infiltration; Topical
Oral
Topical
Topical
Vaginal
Oral
Oral","7.5 mL/100mL
2 g/100mL
.1 g/100mL
.75 %
0.22 mg
5 %
20 mg/mL
.5 mg
3 mg
20 mg/mL
.3 mg
150 mcg
.15 mg
.4 g/g
180 mg
240 mg
300 mg
350 mg
240 mg
240 mg
300 mg
.1 g/g
.5 %
25 mg
2.5 g/100mL
0.09 mg
5 %
1 %
1 %",Investigated for use/treatment in breast disorders (unspecified) and pain (acute or chronic).
N(N(C(N([H])[H])=N[H])[H])([H])[H],"DB05383
DB02533",79-17-4,Pimagedine,"Aminoguanidine
Hydrazinecarboximidamide",small molecule,,,,,Investigated for use/treatment in diabetic kidney disease.
[O-]Cl=O,DB05389,,WF10,,small molecule,,,,,"Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, cancer/tumors (unspecified), HIV infection, and inflammatory disorders (unspecified)."
C(C(C([H])([H])[H])(C([H])([H])[H])C1=C([H])C(SC(C([H])([H])[H])(C([H])([H])[H])SC2=C([H])C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=C(OC(=O)C(C(C(O[H])=O)([H])[H])([H])[H])C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=C2[H])=C([H])C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=C1O[H])([H])([H])[H],DB05399,216167-82-7,Succinobucol,,small molecule,,,,,"Investigated for use/treatment in atherosclerosis, coronary artery disease, diabetes mellitus type 2, and in-stent restenosis."
C(C(=O)N(C1=C([H])C([H])=C(OC(=O)C(C(C(O[N+]([O-])=O)([H])[H])([H])[H])([H])[H])C([H])=C1[H])[H])([H])([H])[H],DB05409,,NCX 701,,small molecule,,,,,Investigated for use/treatment in pain (acute or chronic).
C(C1=C(C2=C([H])C([H])=C(O[H])C([H])=C2[H])N(C(C2=C([H])C([H])=C(OC(C(N3C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])([H])[H])([H])[H])C([H])=C2[H])([H])[H])C2=C1C(=C(O[H])C(=C2[H])[H])[H])([H])([H])[H],DB05414,198480-55-6,Pipendoxifene,,small molecule,,,,,Investigated for use/treatment in breast cancer.
C(C1=C(C(SC2=C([H])C(C([H])([H])[H])=C(OC(C(O[H])=O)([H])[H])C([H])=C2[H])([H])[H])SC(C2=C([H])C([H])=C(C(F)(F)F)C([H])=C2[H])=N1)([H])([H])[H],"DB05416
DB13015",317318-70-0,GW-501516,GW 501516,small molecule,,,,,Investigated for use/treatment in hyperlipidemia.
C(C1=C([O-])C(=O)C([H])=C([H])O1)([H])([H])[H],DB05420,,gallium maltolate,,small molecule,,,,,"Investigated for use/treatment in bladder cancer, lymphoma (unspecified), multiple myeloma, paget's disease, and prostate cancer."
FC1=C(Cl)C([H])=C(N(C2=NC([H])=NC3=C(C(OC(C(C(N4C([H])([H])C([H])([H])OC([H])([H])C4([H])[H])([H])[H])([H])[H])([H])[H])=C(N(C(=O)C(=C([H])[H])[H])[H])C([H])=C23)[H])[H])C([H])=C1[H],DB05424,267243-28-7,Canertinib,,small molecule,,,,,Investigated for use/treatment in breast cancer and lung cancer.
N(C(C(C(C(=O)N(C(C(SC(O[H])([H])[H])([H])[H])(C(=O)N(C(C(O[H])=O)([H])[H])[H])[H])[H])([H])[H])([H])[H])(C(O[H])=O)[H])([H])[H],DB05446,,LJP 1082,,small molecule,,,,,"Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis."
FC(F)(F)C1=C([H])C(C2=C([H])C([H])([H])N(C(C(C3=C([H])C([H])=C(C4=C([H])C([H])=C([H])C([H])=C4[H])C([H])=C3[H])([H])[H])([H])[H])C([H])([H])C2([H])[H])=C([H])C([H])=C1[H],DB05454,,Paliroden,"1-[2-(biphenyl-4-yl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine",small molecule,,,,,Investigated for use/treatment in Alzheimer's disease and Parkinson's disease.
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(=O)OC(C(OC(=O)C(C(C(C(C(C(C(C(=C(C(C(C(C(C(C(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])(C(OP([O-])(=O)OC(C([N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB05456,,ETC-588,,small molecule,,,,,"Investigated for use/treatment in atherosclerosis, coronary artery disease, and vascular diseases."
C(C(C(=O)N(C1=C(C([H])([H])[H])C([H])=C(C(=O)N2C([H])([H])C([H])([H])C(N(C([H])([H])[H])C(C(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])([H])[H])([H])C([H])([H])C2([H])[H])C([H])=C1C([H])([H])[H])[H])([H])[H])([H])([H])[H],DB05461,,OPC-28326,,small molecule,,,,,Investigated for use/treatment in peripheral vascular disease and raynaud's disease.
C(C(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])(C1=C([H])C([H])=C(OC(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB05462,,Chlorotoxin I-131,,small molecule,,,,,"Investigated for use/treatment in various forms of brain cancer; Malignant Glioma, Glioblastoma Multiforme, GBM, Anaplastic Astrocytoma,  Oligo-Astrocytoma,  Gliosarcoma"
C(OC1=C(OC(C(C(N2C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C2N=C(N=C(N3C([H])([H])C([H])([H])N(C(=O)N(C4=C([H])C([H])=C(OC(C([H])([H])[H])(C([H])([H])[H])[H])C([H])=C4[H])[H])C([H])([H])C3([H])[H])C2=C1[H])[H])([H])([H])[H],DB05465,387867-13-2,Tandutinib,,small molecule,,,,,Investigated for use/treatment in leukemia (myeloid).
N(C(=O)N(C1=C([H])C([H])=C(C(N([H])[H])=O)C(C2=C(F)C([H])=C(F)C([H])=C2[H])=N1)C1=C(F)C([H])=C([H])C([H])=C1F)([H])[H],DB05470,,VX-702,,small molecule,,,,,"Investigated for use/treatment in coronary artery disease, inflammatory disorders (unspecified), and rheumatoid arthritis."
C(C1=C([H])C([N+]([O-])=O)=C(N(C(C(C(N([H])[H])([H])[H])([H])[H])([H])[H])[H])C([H])=C1[H])([H])([H])[H],"DB05492
DB08290",,Epicept NP-1,,small molecule,,,,,Investigated for use/treatment in neuropathy (diabetic) and pain (acute or chronic).
C(C(C(C1(C(C(C([H])([H])[H])([H])[H])([H])[H])C([H])([H])C([H])([H])C2(C([H])([H])C([H])([H])N(C(C(C(N(C(C([H])([H])[H])([H])[H])C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C2([H])[H])C([H])([H])C1([H])[H])([H])[H])([H])[H])([H])([H])[H],DB05513,123018-47-3,Atiprimod,"antiprimod
azaspirane",small molecule,,,,,"Investigated for use/treatment in cancer/tumors (unspecified), multiple myeloma, and rheumatoid arthritis."
C(C(OC1=C(N(C(=O)C(=C(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])[H])[H])[H])C([H])=C2C(N(C3=C([H])C(Cl)=C(F)C([H])=C3[H])[H])=C(C(=NC2=C1[H])[H])C#N)([H])[H])([H])([H])[H],DB05524,257933-82-7,Pelitinib,(2E)-N-(4-((3-chloro-4-fluorophenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide,small molecule,Humans and other mammals,,,,Investigated for use/treatment in colorectal cancer and lung cancer.
C(OC(C(OC1(C(O[H])([H])C(C(OP(O[H])(=S)OC2(C(C(OP(O[H])(=S)OC3(C(C(OP(O[H])(=S)OC4(C(C(OP(O[H])(=S)OC5(C(C(OP(O[H])(=S)OC6(C([H])([H])C(N7C([H])=C(C([H])([H])[H])C(=N[H])N=C7O[H])([H])OC6(C(OP(O[H])(=S)OC6(C([H])([H])C(N7C([H])=C(C([H])([H])[H])C(O[H])=NC7=O)([H])OC6(C(OP(O[H])(=S)OC6(C([H])([H])C(N7C([H])=C(C([H])([H])[H])C(O[H])=NC7=O)([H])OC6(C(OP(O[H])(=S)OC6(C([H])([H])C(N7C([H])=C(C([H])([H])[H])C(=N[H])N=C7O[H])([H])OC6(C(OP(O[H])(=S)OC6(C([H])([H])C(N7C([H])=NC8=C7N(C(=N[H])N=C8O[H])[H])([H])OC6(C(OP(O[H])(=S)OC6(C([H])([H])C(N7C([H])=C(C([H])([H])[H])C(O[H])=NC7=O)([H])OC6(C(OP(O[H])(=S)OC6(C([H])([H])C(N7C([H])=C(C([H])([H])[H])C(=N[H])N=C7O[H])([H])OC6(C(OP(O[H])(=S)OC6(C([H])([H])C(N7C([H])=C(C([H])([H])[H])C(O[H])=NC7=O)([H])OC6(C(OP(O[H])(=S)OC6(C([H])([H])C(N7C([H])=NC8=C7N(C(=N[H])N=C8O[H])[H])([H])OC6(C(OP(O[H])(=S)OC6(C([H])([H])C(N7C([H])=NC8=C(N([H])[H])N=C(N=C78)[H])([H])OC6(C(OP(O[H])(=S)OC6(C(C(OP(O[H])(=S)OC7(C(C(OP(O[H])(=S)OC8(C(C(OP(O[H])(=S)OC9(C(C(OP(O[H])(=S)OC%10(C(C(O[H])([H])[H])([H])OC(N%11C([H])=NC%12=C%11N(C(=N[H])N=C%12O[H])[H])([H])C%10(OC(C(OC([H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])OC(N%10C([H])=C(C([H])([H])[H])C(=N[H])N=C%10O[H])([H])C9(OC(C(OC([H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])OC(N9C([H])=C(C([H])([H])[H])C(=N[H])N=C9O[H])([H])C8(OC(C(OC([H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])OC(N8C([H])=C(C([H])([H])[H])C(O[H])=NC8=O)([H])C7(OC(C(OC([H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])OC(N7C([H])=C(C([H])([H])[H])C(=N[H])N=C7O[H])([H])C6(OC(C(OC([H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])([H])OC(N6C([H])=NC7=C6N(C(=N[H])N=C7O[H])[H])([H])C5(OC(C(OC([H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])OC(N5C([H])=C(C([H])([H])[H])C(=N[H])N=C5O[H])([H])C4(OC(C(OC([H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])OC(N4C([H])=NC5=C(N([H])[H])N=C(N=C45)[H])([H])C3(OC(C(OC([H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])OC(N3C([H])=C(C([H])([H])[H])C(=N[H])N=C3O[H])([H])C2(OC(C(OC([H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])OC1(N1C([H])=C(C([H])([H])[H])C(=N[H])N=C1O[H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB05528,1000120-98-8,Mipomersen,,small molecule,Humans and other mammals,"Injection, solution",Subcutaneous,200 mg/mL,Used in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications.
C(OC1=C2C(N(C(=C2C(=O)C(=O)N2C([H])([H])C([H])([H])N(C(=O)C3=C([H])C([H])=C([H])C([H])=C3[H])C([H])([H])C2([H])[H])[H])[H])=C(OC([H])([H])[H])N=C1[H])([H])([H])[H],DB05532,452296-83-2,BMS-488043,,small molecule,"Humans and other mammals
Human Immunodeficiency Virus",,,,Investigated for use/treatment in HIV infection.
O(C1=NC2=C(C(C3=C2C([H])=C([H])C(S(=O)(=O)N(C(C(C(N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])[H])=C3[H])([H])[H])C2=C(C(=C(C([H])=C12)[H])[H])[H])[H],DB05549,501364-91-6,INO-1001,"(9-(N-(3-Morpholinopropyl)-sulfonyl)-5,6-dihydro-5-oxo-11-H-indeno (1,2-C) isoquinoline methanesulfonic acid",small molecule,,,,,"Investigated for use/treatment in brain cancer, cardiovascular disorders, and myocardial infarction."
C(C(=O)N(C1=C([H])C([H])=C([H])C(N2C([H])([H])C([H])([H])N(C(C(C(C(N(S(=O)(=O)C(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])([H])C2([H])[H])=C1[H])[H])([H])([H])[H],DB05562,740873-06-7,Naluzotan,,small molecule,,,,,Investigated for use/treatment in anxiety disorders and depression.
C(N(C([H])([H])[H])C(C1=C([H])C([H])=C2C(Cl)=C(C(Cl)=C(O[H])C2=N1)[H])([H])[H])([H])([H])[H],DB05565,747408-78-2,PBT-1033,,small molecule,,,,,Investigated for use/treatment in alzheimer's disease.
C(C1(C([H])([H])[H])C([H])([H])N([H])C2=C1C(=C(C(=C2[H])N=C(O[H])C1=C(N(C(C2=C([H])C([H])=NC([H])=C2[H])([H])[H])[H])N=C([H])C([H])=C1[H])[H])[H])([H])([H])[H],DB05575,453562-69-1,Motesanib,,small molecule,,,,,Investigated for use/treatment in solid tumors.
C(OC1=C([H])C([H])=C(N(C([H])([H])[H])C2=NC(C([H])([H])[H])=NC3=C(C(=C(C([H])=C23)[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB05585,827031-83-4,Verubulin,,small molecule,,,,,"Investigated for use/treatment in brain cancer, lung cancer, melanoma, and solid tumors."
C(C(C([H])([H])[H])(N1C2=C(C(=C(S2)[H])[H])C(O[H])=C(C(=O)N(C(C(C(N2C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])[H])C1=O)[H])([H])([H])[H],DB05596,869493-21-0,PRX-03140,,small molecule,,,,,Investigated for use/treatment in alzheimer's disease and memory loss.
FC1=C(C#N)C([H])=C(C(N2C([H])([H])C([H])([H])C(N(C3=NC([H])=NC4=C3C(=C(Cl)S4)[H])[H])([H])C([H])([H])C2([H])[H])([H])[H])C([H])=C1[H],DB05607,,PRX-08066,,small molecule,,,,,Investigated for use/treatment in chronic obstructive pulmonary disease (COPD) and pulmonary hypertension.
C(N1C([H])=C(C2=C(C3=C([H])N(C([H])([H])[H])C4=C3C(=C(C(=C4[H])[N+]([O-])=O)[H])[H])C(=O)N([H])C2=O)C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])([H])[H],DB05608,125313-92-0,MKC-1,,small molecule,,,,,"Investigated for use/treatment in breast cancer, leukemia (unspecified), lung cancer, and solid tumors."
C(C1=C([H])C([H])=C([H])C(C(=NN(C2=C([H])C(N3C([H])([H])C([H])([H])OC([H])([H])C3([H])[H])=NC(OC(C(C3=NC([H])=C([H])C([H])=C3[H])([H])[H])([H])[H])=N2)[H])[H])=C1[H])([H])([H])[H],DB05611,541550-19-0,Apilimod,,small molecule,,,,,Investigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.
C(C1(C([H])([H])[H])C([H])([H])N([H])[Se]C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])([H])[H],DB05631,173026-17-0,ALT-2074,"4,4-dimethyl-2,3-dihydro-1,2-benzoselenazine
4,4-Dimethyl-3,4-dihydro-2H-1,2-benzoselenazine",small molecule,Humans and other mammals,,,,Investigated for use/treatment in cardiovascular disorders and diabetes mellitus type 1 and 2.
C(C1=C([H])C2=C(N=C(N=C2S1)N1C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H])C1=C(F)C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB05642,476148-82-0,DDP-225,DDP225,small molecule,,,,,"Investigated for use/treatment in alzheimer's disease, depression, diarrhea, gastrointestinal diseases and disorders (miscellaneous), and irritable bowel syndrome (IBS)."
C(C1(C([H])([H])[H])C([H])([H])C(OC(=O)C2(C([H])([H])C2([H])[H])[H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])N1O[H])([H])([H])[H],DB05650,,OT-551,,small molecule,Humans and other mammals,,,,"Investigated for use/treatment in cataracts, eye disorders/infections, glaucoma, and macular degeneration."
C(C1(C([H])([H])[H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C2=C1C(=C(C(=O)N(C1=C([H])C(F)=C(C(O[H])=O)C(F)=C1[H])[H])C(O[H])=C2Cl)[H])([H])([H])[H],DB05653,367273-07-2,IRX-5183,,small molecule,Humans and other mammals,,,,"Investigated for use/treatment in adverse effects (chemotherapy) and blood (blood forming organ disorders, unspecified)."
O(P(=O)(N(C(C(Cl)([H])[H])([H])[H])[H])N(C(C(Cl)([H])[H])([H])[H])[H])[H],DB05668,31645-39-3,Palifosfamide,,small molecule,,,,,"Investigated for use/treatment in cancer/tumors (unspecified), lymphoma (unspecified), and sarcoma."
C(C(C([H])([H])[H])(C(N1C(C([H])([H])[H])=NC2=C1C1=NC([H])=C([H])C([H])=C1N=C2N([H])[H])([H])[H])[H])([H])([H])[H],DB05680,227318-75-4,Sotirimod,,small molecule,,,,,Investigated for use/treatment in actinic keratosis and skin infections/disorders.
O(C1=C([H])C([H])=C(C(=NN(C2=C([N+]([O-])=O)C([H])=C([N+]([O-])=O)C([H])=C2[H])[H])C2=C([H])C([H])=C(O[H])C([H])=C2[H])C([H])=C1[H])[H],DB05686,2675-35-6,Sivifene,,small molecule,,,,,"Investigated for use/treatment in cervical dysplasia/cancer, genital warts, and skin cancer."
C(OC1=C([H])C(OC([H])([H])[H])=C(C(=C2C([H])([H])C([H])([H])C([H])([H])N=C2C2=C([H])N=C([H])C([H])=C2[H])[H])C([H])=C1[H])([H])([H])[H],DB05708,148372-04-7,GTS-21,"3-(2,4-dimethoxybenzylidene)anabaseine
Dimethoxybenzylidene anabaseine
DMXB-A
DMXB-Anabaseine",small molecule,Humans and other mammals,,,,Investigated for use/treatment in alzheimer's disease and schizophrenia and schizoaffective disorders.
C(N(N(C(=O)C(C(=O)N(N(C([H])([H])[H])C(=S)C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H])[H])C(=S)C1=C([H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB05719,488832-69-5,Elesclomol,STA-4783,small molecule,Humans and other mammals,,,,Investigated for use/treatment in melanoma.
C(C(C1=C(C(=O)C(N([H])[H])=O)C2=C(OC(C(=O)OC([H])([H])[H])([H])[H])C(=C(C([H])=C2N1C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H])[H])([H])[H])([H])([H])[H],"DB05737
DB12164",172733-08-3,Varespladib methyl,Varespladib methyl ester,small molecule,,,,,Investigated for use/treatment in atherosclerosis and coronary artery disease.
O(C(=N[H])C1=C([H])N=C2N1C(C(C1=C(C32C([H])([H])C([H])([H])N([H])C([H])([H])C3([H])[H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])[H],DB05738,793655-64-8,Vapitadine,,small molecule,,,,,Investigated for use/treatment in atopic dermatitis.
C(N(C([H])([H])[H])C(C(N(C(=O)C(N1C2=C(C(=C(Cl)C(=C2[H])[H])[H])C2=NC3=C([H])C(C([H])([H])[H])=C(C([H])([H])[H])C([H])=C3N=C12)([H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB05772,,Rabeximod,,small molecule,,,,,Investigated for use/treatment in rheumatoid arthritis.
FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br,"DB05791
DB06476",423-55-2,Perflubron,,small molecule,,,,,"Investigated for use/treatment in cardiac surgery, hemorrhage, and ileus."
C(C(N(C(C(=C(C1=C([H])C(Cl)=C(C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])C([H])=C1[H])[H])[H])([H])[H])C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])([H])[H])([H])([H])[H],DB05792,132173-07-0,Arylacenamide,,small molecule,,,,,"Investigated for use/treatment in cancer/tumors (unspecified), immunosuppressive, and prostate cancer."
N(C(C(C(=O)N(C(C(SSC(C(N(C(=O)C(C(N([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H],DB05800,646-08-2,Alethine,"Beta alethine
Beta-alanyl cysteamine disulfide
Beta-alethine
Betathine",small molecule,,,,,"Investigated for use/treatment in blood (blood forming organ disorders, unspecified), lymphoma (unspecified), and multiple myeloma."
C(N(C(=O)N(N(C(C(Cl)([H])[H])([H])[H])S(C([H])([H])[H])(=O)=O)S(C([H])([H])[H])(=O)=O)[H])([H])([H])[H],"DB05817
DB12324",173424-77-6,Laromustine,"Cloretazine
Onrigin",small molecule,,,,,"Investigated for use/treatment in brain cancer, cancer/tumors (unspecified), colorectal cancer, leukemia (lymphoid), leukemia (myeloid), lung cancer, myelodysplastic syndrome, pediatric indications, and solid tumors."
C(SC1=C([H])C(N=C(N([H])[H])N(C([H])([H])[H])C2=C([H])C(SC([H])([H])[H])=C([H])C([H])=C2[H])=C(Cl)C([H])=C1[H])([H])([H])[H],DB05824,,CNS-5161,,small molecule,,,,,"Investigated for use/treatment in migraine and cluster headaches, neuropathy (diabetic), and pain (acute or chronic)."
FC(F)(F)C1=C([H])C(C(F)(F)F)=C([H])C(N(C(=O)N(C2=C(C3=NN([H])N=N3)C([H])=C([H])C(Br)=C2[H])[H])[H])=C1[H],DB05835,,NS-3728,,small molecule,,,,,Investigated for use/treatment in anemia (sickle cell) and cancer/tumors (unspecified).
C(N(C(C(C(=C(C1=C([H])C([H])=C([H])N=C1[H])[H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB05855,15585-43-0,Rivanicline,"(3E)-N-methyl-4-(pyridin-3-yl)but-3-en-1-amine
(E)-metanicotine
(E)-N-Methyl-4-(3-pyridinyl)-3-butene-1-amine
N-methyl-4-(3-pyridinyl)-(3E)-3-buten-1-amine
trans-metanicotine",small molecule,,,,,Investigated for use/treatment in ulcerative colitis.
C(OC1=C([H])C([H])=C([H])C2=C1C(O[H])=C(C(=O)N(C([H])([H])[H])C1=C([H])C([H])=C(C(F)(F)F)C([H])=C1[H])C(=O)N2C([H])([H])[H])([H])([H])[H],DB05861,254964-60-8,Tasquinimod,TASQ,small molecule,,,,,Investigated for use/treatment in prostate cancer.
C(C(OC(=O)C(C([H])([H])[H])=O)([H])[H])([H])([H])[H],DB05869,617-35-6,Ethyl pyruvate,"2-oxopropanoic acid ethyl ester
2-oxopropionic acid ethyl ester
Ethyl 2-oxopropanoate
Ethyl 2-oxopropionate
Ethyl methylglyoxylate
Pyruvic acid ethyl ester
Pyruvic acid, ethyl ester",small molecule,,,,,"Investigated for use/treatment in burns and burn infections, cardiac surgery, inflammatory disorders (unspecified), ischemic reperfusion injury, and sepsis and septicemia."
C(C(C([H])([H])[H])=C(C(OC1=C(Cl)C([H])=C([H])C(N(C(=S)C2=C(C([H])([H])[H])OC([H])=C2[H])[H])=C1[H])([H])[H])[H])([H])([H])[H],"DB05871
DB08679",178870-32-1,UC-781,,small molecule,,,,,Investigated for use/treatment in HIV infection.
C(N(C(=O)C1=C(C2=C([H])C([H])=C(F)C([H])=C2[H])OC2=C(C(N(S(C([H])([H])[H])(=O)=O)[H])=C(OC(C([H])([H])[H])(C([H])([H])[H])[H])C([H])=C12)[H])[H])([H])([H])[H],DB05884,,HCV-086,,small molecule,,,,,"Investigated for use/treatment in hepatitis (viral, C)."
FC(F)(F)OC1=C([H])C([H])=C(N(C(=O)C2=C(N(C(C3=C([H])C([H])=NC4=C(C(=C(C([H])=C34)[H])[H])[H])([H])[H])[H])C([H])=C([H])S2)[H])C([H])=C1[H],DB05913,,OSI-930,,small molecule,,,,,Investigated for use/treatment in solid tumors.
C(N1C([H])([H])C([H])([H])N(C2=C([H])C3=C(N=C(N3[H])C3=C(N([H])[H])C4=C(F)C(=C(C([H])=C4N([H])C3=O)[H])[H])C([H])=C2[H])C([H])([H])C1([H])[H])([H])([H])[H],DB05928,405169-16-6,Dovitinib,,small molecule,,,,,Investigated for use/treatment in multiple myeloma and solid tumors.
C(C(C(N1C(=O)N(C(C([H])([H])[H])([H])[H])C2=C(N(C(=N2)C2=C([H])N(C(C3=C([H])C([H])=C([H])C(C(F)(F)F)=C3[H])([H])[H])N=C2[H])[H])C1=O)([H])[H])([H])[H])([H])([H])[H],DB05936,752222-83-6,CVT-6883,,small molecule,,,,,Investigated for use/treatment in asthma.
O(C1(C([H])([H])N(C(C(C(OC(C(C2=C([H])C3=C(SC(=C3[H])[H])C([H])=C2[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C1([H])[H])[H])[H],DB05938,519187-23-6,Edonerpic,,small molecule,,,,,Investigated for use/treatment in alzheimer's disease.
C1(C([H])([H])C2=C(C(=NN2[H])C2=NN([H])N=N2)C1([H])[H])([H])[H],DB05939,851776-28-8,MK-0354,,small molecule,,,,,Investigated for use/treatment in atherosclerosis.
C(C1=NC([H])=C([H])N1C(C1=C([H])C(C2=C([H])C(C(F)(F)[H])=C(F)C([H])=C2[H])=C([H])N=N1)([H])[H])([H])([H])[H],DB05956,1189088-41-2,EVT-101,,small molecule,,,,,"Investigated for use/treatment in alzheimer's disease, neurologic disorders, pain (acute or chronic), and parkinson's disease."
C(S(=O)(=O)OC(C(N(C(C(Br)([H])[H])([H])[H])C1=C([N+]([O-])=O)C([H])=C([N+]([O-])=O)C([H])=C1C(=O)N(C(C(OP(O[H])(O[H])=O)([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB05968,851627-62-8,PR-104,,small molecule,,,,,Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
C(C(C([H])([H])[H])(C([H])([H])[H])C1=C([H])N=C(C(SC2=C([H])N=C(N(C(=O)C3(C([H])([H])C([H])([H])N([H])C([H])([H])C3([H])[H])[H])[H])S2)([H])[H])O1)([H])([H])[H],DB05969,345627-80-7,SNS-032,,small molecule,,,,,"Investigated for use/treatment in cancer/tumors (unspecified), leukemia (unspecified), lymphoma (unspecified), multiple myeloma, and solid tumors."
C(C(C(=C(C(=C(C([H])([H])[H])C(O[H])=O)[H])[H])[H])=C(C(=C(C(=C(C([H])([H])[H])C(=C(C(=C(C([H])([H])[H])C(O[H])=O)[H])[H])[H])[H])[H])[H])[H])([H])([H])[H],DB05974,27876-94-4,Transcrocetinate,"8,8'-diapo-8,8'-carotenedioic acid
8,8'-diapo-��,��-carotenedioic acid
8,8'-diapocarotenedioic acid
Crocetin
trans-crocetin",small molecule,,,,,"Investigated for use/treatment in cancer/tumors (unspecified), hemorrhage, hypoxia, respiratory failure, and strokes."
C(N1C(N(C2=C([H])C([H])=C(C(F)(F)F)C([H])=C2[H])[H])=NC2=C1C(=C(C(OC1=C([H])C(C3=NC([H])=C(C(F)(F)F)N3[H])=NC([H])=C1[H])=C2[H])[H])[H])([H])([H])[H],DB05984,927880-90-8,RAF-265,,small molecule,,,,,Investigated for use/treatment in melanoma.
C(C(C([H])([H])[H])(C([H])([H])[H])C1=C(C(=C2N([H])C(=O)C(=C(C3=C([H])C([H])=C([H])C([H])=C3[H])[H])N([H])C2=O)[H])N=C([H])N1[H])([H])([H])[H],DB05992,714272-27-2,Plinabulin,,small molecule,,,,,Investigated for use/treatment in cancer/tumors (unspecified).
C(N1C([H])([H])C([H])([H])N(C(C([H])([H])[H])(C([H])([H])[H])C#CC2=C(N(C(=O)C(=C([H])[H])[H])[H])C([H])=C3C(N(C4=C([H])C(Cl)=C(F)C([H])=C4[H])[H])=NC(=NC3=C2[H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB06021,451493-31-5,AV-412,,small molecule,,,,,Investigated for use/treatment in cancer/tumors (unspecified).
C(N1C(=O)C(C([H])([H])[H])=C([H])C(C(=O)N(OC(C(O[H])([H])[H])([H])[H])[H])=C1N(C1=C(F)C([H])=C(I)C([H])=C1[H])[H])([H])([H])[H],DB06061,,AZD-8330,,small molecule,,,,,Investigated for use/treatment in cancer/tumors (unspecified).
C(C(C([H])([H])[H])(C1=C(O[H])C([H])=C(C(=C(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])[H])C([H])=C1O[H])[H])([H])([H])[H],DB06083,79338-84-4,Tapinarof,"3,5-Dihydroxy-4-isopropyl-trans-stilbene
Benvitimod",small molecule,,,,,Investigated for use/treatment in psoriasis and psoriatic disorders.
C(N1C(C(OP(=O)(N(C(C(Br)([H])[H])([H])[H])[H])N(C(C(Br)([H])[H])([H])[H])[H])([H])[H])=C([H])N=C1[N+]([O-])=O)([H])([H])[H],DB06091,918633-87-1,Evofosfamide,,small molecule,,,,,Investigated for use/treatment in solid tumors.
C(OC(C(OC1(C(O[H])([H])C(C(OP(O[H])(=S)OC2(C(C(OP(O[H])(=S)OC3(C(C(OP(O[H])(=S)OC4(C(C(OP(O[H])(=S)OC5(C([H])([H])C(N6C([H])=NC7=C6N(C(=N[H])N=C7O[H])[H])([H])OC5(C(OP(O[H])(=S)OC5(C([H])([H])C(N6C([H])=NC7=C6N(C(=N[H])N=C7O[H])[H])([H])OC5(C(OP(O[H])(=S)OC5(C([H])([H])C(N6C([H])=C(C([H])([H])[H])C(=N[H])N=C6O[H])([H])OC5(C(OP(O[H])(=S)OC5(C([H])([H])C(N6C([H])=C(C([H])([H])[H])C(O[H])=NC6=O)([H])OC5(C(OP(O[H])(=S)OC5(C([H])([H])C(N6C([H])=C(C([H])([H])[H])C(=N[H])N=C6O[H])([H])OC5(C(OP(O[H])(=S)OC5(C([H])([H])C(N6C([H])=NC7=C6N(C(=N[H])N=C7O[H])[H])([H])OC5(C(OP(O[H])(=S)OC5(C([H])([H])C(N6C([H])=C(C([H])([H])[H])C(=N[H])N=C6O[H])([H])OC5(C(OP(O[H])(=S)OC5(C([H])([H])C(N6C([H])=NC7=C6N(C(=N[H])N=C7O[H])[H])([H])OC5(C(OP(O[H])(=S)OC5(C([H])([H])C(N6C([H])=NC7=C6N(C(=N[H])N=C7O[H])[H])([H])OC5(C(OP(O[H])(=S)OC5(C([H])([H])C(N6C([H])=C(C([H])([H])[H])C(=N[H])N=C6O[H])([H])OC5(C(OP(O[H])(=S)OC5(C([H])([H])C(N6C([H])=NC7=C6N(C(=N[H])N=C7O[H])[H])([H])OC5(C(OP(O[H])(=S)OC5(C([H])([H])C(N6C([H])=C(C([H])([H])[H])C(=N[H])N=C6O[H])([H])OC5(C(OP(O[H])(=S)OC5(C(C(OP(O[H])(=S)OC6(C(C(OP(O[H])(=S)OC7(C(C(OP(O[H])(=S)OC8(C(C(O[H])([H])[H])([H])OC(N9C([H])=NC%10=C9N(C(=N[H])N=C%10O[H])[H])([H])C8(OC(C(OC([H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])OC(N8C([H])=NC9=C8N(C(=N[H])N=C9O[H])[H])([H])C7(OC(C(OC([H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])OC(N7C([H])=NC8=C7N(C(=N[H])N=C8O[H])[H])([H])C6(OC(C(OC([H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])OC(N6C([H])=NC7=C(N([H])[H])N=C(N=C67)[H])([H])C5(OC(C(OC([H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])([H])OC(N5C([H])=C(C([H])([H])[H])C(O[H])=NC5=O)([H])C4(OC(C(OC([H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])OC(N4C([H])=C(C([H])([H])[H])C(=N[H])N=C4O[H])([H])C3(OC(C(OC([H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])OC(N3C([H])=NC4=C(N([H])[H])N=C(N=C34)[H])([H])C2(OC(C(OC([H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])OC1(N1C([H])=C(C([H])([H])[H])C(O[H])=NC1=O)[H])[H])([H])[H])([H])[H])([H])([H])[H],DB06094,1002331-21-6,Apatorsen,,small molecule,,,,,Investigated for use/treatment in cancer/tumors (unspecified).
ClC1=C([H])C(N(C(=O)N(C2=NC([H])=C(C(C(N(C3=NC([H])=NC4=C3SC(=C4[H])[H])[H])([H])[H])([H])[H])S2)[H])[H])=C([H])C([H])=C1[H],"DB06134
DB07361",1057249-41-8,SNS-314,"1-(3-chlorophenyl)-3-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}urea",small molecule,,,,,Investigated for use/treatment in solid tumors.
O=C(C(C1=NC([H])=C(C2=C([H])C([H])=C(OC(C(N3C([H])([H])C([H])([H])OC([H])([H])C3([H])[H])([H])[H])([H])[H])C([H])=C2[H])C([H])=C1[H])([H])[H])N(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H],DB06137,897016-82-9,KX-01,,small molecule,,,,,Investigated for use/treatment in cancer/tumors (unspecified).
C(OC1=C([H])C2=C(N(C(=C2C(N2C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C2([H])[H])([H])[H])[H])S(=O)(=O)C2=C(Br)C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])([H])[H],DB06140,701205-60-9,SUVN-502,,small molecule,,,,,Investigated for use/treatment in neurologic disorders.
FC1=C([H])C([H])=C(N2C([H])=C(C3(C([H])([H])C([H])([H])N(C(C(N4C([H])([H])C([H])([H])N([H])C4=O)([H])[H])([H])[H])C([H])([H])C3([H])[H])[H])C3=C2C(=C(C(Cl)=C3[H])[H])[H])C([H])=C1[H],DB06144,106516-24-9,Sertindole,"1-[2-[4-[5-chloro-1-(4-Fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-one
SerLect
Sertindol
Sertindole
Sertindolum",small molecule,Humans and other mammals,,,,Used in the treatment of schizophrenia.
N(C1=C([H])C([H])=C(S(=O)(=O)N(C2=NC([H])=C([H])S2)[H])C([H])=C1[H])([H])[H],DB06147,72-14-0,Sulfathiazole,"2-(P-Aminobenzenesulfonamido)thiazole
2-(P-Aminobenzenesulphonamido)thiazole
2-(Sulfanilylamino)thiazole
2-Sulfanilamidothiazol
2-Sulfanilamidothiazole
2-Sulfonamidothiazole
4-Amino-N-2-thiazolylbenzenesulfonamide
N(1)-2-Thiazolylsulfanilamide
N1-2-Thiazolylsulfanilamide
Sulfanilamidothiazole
Sulfathiazol
Sulfathiazolum
Sulfatiazol
Sulphathiazole",small molecule,,,,,"Sulfathiazole is effective against a wide range of gram positive and gram negative pathogenic microorganisms. Although no longer used in humans, it is used in cattle."
C(OC1=C([H])C(N(S(=O)(=O)C2=C([H])C([H])=C(N([H])[H])C([H])=C2[H])[H])=NC(OC([H])([H])[H])=N1)([H])([H])[H],DB06150,122-11-2,Sulfadimethoxine,"2,4-dimethoxy-6-sulfanilamido-1,3-diazine
2,6-Dimethoxy-4-(P-aminobenzenesulfonamido)pyrimidine
2,6-Dimethoxy-4-sulfanilamidopyrimidine
4-amino-N-(2,6-Dimethoxy-4-pyrimidinyl)benzenesulfonamide
6-Sulfanilamido-2,4-dimethoxypyrimidine
Abcid (tn)
Agribon (tn)
N(1)-(2,6-Dimethoxy-4-pyrimidinyl)sulfanilamide
Sulfadimethoxine
Sulfadimethoxinum
Sulfadimethoxydiazine
Sulfadimetoxina
Sulphadimethoxine",small molecule,Humans and other mammals,,,,For use in the treatment of infections.
C(C(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])(N(C(C([H])([H])[H])(C(O[H])(C1=C([H])C([H])=C(O[H])C([H])=C1[H])[H])[H])[H])[H])([H])([H])[H],DB06152,447-41-6,Nylidrin,"Buphenin
Buphenine",small molecule,,"Tablet
Tablet","Oral
Oral","12 mg
6 mg",
C(N1C([H])([H])C([H])([H])C(=C2C3=C(SC(=C3[H])[H])C([H])([H])C([H])([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB06153,15574-96-6,Pizotifen,Pizotyline,small molecule,,"Tablet
Tablet","Oral
Oral","0.50 mg
1 mg",
[O-][N+](=O)OC(C(C(O[N+]([O-])=O)([H])[H])(C(O[N+]([O-])=O)([H])[H])C(O[N+]([O-])=O)([H])[H])([H])[H],DB06154,78-11-5,Pentaerythritol Tetranitrate,"corpent
PENT
PENTA
Pentaerithrityl tetranitrate
penthrite
TEN",small molecule,,"Tablet, extended release
Tablet
Tablet","Oral
Oral
Oral","80 mg
10 mg
20 mg",
C(C1=C(C2=C([H])C([H])=C(Cl)C([H])=C2[H])N(C2=C(Cl)C([H])=C(Cl)C([H])=C2[H])N=C1C(=O)N(N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])([H])([H])[H],DB06155,168273-06-1,Rimonabant,,small molecule,Humans and other mammals,"Tablet, film coated",Oral,20 mg,"For use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m<sup>2</sup>, or patients wih a BMI greater than 27 kg/m<sup>2</sup> with associated risk factors, such as type 2 diabetes or dyslipidaemia."
ClC1=C([H])C([H])=C(C(N2C([H])=C(C(=O)C(=O)N(C3=C([H])C([H])=NC([H])=C3[H])[H])C3=C2C(=C(C(=C3[H])[H])[H])[H])([H])[H])C([H])=C1[H],DB06169,204205-90-3,Indibulin,,small molecule,,,,,Investigated for use/treatment in solid tumors.
N(C(C(N(C1=C([H])C([H])=C(N(C(C(N([H])[H])([H])[H])([H])[H])[H])C2=C1C(=O)C1=C(C2=O)C([H])=NC([H])=C1[H])[H])([H])[H])([H])[H])([H])[H],DB06193,144510-96-3,Pixantrone,"6,9-bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione
PIX",small molecule,,"Injection, powder, for solution",Intravenous,29 mg,"Currently in Phase III investigation for treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who have failed two prior lines of therapy. Presently, no standard therapy exists for patients with relapsed or refractory NHL. [2] After first line therapy has been initiated, most patients have received their lifetime limit of doxorubicin and further use of anthracyclines may potentially lead to anthracycline-induced congestive heart failure (CHF). Pixantrone is an attractive alternative as a second line agent, due to its lack of cardiac toxicity. [2] 
The phase III trial, PIX-R, is ongoing and will compare pixantrone multidrug therapy with an equivalent regimen in patients with diffuse large B-cell lymphoma (the most common type of NHL).
Previous study results have also suggested the possibility that pixantrone may be safe and effective in doxorubicin naive patients. In myocardial strips which are doxorubicin naive, pixantrone is taken up to a higher degree than in myocardial strips which are doxorubicin exposed, and once absorbed exhibits redox inactivity. [3] 
Pixantrone dimaleate has also been investigated as a treatment for acute myelogenous leukemia, diffuse large B-cell lymphoma, follicular lymphoma, metastatic breast cancer, low grade small lymphocytic lymphomas and general metastatic cancers.     "
C(C1(C([H])([H])C1([H])[H])[H])(N1C([H])([H])C2(C(N(C(C3(C([H])([H])C3([H])[H])[H])([H])[H])C([H])([H])C(C32C([H])([H])C([H])([H])C([H])([H])C3([H])[H])([H])C1([H])[H])([H])[H])[H])([H])[H],DB06200,90961-53-8,Tedisamil,,small molecule,,,,,"Investigated for use/treatment in arrhythmia, atrial fibrillation, and angina."
N(C(=O)C1=C([H])N(C(C2=C(F)C([H])=C([H])C([H])=C2F)([H])[H])N=N1)([H])[H],DB06201,106308-44-5,Rufinamide,Xilep ,small molecule,Humans and other mammals,"Suspension
Suspension
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","40 mg
40 mg/mL
100 mg
200 mg
400 mg
200 mg/1
400 mg/1
100 mg
200 mg
400 mg",Adjunct therapy for treatment of seizures associated with Lennox-Gastaut syndrome.   
C(C1=NN(C2=C([H])C(C([H])([H])[H])=C(C([H])([H])[H])C([H])=C2[H])C(=O)C1=NN(C1=C(O[H])C(C2=C([H])C(C(O[H])=O)=C([H])C([H])=C2[H])=C([H])C([H])=C1[H])[H])([H])([H])[H],DB06210,496775-61-2,Eltrombopag,"Eltrombopag
Eltrombopagum",small molecule,Humans and other mammals,"Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg/1
12.5 mg/1
25 mg/1
50 mg/1
75 mg/1
12.5 mg
25 mg
50 mg
75 mg","Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction. "
O=[Fe]O[Fe]=O,DB06215,1309-38-2,Ferumoxytol,AMI-7228,small molecule,,"Injection
Solution","Intravenous
Intravenous","510 mg/17mL
30 mg","Investigated for use/treatment in anemia, kidney disease, and cardiovascular disorders."
C(N1C([H])([H])C2([H])C(C3=C(OC4=C2C([H])=C([H])C([H])=C4[H])C([H])=C([H])C(Cl)=C3[H])([H])C1([H])[H])([H])([H])[H],DB06216,65576-45-6,Asenapine,,small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet","Sublingual
Sublingual
Sublingual
Sublingual
Sublingual","10 mg/1
10 mg
2.5 mg/1
5 mg
5 mg/1","Used for treatment in psychosis, schizophrenia and schizoaffective disorders, manic disorders, and bipolar disorders as monotherapy or in combination."
C(C1=C([H])C([H])=C([H])N2C(=O)C(C(C(N3C([H])([H])C([H])([H])C(C4=NOC5=C4C(=C(C(F)=C5[H])[H])[H])([H])C([H])([H])C3([H])[H])([H])[H])([H])[H])=C(C([H])([H])[H])N=C12)([H])([H])[H],DB06229,129029-23-8,Ocaperidone,"ND-1087
R 79,598",small molecule,,,,,Investigated for use/treatment in schizophrenia and schizoaffective disorders.
C(C1=C([H])C(S(O[H])(=O)=O)=C(N2C([H])([H])C([H])([H])N([H])C([H])([H])C2([H])[H])C([H])=C1[H])([H])([H])[H],DB06231,133804-44-1,Caldaret,,small molecule,,,,,Investigated for use/treatment in heart disease and myocardial infarction.
C(C1=C(C([H])([H])[H])C2=C(C(=O)C3=C(O2)C(C(C(O[H])=O)([H])[H])=C([H])C([H])=C3[H])C([H])=C1[H])([H])([H])[H],"DB06235
DB13081",,Vadimezan,"AS1404
DMXAA",small molecule,,,,,"Investigated for use/treatment in solid tumors, lung cancer, ovarian cancer, and prostate cancer."
C(OC1=C([H])C2=C(C(N(C(C(C3=C([H])C([H])=C(N(C(=O)C4=C(N(C(=O)C5=C([H])C6=C(C(=C(C([H])=C6N=C5[H])[H])[H])[H])[H])C([H])=C(OC([H])([H])[H])C(OC([H])([H])[H])=C4[H])[H])C([H])=C3[H])([H])[H])([H])[H])C(C2([H])[H])([H])[H])([H])[H])C([H])=C1OC([H])([H])[H])([H])([H])[H],DB06240,206873-63-4,Tariquidar,,small molecule,,,,,"Investigated for use/treatment in ovarian cancer, lung cancer, and breast cancer."
C(C1=C(C(C(O[H])=O)([H])[H])C2=C(C(=C(C(F)=C2[H])[H])[H])C1=C(C1=C([H])C([H])=C(S(C([H])([H])[H])(=O)=O)C([H])=C1[H])[H])([H])([H])[H],DB06246,59973-80-7,Exisulind,"FGN 1
sulindac sulfone",small molecule,,,,,"Investigated for use/treatment in adenomatous polyposis coli, lung cancer, prostate cancer, colon polyps, Barrett's esophagus disease, and pediatric indications."
O=C(N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])C1=C([H])C2=NC(=C(N=C2C([H])=C1[H])[H])[H],DB06247,154235-83-3,CX516,,small molecule,,,,,"Investigated for use/treatment in alzheimer's disease, memory loss, autism, neurologic disorders, dementia, schizophrenia and schizoaffective disorders, attention deficit/hyperactivity disorder (ADHD), and sleep disorders."
C(C(OC(=O)N(C(=N[H])C1=C([H])C([H])=C(OC(C2=C([H])C(C(OC3=C([H])C([H])=C(C(C([H])([H])[H])(C([H])([H])[H])C4=C([H])C([H])=C(O[H])C([H])=C4[H])C([H])=C3[H])([H])[H])=C([H])C([H])=C2[H])([H])[H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB06248,346735-24-8,Amelubant,,small molecule,,,,,"Investigated for use/treatment in asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and rheumatoid arthritis."
C(OC1=C([H])C([H])=C(C2=C(OC3=C([H])C([H])=C(OC(C(N4C([H])([H])C([H])([H])C([H])([H])C([H])([H])C4([H])[H])([H])[H])([H])[H])C([H])=C3[H])C3=C(C(=C(O[H])C(=C3[H])[H])[H])S2)C([H])=C1[H])([H])([H])[H],DB06249,182133-25-1,Arzoxifene,,small molecule,,,,,"Investigated for use/treatment in breast cancer, osteoporosis, and endometrial cancer."
C(C1=NC2=C(C(=C(N=C2[H])[H])[H])N1C(C1(C([H])([H])C([H])([H])N(C(=O)C(=C(C2=C([H])C([H])=C([H])C([H])=C2[H])C2=C([H])C([H])=C(N=NC3=C([H])C(C(O[H])=O)=C(O[H])C([H])=C3[H])C([H])=C2[H])[H])C([H])([H])C1([H])[H])[H])([H])[H])([H])([H])[H],DB06251,188913-58-8,Dersalazine,,small molecule,,,,,Investigated for use/treatment in inflammatory bowel disease.
O(P(O[H])(=O)C(N(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])[H])(P(O[H])(O[H])=O)[H])[H],DB06255,124351-85-5,Incadronic acid,"Cimadronate
Incadronate",small molecule,Humans and other mammals,,,,For the treatment of hypercalcemia associated with malignant disease.
C(C(C(C(C(C(OC(=O)C(C(C(=O)C(N([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB06261,140898-97-1,Hexaminolevulinate,"4-Hexyloxycarbonyl-2-oxobutylammoniumchloride
Hexyl 5-amino-4-oxopentanoate hydrochloride
Hexyl(5-amino-4-oxopentanoat)-hydrochlorid
Pentanoic acid, 5-amino-4-oxo-, hexyl ester, hydrochloride",small molecule,Humans and other mammals,"Kit
Kit; powder, for solution",Intravesical,100 mg,Hexaminolevulinate is indicated for use in the cystoscopic detection of non-muscle invasive papillary cancer of the bladder among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy. 
O(C(=O)C1=NN(C(C2=C(Cl)C([H])=C(Cl)C([H])=C2[H])([H])[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])[H],"DB06266
DB03762",50264-69-2,Lonidamine,"1-(2,4-dichlorbenzyl)-indazole-3-carboxylic acid
DICA
diclondazolic acid
Doridamina
Lonidamin
lonidamina
lonidaminum",small molecule,Humans and other mammals,,,,"Investigated for use/treatment in benign prostatic hyperplasia, prostate disorders, and cancer/tumors (unspecified)."
C(C1=NOC(N(S(=O)(=O)C2=C(C(=O)C(C3=C(C([H])([H])[H])C([H])=C4OC(OC4=C3[H])([H])[H])([H])[H])SC([H])=C2[H])[H])=C1Cl)([H])([H])[H],DB06268,184036-34-8,Sitaxentan,Sitaxsentan,small molecule,Humans and other mammals,"Tablet
Tablet, film coated","Oral
Oral","100 mg
100 mg","Investigated for use/treatment in pulmonary hypertension, connective tissue diseases, hypertension, and congestive heart failure."
N(C(=O)C(C1=C([H])C([H])=C([H])C([H])=C1[H])(C1=C([H])C([H])=C(F)C([H])=C1[H])C1=C([H])C([H])=C(F)C([H])=C1[H])([H])[H],DB06280,289656-45-7,Senicapoc,,small molecule,,,,,Investigated for use/treatment in anemia (sickle cell) and asthma.
C(OC(C(N(C(C1=C([H])N=C(C2=C([H])C3=NC(=C(C(OC4=C(F)C([H])=C(N(C(=S)N(C(=O)C(C5=C([H])C([H])=C(F)C([H])=C5[H])([H])[H])[H])[H])C([H])=C4[H])=C3S2)[H])[H])C([H])=C1[H])([H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB06302,936694-12-1,Glesatinib,,small molecule,,,,,Investigated for use/treatment in cancer/tumors (unspecified).
C(C(C([H])([H])[H])(C1=C([H])C(C(=O)N2C([H])([H])C3=C(C(=C(C(N4C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C4([H])[H])([H])[H])C(=C3[H])[H])[H])C2([H])[H])=C(O[H])C([H])=C1O[H])[H])([H])([H])[H],DB06306,912999-49-6,Onalespib,,small molecule,,,,,Investigated for use/treatment in cancer/tumors (unspecified).
C(C(N(C(C([H])([H])[H])([H])[H])C(C(N(C(C1=C([H])C([H])=C(C2=C([H])C([H])=C(C(F)(F)F)C([H])=C2[H])C([H])=C1[H])([H])[H])C(=O)C(N1C2=C(C(C(C2([H])[H])([H])[H])([H])[H])C(=O)N=C1SC(C1=C([H])C([H])=C(F)C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB06311,356057-34-6,Darapladib,,small molecule,,,,,Investigated for use/treatment in atherosclerosis.
C(ON([H])[H])([H])([H])[H],DB06328,67-62-9,Methoxyamine,,small molecule,,,,,Investigated for use/treatment in cancer/tumors (unspecified).
C(OC1=C(Cl)C(O[H])=C(Cl)C(C(Cl)(Cl)Cl)=N1)([H])([H])[H],DB06331,176046-79-0,4-O-Demethylpenclomedine,"4-Demethylpenclomedine
4-Dm-pen
4-Dmpen
DM-PEN
DMPEN",small molecule,,,,,Investigated for use/treatment in solid tumors.
N(C1=C(N(C(=O)C2=C([H])C([H])=C(C(N(C(=O)C(=C(C3=C([H])N=C([H])C([H])=C3[H])[H])[H])[H])([H])[H])C([H])=C2[H])[H])C([H])=C([H])C(F)=C1[H])([H])[H],DB06334,1616493-44-7,Tucidinostat,Chidamide,small molecule,,,,,Investigated for use/treatment in cancer/tumors (unspecified).
C(C(OC1=NC([H])=C(C2=C([H])C([H])=C(C(N3C(C(C(C([H])([H])[H])(C([H])([H])[H])C(O[H])=O)([H])[H])=C(SC(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C4=C3C(=C(C(OC(C3=NC([H])=C(C([H])([H])[H])C([H])=C3[H])([H])[H])=C4[H])[H])[H])([H])[H])C([H])=C2[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB06346,936350-00-4,Fiboflapon,,small molecule,,,,,Investigated for use/treatment in inflammatory disorders (unspecified).
N(C1=NC2=C(N=C(N2C(C(OC(P(=O)(OC(C(F)(F)F)([H])[H])OC(C(F)(F)F)([H])[H])([H])[H])([H])[H])([H])[H])[H])C(SC2=C([H])C([H])=C([H])C([H])=C2[H])=N1)([H])[H],DB06368,193681-12-8,Alamifovir,MCC-478),small molecule,,,,,"Investigated for use/treatment in hepatitis (viral, B)."
N(S(=O)(=O)C1=C([H])C([H])=C(S(=O)(=O)N(C2=C([H])C([H])=C([H])C3=C2N(C(=C3Cl)[H])[H])[H])C([H])=C1[H])([H])[H],DB06370,165668-41-7,Indisulam,,small molecule,,,,,Investigated for use/treatment in lung cancer.
FC(F)(F)C1=C([H])C(C2=C([H])C([H])([H])N(C(C(C3=C([H])C4=C(C(=C(C([H])=C4C([H])=C3[H])[H])[H])[H])([H])[H])([H])[H])C([H])([H])C2([H])[H])=C([H])C([H])=C1[H],DB06393,135354-02-8,Xaliproden,,small molecule,,,,,Investigated for use/treatment in amyotrophic lateral sclerosis (ALS) and alzheimer's disease.
C(C1=C([H])C(C([H])([H])[H])=C(OC2=C(C3=C([H])SC(N=C4N([H])C([H])([H])C([H])([H])C([H])([H])N4[H])=N3)C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])([H])[H],DB06395,129639-79-8,Abafungin,"abafungina
abafungine
abafunginum",small molecule,,,,,"Investigated for use/treatment in fungal infections, bacterial infection, skin infections/disorders, and onychomycosis."
C(C1=C(C2=C([H])C([H])=C(O[H])C([H])=C2[H])N(C(C2=C([H])C([H])=C(OC(C(N3C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])([H])[H])([H])[H])C([H])=C2[H])([H])[H])C2=C1C(=C(O[H])C(=C2[H])[H])[H])([H])([H])[H],DB06401,198481-32-2,Bazedoxifene,bazedoxifene/conjugated estrogens,small molecule,Humans and other mammals,"Tablet, film coated
Tablet, multilayer, extended release","Oral
Oral",,Investigated for use/treatment in osteoporosis and menopause.
C(C(N(C(C([H])([H])[H])([H])[H])C(C(N(C(=O)C1=C([H])C(Cl)=C(N([H])[H])C([H])=C1[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB06421,891-60-1,Declopramide,,small molecule,,,,,Investigated for use/treatment in colorectal cancer and inflammatory bowel disease.
C(C1=C([H])C(C([H])([H])[H])=C(C(=C2C(=O)N([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])[H])N1[H])([H])([H])[H],DB06436,194413-58-6,Semaxanib,,small molecule,,,,,Investigated for use/treatment in colorectal cancer and lung cancer.
C(C(C([H])([H])[H])(C1=C([H])C(C(C([H])([H])[H])(C([H])([H])[H])[H])=C(C(C(=O)N(S(=O)(=O)OC2=C(C(C([H])([H])[H])(C([H])([H])[H])[H])C([H])=C([H])C([H])=C2C(C([H])([H])[H])(C([H])([H])[H])[H])[H])([H])[H])C(C(C([H])([H])[H])(C([H])([H])[H])[H])=C1[H])[H])([H])([H])[H],DB06442,166518-60-1,Avasimibe,,small molecule,Humans and other mammals,,,,Investigated for use/treatment in peripheral vascular disease.
C(C(N(C(C(C(N(C(C(C(N(C(C(C(N(C(C([H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])([H])[H],DB06445,121749-39-1,Diethylnorspermine,,small molecule,,,,,"Investigated for use/treatment in renal cell carcinoma, pancreatic cancer, melanoma, and lung cancer."
C(C(N1C([H])([H])C([H])([H])N(C(C2=C([H])C([H])=C([H])C([H])=C2[H])(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])C([H])([H])C1([H])[H])([H])[H])(C(C1(OC([H])([H])C([H])([H])O1)C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H],DB06446,84625-59-2,Dotarizine,,small molecule,Humans and other mammals,,,,Investigated for use/treatment in migraine and cluster headaches.
C(OC1=C([H])C([H])=C([H])C(OC([H])([H])[H])=C1C1=C([H])C(C(=O)N(C2(C3(C([H])([H])C4(C(C(C3([H])[H])(C([H])([H])C2(C4([H])[H])[H])[H])([H])[H])[H])[H])C(O[H])=O)[H])=NN1C1=C2C(=C(C(Cl)=C([H])C2=NC([H])=C1[H])[H])[H])([H])([H])[H],DB06455,146362-70-1,Meclinertant,reminertant,small molecule,,,,,"Investigated for use/treatment in colorectal cancer, prostate cancer, schizophrenia and schizoaffective disorders, psychosis, depression, and lung cancer."
FC1=C([H])C([H])=C(C(N2C(=NC3(C([H])([H])C([H])([H])N([H])C([H])([H])C3([H])[H])[H])N([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])([H])[H])C([H])=C1[H],DB06457,75970-99-9,Tecastemizole,"1-((4-flurophenyl)methyl)-N-4-piperidinyl-1H-benzimidazol-2-amine
norastemizole",small molecule,,,,,Investigated for use/treatment in allergic rhinitis.
C(C(C([H])([H])[H])(C1=C(S(C([H])([H])[H])(=O)=O)C([H])=C(C(=O)N(C(N([H])[H])=N[H])[H])C([H])=C1[H])[H])([H])([H])[H],DB06468,159138-80-4,Cariporide,,small molecule,,,,,Investigated for use/treatment in cardiac surgery.
C(C1=C(C(C(Cl)([H])[H])([H])[H])SC([H])=N1)([H])([H])[H],DB06470,,clomethiazole,,small molecule,,,,,Investigated for use/treatment in strokes.
C(C(C(N1C([H])=NC2=C1C(=O)N(C(C(C(C(C(C([H])([H])[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])C(=O)N2C([H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB06479,55242-55-2,Propentofylline,,small molecule,,,,,Investigated for use/treatment in alzheimer's disease.
C(OC(C(C(N1C([H])([H])C([H])([H])C(N(C(=O)C2=C([H])C(Cl)=C(N([H])[H])C3=C2OC(C3([H])[H])([H])[H])[H])([H])C([H])([H])C1([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB06480,179474-81-8,Prucalopride,,small molecule,Humans and other mammals,"Tablet
Tablet","Oral
Oral","1 mg
2 mg","Investigated for use/treatment in constipation, ileus, and pediatric indications."
O(C(C(C(C#C[H])([H])[H])([H])[H])=C(C#N)C(=O)N(C1=C([H])C([H])=C(C(F)(F)F)C([H])=C1[H])[H])[H],DB06481,202057-76-9,Manitimus,,small molecule,,,,,Investigated for use/treatment in immunosuppressive and transplant (rejection).
C(N1C([H])=C(C2=C(C3=C([H])N(C4(C([H])([H])C([H])([H])N(C(C5=NC([H])=C([H])C([H])=C5[H])([H])[H])C([H])([H])C4([H])[H])[H])C4=C3C(=C(C(=C4[H])[H])[H])[H])C(=O)N([H])C2=O)C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])([H])[H],DB06486,170364-57-5,Enzastaurin,,small molecule,,,,,"Investigated for use/treatment in brain cancer, lymphoma (non-hodgkin's), and lung cancer."
C(ON(C(=O)N(C1=C([H])C([H])=C(C2=C(C(N(C([H])([H])[H])C(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])([H])[H])C3=C(N(C(C4=C(F)C([H])=C([H])C([H])=C4F)([H])[H])C(=O)N(C3=O)C3=C([H])C([H])=C([H])C([H])=C3[H])S2)C([H])=C1[H])[H])[H])([H])([H])[H],DB06494,308831-61-0,Sufugolix,,small molecule,,,,,Investigated for use/treatment in endometriosis and uterine fibroids.
C1(C([H])([H])C2=C(C3=C(C(=N2)[H])N([H])C(C2=NOC([H])=C2[H])=N3)C([H])([H])O1)([H])[H],DB06504,,S-8510,,small molecule,,,,,Investigated for use/treatment in alzheimer's disease and dementia.
C(OC1=C([H])C([H])=C(OC(=O)N(C(C(O[H])=O)([H])[H])C(C2=C([H])C([H])=C(OC(C(C3=C(C([H])([H])[H])OC(C4=C([H])C([H])=C([H])C([H])=C4[H])=N3)([H])[H])([H])[H])C([H])=C2[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB06510,331741-94-7,Muraglitazar,,small molecule,,,,,Investigated for use/treatment in diabetes mellitus type 2.
N(C(C(C(S(O[H])(=O)=O)([H])[H])([H])[H])([H])[H])([H])[H],DB06527,3687-18-1,Tramiprosate,NC-531,small molecule,,,,,Investigated for use/treatment in strokes and alzheimer's disease.
O=C(C1=C2N=C(C(=C(C3=C([H])C([H])=NC([H])=C3[H])N2N=C1[H])[H])[H])C1=NC([H])=C([H])C([H])=C1[H],DB06529,96604-21-6,Ocinaplon,,small molecule,,,,,Investigated for use/treatment in anxiety disorders.
C(C(OC(C1=NC2=C(C3=C(N(C2=N[H])[H])C([H])=C([H])C([H])=C3[H])N1C(C(C([H])([H])[H])(C([H])([H])[H])O[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB06530,144875-48-9,Resiquimod,,small molecule,,,,,Investigated for use/treatment in genital herpes.
C(ON(C(=N[H])C1=C([H])C([H])=C(C2=C([H])C([H])=C(C3=C([H])C([H])=C(C(=N[H])N(OC([H])([H])[H])[H])C([H])=C3[H])O2)C([H])=C1[H])[H])([H])([H])[H],DB06532,186953-56-0,Pafuramidine,DB-289,small molecule,,,,,"Investigated for use/treatment in pneumonia, trypanosomiasis, malaria, HIV infection, and infectious and parasitic disease (unspecified)."
O(C(C(C1=C([H])N=C2C(=C(C(=C([H])N12)[H])[H])[H])([H])[H])(P(O[H])(O[H])=O)P(O[H])(O[H])=O)[H],DB06548,180064-38-4,Minodronic acid,Minodronate,small molecule,,,,,"Investigated for use/treatment in multiple myeloma, breast cancer, osteoporosis, and lung cancer."
O=C1N([H])OC2=C1C(C(N(C2([H])[H])[H])([H])[H])([H])[H],DB06554,64603-91-4,Gaboxadol,"4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol
THIP",small molecule,Humans and other mammals,,,,Investigated for use/treatment in sleep disorders and insomnia.
FC1=C([H])C([H])=C(N2C([H])=C(C(C(C(C(N3C([H])([H])C([H])([H])C4(OC([H])([H])C5=C4C(=C(C(=C5[H])[H])[H])[H])C([H])([H])C3([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C3=C2C(=C(C(=C3[H])[H])[H])[H])C([H])=C1[H],DB06555,147817-50-3,Siramesine,,small molecule,,,,,Investigated for use/treatment in anxiety disorders.
C(OC1=C(OC2=C(OC(C(O[H])([H])[H])([H])[H])N=C(C3=C([H])C(C4=NN([H])N=N4)=NC([H])=C3[H])N=C2N(S(=O)(=O)C2=NC([H])=C(C(C([H])([H])[H])(C([H])([H])[H])[H])C([H])=C2[H])[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB06558,180384-57-0,Tezosentan,,small molecule,,,,,"Investigated for use/treatment in congestive heart failure, liver disease, and heart disease."
C(C(C(C1=C(C(N2C([H])=C([H])N=C2C2=C(F)C([H])=C([H])C([H])=N2)([H])[H])N=C([H])N2N=C(C([H])([H])[H])N=C12)([H])[H])([H])[H])([H])([H])[H],DB06579,840486-93-3,Adipiplon,,small molecule,,,,,Investigated for use/treatment in insomnia and sleep disorders.
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(OC1=NC2=C(C(=C(C([H])([H])[H])C(=C2[H])[H])[H])C(=O)O1)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB06586,282526-98-1,Cetilistat,,small molecule,,,,,Investigated for use/treatment in obesity.
C(N(C1=C([H])C2=NN(C([H])([H])[H])C(C([H])([H])[H])=C2C([H])=C1[H])C1=C([H])C([H])=NC(N(C2=C([H])C(S(N([H])[H])(=O)=O)=C(C([H])([H])[H])C([H])=C2[H])[H])=N1)([H])([H])[H],DB06589,444731-52-6,Pazopanib,"GW 78603
Pazopanibum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral","200 mg
400 mg
200 mg
200 mg/1
400 mg",Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy) 
C(OC1=C([H])C([H])=C2C(=C(C(=C(C(C(N(C(C([H])([H])[H])=O)[H])([H])[H])([H])[H])C2=C1[H])[H])[H])[H])([H])([H])[H],DB06594,138112-76-2,Agomelatine,Valdoxan,small molecule,,,,,Agomelatine is indicated for the treatment of major depressive episodes in adults.
C(N1C([H])=C(N(C(=O)C2=C([H])C(N(C(=O)C3=C([H])C(N(C(=O)C4=C([H])C(N(C(=O)C(Br)=C([H])[H])[H])=C([H])N4C([H])([H])[H])[H])=C([H])N3C([H])([H])[H])[H])=C([H])N2C([H])([H])[H])[H])C([H])=C1C(=O)N(C(C(N(C(N([H])[H])=N[H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB06598,203258-60-0,Brostallicin,,small molecule,,,,,Investigated for use/treatment in solid tumors.
C(C1=C(C(C(N(C(C2=C([H])C([H])=C(C(=C(C(O[H])=NO[H])[H])[H])C([H])=C2[H])([H])[H])[H])([H])[H])([H])[H])C2=C(C(=C(C(=C2[H])[H])[H])[H])N1[H])([H])([H])[H],DB06603,404950-80-7,Panobinostat,"(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
panobinostat",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral
Oral","10 mg
10 mg/1
15 mg
15 mg/1
20 mg/1
20 mg","Panobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015. "
C(OC1=C([H])C([H])=C(N2N=C(C(N([H])[H])=O)C3=C2C(=O)N(C(C3([H])[H])([H])[H])C2=C([H])C([H])=C(N3C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3=O)C([H])=C2[H])C([H])=C1[H])([H])([H])[H],"DB06605
DB07828",503612-47-3,Apixaban,"apixab��n
apixabanum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Kit","Oral
Oral
Oral
Oral
Oral
Oral","2.5 mg
5.0 mg
2.5 mg/1
2.5 mg
5 mg/1
5 mg",Apixaban is to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It has also been used to lower the risk of developing venous thrombosis post-orthopedic surgical procedures. 
C(OC1=C(Cl)C([H])=C(Cl)C(N(C2=C(C#N)C([H])=NC3=C(C(OC(C(C(N4C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C4([H])[H])([H])[H])([H])[H])([H])[H])=C(OC([H])([H])[H])C([H])=C23)[H])[H])=C1[H])([H])([H])[H],DB06616,380843-75-4,Bosutinib,"4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile
Bosulif��
Bosutinib
Bosutinib Monohydrate
SKI 606",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg
500 mg
100 mg/1
100 mg
400 mg/1
500 mg
500 mg/1","Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients. "
C(C(OC(=O)N(C1=C(N([H])[H])N=C(N(C(C2=C([H])C([H])=C(F)C([H])=C2[H])([H])[H])[H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB06623,56995-20-1,Flupirtine,Flupirtine,small molecule,Humans and other mammals,,,,Investigated for use/treatment in fibromyalgia.
C(C1=C(N([H])[H])C([H])=C([H])C(C(N2N=NC3=C2N=C(N([H])[H])N=C3C2=C([H])C([H])=C([H])O2)([H])[H])=C1[H])([H])([H])[H],DB06625,442908-10-3,Vipadenant,,small molecule,,,,,Investigated for use/treatment in parkinson's disease.
C(N=C(O[H])C1=C(SC2=C([H])C3=NN(C(C(=C(C4=NC([H])=C([H])C([H])=C4[H])[H])[H])=C3C([H])=C2[H])[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB06626,319460-85-0,Axitinib,"axitinib
axitinibum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","1 mg
3 mg
5 mg
7 mg
1 mg/1
1 mg
3 mg
5 mg
5 mg/1
7 mg",Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
C(OC1=NC(C([H])([H])[H])=C([H])N=C1N(S(=O)(=O)C1=C(C2=C([H])C([H])=C(C3=NN=C([H])O3)C([H])=C2[H])N=C([H])C([H])=C1[H])[H])([H])([H])[H],DB06629,186497-07-4,Zibotentan,,small molecule,,,,,Investigated for use/treatment in prostate cancer.
N(=C1C([H])=C([H])N([H])C([H])=C1[H])[H],DB06637,504-24-5,Dalfampridine,"4-Aminopyridine
4-AP
4-Pyridinamine
4-Pyridylamine
Avitrol
Dalfampridine
Fampridina
Fampridine
Fampridine-SR
Fampridinum
gamma-Aminopyridine
N07XX07
P-Aminopyridine",small molecule,Humans and other mammals,"Tablet, film coated, extended release
Tablet, extended release","Oral
Oral","10 mg/1
10 mg",Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS). 
O(C(C(OC(C(OC1=C([H])C([H])=C(C(=C(C(C(Cl)([H])[H])([H])[H])C2=C([H])C([H])=C([H])C([H])=C2[H])C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB06640,341524-89-8,Fispemifene,,small molecule,,,,,Investigated for use/treatment in male hormonal deficiencies/abnormalities.
C(C(C(C(C(C(C([H])([H])[H])([H])[H])([H])[H])(C(=O)N(C(C(N([H])[H])=O)([H])[H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB06657,92262-58-3,Valrocemide,TVP-1901,small molecule,,,,,Investigated for use/treatment in epilepsy.
C(C1=C(C(=O)N(C2=C([H])C(Cl)=C(C(=O)N3C([H])([H])C4=C(C(=C([H])N4C([H])([H])C4=C3C(=C(C(=C4[H])[H])[H])[H])[H])[H])C([H])=C2[H])[H])C([H])=C(F)C([H])=C1[H])([H])([H])[H],DB06666,168079-32-1,Lixivaptan,,small molecule,,,,,Investigated for use/treatment in hyponatremia and congestive heart failure.
C(OC1=C(OC2=C(OC(C(O[H])([H])[H])([H])[H])N=C(C3=C([H])C(C4=NN=NN4[H])=NC([H])=C3[H])N=C2N(S(=O)(=O)C2=NC([H])=C(C([H])([H])[H])C([H])=C2[H])[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB06677,180384-56-9,Clazosentan,,small molecule,,,,,Investigated for use/treatment in strokes.
N(C(=O)C1=C([H])C2=C(C(=C(C(=C2[H])N2C([H])([H])C([H])([H])N(C(C(C(C(C3=C([H])N([H])C4=C3C(=C(C(=C4[H])[H])C#N)[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])([H])C2([H])[H])[H])[H])O1)([H])[H],DB06684,163521-12-8,Vilazodone,"Vilazodona
Vilazodonum",small molecule,Humans and other mammals,"Kit
Kit; tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg/1
10 mg
20 mg
20 mg/1
40 mg/1
40 mg","Vilazodone is approved for treatment of acute episodes of major depression. Labeling of vilazodone describes an increased risk of suicidal thoughts in children, adolescents and young adults. The use of vilazodone in pediatrics is not indicated. Its use with monoamine oxidase inhibitors (MAOI) is contraindicated due to increased risk of serotonin syndome. Once the MAOI is discontinued, a 14-day washout period must pass before starting vilazodone."
C(C(N(C(=O)C1=C(O[H])C2=C(Cl)C(=C(C([H])=C2N(C([H])([H])[H])C1=O)[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB06685,248281-84-7,Laquinimod,SAIK-MS,small molecule,,,,,Investigated for use/treatment in multiple sclerosis.
[O-][N+]#N,DB06690,10024-97-2,Nitrous oxide,Nitrious oxide,small molecule,,"Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Liquid
Gas
Gas","Respiratory (inhalation)
Rectal
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)","990 mL/L
98 %
99 L/100L
99 mL/L
99 kg/100kg
99.5 L/L
990 mL/L
992 mL/L
995 mL/L
99 L/100L
100 %
99 %",
C(OC1=C([H])C([H])=C(C(N(C(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])C2=NC([H])=C([H])C([H])=C2[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB06691,91-84-9,Mepyramine,"Mepyramine
N-(P-Methoxybenzyl)-n',n'-dimethyl-N-(alpha-pyridyl)ethylenediamine
N-[(4-Methoxyphenyl)methyl]-n',n'-dimethyl-N-2-pyridinyl-1,2-ethanediamine
N',n'-dimethyl-N-(P-methoxybenzyl)-N-(2-pyridyl)ethylenediamine
Pyranisamine
pyrilamine",small molecule,,"Capsule
Powder
Tablet, coated
Capsule, liquid filled
Tablet
Tablet, film coated
Syrup
Solution
Liquid
Liquid
Tablet, extended release
Suspension","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Ophthalmic
Oral
Oral
Oral",,"Mepyramine is a first generation antihistamine used in treating allergies, ymptomatic relief of hypersensitivity reaction, and in pruritic skin disorders."
C(C1=C([H])C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=C([H])C(C([H])([H])[H])=C1C(C1=NC([H])([H])C([H])([H])N1[H])([H])[H])([H])([H])[H],DB06694,526-36-3,Xylometazoline,"Balminil
Xylomethazoline",small molecule,,"Spray
Spray
Spray
Solution
Spray
Solution; spray
Solution; spray
Spray
Solution / drops
Solution / drops
Spray
Solution / drops
Liquid; spray
Solution / drops
Spray
Spray","Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal
Ophthalmic
Nasal
Nasal
Nasal
Nasal
Nasal
Nasal",".01 L/L
10 mg/10mL
.05 mg/10mL
0.1 %
0.1 %
0.1 %
.1 %
.1 %
0.1 %
0.05 %
0.05 %
.1 %
.05 %
.05 %
.015 mL/15mL",It is used for treating nasal congestion and minor inflammation due to allergies or colds.
C(C(C(C(C(C(OC(=O)N=C(N([H])[H])C1=C([H])C([H])=C(N(C(C2=NC3=C(C(=C(C(=C3[H])C(=O)N(C(C(C(=O)OC(C([H])([H])[H])([H])[H])([H])[H])([H])[H])C3=NC([H])=C([H])C([H])=C3[H])[H])[H])N2C([H])([H])[H])([H])[H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB06695,211915-06-9,Dabigatran etexilate,Ethyl 3-[[[4-[[[(hexyloxyl)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino] propanoate,small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral
Oral","110 mg
110 mg/1
150 mg/1
150 mg
75 mg
75 mg/1","Dabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery (based on RE-NOVATE, RE-MODEL, and RE-MOBILIZE trials). In 2010, it was approved in the US and Canada for prevention of stroke and systemic embolism in patients with atrial fibrillation (approval based on the RE-LY trial). Contraindications: severe renal impairment (CrCL < 30 ml/min); haemorrhagic manifestations, bleeding diathesis or spontaneous or pharmacologic impairment of haemostasis; lesions at risk of clinically significant bleeding (e.g. extensive cerebral infarction (haemorrhagic or ischemic) in the last 6 months, active peptic ulcer disease); concomitant treatment with P-glycoprotein inhibitors (e.g. oral ketoconazole, verapamil); and those with known hypersensitivity to dabigatran, dabigatran etexilate or any ingredient used in the formulation or component of the container. As of December 2012, dabigatran is contraindicated in patients with mechanical prosthetic heart valves. "
C(N(C(C(C1=NC([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])[H])([H])([H])[H],DB06698,5638-76-6,Betahistine,"[2-(2-Pyridyl)ethyl]methylamine
2-(beta-Methylaminoethyl)pyridine
2-[2-(Methylamino)ethyl]pyridine
Betahistina
Betahistinum
N-Methyl-2-(2-pyridinyl)ethanamine
N-Methyl-2-pyridineethanamine",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral","16 mg
24 mg
4 mg
8 mg",For the reduction of episodes of vertigo association with M��ni��re's disease.
[O-]C(=O)C(N(C(C(N(C(C([O-])=O)([H])[H])C(C([O-])=O)([H])[H])([H])[H])([H])[H])C(C(C(OP([O-])(=O)OC1(C([H])([H])C([H])([H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])(C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])([H])C1([H])[H])[H])([H])[H])(N(C(C([O-])=O)([H])[H])C(C([O-])=O)([H])[H])[H])([H])[H])([H])[H],DB06705,193901-90-5,Gadofosveset trisodium,Gadofosveset,small molecule,Humans and other mammals,"Injection, solution
Injection, solution
Solution","Intravenous
Intravenous
Intravenous","0.25 mmol/ml
244 mg/mL
244 mg",Gadofosveset trisodium is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.
C(C1=NC([H])([H])C([H])([H])N1[H])(C1=C([H])C([H])=C([H])C2=C(C(=C(C([H])=C12)[H])[H])[H])([H])[H],DB06711,835-31-4,Naphazoline,Nafazolin,small molecule,,"Solution
Liquid
Solution / drops
Liquid
Solution
Solution / drops
Solution / drops
Solution / drops
Spray
Suspension / drops
Liquid
Solution
Solution
Liquid
Liquid
Solution / drops
Solution / drops
Solution / drops","Ophthalmic
Ophthalmic
Ophthalmic
Nasal
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Nasal
Nasal
Ophthalmic
Ophthalmic
Ophthalmic
Nasal
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic","1 mg/mL
.012 %
1 mg/mL
50 mg/100mL
.1 %
.1 %
1 mg/1
.1 mL/20mL
.125 mL/25mL
.1 %
0.1 %
12 mg/100mL
0.012 %
1 mg","Naphazoline is primarily indicated in conditions like Corneal vascularity, Hyperaemia, Itching, Nasal congestion, and can also be given in adjunctive therapy as an alternative drug of choice in Sinusitis"
[K+],DB06715,7681-11-0,Potassium Iodide,"Kaliumiodid
KI
Potassium iodide",small molecule,,"Tablet, extended release
Liquid
Liquid
Tablet, extended release
Tincture
Tablet
Tablet, effervescent
Solution
Liquid
Syrup
Capsule
Capsule, liquid filled
Tablet
Tablet, film coated
Tablet, coated
Powder
Kit
Powder
Solution
Tablet
Tablet
Tablet
Solution
Capsule, gelatin coated","Oral
Topical
Oral
Oral
Topical
Oral
Oral
Topical
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Topical
Oral
Oral
Oral
Oral
Oral
Oral","300 mcg
130 mg/1
1 g/mL
130 mg
65 mg
65 mg/1
65 mg/mL",Potassium Iodide is oral antithyroid agent. Potassium Iodide is used as an adjunct to other antithyroid agents in the treatment of hyperthyroidism and thyrotoxicosis and preoperatively to induce thyroid involution.
C(C(C([H])([H])[H])(C1=C([H])C([H])=C([H])C(C(C([H])([H])[H])(C([H])([H])[H])[H])=C1OC(OP(O[H])(O[H])=O)([H])[H])[H])([H])([H])[H],"DB06716
DB05279",258516-89-1,Fospropofol,Fospropofol,small molecule,Humans and other mammals,Injection,Intravenous,35 mg/mL,For monitored anaesthesia care sedation in patients undergoing diagnostic procedures like bronchoscopy and colonscopy or minor surgical procedures like arthroscopy and bunionectomy. 
C(N1C(C(=O)N(C2=NC([H])=C([H])C([H])=C2[H])[H])=C(O[H])C2=C(C(=C(Cl)S2)[H])S1(=O)=O)([H])([H])[H],DB06725,70374-39-9,Lornoxicam,"Chlortenoxicam
Lornoxicamum",small molecule,Humans and other mammals,,,,"For the treatment of acute mild to moderate pain, as well as pain and inflammation of the joints caused by certain types of rheumatic diseases."
N(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H],DB06728,62-53-3,Aniline,"Aminobenzene
Aminophen
Anilin
Anilina
Aniline oil
Anilinum
Benzenamine
Benzeneamine
Fentanyl impurity F
Huile d'aniline
Kyanol
Phenylamine
Trimethoprim specified impurity K",small molecule,,,,,
N(C1=C([H])C([H])=C(S(=O)(=O)N(C2=C([H])C([H])=NN2C2=C([H])C([H])=C([H])C([H])=C2[H])[H])C([H])=C1[H])([H])[H],DB06729,526-08-9,Sulfaphenazole,"1-Phenyl-5-sulfanilamidopyrazole
3-(P-Aminobenzenesulfonamido)-2-phenylpyrazole
5-Sulfanilamido-1-phenylpyrazole
N'-(1-phenylpyrazol-5-yl)sulfanilamide
N(1)-(1-Phenylpyrazol-5-yl)sulfanilamide
Sulfabid
Sulfafenazol
Sulfafenazolo
Sulfaphenazol
Sulfaphenazolum
Sulphaphenazole",small molecule,Gram negative and gram positive bacteria,,,,For the treatment bacterial infections.
O=C1C([H])=C(C2=C([H])C([H])=C([H])C([H])=C2[H])OC2=C1C1=C([H])C([H])=C([H])C([H])=C1C(=C2[H])[H],DB06732,6051-87-2,beta-Naphthoflavone,"5,6-benzoflavone
beta-NF",small molecule,,,,,
O(C(=O)C(OC(=O)C(C1=C(N(C2=C(Cl)C([H])=C([H])C([H])=C2Cl)[H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])[H],DB06736,89796-99-6,Aceclofenac,"2-[(2,6-dichlorophenyl)amino]benzeneacetic acid carboxymethyl ester
2-[(2,6-dichlorophenyl)amino]phenylacetoxyacetic acid
2-[(2',6'-dichlorophenyl)amino]phenylacetoxyacetic acid
Aceclofenac
ac��clof��nac
Aceclofenac betadex
Aceclofenaco
Aceclofenacum
glycolic acid [o-(2,6-dichloroanilino)phenyl]acetate ester",small molecule,,,,," Indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. "
C(C(C(=O)C1(C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C1([H])[H])C1=C([H])C(O[H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB06738,469-79-4,Ketobemidone,"Cetobemidona
Cetobemidone
Cetobemidonum
Cliradon
Cymidon
Ketobemidone
Ketodur
Ketogan
Ketorax",small molecule,Humans and other mammals,,,,"For the treatment of all types of severe pain, such as postoperative, cancer, kidney stones and fractures."
C(C(C([H])([H])[H])(C([H])([H])[H])C1(C([H])([H])C([H])([H])C(C2=C(O[H])C(=O)C3=C(C(=C(C(=C3[H])[H])[H])[H])C2=O)([H])C([H])([H])C1([H])[H])[H])([H])([H])[H],DB06740,94015-46-0,BW-A 58C,"2-(4-(1,1-Dimethylethyl)cyclohexyl)-3-hydroxy-1,4-naphthalenedione
2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone
2-(4'-t-Butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone
2-[4-(1,1-Dimethylethyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione",small molecule,,,,,
O(C(=O)C1=C(C(=C(C(=O)N(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])[H])[H])C2=C(Cl)C(=C(Cl)C([H])=C2N1[H])[H])[H],DB06741,153436-22-7,Gavestinel,,small molecule,Humans and other mammals,,,,
C(C(OC1=C(OC(C([H])([H])[H])([H])[H])C([H])=C(C(=C2N([H])C([H])([H])C([H])([H])C3=C(C(OC(C([H])([H])[H])([H])[H])=C(OC(C([H])([H])[H])([H])[H])C([H])=C23)[H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB06751,14009-24-6,Drotaverine,"Drotaverin
Drotin",small molecule,Humans and other mammals,,,,Used in the treatment of functional bowel disorders and alleviating pain in renal colic.
C(C(C(=C(C(=C(C([H])([H])[H])C(=C(C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H])[H])[H])[H])[H])[H])=C(C(=C(C(=C(C([H])([H])[H])C(=C(C(=C(C([H])([H])[H])C(=C(C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H])[H])[H])[H])[H])[H])[H])[H])[H])[H])([H])([H])[H],DB06755,7235-40-7,Beta carotene,"beta-carotene
Betacarotene",small molecule,,"Capsule
Capsule
Capsule
Tablet
Tablet
Tablet
Tablet
Tablet
Capsule
Capsule
Capsule
Tablet
Tablet
Tablet, extended release
Capsule
Liquid
Powder
Tablet, chewable
Capsule
Syrup
Tablet, effervescent
Tablet, film coated
Tablet, coated
Kit
Kit
Capsule, liquid filled","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","25000 unit
30000 unit
10000 unit
2500 unit
10000 unit
25000 unit
30000 unit
5712.96 unit
924 unit
5.9 mg
5000 unit
12500 unit
6 mg",
[Mn+2],DB06757,7439-96-5,Manganese,,small molecule,Humans and other mammals,"Tablet
Tablet
Capsule
Tablet, extended release
Capsule
Tablet, effervescent
Powder
Liquid
Capsule
Injection, solution
Tablet
Tablet
Capsule
Tablet
Solution
Solution
Liquid
Injection, solution, concentrate
Injection, solution
Tablet
Tablet
Tablet
Tablet, chewable
Capsule, gelatin coated
Solution","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intravenous
Oral
Oral
Oral
Oral
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Oral
Oral
Oral
Oral
Oral
Intravenous",".95 mg
5 mg
15 mg
30 mg
.1 mg/mL
10 mg
30 mg
10 mg
50 mg
0.1 mg
0.5 mg
6 mg
4 mg",Indicated for use as a supplement to intravenous solutions given for Total Parenteral Nutrition (TPN). Administration helps to maintain plasma levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
C(N1C([H])([H])C([H])([H])C(=C2C3=NC(=C(C(=O)[H])N3C([H])([H])C([H])([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB06766,147084-10-4,Alcaftadine,"6,11-Dihydro-11-(1-Methyl-4-piperidinylidene)-5H-iMidazo[2,1-b][3]benzazepine-3-carboxaldehyde
Alcaftadina
Alcaftadinum
Vilasta",small molecule,,Solution / drops,Ophthalmic,2.5 mg/mL,For the prevention of itching associated with allergic conjunctivitis.
C(N1C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])=NC2=C1C(=C(C(=C2[H])N(C(C(Cl)([H])[H])([H])[H])C(C(Cl)([H])[H])([H])[H])[H])[H])([H])([H])[H],DB06769,16506-27-7,Bendamustine,Ribomustine,small molecule,,"Injection, solution
Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Injection, solution, concentrate
Injection, solution, concentrate
Powder, for solution
Powder, for solution","Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous
Intravenous","25 mg/mL
100 mg/20mL
25 mg/5mL
180 mg/2mL
45 mg/.5mL
100 mg
25 mg",Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
O(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H],DB06770,100-51-6,Benzyl alcohol,"(Hydroxymethyl)benzene
Alcoholum benzylicum
Alcool benzylique
Alcoolbenzylique
alpha-Hydroxytoluene
alpha-Toluenol
Aromatic alcohol
Bentalol
Benzalalcohol
Benzalcohol
Benzenecarbinol
Benzenemethanol
Benzoyl alcohol
Benzyl alcohol
Benzylalkohol
Benzylic alcohol
Hydroxymethylbenzene
Phenylcarbinol
Phenylmethanol
Phenylmethyl alcohol",small molecule,Head lice,"Cream
Gel
Lotion
Gel
Suspension
Gel
Ointment
Gel
Cream
Spray
Aerosol, spray
Gel
Cream
Liquid
Liquid
Lotion
Gel","Topical
Topical
Dental
Dental
Auricular (otic)
Buccal; Topical
Topical
Topical
Topical
Topical
Topical
Topical
Percutaneous; Topical; Transdermal
Percutaneous; Topical; Transdermal
Topical
Topical
Topical","10 mg/g
2.5 %
25 mg
25 mg
100 mg/g
50 mg/g
.1 g/g",Ulesfia (benzyl alcohol) lotion is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. Ulesfia Lotion does not have ovicidal activity.
N#C[Fe-4](C#N)(C#N)(C#N)(C#N)C#N,"DB06783
DB09538",14038-43-8,Prussian blue,"Berlin blue
Ferric ferrocyanide
Ferric hexacyanoferrate
Ferric hexacyanoferrate(II)
Ferrocin
Iron(III) ferrocyanide
Iron(III) hexacyanoferrate(II)
Paris blue
Parisian blue
Prussian blue insoluble",small molecule,,Capsule,Oral,500 mg/1,Indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination. 
C(C(C([H])([H])[H])(C1(N([H])C(=O)C(C(C(C(C(N([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])N([H])C(=O)C(C(C2=C([H])N([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])([H])[H])([H])N([H])C(=O)C(C(C2=C([H])C([H])=C(O[H])C([H])=C2[H])([H])[H])([H])N([H])C(=O)C(N(C(=O)C(N([H])[H])(C(C2=C([H])C3=C(C(=C(C([H])=C3C([H])=C2[H])[H])[H])[H])([H])[H])[H])[H])([H])C([H])([H])SSC([H])([H])C(C(=O)N(C(C(C([H])([H])[H])(O[H])[H])(C(N([H])[H])=O)[H])[H])([H])N([H])C1=O)[H])[H])([H])([H])[H],DB06791,108736-35-2,Lanreotide,,small molecule,,"Solution, gel forming, extended release
Solution, gel forming, extended release
Solution, gel forming, extended release
Injection
Injection
Injection","Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous","120 mg
60 mg
90 mg
120 mg/.5mL
60 mg/.2mL
90 mg/.3mL",Lanreotide is a somatostatin analog approved for treatment of neuroendocrine tumours and acromegaly. (2)
O(C(=O)C(=O)N(C1=C([H])C(C#N)=C([H])C(N(C(=O)C(O[H])=O)[H])=C1Cl)[H])[H],DB06794,53882-12-5,Lodoxamide,"N,N'-(2-chloro-5-cyano-m-phenylene)dioxamate",small molecule,Humans and other mammals,"Solution
Solution / drops","Ophthalmic
Ophthalmic","0.1 %
1 mg/mL","Indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis."
N(C(C1=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C1[H])([H])[H])([H])[H],DB06795,138-39-6,Mafenide,"4-(aminomethyl)benzenesulfonamide
4-Homosufanilamide
Bensulfamide
Maphenidum",small molecule,"Gram negative and gram positive bacteria
Bacteria
Pseudomonas aeruginosa","Cream
Powder, for solution
Cream","Topical
Topical
Topical","85 mg/g
50 g/1
8.5 %",Mafenide is indicated in the treatment of severe burns.
C(C1=NC(C(OP(O[H])(O[H])=O)([H])[H])=C([H])C(C(N(C(C(N(C(C([O-])=O)([H])[H])C(C2=C([H])C(C(OP(O[H])(O[H])=O)([H])[H])=NC(C([H])([H])[H])=C2O[H])([H])[H])([H])[H])([H])[H])C(C([O-])=O)([H])[H])([H])[H])=C1O[H])([H])([H])[H],DB06796,155319-91-8,Mangafodipir,,small molecule,,"Injection, solution
Solution","Intravenous
Intravenous","0.01 mmol/ml
37.9 mg",Indicated for use as an organ-specific paramagnetic contrast agent developed for imaging of the hepatobiliary system and detecting lesions in liver and pancreas.
C1(N2C([H])([H])N3C(N(C2([H])[H])C([H])([H])N1C3([H])[H])([H])[H])([H])[H],"DB06799
DB06146",100-97-0,Methenamine,"1,3,5,7-tetraazatricyclo[3.3.1.13,7]decane
Hexamethylenamine
Hexamethylene tetramine
Hexamethylenetetramine
Hexamethylentetramin
Hexamethylentetraminum
Hexamine
Hexaminum
HMT
HMTA
metenamina
m��th��namine
methenaminum",small molecule,"Staphylococcus saprophyticus
Escherichia coli
Enterococcus faecalis
Enterococcus faecium","Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Granule, effervescent
Capsule
Tablet, coated
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","1 g
500 mg
1 g/1
1000 mg/1
500 mg/1
1000 mg/1",For prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary.  This drug is not used to treat  infection and should only be used after appropriate eradication of infection with antimicrobial agents.
N(C(=O)C(C1=C([H])C([H])=C([H])C(C(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])=C1N([H])[H])([H])[H])([H])[H],DB06802,78281-72-8,Nepafenac,"2-amino-3-Benzoylbenzeneacetamide
AHR 9434
AL 6515
Amfenac amide
Nepafenaco
Nepafenacum",small molecule,,"Suspension
Suspension
Suspension
Suspension
Suspension / drops","Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic
Ophthalmic","0.3 %
3 mg/mL
0.1 %
1 mg/mL
1 mg/mL",For the treatment of pain and inflammation associated with cataract surgery.
O(C1=C(C(=O)N(C2=C(Cl)C([H])=C([N+]([O-])=O)C([H])=C2[H])[H])C([H])=C(Cl)C([H])=C1[H])[H],DB06803,50-65-7,Niclosamide,,small molecule,Helminthic Microorganisms,,,,"For the treatment of tapeworm and intestinal fluke infections: Taenia saginata (Beef Tapeworm), Taenia solium (Pork Tapeworm), Diphyllobothrium latum (Fish Tapeworm), Fasciolopsis buski (large intestinal fluke). Niclosamide is also used as a molluscicide in the control of schistosomiasis."
C(C(C(C(C(C(C(C(C(C1=C([H])C([H])=C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB06804,26027-38-3,Nonoxynol-9,"26-(Nonylphenoxy)-3,6,9,12,15,18,21,24-octaoxahexacosan-1-ol
Nonaethylene glycol mono(nonylphenyl) ether
Nonaethylene glycol nonylphenyl ether
Nonoxynol 9
Nonylphenol octa(oxyethylene) ethanol
P-Nonylphenyl polyethylene glycol ether
PEG-9 nonyl phenyl ether
Polyoxyethylene (9) nonyl phenyl ether
Tergitol NP-9
Tergitol NP9",small molecule,,"Gel
Insert
Gel
Sponge
Aerosol, foam
Film, soluble
Gel, metered","Vaginal
Vaginal
Vaginal
Vaginal
Vaginal
Vaginal
Vaginal","4 g/100g
100 mg/1
3 g/100g
1000 mg/1
125 mg/g
280 mg/1
4 g/100g","Nonoxynol 9 is a surfactant spermicide used for contraception in spermicidal creams, jellies, foams, gel, and lubricants. It is also used in conjuction with other methods of contraception, including condoms, cervical caps and diaphragms."
N(C1=C([H])C(O[H])=C(C(=O)OC2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H],DB06807,133-11-9,Phenyl aminosalicylate,"Fenamisal
Fenamisalum
p-Aminosalol
Phenyl 4-aminosalicylate
Phenyl PAS",small molecule,,,,,
C(N1C([H])([H])C([H])([H])C([H])([H])N([H])C([H])([H])C([H])([H])N([H])C([H])([H])C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H])(C1=C([H])C([H])=C(C(N2C([H])([H])C([H])([H])C([H])([H])N([H])C([H])([H])C([H])([H])N([H])C([H])([H])C([H])([H])C([H])([H])N([H])C([H])([H])C2([H])[H])([H])[H])C([H])=C1[H])([H])[H],DB06809,110078-46-1,Plerixafor,,small molecule,Humans and other mammals,"Solution
Solution","Subcutaneous
Subcutaneous","20 mg
24 mg/1.2mL","Used in combination with granulocyte-colony stimulating factor (G-CSF, filgrastim) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin���s lymphoma (NHL) and multiple myeloma (MM)."
C(C(C(C(C(C(C(C(C(C(C(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB06811,9002-92-0,Polidocanol,"Aethoxy-sklerol
Laureth 9
Laureth-9
Macrogol 9 lauryl ether
Nonaethylene glycol monododecyl ether
Nonaethylene glycol monolauryl ether
PEG-9 lauryl ether
Polydocanol
Polyethylene glycol 450 lauryl ether
Polyoxyl 9 lauryl ether",small molecule,Humans and other mammals,"Injection, solution
Injection, solution
Kit
Kit","Intravenous
Intravenous
Intravenous",".005 g/mL
.01 g/mL
1.3 mg",Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity. 
C(C(C(C1=C([H])C2=C(OC(O2)([H])[H])C([H])=C1[H])([H])[H])(N(C(C(O[H])(C1=C([H])C(O[H])=C(O[H])C([H])=C1[H])[H])([H])[H])[H])[H])([H])([H])[H],DB06814,136-70-9,Protokylol,"Protokylolum
Protoquilol",small molecule,,,,,
[O-][N+]1=C(S[Zn]SC2=[N+]([O-])C([H])=C([H])C([H])=C2[H])C([H])=C([H])C([H])=C1[H],DB06815,13463-41-7,Pyrithione zinc,Zinc Pyrithione,small molecule,Yeast and other fungi,"Shampoo
Shampoo
Shampoo
Lotion
Lotion
Lotion
Shampoo
Soap
Shampoo
Soap
Shampoo
Shampoo
Shampoo
Shampoo
Lotion
Shampoo
Shampoo
Cream
Liquid
Shampoo
Liquid
Liquid
Cream
Liquid; shampoo
Shampoo
Shampoo
Lotion / shampoo
Lotion / shampoo
Lotion / shampoo
Shampoo
Cream
Shampoo
Shampoo
Gel
Suspension
Lotion
Liquid
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo, suspension
Suspension
Lotion / shampoo
Cream
Shampoo
Lotion / shampoo
Suspension
Lotion / shampoo
Lotion
Suspension
Gel
Cream
Shampoo
Spray
Solution
Liquid
Cream
Liquid
Shampoo
Shampoo
Solution
Shampoo
Shampoo
Shampoo
Liquid
Shampoo
Liquid
Shampoo
Liquid
Liquid
Liquid
Liquid
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Solution
Shampoo
Shampoo
Lotion
Shampoo
Cream
Lotion / shampoo
Liquid
Lotion
Lotion / shampoo
Kit
Lotion / shampoo
Lotion / shampoo
Lotion
Lotion / shampoo
Lotion / shampoo
Lotion / shampoo
Lotion / shampoo
Shampoo
Emulsion
Shampoo
Shampoo
Liquid
Lotion
Shampoo
Liquid
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo, suspension
Shampoo
Shampoo
Shampoo
Shampoo
Lotion
Shampoo
Shampoo
Gel
Lotion
Lotion / shampoo
Liquid
Lotion / shampoo
Solution
Cream
Liquid
Liquid
Gel
Shampoo
Shampoo, suspension
Shampoo, suspension
Cream
Shampoo
Shampoo
Liquid
Shampoo
Gel
Shampoo
Shampoo
Shampoo
Liquid
Liquid
Cream
Shampoo
Suspension
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Shampoo
Solution
Shampoo
Aerosol
Shampoo
Shampoo
Suspension
Shampoo
Suspension
Cream
Shampoo, suspension
Lotion
Lotion / shampoo
Shampoo
Rinse
Rinse
Lotion
Shampoo
Soap
Shampoo
Cream
Liquid
Shampoo
Lotion / shampoo
Shampoo
Liquid
Cream
Spray
Soap
Cream","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","1 g/mL
1.2 %
10 mg/mL
1 %
.15 mL/150mL
0.1 %
.15 g/mL
2 g/1000g
10 mg/mL
.05 g/100g
2.0 %
10 mg/1000mg
20 mg/mL
2.14 mg/mL
2.14 mg/mL
10.32 mg/mL
2.14 mg/mL
0.2 %
10.2 mg/mL
10.2 mg/mL
4.9 mg/mL
.2 g/100g
1 %
2.3 g/230g
1.05 g/100mL
.1 g/10g
.5 g/10g
1 g/10g
4.5 mL/300mL
.1 %
5.7 g/285mL
5.8 mg/290mL
0.1 %
.5 g/100mL
.0036 mg/mL
15 g/300mL
3 g/300g
2 %
1 kg/100kg
1.9 g/100mL
10.3 mg/mL
10.4 mg/mL
100 g/mL
9.5 mg/100mL
958 mg/mL
0.5 %
.5 mL/100mL
1 %
1.45 %
1 kg/100L
1 %
1 mL/100mL
1.0 %
1.0 %
2 g/100mL
2.5 mg
20 mg
2.5 mg
.95 g/100g
1 mg/mL
.5 g/100mL
14 mg/mL
1.2 g/100g
2.4 mg/500mL
1.2 g/100mL
10 mL/1000mL
65.7 g/1000mL
3 mg/mL
.05 g/mL
5.28 mg/mL
.0036 mg/mL
.00528 g/mL
.011 mg/mL
.0034 mg/mL
1.0 g
10 mg/10mL
1 kg/100L
1.008 g/100mL
.000048 g/100mL
1.8 mg/300mL
2 g/100mL
7.5 mL/750mL
3.84 mL/384mL
2.5 g/250g
1 g/100mL
1.68 %
6 mg/300mL
.1 mL/100mL
.1 mL/100mL
.0095 g/mL
0.75 %
0.5 %
0.5 %
0.75 %
1 g/mL
.1 g/100mL
5 mg/mL
.5 g/mL
2 g/100mL
20 mg/mL
.5 mg/100mL
1 g/100mL
.01 g/mL
10 mg/mL
7.5 mg/mL
1.5 g/100g
1 g/100g
1 g/100g
1.8 %
1 g/100mL
2 mg/mL
1.5 %
2.1 g/100mL
.00336 g/mL
1 %
5 mL/500mL
.3 mL/100mL
.01 g/g
.01 g/g
1.8 g/100mL
15 g/L
3 g/300g
1.008 g
10 mg/mL
10.5 mg/mL
10 g/500mL
.48 g/100mL
.5 g/100mL
1 mg/mL
.97 mg/mL
.1 g/100mL
0.1 %
1 mL/100mL
1 %
1.0 %
2 g/100g
4.04 g/400mL
.45 mL/100mL
1 mL/100mL
3 mg/1000mL
1 mg/100mL
1 mL/100mL
29 mg/mL
2.41 g/237mL
1 %
1.0 %
.6 mL/360mL
2.1 g/100mL
10 mg/mL
1 mL/100mL
95 mg/mL
9.5 mg/mL
0.95 %
1.9 %
.95 mL/100mL
0.95 %
.01 g/mL
5 g/250g
10 mg/g
3 mg/300mL
.95 g/100mL
1 mg/mL
2 mg
6 mg/mL
1 g
0.25 %
.5 mL/100mL
.5 mL/100mL
1 mg/g
10 mg/mL
1 mg/mL
1.2 g/mL
.01 g/.01g
.005 g/g
5 mg/mL
10 g
2 g/100g
5 g/500g
250 mg/100g
.15 %
2 g/100g
20 mg/400mg
20 mg/400mg
2 g/100mL
0.2 %
0.2 %
2 %
.5 %",Indicated for the treatment of dandruff and seborrheic dermatitis [A27133]. 
C(N(C([H])([H])[H])C1=C([H])C([H])=C2C(C(=C(C(C(=C(C3=C(C([H])([H])[H])N(C4=C([H])C([H])=C([H])C([H])=C4[H])C(C([H])([H])[H])=C3[H])[H])[H])=[N+]2C([H])([H])[H])[H])[H])=C1[H])([H])([H])[H],DB06816,7187-62-4,Pyrvinium,,small molecule,,Suspension,Oral,50 mg,Pyrvinium was once used in the treatment of pinworm infestations [T39].
C(N1C(=O)C(O[H])=C(C(=O)N(C(C2=C([H])C([H])=C(F)C([H])=C2[H])([H])[H])[H])N=C1C(C([H])([H])[H])(C([H])([H])[H])N(C(=O)C1=NN=C(C([H])([H])[H])O1)[H])([H])([H])[H],"DB06817
DB05355",518048-05-0,Raltegravir,,small molecule,Human Immunodeficiency Virus,"Tablet, film coated
Granule, for suspension
Tablet
Tablet, chewable
Tablet, chewable
Tablet, chewable
Tablet, chewable
Tablet, film coated
Tablet, film coated
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg/1
400 mg
100 mg/1
100 mg
25 mg
25 mg/1
400 mg/1
600 mg/1
600 mg",For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
O(C(=O)C(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])[H],"DB06819
DB02000
DB12600",1821-12-1,Phenylbutyric acid,"4-Phenyl-n-butyric acid
4-phenylbutyrate
4-phenylbutyric acid
Benzenebutyric acid
PBA
Phenylbutyrate
��-Phenyl-n-butyric acid
��-phenylbutyric acid
��-Phenylbutanoic acid
��-phenylbutyric acid",small molecule,,"Granule
Tablet
Granule
Powder
Tablet","Oral
Oral
Oral
Oral
Oral","940 mg/g
500 mg
483 mg
.94 g/g
500 mg/1","Adjunctive therapy for the management of chronic urea cycle disorders due to deficiencies in carbamylphosphate (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase. it is indicated in all neonatal- onset efficiency presenting within the first 28 days of life. Also indicated in patients with late-onset, presenting after the first month of life with a history of hyperammonemic encephalopathy.  "
C(OC1=C([H])N=C(N(S(=O)(=O)C2=C([H])C([H])=C(N([H])[H])C([H])=C2[H])[H])N=C1[H])([H])([H])[H],DB06821,651-06-9,Sulfameter,"Sulfa-5-methoxypyrimidine
Sulfamethoxydiazine
Sulfametoxidiazina
Sulfametoxydiazine
Sulfametoxydiazinum",small molecule,,,,,
N(C(C(N(C(C(N(C(C(N([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H],DB06824,112-24-3,Triethylenetetramine,"TETA
Trien
Trientine",small molecule,Humans and other mammals,Capsule,Oral,250 mg/1,Trientine is a copper chelator used in the treatment of Wilson's disease as an alternative to D-penicillamine. It tends to be used in patients who are experiencing serious adverse effects from penicillamine therapy or intolerance of penicillamine. 
C(C(N1C([H])=C([H])C([H])=C1[H])([H])[H])(OC1=C([H])C2=C(N(C(=C2[H])[H])[H])C([H])=C1[H])([H])[H],DB06828,,5-[2-(1H-pyrrol-1-yl)ethoxy]-1H-indole,,small molecule,,,,,
O(C(=O)C(OC1=C(C(O[H])=O)SC(C2=C([H])C(N(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])[H])=C([H])C([H])=C2[H])=C1Br)([H])[H])[H],DB06829,,4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID,,small molecule,,,,,
C(C(C(C(C(C(C(O[H])(P(O[H])(O[H])=O)P(O[H])(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB06830,,"(1-HYDROXYHEPTANE-1,1-DIYL)BIS(PHOSPHONIC ACID)",,small molecule,,,,,
C(OC1=C(N2C(=O)C3=C(Cl)C(=C(C([H])=C3N=C2C(SC2=NC([H])=NC3=C2N=C(N3[H])[H])([H])[H])[H])[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB06831,,2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE,,small molecule,,,,,
O(C1=C([H])C2=C(OC(=N2)C2=C([H])C(F)=C(O[H])C([H])=C2[H])C(C(=C([H])[H])[H])=C1[H])[H],DB06832,,"2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL",,small molecule,,,,,
C(C1=C([H])C([H])=C(N2C([H])=C(C(N(C(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])([H])[H])[H])([H])[H])C3=C2C(=C(C(=C3[H])[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB06833,,1-CYCLOHEXYL-N-{[1-(4-METHYLPHENYL)-1H-INDOL-3-YL]METHYL}METHANAMINE,,small molecule,,,,,
C(N1C([H])=C(C2=C([H])C3=C(N=C(C(=C3[H])[H])[H])N2[H])C2=C1C(=C(C(=C2[H])C(=O)N(C(C([H])([H])[H])(C([H])([H])[H])C(O[H])([H])[H])[H])[H])[H])([H])([H])[H],DB06834,,"N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide",,small molecule,,,,,
C(C(=O)N(C1=NC(C([H])([H])[H])=C(C2=C([H])C(S(=O)(=O)N(C(C(O[H])([H])[H])([H])[H])[H])=C(Cl)C([H])=C2[H])S1)[H])([H])([H])[H],DB06836,593960-11-3,"N-(5-{4-Chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl}-4-methyl-1,3-thiazol-2-yl)acetamide",,small molecule,,,,,
O=C1N=C2C(=C(C3=C(C2=C1C(N(C1=C([H])C([H])=C(S(=O)(=O)N(C2=NC([H])=C([H])C([H])=C2[H])[H])C([H])=C1[H])[H])([H])[H])SC([H])=N3)[H])[H],DB06844,,"4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE",,small molecule,,,,,
C(SC1=C2C(=C(C(=C([H])C2=C(C(=O)N2C([H])([H])C([H])([H])C3(C([H])([H])OC4=C3C(=C(C(N([H])[H])([H])[H])C(=C4[H])[H])[H])C([H])([H])C2([H])[H])S1)[H])[H])[H])([H])([H])[H],DB06848,,"1-(1'-{[3-(methylsulfanyl)-2-benzothiophen-1-yl]carbonyl}spiro[1-benzofuran-3,4'-piperidin]-5-yl)methanamine",,small molecule,,,,,
N(C(C1=C([H])C2=C(OC(C32C([H])([H])C([H])([H])N(C(=O)C(=C(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])[H])C([H])([H])C3([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])[H],DB06849,,"1-[1'-(3-phenylacryloyl)spiro[1-benzofuran-3,4'-piperidin]-5-yl]methanamine",,small molecule,,,,,
C(N(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])(C1=C([H])C([H])=C([H])N=C1[H])([H])[H],DB06851,,N-(pyridin-3-ylmethyl)aniline,,small molecule,,,,,
C(C(C([H])([H])[H])(C(OC1=C([H])C([H])=C([H])C(C2=NC3=C(C(C(N([H])[H])=N[H])=C(F)C([H])=C3N2[H])[H])=C1O[H])([H])[H])[H])([H])([H])[H],"DB06855
DB03494",,6-fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1H-benzoimidazole-5-carboxamidine,,small molecule,,,,,
C(C1=C([H])C(I)=C(O[H])C(C(=O)N(C2=C([H])C(Cl)=C(C(N([H])[H])=N[H])C([H])=C2[H])[H])=C1[H])([H])([H])[H],DB06857,,N-(4-CARBAMIMIDOYL-3-CHORO-PHENYL)-2-HYDROXY-3-IODO-5-METHYL-BENZAMIDE,,small molecule,,,,,
N(C(=N[H])N(OC(C(C(OC1=C([H])C(C(=O)N(C(C(=C([H])[H])[H])([H])[H])C2(C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])=C([H])C(Cl)=C1[H])([H])[H])([H])[H])([H])[H])[H])([H])[H],DB06859,,N-ALLYL-5-AMIDINOAMINOOXY-PROPYLOXY-3-CHLORO-N-CYCLOPENTYLBENZAMIDE,,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C2=C1C(=O)N(C2=O)C1=C([H])C(Cl)=NC([H])=C1[H])([H])([H])[H],DB06860,,"2-(2-chloropyridin-4-yl)-4-methyl-1H-isoindole-1,3(2H)-dione",,small molecule,,,,,
O(C(=O)C1=C(O[H])C([H])=C([H])C(S(=O)(=O)N(C(C(S[H])([H])[H])([H])[H])[H])=C1[H])[H],DB06862,,2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID,,small molecule,,,,,
C(C(OC(C(OC(C(OC(C(OC(C(OC(C(OC(C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB06867,,"3,6,9,12,15,18-HEXAOXAICOSANE",,small molecule,,,,,
O(C(C(OC(N1C([H])=C(SC2=C([H])C([H])=C([H])C([H])=C2[H])C(=O)N([H])C1=O)([H])[H])([H])[H])([H])[H])[H],DB06872,,"1-((2-HYDROXYETHOXY)METHYL)-5-(PHENYLTHIO)PYRIMIDINE-2,4(1H,3H)-DIONE",,small molecule,,,,,
O(C(C(OC(N1C([H])=C(C(C2=C([H])C(OC(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])=C([H])C([H])=C2[H])([H])[H])C(=O)N([H])C1=O)([H])[H])([H])[H])([H])[H])[H],DB06873,,"1-((2-HYDROXYETHOXY)METHYL)-5-(3-(BENZYLOXY)BENZYL)PYRIMIDINE-2,4(1H,3H)-DIONE",,small molecule,,,,,
C(C1=C([H])C(C#N)=C([H])C(C([H])([H])[H])=C1OC1=C(Br)C(C(O[H])([H])[H])=NC(N(C2=C([H])C([H])=C(C#N)C([H])=C2[H])[H])=N1)([H])([H])[H],DB06874,,"(6-[4-(AMINOMETHYL)-2,6-DIMETHYLPHENOXY]-2-{[4-(AMINOMETHYL)PHENYL]AMINO}-5-BROMOPYRIMIDIN-4-YL)METHANOL",,small molecule,,,,,
O(C1=C([H])C([H])=C2C(=C(C(=C(C#N)C2=C1[H])[H])C1=C([H])C(F)=C(O[H])C([H])=C1[H])[H])[H],DB06875,,3-(3-FLUORO-4-HYDROXYPHENYL)-7-HYDROXY-1-NAPHTHONITRILE,,small molecule,,,,,
C(N1C([H])([H])C([H])([H])N(C2=C([H])C([H])=C(C3=C([H])C4=C(N(C(=C4N(C(=O)C4=C([H])N=C([H])C([H])=C4[H])[H])[H])[H])N=C3[H])C([H])=C2[H])C([H])([H])C1([H])[H])([H])([H])[H],DB06876,,"N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE",,small molecule,,,,,
C(N(C([H])([H])[H])C(=O)C1=C([H])C(C2=NN([H])C([H])=C2C2=C([H])C([H])=C([H])C([H])=C2[H])=C([H])N1[H])([H])([H])[H],DB06877,,"N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE",,small molecule,,,,,
C(C(N1C2=C(F)C(=C(C(F)=C2C(N([H])[H])=NC21C([H])([H])C([H])([H])N(C(=O)C1=C([H])N=C(C#N)C([H])([H])C1([H])[H])C([H])([H])C2([H])[H])[H])[H])([H])[H])([H])([H])[H],DB06879,,"5-(4'-AMINO-1'-ETHYL-5',8'-DIFLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLINE]-1-YLCARBONYL)PICOLINONITRILE",,small molecule,,,,,
C(C(C(C(=O)C(O[H])=C(OP(O[H])(O[H])=O)[H])([H])[H])([H])[H])([H])([H])[H],DB06881,,(1Z)-2-HYDROXY-3-OXOHEX-1-EN-1-YL DIHYDROGEN PHOSPHATE,,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C1=NN(C2=C([H])C(N([H])[H])=C([H])C([H])=C2[H])C(N(C(=O)N(C2=C([H])C([H])=C([H])C3=C(C(=C(C([H])=C23)[H])[H])[H])[H])[H])=C1[H])([H])([H])[H],DB06882,,1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea,,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C1=NN(C2=C([H])C(N([H])[H])=C([H])C([H])=C2[H])C(N(C(=O)N(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])[H])=C1[H])([H])([H])[H],DB06883,,1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea,,small molecule,,,,,
C(C(C([H])([H])[H])(C1=C([H])C([H])=C(C(N(N(C(=O)C2=C([H])C([H])=C(O[H])C([H])=C2[H])[H])[H])([H])[H])C([H])=C1[H])[H])([H])([H])[H],DB06884,,4-HYDROXY-N'-(4-ISOPROPYLBENZYL)BENZOHYDRAZIDE,,small molecule,,,,,
O(C(=O)C(C(ON=C(C1=C(C(F)(F)F)C([H])=C([H])C([H])=C1[H])[H])([H])[H])([H])[H])[H],DB06885,,3-[({(1E)-[2-(trifluoromethyl)phenyl]methylidene}amino)oxy]propanoic acid,,small molecule,,,,,
O=C1N(C(C2=NN=NN2[H])([H])[H])C([H])=NC2=C1C1=C(S2)C([H])([H])C([H])([H])C([H])([H])C1([H])[H],DB06889,,"3-(1H-tetrazol-5-ylmethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one",,small molecule,,,,,
N(C1=C(Cl)C([H])=C(S(=O)(=O)N(C2=NN=C(S(N([H])[H])(=O)=O)S2)[H])C([H])=C1F)([H])[H],DB06891,,"5-{[(4-AMINO-3-CHLORO-5-FLUOROPHENYL)SULFONYL]AMINO}-1,3,4-THIADIAZOLE-2-SULFONAMIDE",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(S(O[H])(=O)=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB06893,,1-DECANE-SULFONIC-ACID,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB06894,,1-DODECANOL,,small molecule,,,,,
FC1=C([H])C([H])=C(N2C([H])=C([H])C([H])=C(C(=O)N(C3=C([H])C(F)=C(OC4=C5C(=C(N([H])C5=NC([H])=C4[H])[H])[H])C([H])=C3[H])[H])C2=O)C([H])=C1[H],DB06896,,"1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide",,small molecule,,,,,
C(N1C(N([H])[H])=NC2=NC(=C(C([H])=C12)C1=C([H])C([H])=C(O[H])C([H])=C1[H])[H])([H])([H])[H],DB06898,,"4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol",,small molecule,,,,,
C(C(C1=NC(N([H])[H])=NC(N([H])[H])=C1C1=C([H])C2=C(SC(C([H])([H])[H])(C([H])([H])[H])C(=O)N2C(C(N(C(C([H])([H])[H])=O)[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB06899,,"N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOTHIAZIN-4-YL]ETHYL}ACETAMIDE",,small molecule,,,,,
N(C(=N[H])N(C1=C([H])C([H])=C(C(O[H])([H])[H])C([H])=C1[H])[H])([H])[H],DB06900,,1-[4-(hydroxymethyl)phenyl]guanidine,,small molecule,,,,,
C(C(C([H])([H])[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C1=C([H])C([H])=C(O[H])C([H])=C1[H])([H])([H])[H],DB06902,,4-(1-methyl-1-phenylethyl)phenol,,small molecule,,,,,
C(C(OC(=O)C1=C(O[H])N=C(N([H])[H])N=C1[H])([H])[H])([H])([H])[H],DB06906,,2-AMINO-4-HYDROXYPYRIMIDINE-5-CARBOXYLIC ACID ETHYL ESTER,,small molecule,,,,,
O(C(=O)C1=C([H])C2=C(N=C(O2)C2=C(Cl)C([H])=C([H])C([H])=C2Cl)C([H])=C1[H])[H],DB06907,,"2-(2,6-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC ACID",,small molecule,,,,,
C(C(N1N=C([H])C2=C1N=C(C(C(=O)N(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H])=C2N(C1(C([H])([H])C([H])([H])OC([H])([H])C1([H])[H])[H])[H])[H])([H])[H])([H])([H])[H],DB06909,,"1-ethyl-N-(phenylmethyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide",,small molecule,,,,,
O=C(C(C(C(C(=C(C(C(C(=C(C(C(C(=O)[H])([H])[H])([H])[H])C(=O)[H])[H])([H])[H])([H])[H])C(=O)[H])[H])([H])[H])([H])[H])([H])[H])[H],DB06912,,"UNDECA-3,7-DIENE-1,3,7,11-TETRACARBALDEHYDE",,small molecule,,,,,
ClC1=C([H])C([H])=C(C(C(C2(C(N3C([H])=C([H])N=C3[H])([H])[H])OC([H])([H])C([H])([H])O2)([H])[H])([H])[H])C([H])=C1[H],DB06914,,"1-({2-[2-(4-CHLOROPHENYL)ETHYL]-1,3-DIOXOLAN-2-YL}METHYL)-1H-IMIDAZOLE",,small molecule,,,,,
O(C1=C([H])C(O[H])=C2C(O[H])=C(C(O[H])=C(O[H])C2=C1[H])[H])[H],DB06915,,"naphthalene-1,2,4,5,7-pentol",,small molecule,,,,,
FC1=C([H])C([H])=C(C(=O)C2=C([H])C([H])=NC([H])=C2[H])C([H])=C1[H],DB06917,,(4-fluorophenyl)(pyridin-4-yl)methanone,,small molecule,,,,,
C(C1=C(C2=C([H])C3=C(C(=C(C(=C3[H])[H])C(N([H])[H])=N[H])[H])N2[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB06918,,2-(2-METHYLPHENYL)-1H-INDOLE-6-CARBOXIMIDAMIDE,,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C(C2=C([H])C3=C(C(=C(C(=C3[H])C(N([H])[H])=N[H])[H])[H])N2[H])=C1[H])([H])([H])[H],DB06923,,2-(3-METHYLPHENYL)-1H-INDOLE-5-CARBOXIMIDAMIDE,,small molecule,,,,,
C(C1=C(C2=C([H])C3=C(N=C(N([H])[H])N=C3C([H])=C2[H])[H])C([H])=C(C(=O)N(C2=C([H])C([H])=C([H])C(C(F)(F)F)=C2[H])[H])C([H])=C1[H])([H])([H])[H],DB06925,,3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE,,small molecule,,,,,
O(C1=C([H])C([H])=C(C2=C([H])C3=C(C(O[H])=C(C(C(C#N)([H])[H])=C3O2)[H])[H])C([H])=C1[H])[H],DB06927,,[5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE,,small molecule,,,,,
N(C(=N[H])N(C(=O)C(N1C(C2=C([H])C([H])=C([H])C([H])=C2[H])=C([H])C([H])=C1C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H])([H])[H],DB06930,,"N-[amino(imino)methyl]-2-(2,5-diphenyl-1H-pyrrol-1-yl)acetamide",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(O[H])(P(O[H])(O[H])=O)P(O[H])(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB06931,,"(1-HYDROXYNONANE-1,1-DIYL)BIS(PHOSPHONIC ACID)",,small molecule,,,,,
C(OC1=C([H])C2=NC(=C3C(N([H])[H])=NC4=C(C([H])([H])[H])C(N([H])[H])=C(C([H])=C4C3=C2C([H])=C1OC([H])([H])[H])[H])[H])([H])([H])[H],DB06932,,"10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine",,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])N(S(=O)(=O)C1=C([H])C([H])=C(C2=C([H])C3=C(N(C4=NC([H])=C([H])C([H])=C4[H])[H])C(=C(C([H])=C3N=C2[H])[H])[H])C([H])=C1[H])[H])([H])([H])[H],DB06933,,N-(tert-butyl)-4-[5-(pyridin-2-ylamino)quinolin-3-yl]benzenesulfonamide,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C(C2=C(F)C([H])=C([H])C([H])=C2F)C([H])=C1[H])[H],DB06935,,"2',6'-DIFLUOROBIPHENYL-4-CARBOXYLIC ACID",,small molecule,,,,,
O(C1=C([H])C2=C(C(=NO2)C2=C(O[H])C([H])=C(O[H])C([H])=C2[H])C([H])=C1[H])[H],DB06937,,"4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL",,small molecule,,,,,
C(N(C(=O)C1=NC([H])=C([H])C(OC2=C([H])C3=C(N=C(N(C4=C([H])C(C(F)(F)F)=C(Cl)C([H])=C4[H])[H])N3[H])C([H])=C2[H])=C1[H])[H])([H])([H])[H],DB06938,,4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide,,small molecule,,,,,
C(C(N(C(=O)C1=C([H])N2N=C(N=C(N(C3=C(C([H])([H])[H])C([H])=C([H])C(C(=O)N(OC([H])([H])[H])[H])=C3[H])[H])C2=C1C([H])([H])[H])[H])[H])([H])[H])([H])([H])[H],DB06940,,"N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide",,small molecule,,,,,
C(N1C([H])([H])C([H])([H])N(C2=C(C(N=NC(N([H])[H])=S)([H])[H])C([H])=C([H])C([H])=C2[H])C([H])([H])C1([H])[H])([H])([H])[H],DB06941,,(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide,,small molecule,,,,,
O=C(C(C1=C([H])C2=C(C(=C(C([H])=C2C([H])=C1[H])[H])[H])[H])([H])[H])N(C1=C([H])C(C2(C([H])([H])C2([H])[H])[H])=NN1[H])[H],DB06944,,N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide,,small molecule,,,,,
O(N(C(=O)C1(C([H])([H])C([H])([H])OC([H])([H])C1([H])[H])S(=O)(=O)C1=C([H])C([H])=C(OC2=C([H])C([H])=C(C(F)(F)F)C([H])=C2[H])C([H])=C1[H])[H])[H],DB06945,,N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide,,small molecule,,,,,
C(OC1=NC(N(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])=NC2=C1N(C(=N2)[H])[H])(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])([H])[H],DB06948,,2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE,,small molecule,,,,,
O(C1=C(Br)C(O[H])=C(C(=NN(C(=O)C2=C([H])C3=C(C(=C(C([H])=C3C([H])=C2[H])[H])[H])[H])[H])[H])C([H])=C1Br)[H],DB06949,,"N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]naphthalene-2-carbohydrazide",,small molecule,,,,,
O(C1=C(Br)C(O[H])=C(C(=NN(C(=O)C2=C([H])C([H])=C(Cl)C([H])=C2[H])[H])[H])C([H])=C1Br)[H],DB06950,,"4-chloro-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide",,small molecule,,,,,
N(S(=O)(=O)OC1=C([H])C2=C(C(=C(C(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])([H])[H])S2(=O)=O)[H])C([H])=C1[H])([H])[H],DB06954,,"2-(cycloheptylmethyl)-1,1-dioxido-1-benzothiophen-6-yl sulfamate",,small molecule,,,,,
O(C(=O)C1=C(C2=C([H])N([H])C3=C(Cl)C(=C(C([H])=C23)[H])[H])C(C2=C([H])N([H])C3=C2C(=C(C(=C3Cl)[H])[H])[H])=C(C(O[H])=O)N1[H])[H],DB06955,,"3,4-bis(7-chloro-1H-indol-3-yl)-1H-pyrrole-2,5-dicarboxylic acid",,small molecule,,,,,
C(C(=O)C1=C([H])C([H])=C(N(C(=O)C2=C(C3=C([H])C(Cl)=C(O[H])C([H])=C3O[H])N([H])N=C2[H])[H])C([H])=C1[H])([H])([H])[H],DB06956,,"N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE",,small molecule,,,,,
C(S(=O)(=O)C1=C([H])C([H])=C(C(N2C([H])([H])C([H])([H])N(C3=C(C4=C([H])C(Cl)=C(O[H])C([H])=C4O[H])N([H])N=C3[H])C([H])([H])C2([H])[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB06957,,"4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL",,small molecule,,,,,
C(C(N(C(=O)C1=NN([H])C(C2=C([H])C(Cl)=C(O[H])C([H])=C2O[H])=C1N1C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H])[H])([H])[H])([H])([H])[H],DB06958,,"5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE",,small molecule,,,,,
C(C(N(C(=O)C1=NOC(C2=C([H])C(Cl)=C(O[H])C([H])=C2O[H])=C1C1=C([H])C([H])=C(C(N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])([H])[H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB06961,,"5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide",,small molecule,,,,,
N(C(C1=C([H])C2=C(OC(C32C([H])([H])C([H])([H])N(C(=O)C2=C([H])C([H])=C(C#CC4=C([H])C([H])=C([H])C([H])=C4[H])O2)C([H])([H])C3([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])[H],DB06962,,"(5-(aminomethyl)-2H-spiro[benzofuran-3,4'-piperidine]-1'-yl)(5-(phenylethynyl)furan-2-yl)methanone",,small molecule,,,,,
C(C(N(C(=O)C1=NOC(C2=C([H])C(Cl)=C(O[H])C([H])=C2O[H])=C1C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB06964,,"5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE",,small molecule,,,,,
C(C(C1=NC(N([H])[H])=NC(N([H])[H])=C1C1=C([H])C2=C(C3=C(N2C(C(C(OC([H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C([H])C([H])=C3[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB06967,,"6-ETHYL-5-[9-(3-METHOXYPROPYL)-9H-CARBAZOL-2-YL]PYRIMIDINE-2,4-DIAMINE",,small molecule,,,,,
C(C(C(C(N1C([H])=C([H])N=C1[H])([H])[H])([H])[H])([H])[H])(C(C(N1C([H])=C([H])N=C1[H])([H])[H])([H])[H])([H])[H],DB06968,,"1,1'-HEXANE-1,6-DIYLBIS(1H-IMIDAZOLE)",,small molecule,,,,,
C(C(N(C(=O)C1=C([H])C2=C(N=C(N([H])[H])N=C2C2=C([H])C(OC(C(N3C([H])([H])C([H])([H])C([H])([H])C3([H])[H])([H])[H])([H])[H])=C(Cl)C([H])=C2Cl)S1)[H])([H])[H])([H])([H])[H],DB06969,,"2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide",,small molecule,,,,,
C(C(N(C(C([H])([H])[H])([H])[H])S(=O)(=O)C1=C([H])C(C(=O)N(C2=C(C#N)C3=C(C(C(C3([H])[H])([H])[H])([H])[H])S2)[H])=C(Cl)C([H])=C1[H])([H])[H])([H])([H])[H],DB06970,,"2-CHLORO-N-(3-CYANO-5,6-DIHYDRO-4H-CYCLOPENTA[B]THIOPHEN-2-YL)-5-DIETHYLSULFAMOYL-BENZAMIDE",,small molecule,,,,,
C(N(C(C(OC1=C([H])C([H])=C(C2=C([H])C([H])=C(C#N)C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])C(=O)N(O[H])[H])([H])([H])[H],DB06971,,"N-{2-[(4'-CYANO-1,1'-BIPHENYL-4-YL)OXY]ETHYL}-N'-HYDROXY-N-METHYLUREA",,small molecule,,,,,
C(C(C([H])([H])[H])(C1=C([H])C([H])=C(O[H])C([H])=C1[H])C1=C([H])C([H])=C(O[H])C([H])=C1[H])([H])([H])[H],DB06973,,"4,4'-PROPANE-2,2-DIYLDIPHENOL",,small molecule,,,,,
C(OC1=C([H])C2=C(N=C(N(S2(=O)=O)[H])C2=C(O[H])C(C3=C([H])C([H])=C([H])C([H])=C3[H])=NN(C(C(C(C([H])([H])[H])(C([H])([H])[H])[H])([H])[H])([H])[H])C2=O)C([H])=C1[H])([H])([H])[H],DB06974,,"5-hydroxy-4-(7-methoxy-1,1-dioxido-2H-1,2,4-benzothiadiazin-3-yl)-2-(3-methylbutyl)-6-phenylpyridazin-3(2H)-one",,small molecule,,,,,
C(OC1=C([H])C([H])=C(C(=O)N(N=C(C2=C(O[H])C(Br)=C(O[H])C(Br)=C2[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB06978,,"N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]-4-methoxybenzohydrazide",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(SC1=C(C(O[H])=O)N=NN1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB06979,,"5-(dodecylthio)-1H-1,2,3-triazole-4-carboxylic acid",,small molecule,,,,,
O(C(C1=C2N=C(C(=C(N(C(C3=C([H])N=C([H])C([H])=C3[H])([H])[H])[H])N2N=C1[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H],DB06983,,"(5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol",,small molecule,,,,,
O(C(=O)C1=C(N(C(=O)N2C([H])([H])C([H])([H])C(C3=C(C(F)(F)F)C([H])=C([H])C([H])=C3[H])([H])C([H])([H])C2([H])[H])[H])C([H])=C([H])C([H])=C1[H])[H],DB06985,,2-[({4-[2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)amino]benzoic acid,,small molecule,,,,,
C(OC(=O)C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])(C(C1=C([H])C([H])=C(N(S(O[H])(=O)=O)[H])C([H])=C1[H])([H])[H])C(=O)OC([H])([H])[H])([H])([H])[H],DB06989,,{4-[2-BENZYL-3-METHOXY-2-(METHOXYCARBONYL)-3-OXOPROPYL]PHENYL}SULFAMIC ACID,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C(C(=NOC(C(ON=C(C2=C([H])C(=O)N([H])C(=O)N2[H])[H])([H])[H])([H])[H])[H])C([H])=C1[H])[H],DB06990,,"4-[(1E,7E)-8-(2,6-DIOXO-1,2,3,6-TETRAHYDROPYRIMIDIN-4-YL)-3,6-DIOXA-2,7-DIAZAOCTA-1,7-DIEN-1-YL]BENZOIC ACID",,small molecule,,,,,
C(C1=C(F)C([H])=C(C2=NC(C(=O)N3C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C3([H])[H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])([H])[H],DB06992,,"(3,3-dimethylpiperidin-1-yl)(6-(3-fluoro-4-methylphenyl)pyridin-2-yl)methanone",,small molecule,,,,,
N(C1=NC([H])=C([H])C(OC2=C(F)C([H])=C(N(C(=O)N(C(=O)C(C3=C([H])C([H])=C(F)C([H])=C3[H])([H])[H])[H])[H])C([H])=C2[H])=C1[H])([H])[H],DB06995,,N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide,,small molecule,,,,,
FC1=C([H])C([H])=C(C(C(=O)N(C(=O)N(C2=C([H])C(F)=C(OC3=C4C(=C(N([H])C4=NC([H])=C3[H])[H])[H])C([H])=C2[H])[H])[H])([H])[H])C([H])=C1[H],DB06997,,"2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide",,small molecule,,,,,
C(C(C(S(=O)(=O)N(C1=C([H])C([H])=C(F)C(C(=O)C2=C([H])N([H])C3=NC(=C(Cl)C([H])=C23)[H])=C1F)[H])([H])[H])([H])[H])([H])([H])[H],DB06999,,"N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide",,small molecule,,,,,
C(C(S(=O)(=O)N(C1=C(F)C(C(=O)C2=C([H])N([H])C3=C2C(=C(C(=N3)[H])C2=C([H])N=C([H])C([H])=C2[H])[H])=C(F)C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB07000,,"N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide",,small molecule,,,,,
C(OC1=C([H])C(N(C2(C([H])([H])C([H])([H])N(C(=O)C3=C([H])C([H])=C(C#N)C([H])=C3[H])C([H])([H])C2([H])[H])[H])[H])=NC([H])=C1[H])([H])([H])[H],DB07002,,4-({4-[(4-methoxypyridin-2-yl)amino]piperidin-1-yl}carbonyl)benzonitrile,,small molecule,,,,,
C(C(C(C(C#CC1=C([H])C([H])=C(C(=O)N(N(C(=S)N(C([H])([H])[H])[H])[H])[H])O1)([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07004,,2-[(5-hex-1-yn-1-ylfuran-2-yl)carbonyl]-N-methylhydrazinecarbothioamide,,small molecule,,,,,
C(OC1=C(C2=C3C(=O)N(C(=O)C3=C3C(N(C(C(C(O[H])([H])[H])([H])[H])([H])[H])C4=C3C([H])=C(O[H])C([H])=C4[H])=C2[H])[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB07006,,"9-HYDROXY-6-(3-HYDROXYPROPYL)-4-(2-METHOXYPHENYL)PYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE",,small molecule,,,,,
C1(OC2=C(C(=C(OC3=NC(OC4=C([H])C([H])=C(N5C([H])=C([H])N=C5[H])C([H])=C4[H])=NC([H])=C3[H])C(=C2[H])[H])[H])O1)([H])[H],DB07008,,"4-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PYRIMIDINE",,small molecule,,,,,
O(C1=C([H])C2=C(N=C(O2)C2=C([H])C([H])=C([H])C3=C(O[H])C(=C(C([H])=C23)[H])[H])C([H])=C1[H])[H],DB07009,,"2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL",,small molecule,,,,,
ClC1=C([H])C(C2=C([H])N([H])N=C2C2=C([H])N([H])C(C(=O)N(C(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])[H])=C2[H])=C([H])C([H])=C1[H],DB07010,,N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE,,small molecule,,,,,
N(C1=NC2=C(C(=C3N=C([H])N([H])C3=C2[H])[H])C(=O)N1[H])([H])[H],DB07012,,"6-AMINO-3,7-DIHYDRO-IMIDAZO[4,5-G]QUINAZOLIN-8-ONE",,small molecule,,,,,
C(C#CC(N(C1=C([H])C([H])=C(S(=O)(=O)C(C2(C([H])([H])C([H])([H])N(C(=O)OC(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])C2([H])[H])C(=O)N(O[H])[H])([H])[H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB07013,,TERT-BUTYL 4-({[4-(BUT-2-YN-1-YLAMINO)PHENYL]SULFONYL}METHYL)-4-[(HYDROXYAMINO)CARBONYL]PIPERIDINE-1-CARBOXYLATE,,small molecule,,,,,
C(OC1=C(F)C([H])=C(C(SC2=NN=C(C3=C([H])C4=C(OC(O4)([H])[H])C([H])=C3[H])O2)([H])[H])C([H])=C1[H])([H])([H])[H],DB07014,,"2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole",,small molecule,,,,,
C(C(C1=C(C([H])([H])[H])N([H])C(=O)C(N(C([H])([H])[H])C(C(OC([H])([H])[H])([H])[H])([H])[H])=C1C(C1=C([H])C(C([H])([H])[H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB07018,,5-ETHYL-3-[(2-METHOXYETHYL)METHYLAMINO]-6-METHYL-4-(3-METHYLBENZYL)PYRIDIN-2(1H)-ONE,,small molecule,,,,,
O=C(N(C1=C([H])C(C2=NN([H])C3=C2C(=C(C(=C3[H])[H])C2=NN([H])C([H])=N2)[H])=C([H])C([H])=C1[H])[H])C1=C([H])C([H])=C([H])O1,DB07020,,"N-{3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenyl}furan-2-carboxamide",,small molecule,,,,,
N(C(=N[H])C1=C([H])C([H])=C2C(=C(C(=C(N(C(=O)C3=C([H])C([H])=C([H])C(S(=O)(=O)OC(C(C(O[H])([H])[H])([H])[H])([H])[H])=C3[H])[H])C2=C1[H])[H])[H])[H])([H])[H],DB07022,,3-Hydroxypropyl 3-[(7-carbamimidoyl-1-naphthyl)carbamoyl]benzenesulfonate,,small molecule,,,,,
C(C1=C([H])C(N2C([H])([H])C([H])([H])C([H])([H])S2(=O)=O)=C2OC(=C(O[H])C(=O)C2=C1[H])C1=C([H])C(O[H])=C(O[H])C([H])=C1[H])([H])([H])[H],DB07024,,"2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE",,small molecule,,,,,
N(C(C1(C([H])([H])C([H])([H])N(C(C2=C([H])C3=C(N(C(=C3[H])C3=C([H])C4=C(C(=C(C(=C4[H])[H])[H])[H])N([H])C3=O)[H])C([H])=C2[H])([H])[H])C([H])([H])C1([H])[H])[H])([H])[H])([H])[H],DB07025,,3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE,,small molecule,,,,,
O(C(=O)C(OC1=C(C(=O)N(C(C2=C(F)C([H])=C(Br)C([H])=C2[H])([H])[H])[H])C([H])=C([H])C(Cl)=C1[H])([H])[H])[H],DB07028,,(2-{[(4-BROMO-2-FLUOROBENZYL)AMINO]CARBONYL}-5-CHLOROPHENOXY)ACETIC ACID,,small molecule,,,,,
C(C1=C([H])C(OC2=C([H])C3=C(OC(O3)([H])[H])C([H])=C2[H])=NC(OC2=C([H])C([H])=C(N3C([H])=C([H])N=C3[H])C([H])=C2[H])=N1)([H])([H])[H],DB07029,,"4-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]-6-METHYLPYRIMIDINE",,small molecule,,,,,
O(C(=O)C(OC1=C(C(=O)N(C(C2=C([H])C([N+]([O-])=O)=C([H])C([H])=C2[H])([H])[H])[H])C([H])=C([H])C(Cl)=C1[H])([H])[H])[H],DB07030,,(5-CHLORO-2-{[(3-NITROBENZYL)AMINO]CARBONYL}PHENOXY)ACETIC ACID,,small molecule,,,,,
O(C1=C([H])C([H])=C(C2=C([H])C3=C(C(=C(C(O[H])=C3[H])[H])[H])O2)C([H])=C1[H])[H],DB07032,,2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL,,small molecule,,,,,
O(N=C1C2=C(C(=C(C(OC(C(O[H])=O)([H])[H])=C2[H])[H])[H])C2=C1C(=C(OC(C(O[H])=O)([H])[H])C(=C2[H])[H])[H])[H],DB07034,,"2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID",,small molecule,,,,,
C(C(C1=C(C([H])([H])[H])N([H])C(=O)C(I)=C1OC1=C([H])C(C(=C(C#N)[H])[H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB07035,,"(2E)-3-{3-[(5-ETHYL-3-IODO-6-METHYL-2-OXO-1,2-DIHYDROPYRIDIN-4-YL)OXY]PHENYL}ACRYLONITRILE",,small molecule,,,,,
O(C(=O)C1=C(N(C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])[H])C([H])=C([H])C([H])=C1[H])[H],DB07038,,2-(cyclohexylamino)benzoic acid,,small molecule,,,,,
N(C(=O)C1=C([H])C2=C(OC3=C(C2=O)C([H])=C(F)C([H])=C3[H])N=C1N([H])[H])([H])[H],DB07040,,"2-amino-7-fluoro-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxamide",,small molecule,,,,,
C(C(C([H])([H])[H])(C(N(C(=O)C1=C([H])C([H])=C(OC2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])[H])([H])[H])C1=NC2=NC(N([H])[H])=NC(N([H])[H])=C2C([H])=C1[H])([H])([H])[H],DB07041,,"N-[2-(2,4-diaminopyrido[2,3-d]pyrimidin-7-yl)-2-methylpropyl]-4-phenoxybenzamide",,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C1=NC(N(C(C(C2=C([H])N([H])C([H])=N2)([H])[H])([H])[H])[H])=C2C(=C(C(N([H])[H])=O)C(N([H])[H])=NC2=N1)[H])([H])([H])[H],DB07042,,"7-amino-2-tert-butyl-4-{[2-(1H-imidazol-4-yl)ethyl]amino}pyrido[2,3-d]pyrimidine-6-carboxamide",,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C1=NC(N2C([H])([H])C([H])([H])N(C3=NC([H])=C([H])C([H])=N3)C([H])([H])C2([H])[H])=C2C(=C(C(N([H])[H])=O)C(N([H])[H])=NC2=N1)[H])([H])([H])[H],DB07043,,"7-amino-2-tert-butyl-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrido[2,3-d]pyrimidine-6-carboxamide",,small molecule,,,,,
O(C1=C(Br)C(O[H])=C(C(=NN(C(=O)C2=C([H])C(Br)=C([H])C([H])=C2[H])[H])[H])C([H])=C1Br)[H],DB07044,,"3-bromo-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide",,small molecule,,,,,
O(C(=O)C1=C(O[H])C([H])=C([H])C(C2=C(Cl)C([H])=C(Cl)C([H])=C2[H])=C1[H])[H],DB07047,,"2',4'-DICHLORO-4-HYDROXY-1,1'-BIPHENYL-3-CARBOXYLIC ACID",,small molecule,,,,,
N(S(=O)(=O)C1=NN=C(N(S(=O)(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])[H])S1)([H])[H],DB07050,,"5-[(phenylsulfonyl)amino]-1,3,4-thiadiazole-2-sulfonamide",,small molecule,,,,,
C(C(OC(=O)C1=C(C([H])([H])[H])N(C2=C([H])C([H])=C([H])C([H])=C2[H])[N+]([H])=C1C([H])([H])[H])([H])[H])([H])([H])[H],DB07051,,"3,5-DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER",,small molecule,,,,,
C(C(C(C1=C(OC(C(C(OC2=C([H])C3=C(N(C(C(O[H])=O)([H])[H])C(=C3[H])[H])C([H])=C2[H])([H])[H])([H])[H])([H])[H])C([H])=C([H])C2=C1ON=C2C(F)(F)F)([H])[H])([H])[H])([H])([H])[H],DB07053,,2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID,,small molecule,,,,,
O=C1N(C(C(C2=NN=NN2[H])([H])[H])([H])[H])C(=O)C2=C1C(=C(C(=C2[H])[H])[H])[H],DB07055,,"2-[2-(1H-tetrazol-5-yl)ethyl]-1H-isoindole-1,3(2H)-dione",,small molecule,,,,,
C(C(N(C(C([H])([H])[H])([H])[H])C(=O)C(C1=C([H])C([H])=C([H])C(N(S(=O)(=O)C2=C([H])C([H])=C([H])C(Cl)=C2C([H])([H])[H])[H])=N1)([H])[H])([H])[H])([H])([H])[H],DB07056,,"2-(6-{[(3-chloro-2-methylphenyl)sulfonyl]amino}pyridin-2-yl)-N,N-diethylacetamide",,small molecule,,,,,
C(OC1=C([H])C([H])=C(N2C([H])=NC3=C2C(=C(C(=C3[H])[H])C2=NN([H])C(=S)O2)[H])C([H])=C1[H])([H])([H])[H],DB07058,,"5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione",,small molecule,,,,,
C(C(C1=NC(N([H])[H])=NC(N([H])[H])=C1C1=C([H])C2=C(OC(C([H])([H])[H])(C([H])([H])[H])C(=O)N2C(C(N(C(C([H])([H])[H])=O)[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB07059,,"N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOXAZIN-4-YL]ETHYL}ACETAMIDE",,small molecule,,,,,
C(C(C([H])([H])[H])(C(C(N1N2C(=C(C([H])=C2C(O[H])=C(C2=NC3=C(C(=C(N(S(C([H])([H])[H])(=O)=O)[H])C(=C3[H])[H])[H])S(=O)(=O)N2[H])C1=O)[H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB07062,,"N-{3-[4-hydroxy-1-(3-methylbutyl)-2-oxo-1,2-dihydropyrrolo[1,2-b]pyridazin-3-yl]-1,1-dioxido-2H-1,2,4-benzothiadiazin-7-yl}methanesulfonamide",,small molecule,,,,,
O(C(=O)C(N1C([H])=C(C(C2=NC3=C(F)C(F)=C(C(F)=C3S2)[H])([H])[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])[H],DB07063,,"{3-[(4,5,7-TRIFLUORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-1H-INDOL-1-YL}ACETIC ACID",,small molecule,,,,,
ClC1=C(Cl)C(C2=NC3=C(SC#N)C(=NN3C(N(C(C3=C([H])C([H])=NC([H])=C3[H])([H])[H])[H])=C2[H])[H])=C([H])C([H])=C1[H],DB07065,,"5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine",,small molecule,,,,,
C(C(OC(=O)C(C(C(N(C(=O)OC(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])[H])([H])[H])([H])[H])(C(C1=C([H])C([H])=C(N(S(O[H])(=O)=O)[H])C([H])=C1[H])([H])[H])C(=O)OC(C([H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07068,,"(4-{4-[(TERT-BUTOXYCARBONYL)AMINO]-2,2-BIS(ETHOXYCARBONYL)BUTYL}PHENYL)SULFAMIC ACID",,small molecule,,,,,
O(C(=O)C(N(C(=O)C1=C([H])C(O[H])=C([H])C([H])=C1[H])[H])([H])[H])[H],DB07069,,3-Hydroxyhippuric acid,,small molecule,,,,,
C(C1(C([H])([H])[H])C([H])([H])C2=C(SC(=N2)N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])C(=O)C1([H])[H])([H])([H])[H],DB07073,,"5,5-dimethyl-2-morpholin-4-yl-5,6-dihydro-1,3-benzothiazol-7(4H)-one",,small molecule,,,,,
C(OC(=O)C1=C([H])C2=C(C(=C(C([H])=C2C(N(C(=O)C2=C(C([H])([H])[H])C(O[H])=C([H])C([H])=C2[H])[H])=C1[H])C(N([H])[H])=N[H])[H])[H])([H])([H])[H],DB07074,,6-CARBAMIMIDOYL-4-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-NAPHTHALENE-2-CARBOXYLIC ACID METHYL ESTER,,small molecule,,,,,
N(C(C1(C([H])([H])C([H])([H])N(C(C2=C([H])C3=C(N(C(=C3[H])C3=NN([H])C4=C3C(=C(C(=C4[H])C#N)[H])[H])[H])C([H])=C2[H])([H])[H])C([H])([H])C1([H])[H])[H])([H])[H])([H])[H],DB07075,,3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE,,small molecule,,,,,
N(C(=N[H])C1=C([H])C([H])=C2C(=C(C(=C([H])C2=C1[H])[H])C(=O)N(C1=C([H])C(OC2(C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])=C([H])C([H])=C1[H])[H])[H])([H])[H],DB07076,,6-[(Z)-AMINO(IMINO)METHYL]-N-[3-(CYCLOPENTYLOXY)PHENYL]-2-NAPHTHAMIDE,,small molecule,,,,,
C(OC1=C(O[H])C([H])=C([H])C(C2=C([H])C3=C(C(=C(C4=C([H])C([H])=C([H])N4[H])[H])C(=O)N3[H])C([H])=C2[H])=C1[H])([H])([H])[H],DB07078,,"(3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE",,small molecule,,,,,
C(C#CC(OC1=C([H])C([H])=C(S(=O)(=O)C(C(C(S[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB07079,,3-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}propane-1-thiol,,small molecule,,,,,
O(C(C1=C([H])C([H])=C(N(C(C(F)(F)F)([H])[H])S(=O)(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])(C(F)(F)F)C(F)(F)F)[H],DB07080,,"N-(2,2,2-TRIFLUOROETHYL)-N-{4-[2,2,2-TRIFLUORO-1-HYDROXY-1-(TRIFLUOROMETHYL)ETHYL]PHENYL}BENZENESULFONAMIDE",,small molecule,,,,,
O(C(C1=C([H])C([H])=C(N(C(C(F)(F)F)([H])[H])[H])C([H])=C1[H])(C(F)(F)F)C(F)(F)F)[H],DB07082,,"1,1,1,3,3,3-HEXAFLUORO-2-{4-[(2,2,2-TRIFLUOROETHYL)AMINO]PHENYL}PROPAN-2-OL",,small molecule,,,,,
C(C(=O)N(C1=C([H])C2=C(OC(C(OC(C(OC3=C(OC(C(OC(C(O2)([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C([H])C([H])=C3[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])[H])([H])([H])[H],DB07084,,"N-(6,7,9,10,17,18,20,21-octahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecin-2-yl)acetamide",,small molecule,,,,,
C(C(=O)C1=C([H])C(F)=C(Cl)C([H])=C1N(C(C(=O)N(C1=C(C(O[H])=O)C([H])=C([H])C([H])=C1[H])[H])([H])[H])[H])([H])([H])[H],DB07085,,2-{[N-(2-ACETYL-5-CHLORO-4-FLUOROPHENYL)GLYCYL]AMINO}BENZOIC ACID,,small molecule,,,,,
C(C(C(OC1=C([H])C([H])=C(C2=C([H])SC(C3=C(Cl)C([H])=C([H])C([H])=C3[H])=C2C(C(=O)N(C(N([H])[H])=N[H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB07089,,N-[amino(imino)methyl]-2-[2-(2-chlorophenyl)-4-(4-propoxyphenyl)-3-thienyl]acetamide,,small molecule,,,,,
O(C(=O)C(N1C([H])=C([H])C(=O)N(C(C2=NC3=C(C(=C(C(Cl)=C3[H])[H])[H])S2)([H])[H])C1=O)([H])[H])[H],DB07093,,"{3-[(5-CHLORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL}ACETIC ACID",,small molecule,,,,,
N(C(C1=C([H])C([H])=C(C2=C([H])C([H])=C([H])S2)S1)([H])[H])([H])[H],DB07094,,"1-(2,2'-bithiophen-5-yl)methanamine",,small molecule,,,,,
N(C1=C([H])C([H])=C2C(=O)N(C(=O)C3=C2C1=C(C(=C3[H])[H])[H])[H])([H])[H],DB07096,,"6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE",,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C1=C([H])C([H])=C(C(=O)N(N=C(C2=C(O[H])C(Br)=C(O[H])C(Br)=C2[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB07097,,"4-tert-butyl-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide",,small molecule,,,,,
O(C1=C(Br)C(O[H])=C(C(=NN(C(=O)C2=C([H])C([H])=C(Br)C([H])=C2[H])[H])[H])C([H])=C1Br)[H],DB07098,,"4-bromo-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide",,small molecule,,,,,
N(C(C(=O)N(C1=C([H])C([H])=C(OC(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])C([H])=C1[H])[H])([H])[H])([H])[H],DB07099,,N-[4-(benzyloxy)phenyl]glycinamide,,small molecule,,,,,
O(C1=C([H])C(O[H])=C(Cl)C([H])=C1C1=C(N2C([H])([H])C([H])([H])N([H])C([H])([H])C2([H])[H])C([H])=NN1[H])[H],DB07100,,"4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL",,small molecule,,,,,
N(C(C(C(C(=O)N(C1=C([H])C([H])=C(OC(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])C([H])=C1[H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB07104,,4-amino-N-[4-(benzyloxy)phenyl]butanamide,,small molecule,,,,,
C(N(C([H])([H])[H])C(C(C(C(SC(N([H])[H])=N[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07106,,4-(DIMETHYLAMINO)BUTYL IMIDOTHIOCARBAMATE,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C(C2=C([H])C([H])=C(F)C([H])=C2[H])C([H])=C1[H])[H],DB07108,,"4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID",,small molecule,,,,,
C(OC1=C(O[H])C([H])=C(C(=C(C(O[H])=O)[H])[H])C([H])=C1[H])([H])([H])[H],DB07109,,(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoic acid,,small molecule,,,,,
FC1=C([H])C([H])=C(C(C2(C([H])([H])C([H])([H])N([H])C([H])([H])C2([H])[H])[H])([H])[H])C([H])=C1[H],DB07110,,4-(4-FLUOROBENZYL)PIPERIDINE,,small molecule,,,,,
O(C(=O)C(N(C(=O)C1=NC([H])=C2C(I)=C(C(=C([H])C2=C1O[H])[H])[H])[H])([H])[H])[H],DB07112,,N-[(4-HYDROXY-8-IODOISOQUINOLIN-3-YL)CARBONYL]GLYCINE,,small molecule,,,,,
C(S(=O)(=O)N(C1=C([H])C([H])=C(C(O[H])=O)C([H])=C1[H])[H])([H])([H])[H],DB07114,,4-[(METHYLSULFONYL)AMINO]BENZOIC ACID,,small molecule,,,,,
C(N(C(C1=C([H])C([H])=C(Cl)C([H])=C1[H])([H])[H])S(=O)(=O)C1=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C1[H])([H])([H])[H],DB07115,,"N-(4-chlorobenzyl)-N-methylbenzene-1,4-disulfonamide",,small molecule,,,,,
O=C1N([H])C(=O)C(N2C([H])([H])C([H])([H])N(C3=NC([H])=C([H])C([H])=N3)C([H])([H])C2([H])[H])(C2=C([H])C([H])=C(OC3=C([H])C([H])=C([H])C([H])=C3[H])C([H])=C2[H])C(=O)N1[H],DB07117,,"5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE",,small molecule,,,,,
C(C1=C([H])C(=O)OC2=C1C(=C(C(O[H])=C2[H])[H])[H])([H])([H])[H],DB07118,90-33-5,Hymecromone,,small molecule,,,,,
O(C1=C([H])C([H])=C(C2=C([H])C([H])=C3C(C(=C(C(O[H])=C3Cl)[H])[H])=C2[H])C([H])=C1[H])[H],DB07119,,1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL,,small molecule,,,,,
N(C(=N[H])N(N(C(=O)N(C1=C([H])C([H])=C([H])C([H])=C1[H])C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H])([H])[H],DB07120,,"N4-(N,N-DIPHENYLCARBAMOYL)-AMINOGUANIDINE",,small molecule,,,,,
N(C(=N[H])N(C1=C([H])C([H])=C(C(C(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])C([H])=C1[H])[H])([H])[H],DB07122,,1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine,,small molecule,,,,,
C(C1=C([H])C([H])=C(C(=O)N2C([H])([H])C([H])([H])C(C(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])([H])C([H])([H])C2([H])[H])C([H])=C1[H])([H])([H])[H],DB07123,,N-(4-METHYLBENZOYL)-4-BENZYLPIPERIDINE,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(N(C2=NC(OC(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])([H])[H])=C3N=C(N([H])C3=N2)[H])[H])C([H])=C1[H])([H])[H],DB07126,,O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE,,small molecule,,,,,
C(C1=NC(C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])(C(C2=C([H])C([H])=C(N(S(O[H])(=O)=O)[H])C([H])=C2[H])([H])[H])C2=NOC(C([H])([H])[H])=N2)=NO1)([H])([H])[H],DB07127,,"{4-[2,2-BIS(5-METHYL-1,2,4-OXADIAZOL-3-YL)-3-PHENYLPROPYL]PHENYL}SULFAMIC ACID",,small molecule,,,,,
C(C(C(C(N(C1=C([H])C(C([H])([H])[H])=NC2=NC(N(C3=C(C([H])([H])[H])C([H])=C([H])C(Cl)=C3[H])[H])=NN12)[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07128,,"N7-BUTYL-N2-(5-CHLORO-2-METHYLPHENYL)-5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE-2,7-DIAMINE",,small molecule,,,,,
O(C(=O)C(OC1=C(C(O[H])=O)SC(C2=C([H])C([H])=C([H])C([H])=C2[H])=C1Br)([H])[H])[H],DB07130,,4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID,,small molecule,,,,,
ClC1=C(C2=C([H])C([H])=C([H])C([H])=C2[H])SC([H])=C1N1C([H])([H])C(=O)N([H])S1(=O)=O,DB07134,,"5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE",,small molecule,,,,,
FC1=C([H])C(F)=C(SC2=NN3C(=NC(=O)C(C4=C(Cl)C([H])=C([H])C([H])=C4Cl)=C3C([H])=C2[H])[H])C([H])=C1[H],"DB07138
DB12790",209410-46-8,Neflamapimod,,small molecule,,,,,
O(C(=O)C(C(C1=C([H])C([H])=C(C2=C([H])C([N+]([O-])=O)=C([H])C([H])=C2[H])S1)([H])[H])([H])[H])[H],DB07139,,3-[5-(3-nitrophenyl)thiophen-2-yl]propanoic acid,,small molecule,,,,,
C(C(N1C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H])([H])[H])(N(C1=C2C(OC(=C2C2=C([H])C([H])=C([H])C([H])=C2[H])C2=C([H])C([H])=C([H])C([H])=C2[H])=NC([H])=C1[H])[H])([H])[H],DB07146,,"2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE",,small molecule,,,,,
O(N=C(C1=C([H])C([H])=C(C2=C([H])C([H])=C(O[H])C([H])=C2[H])C2=C(C(=C(C([H])=C12)[H])[H])[H])[H])[H],DB07150,,4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME,,small molecule,,,,,
C(C1=C(O[H])C([H])=C([H])C(C2=NC(=O)N=C(C3=C([H])C([H])=C([H])C([H])=C3[H])C2([H])[H])=C1[H])([H])([H])[H],DB07151,,4-(4-hydroxy-3-methylphenyl)-6-phenylpyrimidin-2(5H)-one,,small molecule,,,,,
C(C(=O)N(C1=NC(C2=NC(C([H])([H])[H])=C(F)C([H])=C2[H])=C(C2=C([H])C3=NC(=C(N=C3C([H])=C2[H])[H])[H])N1[H])[H])([H])([H])[H],DB07152,,N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide,,small molecule,,,,,
C(OC1=C([H])C(C(C([H])([H])[H])(C([H])([H])[H])C#CC2=C(N([H])[H])N=C(N([H])[H])N=C2C([H])([H])[H])=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])([H])([H])[H],DB07153,,"6-methyl-5-[3-methyl-3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine",,small molecule,,,,,
BrC1=C([H])C2=C(C(=O)N(C(=O)C2=C(N(C2=C([H])C([H])=C(C(N3C([H])([H])C([H])([H])C([H])([H])C3([H])[H])([H])[H])C([H])=C2[H])[H])[H])[H])C([H])=C1[H],DB07156,,"(4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione",,small molecule,,,,,
C(C(N1C(=O)C2=C(N(N=C2C([H])([H])[H])[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])([H])[H],DB07158,,"5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE",,small molecule,,,,,
C(OC1=C([H])C(N(C2=NC(N(C3=NC4=C(OC(C([H])([H])[H])(C([H])([H])[H])C(=O)N4[H])C([H])=C3[H])[H])=C(F)C([H])=N2)[H])=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])([H])([H])[H],DB07159,,"6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",,small molecule,,,,,
N(C1=NN([H])C2=C1C(=C(C(=C2[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H],DB07161,,5-phenyl-1H-indazol-3-amine,,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])N(S(=O)(=O)C1=C([H])C([H])=C(C2=C([H])C3=C(N(N=C3N([H])[H])[H])C([H])=C2[H])C([H])=C1[H])[H])([H])([H])[H],DB07162,,4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide,,small molecule,,,,,
N(C(C(N(C1=C2C3C(=C(C(=C2F)[H])[H])N(C(=O)C=3C(C2=C([H])C([H])=C([H])N2[H])=C1[H])[H])[H])([H])[H])([H])[H])([H])[H],DB07163,,5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE,,small molecule,,,,,
C1(C([H])([H])C1(N(C1=NC(C2=C3C(=C(C(=NN3N=C2[H])[H])[H])[H])=C([H])C([H])=N1)[H])[H])([H])[H],DB07164,,"N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine",,small molecule,,,,,
C(C1(C([H])([H])C([H])([H])N(C2=C(N(C(=O)C3=C([H])C([H])=C(C#N)O3)[H])C([H])=C(C(O[H])([H])[H])C([H])=C2[H])C([H])([H])C1([H])[H])[H])([H])([H])[H],DB07167,,5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE,,small molecule,,,,,
C(N(C1=NC(N(C2=C([H])C([H])=C(C(C#N)([H])[H])C([H])=C2[H])[H])=NC(N(C2=NN([H])C(C3(C([H])([H])C3([H])[H])[H])=C2[H])[H])=C1[H])[H])([H])([H])[H],DB07168,,[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrile,,small molecule,,,,,
O(C(C(C(C(C(C(C(O[H])([H])[H])([H])[H])(C(C(C(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB07171,,"5-(2-hydroxyethyl)nonane-1,9-diol",,small molecule,,,,,
C(C(C1=NC(N([H])[H])=NC(N([H])[H])=C1C1=C([H])C2=C(OC(C([H])([H])[H])(C([H])([H])[H])C(=O)N2C(C(C(OC([H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB07174,,"6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-4-(3-METHOXYPROPYL)-2,2-DIMETHYL-2H-1,4-BENZOXAZIN-3(4H)-ONE",,small molecule,,,,,
C(C1=C(N(S(C([H])([H])[H])(=O)=O)[H])C([H])=C(N(C2=NC([H])=NC(C3=C([H])C([H])=C([H])C([H])=C3[H])=C2[H])[H])C([H])=C1[H])([H])([H])[H],DB07175,,N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide,,small molecule,,,,,
N(C1=C2C(=C(C(=C(S(O[H])(=O)=O)C2=C([H])C([H])=C1[H])[H])[H])[H])([H])[H],DB07176,,5-aminonaphthalene-1-sulfonic acid,,small molecule,,,,,
C(C(C(C(C(C(=O)C(=C(C1(C(O[H])([H])C([H])([H])C(=O)C1(C(C(=C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07177,,"(5E,13E)-11-HYDROXY-9,15-DIOXOPROSTA-5,13-DIEN-1-OIC ACID",,small molecule,,,,,
C(C(C(C(C(C1=C([H])C(O[H])=C(OC2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07178,,5-PENTYL-2-PHENOXYPHENOL,,small molecule,,,,,
C(C1=C(C2=NC3=C(Br)C(=NN3C(N(C(C3=C([H])[N+]([O-])=C([H])C([H])=C3[H])([H])[H])[H])=C2[H])[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB07179,,"3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide",,small molecule,,,,,
C(N(C(=O)C1=C(C([H])([H])[H])N([H])C(C(=C2C(=O)N([H])C3=C2C(=C(Cl)C(=C3[H])[H])[H])[H])=C1C([H])([H])[H])[H])([H])([H])[H],DB07180,,"5-[(Z)-(5-Chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N,2,4-trimethyl-1H-pyrrole-3-carboxamide",,small molecule,,,,,
O=C(N(C1=C([H])C([H])=C(OC2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])[H])C1=C(N(C(C2=C([H])C([H])=NC([H])=C2[H])([H])[H])[H])N=C([H])C([H])=C1[H],DB07183,,N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide,,small molecule,,,,,
C(C(OC(N1C(=O)N([H])C(=O)C(C(C([H])([H])[H])(C([H])([H])[H])[H])=C1SC1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB07184,,"6-(cyclohexylsulfanyl)-1-(ethoxymethyl)-5-(1-methylethyl)pyrimidine-2,4(1H,3H)-dione",,small molecule,,,,,
O(C(=O)C1=C(N(C(=O)C(OC2=C([H])C([H])=C(Cl)C([H])=C2[H])([H])[H])[H])C([H])=C([H])C([H])=C1[H])[H],DB07185,,2-{[(4-CHLOROPHENOXY)ACETYL]AMINO}BENZOIC ACID,,small molecule,,,,,
C(N1C([H])([H])C([H])([H])N(C2=C([H])C([H])=C(C(=O)N(C3=NN([H])C4=C(N(C([H])=C34)C(=O)C(C3=C([H])C([H])=C([H])S3)([H])[H])[H])[H])C([H])=C2[H])C([H])([H])C1([H])[H])([H])([H])[H],DB07186,,"4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE",,small molecule,,,,,
C(C1=C(S(=O)(=O)C2=NN([H])C(=O)C([H])=C2[H])OC2=C1C(=C(Cl)C(=C2[H])[H])[H])([H])([H])[H],DB07187,,6-[(5-CHLORO-3-METHYL-1-BENZOFURAN-2-YL)SULFONYL]PYRIDAZIN-3(2H)-ONE,,small molecule,,,,,
C(N(C(C1=C(C2=C([H])C([H])=C([H])S2)C([H])=C([H])C([H])=C1[H])([H])[H])[H])([H])([H])[H],DB07196,,N-methyl-1-(2-thiophen-2-ylphenyl)methanamine,,small molecule,,,,,
O(C(=O)C(OC1=C(C(O[H])=O)SC(C2=C([H])C([H])=C(O[H])C([H])=C2[H])=C1Br)([H])[H])[H],DB07197,,4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID,,small molecule,,,,,
O(C1=C([H])C([H])=C(C2=C([H])C3=C(C(O[H])=C(C(C#N)=C3O2)[H])[H])C([H])=C1[H])[H],DB07198,,5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE,,small molecule,,,,,
C(C1=NOC(C2=C(C3=C([H])C([H])=C([H])C([H])=C3[H])C3=C(C(=C(C(Cl)=C3[H])[H])[H])N([H])C2=O)=C1[H])([H])([H])[H],DB07202,,6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE,,small molecule,,,,,
ClC1=C([H])C(N(C2=NC(OC(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])([H])[H])=C3N(C(=NC3=N2)[H])[H])[H])=C([H])C([H])=C1[H],DB07203,,6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE,,small molecule,,,,,
N(C1=NC(C(C(C2=C([H])C3=C(C(=C(N3[H])[H])[H])C([H])=C2[H])([H])[H])([H])[H])=C([H])C([H])=C1[H])([H])[H],DB07206,,6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE,,small molecule,,,,,
N(C(=N[H])C1=C([H])C2=C(N(C(=N2)C2=NN([H])C(C3=C([H])C([H])=C([H])C([H])=C3[H])=C2O[H])[H])C([H])=C1[H])([H])[H],DB07207,,2-(4-HYDROXY-5-PHENYL-1H-PYRAZOL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE,,small molecule,,,,,
BrC1=C2N=C(C(=C(N(C(C3=C([H])C([H])=NC([H])=C3[H])([H])[H])[H])N2N=C1[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H],DB07210,,"3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine",,small molecule,,,,,
C(C1=C(C(=O)N(C2=C([H])C([H])=C([H])C3=C(C(=C(C([H])=C23)C(N([H])[H])=N[H])[H])[H])[H])C([H])=C([H])C([H])=C1O[H])([H])([H])[H],DB07212,,N-(7-CARBAMIMIDOYL-NAPHTHALEN-1-YL)-3-HYDROXY-2-METHYL-BENZAMIDE,,small molecule,,,,,
O(C(C1=NN([H])N=C1C1=C([H])C2=C(C(=NN2[H])C2=C([H])C3=C(C(=C(C(C(N4C([H])([H])C([H])([H])C([H])([H])C([H])([H])C4([H])[H])([H])[H])=C3[H])[H])[H])N2[H])C([H])=C1[H])([H])[H])[H],DB07213,,"(5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL",,small molecule,,,,,
C(C1=C(C(=O)N(C(C2=C([H])C([H])=C(OC(C([H])([H])[H])(C([H])([H])[H])C(O[H])=O)C([H])=C2[H])([H])[H])[H])SC(C2=C([H])C([H])=C(C(F)(F)F)C([H])=C2[H])=N1)([H])([H])[H],DB07215,,"2-METHYL-2-(4-{[({4-METHYL-2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL}CARBONYL)AMINO]METHYL}PHENOXY)PROPANOIC ACID",,small molecule,,,,,
FC1=C(C(=O)N(C2=C(C#N)C3=C(C(C(C(C3([H])[H])([H])[H])([H])[H])([H])[H])S2)[H])C([H])=C([H])C([H])=C1[H],DB07217,,"N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide",,small molecule,,,,,
C(N1N=C(C([H])([H])[H])C2=C1N(O[H])C1=C(C2=O)C([H])=C(Cl)C([H])=C1[H])([H])([H])[H],DB07218,,"6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE",,small molecule,,,,,
O=C(C(C1=C([H])C([H])=C(N2C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])C([H])=C1[H])([H])[H])N(C1=NN([H])C2=C1C(=C(C(=C2[H])[H])N1C([H])([H])C([H])([H])C([H])([H])S1(=O)=O)[H])[H],DB07220,,"N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C([P+](C([H])([H])[H])(C([H])([H])[H])C(C(P(O[H])(O[H])=O)(P(O[H])(O[H])=O)[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07221,,"(2,2-DIPHOSPHONOETHYL)(DODECYL)DIMETHYLPHOSPHONIUM",,small molecule,,,,,
ClC1=C(C2=C3C(=O)N(C(=O)C3=C3C(N(C4=C3C([H])=C(N(C(=O)[H])[H])C([H])=C4[H])[H])=C2[H])[H])C([H])=C([H])C([H])=C1[H],DB07226,,"N-[4-(2-CHLOROPHENYL)-1,3-DIOXO-1,2,3,6-TETRAHYDROPYRROLO[3,4-C]CARBAZOL-9-YL]FORMAMIDE",,small molecule,,,,,
ClC1=C([H])C(N2C([H])([H])C([H])([H])N(C(C3=C([H])N=C([H])N3C(C3=C([H])C([H])=C(C#N)C([H])=C3[H])([H])[H])([H])[H])C([H])([H])C2=O)=C([H])C([H])=C1[H],DB07227,,4-[(5-{[4-(3-CHLOROPHENYL)-3-OXOPIPERAZIN-1-YL]METHYL}-1H-IMIDAZOL-1-YL)METHYL]BENZONITRILE,,small molecule,,,,,
C(OC1=C([H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])=C(O[H])C(C2=C([H])C3=C(C(=C(C(=C3[H])C(N([H])[H])=N[H])[H])[H])N2[H])=C1[H])([H])([H])[H],DB07229,,"3-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-5-METHOXY-1,1'-BIPHENYL-2-OLATE",,small molecule,,,,,
O(C1=C([H])C([H])=C(C2=C(Br)C3=C(C(=C(O[H])C(=C3[H])[H])[H])C2=O)C([H])=C1[H])[H],DB07230,,3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE,,small molecule,,,,,
O(C1=C([H])C2=C(C(=NO2)C2=C([H])C3=C(C(=C(O[H])C([H])=C3C([H])=C2[H])[H])[H])C([H])=C1[H])[H],DB07236,,3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL,,small molecule,,,,,
C(N(C(=O)C1=C(C2=C([H])C([H])=C(F)C([H])=C2[H])OC2=C(C(N(C(C(O[H])([H])[H])([H])[H])S(C([H])([H])[H])(=O)=O)=C(C([H])=C12)C1(C([H])([H])C1([H])[H])[H])[H])[H])([H])([H])[H],"DB07238
DB12516",691852-58-1,Nesbuvir,,small molecule,,,,,
O(C(=O)C(C(ON=C1C2=C(C(=C(C(=C2[H])[H])[H])[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])[H],DB07240,,3-[(9H-fluoren-9-ylideneamino)oxy]propanoic acid,,small molecule,,,,,
O(C(=O)C1=C2C(C3=C(C4=C2C2=C(C(=C(C(=C2[H])[H])[H])[H])N4[H])N([H])C2=C3C(=C(C(=C2[H])[H])[H])[H])=C(O[H])N1[H])[H],DB07241,,"7-carboxy-5-hydroxy-12,13-dihydro-6H-indolo[2,3-a]pyrrolo[3,4-c]carbazole",,small molecule,,,,,
C(C(C1=NC(N([H])[H])=NC(N([H])[H])=C1C1=C([H])C([H])=C(N(C(C2=C([H])C(F)=C([H])C(F)=C2[H])([H])[H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB07244,,"5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE",,small molecule,,,,,
C(OC1=C([H])C(C2=C([H])C(C(C(C3=NC(N([H])[H])=C([H])C([H])=C3[H])([H])[H])([H])[H])=C([H])C([H])=C2[H])=C([H])C([H])=C1[H])([H])([H])[H],DB07245,,6-[2-(3'-METHOXYBIPHENYL-3-YL)ETHYL]PYRIDIN-2-AMINE,,small molecule,,,,,
N(C(=O)N(C(C1=C([H])C(C2=C(O[H])C(C3=C([H])C4=C(C(=C(N=C4[H])[H])[H])N3[H])=C([H])C([H])=C2[H])=C([H])C([H])=C1[H])([H])[H])[H])([H])[H],DB07247,,"[2'-HYDROXY-3'-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-BIPHENYL-3-YLMETHYL]-UREA",,small molecule,,,,,
C(OC1=C([H])C(N(C2=NC3=C(C(=C(N3C3=NC([H])=C([H])C([H])=C3[H])[H])[H])C([H])=N2)[H])=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])([H])([H])[H],DB07248,,"7-PYRIDIN-2-YL-N-(3,4,5-TRIMETHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE",,small molecule,,,,,
C(OC1=C(OC(C(C(N2C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C2N=C(N=C(N(C3=C(Cl)C([H])=C([H])C4=C3OC(O4)([H])[H])[H])C2=C1[H])[H])([H])([H])[H],DB07249,,"N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine",,small molecule,,,,,
C(OC1=C([H])C(N(C2=NC([H])=C([H])C(N(C3=C(Cl)C([H])=C([H])C4=C3OC(O4)([H])[H])[H])=N2)[H])=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])([H])([H])[H],DB07250,,"N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3,4,5- TRIMETHOXYPHENYL)PYRIMIDINE-2,4-DIAMINE",,small molecule,,,,,
C(OC1=C([H])C(N(C2=NC([H])=NC(N(C3=C([H])C(Cl)=C(OC([H])([H])[H])C([H])=C3[H])[H])=N2)[H])=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])([H])([H])[H],DB07251,,"N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE",,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C([H])C(N(C2=NC([H])=C([H])C(N(C3=C(Cl)C([H])=C([H])C4=C3OC(O4)([H])[H])[H])=N2)[H])=C1[H])([H])[H],DB07252,,"3-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide",,small molecule,,,,,
C(S(=O)(=O)C1=C([H])C([H])=C([H])C(N(C2=NC([H])=C([H])C(N(C3=C(Cl)C([H])=C([H])C4=C3OC(O4)([H])[H])[H])=N2)[H])=C1[H])([H])([H])[H],DB07253,,"N'-(5-chloro-1,3-benzodioxol-4-yl)-N-(3-methylsulfonylphenyl)pyrimidine-2,4-diamine",,small molecule,,,,,
C(S(=O)(=O)N(C1=C([H])C([H])=C([H])C(N(C2=NC([H])=C([H])C(N(C3=C(Cl)C([H])=C([H])C4=C3OC(O4)([H])[H])[H])=N2)[H])=C1[H])[H])([H])([H])[H],DB07254,,"N-[3-[[4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL]AMINO]PHENYL]METHANESULFONAMIDE",,small molecule,,,,,
ClC1=C(N(C2=NC(N(C3=C([H])C(N4C([H])([H])C([H])([H])OC([H])([H])C4([H])[H])=C([H])C([H])=C3[H])[H])=NC([H])=C2[H])[H])C2=C(OC(O2)([H])[H])C([H])=C1[H],DB07255,,"N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3-MORPHOLIN-4-YLPHENYL)PYRIMIDINE-2,4-DIAMINE",,small molecule,,,,,
N(C(=O)C1=C([H])C([H])=C([H])C(N(C2=NC([H])=C([H])C(N(C3=C(Cl)C([H])=C([H])C4=C3OC(O4)([H])[H])[H])=N2)[H])=C1[H])([H])[H],DB07256,,"3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDE",,small molecule,,,,,
C(N1C([H])=C(C(C(O[H])([H])[H])([H])[H])C2=C3C(=O)N([H])C(=O)C3=C(C([H])=C12)C1=C(Cl)C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB07257,,"4-(2-chlorophenyl)-8-(2-hydroxyethyl)-6-methylpyrrolo[3,4-e]indole-1,3(2H,6H)-dione",,small molecule,,,,,
N(C(C1=C([H])C([H])=C(C2=C([H])C([H])=C([H])S2)C([H])=C1[H])([H])[H])([H])[H],DB07259,,1-(4-thiophen-2-ylphenyl)methanamine,,small molecule,,,,,
N(C(=N[H])N(C(=N[H])SC(C1=C([H])C(C(F)(F)F)=C([H])C([H])=C1[H])([H])[H])[H])([H])[H],DB07262,,1-{[N-(1-IMINO-GUANIDINO-METHYL)]SULFANYLMETHYL}-3-TRIFLUOROMETHYL-BENZENE,,small molecule,,,,,
O(C(=O)C(C(N1C2=C(C(=C3C(=O)N([H])C(=O)C3=C2C2=C1C(=C(C(O[H])=C2[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H])([H])[H])[H],DB07265,,"3-(9-HYDROXY-1,3-DIOXO-4-PHENYL-2,3-DIHYDROPYRROLO[3,4-C]CARBAZOL-6(1H)-YL)PROPANOIC ACID",,small molecule,,,,,
C(C(N1C(=O)C(C([H])([H])[H])(C([H])([H])[H])C2=C1C(=C1C(=C2[H])N([H])C2=C1C(C(C(C1=C2N([H])N=C1C([H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])([H])[H],DB07266,,"8-ethyl-3,10,10-trimethyl-4,5,6,8,10,12-hexahydropyrazolo[4',3':6,7]cyclohepta[1,2-b]pyrrolo[2,3-f]indol-9(1H)-one",,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C(C2=NC3=C(C(=C(C([H])=C3C(N(C3=C([H])C([H])=NC([H])=C3[H])[H])=N2)[H])[H])[H])=N1)([H])([H])[H],DB07267,,2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine,,small molecule,,,,,
N(C(=O)C1=C(N(C2=NC(N(C3=C([H])C(O[H])=C([H])C([H])=C3[H])[H])=NC([H])=C2[H])[H])C([H])=C([H])C([H])=C1[H])([H])[H],DB07268,,2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE,,small molecule,,,,,
C(OC1=C([H])C2=C(OC(N(S(=O)(=O)C3=C(Cl)C([H])=C([H])C(Cl)=C3[H])[H])=N2)C(C2=C([H])C(N([H])[H])=C([H])C([H])=C2[H])=C1[H])([H])([H])[H],DB07270,,"N-[7-(3-AMINOPHENYL)-5-METHOXY-1,3-BENZOXAZOL-2-YL]-2,5-DICHLOROBENZENESULFONAMIDE",,small molecule,,,,,
C(C(OC1=C(C#N)C(N([H])[H])=C([H])C(N(C(=O)C(C2=C([H])C(OC([H])([H])[H])=C(Br)C([H])=C2OC([H])([H])[H])([H])[H])[H])=N1)([H])[H])([H])([H])[H],DB07272,,"N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE",,small molecule,,,,,
C(OC1=C(OC([H])([H])[H])C([H])=C2C(OC3=C([H])C([H])=C4C(C(=C(C(=C4C(=O)N(C4(C([H])([H])C4([H])[H])[H])[H])[H])[H])[H])=C3[H])=C(C(=NC2=C1[H])[H])[H])([H])([H])[H],DB07274,,"N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide",,small molecule,,,,,
C(C(C([H])([H])[H])(C(C(N1C(=O)C(C2=NS(=O)(=O)C3=C(C(=C(C(=C3[H])[H])[H])[H])N2[H])=C(O[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB07275,,"3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1-(3-methylbutyl)quinolin-2(1H)-one",,small molecule,,,,,
C(C(OC1=C(C#N)C([H])=C([H])C(C(=O)N(C(C2=C(OC([H])([H])[H])C([H])=C([H])C(OC([H])([H])[H])=C2[H])([H])[H])[H])=N1)([H])[H])([H])([H])[H],DB07276,,"5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE",,small molecule,,,,,
C(N(C([H])([H])[H])C1=C([H])C([H])=C(C2=C(N([H])[H])N=C([H])N=C2C#CC2=C([H])N=C(N3C([H])([H])C([H])([H])OC([H])([H])C3([H])[H])C([H])=C2[H])C([H])=C1[H])([H])([H])[H],DB07280,,5-[4-(DIMETHYLAMINO)PHENYL]-6-[(6-MORPHOLIN-4-YLPYRIDIN-3-YL)ETHYNYL]PYRIMIDIN-4-AMINE,,small molecule,,,,,
N(C1=NC([H])=C([H])C([H])=C1N(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H])([H])[H],DB07281,,"N~3~-BENZYLPYRIDINE-2,3-DIAMINE",,small molecule,,,,,
C(OC1=C(C(=NOC(C(C(O[H])=O)([H])[H])([H])[H])[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB07282,,3-({[(1Z)-(2-methoxyphenyl)methylidene]amino}oxy)propanoic acid,,small molecule,,,,,
O(C(=O)C1=C2N(C(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])C3=C(C2=C([H])C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H],DB07283,,"9-benzyl-2,3,4,9-tetrahydro-1H-carbazole-8-carboxylic acid",,small molecule,,,,,
N(C1=NC([H])=C([H])C([H])=C1N(C(C1=C([H])C(C2=C([H])N=C([H])C([H])=C2[H])=C([H])C([H])=C1[H])([H])[H])[H])([H])[H],DB07284,,"N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE",,small molecule,,,,,
O(C1=C(OC2=C(Cl)C([H])=C(Cl)C([H])=C2[H])C([H])=C([H])C(C(C2=NC([H])=C([H])C([H])=C2[H])([H])[H])=C1[H])[H],DB07287,,"2-(2,4-DICHLOROPHENOXY)-5-(PYRIDIN-2-YLMETHYL)PHENOL",,small molecule,,,,,
ClC1=C([H])C([H])=C(N(C(=O)C2=C(N(C(C3=C([H])C([H])=NC([H])=C3[H])([H])[H])[H])C([H])=C([H])C([H])=C2[H])[H])C([H])=C1[H],DB07288,,N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide,,small molecule,,,,,
O(C(=O)C(OC1=C(C(O[H])=O)SC(C2=C([H])C(N(C(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])[H])=C([H])C([H])=C2[H])=C1Br)([H])[H])[H],DB07289,,5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID,,small molecule,,,,,
N(C1=C(C#N)C([H])=NN1C1=C([H])C([H])=C(Cl)C([H])=C1[H])([H])[H],DB07291,,5-amino-1-(4-chlorophenyl)-1H-pyrazole-4-carbonitrile,,small molecule,,,,,
N(C1=NC(C2=C([H])C([H])=C(O[H])C([H])=C2[H])=C([H])S1)([H])[H],DB07292,,"4-(2-amino-1,3-thiazol-4-yl)phenol",,small molecule,,,,,
C(C(=O)C(N(C(=O)OC(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H])([H])[H])([H])([H])[H],DB07293,,benzyl (2-oxopropyl)carbamate,,small molecule,,,,,
O(C(=O)C(=O)N(C1=C([H])C([H])=C([H])C2=C(C(=C(O[H])C([H])=C12)[H])[H])C1=C(C(O[H])=O)C([H])=C([H])C([H])=C1[H])[H],DB07295,,2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID,,small molecule,,,,,
O(C1=C(C2=C([H])C([H])=C(Cl)C([H])=C2[H])C(=O)OC1=C(C1=C([H])C([H])=C([H])C2=C(C(=C(C([H])=C12)[H])[H])[H])[H])[H],DB07296,,(5Z)-3-(4-CHLOROPHENYL)-4-HYDROXY-5-(1-NAPHTHYLMETHYLENE)FURAN-2(5H)-ONE,,small molecule,,,,,
C(C(N1C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H])([H])[H])(N(C1=C2C(OC(=C2C2=C([H])C([H])=C([H])C([H])=C2[H])C2=C([H])C([H])=C([H])C([H])=C2[H])=NC([H])=N1)[H])([H])[H],DB07297,,"5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE",,small molecule,,,,,
O(C(=O)C(OC1=C(C(O[H])=O)SC2=NC(=C(C([H])=C12)[H])[H])([H])[H])[H],DB07298,,"3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID",,small molecule,,,,,
C(OC(C(OC1=C([H])C2=NC(=C3C(N([H])[H])=NC(N4C([H])=C([H])N=C4[H])=C([H])C3=C2C([H])=C1OC([H])([H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB07300,,"2-(1H-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine",,small molecule,,,,,
N1(C2=C(C(=C(C(=C2[H])[H])[H])[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])[H],DB07301,,9H-CARBAZOLE,,small molecule,,,,,
C(OC1=C([H])N=C([H])C(C2=C([H])C(C(N(C3=C(N([H])[H])N=C([H])C([H])=C3[H])[H])([H])[H])=C([H])C([H])=C2[H])=C1[H])([H])([H])[H],DB07303,,"N~3~-[3-(5-METHOXYPYRIDIN-3-YL)BENZYL]PYRIDINE-2,3-DIAMINE",,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C(C2=C(OC(F)(F)F)C([H])=C([H])C([H])=C2[H])O1)[H],DB07304,,5-[2-(TRIFLUOROMETHOXY)PHENYL]-2-FUROIC ACID,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C(C2=C(Cl)C([H])=C([N+]([O-])=O)C([H])=C2[H])O1)[H],DB07305,,5-(2-CHLORO-4-NITROPHENYL)-2-FUROIC ACID,,small molecule,,,,,
C(C(OC(=O)N1C([H])([H])C([H])([H])C(N(C2=NC([H])=C([H])C(Cl)=C2[H])[H])([H])C([H])([H])C1([H])[H])([H])[H])([H])([H])[H],DB07306,,ETHYL 4-[(4-CHLOROPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE,,small molecule,,,,,
C(C1=C(C2=C3C(=C(C(=C([H])C3=C([H])N=N2)C2=C(C([H])([H])[H])C([H])=C([H])C(C(=O)N(C3(C([H])([H])C3([H])[H])[H])[H])=C2[H])[H])[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB07307,,N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C(C(C2=C(Cl)C([H])=C([H])C([H])=C2[H])([H])[H])O1)[H],DB07308,,5-(2-CHLOROBENZYL)-2-FUROIC ACID,,small molecule,,,,,
O(C(=O)C1=C(N(S(=O)(=O)C2=C([H])C([H])=C(Cl)C([H])=C2[H])[H])C([H])=C([H])C(Br)=C1[H])[H],DB07309,,5-BROMO-2-{[(4-CHLOROPHENYL)SULFONYL]AMINO}BENZOIC ACID,,small molecule,,,,,
ClC1=C([H])C2=C(OC(C(C(C(C(OC3=C([H])N=C([H])C(N(C(=O)N2[H])[H])=N3)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H],DB07311,,"18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE",,small molecule,,,,,
ClC1=C([H])C2=C(OC(N(S(=O)(=O)C3=C(Cl)C([H])=C([H])C(Cl)=C3[H])[H])=N2)C([H])=C1[H],DB07312,,"2,5-DICHLORO-N-(5-CHLORO-1,3-BENZOXAZOL-2-YL)BENZENESULFONAMIDE",,small molecule,,,,,
C(C1=C([H])C(C(O[H])=O)=C(N(S(=O)(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])[H])C([H])=C1[H])([H])([H])[H],DB07313,,5-METHYL-2-[(PHENYLSULFONYL)AMINO]BENZOIC ACID,,small molecule,,,,,
C(OC1=C([H])C(OC([H])([H])[H])=C(Cl)C([H])=C1N(C(=O)N(C1=NC([H])=C(C#N)N=C1[H])[H])[H])([H])([H])[H],DB07314,,"1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA",,small molecule,,,,,
O=C1OC([H])([H])C([H])([H])C1=C(N(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H],DB07317,,(3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one,,small molecule,,,,,
N(C1=NC(C2=C([H])C3=C(C(=C(C([H])=C3C([H])=C2Br)[H])[H])[H])=NC(N([H])[H])=N1)([H])[H],DB07319,,"6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE",,small molecule,,,,,
C(OC1=C([H])C2=C(OC(N(S(=O)(=O)C3=C(Cl)C([H])=C([H])C(Cl)=C3[H])[H])=N2)C(C2=C([H])N=C(OC([H])([H])[H])C([H])=C2[H])=C1[H])([H])([H])[H],DB07321,,"2,5-DICHLORO-N-[5-METHOXY-7-(6-METHOXYPYRIDIN-3-YL)-1,3-BENZOXAZOL-2-YL]BENZENESULFONAMIDE",,small molecule,,,,,
O(C(=O)C1=C(N(S(=O)(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])[H])C([H])=C([H])C2=C1C(C(C(C2([H])[H])([H])[H])([H])[H])([H])[H])[H],DB07322,,"2-[(PHENYLSULFONYL)AMINO]-5,6,7,8-TETRAHYDRONAPHTHALENE-1-CARBOXYLIC ACID",,small molecule,,,,,
C(N(C([H])([H])[H])C(C(=C(C1=C(S(=O)(=O)N(C2=C(C(O[H])=O)C3=C(C(C(C(C3([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C2[H])[H])C([H])=C([H])C(F)=C1[H])[H])[H])([H])[H])([H])([H])[H],DB07323,,"2-[({2-[(1Z)-3-(DIMETHYLAMINO)PROP-1-ENYL]-4-FLUOROPHENYL}SULFONYL)AMINO]-5,6,7,8-TETRAHYDRONAPHTHALENE-1-CARBOXYLIC ACID",,small molecule,,,,,
C(C1=C([H])C(C#CC2=C(C(N(N3C([H])=C([H])OC3=O)[H])([H])[H])C([H])=C([H])C([H])=C2[H])=NC(N([H])[H])=N1)([H])([H])[H],DB07324,,"3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE",,small molecule,,,,,
C(C1=C([H])C(C(N(S(=O)(=O)C2=C([H])C(N(C(=C3C([H])([H])C([H])([H])OC3=O)[H])[H])=C([H])C([H])=C2[H])[H])([H])[H])=NC(N([H])[H])=N1)([H])([H])[H],DB07325,,N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE,,small molecule,,,,,
FC(F)(F)C1=C([H])C([H])=C([H])C(N(C2=NOC3=C2C(=C(C(Cl)=C3C(=O)N(C2=C([H])N=C([H])N=C2[H])[H])[H])[H])[H])=C1[H],DB07326,,"6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide",,small molecule,,,,,
O(C(=O)C(C(C(C(N(C(C1=C([H])C([H])=C([N+]([O-])=O)C([H])=C1[H])([H])[H])C(P(O[H])(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB07329,,1-[N-4'-NITROBENZYL-N-4'-CARBOXYBUTYLAMINO]METHYLPHOSPHONIC ACID,,small molecule,,,,,
C(C(C(N1C([H])([H])C([H])([H])C(C2=NC3=C(C(=C(C(C(N([H])[H])=O)=C3N2[H])[H])[H])[H])([H])C([H])([H])C1([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07330,,trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium,,small molecule,,,,,
O(C(=O)C(C1=C([H])C([H])=C([N+]([O-])=O)C([H])=C1[H])([H])[H])[H],DB07331,,2-(4-NITROPHENYL)ACETIC ACID,,small molecule,,,,,
C(OC1=C(N(C2=NC([H])=C(C3=C([H])C(C4=C([H])N=C([H])C([H])=C4[H])=C([H])C([H])=C3[H])O2)[H])C([H])=C(S(=O)(=O)N(C(C2(C([H])([H])C2([H])[H])[H])([H])[H])[H])C([H])=C1[H])([H])([H])[H],DB07333,,"N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE",,small molecule,,,,,
C(C(S(=O)(=O)C1=C([H])C(N(C2=NC([H])=C(C3=C([H])C(C4=NC([H])=C([H])C([H])=C4[H])=C([H])C([H])=C3[H])O2)[H])=C(OC([H])([H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB07334,,"N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE",,small molecule,,,,,
C(C(C([H])([H])[H])(N1N=C(C2=C([H])C([H])=C([H])C(O[H])=C2[H])C2=C(N([H])[H])N=C(N=C12)[H])[H])([H])([H])[H],DB07335,,"3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL",,small molecule,,,,,
C(OC1=C(O[H])C([H])=C([H])C(C2=C([H])C3=C(C(=NN3[H])C3=NC4=C(C(=C(C(=C4[H])[H])[H])[H])N3[H])C([H])=C2[H])=C1[H])([H])([H])[H],DB07336,,4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL,,small molecule,,,,,
N(C1=NC(C(C2=C(Cl)C([H])=C([H])C3=C2C(=C(N3[H])[H])[H])([H])[H])=NC(N(C2=C([H])C([H])=C(C#N)C([H])=C2[H])[H])=N1)([H])[H],DB07337,,"4-[4-AMINO-6-(5-CHLORO-1H-INDOL-4-YLMETHYL)-[1,3,5]TRIAZIN-2-YLAMINO]-BENZONITRILE",,small molecule,,,,,
O(C(=O)C1=C([N+]([O-])=O)C([H])=C([H])C(OC2=C(Cl)C([H])=C(C(F)(F)F)C([H])=C2[H])=C1[H])[H],DB07338,,5-[2-CHLORO-4-(TRIFLUOROMETHYL)PHENOXY]-2-NITROBENZOIC ACID,,small molecule,,,,,
C1(C([H])([H])C([H])([H])C(N(C2=C3N=C(N([H])C3=NC(N(C3=C([H])C([H])=C(N4C([H])([H])C([H])([H])OC([H])([H])C4([H])[H])C([H])=C3[H])[H])=N2)[H])[H])([H])C([H])([H])C1([H])[H])([H])[H],DB07340,,"N~6~-cyclohexyl-N~2~-(4-morpholin-4-ylphenyl)-9H-purine-2,6-diamine",,small molecule,,,,,
N(C1=NC(OC2=C(Cl)C([H])=C([H])C([H])=C2Cl)=NC(N(C2=C([H])C([H])=C(C#N)C([H])=C2[H])[H])=N1)([H])[H],DB07343,,"4-[4-AMINO-6-(2,6-DICHLORO-PHENOXY)-[1,3,5]TRIAZIN-2-YLAMINO]-BENZONITRILE",,small molecule,,,,,
C(C(OC(C(OC(C(OC(C(OC(C(OC(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07344,,"3,6,9,12,15-PENTAOXAHEPTADECAN-1-OL",,small molecule,,,,,
N(C(C(C1=C([H])C(C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])=C(O[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H],DB07345,,4-(2-aminoethyl)-2-cyclohexylphenol,,small molecule,,,,,
C(C(C1=C(O[H])C([H])=C([H])C(C(C(N([H])[H])([H])[H])([H])[H])=C1[H])([H])[H])([H])([H])[H],DB07346,,4-(2-aminoethyl)-2-ethylphenol,,small molecule,,,,,
N(C(C(C1=C([H])C([H])=C(S(F)(=O)=O)C([H])=C1[H])([H])[H])([H])[H])([H])[H],DB07347,34284-75-8,4-(2-Aminoethyl)Benzenesulfonyl Fluoride,,small molecule,,,,,
C(N1C([H])=C(C(=O)C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])C([H])=C1C(=C(C(=O)N(O[H])[H])[H])[H])([H])([H])[H],DB07350,,(2E)-N-hydroxy-3-[1-methyl-4-(phenylacetyl)-1H-pyrrol-2-yl]prop-2-enamide,,small molecule,,,,,
O(C1=C([H])C([H])=C(C2=C([H])C(=O)C3=C(C(=C(O[H])C(=C3O[H])[H])[H])O2)C([H])=C1[H])[H],DB07352,520-36-5,Apigenin,,small molecule,,,,,
C(OC1=C(OC([H])([H])[H])C([H])=C2C3=C([N+](=C([H])C2=C1[H])[H])C1=C(C2=C(C([H])=C1C3([H])[H])OC([H])([H])O2)[H])([H])([H])[H],DB07354,,"2,3-DIMETHOXY-12H-[1,3]DIOXOLO[5,6]INDENO[1,2-C]ISOQUINOLIN-6-IUM",,small molecule,,,,,
C(C(C(C(C(C(C(OC1=C([H])C([H])=C([H])C(C(O[H])=O)=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07355,,3-(heptyloxy)benzoic acid,,small molecule,,,,,
C(N1C([H])=NN=C1SC1=C([H])C(C(=O)N(C2=NC(C([H])([H])[H])=C([H])S2)[H])=C(N([H])[H])C([H])=C1[H])([H])([H])[H],DB07358,,"2-amino-N-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]benzamide",,small molecule,,,,,
C(N1C([H])=NN=C1SC1=C([H])C([H])=C(SC2=C([H])C([H])=C(F)C([H])=C2[H])C(C(=O)N(C2=NC(C([H])([H])[H])=C([H])S2)[H])=N1)([H])([H])[H],DB07359,,"3-[(4-fluorophenyl)sulfanyl]-N-(4-methyl-1,3-thiazol-2-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridine-2-carboxamide",,small molecule,,,,,
FC(F)(F)C1=C([H])C([H])=C([H])C(N(C(=O)N(C2=NC([H])=C(C(C(N(C3=NC([H])=NC4=C3SC(=C4[H])[H])[H])([H])[H])([H])[H])S2)[H])[H])=C1[H],DB07360,,"1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea",,small molecule,,,,,
C(N1N=C([H])C2=C1C(N(C(C(C1=C([H])N=C(N(C(=O)N(C3=C([H])C(C(F)(F)F)=C([H])C([H])=C3[H])[H])[H])S1)([H])[H])([H])[H])[H])=NC(=N2)[H])([H])([H])[H],DB07362,,"1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea",,small molecule,,,,,
C(C1=C([H])C([H])=C(C(N(S(=O)(=O)C2=C([H])C([H])=C(S(N([H])[H])(=O)=O)S2)[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB07363,,"THIOPHENE-2,5-DISULFONIC ACID 2-AMIDE-5-(4-METHYL-BENZYLAMIDE)",,small molecule,,,,,
C(C(C(C(C1=C(C2=C([H])C([H])=C(O[H])C([H])=C2[H])N([H])C2=C1N=C(C(=N2)[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07364,,"6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE",,small molecule,,,,,
C(S(=O)(=O)C1=C([H])C([H])=C(C(N([H])[H])=N[H])C([H])=C1[H])([H])([H])[H],DB07368,,4-(METHYLSULFONYL)BENZENECARBOXIMIDAMIDE,,small molecule,,,,,
C(N(C1=C([H])C([H])=C([H])C(Cl)=C1[H])S(=O)(=O)C1=C([H])C2=C(C(C3=C(C([H])([H])[H])C(C([H])([H])[H])=C(C([H])([H])[H])N3[H])([H])[H])C(=O)N=C2C([H])=C1[H])([H])([H])[H],DB07369,,"N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide",,small molecule,,,,,
C(C1=C2C(=C(C(=C([H])C2=C(C(C(C(O[H])=O)([H])[H])([H])[H])C2=C(C(=C(C([H])=C12)[H])[H])[H])[H])[H])[H])([H])([H])[H],DB07371,,3-(10-methyl-9-anthryl)propanoic acid,"3-(10-methyl-9-anthryl)propionic acid
3-(10-METHYL-ANTHRACEN-9-YL)-PROPIONIC ACID",small molecule,,,,,
C(N(C([H])([H])[H])C1=C2C(=C(C(=C(S(O[H])(=O)=O)C2=C([H])C([H])=C1[H])[H])[H])[H])([H])([H])[H],DB07376,,5-(DIMETHYLAMINO)-1-NAPHTHALENESULFONIC ACID(DANSYL ACID),,small molecule,,,,,
C1(C([H])([H])C1(C1=NN([H])C(N(C2=C([H])C([H])=NC(N(C3=C([H])C4=C(N(C(=N4)[H])[H])C([H])=C3[H])[H])=N2)[H])=C1[H])[H])([H])[H],DB07382,,"N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine",,small molecule,,,,,
C(C(C(C(S(=O)(=O)C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07387,,3-(BUTYLSULPHONYL)-PROPANOIC ACID,,small molecule,,,,,
C(C(OC(=O)N1C([H])([H])C([H])([H])C(N(C2=NC([H])=C([H])C(C([H])([H])[H])=C2[H])[H])([H])C([H])([H])C1([H])[H])([H])[H])([H])([H])[H],DB07388,,ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE,,small molecule,,,,,
C(C1=C([H])C(C(C(N(C(=O)C2=C([H])C([H])=C(C#N)C([H])=C2[H])[H])([H])[H])([H])[H])=NC(N([H])[H])=C1[H])([H])([H])[H],DB07389,,N-[2-(6-AMINO-4-METHYLPYRIDIN-2-YL)ETHYL]-4-CYANOBENZAMIDE,,small molecule,,,,,
C(C(N(C1=NC(Cl)=NC(N(C(C([H])([H])[H])(C([H])([H])[H])[H])[H])=N1)[H])([H])[H])([H])([H])[H],DB07392,,"2-CHLORO-4-ISOPROPYLAMINO-6-ETHYLAMINO -1,3,5-TRIAZINE",,small molecule,,,,,
C1(C([H])([H])C([H])([H])C2=C(P(C(C3=NC([H])=C([H])C([H])=C3[H])=C2C1([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])C1=NC([H])=C([H])C([H])=C1[H])([H])[H],DB07393,,"2-(2-PHENYL-3-PYRIDIN-2-YL-4,5,6,7-TETRAHYDRO-2H-ISOPHOSPHINDOL-1-YL)PYRIDINE",,small molecule,,,,,
O(C(=O)C1=C([H])C(OC(F)(F)F)=C(N(C(=O)N(C(=O)C2=C(Cl)C([H])=C(F)C(F)=C2[H])[H])[H])C([H])=C1[H])[H],DB07395,,"4-[3-(2-Chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid",,small molecule,,,,,
O(C(=O)C1(C([H])([H])C([H])([H])N(C2=C(N(C(=O)N(C(=O)C3=C(Cl)C([H])=C(F)C(F)=C3[H])[H])[H])C([H])=C(F)C([H])=C2[H])C([H])([H])C1([H])[H])[H])[H],DB07396,,"1-{2-[3-(2-Chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid",,small molecule,,,,,
N(C(=O)C1=C(N(C(=O)C2(C([H])([H])C2([H])[H])[H])[H])SC2=C1C(C(C(C2([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB07398,,"2-[(CYCLOPROPYLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE",,small molecule,,,,,
C(OC(=C(C(=O)OC([H])([H])[H])C1=C(OC2=NC([H])=NC(OC3=C(C#N)C([H])=C([H])C([H])=C3[H])=C2[H])C([H])=C([H])C([H])=C1[H])[H])([H])([H])[H],DB07401,,METHYL (2Z)-2-(2-{[6-(2-CYANOPHENOXY)PYRIMIDIN-4-YL]OXY}PHENYL)-3-METHOXYACRYLATE,,small molecule,,,,,
O(C(C(C1=C([H])C(C2=C([H])C(C3=C([H])C([H])=C([H])C([H])=C3[H])=C([H])C([H])=C2[H])=C([H])C([H])=C1[H])([H])[H])(P(O[H])(O[H])=O)P(O[H])(O[H])=O)[H],DB07404,,"(1-HYDROXY-1-PHOSPHONO-2-[1,1';3',1'']TERPHENYL-3-YL-ETHYL)-PHOSPHONIC ACID",,small molecule,,,,,
N(C1=NC2(C([H])([H])C([H])([H])N(C(=O)C3=C([H])N=C(C#N)C([H])=C3[H])C([H])([H])C2([H])[H])N([H])C2=C(F)C(=C(C(F)=C12)[H])[H])([H])[H],DB07405,,"1-(6-CYANO-3-PYRIDYLCARBONYL)-5',8'-DIFLUOROSPIRO[PIPERIDINE-4,2'(1'H)-QUINAZOLINE]-4'-AMINE",,small molecule,,,,,
C(OC1=C(C2=C([H])C([H])=C(C(O[H])=O)O2)C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB07407,,5-(2-METHOXYPHENYL)-2-FUROIC ACID,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C(C2=C([N+]([O-])=O)C([H])=C([H])C([H])=C2[H])O1)[H],DB07408,,5-(2-NITROPHENYL)-2-FUROIC ACID,,small molecule,,,,,
O(C(C(C1=C([H])C(C2=C([H])C([H])=C(C3=C([H])C([H])=C([H])C([H])=C3[H])C([H])=C2[H])=C([H])C([H])=C1[H])([H])[H])(P(O[H])(O[H])=O)P(O[H])(O[H])=O)[H],DB07409,,"(1-HYDROXY-1-PHOSPHONO-2-[1,1';4',1'']TERPHENYL-3-YL-ETHYL)-PHOSPHONIC ACID",,small molecule,,,,,
O(C(C(C1=C([H])C(C2=C3OC4=C(C3=C([H])C([H])=C2[H])C([H])=C([H])C([H])=C4[H])=C([H])C([H])=C1[H])([H])[H])(P(O[H])(O[H])=O)P(O[H])(O[H])=O)[H],DB07410,,[2-(3-DIBENZOFURAN-4-YL-PHENYL)-1-HYDROXY-1-PHOSPHONO-ETHYL]-PHOSPHONIC ACID,,small molecule,,,,,
N(C(C1=C(C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H],DB07412,,1-biphenyl-2-ylmethanamine,,small molecule,,,,,
O(P(=O)(OC1=C([H])C([H])=C([N+]([O-])=O)C([H])=C1[H])OC1=C([H])C([H])=C([N+]([O-])=O)C([H])=C1[H])[H],DB07418,,bis(4-nitrophenyl) hydrogen phosphate,,small molecule,,,,,
C(C(C([H])([H])[H])(C1=C(O[H])C([H])=C([H])C(C(C2=C(C([H])([H])[H])C([H])=C(OC(C(O[H])=O)([H])[H])C([H])=C2C([H])([H])[H])([H])[H])=C1[H])[H])([H])([H])[H],"DB07425
DB06018",211110-63-3,Sobetirome,,small molecule,,,,,
O(C(C(OC1=C([H])C(C2=C([H])C(C3=C([H])C([H])=C([H])C([H])=C3[H])=C([H])C([H])=C2[H])=C([H])C([H])=C1[H])([H])[H])(P(O[H])(O[H])=O)P(O[H])(O[H])=O)[H],DB07426,,"[1-HYDROXY-2-(1,1':3',1''-TERPHENYL-3-YLOXY)ETHANE-1,1-DIYL]BIS(PHOSPHONIC ACID)",,small molecule,,,,,
C(OC1=C(OC(C2=NC([H])=C([H])C([H])=C2[H])([H])[H])C([H])=C(C([H])([H])[H])C([H])=C1[H])([H])([H])[H],DB07427,,2-[(2-methoxy-5-methylphenoxy)methyl]pyridine,,small molecule,,,,,
C(OC1=C([H])C(OC(C2=C([H])C([H])=NC([H])=C2[H])([H])[H])=C(C([H])([H])[H])C([H])=C1[H])([H])([H])[H],DB07428,,4-[(5-methoxy-2-methylphenoxy)methyl]pyridine,,small molecule,,,,,
C(C(N(C(C([H])([H])[H])([H])[H])S(=O)(=O)C1=C(Br)C([H])=C([H])C(C(=O)N(C2=C(C(O[H])=O)C([H])=C([H])C([H])=C2[H])[H])=C1[H])([H])[H])([H])([H])[H],DB07429,,2-({[4-bromo-3-(diethylsulfamoyl)phenyl]carbonyl}amino)benzoic acid,,small molecule,,,,,
O(C(C(OC(N1C([H])=C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])C(=O)N([H])C1=O)([H])[H])([H])[H])([H])[H])[H],DB07437,,"1-((2-HYDROXYETHOXY)METHYL)-5-BENZYLPYRIMIDINE-2,4(1H,3H)-DIONE",,small molecule,,,,,
O(C(C(OC(N1C(=O)N([H])C(=O)C(C(C2=C([H])C(OC(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])=C([H])C([H])=C2[H])([H])[H])=C1O[H])([H])[H])([H])[H])([H])[H])[H],DB07439,,"1-((2-HYDROXYETHOXY)METHYL)-5-(3-(BENZYLOXY)BENZYL)-6-HYDROXYPYRIMIDINE-2,4(1H,3H)-DIONE",,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C1=C([H])C([H])=C(S(O[H])(=O)=O)C([H])=C1[H])([H])([H])[H],DB07440,,4-TERT-BUTYLBENZENESULFONIC ACID,,small molecule,,,,,
C(N1C2=C(C(=C(C(=C2[H])[H])[H])[H])C(C#N)(C(=O)N(C(C(C(O[H])=O)([H])[H])([H])[H])[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])([H])[H],DB07441,,"3-{[(9-CYANO-9,10-DIHYDRO-10-METHYLACRIDIN-9-YL)CARBONYL]AMINO}PROPANOIC ACID",,small molecule,,,,,
C(C(O[H])=C(C#N)C(=O)N(C1=C([H])C([H])=C(C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])[H])([H])([H])[H],DB07443,,(2Z)-N-biphenyl-4-yl-2-cyano-3-hydroxybut-2-enamide,,small molecule,,,,,
C(C1=C([H])C2=C(N(C(C(C(N([H])[H])([H])[H])([H])[H])([H])[H])C3=C([H])C(C([H])([H])[H])=C4C(=O)N(C(=O)C4=C32)[H])C([H])=C1[H])([H])([H])[H],DB07444,,"6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE",,small molecule,,,,,
O(C1=C(Br)C(O[H])=C(C(=NN(C(=O)C2=C([H])N=C([H])C([H])=C2[H])[H])[H])C([H])=C1Br)[H],DB07445,,"N'-[(1E)-(3,5-DIBROMO-2,4-DIHYDROXYPHENYL)METHYLENE]NICOTINOHYDRAZIDE",,small molecule,,,,,
N(C1=NC2=C(C3=C(C([H])=C2N1[H])C(=O)N([H])C(N([H])[H])=N3)[H])([H])[H],DB07452,,"2,6-diamino-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,small molecule,,,,,
O=C1C([H])=C(C2=C([H])C([H])=C([H])C([H])=C2[H])OC2=C1C(=C(C1=C([H])C([H])=C([H])C([H])=C12)[H])[H],DB07453,,2-PHENYL-4H-BENZO[H]CHROMEN-4-ONE,,small molecule,,,,,
N(C(C(C(N1C([H])=C(C2=C(C3=C([H])N([H])C4=C3C(=C(C(=C4[H])[H])[H])[H])C(=O)N([H])C2=O)C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB07457,,"3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE",,small molecule,,,,,
O=C(N(C(C1=NC([H])=C([H])C([H])=C1[H])([H])[H])[H])C1=C([H])C([H])=C(OC2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H],DB07459,,4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE,,small molecule,,,,,
C(N(C(=O)C1=C(N(C2=C(Cl)C([H])=NC(N(C3=C(OC([H])([H])[H])C([H])=C(N4C([H])([H])C([H])([H])OC([H])([H])C4([H])[H])C([H])=C3[H])[H])=N2)[H])C([H])=C([H])C([H])=C1[H])[H])([H])([H])[H],DB07460,,2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE,,small molecule,,,,,
O(C1=C([H])C([H])=C(C(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])C([N+]([O-])=O)=C1O[H])[H],DB07462,,"(3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE",,small molecule,,,,,
C(C1=C([H])C(N2C([H])=C([H])N=C2[H])=C([H])C2=C1N=C(N2[H])C1=C(N(C(C2=NC([H])=C([H])C([H])=C2[H])([H])[H])[H])C([H])=C([H])N([H])C1=O)([H])([H])[H],DB07474,,3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(N(C(=O)C2=C(S[H])C([H])=C([H])C([H])=C2[H])[H])C([H])=C1[H])([H])[H],DB07476,,N-[4-(AMINOSULFONYL)PHENYL]-2-MERCAPTOBENZAMIDE,,small molecule,,,,,
O(C(=O)C(C1=C([H])C([H])=C(C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H])[H],DB07477,5728-52-9,Felbinac,,small molecule,,,,,
O(C1=C(O[H])C([H])=C(C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])[H],DB07478,,"1,1'-BIPHENYL-3,4-DIOL",,small molecule,,,,,
O(P(O[H])(=O)OC1=C([H])C([H])=C(C(C2=C([H])C([H])=C(OP(O[H])(O[H])=O)C([H])=C2[H])([H])[H])C([H])=C1[H])[H],DB07480,,4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN,,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])OC(=O)N(C(C1=C([H])N([H])C2=C1C(=O)N(C(N([H])[H])=N2)[H])([H])[H])[H])([H])([H])[H],DB07481,,"tert-butyl [(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl]carbamate",,small molecule,,,,,
O(C1=C([H])C([H])=C(C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])C2=C([H])C([H])=C(O[H])C([H])=C2[H])C([H])=C1[H])[H],DB07485,,"4,4'-cyclohexane-1,1-diyldiphenol",,small molecule,,,,,
N(C1=C([H])C([H])=C([H])C(SC2=C(C(F)(F)F)C(C(F)(F)F)=C(C(=C(C(=O)N3C([H])([H])C([H])([H])OC([H])([H])C3([H])[H])[H])[H])C([H])=C2[H])=C1[H])([H])[H],DB07486,,"3-({4-[(1E)-3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-2,3-bis(trifluoromethyl)phenyl}sulfanyl)aniline",,small molecule,,,,,
C(OC1=C([H])C([H])=C(N=C2N([H])C(N([H])[H])=C(C(=O)C3=C([H])C([H])=C(OC([H])([H])[H])C([H])=C3[H])S2)C([H])=C1[H])([H])([H])[H],DB07488,,"{(2Z)-4-AMINO-2-[(4-METHOXYPHENYL)IMINO]-2,3-DIHYDRO-1,3-THIAZOL-5-YL}(4-METHOXYPHENYL)METHANONE",,small molecule,,,,,
N(C1=C(C(=O)C2=C([H])C([H])=C(F)C([H])=C2[H])SC(N(C2=C([H])C([H])=C([H])C(Cl)=C2[H])[H])=[N+]1[H])([H])[H],DB07489,,"4-Amino-2-[(3-chlorophenyl)amino]-5-(4-fluorobenzoyl)-1,3-thiazol-3-ium",,small molecule,,,,,
N(C1=C(Br)C(C(O[H])=O)=C(Br)C(C(O[H])=O)=C1Br)([H])[H],DB07491,,"5-amino-2,4,6-tribromobenzene-1,3-dicarboxylic acid",,small molecule,,,,,
BrC1=C([H])C2=C(N(C(=O)C2=C2N([H])C3=C(C(=C(C(=C3[H])[H])[H])[H])C2=O)[H])C([H])=C1[H],DB07493,,"(2Z)-5'-BROMO-2,3'-BIINDOLE-2',3(1H,1'H)-DIONE AMMONIATE",,small molecule,,,,,
C(C(N(C(=O)C1=NN([H])C(C2=C([H])C(Cl)=C(O[H])C([H])=C2O[H])=C1C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB07495,,"5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE",,small molecule,,,,,
O=C(N(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])N(C1=C([H])C([H])=C([H])C([H])=C1[H])[H],DB07496,,"1,3-DIPHENYLUREA",,small molecule,,,,,
O(C(=O)C(C(C(C1=NC(C2=C([H])C([H])=C([H])C([N+]([O-])=O)=C2[H])=NO1)([H])[H])([H])[H])([H])[H])[H],DB07498,,"4-[3-(3-NITROPHENYL)-1,2,4-OXADIAZOL-5-YL]BUTANOIC ACID",,small molecule,,,,,
N(C(=N[H])N(C(C(C(C(N(C(=O)C1=C([H])SC(C2=C([H])SC([H])=N2)=N1)[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H],DB07499,,"N-(4-{[amino(imino)methyl]amino}butyl)-2,4'-bi-1,3-thiazole-4-carboxamide",,small molecule,,,,,
C(OC1=C([H])C(O[H])=C(C(=O)C(=C(C2=C([H])C([H])=C(O[H])C([H])=C2[H])[H])[H])C([H])=C1C(C(=C(C([H])([H])[H])C([H])([H])[H])[H])([H])[H])([H])([H])[H],DB07500,,(2E)-1-[2-hydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one,,small molecule,,,,,
O(C1=C([H])C2=C(C(=NO2)C2=C([H])C(Br)=C(O[H])C([H])=C2O[H])C([H])=C1[H])[H],DB07502,,"4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol",,small molecule,,,,,
FC1(F)OC2=C(C(=C(C(=C3SC(=O)N([H])C3=O)[H])C(=C2[H])[H])[H])O1,DB07503,,"(5E)-5-[(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)METHYLENE]-1,3-THIAZOLIDINE-2,4-DIONE",,small molecule,,,,,
C(C1=C2C(=O)N(C(=O)C2=C([H])C([H])=C1[H])C1=C(O[H])C([H])=C([H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])=C1[H])([H])([H])[H],DB07507,,"2-(4-hydroxybiphenyl-3-yl)-4-methyl-1H-isoindole-1,3(2H)-dione",,small molecule,,,,,
C(N1C(C(C2=C([H])C([H])=C(C(N([H])[H])=N[H])C([H])=C2[H])([H])[H])=NC2=C1C(=C(C(N(S(=O)(=O)C1=C([H])C([H])=C([H])C([H])=C1[H])[H])=C2[H])[H])[H])([H])([H])[H],DB07508,,4-(5-BENZENESULFONYLAMINO-1-METHYL-1H-BENZOIMIDAZOL-2-YLMETHYL)-BENZAMIDINE,,small molecule,,,,,
C(C(C(C(C(C(C(C(C1=C([H])C([H])=C2C(=C3C([H])=C([H])C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])=[N+]3[B-](F)(F)N12)[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07509,,difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron,,small molecule,,,,,
O(C(=O)C(O[H])=C(F)C(=C(C(=O)C1=C([H])C([H])=C(F)C([H])=C1[H])[H])[H])[H],DB07510,,"3-fluoro-6-(4-fluorophenyl)-2-hydroxy-6-oxohexa-2,4-dienoic acid",,small molecule,,,,,
C(C1=C2C(=O)N(C(=O)C2=C([H])C([H])=C1[H])C1=C([H])C([H])=C(C#N)C([H])=C1[H])([H])([H])[H],DB07511,,"4-(4-methyl-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)benzonitrile",,small molecule,,,,,
ClC1=C([H])C(C(OC2=C([H])C3=C(C(C(=O)[H])=C(C(=O)O3)[H])C([H])=C2[H])([H])[H])=C([H])C([H])=C1[H],DB07512,,7-[(3-CHLOROBENZYL)OXY]-2-OXO-2H-CHROMENE-4-CARBALDEHYDE,,small molecule,,,,,
C(N(C(C1=C([H])C(=O)OC2=C1C(=C(C(OC(C1=C([H])C([H])=C([H])C(Cl)=C1[H])([H])[H])=C2[H])[H])[H])([H])[H])[H])([H])([H])[H],DB07513,,7-[(3-CHLOROBENZYL)OXY]-4-[(METHYLAMINO)METHYL]-2H-CHROMEN-2-ONE,,small molecule,,,,,
C(C1=C(C2=C([H])C3=C(N=C(N([H])[H])N=C3C([H])=C2[H])[H])C(=O)N(C2=C([H])C3=C(C(C([H])([H])[H])(C([H])([H])[H])C(N3[H])([H])[H])C([H])=C2[H])C([H])=C1[H])([H])([H])[H],DB07514,,"3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one",,small molecule,,,,,
O(C(=O)C(O[H])=C(Cl)C(=C(C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H])[H],DB07516,,"(2Z,4E)-3-chloro-2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid",,small molecule,,,,,
C(C(C(C1=C(C([H])([H])[H])C(C(O[H])=O)=C(C(C(C(O[H])=O)([H])[H])([H])[H])O1)([H])[H])([H])[H])([H])([H])[H],DB07517,,3-CARBOXY-4-METHYL-5-PROPYL-2-FURANPROPIONIC,,small molecule,,,,,
N(C1=C([H])N([H])C2=NC(=C(C([H])=C12)[H])[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])[H],DB07524,,"N-phenyl-1H-pyrrolo[2,3-b]pyridin-3-amine",,small molecule,,,,,
C(OC1=C([H])C(C(C2=C([H])N([H])C3=C2C(=C(C(=N3)[H])[H])[H])([H])[H])=C([H])C([H])=C1[H])([H])([H])[H],DB07525,,"3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine",,small molecule,,,,,
C(N(C([H])([H])[H])C1=C2C(=C(C(=C(S(=O)(=O)N(C(C(C(C(N(C(=O)C(C(S[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])C2=C([H])C([H])=C1[H])[H])[H])[H])([H])([H])[H],DB07526,,N-[4-({[5-(DIMETHYLAMINO)-1-NAPHTHYL]SULFONYL}AMINO)BUTYL]-3-SULFANYLPROPANAMIDE,,small molecule,,,,,
C(C1=C(C2=C([H])C3=C(N=C(N([H])[H])N=C3C([H])=C2[H])[H])C(=O)N(C2=C([H])C([H])=C([H])C(C(F)(F)F)=C2[H])C([H])=C1[H])([H])([H])[H],DB07528,,3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one,,small molecule,,,,,
N(=C1N([H])C(=O)C(=C(C2=NC([H])=C([H])C([H])=C2[H])[H])S1)[H],DB07529,,"2-IMINO-5-(1-PYRIDIN-2-YL-METH-(E)-YLIDENE)-1,3-THIAZOLIDIN-4-ONE",,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(C2=C([H])C([H])=C(C(=C3SC(=O)N([H])C3=O)[H])O2)C([H])=C1[H])([H])[H],DB07531,,"4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE",,small molecule,,,,,
C(N(S(=O)(=O)C1=C([H])C([H])=C(C2=C([H])C([H])=C(C(=C3SC(=N[H])N([H])C3=O)[H])O2)C([H])=C1[H])[H])([H])([H])[H],DB07533,,"4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE",,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(C2=C([H])C([H])=C(C(=C3SC(=N[H])N([H])C3=O)[H])O2)C([H])=C1[H])([H])[H],DB07534,,"4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE",,small molecule,,,,,
N(C1=NC(C(C(C2=C([H])C3=C(C(=C(N3[H])[H])[H])C([H])=C2[H])([H])[H])([H])[H])=C([H])C(=O)N1[H])([H])[H],DB07535,,2-amino-6-[2-(1H-indol-6-yl)ethyl]pyrimidin-4(3H)-one,,small molecule,,,,,
C(C1=C(C(=O)N(C2=C([H])N=C(N([H])[H])C([H])=C2[H])[H])C([H])=C(C(=O)N(C(C(C2(C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])([H])[H])([H])[H])[H])C([H])=C1[H])([H])([H])[H],DB07537,,"N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide",,small molecule,,,,,
N(S(=O)(=O)C1=C(C(F)(F)F)C([H])=C(C2=C([H])C([H])=C(C(=C3SC(=N[H])N([H])C3=O)[H])O2)C([H])=C1[H])([H])[H],DB07538,,"4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE",,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C(C2=C([H])C([H])=C(C(=C3SC(=N[H])N([H])C3=O)[H])O2)C([H])=C1[H])[H],DB07539,,"4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID",,small molecule,,,,,
C(C(C1=C([H])C([H])=C(C2=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C2[H])O1)=C1SC(=N[H])N([H])C1=O)([H])([H])[H],DB07540,,"4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE",,small molecule,,,,,
O(B(O[H])C1=C([H])C(N(S(=O)(=O)C2=C([H])C(S(=O)(=O)C3=C([H])C([H])=C([H])C([H])=C3[H])=C([H])S2)[H])=C(C(O[H])=O)C([H])=C1[H])[H],DB07541,,4-(dihydroxyboranyl)-2-({[4-(phenylsulfonyl)thiophen-2-yl]sulfonyl}amino)benzoic acid,,small molecule,,,,,
FC(F)(F)C1=C(S(=O)(=O)N(N(C(=O)C2=C([H])C3=C(C(=C(C(Cl)=C3[H])[H])[H])O2)[H])[H])C([H])=C([H])C([H])=C1[H],DB07544,,N'-(5-CHLOROBENZOFURAN-2-CARBONYL)-2-(TRIFLUOROMETHYL)BENZENESULFONOHYDRAZIDE,,small molecule,,,,,
FC(F)(F)C1=C([H])C(N(C2=NC(N(C3=C([H])C(N(C(=O)C4(C([H])([H])C4([H])[H])[H])[H])=C([H])C([H])=C3[H])[H])=NC([H])=C2[H])[H])=C([H])C([H])=C1[H],DB07545,,N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE,,small molecule,,,,,
C(C(C([H])([H])[H])(N(C1=C([H])C2=C(C(=NN2C2=C([H])N=C([H])C(N3C([H])=C([H])C(C(C(O[H])=O)([H])[H])=C3[H])=N2)[H])C([H])=C1[H])[H])[H])([H])([H])[H],DB07546,,[1-(6-{6-[(1-methylethyl)amino]-1H-indazol-1-yl}pyrazin-2-yl)-1H-pyrrol-3-yl]acetic acid,,small molecule,,,,,
C(C1=C(S(=O)(=O)N(C2=C(C(O[H])=O)SC(C3=C([H])C([H])=C(C#N)C([H])=C3[H])=C2[H])[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB07547,,5-(4-CYANOPHENYL)-3-{[(2-METHYLPHENYL)SULFONYL]AMINO}THIOPHENE-2-CARBOXYLIC ACID,,small molecule,,,,,
C(C1=C([H])N=C(N(C(C(F)(F)C2=NC([H])=C([H])C([H])=C2[H])([H])[H])[H])C(=O)N1C(C(=O)N(C(C1=C(F)C([H])=C([H])C([H])=N1)([H])[H])[H])([H])[H])([H])([H])[H],DB07548,,"2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-6-PYRIDINYL)METHYL]ACETAMIDE",,small molecule,,,,,
C(C1=C([H])[N+]([H])=C(N(C(C(F)(F)C2=[N+]([H])C([H])=C([H])C([H])=C2[H])([H])[H])[H])C(=O)N1C(C(=O)N(C(C1=C(F)C(C([H])([H])[H])=C([H])C([H])=N1)([H])[H])[H])([H])[H])([H])([H])[H],DB07549,,"2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-3-METHYL-6-PYRIDINYL)METHYL]ACETAMIDE",,small molecule,,,,,
[O-][N+]1=C(C(F)(F)C(N(C2=NC([H])=C(Cl)N(C(C(=O)N(C(C3=C(F)C([H])=C([H])C([H])=C3[H])([H])[H])[H])([H])[H])C2=O)[H])([H])[H])C([H])=C([H])C([H])=C1[H],DB07550,,"2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(1-OXIDO-2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUOROPHENYL)METHYL]ACETAMIDE",,small molecule,,,,,
FC(F)(F)C(=O)C(C(C(C(C(C(C(=O)N(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB07553,,"9,9,9-TRIFLUORO-8-OXO-N-PHENYLNONANAMIDE",,small molecule,,,,,
C(C(O[H])=C(C#N)C(=O)N(C1=C([H])C(Cl)=C(C2=C(Cl)C([H])=C([H])C([H])=C2[H])C([H])=C1[H])[H])([H])([H])[H],DB07559,,"(2Z)-2-cyano-N-(2,2'-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide",,small molecule,,,,,
C(C(OC1=C([H])C([H])=C([H])C(C2=C([H])C([H])=C(N(C(=O)C(C#N)=C(C([H])([H])[H])O[H])[H])C([H])=C2[H])=C1[H])([H])[H])([H])([H])[H],DB07561,,(2Z)-2-cyano-N-(3'-ethoxybiphenyl-4-yl)-3-hydroxybut-2-enamide,,small molecule,,,,,
C(N(C([H])([H])[H])C1=C([H])C([H])=C(N(C2=NC([H])=C([H])C(C3=C(C([H])([H])[H])N=C(C([H])([H])[H])S3)=N2)[H])C([H])=C1[H])([H])([H])[H],DB07562,,"N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE",,small molecule,,,,,
C(N1C([H])([H])C([H])([H])N(C2=C([H])C([H])=C(C(C3=C([H])C4=C(N=C(C(N([H])[H])([H])[H])N=C4[H])N3C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])([H])[H])C([H])=C2[H])C([H])([H])C1([H])[H])([H])([H])[H],DB07563,,"1-{7-cyclohexyl-6-[4-(4-methylpiperazin-1-yl)benzyl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl}methanamine",,small molecule,,,,,
N(C1=NC2=C(C(=C3N=C(N(C(C(N4C([H])([H])C([H])([H])OC([H])([H])C4([H])[H])([H])[H])([H])[H])[H])N([H])C3=C2[H])[H])C(=O)N1[H])([H])[H],DB07564,,"6-amino-2-[(2-morpholin-4-ylethyl)amino]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,small molecule,,,,,
O(C(=O)C1=C([H])C2=C(C(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])=C(N2C(C(=O)N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])([H])[H])C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])[H],DB07570,,3-CYCLOHEXYL-1-(2-MORPHOLIN-4-YL-2-OXOETHYL)-2-PHENYL-1H-INDOLE-6-CARBOXYLIC ACID,,small molecule,,,,,
C(C1=C([H])C([H])=C(S(=O)(=O)N(C(C(C(OC(=O)N(C2=C([H])C([H])=NC([H])=C2[H])[H])([H])[H])([H])[H])([H])[H])[H])C([H])=C1[H])([H])([H])[H],DB07572,,3-{[(4-methylphenyl)sulfonyl]amino}propyl pyridin-4-ylcarbamate,,small molecule,,,,,
C(C(C1=NC(N([H])[H])=NC(N([H])[H])=C1C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB07577,,"6-ETHYL-5-PHENYLPYRIMIDINE-2,4-DIAMINE",,small molecule,,,,,
C(C1=NC2=C(C(=C(N=C2[H])[H])[H])N1C1=C([H])C([H])=C(C(N2C(=O)SC3=C2C(=C(C(=C3[H])[H])[H])[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB07578,,"3-[4-(2-METHYL-IMIDAZO[4,5-C]PYRIDIN-1-YL)BENZYL]-3H-BENZOTHIAZOL-2-ONE",,small molecule,,,,,
C(C1=NN=C(C2=C(N(C3=NC([H])=NC4=C3C(=C(N4[H])[H])[H])[H])C([H])=C([H])C([H])=C2[H])N1[H])([H])([H])[H],DB07584,,"N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine",,small molecule,,,,,
ClC1=C([H])N([H])C2=NC(=NC(N3C([H])([H])C([H])([H])C4=C(N=C(N4[H])[H])C3([H])[H])=C12)[H],DB07585,,"5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine",,small molecule,,,,,
C(N(C([H])([H])[H])C(=O)C1=C([H])C(N(C(=O)C2=C([H])C([H])=C(C([H])([H])[H])C([H])=C2[H])[H])=C([H])C(C2=C([H])C([H])=C(C(=O)N(O[H])[H])C([H])=C2[H])=C1[H])([H])([H])[H],DB07586,,"5-(4-METHYL-BENZOYLAMINO)-BIPHENYL-3,4'-DICARBOXYLIC ACID 3-DIMETHYLAMIDE-4'-HYDROXYAMIDE",,small molecule,,,,,
O(C(=O)C1=C(C2=C([H])N([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])C(C2=C([H])N([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])=C(C(O[H])=O)N1[H])[H],DB07588,,"3,4-DI-1H-INDOL-3-YL-1H-PYRROLE-2,5-DICARBOXYLIC ACID",,small molecule,,,,,
O=C(N(C1(C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])[H])C(=O)N(C1=NC([H])=C([H])S1)[H],DB07591,,N1-CYCLOPENTYL-N2-(THIAZOL-2-YL)OXALAMIDE,,small molecule,,,,,
C(C(C1=C([H])C(C2=C(C3=C([H])C4=C(OC(C(O4)([H])[H])([H])[H])C([H])=C3[H])C(C([H])([H])[H])=NN2[H])=C(O[H])C([H])=C1O[H])([H])[H])([H])([H])[H],DB07594,,"4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL",,small molecule,,,,,
BrC1=C([H])C(C2=NC3=[N+](N(C(=C3[H])[H])[H])C(N(C(C3=C([H])C([H])=NC([H])=C3[H])([H])[H])[H])=C2[H])=C([H])C([H])=C1[H],DB07595,,"(5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE",,small molecule,,,,,
C(ON=C(C(=O)N(C(B(O[H])O[H])([H])[H])[H])C1=C([H])SC(N([H])[H])=N1)([H])([H])[H],DB07599,,[(2-AMINO-ALPHA-METHOXYIMINO-4-THIAZOLYLACETYL)AMINO]METHYLBORONIC ACID,,small molecule,,,,,
O(C1=C([H])C(O[H])=C(Cl)C([H])=C1C1=NOC2=C1C(=C(N(C(C(N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H])([H])[H])([H])[H])[H])C(=C2[H])[H])[H])[H],DB07601,,"4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol",,small molecule,,,,,
[O-][N+]1=C([H])C([H])=C([H])C2=C1C(=C(S2)C(=O)N1C([H])([H])C([H])([H])N(S(=O)(=O)C2=C([H])C3=C(C(=C(C(Cl)=C3[H])[H])[H])N2[H])C([H])([H])C1([H])[H])[H],DB07605,,"2-({4-[(5-CHLORO-1H-INDOL-2-YL)SULFONYL]PIPERAZIN-1-YL}CARBONYL)THIENO[3,2-B]PYRIDINE 4-OXIDE",,small molecule,,,,,
C(C(C1=NN(C2=C(Cl)C([H])=C(Cl)C([H])=C2Cl)C2=C1C(=O)N(C(C(C1=C([H])C(O[H])=C(O[H])C([H])=C1[H])([H])[H])=N2)[H])([H])[H])([H])([H])[H],DB07606,,"6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE",,small molecule,,,,,
C(N(C([H])([H])[H])C(C1=C([H])C([H])=C(C2=C([H])N=C([H])C([H])=C2[H])O1)([H])[H])([H])([H])[H],DB07609,,"N,N-DIMETHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE",,small molecule,,,,,
O(C1=C(O[H])C2=C(C(=C(C([H])=C2C([H])=C1[H])[H])[H])[H])[H],DB07610,,"NAPHTHALENE-1,2-DIOL",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(S[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07611,,DECANE-1-THIOL,,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])N(C1=NC(C(F)(F)F)=NC2=C(C(=C(C([H])=C12)C1=C([H])C(N([H])[H])=C([H])C([H])=C1[H])[H])[H])[H])([H])([H])[H],DB07612,,6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE,,small molecule,,,,,
N1(C([H])=C([H])C(C2=C([H])C(C3=C([H])C([H])=C([H])C([H])=C3[H])=NO2)=N1)[H],DB07613,,3-phenyl-5-(1H-pyrazol-3-yl)isoxazole,,small molecule,,,,,
N1(C([H])=C([H])C(C2=C([H])N=C(C3=C([H])C([H])=C([H])C([H])=C3[H])S2)=N1)[H],DB07614,,"PHENYL-5-(1H-PYRAZOL-3-YL)-1,3-THIAZOLE",,small molecule,,,,,
C(OC1=C(OC([H])([H])[H])C([H])=C(C(=C(C(=O)N(C2=C(C(O[H])=O)C([H])=C([H])C([H])=C2[H])[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB07615,53902-12-8,Tranilast,"N-(3,4-Dimethoxycinnamoyl)anthranilic acid
tranilast
tranilastum",small molecule,Humans and other mammals,,,,"For the treatment of bronchial asthma, keloid and hypertrophic scar, and allergic disorders such as asthma, allergic rhinitis and atopic dermatitis."
C(C1=C(F)C([H])=C([H])C(C2=C([H])SC(N(C3=C([H])C(O[H])=C(C(O[H])=O)C([H])=C3[H])[H])=N2)=C1[H])([H])([H])[H],DB07616,,"4-{[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino}-2-hydroxybenzoic acid",,small molecule,,,,,
C(N(C(C1=C([H])C([H])=C(C2=C([H])N=C([H])C([H])=C2[H])O1)([H])[H])[H])([H])([H])[H],DB07617,,N-METHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE,,small molecule,,,,,
N(C(C1(C([H])([H])C([H])([H])N(C(C(=O)N(C2=C3C(=O)C4=C(C5(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C5([H])[H])[H])N([H])N=C4C3=C([H])C([H])=C2[H])[H])([H])[H])C([H])([H])C1([H])[H])[H])([H])[H])([H])[H],DB07618,,"2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE",,small molecule,,,,,
C(C1=C([H])C(S(=O)(=O)C2=C([N+]([O-])=O)C([H])=C(C(F)(F)F)C([H])=C2[N+]([O-])=O)=C(Cl)C([H])=C1Cl)([H])([H])[H],DB07620,,"2-[(2,4-DICHLORO-5-METHYLPHENYL)SULFONYL]-1,3-DINITRO-5-(TRIFLUOROMETHYL)BENZENE",,small molecule,,,,,
N(C(C1=C([H])C([H])=C(C2=C([H])N=C([H])C([H])=C2[H])O1)([H])[H])([H])[H],DB07621,,(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE,,small molecule,,,,,
C(N1C([H])([H])C([H])([H])N(N(C(=O)N(C2=C([H])C([H])=C([H])C3=C2C(=O)C2=C(C4=C(C([H])([H])[H])N=C(C([H])([H])[H])S4)N([H])N=C23)[H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB07622,,"1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA",,small molecule,,,,,
S(SC1=C([H])C([H])=NC([H])=C1[H])C1=C([H])C([H])=NC([H])=C1[H],DB07623,,"4,4'-DIPYRIDYL DISULFIDE",,small molecule,,,,,
C(C(OC1=C([H])C(N(C(=O)C2=C([H])C(C([H])([H])[H])=C(OC(C(N([H])[H])([H])[H])([H])[H])C(C([H])([H])[H])=C2[H])[H])=C(OC(C([H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB07625,,"4-(2-aminoethoxy)-N-(2,5-diethoxyphenyl)-3,5-dimethylbenzamide",,small molecule,,,,,
C(C(OC1=C(Cl)C([H])=C(N2C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])C([H])=C1N(C(=O)C1=C([H])C(C([H])([H])[H])=C(OC(C(N([H])[H])([H])[H])([H])[H])C(C([H])([H])[H])=C1[H])[H])([H])[H])([H])([H])[H],DB07626,,"4-(2-aminoethoxy)-N-(3-chloro-2-ethoxy-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide",,small molecule,,,,,
C(N1C2=C(SC(C([H])([H])[H])=C2[H])C2=C1C(=O)N(C(C1=C(F)C([H])=C([H])C([H])=C1[H])([H])[H])N=C2[H])([H])([H])[H],DB07628,,"6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one",,small molecule,,,,,
N(S(=O)(=O)C1=NN=C(C2=C(Cl)C([H])=C([H])C([H])=C2[H])S1)([H])[H],DB07632,,"5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide",,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C(C([H])([H])[H])=C1OC(C(O[H])=O)([H])[H])([H])([H])[H],DB07634,,"(2,6-DIMETHYL-PHENOXY)-ACETIC ACID",,small molecule,,,,,
O(C1=C([H])C([H])=C(C(=O)C2=C([H])C([H])=C(O[H])C([H])=C2[H])C([H])=C1[H])[H],DB07635,,bis(4-hydroxyphenyl)methanone,,small molecule,,,,,
C(C(C(C(C(C(C(C1=C(O[H])C(=O)C2=C(N=C(S2)[H])C1=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07636,,"5-HEPTYL-6-HYDROXY-1,3-BENZOTHIAZOLE-4,7-DIONE",,small molecule,,,,,
C(C(OC(=O)C(C(C1=C([H])C2=C(C(=C(C([H])=C2C([H])=C1[H])[H])C(N([H])[H])(N([H])[H])[H])[H])([H])[H])(C1=C([H])C([H])=C(OC2(C([H])([H])C([H])([H])N([H])C2([H])[H])[H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB07639,,3-(7-DIAMINOMETHYL-NAPHTHALEN-2-YL)-PROPIONIC ACID ETHYL ESTER,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C1=C(C([H])([H])[H])C(=O)C(OC([H])([H])[H])=C(OC([H])([H])[H])C1=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07640,,"2-decyl-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(P(C([H])([H])[H])(C([H])([H])[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07641,,DECYL(DIMETHYL)PHOSPHINE OXIDE,,small molecule,,,,,
N(C1=NC(N([H])[H])=C2C(OC(C3(C([H])([H])C([H])([H])N(C(C4=C(F)C([H])=C([H])C([H])=C4[H])([H])[H])C([H])([H])C3([H])[H])[H])([H])[H])=C(C(=C([H])C2=N1)[H])[H])([H])[H],DB07642,,"5-{[1-(2-fluorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine",,small molecule,,,,,
N(C1=NC(N([H])[H])=C2C(OC(C3(C([H])([H])C([H])([H])N(C(C4=C([H])C([H])=C([H])C(Cl)=C4Cl)([H])[H])C([H])([H])C3([H])[H])[H])([H])[H])=C(C(=C([H])C2=N1)[H])[H])([H])[H],DB07643,,"5-{[1-(2,3-dichlorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine",,small molecule,,,,,
O(C(=O)C(C(C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB07645,,SEBACIC ACID,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C([N+](C([H])([H])[H])(C([H])([H])[H])[O-])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07646,,"UNDECYLAMINE-N,N-DIMETHYL-N-OXIDE",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(OC(=O)[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07650,,DECYL FORMATE,,small molecule,,,,,
O(C(=O)C(N(C1=NC([H])=NC2=C1C(=C(O2)C1=C([H])C([H])=C([H])C([H])=C1[H])C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H])[H],DB07653,,"N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE",,small molecule,,,,,
C(N(C(C(O[H])([H])[H])([H])[H])C1=C2C(OC(=C2C2=C([H])C([H])=C([H])C([H])=C2[H])C2=C([H])C([H])=C([H])C([H])=C2[H])=NC([H])=N1)([H])([H])[H],DB07654,,"(5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC",,small molecule,,,,,
O(C(C(N(C1=NC([H])=NC2=C1C(=C(N2[H])C1=C([H])C([H])=C([H])C([H])=C1[H])C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H])([H])[H])[H],DB07655,,"3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE",,small molecule,,,,,
O(C1=C([H])C([H])=C2C(O[H])=C(C(=C([H])C2=C1[H])[H])[H])[H],DB07661,,"1,6-DIHYDROXY NAPHTHALENE",,small molecule,,,,,
BrC1=C([H])C(N(C2=NC([H])=NC3=C(C(=C(N(C(=O)C(=C([H])[H])[H])[H])C([H])=C23)[H])[H])[H])=C([H])C([H])=C1[H],DB07662,,N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE,,small molecule,,,,,
N(C1=NC(N(C2=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C2[H])[H])=NN1C(=S)N(C1=C(F)C([H])=C([H])C([H])=C1F)[H])([H])[H],DB07664,,"5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE",,small molecule,,,,,
N(C(=N[H])N(OC(C(N(C(=O)C(C1=C(C#N)C([H])=C([H])C(N(C(C(F)(F)C2=NC([H])=C([H])C([H])=C2[H])([H])[H])[H])=C1F)([H])[H])[H])([H])[H])([H])[H])[H])([H])[H],DB07665,,"N-[2-(carbamimidamidooxy)ethyl]-2-{6-cyano-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-fluorophenyl}acetamide",,small molecule,,,,,
C(C1=C([H])C(N=NC2=C(C(O[H])=O)C([H])=C([H])C([H])=C2[H])=C([H])C(C([H])([H])[H])=C1O[H])([H])([H])[H],DB07667,,"2-((3',5'-DIMETHYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID",,small molecule,,,,,
C(C(N(C(C([H])([H])[H])([H])[H])C1=C([H])C(O[H])=C(C(=C(C([H])([H])[H])C(O[H])=O)[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB07668,,3-(4-DIETHYLAMINO-2-HYDROXY-PHENYL)-2-METHYL-PROPIONIC ACID,,small molecule,,,,,
C(C1=C(C([H])([H])[H])C(=O)C2=C(C(=C(C(=C2[H])[H])[H])[H])C1=O)([H])([H])[H],DB07669,,"2,3-DIMETHYL-1,4-NAPHTHOQUINONE",,small molecule,,,,,
C(N(C1=C([H])C([H])=NN1C1=C([H])C([H])=C([H])C([H])=C1[H])S(=O)(=O)C1=C([H])C([H])=C(C([H])([H])[H])C([H])=C1[H])([H])([H])[H],DB07670,,4-METHYL-N-METHYL-N-(2-PHENYL-2H-PYRAZOL-3-YL)BENZENESULFONAMIDE,,small molecule,,,,,
C(C(OP(O[H])(=S)OC(C([H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07674,,"O,O-DIETHYL HYDROGEN THIOPHOSPHATE",,small molecule,,,,,
C(C1=NC2=C(C(SC(C2([H])[H])([H])[H])([H])[H])C(=O)N1[H])([H])([H])[H],DB07677,,"2-methyl-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(S([O-])(=O)=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07681,,DODECANESULFONATE ION,,small molecule,,,,,
C(N(C([H])([H])[H])C1=C2C(=C(C(=C([H])C2=C([H])C([H])=C1[H])S(O[H])(=O)=O)[H])[H])([H])([H])[H],DB07684,,5-(DIMETHYLAMINO)-2-NAPHTHALENESULFONIC ACID,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(N(C2=C([H])C(OC(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])([H])[H])=NC3=NC(=NN23)[H])[H])C([H])=C1[H])([H])[H],DB07685,,"4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE",,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(N(C2=C([H])C(N(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])[H])=NC3=NC(=NN23)[H])[H])C([H])=C1[H])([H])[H],DB07686,,"4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE",,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(N(C2=C([H])C(OC3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])=NC3=NC(=NN23)[H])[H])C([H])=C1[H])([H])[H],DB07688,,"4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE",,small molecule,,,,,
C(OC(=O)C1(C([H])([H])C([H])([H])N(C(=O)C2=C([H])C([H])=C(N(C(C3=NC4=C(N([H])[H])N=C(N([H])[H])N=C4N=C3[H])([H])[H])[H])C([H])=C2[H])C([H])([H])C1([H])[H])[H])([H])([H])[H],DB07689,,"METHYL 1-(4-{[(2,4-DIAMINOPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)PIPERIDINE-4-CARBOXYLATE",,small molecule,,,,,
O(C(=O)C1=C(N(C(=O)C2=C([H])C([H])=C([H])C(S(=O)(=O)N3C([H])([H])C([H])([H])C4=C(C(=C(C(=C4[H])[H])[H])[H])C3([H])[H])=C2[H])[H])C([H])=C([H])C([H])=C1[H])[H],DB07691,,"2-({[3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)phenyl]carbonyl}amino)benzoic acid",,small molecule,,,,,
FC1=C([H])C([H])=C([H])C(F)=C1S(=O)(=O)N1C([H])([H])C([H])([H])N(S(=O)(=O)C2=C([H])C3=C(OC(C(O3)([H])[H])([H])[H])C([H])=C2[H])C([H])([H])C1([H])[H],DB07692,,"1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine",,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C(C([H])([H])[H])=C1C(=O)N(C1=C([H])C(Br)=C(O[H])C(Br)=C1[H])[H])([H])([H])[H],DB07693,,"N-(3,5-dibromo-4-hydroxyphenyl)-2,6-dimethylbenzamide",,small molecule,,,,,
O(C1=C(Br)C([H])=C(N(C(=O)C2=C(Cl)C([H])=C([H])C(Cl)=C2[H])[H])C([H])=C1Br)[H],DB07694,,"2,5-dichloro-N-(3,5-dibromo-4-hydroxyphenyl)benzamide",,small molecule,,,,,
C(C1=C([H])C(C(=O)N(C2=C([H])C(Br)=C(O[H])C(Br)=C2[H])[H])=C([H])C(C([H])([H])[H])=C1O[H])([H])([H])[H],DB07695,,"N-(3,5-dibromo-4-hydroxyphenyl)-4-hydroxy-3,5-dimethylbenzamide",,small molecule,,,,,
C(OC1=C([H])C([H])=C(S(=O)(=O)N2C([H])([H])C([H])([H])N(S(=O)(=O)C3=C([H])C4=C(OC(C(O4)([H])[H])([H])[H])C([H])=C3[H])C([H])([H])C2([H])[H])C([H])=C1[H])([H])([H])[H],DB07697,,"1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine",,small molecule,,,,,
N(C1=C([H])C([H])=C([H])C(C2=C3N=C(N(C4=C([H])C([H])=C([H])C(Cl)=C4[H])[H])C(=C([H])N3N=C2[H])[H])=C1[H])([H])[H],DB07698,,"3-(3-aminophenyl)-N-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-amine",,small molecule,,,,,
C(OC1=C([H])C([H])=C(C(C(C2=C3N=C(N([H])C3=C([H])C3=C2N=C(N([H])[H])N(C3=O)[H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB07704,,"6-AMINO-4-[2-(4-METHOXYPHENYL)ETHYL]-1,7-DIHYDRO-8H-IMIDAZO[4,5-G]QUINAZOLIN-8-ONE",,small molecule,,,,,
O(C1=C([H])C([H])=C(N2N=C3C(=C(C(O[H])=C([H])C3=C2Cl)[H])[H])C([H])=C1[H])[H],DB07708,,3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,,small molecule,,,,,
C(C(C1=C2C(=C(O[H])C(=C([H])C2=NN1C1=C([H])C([H])=C(O[H])C([H])=C1[H])[H])[H])([H])[H])([H])([H])[H],DB07712,,3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,,small molecule,,,,,
C(C1=C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C(=O)C2=C(C(=C(C(=C2[H])[H])[H])[H])C1=O)([H])([H])[H],DB07714,,"6-(3-METHYL-1,4-DIOXO-1,4-DIHYDRONAPHTHALEN-2-YL)HEXANOIC ACID",,small molecule,,,,,
C(C1=C([H])C(O[H])=C2C(=O)C3=C(O[H])C([H])=C(O[H])C([H])=C3C(=O)C2=C1[H])([H])([H])[H],"DB07715
DB12653",518-82-1,Emodin,"1,3,8-trihydroxy-6-methyl-9,10-anthracenedione
1,3,8-trihydroxy-6-methyl-9,10-anthraquinone
Schuttgelb",small molecule,,,,,
O(C(=O)C(=O)C(C1=C([H])C([H])=C(O[H])C([H])=C1[H])([H])[H])[H],DB07718,,3-(4-HYDROXY-PHENYL)PYRUVIC ACID,,small molecule,,,,,
C(C(OP(=O)(OC(C([H])([H])[H])([H])[H])OC1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB07721,,DIETHYL 4-METHOXYPHENYL PHOSPHATE,,small molecule,,,,,
O(C(C(C(OC1=C([H])C([H])=C([N+]([O-])=O)C([H])=C1[H])([H])[H])([H])[H])([H])[H])[H],DB07722,,3-(4-NITRO-PHENOXY)-PROPAN-1-OL,,small molecule,,,,,
C(OC1=C([H])C2=C(N(C(=C2C(C(C(O[H])=O)([H])[H])([H])[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB07723,,3-(5-methoxy-1H-indol-3-yl)propanoic acid,,small molecule,,,,,
C(OC1=C([H])C([H])=C(S(=O)(=O)N2C([H])=C(C(C(C(O[H])=O)([H])[H])([H])[H])C3=C2C(=C(C(OC([H])([H])[H])=C3[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB07724,835619-41-5,Indeglitazar,,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C1=C(O[H])C([H])=C([H])C(O[H])=C1[H])([H])([H])[H],DB07726,,"2-tert-butylbenzene-1,4-diol",,small molecule,,,,,
FC1=C(C2=NC([H])=C([H])C(C3=C([H])C4=C(C(C(N(C4=O)[H])([H])[H])([H])[H])N3[H])=C2[H])C([H])=C([H])C([H])=C1[H],DB07728,,"2-[2-(2-FLUOROPHENYL)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE",,small molecule,,,,,
FC1=C([H])C(C(=O)N(C2=C([H])C(C3=NN=NN3[H])=C([H])C([H])=C2[H])[H])=C([H])C([H])=C1[H],DB07729,,3-fluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzamide,,small molecule,,,,,
O(C1=C([H])C([H])=C([H])C(C2=C([H])C(=O)N([H])S2(=O)=O)=C1[H])[H],DB07730,,"5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE",,small molecule,,,,,
N(C1=C(N=NC2=C([H])C([H])=C(O[H])C([H])=C2[H])C(N([H])[H])=NN1[H])([H])[H],DB07731,,"4-[(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYL]PHENOL",,small molecule,,,,,
O(P(O[H])(=O)OC(C(N(S(=O)(=O)C1=C([H])C2=C(C(=C(C([H])=C2C([H])=C1[H])[H])[H])[H])[H])([H])[H])([H])[H])[H],DB07732,,2-[(2-NAPHTHYLSULFONYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE,,small molecule,,,,,
C(N1N=C(C(F)(F)F)C2=C1SC(=C2[H])C(=O)N(C(C(S[H])([H])[H])([H])[H])[H])([H])([H])[H],DB07733,,"1-METHYL-3-TRIFLUOROMETHYL-1H-THIENO[2,3-C]PYRAZOLE-5-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)-AMIDE",,small molecule,,,,,
S(C(C(C(C(=O)N(C1(C([H])([H])C([H])([H])N(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])C([H])([H])C1([H])[H])[H])[H])([H])[H])([H])[H])([H])[H])[H],DB07734,,N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide,,small molecule,,,,,
C(OC1=C([H])C([H])=C([H])C(OC([H])([H])[H])=C1C(N1C([H])([H])C([H])([H])C(N(C(=O)C(C(C(S[H])([H])[H])([H])[H])([H])[H])[H])([H])C([H])([H])C1([H])[H])([H])[H])([H])([H])[H],DB07735,,"N-[1-(2,6-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide",,small molecule,,,,,
C(OC1=C(OC([H])([H])[H])C(C(N2C([H])([H])C([H])([H])C(N(C(=O)C(C(C(S[H])([H])[H])([H])[H])([H])[H])[H])([H])C([H])([H])C2([H])[H])([H])[H])=C([H])C(Br)=C1[H])([H])([H])[H],DB07738,,"N-[1-(5-bromo-2,3-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide",,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(C(=O)N(C(C2=C(F)C(F)=C([H])C([H])=C2[H])([H])[H])[H])C([H])=C1[H])([H])[H],DB07742,,"N-(2,3-DIFLUORO-BENZYL)-4-SULFAMOYL-BENZAMIDE",,small molecule,,,,,
FC(F)(F)C1=NN=C(SC(=O)C2=C([H])C([H])=C(C#CC3=C([H])C([H])=C([H])C([H])=C3[H])O2)N1[H],DB07743,,"S-[5-(TRIFLUOROMETHYL)-4H-1,2,4-TRIAZOL-3-YL] 5-(PHENYLETHYNYL)FURAN-2-CARBOTHIOATE",,small molecule,,,,,
O(P(O[H])(=O)OC(C(N(C(=O)C1=C([H])C([H])=C(OC(F)(F)F)C([H])=C1[H])[H])([H])[H])([H])[H])[H],DB07745,,2-{[4-(TRIFLUOROMETHOXY)BENZOYL]AMINO}ETHYL DIHYDROGEN PHOSPHATE,,small molecule,,,,,
C(C(C1=C(C([H])([H])[H])C(C(O[H])=O)=C(N(S(=O)(=O)C2=C([H])C([H])=C(F)C([H])=C2[H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB07746,,3-ETHYL-6-{[(4-FLUOROPHENYL)SULFONYL]AMINO}-2-METHYLBENZOIC ACID,,small molecule,,,,,
O(P(O[H])(=O)OC(C(N(S(=O)(=O)C1=C([H])C([H])=C(OC(F)(F)F)C([H])=C1[H])[H])([H])[H])([H])[H])[H],DB07748,,2-({[4-(TRIFLUOROMETHOXY)PHENYL]SULFONYL}AMINO)ETHYL DIHYDROGEN PHOSPHATE,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C(C2=C([H])C(F)=C([H])C(F)=C2[H])C([H])=C1[H])[H],DB07753,,"3',5'-DIFLUOROBIPHENYL-4-CARBOXYLIC ACID",,small molecule,,,,,
C(C1=NC2=C(C(=C(C(F)=C2C(N([H])[H])=C1C(SC(C1=C([H])C(C(O[H])(O[H])C(F)(F)F)=C([H])C([H])=C1[H])([H])[H])([H])[H])[H])[H])[H])([H])([H])[H],DB07756,,"1-[3-({[(4-AMINO-5-FLUORO-2-METHYLQUINOLIN-3-YL)METHYL]THIO}METHYL)PHENYL]-2,2,2-TRIFLUOROETHANE-1,1-DIOL",,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C(C2=C(Cl)C([H])=C([H])C(Cl)=C2[H])O1)[H],DB07758,,"5-(2,5-DICHLOROPHENYL)-2-FUROIC ACID",,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C(C2=C(C(F)(F)F)C([H])=C([H])C([H])=C2[H])O1)[H],DB07759,,5-[2-(TRIFLUOROMETHYL)PHENYL]-2-FUROIC ACID,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C([H])C(C(=NOC(C(ON=C(C2=C([H])C(=O)N([H])C(=O)N2[H])[H])([H])[H])([H])[H])[H])=C1[H])[H],DB07760,,"3-[(1E,7E)-8-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-3,6-dioxa-2,7-diazaocta-1,7-dien-1-yl]benzoic acid",,small molecule,,,,,
C(C(C(C(C([H])([H])[H])([H])[H])(C(=O)N(C1=C(N(C(C([H])([H])[H])=O)[H])C([H])=C([H])C(C(O[H])=O)=C1[H])[H])[H])([H])[H])([H])([H])[H],DB07762,,4-(N-ACETYLAMINO)-3-[N-(2-ETHYLBUTANOYLAMINO)]BENZOIC ACID,,small molecule,,,,,
O(C(=O)C1=C(C2(C3=C(C(=C(O[H])C(=C3[H])[H])[H])OC3=C2C(=C(C(O[H])=C3[H])[H])[H])[H])C([H])=C([H])C([H])=C1[H])[H],DB07764,,FLUORESCIN,,small molecule,,,,,
C(OC(=O)C1(C([H])([H])C([H])([H])N(C(=O)C2=C([H])C([H])=C(N(C([H])([H])[H])C(C3=NC4=C(N([H])[H])N=C(N([H])[H])N=C4N=C3[H])([H])[H])C([H])=C2[H])C([H])([H])C1([H])[H])[H])([H])([H])[H],DB07765,,"METHYL 1-(4-{[(2,4-DIAMINOPTERIDIN-6-YL)METHYL](METHYL)AMINO}BENZOYL)PIPERIDINE-4-CARBOXYLATE",,small molecule,,,,,
C(OC1=C(O[H])C([H])=C([H])C(C(=C(C(O[H])=O)[H])[H])=C1[H])([H])([H])[H],DB07767,1135-24-6,Ferulic acid,,small molecule,,,,,
C(C1=C([H])C([H])=C(S(=O)(=O)N(C2=C(C(O[H])=O)SC(C3=C([H])C([H])=C(F)C([H])=C3[H])=C2[H])[H])C([H])=C1[H])([H])([H])[H],DB07770,,5-(4-FLUOROPHENYL)-3-{[(4-METHYLPHENYL)SULFONYL]AMINO}THIOPHENE-2-CARBOXYLIC ACID,,small molecule,,,,,
C(C(C([H])([H])[H])=C(C(C(C(C([H])([H])[H])=C(C(C(C(C([H])([H])[H])=C(C(ON(C(=O)C(P(O[H])(O[H])=O)([H])[H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB07771,,"[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID",,small molecule,,,,,
O(P(O[H])(=O)OC(C(C(C1=C([H])N([H])C2=C1C(=C(F)C(=C2[H])[H])[H])([H])[H])([H])[H])([H])[H])[H],DB07773,,5-FLUOROINDOLE PROPANOL PHOSPHATE,,small molecule,,,,,
O(C1=C([H])C2=C(C(=O)C(O2)=C(C2=C(O[H])C(Br)=C(O[H])C(Br)=C2[H])[H])C(O[H])=C1[H])[H],DB07775,,"3',5'-DIBROMO-2',4,4',6'-TETRAHYDROXY AURONE",,small molecule,,,,,
O=C1C([H])=C(C2=C([H])C([H])=C([H])C([H])=C2[H])OC2=C1C(=C(C(=C2[H])[H])[H])[H],"DB07776
DB11139",525-82-6,Flavone,"2-Phenyl-4-benzopyron
2-Phenyl-4-chromone
2-phenyl-4H-1-benzopyran-4-one
2-phenyl-4H-benzopyran-4-one
2-phenyl-��-benzopyrone
2-Phenylbenzopyran-4-one
2-phenylchromone
Flavon",small molecule,,"Tablet, coated",Oral,,
C(C(OC1=C(F)C(C(C(N(C(=S)N(C2=NC([H])=C(C#N)C([H])=C2[H])[H])[H])([H])[H])([H])[H])=NC([H])=C1[H])([H])[H])([H])([H])[H],DB07781,,N-[[3-FLUORO-4-ETHOXY-PYRID-2-YL]ETHYL]-N'-[5-NITRILOMETHYL-PYRIDYL]-THIOUREA,,small molecule,,,,,
FC1=C2C(=O)N(C(=O)N(C(C(C(C(N3C([H])([H])C([H])([H])C(C4=C([H])C([H])=C([H])C([H])=C4[H])=C([H])C3([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C2=C([H])C([H])=C1[H])[H],DB07787,,"5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE",,small molecule,,,,,
C(C1=C([H])C(N(C(=O)N=C2N([H])C([H])=C(C(C(N(C3=NC([H])=NC(N(C4=NN([H])C([H])=N4)[H])=C3[H])[H])([H])[H])([H])[H])S2)[H])=C(C(F)(F)F)O1)([H])([H])[H],DB07789,,"1-[5-methyl-2-(trifluoromethyl)furan-3-yl]-3-[(2Z)-5-(2-{[6-(1H-1,2,4-triazol-3-ylamino)pyrimidin-4-yl]amino}ethyl)-1,3-thiazol-2(3H)-ylidene]urea",,small molecule,,,,,
C(OC(C(N(S(=O)(=O)C1=C([H])C([H])=C(N(C2=NC(C3=C([H])N=C(C([H])([H])[H])N3C(C([H])([H])[H])(C([H])([H])[H])[H])=C([H])C([H])=N2)[H])C([H])=C1[H])[H])([H])[H])([H])[H])([H])([H])[H],DB07790,,N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE,,small molecule,,,,,
C(N(S(=O)(=O)C1=C([H])C([H])=C(N(C2=NC(C3=C([H])N=C(C([H])([H])[H])N3C3(C([H])([H])C3([H])[H])[H])=C([H])C([H])=N2)[H])C([H])=C1[H])[H])([H])([H])[H],DB07791,,4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE,,small molecule,,,,,
N(C1=NN([H])C2=C1C(=C(N=N2)C1=C2C(=C(C(=C([H])N2N=C1C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H])[H])[H])([H])[H],DB07794,,"5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE",,small molecule,,,,,
O(C1=C([H])C2=C(C(=O)C(O[H])=C(O2)C2=C([H])C(O[H])=C(O[H])C([H])=C2[H])C([H])=C1[H])[H],DB07795,,"3,7,3',4'-TETRAHYDROXYFLAVONE",,small molecule,,,,,
C(C(OC1=C(F)C(C(C(N(C(=S)N(C2=NC([H])=C(Cl)C([H])=C2[H])[H])[H])([H])[H])([H])[H])=NC([H])=C1[H])([H])[H])([H])([H])[H],DB07797,,N-[[3-FLUORO-4-ETHOXY-PYRID-2-YL]ETHYL]-N'-[5-CHLORO-PYRIDYL]-THIOUREA,,small molecule,,,,,
ClC1=C([H])N=C(N(S(=O)(=O)C2=C(N(C(=O)C3=C([H])C([H])=C(N4C([H])=C([H])C([H])=C([H])C4=O)C([H])=C3[H])[H])C([H])=C([H])C([H])=C2[H])[H])C([H])=C1[H],DB07800,,N-(2-(((5-CHLORO-2-PYRIDINYL)AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE,,small molecule,,,,,
C(C(C(C(N(C(=O)C1=C([H])C(N(C(=O)C(C(C(C(C(N(C2=NC([H])=NC3=C2N=C(N3[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])=C([H])C([H])=C1[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07801,,N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide,,small molecule,,,,,
C(C1=C(Br)C(=O)OC2=C1C(=C(C(O[H])=C2Br)[H])[H])([H])([H])[H],DB07802,,"3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE",,small molecule,,,,,
O(C(=O)C1=C([H])N([H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])=N1)[H],DB07803,,2-phenyl-1H-imidazole-4-carboxylic acid,,small molecule,,,,,
C(C(C([H])([H])[H])(C(Cl)([H])[H])C(=O)N(C1=C([H])C([H])=C(C(F)(F)F)C([H])=C1[H])[H])([H])([H])[H],DB07805,,"3-CHLORO-2,2-DIMETHYL-N-[4-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE",,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C(C(=O)C2=C([H])C(N(C(C3=C([H])C([H])=C(C(N([H])[H])=N[H])C([H])=C3[H])([H])[H])[H])=NC([H])=C2[H])=C1[H])([H])([H])[H],DB07809,,4-({[4-(3-METHYLBENZOYL)PYRIDIN-2-YL]AMINO}METHYL)BENZENECARBOXIMIDAMIDE,,small molecule,,,,,
O(C1=C([H])C([H])=C(C(C(C(=O)C2=C(O[H])C([H])=C(O[H])C([H])=C2O[H])([H])[H])([H])[H])C([H])=C1[H])[H],DB07810,,"3-(4-HYDROXYPHENYL)-1-(2,4,6-TRIHYDROXYPHENYL)PROPAN-1-ONE",,small molecule,,,,,
C(C1=NN=C(C2=C([H])C(C([H])([H])[H])=C(C3=C(C([H])([H])[H])C([H])=C([H])C(C(=O)N(C4(C([H])([H])C4([H])[H])[H])[H])=C3[H])C([H])=C2[H])O1)([H])([H])[H],DB07811,,"N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide",,small molecule,,,,,
O(C(=O)C(N=C(N(C(C1=C([H])C([H])=C([H])C([H])=C1[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H])N(C1=C([H])C([H])=C(C#N)C([H])=C1[H])[H])([H])[H])[H],DB07816,,N-(P-CYANOPHENYL)-N'-DIPHENYLMETHYL-GUANIDINE-ACETIC ACID,,small molecule,,,,,
O=C(N(C1=NC([H])=C([H])S1)[H])N(C1=C([H])C([H])=C([H])C(S(=O)(=O)N2C([H])([H])C([H])([H])N(C3=NC([H])=C([H])C([H])=C3[H])C([H])([H])C2([H])[H])=C1[H])[H],DB07817,,"1-{3-[(4-pyridin-2-ylpiperazin-1-yl)sulfonyl]phenyl}-3-(1,3-thiazol-2-yl)urea",,small molecule,,,,,
O(N(C(=O)C(=C(C1=C(Cl)C([H])=C(Cl)C([H])=C1[H])[H])[H])[H])[H],DB07818,,"(2E)-3-(2,4-DICHLOROPHENYL)-N-HYDROXYACRYLAMIDE",,small molecule,,,,,
O(N(C(=O)C(=C(C1=C([H])C([H])=C(Cl)C([H])=C1[H])[H])[H])[H])[H],DB07819,,(2E)-3-(4-CHLOROPHENYL)-N-HYDROXYACRYLAMIDE,,small molecule,,,,,
C(C(OC(N1C(=O)N([H])C(=O)C(C(C([H])([H])[H])(C([H])([H])[H])[H])=C1C(C1=C([H])C(C([H])([H])[H])=C([H])C(C([H])([H])[H])=C1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07820,,"6-(3',5'-DIMETHYLBENZYL)-1-ETHOXYMETHYL-5-ISOPROPYLURACIL",,small molecule,,,,,
C(C(C1=C(C([H])([H])[H])N([H])N(C2=NN=NN2[H])C1=O)([H])[H])([H])([H])[H],DB07824,,"4-ethyl-5-methyl-2-(1H-tetrazol-5-yl)-1,2-dihydro-3H-pyrazol-3-one",,small molecule,,,,,
ClC1=C([H])C(C(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])=C(OC(C(=O)N(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])([H])[H])C([H])=C1[H],DB07826,,2-[4-chloro-2-(phenylcarbonyl)phenoxy]-N-phenylacetamide,,small molecule,,,,,
C(N1C(=O)N(C(C2=C([H])C([H])=C(C(O[H])=O)C([H])=C2[H])([H])[H])C(=O)C2=C1C(=C(C(=C2[H])C#CC(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H])[H])([H])([H])[H],DB07827,,"4-{[1-METHYL-2,4-DIOXO-6-(3-PHENYLPROP-1-YN-1-YL)-1,4-DIHYDROQUINAZOLIN-3(2H)-YL]METHYL}BENZOIC ACID",,small molecule,,,,,
FC1=C([H])C([H])=C(C2=NN([H])C([H])=C2C2=C([H])C([H])=NC([H])=C2[H])C([H])=C1[H],DB07829,,4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE,,small molecule,,,,,
C(C(C(C1=C(C(F)(F)F)C([H])=C(N(C(=O)C2=C(N(C(C3=C([H])N([H])C(=O)C([H])=C3[H])([H])[H])[H])C([H])=C([H])C([H])=C2[H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB07831,,"2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE",,small molecule,,,,,
C(C1=C(N(C2=C3C(=C(C(=C([H])C3=NC([H])=C2[H])C2=C([H])SC(C(=O)[H])=N2)[H])[H])[H])C([H])=C(O[H])C([H])=C1[H])([H])([H])[H],DB07832,,"4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde",,small molecule,,,,,
C(C1=NN=C(C2=C([H])C(C3=C([H])C([H])=C(C(=O)N(C4=C([H])C(C#N)=C([H])C([H])=C4[H])[H])C([H])=C3[H])=C(C([H])([H])[H])C([H])=C2[H])O1)([H])([H])[H],DB07833,,"N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide",,small molecule,,,,,
C(C1=NN=C(C2=C([H])C(C3=C([H])C([H])=C(C(=O)N(C(C4(C([H])([H])C4([H])[H])[H])([H])[H])[H])C([H])=C3[H])=C(C([H])([H])[H])C([H])=C2[H])O1)([H])([H])[H],DB07834,,"N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide",,small molecule,,,,,
C(C1=C(C2=C([H])C([H])=C(C(=O)N(C(C3(C([H])([H])C3([H])[H])[H])([H])[H])[H])C([H])=C2[H])C([H])=C(C(=O)N(C2(C([H])([H])C2([H])[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB07835,,"N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide",,small molecule,,,,,
O(C(=O)C(C1=C([H])C([H])=C(C2=C([H])N([H])C3=C2C(=C(C(=N3)[H])C2=C([H])C3=C(C(=C(C([H])=C3C([H])=C2[H])[H])[H])[H])[H])C([H])=C1[H])([H])[H])[H],DB07837,,"[4-(5-naphthalen-2-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl]acetic acid",,small molecule,,,,,
O(C1=C(C(=C2SC(=S)N(C(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])C2=O)[H])C([H])=C([H])C([H])=C1[N+]([O-])=O)[H],DB07838,,(Z)-3-BENZYL-5-(2-HYDROXY-3-NITROBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE,,small molecule,,,,,
C(OC1=C([H])C([H])=C([H])C(C(O[H])=C2C([H])=NC3=NC(=C(C(C4=C([H])C(F)=C([H])C(F)=C4[H])=C23)[H])[H])=C1[H])([H])([H])[H],DB07840,,"(E)-[4-(3,5-difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol",,small molecule,,,,,
C(OC1=C(N(C2=NC(N(C3=C(C(N([H])[H])=O)C(F)=C([H])C([H])=C3[H])[H])=C3C(=C(N([H])C3=N2)[H])[H])[H])C([H])=C([H])C(C(S(C([H])([H])[H])(=O)=O)([H])[H])=C1[H])([H])([H])[H],DB07845,,"2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide",,small molecule,,,,,
C(C(C1=C(N=C(O[H])OC2=C([H])C3=C(N(C([H])([H])[H])C4(C3(C([H])([H])[H])C([H])([H])C([H])([H])[N+]4(C([H])([H])[H])[O-])[H])C([H])=C2[H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB07846,,"1S,3AS,8AS-TRIMETHYL-1-OXIDO-1,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL 2-ETHYLPHENYLCARBAMATE",,small molecule,,,,,
C(C1=NC(C(O[H])=O)=NN1C1=C([H])C(Cl)=C([H])C(Cl)=C1[H])([H])([H])[H],DB07852,,"1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID",,small molecule,,,,,
C(N(C(C1=C([H])C([H])=C(C2=NC([H])=NC3=C2N=C(N3[H])[H])C([H])=C1[H])([H])[H])[H])([H])([H])[H],DB07854,,N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE,,small molecule,,,,,
ClC1=C([H])C([H])=C(C2(C([H])([H])C([H])([H])N([H])C([H])([H])C2([H])[H])C2=C([H])C([H])=C(C3=NC([H])=NC4=C3N=C(N4[H])[H])C([H])=C2[H])C([H])=C1[H],DB07856,,6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE,,small molecule,,,,,
ClC1=C([H])C([H])=C(C2(C([H])([H])C([H])([H])N([H])C([H])([H])C2([H])[H])C2=C([H])C([H])=C(C3=C([H])N([H])N=C3[H])C([H])=C2[H])C([H])=C1[H],DB07859,,4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE,,small molecule,,,,,
C(C(C(C(C([H])([H])[H])([H])[H])(N1C([H])=C([H])C2=C3C(N([H])[H])=NC(N([H])[H])=NC3=C(C([H])=C12)[H])[H])([H])[H])([H])([H])[H],DB07862,,"7-(1-ETHYL-PROPYL)-7H-PYRROLO-[3,2-F]QUINAZOLINE-1,3-DIAMINE",,small molecule,,,,,
[O-][N+](=O)C1=C([H])C(C(=O)N(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])=C(Cl)C([H])=C1[H],DB07863,,2-chloro-5-nitro-N-phenylbenzamide,,small molecule,,,,,
C(C(C([H])([H])[H])(C1=C(OC#CC2(C([H])([H])C2([H])[H])[H])C2=C(C(=C(C(F)=C2[H])[H])[H])N([H])C1=O)[H])([H])([H])[H],DB07864,,4-[(CYCLOPROPYLETHYNYL)OXY]-6-FLUORO-3-ISOPROPYLQUINOLIN-2(1H)-ONE,,small molecule,,,,,
O=C1C([H])([H])C([H])([H])C([H])([H])C(N(C2=NN=NN2[H])[H])=C1[H],DB07865,,3-(1H-tetrazol-5-ylamino)cyclohex-2-en-1-one,,small molecule,,,,,
C(C(C(C1=C(OC2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])C2=C(C(=C(C(Cl)=C2[H])[H])[H])N([H])C1=O)([H])[H])([H])[H])([H])([H])[H],DB07867,,6-CHLORO-4-(CYCLOHEXYLOXY)-3-PROPYLQUINOLIN-2(1H)-ONE,,small molecule,,,,,
C(C(C(C1=C(SC2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])C2=C(C(=C(C(Cl)=C2[H])[H])[H])N([H])C1=O)([H])[H])([H])[H])([H])([H])[H],DB07868,,6-CHLORO-4-(CYCLOHEXYLSULFANYL)-3-PROPYLQUINOLIN-2(1H)-ONE,,small molecule,,,,,
C(C(C([H])([H])[H])(C1=C(OC2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])C2=C(C(=C(C(Cl)=C2[H])[H])[H])N([H])C1=O)[H])([H])([H])[H],DB07871,,6-CHLORO-4-(CYCLOHEXYLOXY)-3-ISOPROPYLQUINOLIN-2(1H)-ONE,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(O[H])(P(O[H])(O[H])=O)P(O[H])(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07873,,"(1-HYDROXYDODECANE-1,1-DIYL)BIS(PHOSPHONIC ACID)",,small molecule,,,,,
C(C(C([H])([H])[H])(N(C(C(C(N1C(SC2=C(Br)C([H])=C3OC(OC3=C2[H])([H])[H])=NC2=C1N=C(N=C2N([H])[H])[H])([H])[H])([H])[H])([H])[H])[H])[H])([H])([H])[H],DB07877,,"8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE",,small molecule,,,,,
O(N(C(=O)C1=C([H])C([H])=C(C(=O)N2C([H])([H])C([H])([H])N3C(=NC(=C3C3=C([H])C([H])=C([H])C([H])=C3[H])[H])C2([H])[H])S1)[H])[H],DB07879,,"N-hydroxy-5-[(3-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)carbonyl]thiophene-2-carboxamide",,small molecule,,,,,
O(C(=O)C1=C(N=NC2=C([H])C([H])=C(O[H])C([H])=C2[H])C([H])=C([H])C([H])=C1[H])[H],DB07880,,2-((4'-HYDROXYPHENYL)-AZO)BENZOIC ACID,,small molecule,,,,,
O(C1=C(SC(C(C(=C(P(O[H])(O[H])=O)[H])[H])([H])[H])([H])[H])C([H])=C([H])C([H])=C1[H])[H],DB07890,,4-(2-HYDROXYPHENYLTHIO)-1-BUTENYLPHOSPHONIC ACID,,small molecule,,,,,
C(C1=C(SC2=C([H])C([H])=C([H])C([H])=C2[H])N(C(OC(C(O[H])([H])[H])([H])[H])([H])[H])C(=O)N([H])C1=O)([H])([H])[H],DB07892,,1-(2-HYDROXYETHYLOXYMETHYL)-6-PHENYL THIOTHYMINE,,small molecule,,,,,
O(C1=C(SC(C(C(=C(P(O[H])(O[H])=O)[H])[H])([H])[H])([H])[H])C([H])=C(F)C([H])=C1[H])[H],DB07894,,4-(2-HYDROXY-4-FLUOROPHENYLTHIO)-BUTYLPHOSPHONIC ACID,,small molecule,,,,,
O(C(C(C(C(C(C(C(C(N(C(O[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB07897,,1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE,,small molecule,,,,,
C(C1=NC(C2=NC([H])=C([H])C([H])=C2[H])=NC(N(C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])[H])=C1Cl)([H])([H])[H],DB07901,,5-CHLORO-6-METHYL-N-(2-PHENYLETHYL)-2-PYRIDIN-2-YLPYRIMIDIN-4-AMINE,,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])OC(=O)N(C1=C([H])C([H])=C([H])N=C1C(=O)N(C1=NC([H])=C([H])S1)[H])[H])([H])([H])[H],DB07902,,"TERT-BUTYL {2-[(1,3-THIAZOL-2-YLAMINO)CARBONYL]PYRIDIN-3-YL}CARBAMATE",,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C(=O)N(C1=C([H])C([H])=C([H])N=C1C(=O)N(C1=NC([H])=C([H])S1)[H])[H])([H])([H])[H],DB07903,,"3-[(2,2-DIMETHYLPROPANOYL)AMINO]-N-1,3-THIAZOL-2-YLPYRIDINE-2-CARBOXAMIDE",,small molecule,,,,,
C(C1=C(C(C(O[H])([H])[H])([H])[H])C(=O)OC2=C1C(=C(C(O[H])=C2[H])[H])[H])([H])([H])[H],DB07908,,7-HYDROXY-4-METHYL-3-(2-HYDROXY-ETHYL)COUMARIN,,small molecule,,,,,
[O-]C(=O)C(=O)C(=C(C(C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H])[H],DB07911,,"(3E)-2,6-DIOXO-6-PHENYLHEX-3-ENOATE",,small molecule,,,,,
C(C(C(C(C(C(=O)C(P(O[H])(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07912,,2-OXOHEPTYLPHOSPHONIC ACID,,small molecule,,,,,
C(C(N1C([H])([H])C([H])([H])C(OC(C2=C([H])C([H])=C([H])C([H])=C2[H])(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])([H])C([H])([H])C1([H])[H])([H])[H])(C(C1=NN=NN1[H])([H])[H])([H])[H],DB07917,,4-(BENZHYDRYLOXY)-1-[3-(1H-TETRAAZOL-5-YL)PROPYL]PIPERIDINE,,small molecule,,,,,
C(C(C(C(C(C(C(C1=[N+]([O-])C2=C(C(=C(C([H])=C2C(O[H])=C1[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07918,,2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE,,small molecule,,,,,
C(OC1=C([H])C2=C(C3=C(N2[H])C(C([H])([H])[H])=NC([H])=C3[H])C([H])=C1[H])([H])([H])[H],DB07919,,7-METHOXY-1-METHYL-9H-BETA-CARBOLINE,,small molecule,,,,,
O=NC(=O)C(N(S(=O)(=O)C1=C([H])C([H])=C(C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])[H])([H])[H],DB07920,,N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide,,small molecule,,,,,
FC1=C([H])C([H])=C(S(=O)(=O)N(C(C(=O)N=O)([H])[H])[H])C([H])=C1[H],DB07921,,2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide,,small molecule,,,,,
O=NC(=O)C(N(S(=O)(=O)C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H],DB07922,,N-oxo-2-(phenylsulfonylamino)ethanamide,,small molecule,,,,,
O(C(=O)C1=C(S(=O)(=O)N(C2=C(O[H])C([H])=C(C(O[H])=O)C([H])=C2[H])[H])C([H])=C([H])S1)[H],DB07927,,3-[(4-Carboxy-2-hydroxyphenyl)sulfamoyl]-2-thiophenecarboxylic acid,,small molecule,,,,,
C(C1=C([H])C(C(=O)N(N(C(=O)C2=C(C([H])([H])[H])C3=C(OC(C(O3)([H])[H])([H])[H])C([H])=C2[H])[H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=C([H])C(C([H])([H])[H])=C1[H])([H])([H])[H],DB07929,,"N-(TERT-BUTYL)-3,5-DIMETHYL-N'-[(5-METHYL-2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)CARBONYL]BENZOHYDRAZIDE",,small molecule,,,,,
C(C1=NN([H])C2=C1C(OC1=C([H])C(C#N)=C([H])C(C#N)=C1[H])=C(F)C(=C2[H])[H])([H])([H])[H],DB07935,,"5-[(5-fluoro-3-methyl-1H-indazol-4-yl)oxy]benzene-1,3-dicarbonitrile",,small molecule,,,,,
C(C(C(C(OC1=NC(N(C(C(N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])([H])[H])([H])[H])[H])=C2N=C(N(C(C3=C(F)C([H])=C([H])C([H])=C3F)([H])[H])C2=N1)[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB07937,,"2-butoxy-9-(2,6-difluorobenzyl)-N-(2-morpholin-4-ylethyl)-9H-purin-6-amine",,small molecule,,,,,
IC1=C([H])C(C(N(C2=C3C(C(C(C([H])([H])C3=NC3=C(C(=C(C([H])=C23)[H])[H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])=C([H])C([H])=C1[H],DB07940,,"9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE",,small molecule,,,,,
C(N(C(=O)C1=C([H])C(N2C(C([H])([H])[H])=C([H])C(OC(C3=C(F)C([H])=C(F)C([H])=C3[H])([H])[H])=C(Br)C2=O)=C(C([H])([H])[H])C([H])=C1[H])[H])([H])([H])[H],"DB07941
DB11722",586379-66-0,PH-797804,,small molecule,,,,,
FC1=C([H])C([H])=C(C2=C([H])N([H])N=C2C2=C([H])C(F)=NC([H])=C2[H])C([H])=C1[H],DB07942,,2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine,,small molecule,,,,,
O(C(C(=O)N1C([H])([H])C([H])([H])C(C2=NN([H])C(C3=C([H])C([H])=C(Cl)C([H])=C3[H])=C2C2=NC([H])=NC([H])=C2[H])([H])C([H])([H])C1([H])[H])([H])[H])[H],DB07943,,2-{4-[5-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxoethanol,,small molecule,,,,,
C(C1=C([H])C(N(S(=O)(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])[H])=C([H])C(OC(C(N(C2=C([H])C([H])=[N+]([H])C([H])=C2[H])[H])([H])[H])([H])[H])=C1[H])([H])([H])[H],DB07944,,N-{3-METHYL-5-[2-(PYRIDIN-4-YLAMINO)-ETHOXY]-PHENYL}-BENZENESULFONAMIDE,,small molecule,,,,,
N(C(=O)C1=C([H])C([H])=C([H])C(C(N2C3=C(C(C(C(C(C3([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C3=C(C(=C(C(C(O[H])=O)=C23)[H])[H])[H])([H])[H])=C1[H])([H])[H],DB07945,,"5-(3-carbamoylbenzyl)-5,6,7,8,9,10-hexahydrocyclohepta[b]indole-4-carboxylic acid",,small molecule,,,,,
N(C(=N[H])N(OC(C(N(C(=O)C(C1=C(Cl)C([H])=C([H])C(N(C(C(F)(F)C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])[H])=C1F)([H])[H])[H])([H])[H])([H])[H])[H])([H])[H],DB07946,,"N-[2-({[amino(imino)methyl]amino}oxy)ethyl]-2-{6-chloro-3-[(2,2-difluoro-2-phenylethyl)amino]-2-fluorophenyl}acetamide",,small molecule,,,,,
ClC1=C([H])C([H])=C(C(OC(C(N(C(C(N(S(=O)(=O)C2=C([H])C([H])=C([H])C3=C(N=C(C([H])=C23)[H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H],DB07947,,ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE,,small molecule,,,,,
O(C(=O)C(ON=C1C2=C(C(=C(C([H])([H])C2=NC1=C1C(=O)N=C2C(C(=C(C([H])=C12)[H])[H])([H])[H])[H])[H])[H])([H])[H])[H],DB07949,,"({[(3E)-2'-OXO-2',7'-DIHYDRO-2,3'-BIINDOL-3(7H)-YLIDENE]AMINO}OXY)ACETIC ACID",,small molecule,,,,,
O(C(=O)C(C1=C([H])N([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])[H],DB07950,,1H-INDOL-3-YLACETIC ACID,,small molecule,,,,,
O(C(=O)C(N(C(=O)C(C1=C([H])N([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])[H])([H])[H])[H],DB07952,,N-[1H-INDOL-3-YL-ACETYL]GLYCINE ACID,,small molecule,,,,,
C(C(C([H])([H])[H])(C(N1C2=C(N=C(N2[H])[H])C(=O)N(C([H])([H])[H])C1=O)([H])[H])[H])([H])([H])[H],DB07954,28822-58-4,3-isobutyl-1-methyl-7H-xanthine,"1-methyl-3-(2-methylpropyl)-7H-purine-2,6-dione
1-methyl-3-isobutylxanthine
3-isobutyl-1-methyl-3,7-dihydro-1H-purine-2,6-dione
3-isobutyl-1-methylxanthine
3-Isobutyl-1-methyxanthine
IBMX",small molecule,,,,,
N(C1=C([H])C(C(=O)[H])=C(C(C(=O)OC(C(Br)([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H],DB07955,,(2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE,,small molecule,,,,,
C(C(C(C1=C([H])C(C(C(O[H])=O)([H])[H])=C2N(C(C(C(N([H])[H])=O)([H])[H])=C([H])C2=C1[H])[H])([H])[H])([H])[H])([H])([H])[H],DB07958,,(2-CARBAMOYLMETHYL-5-PROPYL-OCTAHYDRO-INDOL-7-YL)ACETIC ACID,,small molecule,,,,,
N1(N=C(C2=NC3=C(C(=C(C(=C3[H])[H])[H])[H])N2[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])[H],DB07959,,3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE,,small molecule,,,,,
ClC1=C([H])C([H])=C([H])C(Cl)=C1C(C(=N[H])N(C(=S)N(C1=C([H])C([H])=C(C#N)C([H])=C1[H])[H])[H])([H])[H],DB07961,,"1-(4-CYANO-PHENYL)-3-[2-(2,6-DICHLORO-PHENYL)-1-IMINO-ETHYL]-THIOUREA",,small molecule,,,,,
C(OC(=O)C(C(N(C(=O)C1=C([H])C(C2=C(F)C([H])=C(F)C([H])=C2[H])=C([H])C(I)=C1O[H])[H])([H])[H])([H])[H])([H])([H])[H],DB07962,,"METHYL N-[(2',4'-DIFLUORO-4-HYDROXY-5-IODOBIPHENYL-3-YL)CARBONYL]-BETA-ALANINATE",,small molecule,,,,,
O(C(=O)C(C(N(C(=O)C1=C([H])C(C2=C(F)C([H])=C(F)C([H])=C2[H])=C([H])C(I)=C1O[H])[H])([H])[H])([H])[H])[H],DB07963,,"N-[(2',4'-DIFLUORO-4-HYDROXY-5-IODOBIPHENYL-3-YL)CARBONYL]-BETA-ALANINE",,small molecule,,,,,
C(N1C([H])([H])C([H])([H])N(C(C(N2C([H])=NC3=C(N(C4(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C4([H])[H])[H])[H])N=C(N=C23)C#N)([H])[H])([H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB07965,,6-(cyclohexylamino)-9-[2-(4-methylpiperazin-1-yl)-ethyl]-9H-purine-2-carbonitrile,6-(Cyclohexylamino)-9-[2-(4-methyl-1-piperazinyl)ethyl]-9H-purine-2-carbonitrile,small molecule,,,,,
N#CC(C1=C([H])C([H])=C(N(C2=NC3=C(C(=C(C([H])=C3C(N(C3=NN([H])C(C4(C([H])([H])C4([H])[H])[H])=C3[H])[H])=N2)[H])[H])[H])[H])C([H])=C1[H])([H])[H],DB07966,,[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile,,small molecule,,,,,
N#CC1=NC2=C(N=C(N2C2(C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])[H])C(N(C2=C(OC(C(C(N3C([H])=C([H])N=C3[H])([H])[H])([H])[H])([H])[H])C([H])=C([H])C([H])=C2[H])[H])=N1,DB07967,,9-CYCLOPENTYL-6-[2-(3-IMIDAZOL-1-YL-PROPOXY)-PHENYLAMINO]-9H-PURINE-2-CARBONITRILE,,small molecule,,,,,
C(OC1=C(N(C(=O)N(C(=O)C2=C(Cl)C([H])=C(F)C([H])=C2[H])[H])[H])C([H])=C(O[H])C([H])=C1[H])([H])([H])[H],DB07968,,N-(2-CHLORO-4-FLUOROBENZOYL)-N'-(5-HYDROXY-2-METHOXYPHENYL)UREA,,small molecule,,,,,
C(N1C([H])([H])C([H])([H])N(C2=C([H])N=C3C(=C(C(=C(C4=C([H])C(O[H])=C([H])C([H])=C4[H])C3=N2)[H])C(F)(F)F)[H])C([H])([H])C1([H])[H])([H])([H])[H],DB07969,,3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol,,small molecule,,,,,
C(C1=C(N(C2=C([H])N=C([H])C(C(N([H])[H])=O)=C2[H])[H])C([H])=C(C(=O)N(C2=C([H])C([H])=C([H])C(C(F)(F)F)=C2[H])[H])C([H])=C1[H])([H])([H])[H],DB07970,,5-[(2-methyl-5-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)amino]pyridine-3-carboxamide,,small molecule,,,,,
N(C1=C([H])C([H])=C(SC2=C([H])C([H])=C(N3C(=O)C4=C(C(=C(N([H])[H])C(=C4[H])[H])[H])C3=O)C([H])=C2[H])C([H])=C1[H])([H])[H],DB07971,,"5-AMINO-2-{4-[(4-AMINOPHENYL)SULFANYL]PHENYL}-1H-ISOINDOLE-1,3(2H)-DIONE",,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C(N2C([H])=NC3=C2C(=C(C(N([H])[H])=C3[H])[H])[H])=C1[H])([H])([H])[H],DB07972,,1-(3-METHYLPHENYL)-1H-BENZIMIDAZOL-5-AMINE,,small molecule,,,,,
C(OC1=C([H])C([H])=C([H])C(C(N2C(C(=O)N(C3(C([H])([H])C([H])([H])N(C(C([H])([H])[H])(C([H])([H])[H])[H])C([H])([H])C3([H])[H])[H])[H])=C([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])([H])[H])=C1[H])([H])([H])[H],DB07973,,N-(1-ISOPROPYLPIPERIDIN-4-YL)-1-(3-METHOXYBENZYL)-1H-INDOLE-2-CARBOXAMIDE,,small molecule,,,,,
C(C(C([H])([H])[H])(N1C([H])([H])C([H])([H])C(N(C(=O)C2=C([H])C3=C(C(=C(C(=C3[H])[H])[H])[H])N2C(C(=O)N(C2=C([H])C([H])=C(Cl)C([H])=C2[H])[H])([H])[H])[H])([H])C([H])([H])C1([H])[H])[H])([H])([H])[H],DB07974,,1-{2-[(4-CHLOROPHENYL)AMINO]-2-OXOETHYL}-N-(1-ISOPROPYLPIPERIDIN-4-YL)-1H-INDOLE-2-CARBOXAMIDE,,small molecule,,,,,
O(C(=O)C1=C(C(=O)N(C2=C(F)C([H])=C(C3=C([H])C(OC(F)(F)F)=C([H])C([H])=C3[H])C([H])=C2F)[H])C([H])([H])C([H])([H])C1([H])[H])[H],DB07975,,"2-({[3,5-DIFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID",,small molecule,,,,,
C(OC1=C([H])C([H])=C([H])C(C2=C([H])C(F)=C(N(C(=O)C3=C(C(O[H])=O)SC([H])=C3[H])[H])C([H])=C2[H])=C1[H])([H])([H])[H],DB07976,,3-{[(3-FLUORO-3'-METHOXYBIPHENYL-4-YL)AMINO]CARBONYL}THIOPHENE-2-CARBOXYLIC ACID,,small molecule,,,,,
O(C(=O)C1=C(C(=O)N(C2=C(F)C([H])=C(C3=C([H])C(OC(F)(F)F)=C([H])C([H])=C3[H])C([H])=C2F)[H])C([H])=C([H])S1)[H],DB07977,,"3-({[3,5-DIFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)THIOPHENE-2-CARBOXYLIC ACID",,small molecule,,,,,
O(C(=O)C1=C(C(=O)N(C2=C(F)C(F)=C(C3=C([H])C(OC(F)(F)F)=C([H])C([H])=C3[H])C(F)=C2F)[H])C([H])=C([H])C1([H])[H])[H],DB07978,,"2-({[2,3,5,6-TETRAFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)CYCLOPENTA-1,3-DIENE-1-CARBOXYLIC ACID",,small molecule,,,,,
O(C(=O)C(=N[H])C(C1=C([H])C(O[H])=C(O[H])C([H])=C1[H])([H])[H])[H],DB07979,,"(2E)-3-(3,4-DIHYDROXYPHENYL)-2-IMINOPROPANOIC ACID",,small molecule,,,,,
C(C(C([H])([H])[H])(N1C(C([H])([H])[H])=NC([H])=C1C1=C([H])C([H])=NC(N(C2=C([H])C([H])=C(N3C([H])([H])C([H])([H])N(C(=O)C(O[H])([H])[H])C([H])([H])C3([H])[H])C([H])=C2[H])[H])=N1)[H])([H])([H])[H],DB07982,,2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol,,small molecule,,,,,
C(OC1=C([H])C2=C(N(C(=O)C3=C([H])C([H])=C(I)C([H])=C3[H])C(C([H])([H])[H])=C2C(C(O[H])=O)([H])[H])C([H])=C1[H])([H])([H])[H],DB07983,,1-(4-IODOBENZOYL)-5-METHOXY-2-METHYL INDOLE-3-ACETIC ACID,,small molecule,,,,,
O(C(=O)C(N(S(=O)(=O)C1=C([H])C([H])=C(N2C([H])([H])C([H])([H])C(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])C([H])([H])C2([H])[H])C([H])=C1[H])[H])([H])[H])[H],DB07986,,[4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID,,small molecule,,,,,
O(S(=O)(=O)OC1=C([H])N([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])[H],DB07992,,3-SULFOOXY-1H-INDOLE,,small molecule,,,,,
N(C1=NC([H])=C([H])C([H])=C1N(C(C1=C([H])C(C2=C([H])C3=C(C(=C(N3[H])[H])[H])C([H])=C2[H])=C([H])C([H])=C1[H])([H])[H])[H])([H])[H],DB07993,,"N~3~-[3-(1H-INDOL-6-YL)BENZYL]PYRIDINE-2,3-DIAMINE",,small molecule,,,,,
N(C1=C(N(C(C2=C(OC(C3=NC([H])=C([H])C([H])=C3[H])([H])[H])C([H])=C([H])C(C3=C([H])C4=C(C(=C(N4[H])[H])[H])C([H])=C3[H])=C2[H])([H])[H])[H])C([H])=C([H])C([H])=N1)([H])[H],DB07994,,"N~3~-[5-(1H-INDOL-6-YL)-2-(PYRIDIN-2-YLMETHOXY)BENZYL]PYRIDINE-2,3-DIAMINE",,small molecule,,,,,
BrC1=C([H])C([H])=C(C(=C(C(N(C(C(N(S(=O)(=O)C2=C([H])C([H])=C([H])C3=C(N=C(C([H])=C23)[H])[H])[H])([H])[H])([H])[H])[H])([H])[H])[H])[H])C([H])=C1[H],DB07995,,N-[2-(4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE SULFONAMIDE,,small molecule,,,,,
C(N(C(C(N(S(=O)(=O)C1=C([H])C([H])=C([H])C2=C(N=C(C([H])=C12)[H])[H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB07997,,N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE,,small molecule,,,,,
O(C(=O)C(OC(=O)C1=C([H])C2=C(C(=C(C([H])=C2C2=C1S(=O)(=O)N(C(C(O[H])=O)([H])[H])C2=O)[H])[H])[H])([H])[H])[H],DB07999,,"{4-[(CARBOXYMETHOXY)CARBONYL]-3,3-DIOXIDO-1-OXONAPHTHO[1,2-D]ISOTHIAZOL-2(1H)-YL}ACETIC ACID",,small molecule,,,,,
O(C(=O)C(N1C(=O)C2=C(C(=C(C3=C([H])C([H])=C([H])C([H])=C32)[H])C(O[H])=O)S1(=O)=O)([H])[H])[H],DB08000,,"2-(CARBOXYMETHYL)-1-OXO-1,2-DIHYDRONAPHTHO[1,2-D]ISOTHIAZOLE-4-CARBOXYLIC ACID 3,3-DIOXIDE",,small molecule,,,,,
C(OC(=O)C1=C(OC(C(=C(C2=C([H])C(C3=C(C(O[H])([H])[H])C(C(O[H])=O)=NO3)=C([H])C([H])=C2[H])[H])[H])([H])[H])C([H])=C([H])C([H])=C1O[H])([H])([H])[H],DB08001,,5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID,,small molecule,,,,,
C(C(N(C(=O)N1C([H])([H])C([H])([H])C(N(C2=NC(C3=C([H])N([H])C4=C3C(=C(C(=C4[H])[H])[H])[H])=C(Cl)C([H])=N2)[H])([H])C([H])([H])C1([H])[H])[H])([H])[H])([H])([H])[H],DB08005,,4-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-N-ethylpiperidine-1-carboxamide,,small molecule,,,,,
C(C1=NC2=NC(=NN2C(N(C2=C([H])C3=C(C4=C([H])C([H])=C([H])C([H])=C4C([H])=C3C([H])=C2[H])[H])[H])=C1[H])[H])([H])([H])[H],DB08006,,"N-anthracen-2-yl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",,small molecule,,,,,
C(C1=NC2=NC(=NN2C(N(C2=C([H])C([H])=C(C(F)(F)F)C([H])=C2[H])[H])=C1[H])[H])([H])([H])[H],DB08008,,"5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine",,small molecule,,,,,
C(C(N(C(C([H])([H])[H])([H])[H])C(C(N(C(=O)C1=C(C([H])([H])[H])N([H])C(C(=C2C(=O)N([H])C3=C2C(=C(Cl)C(=C3[H])[H])[H])[H])=C1C([H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08009,,"5-[(E)-(5-CHLORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]-N-[2-(DIETHYLAMINO)ETHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE",,small molecule,,,,,
O(N=C1C(=O)N(C(C2=C([H])C(F)=C([H])C3=C2OC(OC3([H])[H])([H])[H])([H])[H])C2=C1C(C(=C(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H])=C(C(=C2[H])[H])[H])[H],DB08010,,"(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime",,small molecule,,,,,
O(N=C1C(=O)N(C(C2=C([H])C(F)=C([H])C3=C2OC(OC3([H])[H])([H])[H])([H])[H])C2=C1C(=C(F)C(=C2[H])[H])[H])[H],DB08011,,"(3E)-5-fluoro-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-1H-indole-2,3-dione 3-oxime",,small molecule,,,,,
C(C(OC(=O)C1=C([H])C([H])=C(OC(C(C2(C([H])([H])C([H])([H])N(C3=NN=C(C([H])([H])[H])C([H])=C3[H])C([H])([H])C2([H])[H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB08012,,(METHYLPYRIDAZINE PIPERIDINE ETHYLOXYPHENYL)ETHYLACETATE,,small molecule,,,,,
C(C(OC(=O)C1=C([H])C([H])=C(OC(C(C(C2(C([H])([H])C([H])([H])N(C3=NN=C(C([H])([H])[H])C([H])=C3[H])C([H])([H])C2([H])[H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB08013,,(METHYLPYRIDAZINE PIPERIDINE PROPYLOXYPHENYL)ETHYLACETATE,,small molecule,,,,,
C(C(OC(=O)C1=C([H])C([H])=C(OC(C(C(C(C2(C([H])([H])C([H])([H])N(C3=NN=C(C([H])([H])[H])C([H])=C3[H])C([H])([H])C2([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB08014,,(METHYLPYRIDAZINE PIPERIDINE BUTYLOXYPHENYL)ETHYLACETATE,,small molecule,,,,,
O(N=C1C(=O)N(C(C2=C([H])C(F)=C([H])C3=C2OC(OC3([H])[H])([H])[H])([H])[H])C2=C1C(=C(C(=C2[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])[H],DB08015,,"(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1H-indole-2,3-dione 3-oxime",,small molecule,,,,,
O(P(O[H])(=O)OC(C(C(C(C1=C(Cl)N([H])C(=O)N([H])C1=O)([H])[H])([H])[H])([H])[H])([H])[H])[H],DB08016,,"4-(6-CHLORO-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL) BUTYL PHOSPHATE",,small molecule,,,,,
C(OC1=NN=C(N2C([H])([H])C([H])([H])N(C3=C([H])C(C([H])([H])[H])=C([H])C([H])=C3[H])C([H])([H])C2([H])[H])C([H])=C1[H])([H])([H])[H],DB08017,,3-METHOXY-6-[4-(3-METHYLPHENYL)-1-PIPERAZINYL]PYRIDAZINE,,small molecule,,,,,
ClC1=C([H])C([H])=C([H])C(N(C(=O)C2=C([H])C([H])=C(Br)O2)[H])=C1N1C([H])([H])C([H])([H])N(C(C#C[H])([H])[H])C([H])([H])C1([H])[H],DB08021,,5-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamide,,small molecule,,,,,
C(N(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])C1=NC(C2=C([H])N=C3C(=C(C(=C([H])N23)[H])[H])[H])=C([H])C([H])=N1)([H])([H])[H],DB08023,,"N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amine",,small molecule,,,,,
C(N(C(=O)C(N1C([H])([H])C([H])([H])C(N(C2=NC(C3=C([H])N=C4C(=C(C(=C([H])N34)[H])[H])[H])=C([H])C([H])=N2)[H])([H])C([H])([H])C1([H])[H])([H])[H])[H])([H])([H])[H],DB08026,,"2-{4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]piperidin-1-yl}-N-methylacetamide",,small molecule,,,,,
C(N(C([H])([H])[H])C(C1=C([H])C([H])=C(C(SC(C(N(C(=O)N(C2=C([H])C(Cl)=C(C([H])([H])[H])C([H])=C2[H])[H])[H])([H])[H])([H])[H])([H])[H])O1)([H])[H])([H])([H])[H],DB08027,,1-(3-chloro-4-methylphenyl)-3-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)thio]ethyl}urea,,small molecule,,,,,
ClC1=C([H])C([H])=C(C2=NN([H])C(=NC(C(C(=C([H])[H])[H])([H])[H])([H])[H])SC2([H])[H])C([H])=C1[H],DB08028,,"BUT-3-ENYL-[5-(4-CHLORO-PHENYL)-3,6-DIHYDRO-[1,3,4]THIADIAZIN-2-YLIDENE]-AMINE",,small molecule,,,,,
O(C(C(N(C(C(=O)N(O[H])[H])([H])[H])S(=O)(=O)C1=C([H])C([H])=C(C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])[H],DB08029,,N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide,,small molecule,,,,,
O(N(C(=O)C(C(OC1=C([H])C([H])=C(C2=C([H])C([H])=C(C#N)C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])[H])[H],DB08030,,3-[(4'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide,,small molecule,,,,,
C(C(C([H])([H])[H])(N(C(=O)C1=C([H])C2=C(C(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])=C3N2C([H])([H])C([H])([H])OC2=C3C(=C(C(=C2[H])[H])[H])[H])C([H])=C1[H])[H])C(O[H])=O)([H])([H])[H],DB08031,,"N-[(13-CYCLOHEXYL-6,7-DIHYDROINDOLO[1,2-D][1,4]BENZOXAZEPIN-10-YL)CARBONYL]-2-METHYL-L-ALANINE",,small molecule,,,,,
C(C(N(C(C([H])([H])[H])([H])[H])C(=O)C1=C(N(C(=O)C2=C([H])C([H])=C([H])S2)[H])SC2=C1C(C(C(C2([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08032,,"N,N-DIETHYL-2-[(2-THIENYLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE",,small molecule,,,,,
C(OC1=C(C(=NN(C(=O)C2=C([H])C(O[H])=C(O[H])C([H])=C2[H])[H])[H])C2=C(C(=C(C([H])=C2C([H])=C1[H])[H])[H])[H])([H])([H])[H],DB08034,,"(E)-3,4-DIHYDROXY-N'-[(2-METHOXYNAPHTHALEN-1-YL)METHYLENE]BENZOHYDRAZIDE",,small molecule,,,,,
C(C1=C([H])C(C(C2=NN(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C3=C2C(N([H])[H])=NC(=N3)[H])([H])[H])=C(C([H])([H])[H])C([H])=C1[H])([H])([H])[H],DB08035,,"1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE",,small molecule,,,,,
O=C1N([H])C([H])([H])C2=C3C(=C4N([H])C5=C(C(=C(C(=C5[H])[H])[H])[H])C4=C12)N([H])C1=C3C(=C(C(=C1[H])[H])[H])[H],DB08036,,"6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one",,small molecule,,,,,
C(N(C([H])([H])[H])S(=O)(=O)C1=C([H])C2=C(N(C(=O)C2=C(C2=C([H])C3=C(C(C(C(C3([H])[H])([H])[H])([H])[H])([H])[H])N2[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB08039,,"(3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE",,small molecule,,,,,
C(OC1=C([H])C(N(C2=NC(N(C([H])([H])[H])C3=C([H])C4=C(C(C([H])([H])[H])=NN4[H])C([H])=C3[H])=C([H])C([H])=N2)[H])=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])([H])([H])[H],DB08042,,"N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine",,small molecule,,,,,
FC(F)(F)C1=C([H])C(N(C(=O)N(C2=C([H])C([H])=C(OC3=C([H])C([H])=NC([H])=C3[H])C([H])=C2[H])[H])[H])=C([H])C([H])=C1[H],DB08043,,1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA,,small molecule,,,,,
N(C(C(C(OC1=C([H])C([H])=C(C2=C(C3=C([H])C(Cl)=C(O[H])C([H])=C3O[H])N([H])N=C2[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H],DB08045,,"4-{4-[4-(3-AMINOPROPOXY)PHENYL]-1H-PYRAZOL-5-YL}-6-CHLOROBENZENE-1,3-DIOL",,small molecule,,,,,
O(C1=C([H])C(O[H])=C(C2=NN(C(C(=C([H])[H])[H])([H])[H])C3=C(C(=C(C([H])=C23)[H])[H])C(F)(F)F)C([H])=C1[H])[H],DB08047,,"4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol",,small molecule,,,,,
O(C1=C([H])C2=C(C(=NN2[H])C2=C(O[H])C([H])=C(O[H])C([H])=C2[H])C([H])=C1[H])[H],DB08048,,"4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL",,small molecule,,,,,
O(C1=C([H])C([H])=C2C(OC(=O)C(=C2C2=C([H])C([H])=C([H])C([H])=C2[H])[H])=C1O[H])[H],DB08049,,"7,8-dihydroxy-4-phenyl-2H-chromen-2-one",,small molecule,,,,,
O(C(=O)C(=O)C(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])[H],DB08050,,5-phenyl-2-keto-valeric acid,,small molecule,,,,,
N(C1=NC([H])=NC2=C1C(=NN2C1(C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])C1=C([H])N=C2N(C(=C([H])C2=C1[H])[H])[H])([H])[H],DB08052,,"1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",,small molecule,,,,,
C(OC1=C(OC([H])([H])[H])C([H])=C(C2=NN(C3(C([H])([H])C([H])([H])C3([H])[H])[H])C3=NC(=NC(N([H])[H])=C23)[H])C([H])=C1[H])([H])([H])[H],DB08053,,"1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",,small molecule,,,,,
C(C(C([H])([H])[H])(N1N=C(C2=C([H])C3=C(C(=C(N=C3C([H])=C2[H])[H])[H])[H])C2=C1N=C(N=C2N([H])[H])[H])[H])([H])([H])[H],DB08054,,"1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",,small molecule,,,,,
ClC1=C(N(C2=NC([H])=C(C3=C([H])C([H])=C([H])C([H])=C3[H])N3C(=NC([H])=C23)[H])[H])C([H])=C([H])C([H])=C1[H],DB08055,,"N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine",,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C(C([H])([H])[H])=C1N(C1=NC([H])=C(C2=C([H])C([H])=C([H])C([H])=C2[H])N2C(=NC([H])=C12)[H])[H])([H])([H])[H],DB08056,,"N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine",,small molecule,,,,,
FC1=C(C(=O)N2C([H])([H])C([H])([H])C([H])([H])N([H])C([H])([H])C2([H])[H])C([H])=C(C(C2=NN([H])C(=O)C3=C2C(=C(C(=C3[H])[H])[H])[H])([H])[H])C([H])=C1[H],DB08058,,"4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one",,small molecule,,,,,
N(C1=C(C(=O)C(C(C(O[H])=O)([H])[H])([H])[H])C([H])=C([H])C([H])=C1[H])([H])[H],DB08060,,4-(2-AMINOPHENYL)-4-OXOBUTANOIC ACID,,small molecule,,,,,
ClC1=C([H])C([H])=C(C2=NN([H])C(C3(C([H])([H])C([H])([H])N([H])C([H])([H])C3([H])[H])[H])=C2[H])C([H])=C1[H],DB08061,,4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE,,small molecule,,,,,
C(SC1=NN=C(C2=C([H])C([H])=C(Cl)C([H])=C2[H])N1[H])([H])([H])[H],DB08062,,"3-(4-CHLOROPHENYL)-5-(METHYLTHIO)-4H-1,2,4-TRIAZOLE",,small molecule,,,,,
C(OC1=C([H])C([H])=C(N(C2=C(C3=C([H])C([H])=C([H])C([H])=C3[H])C(=O)N(C(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])C2=O)[H])C([H])=C1[H])([H])([H])[H],DB08063,,"1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE",,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C1=NN([H])C(N(C(=O)N(C2=C([H])C(C(OC3=C([H])N=C([H])C([H])=C3[H])([H])[H])=C(Cl)C([H])=C2[H])[H])[H])=C1[H])([H])([H])[H],DB08064,,N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA,,small molecule,,,,,
N1(C([H])=C([H])C(C2=NC3=C(C(=C(C(=C3[H])[H])[H])[H])N2[H])=N1)[H],DB08065,,2-(1H-pyrazol-3-yl)-1H-benzimidazole,,small molecule,,,,,
O=C(N(C1=C([H])N([H])N=C1C1=NC2=C(C(=C(C(=C2[H])[H])[H])[H])N1[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H],DB08066,,N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE,,small molecule,,,,,
O=C(N(C1(C([H])([H])C1([H])[H])[H])[H])N(C1=C([H])N([H])N=C1C1=NC2=C(C(=C(C([N+]3(C([H])([H])C([H])([H])OC([H])([H])C3([H])[H])[H])([H])[H])C(=C2[H])[H])[H])N1[H])[H],DB08067,,4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM,,small molecule,,,,,
C(C1=C(C2=NN([H])C(=S)N2N([H])[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB08069,,"4-AMINO-5-(2-METHYLPHENYL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOLE-3-THIONE",,small molecule,,,,,
C(C1=NN([H])C([H])=C1C1=C([H])C([H])=C(C(C(N([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB08070,,2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE,,small molecule,,,,,
C(C(C([H])([H])[H])(OC1=C([H])C([H])=C([H])C(N(C(=O)C2=C([H])C(Cl)=C(OC(C(N([H])[H])([H])[H])([H])[H])C(Cl)=C2[H])[H])=C1[H])[H])([H])([H])[H],DB08072,,"4-(2-AMINOETHOXY)-3,5-DICHLORO-N-[3-(1-METHYLETHOXY)PHENYL]BENZAMIDE",,small molecule,,,,,
C(C(C([H])([H])[H])=C(C(N1C([H])=NC(N([H])[H])=C2N=C(N=C12)[H])([H])[H])[H])([H])([H])[H],DB08074,,3-(3-methylbut-2-en-1-yl)-3H-purin-6-amine,,small molecule,,,,,
N(C1=NC(C2=NC(N([H])[H])=NC([H])=C2[H])=C([H])S1)([H])[H],DB08075,,"4-(2-amino-1,3-thiazol-4-yl)pyrimidin-2-amine",,small molecule,,,,,
C(C1=NC(C2=NC(N([H])[H])=NC([H])=C2[H])=C([H])N1C(C1=C(Cl)C([H])=C([H])C([H])=C1Cl)([H])[H])([H])([H])[H],DB08076,,"4-[1-(2,6-dichlorobenzyl)-2-methyl-1H-imidazol-4-yl]pyrimidin-2-amine",,small molecule,,,,,
C(C(C([H])([H])[H])(OC1=C([H])C([H])=C(N(C(=O)N(C2=C([H])C(Cl)=C([H])C(Cl)=C2[H])[H])[H])C([H])=C1[H])C(O[H])=O)([H])([H])[H],DB08077,,"2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID",,small molecule,,,,,
C(C(C(C1=C(OC(C(C(OC2=C([H])C([H])=C(OC(C(O[H])=O)([H])[H])C([H])=C2[H])([H])[H])([H])[H])([H])[H])C([H])=C([H])C(C(C([H])([H])[H])=O)=C1O[H])([H])[H])([H])[H])([H])([H])[H],DB08078,,{4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy}acetic acid,,small molecule,,,,,
C(OC1=C([H])C([H])=C2C(OC(C3=NN=C4C(=C(C(=NN34)C3=C([H])C([H])=C([H])C([H])=C3[H])[H])[H])([H])[H])=C(C(=NC2=C1[H])[H])[H])([H])([H])[H],"DB08079
DB12603",1002304-34-8,AMG-208,"7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline",small molecule,,,,,
O(C(C(N(C(=O)C1=C([H])C([H])=C(Cl)C([H])=C1[H])[H])([H])[H])([H])[H])[H],DB08082,,N-(2-AMINOETHYL)-P-CHLOROBENZAMIDE,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C2=C(N(C(=N2)C2=C([H])SC([H])=N2)[H])C([H])=C1[H])([H])[H],DB08083,,"2-(1,3-thiazol-4-yl)-1H-benzimidazole-5-sulfonamide",,small molecule,,,,,
O(C(=O)C(OC1=C(C(=S)N(C(C2=C(F)C([H])=C(Br)C([H])=C2[H])([H])[H])[H])C([H])=C([H])C(F)=C1[H])([H])[H])[H],DB08084,,IDD594,,small molecule,,,,,
C(C(C(C(C(C(C1=C([H])C([H])=C(C(=O)C(=C([H])[H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08085,,1-(4-HEXYLPHENYL)PROP-2-EN-1-ONE,,small molecule,,,,,
FC(F)(F)C(N(C(C(F)(F)F)([H])[H])C1=C([H])C2=C(N(C(=O)C(=C2C(F)(F)F)[H])[H])C([H])=C1[H])([H])[H],DB08089,328947-93-9,LGD-2226,"6-(Bis-(2,2,2-trifluoroethyl)amino)-4-trifluoromethyl-1H-quinolin-2-one",small molecule,,,,,
FC1=C([H])C(N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])=C([H])C(C(=O)N(C2=C([H])C3=C(N(C(=C3C(C(C3=C([H])C([H])=NC([H])=C3[H])([H])[H])([H])[H])[H])[H])C([H])=C2[H])[H])=C1[H],DB08091,,3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE,,small molecule,,,,,
FC1=C([H])C(N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])=C([H])C(C(=O)N(C2=C([H])C3=C(N(C(=C3[H])[H])[H])C([H])=C2[H])[H])=C1[H],DB08092,,3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide,,small molecule,,,,,
N(C1=C(OC(C2=C([H])C([H])=C([H])C3=C(C(=C(C([H])=C23)[H])[H])[H])([H])[H])C([H])=C([H])C([H])=N1)([H])[H],DB08093,,3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE,,small molecule,,,,,
C(OC1=C([H])C([H])=C(F)C(F)=C1C(=O)C1=C(N([H])[H])N=C(N(C2(C([H])([H])C([H])([H])N(S(C([H])([H])[H])(=O)=O)C([H])([H])C2([H])[H])[H])[H])N=C1[H])([H])([H])[H],DB08094,,"(4-AMINO-2-{[1-(METHYLSULFONYL)PIPERIDIN-4-YL]AMINO}PYRIMIDIN-5-YL)(2,3-DIFLUORO-6-METHOXYPHENYL)METHANONE",,small molecule,,,,,
C(C(N1C(N(C2=C(Cl)C([H])=C([H])C([H])=C2[H])[H])=NC2=C1N=C(N(C1=C(F)C([H])=C([H])C([H])=C1F)[H])N=C2[H])([H])[H])([H])([H])[H],DB08096,,"8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM",,small molecule,,,,,
C(C(C([H])([H])[H])(N1C(N(C2=C(F)C([H])=C([H])C([H])=C2[H])[H])=NC2=C1N=C(OC1=C(F)C([H])=C([H])C([H])=C1F)N=C2[H])[H])([H])([H])[H],DB08097,,"2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE",,small molecule,,,,,
O(C(=O)C(SC1=NN=C(C2=C([H])C([H])=C([N+]([O-])=O)O2)O1)([H])[H])[H],DB08098,,"{[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-yl]thio}acetic acid",,small molecule,,,,,
C(C1=C([H])C(C(=C(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])[H])=C([H])C(C([H])([H])[H])=C1O[H])([H])([H])[H],DB08100,,"2,6-dimethyl-4-[(E)-2-phenylethenyl]phenol",,small molecule,,,,,
O(C1=C(Br)C([H])=C(C(=C(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])[H])C([H])=C1Br)[H],DB08101,,"2,6-dibromo-4-[(E)-2-phenylethenyl]phenol",,small molecule,,,,,
O(C1=C(Br)C([H])=C(C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1Br)[H],DB08102,,"3,5-dibromobiphenyl-4-ol",,small molecule,,,,,
O(C1=C(Br)C([H])=C(OC2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1Br)[H],DB08103,,"2,6-dibromo-4-phenoxyphenol",,small molecule,,,,,
O(C1=C(Br)C([H])=C(N(C(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])[H])C([H])=C1Br)[H],DB08104,,"N-(3,5-dibromo-4-hydroxyphenyl)benzamide",,small molecule,,,,,
O(C1=C([H])C([H])=C(C(C2=NN=C3C(=C(C(=NN23)C2=C([H])C([H])=C([H])C([H])=C2[H])[H])[H])([H])[H])C([H])=C1[H])[H],DB08111,,"4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]phenol",,small molecule,,,,,
N1(N=C(C2=C([H])C([H])=NC([H])=C2[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])[H],DB08113,,3-pyridin-4-yl-1H-indazole,,small molecule,,,,,
N(C1=NC([H])=C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])S1)([H])[H],DB08114,,"5-benzyl-1,3-thiazol-2-amine",,small molecule,,,,,
N(C(C(OC(=O)C(C1=C([H])C([H])=C([H])C2=C(C(=C(C([H])=C12)[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB08115,,2-aminoethyl naphthalen-1-ylacetate,,small molecule,,,,,
C(N(C1=C(C(=O)N(C2=NC(C([H])([H])[H])=C([H])S2)[H])C([H])=C(SC2=NN=C([H])N2C([H])([H])[H])C([H])=C1[H])[H])([H])([H])[H],DB08118,,"2-(methylamino)-N-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]benzamide",,small molecule,,,,,
C(N(S(=O)(=O)C1=C([H])C([H])=C(N(C(=C2C(=O)N([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])[H])[H])C([H])=C1[H])[H])([H])([H])[H],DB08122,,"N-METHYL-4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE",,small molecule,,,,,
C(N(S(=O)(=O)C(C1=C([H])C([H])=C(N(N=C2C(=O)N([H])C3=C(C(=C4N=C([H])SC4=C23)[H])[H])[H])C([H])=C1[H])([H])[H])[H])([H])([H])[H],DB08123,,"N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE",,small molecule,,,,,
O=C1N([H])C2=C(C(=C(C(=C2[H])[H])C2=C([H])N=C([H])O2)[H])C1=C(N(C1=C([H])C2=C(C(S(=O)(=O)C2([H])[H])([H])[H])C([H])=C1[H])[H])[H],DB08124,,"3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE",,small molecule,,,,,
O=C1N([H])C2=C(C(=C(C(=C2[H])[H])[H])[H])C1=C(N(C1=C([H])C([H])=C(S(=O)(=O)N(C2=NC([H])=C([H])S2)[H])C([H])=C1[H])[H])[H],DB08125,,"4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE",,small molecule,,,,,
N(C(=N[H])N(S(=O)(=O)C1=C([H])C([H])=C(N(C(=C2C(=O)N([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])[H])[H])C([H])=C1[H])[H])([H])[H],DB08126,,"3-{[4-([AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE",,small molecule,,,,,
C(C(=C(C([H])([H])[H])C(=C(C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H])[H])[H])[H])([H])([H])[H],DB08127,,"1,3,3-trimethyl-2-[(1E,3E)-3-methylpenta-1,3-dien-1-yl]cyclohexene",,small molecule,,,,,
N(C(C(N(C1=NN=C(C2=C([H])C([H])=C(F)C(F)=C2N(C2=C(F)C([H])=C(I)C([H])=C2[H])[H])O1)[H])([H])[H])([H])[H])([H])[H],DB08130,,"N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine",,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C([H])C2=C(O[H])C(=C(C([H])=C12)[H])[H])([H])[H],DB08132,,5-hydroxynaphthalene-1-sulfonamide,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(N(C(=O)C2=NN([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])[H])C([H])=C1[H])([H])[H],DB08133,,N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(N(C2=C([H])N=C([H])C(Cl)=N2)[H])C([H])=C1[H])([H])[H],DB08134,,4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide,,small molecule,,,,,
O=C(N(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])C1=NN([H])C([H])=C1[H],DB08135,,N-phenyl-1H-pyrazole-3-carboxamide,,small molecule,,,,,
C(C(=O)N(C1=C([H])N([H])N=C1C(=O)N(C1=C([H])C([H])=C(F)C([H])=C1[H])[H])[H])([H])([H])[H],DB08136,,4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide,,small molecule,,,,,
FC1=C([H])C([H])=C(N(C(=O)C2=NN([H])C([H])=C2N(C(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])[H])[H])C([H])=C1[H],DB08137,,(4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide,,small molecule,,,,,
FC1=C([H])C([H])=C(N(C(=O)C2=NN([H])C([H])=C2N(C(=O)C2=C(F)C([H])=C([H])C([H])=C2F)[H])[H])C([H])=C1[H],DB08138,,"{[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide",,small molecule,,,,,
C(C(C([H])([H])[H])(N(C1=C([H])C(Cl)=NC2=C(C(=NN12)[H])C#N)[H])[H])([H])([H])[H],DB08139,,"5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile",,small molecule,,,,,
ClC1=C([H])C([H])=C([H])C(Cl)=C1C(=O)N(C1=C([H])N([H])N=C1C(=O)N(C1(C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H])[H])[H])[H],DB08142,,"4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide",,small molecule,,,,,
N(C1=NC([H])=C2C(=C(C(N([H])[H])=NC2=N1)C1=C(Br)C([H])=C([H])C([H])=C1Br)[H])([H])[H],DB08144,,"6-(2,6-dibromophenyl)pyrido[2,3-d]pyrimidine-2,7-diamine",,small molecule,,,,,
C(OC1=C([H])C([H])=C([H])C(OC([H])([H])[H])=C1C1=C([H])C2=C(N=C(N([H])[H])N=C2N=C1N([H])[H])[H])([H])([H])[H],DB08145,,"6-(2,6-DIMETHOXYPHENYL)PYRIDO[2,3-D]PYRIMIDINE-2,7-DIAMINE",,small molecule,,,,,
N(C1=NC2=NC(N3C([H])([H])C([H])=C([H])C3([H])[H])=C(C([H])=C2C([H])=N1)C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H],DB08146,,"7-(2,5-dihydropyrrol-1-yl)-6-phenyl-pyrido[6,5-d]pyrimidin-2-amine",,small molecule,,,,,
O(C(=O)C(=O)C(C(=O)C1=C([H])C(N(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])=C([H])C([H])=C1[H])([H])[H])[H],DB08147,,"4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid",,small molecule,,,,,
N(C(C1(C([H])([H])C([H])([H])N(C2=NC([H])=NC3=C2C(=C(N3[H])[H])[H])C([H])([H])C1([H])[H])C1=C([H])C([H])=C(Cl)C([H])=C1[H])([H])[H])([H])[H],DB08148,,"1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine",,small molecule,,,,,
N(C(C1(C(C2=C([H])C([H])=C(Cl)C([H])=C2[H])([H])[H])C([H])([H])C([H])([H])N(C2=NC([H])=NC3=C2C(=C(N3[H])[H])[H])C([H])([H])C1([H])[H])([H])[H])([H])[H],DB08149,,"1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine",,small molecule,,,,,
[N+](C1(C(C2=C([H])C([H])=C(Cl)C([H])=C2[H])([H])[H])C([H])([H])C([H])([H])N(C2=NC([H])=NC3=C2C(=C(N3[H])[H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB08150,,"4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium",,small molecule,,,,,
O(C1=C([H])C(O[H])=C(Cl)C2=C1C(=O)OC(C(C(=C(C(C(C(C(C(C(=O)C2([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])[H])[H],DB08153,,"(5E)-14-CHLORO-15,17-DIHYDROXY-4,7,8,9,10,11-HEXAHYDRO-2-BENZOXACYCLOPENTADECINE-1,12(3H,13H)-DIONE",,small molecule,,,,,
ClC1=C([H])C(C#N)=C([H])C(OC2=C(Cl)C([H])=C([H])C(OC(C3=NN([H])C4=C3C(=C(C(=C4[H])[H])[H])[H])([H])[H])=C2[H])=C1[H],DB08154,,3-chloro-5-[2-chloro-5-(1H-indazol-3-ylmethoxy)phenoxy]benzonitrile,,small molecule,,,,,
C(C(=O)N(C(C(C1=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C1[H])([H])[H])([H])[H])[H])([H])([H])[H],DB08155,,N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(C(C(C(O[H])=O)([H])[H])([H])[H])C([H])=C1[H])([H])[H],DB08156,,3-[4-(AMINOSULFONYL)PHENYL]PROPANOIC ACID,,small molecule,,,,,
C(C(OC(=O)C(C(C1=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08157,,ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE,,small molecule,,,,,
O(C(=O)C(C(C(N1C2=C(C(=O)C3=C2C([H])=C([H])C([H])=C3[H])C2=C(C(=C(C(=C2[H])[H])[H])[H])C1=O)([H])[H])([H])[H])([H])[H])[H],DB08159,,"4-(5,11-DIOXO-5H-INDENO[1,2-C]ISOQUINOLIN-6(11H)-YL)BUTANOATE",,small molecule,,,,,
O=S(=O)(N1C([H])([H])C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H])C1=C([H])C([H])=C([H])C2=C(N=C(C([H])=C12)[H])[H],"DB08162
DB12469",103745-39-7,Fasudil,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C2=C(C(C(C2([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H],DB08165,,indane-5-sulfonamide,,small molecule,,,,,
C(C1=C([H])C(=O)OC2=C1C(=C(C(N([H])[H])=C2[H])[H])[H])([H])([H])[H],DB08168,,7-AMINO-4-METHYL-CHROMEN-2-ONE,,small molecule,,,,,
O(C(C1(C([H])([H])C1([H])[H])[H])=C(C#N)C(=O)N(C1=C([H])C([H])=C(C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])[H])[H],DB08169,,(2Z)-N-biphenyl-4-yl-2-cyano-3-cyclopropyl-3-hydroxyprop-2-enamide,,small molecule,,,,,
O(C(=O)C(C(C(C(C(C(C(C(C(C(S[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB08171,,11-MERCAPTOUNDECANOIC ACID,,small molecule,,,,,
C(OC1=C(C2=C([H])C(Cl)=C(N(C(=O)C(C#N)=C(C([H])([H])[H])O[H])[H])C([H])=C2[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB08172,,(2Z)-N-(3-chloro-2'-methoxybiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide,,small molecule,,,,,
ClC1=C([H])C([H])=C(C(=O)N(C(C(N(C(=O)C2=C([H])C([H])=C(N3C([H])=C([H])C([H])=C([H])C3=O)C([H])=C2[H])[H])([H])[H])([H])[H])[H])S1,DB08173,,5-CHLORO-N-(2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)ETHYL)THIOPHENE-2-CARBOXAMIDE,,small molecule,,,,,
FC1=C([H])C([H])=C(C(C(C(=C([H])[H])C(=N[H])[H])([H])[H])([H])[H])C([H])=C1[H],DB08176,,(1Z)-4-(4-FLUOROPHENYL)-2-METHYLIDENEBUTAN-1-IMINE,,small molecule,,,,,
O(C(=O)C(C(N1C(=S)SC(=C(C2=C([H])C([H])=C(C3=C([H])C([H])=C(Cl)C([H])=C3[H])O2)[H])C1=O)([H])[H])([H])[H])[H],DB08177,,(E)-3-(5((5-(4-CHLOROPHENYL)FURAN-2-YL)METHYLENE)-4-OXO-2-THIOXOTHIAZOLIDIN-3-YL)PROPANOIC ACID,,small molecule,,,,,
C(OC1=C2C(N(C(=C2C2=NC(N([H])[H])=NC([H])=C2[H])[H])[H])=NC([H])=C1[H])([H])([H])[H],DB08178,,"4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine",,small molecule,,,,,
C(OC(=O)C1=C(O[H])C([H])=C(OC2=C(O[H])C(O[H])=C([H])C(C([H])([H])[H])=C2[H])C([H])=C1C([H])([H])[H])([H])([H])[H],DB08179,,"methyl 4-(2,3-dihydroxy-5-methylphenoxy)-2-hydroxy-6-methylbenzoate",,small molecule,,,,,
C(C1=C(O[H])C([H])=C([H])C(N=NC2=C(C(O[H])=O)C([H])=C([H])C([H])=C2[H])=C1[H])([H])([H])[H],DB08181,,2-((3'-METHYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID,,small molecule,,,,,
C(C(C(OC1=C2C(N(C(=C2C2=NC(N([H])[H])=NC([H])=C2[H])[H])[H])=NC([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB08182,,"4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine",,small molecule,,,,,
C(C1=C(C2=C([H])C3=C(C(=C(C(=C3[H])C(N([H])[H])=N[H])[H])[H])N2[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB08184,,2-(2-METHYLPHENYL)-1H-INDOLE-5-CARBOXIMIDAMIDE,,small molecule,,,,,
C(N1C([H])=C(C(=C(C(C([H])([H])[H])=O)[H])[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])([H])[H],DB08186,,(3E)-4-(1-METHYL-1H-INDOL-3-YL)BUT-3-EN-2-ONE,,small molecule,,,,,
C(C(OC(N1C(=O)N([H])C(=O)C(C(C([H])([H])[H])(C([H])([H])[H])[H])=C1C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],"DB08188
DB12488",149950-60-7,Emivirine,"1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)pyrimidine-2,4(1H,3H)-dione
6-benzyl-1-(ethoxymethyl)-5-(1-methylethyl)uracil",small molecule,,,,,
C(OC1=C([H])C2=C(N(C(I)=C2C(C(N(C(C([H])([H])[H])=O)[H])([H])[H])([H])[H])[H])C([H])=C1[H])([H])([H])[H],DB08190,,N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]acetamide,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C(C2=C([H])N([H])C3=C2C(=C(C(=N3)[H])C2=C([H])C([H])=C([H])C([H])=C2[H])[H])C([H])=C1[H])[H],DB08191,,"4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid",,small molecule,,,,,
O(C(=O)C(C1=C([H])C([H])=C([H])C([N+]([O-])=O)=C1[H])([H])[H])[H],DB08193,,2-(3-NITROPHENYL)ACETIC ACID,,small molecule,,,,,
C(C1=NC(N([H])[H])=NC2=C1C(SC(C2([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08194,,"4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine",,small molecule,,,,,
C(OC1=C([H])C(N=NC2=C(C(O[H])=O)C([H])=C([H])C([H])=C2[H])=C([H])C(OC([H])([H])[H])=C1O[H])([H])([H])[H],DB08196,,"2-((3',5'-DIMETHOXY-4'-HYDROXYPHENYL)AZO)BENZOIC ACID",,small molecule,,,,,
C(N1C([H])([H])C([H])([H])N(N(C(=S)N(C2=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C2[H])[H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB08202,,4-({[(4-METHYLPIPERAZIN-1-YL)AMINO]CARBONOTHIOYL}AMINO)BENZENESULFONAMIDE,,small molecule,,,,,
C(OC(C(C(OC([H])([H])[H])([H])[H])(N1C([H])=C([H])C2=C1C(=C(C1=NC(N([H])[H])=NC(N([H])[H])=C12)[H])[H])[H])([H])[H])([H])([H])[H],DB08203,,"7-[2-METHOXY-1-(METHOXYMETHYL)ETHYL]-7H-PYRROLO[3,2-F] QUINAZOLINE-1,3-DIAMINE",,small molecule,,,,,
O(C1=C([H])C([H])=C(C2(OC(=O)C3=C4C(=C(C(=C3[H])[H])[H])C(=C(C([H])=C24)[H])[N+]([O-])=O)C2=C([H])C([H])=C(O[H])C([H])=C2[H])C([H])=C1[H])[H],DB08204,,3-DIPHENOL-6-NITRO-3H-BENZO[DE]ISOCHROMEN-1-ONE,,small molecule,,,,,
C(C1=C([H])C(C2=NC3=C(C(=C(C(=C3[H])[H])[H])[H])O2)=C([H])C(C([H])([H])[H])=C1O[H])([H])([H])[H],DB08205,,"4-(1,3-BENZOXAZOL-2-YL)-2,6-DIMETHYLPHENOL",,small molecule,,,,,
O(C1=C(Br)C([H])=C(C2=NC3=C(C(=C(C(=C3[H])[H])[H])[H])O2)C([H])=C1Br)[H],DB08206,,"4-(1,3-BENZOXAZOL-2-YL)-2,6-DIBROMOPHENOL",,small molecule,,,,,
C(C1=C([H])C(C2=NC3=C(C(=C(C(=C3[H])[H])[H])[H])O2)=C([H])C(C([H])([H])[H])=C1[H])([H])([H])[H],DB08207,,"2-(3,5-DIMETHYLPHENYL)-1,3-BENZOXAZOLE",,small molecule,,,,,
O(C(C(ON(C(=O)C1=C([H])C([H])=C(F)C(F)=C1N(C1=C(F)C([H])=C(C#C[H])C([H])=C1[H])[H])[H])([H])[H])([H])[H])[H],DB08208,,"2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE",,small molecule,,,,,
C(N(C([H])([H])[H])C1=C([H])C([H])=C(N=NC2=C(C(O[H])=O)C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])([H])[H],DB08209,,2-(4-DIMETHYLAMINOPHENYL)DIAZENYLBENZOIC ACID,,small molecule,,,,,
C(N1C([H])=C([H])N=C1SC1=C([H])C(C(=O)N(C2=NC([H])=C([H])S2)[H])=C(N([H])[H])C([H])=C1F)([H])([H])[H],DB08210,,"2-AMINO-4-FLUORO-5-[(1-METHYL-1H-IMIDAZOL-2-YL)SULFANYL]-N-(1,3-THIAZOL-2-YL)BENZAMIDE",,small molecule,,,,,
N(C(=O)C1=C(S(=O)(=O)N2C([H])([H])C([H])([H])C([H])([H])C2([H])[H])C2=C(C(=C(C(Br)=C2[H])[H])[H])N1[H])([H])[H],DB08211,,5-bromo-3-(pyrrolidin-1-ylsulfonyl)-1H-indole-2-carboxamide,,small molecule,,,,,
O(C1=C([H])C([H])=C(N2C([H])=C([H])N=C2[H])C([H])=C1[H])[H],DB08214,,4-(1H-IMIDAZOL-1-YL)PHENOL,,small molecule,,,,,
C(C(N(C1=NC(SC([H])([H])[H])=NC(N(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])[H])=N1)[H])([H])[H])([H])([H])[H],DB08215,,2-T-BUTYLAMINO-4-ETHYLAMINO-6-METHYLTHIO-S-TRIAZINE,,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C1=C(O[H])C([H])=C([H])C(N=NC2=C(C(O[H])=O)C([H])=C([H])C([H])=C2[H])=C1[H])([H])([H])[H],DB08216,,2-((3'-TERTBUTYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID,,small molecule,,,,,
C(C1(C([H])([H])[H])C([H])=C(C(SS(C([H])([H])[H])(=O)=O)([H])[H])C(C([H])([H])[H])(C([H])([H])[H])N1O[H])([H])([H])[H],DB08217,,"S-[(1-Hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl] methanesulfonothioate",,small molecule,,,,,
[O-][N+](=O)C1=C([H])C(N=C2N=C([H])C([H])([H])C(C3=C([H])C(C(N4C([H])=NC([H])=N4)([H])[H])=C([H])C([H])=C3[H])=N2)=C([H])C([H])=C1[H],DB08218,,"HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM",,small molecule,,,,,
C(C1=C(C2=NC(=NC3=C([H])C([H])=C(N4C([H])([H])C([H])([H])OC([H])([H])C4([H])[H])C([H])=C3[H])N=C([H])C2([H])[H])SC(=N[H])N1[H])([H])([H])[H],DB08219,,"4-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE",,small molecule,,,,,
C(C1=C(N(C2=NC([H])=C([H])C([H])=C2C2=NC([H])=NC([H])=C2[H])[H])C([H])=C(N(C(=O)C2=C([H])C([H])=C([H])C(C(F)(F)F)=C2[H])[H])C([H])=C1[H])([H])([H])[H],DB08221,,N-{4-METHYL-3-[(3-PYRIMIDIN-4-YLPYRIDIN-2-YL)AMINO]PHENYL}-3-(TRIFLUOROMETHYL)BENZAMIDE,,small molecule,,,,,
C(C(C(C(C(C([H])([H])[H])=C(C(=C(C([H])([H])[H])C(=O)C1=C(O[H])C([H])=C(C(C(C(C(=C(N(C(=O)OC([H])([H])[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])OC1=O)[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08226,,Myxopyronin B,,small molecule,,,,,
C(C1(C([H])([H])[H])C([H])([H])C(N2C(=O)C([H])([H])C([H])([H])C2=O)([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])N1O[H])([H])([H])[H],DB08227,,"1-(1-HYDROXY-2,2,6,6-TETRAMETHYLPIPERIDIN-4-YL)PYRROLIDINE-2,5-DIONE",,small molecule,,,,,
C(OC1=C([H])C([H])=C(OC([H])([H])[H])C2=C1N(C([H])([H])[H])C(=O)C(=C2C([H])([H])[H])[H])([H])([H])[H],DB08228,,"5,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one",,small molecule,,,,,
O(C1=C([H])C2=C(C(=O)C(=C(O2)C2=C([H])C(O[H])=C(O[H])C(O[H])=C2[H])[H])C(O[H])=C1[H])[H],DB08230,,"5,7-DIHYDROXY-2-(3,4,5-TRIHYDROXYPHENYL)-4H-CHROMEN-4-ONE",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08231,544-63-8,Myristic acid,"1-tridecanecarboxylic acid
N-tetradecan-1-oic acid
N-tetradecanoic acid
Tetradecanoic acid",small molecule,,,,,
N(C1=NC2=C(N(C(=C2[H])C2=C([H])C(C(C(O[H])=O)([H])[H])=C([H])C(C3=C([H])C([H])=C([H])C([N+]([O-])=O)=C3[H])=C2O[H])[H])C([H])=C1[H])([H])[H],DB08232,,"[5-(5-Amino-1H-pyrrolo[3,2-b]pyridin-2-yl)-6-hydroxy-3'-nitro-3-biphenylyl]acetic acid",,small molecule,,,,,
O(C1=C([H])C([H])=C(N(C2=NC3=C(N=C(N3[H])[H])C(OC(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])([H])[H])=N2)[H])C([H])=C1[H])[H],DB08233,,6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE,,small molecule,,,,,
C(C(C1=NC(N([H])[H])=NC(N([H])[H])=C1C#CC(C1=C(OC([H])([H])[H])C([H])=C([H])C(OC([H])([H])[H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB08234,,"5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine",,small molecule,,,,,
C(C1=C(C(C(N(C(=O)C2=C([H])C([H])=C([H])S2)[H])([H])[H])([H])[H])C2=C(C(=C(C(=C2[H])[H])[H])[H])N1[H])([H])([H])[H],DB08235,,N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide,,small molecule,,,,,
N(C1=C2C(=C(C(=C([H])C2=C([H])C([H])=C1[H])S(O[H])(=O)=O)[H])[H])([H])[H],DB08238,,5-AMINO-NAPHTALENE-2-MONOSULFONATE,,small molecule,,,,,
O(P(O[H])(=O)OC1=C([H])C2=C(C(=C(C([H])=C2C([H])=C1C(=O)N(C1=C([H])C([H])=C(Cl)C([H])=C1[H])[H])[H])[H])[H])[H],DB08240,,N-(4-CHLOROPHENYL)-3-(PHOSPHONOOXY)NAPHTHALENE-2-CARBOXAMIDE,,small molecule,,,,,
N(C(=O)C1=C([H])C([H])=C(N(C2=NC(OC(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])([H])[H])=C3N=C(N([H])C3=N2)[H])[H])C([H])=C1[H])([H])[H],DB08241,,4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE,,small molecule,,,,,
C(N(C(=O)C1=C([H])C(N(C2=NC([H])=NC3=C2C(=NN3C2=C([H])C([H])=C([H])C([H])=C2[H])[H])[H])=C(C([H])([H])[H])C([H])=C1[H])[H])([H])([H])[H],DB08242,,"N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide",,small molecule,,,,,
C(C(C([H])([H])[H])(C1=NC2=C(N=C(N([H])[H])N=C2OC(C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])([H])[H])N1[H])[H])([H])([H])[H],DB08247,,6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE,,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C(N(C2=NC(OC(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])([H])[H])=C3N=C(N([H])C3=N2)[H])[H])=C([H])C([H])=C1[H])([H])[H],DB08248,,3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE,,small molecule,,,,,
C(C(C(C(C(C(C(C(OC(C(OC(C(OC(C(OC(C(OC(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08249,,"3,6,9,12,15-PENTAOXATRICOSAN-1-OL",,small molecule,,,,,
O(C(=O)C1=C(N=NC2=C([H])C([H])=C(O[H])C3=C(C(=C(C([H])=C23)[H])[H])[H])C([H])=C([H])C([H])=C1[H])[H],DB08252,,2-((4'-HYDROXYNAPHTHYL)-AZO)BENZOIC ACID,,small molecule,,,,,
O(S(=O)(=O)C1=C([H])C2=C(C(=C(C([H])=C2C([H])=C1[H])[H])[H])[H])[H],DB08254,,2-NAPHTHALENESULFONIC ACID,,small molecule,,,,,
O(C(=O)C(N(C(=O)N(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])[H])[H])([H])[H])[H],DB08256,,N-[(CYCLOHEXYLAMINO)CARBONYL]GLYCINE,,small molecule,,,,,
O(C(=O)C(C(C(N(C(=O)N(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])[H],DB08257,,4-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}BUTANOIC ACID,,small molecule,,,,,
O(C(=O)C(C(C(C(C(N(C(=O)N(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB08258,,6-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEXANOIC ACID,,small molecule,,,,,
O(C(=O)C(C(C(C(C(C(N(C(=O)N(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB08259,,7-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEPTANOIC ACID,,small molecule,,,,,
O(C(=O)C1=C([H])C2=C(C(=C(C([H])=C2C([H])=C1[H])C(O[H])=O)[H])[H])[H],DB08262,1141-38-4,"2,6-dicarboxynaphthalene",,small molecule,,,,,
C(C1=C([H])C([H])=C(S(=O)(=O)N2N=C([H])C3=C(C(=C(C(=C3[H])[H])[H])[H])B2O[H])C([H])=C1[H])([H])([H])[H],DB08265,,"2-(TOLUENE-4-SULFONYL)-2H-BENZO[D][1,2,3]DIAZABORININ-1-OL",,small molecule,,,,,
N(C1=NC2=C(C(=C3N([H])C([H])=NC3=C2C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])[H])C(=O)N1[H])([H])[H],DB08267,,"6-amino-4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,small molecule,,,,,
C(C1=C([H])C([H])=C(C(C(C2=C3N=C(N([H])C3=C([H])C3=C2N=C(N([H])[H])N(C3=O)[H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB08268,,"6-AMINO-4-[2-(4-METHYLPHENYL)ETHYL]-1,7-DIHYDRO-8H-IMIDAZO[4,5-G]QUINAZOLIN-8-ONE",,small molecule,,,,,
C(OC1=C([H])C([H])=C(S(=O)(=O)N(C(C(C([H])([H])[H])(C([H])([H])[H])[H])([H])[H])C(C(=O)N(O[H])[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB08271,,N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID,,small molecule,,,,,
O(C1=C(I)C([H])=C(C(C(=O)N(C(C(C(C(C(C([O-])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])C([H])=C1[N+]([O-])=O)[H],DB08273,,4-HYDROXY-5-IODO-3-NITROPHENYLACETYL-EPSILON-AMINOCAPROIC ACID ANION,,small molecule,,,,,
O(C1=C(C2=NC3=C(C(=C(C(=C3[H])[H])[H])[H])S(=O)(=O)N2[H])C(=O)N(C(C(C2(C([H])([H])C2([H])[H])[H])([H])[H])([H])[H])C2=C1C(=C(F)C(=C2[H])[H])[H])[H],DB08278,,"1-(2-CYCLOPROPYLETHYL)-3-(1,1-DIOXIDO-2H-1,2,4-BENZOTHIADIAZIN-3-YL)-6-FLUORO-4-HYDROXYQUINOLIN-2(1H)-ONE",,small molecule,,,,,
BrC1=C([H])C([H])=C(N(C(=S)OC(C(N2C(=O)C3=C(C(=C(C(=C3[H])[H])[H])[H])C2=O)([H])[H])([H])[H])[H])C([H])=C1[H],DB08281,,"O-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl] (4-bromophenyl)thiocarbamate",,small molecule,,,,,
ClC1=C([H])C([H])=C(N(C(=S)OC(C(N2C(=O)C3=C(C(=C(C(=C3[H])[H])[H])[H])C2=O)([H])[H])([H])[H])[H])C([H])=C1[H],DB08282,,"O-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl] (4-chlorophenyl)thiocarbamate",,small molecule,,,,,
IC1=C([H])C([H])=C(N(C(=S)OC(C(N2C(=O)C3=C(C(=C(C(=C3[H])[H])[H])[H])C2=O)([H])[H])([H])[H])[H])C([H])=C1[H],DB08284,,"O-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl] (4-iodophenyl)thiocarbamate",,small molecule,,,,,
O(C(=O)C(OC1=C([H])C([H])=C([H])C2=C(C(=C(C([H])=C12)[H])[H])[H])([H])[H])[H],DB08286,,NAPHTHYLOXYACETIC ACID,,small molecule,,,,,
O(C(=O)C(C(C(C(=O)N(C1=C([H])C([H])=C(C(C([N+]2([O-])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])([H])[H])([H])[H])C([H])=C1[H])[H])([H])[H])([H])[H])([H])[H])[H],DB08289,,N-(PARA-GLUTARAMIDOPHENYL-ETHYL)-PIPERIDINIUM-N-OXIDE,,small molecule,,,,,
N(C(C(C(N(C1=C([N+]([O-])=O)C([H])=C([H])C([H])=C1[H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB08291,,N-(3-AMINOPROPYL)-2-NITROBENZENAMINE,,small molecule,,,,,
O(C(=O)C(C1=C([H])C([N+]([O-])=O)=C(O[H])C([H])=C1[H])([H])[H])[H],DB08294,,2-(4-HYDROXY-3-NITROPHENYL)ACETIC ACID,,small molecule,,,,,
O(C1=C([N+]([O-])=O)C([H])=C(C(C(=O)N(C(C(C(C(C(C([O-])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])C([H])=C1[H])[H],DB08295,,4-HYDROXY-3-NITROPHENYLACETYL-EPSILON-AMINOCAPROIC ACID ANION,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C(C2=C([H])C3=C(C(=C(N=C3C(C3=C([H])C([H])=C([H])C([N+]([O-])=O)=C3[H])=N2)[H])[H])[H])C([H])=C1[H])[H],DB08299,,"4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid",,small molecule,,,,,
C(N1N=C(C2=C([H])C3=C(C(=C(C([H])=C3C([H])=C2[H])[H])[H])[H])C2=C1N=C(N=C2N([H])[H])[H])([H])([H])[H],DB08300,,"1-methyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine",,small molecule,,,,,
C(C1=C([H])C([H])=C(S(=O)(=O)N(C(=O)N(C2=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C2[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB08301,,N-({[4-(AMINOSULFONYL)PHENYL]AMINO}CARBONYL)-4-METHYLBENZENESULFONAMIDE,,small molecule,,,,,
C(C(C(C(=C(C1=C([H])C([H])=C(C2=C([H])C(C(O[H])=O)=C([H])C([H])=C2[H])O1)[H])[N+]([O-])=O)([H])[H])([H])[H])([H])([H])[H],DB08302,,3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid,,small molecule,,,,,
O(C(=O)C1=C(S(=O)(=O)N(C2=C([H])C([N+]([O-])=O)=C([H])C([H])=C2[H])[H])C([H])=C([H])S1)[H],DB08306,850635-41-5,3-[(3-Nitrophenyl)sulfamoyl]-2-thiophenecarboxylic acid,,small molecule,,,,,
O(C(C1=C([N+]([O-])=O)C([H])=C(C(F)(F)F)C([H])=C1[H])=C1C(=O)C([H])([H])C([H])([H])C([H])([H])C1=O)[H],DB08307,,"2-{HYDROXY[2-NITRO-4-(TRIFLUOROMETHYL)PHENYL]METHYLENE}CYCLOHEXANE-1,3-DIONE",,small molecule,,,,,
O(C(C(C(N(C(C(S(=O)(=O)C1=C([H])C([H])=C(N(C2=NC(OC(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])([H])[H])=C3N=C(N([H])C3=N2)[H])[H])C([H])=C1[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])[H],DB08309,,3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL,,small molecule,,,,,
N(C1=NC(OC(C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])([H])[H])=C(N=O)C(N([H])[H])=N1)([H])[H],DB08312,,"6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE",,small molecule,,,,,
C(OC(=O)N(C1=NC2=C(C(=C(C(=C2[H])[H])C(=O)C2=C([H])C([H])=C([H])S2)[H])N1[H])[H])([H])([H])[H],DB08313,,nocodazole,,small molecule,,,,,
N(C1=NC([H])=C(C(=O)C2=C([H])C([H])=C([H])C(Br)=C2[H])O1)([H])[H],DB08314,,"(2-AMINO-1,3-OXAZOL-5-YL)-(3-BROMOPHENYL)METHANONE",,small molecule,,,,,
N(C1=NC([H])=C(C(=O)N(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])O1)([H])[H],DB08315,,"2-AMINO-N,N-BIS(PHENYLMETHYL)-1,3-OXAZOLE-5-CARBOXAMIDE",,small molecule,,,,,
C(C1(C([H])([H])[H])C([H])([H])C(=O)C2=C(N([H])[H])N=C(N=C2C1([H])[H])[H])([H])([H])[H],DB08316,,"4-amino-7,7-dimethyl-7,8-dihydroquinazolin-5(6H)-one",,small molecule,,,,,
C(C1=C2C(N([H])[H])=NC(N([H])[H])=NC2=C([H])C([H])=C1C1=C([H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB08317,,"5-methyl-6-phenylquinazoline-2,4-diamine",,small molecule,,,,,
N(C1=NC(OC(C(OC2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])=NC(N([H])[H])=N1)([H])[H],DB08318,,"6-(2-phenoxyethoxy)-1,3,5-triazine-2,4-diamine",,small molecule,,,,,
C(C(C([H])([H])[H])(N1C([H])=NC2=C1N(C(N(C(C(O[H])([H])[H])([H])[H])[H])=NC2=NC1=C([H])C([H])=C([H])C(Cl)=C1[H])[H])[H])([H])([H])[H],DB08325,,2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9-ISOPROPYLPURINE,,small molecule,,,,,
O(C1=C([H])C2=C(N=C(S2)C2=NC(=O)C([H])([H])S2)C([H])=C1[H])[H],DB08326,,"2-(6-HYDROXY-1,3-BENZOTHIAZOL-2-YL)-1,3-THIAZOL-4(5H)-ONE",,small molecule,,,,,
O(C(=O)C(C1=C(O[H])C([H])=C([H])C(O[H])=C1[H])([H])[H])[H],DB08327,,"2-(3,6-DIHYDROXYPHENYL)ACETIC ACID",,small molecule,,,,,
N(S(=O)(=O)C1=C([H])C([H])=C(N2C([H])([H])C([H])([H])C([H])([H])C([H])([H])S2(=O)=O)C([H])=C1[H])([H])[H],DB08329,61-56-3,Sulthiame,Sultiame,small molecule,,,,,
C(OC(=C(C(=O)OC([H])([H])[H])C1=C(C(=C(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])[H])C([H])=C([H])C([H])=C1[H])[H])([H])([H])[H],DB08330,,METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE,,small molecule,,,,,
N(C1=NC([H])=C([H])N1[H])(C1=C([H])C([H])=C(N(C2=C([H])C([H])=C(N(C3=NC([H])=C([H])N3[H])[H])C([H])=C2[H])[H])C([H])=C1[H])[H],DB08331,,"N-1H-imidazol-2-yl-N'-[4-(1H-imidazol-2-ylamino)phenyl]benzene-1,4-diamine",,small molecule,,,,,
O(C1=C([H])C([H])=C(C(=NOC(=O)C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])[H])C([H])=C1[H])[H],DB08333,,4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME,,small molecule,,,,,
O(C1=C(F)C([H])=C(C(=NOC(=O)C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])[H])C([H])=C1[H])[H],DB08334,,3-FLUORO-4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME,,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C(C(=O)ON=C(C1=C([H])C([H])=C(O[H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB08335,,"4-HYDROXYBENZALDEHYDE O-(3,3-DIMETHYLBUTANOYL)OXIME",,small molecule,,,,,
O=C1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2=C3N=C(N=C(N(C4(C([H])([H])C4([H])[H])[H])[H])N3N=C2[H])N([H])C2=C(C(=C([H])C(=C2[H])N1[H])[H])[H],DB08338,,"19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one",,small molecule,,,,,
C(N1C(=O)C(C2=C(Cl)C([H])=C([H])C([H])=C2Cl)=C([H])C2=C1N=C(N(C1=C([H])C(C(O[H])([H])[H])=C([H])C([H])=C1[H])[H])N=C2[H])([H])([H])[H],DB08339,,"6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}-8-METHYLPYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE",,small molecule,,,,,
N(C1=C([H])C([H])=C([H])C([H])=C1[H])(C1=NC2=C(C(=NN2C(N(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])=N1)[H])[H])[H],DB08340,,"N,N'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE",,small molecule,,,,,
N#CC1=C2N=C(N(C3=C([H])C([H])=C([H])C([H])=C3[H])[H])N=C(N(C(C(C3=C([H])N=C([H])N3[H])([H])[H])([H])[H])[H])N2N=C1[H],DB08345,,"4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE",,small molecule,,,,,
O(C1=C([H])C(O[H])=C(Cl)C2=C1C(=O)OC(C(C(=C(C(C(C(C(C(=O)C2([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])([H])[H])[H],DB08346,,"(5Z)-13-CHLORO-14,16-DIHYDROXY-3,4,7,8,9,10-HEXAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,11(12H)-DIONE",,small molecule,,,,,
C(N(C([H])([H])[H])C(C(=O)N(C1=C([H])C2=C(N(C(=O)C3=C2C([H])=C([H])C([H])=C3[H])[H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB08348,,"N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE",,small molecule,,,,,
C(N1C2=C(C(=NN2C2=C(F)C([H])=C(F)C([H])=C2[H])[H])C(N(C2=C(C([H])([H])[H])C([H])=C([H])C(C(=O)N(C3(C([H])([H])C3([H])[H])[H])[H])=C2[H])[H])=C([H])C1=O)([H])([H])[H],DB08349,,"N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide",,small molecule,,,,,
C(OC1=C(C2=C([H])N([H])C3=NC(=C(C([H])=C23)C2=C([H])C(C(=O)N(C([H])([H])[H])C([H])([H])[H])=C([H])N=C2[H])[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB08350,,"5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE",,small molecule,,,,,
C(C1=C(C2=C([H])C3=C(N=C(N(C(C(N4C([H])([H])C([H])([H])OC([H])([H])C4([H])[H])([H])[H])([H])[H])[H])N=C3C([H])=C2[H])[H])C([H])=C(C(=O)N(C2(C([H])([H])C2([H])[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB08351,,N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide,,small molecule,,,,,
C(C(C([H])([H])[H])(N(C1=NC2=C(C(=C(C(=C2[H])[H])C2=C(C3=C(F)C([H])=C([H])C([H])=C3[H])N=C([H])O2)[H])S1)[H])[H])([H])([H])[H],DB08352,,"6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine",,small molecule,,,,,
N#CC1=C2N=C(N(C(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])([H])[H])[H])N=C(N(C3=C([H])C([H])=C([H])C([H])=C3[H])[H])N2N=C1[H],DB08353,,"2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE",,small molecule,,,,,
ClC1=C([H])C([H])=C(C(N(C2=NC3=C(C(=NN3C(N(C3=C([H])C([H])=C([H])C([H])=C3[H])[H])=N2)[H])C#N)[H])([H])[H])C([H])=C1[H],DB08354,,"2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE",,small molecule,,,,,
C(N1N=C(C(O[H])=O)C2=C1C1=NC(N(C3=C([H])C([H])=C([H])C([H])=C3[H])[H])=NC([H])=C1C(C2([H])[H])([H])[H])([H])([H])[H],DB08355,,"1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid",,small molecule,,,,,
C(OC1=C([H])C([H])=C(C2=C(C([H])([H])[H])N([H])N=C2C2=C(O[H])C([H])=C(O[H])C([H])=C2[H])C([H])=C1[H])([H])([H])[H],DB08356,,"4-[4-(4-methoxyphenyl)-5-methyl-1H-pyrazol-3-yl]benzene-1,3-diol",,small molecule,,,,,
C(C(OC(C(OC(C(OC(C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08357,,1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE,,small molecule,,,,,
O=C1N([H])C([H])([H])C([H])([H])C2=C1C(=C(N2[H])C1=C([H])C(C2=C([H])C3=C(C(=C(C([H])=C3N=C2[H])[H])[H])[H])=NC([H])=C1[H])[H],DB08358,,"2-(2-QUINOLIN-3-YLPYRIDIN-4-YL)-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE",,small molecule,,,,,
C(C(=O)C1=C(C([H])([H])[H])N=C(N(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])S1)([H])([H])[H],DB08359,,2-PHENYLAMINO-4-METHYL-5-ACETYL THIAZOLE,,small molecule,,,,,
C(C(N1C([H])([H])C([H])([H])N(C2=NC3=C(C(=NN3C(N(C3=C([H])C([H])=C([H])C([H])=C3[H])[H])=N2)[H])C#N)C([H])([H])C1([H])[H])([H])[H])([H])([H])[H],DB08360,,"2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE",,small molecule,,,,,
C(C(=O)N(C1=C([H])C(N(C2=NC3=C(C(=NN3C(N(C3=C([H])C([H])=C([H])C([H])=C3[H])[H])=N2)[H])C#N)[H])=C([H])C([H])=C1[H])[H])([H])([H])[H],DB08362,,"N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE",,small molecule,,,,,
C(C(N1C2=C(C(=C(C(=C2[H])[H])[H])[H])C2=C1C(=C(C(C(N(C([H])([H])[H])[H])([H])[H])=C2[H])[H])[H])([H])[H])([H])([H])[H],DB08363,,1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(=O)C(N=C(C1=C(C(OP(O[H])(O[H])(O[H])[H])([H])[H])C([H])=NC(C([H])([H])[H])=C1O[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08364,,1-{[(1E)-(3-HYDROXY-2-METHYL-5-{[(TRIHYDROXY-LAMBDA^5^-PHOSPHANYL)OXY]METHYL}PYRIDIN-4-YL)METHYLIDENE]AMINO}UNDECAN-2-ONE,,small molecule,,,,,
C(N1C2=C(C(=C3C(=O)N([H])C(=O)C3=C2C(Br)=C1C(=O)N(C(C(O[H])([H])[H])([H])[H])[H])C1=C(Cl)C([H])=C([H])C([H])=C1[H])[H])([H])([H])[H],DB08365,,"8-bromo-4-(2-chlorophenyl)-N-(2-hydroxyethyl)-6-methyl-1,3-dioxo-1,2,3,6-tetrahydropyrrolo[3,4-e]indole-7-carboxamide",,small molecule,,,,,
C(N1C([H])=C([H])N=C1[H])(C1=C([H])C([H])=C(C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H],DB08369,,1-(biphenyl-4-ylmethyl)-1H-imidazole,,small molecule,,,,,
C(C(OC1=C(F)C(C(C(N(C(=S)N(C2=NC([H])=C(C([H])([H])[H])C([H])=C2[H])[H])[H])([H])[H])([H])[H])=NC([H])=C1[H])([H])[H])([H])([H])[H],DB08372,,1-[2-(4-ETHOXY-3-FLUOROPYRIDIN-2-YL)ETHYL]-3-(5-METHYLPYRIDIN-2-YL)THIOUREA,,small molecule,,,,,
C(S(=O)(=O)C1=C([H])C(Cl)=C(C2=C([H])C(Cl)=C(S(C([H])([H])[H])(=O)=O)C([H])=C2Cl)C([H])=C1Cl)([H])([H])[H],DB08373,,"4,4'-BIS([H]METHYLSULFONYL)-2,2',5,5'-TETRACHLOROBIPHENYL",,small molecule,,,,,
FC1=C(C(C2=NN([H])C(=O)C([H])=C2[H])([H])[H])C([H])=C([H])C(Cl)=C1OC1=C([H])C([H])=C([H])C([H])=C1[H],DB08379,,6-(4-chloro-2-fluoro-3-phenoxybenzyl)pyridazin-3(2H)-one,,small molecule,,,,,
C(OC1=C([H])C([H])=C(C2=C(C3=C([H])C([H])=C(OC([H])([H])[H])C([H])=C3[H])N=C(C3=C([H])C([H])=C([H])S3)N2[H])C([H])=C1[H])([H])([H])[H],DB08383,,"4,5-bis(4-methoxyphenyl)-2-thiophen-2-yl-1H-imidazole",,small molecule,,,,,
C(OC1=C([H])C([H])=C(C2=NN([H])C([H])=C2C(C2=C([H])C([H])=NC([H])=C2[H])([H])[H])C([H])=C1[H])(C1=NC2=C(C(=C(C([H])=C2C([H])=C1[H])[H])[H])[H])([H])[H],DB08384,,2-({4-[4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline,,small molecule,,,,,
O(C(=O)N1C([H])([H])C([H])([H])C(C(C2=C([H])C3=C(C(=C(C([H])=C3N=C2[H])[H])[H])[H])([H])[H])([H])C([H])([H])C1([H])[H])[H],DB08385,,4-(quinolin-3-ylmethyl)piperidine-1-carboxylic acid,,small molecule,,,,,
C(OC1=C([H])C([H])=C(C2=NN([H])C([H])=C2C2=C([H])C([H])=NC([H])=C2[H])C([H])=C1[H])(C1=NC2=C(C(=C(C([H])=C2C([H])=C1[H])[H])[H])[H])([H])[H],DB08386,,2-{[4-(4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline,,small molecule,,,,,
C(N1C([H])=C(C2=C([H])C([H])=NC([H])=C2[H])C(C2=C([H])C([H])=C(OC(C3=NC4=C(C(=C(C([H])=C4C([H])=C3[H])[H])[H])[H])([H])[H])C([H])=C2[H])=N1)([H])([H])[H],DB08387,,2-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline,,small molecule,,,,,
C(C(OC(C(C1(OC2=C([H])C([H])=C(OC3=C([H])C([H])=C(F)C([H])=C3[H])C([H])=C2[H])C(=O)N([H])C(=O)N([H])C1=O)([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08388,,"5-(2-ETHOXYETHYL)-5-[4-(4-FLUOROPHENOXY)PHENOXY]PYRIMIDINE-2,4,6(1H,3H,5H)-TRIONE",,small molecule,,,,,
C(OC1=C([H])C([H])=C(C2=C(C3=C([H])C([H])=C(OC([H])([H])[H])C([H])=C3[H])C3=C(N(C(C(O[H])([H])[H])([H])[H])[H])N=C(N=C3O2)[H])C([H])=C1[H])([H])([H])[H],DB08392,,"2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL",,small molecule,,,,,
O(C(C(N(C1=C2C(OC(=C2C2=C([H])C([H])=C([H])C([H])=C2[H])C2=C([H])C([H])=C([H])C([H])=C2[H])=NC([H])=N1)[H])([H])[H])([H])[H])[H],DB08393,,"2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL",,small molecule,,,,,
C(C(OC(N1OC(=O)C(C2=C([H])C([H])=C(F)C([H])=C2[H])=C1C1=NC(OC2=C(O[H])C([H])=C([H])C([H])=C2[H])=NC([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB08395,,2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE,,small molecule,,,,,
O(C(=O)C(C(C(N(C(=C1N=C(C2=C([H])C([H])=C([H])C([H])=C2[H])OC1=O)[H])[H])([H])[H])([H])[H])([H])[H])[H],DB08396,,"4-{[(Z)-(5-OXO-2-PHENYL-1,3-OXAZOL-4(5H)-YLIDENE)METHYL]AMINO}BUTANOIC ACID",,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C2C(=C(C(=C([H])C2=C1[H])[H])C(F)(F)P(O[H])(O[H])=O)[H])[H],DB08397,,6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID,,small molecule,,,,,
C(N1C(N([H])[H])=NC2=NC(=C(C([H])=C12)C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])([H])[H],"DB08398
DB12735",105650-23-5,"2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine","2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
PhIP",small molecule,,,,,
O(C1=C([H])C(C(=C(C2=C([H])C(O[H])=C(O[H])C([H])=C2[H])[H])[H])=C([H])C(O[H])=C1[H])[H],DB08399,,PICEATANNOL,,small molecule,,,,,
O(C(=O)N1C([H])([H])C([H])([H])C(C(C2=C([H])C([H])=C([H])C(OC3=NC([H])=C(C(F)(F)F)C([H])=C3[H])=C2[H])([H])[H])([H])C([H])([H])C1([H])[H])[H],DB08400,,4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzyl)piperidine-1-carboxylic acid,,small molecule,,,,,
O(C(=O)C1=C(N(C(=O)C2=C(Cl)C([H])=C(Cl)C([H])=C2[H])[H])C([H])=C([H])C(OC2=NC([H])=C([H])C([H])=N2)=C1[H])[H],DB08402,,"2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID",,small molecule,,,,,
N(C1=NC2=NC(=C(C(N3C4=C(C(=C(C(=C4[H])[H])[H])[H])C([H])=C([H])C4=C3C(=C(C(=C4[H])[H])[H])[H])([H])[H])N=C2C(N([H])[H])=N1)[H])([H])[H],DB08406,,"[N-(2,4-DIAMINOPTERIDIN-6-YL)-METHYL]-DIBENZ[B,F]AZEPINE",,small molecule,,,,,
O(C(=O)C(N(C(=O)C(C(C(C(=O)N(C(C1=C([H])C([H])=C([N+]([O-])=O)C([H])=C1[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])[H],DB08410,,PARA-NITROBENZYL GLUTARYL GLYCINIC ACID,,small molecule,,,,,
N(C1=C(C(=O)C2=C([H])C(OC3(C([H])([H])C([H])([H])N([H])C([H])([H])C3([H])[H])[H])=C([H])C([H])=C2[H])C([H])=NN1C1=C([H])C([H])=C(F)C([H])=C1[H])([H])[H],DB08423,,[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE,,small molecule,,,,,
C(=C(S(=O)(=O)OC1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H],DB08433,,phenyl ethenesulfonate,,small molecule,,,,,
C(C(C(C(N1C(C(C2=C([H])C3=C(OC(O3)([H])[H])C([H])=C2[H])([H])[H])=NC2=C1N=C(N=C2N([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08436,,"8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-",,small molecule,,,,,
C(C(C(=O)N(S(=O)(=O)C1=C([H])C([H])=C(C2=C(C([H])([H])[H])ON=C2C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB08439,198470-84-7,Parecoxib,,small molecule,Humans and other mammals,"Injection, powder, for solution",Intramuscular; Intravenous,40 mg,Used for short term perioperative pain control.
C(C(=O)N(C1=C([H])C2=C(C(=C(N=C2C2=NC(=C(C([H])=C12)[H])[H])[H])[H])[H])[H])([H])([H])[H],DB08440,,"N-1,10-phenanthrolin-5-ylacetamide",,small molecule,,,,,
BrC1=C2N(C(C(C(N(S(=O)(=O)C3=C([H])C([H])=C([H])C(N([H])C(=N2)N=C1[H])=C3[H])[H])([H])[H])([H])[H])([H])[H])[H],DB08441,,"6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE",,small molecule,,,,,
O(C1=C([H])C(O[H])=C(C(=O)N2C([H])=C([H])C([H])=C2[H])C(O[H])=C1[H])[H],DB08443,,"2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol",,small molecule,,,,,
C(C1=C([H])C(OC2=C(Br)C([H])=C(C(C3=NN([H])C4=C3C(=C(N=N4)[H])[H])([H])[H])C([H])=C2[H])=C([H])C(C#N)=C1[H])([H])([H])[H],DB08444,,"3-[2-bromo-4-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-methylbenzonitrile",,small molecule,,,,,
FC1=C(C(C2=NN([H])C3=C2C(=C(N=N3)[H])[H])([H])[H])C([H])=C([H])C(Br)=C1OC1=C([H])C(Cl)=C([H])C(C#N)=C1[H],DB08446,,"3-[6-bromo-2-fluoro-3-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-chlorobenzonitrile",,small molecule,,,,,
C(N(C([H])([H])[H])C(C1=C([H])N([H])C2=C(C(C(C(O[H])([H])[H])([H])[H])([H])[H])C(=C(C([H])=C12)[H])[H])([H])[H])([H])([H])[H],DB08447,,3-{3-[(DIMETHYLAMINO)METHYL]-1H-INDOL-7-YL}PROPAN-1-OL,,small molecule,,,,,
O(C(=O)C(N1C([H])=C(C(C2=NC3=C(F)C(F)=C(C(F)=C3S2)[H])([H])[H])C2=C1N=C(C(=C2[H])[H])[H])([H])[H])[H],DB08449,,"2-(3-((4,5,7-trifluorobenzo[d]thiazol-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)acetic acid",,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C(C2=NC3=C(C(=C(C([H])=C3C(N(C3=C([H])C4=C(N(N=C4[H])[H])C([H])=C3[H])[H])=N2)[H])[H])[H])=N1)([H])([H])[H],DB08450,,N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine,,small molecule,,,,,
C(S(=O)(=O)N(C1=C([H])C([H])=C([H])C2=C(C(=C(N=C12)[H])[H])[H])[H])([H])([H])[H],DB08451,,N-(QUINOLIN-8-YL)METHANESULFONAMIDE,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C1=[N+]([O-])C2=C(C(=C(C([H])=C2C(O[H])=C1[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08453,,2-NONYL-4-HYDROXYQUINOLINE N-OXIDE,,small molecule,,,,,
C(C1=C([H])C(N(C2=NC(C3=C([H])C([H])=C([H])C([H])=C3[H])=NC3=C(C(=C(C([H])=C23)[H])[H])[H])[H])=NN1[H])([H])([H])[H],DB08454,,N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE,,small molecule,,,,,
C(C(C(=C(C1=C(C([H])([H])[H])C(C([H])([H])[H])=C(O[H])C([H])=C1C([H])([H])[H])[H])[H])=C(C(=C(C(C([H])([H])[H])=C(C(O[H])=O)[H])[H])[H])[H])([H])([H])[H],DB08455,65316-65-6,Ro 12-7310,"(2E,4E,6E,8E)-9-(4-Hydroxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid",small molecule,,,,,
C(C1(C([H])([H])[H])N(O[H])C(C([H])([H])[H])(C([H])([H])[H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])=C1C(SS(C([H])([H])[H])(=O)=O)([H])[H])([H])([H])[H],DB08456,,"S-[(1-Hydroxy-2,2,5,5-tetramethyl-4-phenyl-2,5-dihydro-1H-pyrrol-3-yl)methyl] methanesulfonothioate",,small molecule,,,,,
C(C1=C(C(SC(C2=C([H])C([H])=C([H])O2)([H])[H])([H])[H])C(OC2=C([H])C(C([H])([H])[H])=C([H])C(C([H])([H])[H])=C2[H])=C(I)C(=O)N1[H])([H])([H])[H],DB08457,,"4-(3,5-DIMETHYLPHENOXY)-5-(FURAN-2-YLMETHYLSULFANYLMETHYL)-3-IODO-6-METHYLPYRIDIN-2(1H)-ONE",,small molecule,,,,,
C(N(C(C(=C(C(OC1=C([H])C([H])=C(C(=O)C2=C([H])C([H])=C(Br)C([H])=C2[H])C([H])=C1[H])([H])[H])[H])[H])([H])[H])C1(C([H])([H])C1([H])[H])[H])([H])([H])[H],DB08458,,(4-BROMOPHENYL)[4-({(2E)-4-[CYCLOPROPYL(METHYL)AMINO]BUT-2-ENYL}OXY)PHENYL]METHANONE,,small molecule,,,,,
ClC1=C([H])C(C#N)=C([H])C(OC2=C(Cl)C([H])=C([H])C(OC(C3=NN([H])C4=C3C(=C(C(=N4)[H])[H])[H])([H])[H])=C2[H])=C1[H],DB08459,,"3-chloro-5-[2-chloro-5-(1H-pyrazolo[3,4-b]pyridin-3-ylmethoxy)phenoxy]benzonitrile",,small molecule,,,,,
N(C1=NC2=C(C(C(OC3=C([H])C(OC4=C([H])C(Cl)=C([H])C(C#N)=C4[H])=C(Cl)C([H])=C3[H])([H])[H])=NN2[H])C([H])=C1[H])([H])[H],DB08460,,"3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridin-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile",,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])N1N=C(C(C2=C([H])C([H])=C([H])C(O[H])=C2[H])([H])[H])C2=C(N([H])[H])N=C(N=C12)[H])([H])([H])[H],DB08461,,"3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL",,small molecule,,,,,
C(=C(C(=O)N(C1=C([H])C2=C(N(C3=C([H])C([H])=C([H])C([H])=C3[H])[H])N=C(N=C2C([H])=C1[H])[H])[H])[H])([H])[H],DB08462,,N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE,,small molecule,,,,,
C(OC(=O)C1=C(C(C(C(=O)N(C2=C(O[H])C([H])=C(OC([H])([H])[H])C(O[H])=C2[H])[H])([H])[H])([H])[H])C(Cl)=C(O[H])C([H])=C1O[H])([H])([H])[H],DB08464,,"METHYL 3-CHLORO-2-{3-[(2,5-DIHYDROXY-4-METHOXYPHENYL)AMINO]-3-OXOPROPYL}-4,6-DIHYDROXYBENZOATE",,small molecule,,,,,
C(OC1=C([H])C(N([H])[H])=C(OC([H])([H])[H])C(C(C(OC(=O)C2=C([H])C(Cl)=C(O[H])C([H])=C2O[H])([H])[H])([H])[H])=C1OC([H])([H])[H])([H])([H])[H],DB08465,,"2-(3-AMINO-2,5,6-TRIMETHOXYPHENYL)ETHYL 5-CHLORO-2,4-DIHYDROXYBENZOATE",,small molecule,,,,,
O(C1=C([H])C([H])=C(C(C(C2=C([H])C(O[H])=C([H])C(O[H])=C2[H])([H])[H])([H])[H])C([H])=C1[H])[H],DB08466,,"5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol",,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])OC(=O)N1C([H])([H])C([H])([H])C(C2=NC(C3=C([H])C([H])=C([H])S3)=NO2)([H])C([H])([H])C1([H])[H])([H])([H])[H],DB08469,,"tert-butyl 4-(3-thiophen-2-yl-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate",,small molecule,,,,,
FC1=C([H])C([H])=C(C2=NN=C(C3=C([H])C([H])=C([H])C([H])=C3[H])N2[H])C([H])=C1[H],DB08470,,"3-(4-fluorophenyl)-5-phenyl-4H-1,2,4-triazole",,small molecule,,,,,
O=C(C(C1=C([H])C([H])=C([H])S1)([H])[H])N1C([H])([H])C([H])([H])C(C2=NC(C3=C([H])C([H])=C([H])S3)=NO2)([H])C([H])([H])C1([H])[H],DB08471,,"1-(thiophen-2-ylacetyl)-4-(3-thiophen-2-yl-1,2,4-oxadiazol-5-yl)piperidine",,small molecule,,,,,
N(C(=N[H])N(C(=N[H])N(C1=C(Cl)C([H])=C([H])C(C(F)(F)F)=C1[H])[H])[H])([H])[H],DB08478,,N-[2-chloro-5-(trifluoromethyl)phenyl]imidodicarbonimidic diamide,,small molecule,,,,,
C(OC1=C([H])C(OC([H])([H])[H])=C([H])C(N(C(=N[H])N(C(N([H])[H])=N[H])[H])[H])=C1[H])([H])([H])[H],DB08479,,"N-(3,5-dimethoxyphenyl)imidodicarbonimidic diamide",,small molecule,,,,,
C(C1=C([H])C([H])=C(C(=C2SC(N(S(=O)(=O)C3=C([H])C([H])=C(C([H])([H])[H])C([H])=C3[H])[H])=NC2=O)[H])O1)([H])([H])[H],DB08481,,"4-METHYL-N-{(5E)-5-[(5-METHYL-2-FURYL)METHYLENE]-4-OXO-4,5-DIHYDRO-1,3-THIAZOL-2-YL}BENZENESULFONAMIDE",,small molecule,,,,,
N(C1=C([H])C([H])=C(S(=O)(=O)N(C(=O)N(C(C(S[H])([H])[H])([H])[H])[H])[H])C([H])=C1[H])([H])[H],DB08484,,4-AMINO-N-[(2-SULFANYLETHYL)CARBAMOYL]BENZENESULFONAMIDE,,small molecule,,,,,
C(C1=C([H])C(N(C(=O)C(C2=C([H])C([H])=C(OC(C([H])([H])[H])(C([H])([H])[H])C(O[H])=O)C([H])=C2[H])([H])[H])[H])=C([H])C(C([H])([H])[H])=C1[H])([H])([H])[H],"DB08486
DB06459",131179-95-8,Efaproxiral,,small molecule,,,,,
N(C(=N[H])C1=C([H])C([H])=C([H])C(C(N2C([H])([H])C([H])([H])N(S(=O)(=O)C3=C([H])C4=C(C(=C(Cl)C(=C4[H])[H])[H])S3)C([H])([H])C2=O)([H])[H])=C1[H])([H])[H],DB08487,,3-({4-[(6-CHLORO-1-BENZOTHIEN-2-YL)SULFONYL]-2-OXOPIPERAZIN-1-YL}METHYL)BENZENECARBOXIMIDAMIDE,,small molecule,,,,,
ClC1=C([H])C([H])=C(C(=C(S(=O)(=O)N2C([H])([H])C([H])([H])N(C(C3=C([H])C4=C(C(=C(N=C4[H])[H])[H])N3[H])([H])[H])C(=O)C2([H])[H])[H])[H])S1,DB08488,,"4-{[(E)-2-(5-CHLOROTHIEN-2-YL)VINYL]SULFONYL}-1-(1H-PYRROLO[3,2-C]PYRIDIN-2-YLMETHYL)PIPERAZIN-2-ONE",,small molecule,,,,,
O(N(C(=O)C1(C(S(=O)(=O)C2=C([H])C([H])=C(OC3=C([H])C([H])=C(Cl)C([H])=C3[H])C([H])=C2[H])([H])[H])C([H])([H])C([H])([H])OC([H])([H])C1([H])[H])[H])[H],"DB08490
DB12372",193022-04-7,CTS-1027,,small molecule,,,,,
O(N(C(=O)C(C1(C([H])([H])C([H])([H])OC([H])([H])C1([H])[H])S(=O)(=O)C1=C([H])C([H])=C(OC2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H])[H])[H],DB08491,,N-HYDROXY-2-[4-(4-PHENOXY-BENZENESULFONYL)-TETRAHYDRO-PYRAN-4-YL]-ACETAMIDE,,small molecule,,,,,
C(C(C(C(C(C(C#CC1=C(C(=C(C(O[H])=O)[H])[H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08492,,(2E)-3-(2-OCT-1-YN-1-YLPHENYL)ACRYLIC ACID,,small molecule,,,,,
C(C1=C([H])C2=C(N(C(C(C2([H])[H])([H])[H])([H])[H])C(=O)SC(C(=O)N(C2=C(Cl)C([H])=C(S(N([H])[H])(=O)=O)C([H])=C2[H])[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB08494,,"S-{2-[(2-chloro-4-sulfamoylphenyl)amino]-2-oxoethyl} 6-methyl-3,4-dihydroquinoline-1(2H)-carbothioate",,small molecule,,,,,
N(C(=N[H])C1=C([H])C([H])=C(C(N2C([H])([H])C([H])([H])N(S(=O)(=O)C3=C([H])C4=C(C(=C(Cl)C(=C4[H])[H])[H])S3)C([H])([H])C2=O)([H])[H])C([H])=C1[H])([H])[H],DB08495,,4-({4-[(6-CHLORO-1-BENZOTHIEN-2-YL)SULFONYL]-2-OXOPIPERAZIN-1-YL}METHYL)BENZENECARBOXIMIDAMIDE,,small molecule,,,,,
FC(C(OC1=C([H])C(N(C(=O)C(C(C(=O)N(C2=C([H])C3=C(C(=O)N(C(=O)C3=O)[H])C([H])=C2[H])[H])([H])[H])([H])[H])[H])=C([H])C([H])=C1[H])([H])[H])([H])[H],DB08499,,"N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide",,small molecule,,,,,
C(C(OC(=O)N(C(C(C(N(C(=O)OC(C([H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])([H])[H],DB08501,,"DIETHYL PROPANE-1,3-DIYLBISCARBAMATE",,small molecule,,,,,
C(C(C([H])([H])[H])(C1=C(SC2=C([H])C(Cl)=C([H])C(Cl)=C2[H])N(C(C2=C([H])C([H])=NC([H])=C2[H])([H])[H])C(C(OC(N([H])[H])=O)([H])[H])=N1)[H])([H])([H])[H],"DB08502
DB06456",,Capravirine,Capravirine,small molecule,,,,,Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection.
C(OC1=C([H])C(Cl)=C(OC(C(C(C(C(C(N2C([H])=C([H])N=C2[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB08509,,1-[6-(2-CHLORO-4-METHYXYPHENOXY)-HEXYL]-IMIDAZOLE,,small molecule,,,,,
C(C1=NC2=C(C3=C(C([H])=C2N1[H])C(=O)N([H])C(N([H])[H])=N3)[H])([H])([H])[H],DB08511,,"6-amino-2-methyl-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,small molecule,,,,,
N(C1=NC2=C(C(=C3N=C(N(C(C4=C([H])C([H])=C([H])C5=C(C(=C(C([H])=C45)[H])[H])[H])([H])[H])[H])N([H])C3=C2[H])[H])C(=O)N1[H])([H])[H],DB08512,,"6-amino-2-[(1-naphthylmethyl)amino]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C(N(C2=C(C(N([H])[H])=O)C([H])=NC(N(C3=C([H])C([H])=C(C(C(O[H])=O)([H])[H])C([H])=C3[H])[H])=N2)[H])=C1[H])([H])([H])[H],DB08513,,[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID,,small molecule,,,,,
N(C1=NC2=C(C3=C(C([H])=C2C(=O)N1[H])N([H])C(N(C(C1=C([H])C([H])=C([H])S1)([H])[H])[H])=N3)[H])([H])[H],DB08514,,"6-amino-2-[(thiophen-2-ylmethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one",,small molecule,,,,,
C(OC1=C([H])C(N(C2=NC(N(C3=C([H])C4=C(C(C([H])([H])[H])=NN4[H])C([H])=C3[H])[H])=C([H])C([H])=N2)[H])=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])([H])([H])[H],DB08519,,"N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine",,small molecule,,,,,
FC1=C([H])C([H])=C(C2=C(C3=C([H])C([H])=NC([H])=C3[H])N(C(C3(C([H])([H])C3([H])[H])[H])([H])[H])C([H])=N2)C([H])=C1[H],DB08522,,4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE,,small molecule,,,,,
O(C(N(O[H])C(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB08523,,[HYDROXY(3-PHENYLPROPYL)AMINO]METHANOL,,small molecule,,,,,
O(N(C(C(OC1=C([H])C([H])=C([H])C(C(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])=C1[H])([H])[H])([H])[H])C(=O)[H])[H],DB08524,,2-(3-BENZOYLPHENOXY)ETHYL(HYDROXY)FORMAMIDE,,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C(C(C(C(N(O[H])C(=O)[H])([H])[H])([H])[H])([H])[H])=N1)([H])([H])[H],DB08525,,HYDROXY[3-(6-METHYLPYRIDIN-2-YL)PROPYL]FORMAMIDE,,small molecule,,,,,
N(C(=O)C1=NN(C2=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C2[H])C2=C1C(=C(C1=C2C([H])=NN1[H])[H])[H])([H])[H],DB08527,,"1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE",,small molecule,,,,,
C(C1=C([H])C(S(=O)(=O)C2=C(C#N)C(N([H])[H])=C([H])C([H])=C2[H])=C([H])C(C([H])([H])[H])=C1[H])([H])([H])[H],DB08528,,"2-AMINO-6-(3,5-DIMETHYLPHENYL)SULFONYLBENZONITRILE",,small molecule,,,,,
C(C(C(C(C(C(=C(C(C(C(C(=C(C(C(C(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])[H])([H])[H])(P(O[H])(O[H])=O)P(O[H])(O[H])=O)([H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08529,,"(6E,11E)-HEPTADECA-6,11-DIENE-9,9-DIYLBIS(PHOSPHONIC ACID)",,small molecule,,,,,
C(N1C2=C(N(C(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])C(=N2)N2C([H])([H])C([H])([H])[N+]([H])([H])C([H])([H])C2([H])[H])C(=O)N(C([H])([H])[H])C1=O)([H])([H])[H],DB08530,,"7-BENZYL-1,3-DIMETHYL-8-PIPERAZIN-1-YL-3,7-DIHYDRO-PURINE-2,6-DIONE",,small molecule,,,,,
ClC1=C(Cl)C(C2=NC3=C(C(=NN3C(N(C(C3=C([H])C([H])=NC([H])=C3[H])([H])[H])[H])=C2[H])[H])[H])=C([H])C([H])=C1[H],DB08531,,"5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine",,small molecule,,,,,
FC1=C(C2=C([H])N3C(=C(N=C3C(N(C(C3=C([H])N=C([H])C([H])=C3[H])([H])[H])[H])=N2)[H])[H])C([H])=C([H])C([H])=C1[H],DB08532,,"6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine",,small molecule,,,,,
C(C1=C([H])N=C2N1C(=C(N=C2N(C(C1=C([H])C([H])=NC([H])=C1[H])([H])[H])[H])[H])[H])([H])([H])[H],DB08533,,"3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine",,small molecule,,,,,
FC1=C(C2=NC3=C(C(=NN3C(N(C(C3=C([H])C([H])=NC([H])=C3[H])([H])[H])[H])=C2[H])[H])[H])C([H])=C([H])C([H])=C1[H],DB08534,,"5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine",,small molecule,,,,,
BrC1=C2N=C(C(=C(N(C(C3=C([H])N=C([H])C([H])=C3[H])([H])[H])[H])N2N=C1[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H],DB08535,,"3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine",,small molecule,,,,,
BrC1=C2C(=C(C(=C(N(C(C3=C([H])N=C([H])N=C3[H])([H])[H])[H])N2N=C1[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])[H],DB08536,,"3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine",,small molecule,,,,,
BrC1=C([H])N=C2N1C(=C(C(=C2N(C(C1=C([H])N=C([H])N=C1[H])([H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])[H],DB08537,,"3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine",,small molecule,,,,,
C(C(C1=C2N=C(C(=C(N(C(C3=C([H])N=C(N([H])[H])N=C3[H])([H])[H])[H])N2N=C1[H])[H])C1=C(F)C([H])=C([H])C([H])=C1F)([H])[H])([H])([H])[H],DB08538,,"N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine",,small molecule,,,,,
C(N(C1=C([H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])=NC2=C(C(=NN12)[H])C1(C([H])([H])C1([H])[H])[H])[H])(C1=C([H])N=C([H])C([H])=C1[H])([H])[H],DB08539,,"3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine",,small molecule,,,,,
C(C(OC(=O)C1=C([H])SC(N2C([H])([H])C([H])([H])N(C3=NC4=C(C(=C(C(=C4[H])[H])[H])[H])SC3([H])[H])C([H])([H])C2([H])[H])=N1)([H])[H])([H])([H])[H],DB08540,,"2-[4-(2H-1,4-BENZOTHIAZINE-3-YL)-PIPERAZINE-1-LY]-1,3-THIAZOLE-4-CARBOXYLIC ACID ETHYLESTER",,small molecule,,,,,
ClC1=C(Cl)C2=C(C(C(N(C2([H])[H])[H])([H])[H])([H])[H])C([H])=C1[H],DB08550,61563-24-4,"7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline",,small molecule,,,,,
O(N=C1C([H])([H])C([H])([H])C2=C1C(=C(C(=C2[H])C1=C([H])N(C2(C([H])([H])C([H])([H])N([H])C([H])([H])C2([H])[H])[H])N=C1C1=C([H])C([H])=NC([H])=C1[H])[H])[H])[H],DB08553,,"(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime",,small molecule,,,,,
C(OC1=C([H])C2=C(C(=NC(C2([H])[H])([H])[H])C2=C([H])C([H])=C([H])C(Br)=C2[H])C([H])=C1Cl)([H])([H])[H],DB08555,,"1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline",,small molecule,,,,,
C(C(=O)C1=C([H])C([H])=C(C2=C([H])C(N(S(=O)(=O)C3=C(C([H])([H])[H])C([H])=C(C([H])([H])[H])C([H])=C3[H])[H])=C(C(O[H])=O)S2)S1)([H])([H])[H],DB08556,,"5'-ACETYL-4-{[(2,4-DIMETHYLPHENYL)SULFONYL]AMINO}-2,2'-BITHIOPHENE-5-CARBOXYLIC ACID",,small molecule,,,,,
C(OC(C(N(C1=C(C(N([H])[H])=O)C([H])=C([H])C(N2C3=C(C(=O)C(C(C3([H])[H])([H])[H])([H])[H])C3=C2C(=C(C(=C3[H])[H])[H])[H])=C1[H])[H])([H])[H])([H])[H])([H])([H])[H],DB08557,,"2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide",,small molecule,,,,,
FC1=C([H])C([H])=C(N2N=C(C3=C([H])C([H])=C([H])S3)C([H])=C2N(S(=O)(=O)C2=C([H])C(F)=C([H])C([H])=C2[H])[H])C([H])=C1[H],DB08560,,3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE,,small molecule,,,,,
O=C(OC(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])C1=C([H])N2C(=C(C(=O)N(C(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])C2=O)[H])S1,DB08561,,"BENZYL 6-BENZYL-5,7-DIOXO-6,7-DIHYDRO-5H-[1,3]THIAZOLO[3,2-C]PYRIMIDINE-2-CARBOXYLATE",,small molecule,,,,,
O(C(=O)C(C(C(C(=O)N(C1=C([H])C([H])=C(C(=C(C2=C([H])C([H])=C([H])C([H])=C2[H])[H])[H])C([H])=C1[H])[H])([H])[H])([H])[H])([H])[H])[H],DB08562,,4-(4-STYRYL-PHENYLCARBAMOYL)-BUTYRIC ACID,,small molecule,,,,,
C(N(C([H])([H])[H])C(C(=C(C(=O)N(C1=C([H])C([H])=C2N=C(N=C(N(C3=C([H])C([H])=C([H])C(Br)=C3[H])[H])C2=C1[H])[H])[H])[H])[H])([H])[H])([H])([H])[H],DB08564,,(2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide,,small molecule,,,,,
C(C(=O)N(C1=C([N+]([O-])=O)C([H])=C(C(O[H])=O)C([H])=C1O[H])[H])([H])([H])[H],DB08570,,4-(ACETYLAMINO)-3-HYDROXY-5-NITROBENZOIC ACID,,small molecule,,,,,
C(C(=O)N(C1=C(O[H])C([H])=C(C(O[H])=O)C([H])=C1N([H])[H])[H])([H])([H])[H],DB08571,,4-(ACETYLAMINO)-5-AMINO-3-HYDROXYBENZOIC ACID,,small molecule,,,,,
N(C(=O)C1=C([H])C([H])=C(N(C2=NC(OC(C3(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])[H])([H])[H])=C(N=O)C(N([H])[H])=N2)[H])C([H])=C1[H])([H])[H],DB08572,,4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE,,small molecule,,,,,
O(C(=O)C1=C(S(=O)(=O)N(C2=C([H])C([H])=C(Cl)C([H])=C2[H])[H])C([H])=C([H])S1)[H],DB08573,,3-[(4-CHLOROANILINO)SULFONYL]THIOPHENE-2-CARBOXYLIC ACID,,small molecule,,,,,
C(N(C(C(=O)C1=NN=C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])O1)([H])[H])[H])([H])([H])[H],DB08576,,"1-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)-2-(METHYLAMINO)ETHANONE",,small molecule,,,,,
C(C1=C([H])N([H])C(C(=C2C(=O)N([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])[H])=C1C(C(C(O[H])=O)([H])[H])([H])[H])([H])([H])[H],DB08577,,3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE,,small molecule,,,,,
O(C(=O)C(C(C(=O)N(C1=NC([H])=C(Br)C([H])=C1[H])[H])([H])[H])([H])[H])[H],DB08578,,4-[(5-bromopyridin-2-yl)amino]-4-oxobutanoic acid,,small molecule,,,,,
C(C(N1N=C([H])C([H])=C1C1=C([H])N([H])C2=NC(=C(C([H])=C12)C1=C([H])C(C(=O)N(C([H])([H])[H])C([H])([H])[H])=C(N([H])[H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB08583,,"2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide",,small molecule,,,,,
C(N1C([H])=C(C2=NN3C(SC4=C([H])C5=C(C(=C(N=C5C([H])=C4[H])[H])[H])[H])=NN=C3C([H])=C2[H])C([H])=N1)([H])([H])[H],DB08584,,"6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinoline",,small molecule,,,,,
C(OC1=C([H])C(C(=C(C(O[H])=O)[H])[H])=C([H])C(OC([H])([H])[H])=C1O[H])([H])([H])[H],DB08587,,SINAPINATE,,small molecule,,,,,
C(OC(=O)C1=C([H])C(OC([H])([H])[H])=C(O[H])C(OC([H])([H])[H])=C1[H])([H])([H])[H],DB08589,,SYRINGATE,,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])C(=O)OC1=C([H])C2=C(N(C(C(C(O[H])([H])[H])([H])[H])([H])[H])C(N(C(=O)C3=C([H])C([H])=C([H])C([N+]([O-])=O)=C3[H])[H])=N2)C([H])=C1[H])([H])([H])[H],DB08590,,1-(3-HYDROXYPROPYL)-2-[(3-NITROBENZOYL)AMINO]-1H-BENZIMIDAZOL-5-YL PIVALATE,,small molecule,,,,,
C(OC1=C(N2C([H])([H])C(=O)N([H])S2(=O)=O)C([H])=C(C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])([H])[H],DB08591,,"5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE",,small molecule,,,,,
O=C1C([H])([H])N(C2=C([H])C([H])=C([H])C([H])=C2[H])S(=O)(=O)N1[H],DB08593,,"1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE",,small molecule,,,,,
C(N(N(C(=O)OC(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])[H])C#N)([H])([H])[H],DB08594,,TERT-BUTYL 2-CYANO-2-METHYLHYDRAZINECARBOXYLATE,,small molecule,,,,,
C(C(N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])([H])[H])(OC1=C([H])C([H])=C(C2=C([H])N3N=C(C(C4=C([H])C([H])=NC([H])=C4[H])=C3N=C2[H])[H])C([H])=C1[H])([H])[H],DB08597,,"6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine",,small molecule,,,,,
C(C(C(C([Sn](C(C(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])(C(C(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08601,,tributylstannanyl,,small molecule,,,,,
C(SC1=NC2=C(C(=C(C(=C2[H])[H])[H])[H])C(=O)N1C1=C(F)C([H])=C([H])C([H])=C1F)([H])([H])[H],DB08602,,"3-(2,6-difluorophenyl)-2-(methylthio)quinazolin-4(3H)-one",,small molecule,,,,,
O(C1=C(OC2=C(Cl)C([H])=C(Cl)C([H])=C2[H])C([H])=C([H])C(Cl)=C1[H])[H],DB08604,3380-34-5,Triclosan,"2,4,4'-Trichloro-2'-hydroxydiphenyl ether
5-Chloro-2-(2,4-dichloro-phenoxy)-phenol
Triclosan
Triclosanum",small molecule,"Fungi, yeast and protozoans
Bacteria","Gel
Solution
Liquid
Lotion
Solution
Liquid
Liquid
Solution
Gel; soap
Soap
Liquid
Kit
Soap
Soap
Liquid
Lotion
Solution
Liquid
Liquid
Liquid
Soap
Soap
Soap
Liquid
Liquid
Gel
Liquid
Soap
Soap
Liquid
Liquid
Liquid
Solution
Liquid
Soap
Soap
Solution
Soap
Solution
Lotion / shampoo
Lotion
Liquid
Liquid
Solution
Liquid
Soap
Solution
Spray
Soap
Swab
Lotion
Soap
Soap
Soap
Soap
Lotion
Liquid
Liquid
Kit
Liquid
Liquid
Gel
Cream
Liquid
Liquid
Lotion
Soap
Spray
Liquid
Solution
Liquid
Solution
Soap
Soap
Liquid
Lotion
Liquid
Lotion
Soap
Lotion
Gel
Cream
Gel
Liquid
Soap
Liquid
Liquid
Lotion
Suspension
Soap
Gel
Liquid
Cream
Paste, dentifrice
Gel, dentifrice
Paste, dentifrice
Lotion
Soap
Soap
Liquid
Soap
Liquid
Liquid
Liquid
Liquid
Soap
Aerosol
Gel
Soap
Liquid
Cream
Liquid
Liquid
Solution
Spray
Solution
Solution
Solution
Solution
Solution
Solution
Aerosol, foam
Liquid
Liquid
Solution
Solution
Liquid
Solution
Solution
Solution
Liquid
Lotion
Solution
Solution
Solution
Liquid
Spray
Cream
Liquid
Soap
Soap
Liquid
Soap
Lotion
Liquid
Aerosol
Liquid
Shampoo
Aerosol
Soap
Soap
Soap
Solution
Aerosol, spray
Soap
Gel
Gel
Soap
Gel
Cloth
Liquid
Liquid
Liquid
Liquid
Liquid
Solution
Liquid
Liquid
Soap
Soap
Soap
Liquid
Lotion
Solution
Liquid
Solution
Solution
Cream
Liquid
Liquid
Liquid
Gel
Solution
Lotion
Soap
Liquid
Soap
Liquid
Soap
Solution
Liquid
Gel
Soap
Soap
Soap
Liquid
Liquid
Liquid
Liquid
Gel
Soap
Liquid
Soap
Gel
Liquid
Liquid
Liquid
Soap
Soap
Liquid
Soap
Soap
Soap
Soap
Soap
Liquid
Liquid
Solution
Liquid
Soap
Cloth
Soap
Liquid
Liquid
Lotion
Cream
Liquid
Liquid
Liquid
Liquid
Solution
Solution
Swab
Solution
Soap
Liquid
Soap
Soap
Liquid
Liquid
Liquid
Liquid
Gel
Lotion
Soap
Soap
Liquid
Liquid
Liquid
Liquid
Liquid
Gel
Liquid
Solution
Solution
Solution
Soap
Liquid
Solution
Gel
Gel
Soap
Liquid
Soap
Soap
Soap
Soap
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Soap
Lotion
Lotion
Liquid
Liquid
Liquid
Lotion
Shampoo
Lotion
Soap
Gel
Liquid; shampoo
Soap
Cream
Cream
Liquid
Liquid
Paste
Lotion
Sponge
Liquid
Liquid
Liquid
Soap
Gel
Liquid
Soap
Lotion
Lotion
Spray
Liquid
Lotion
Soap
Soap
Soap
Gel
Soap
Liquid
Liquid
Liquid","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Dental
Dental
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Vaginal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Percutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Dental
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Dental
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","1.0 %
11.7 g/100mL
0.10 %
1.15 mg/mL
.3 g/10mL
.3 g/100g
.15 g/100g
.5 %
.003 mL/mL
0.50 %
.1 mL/100mL
3 mg/g
0.58 %
0.30 %
.7 g/mL
.7 g/mL
.476 mL/340mL
1.15 mg/100mL
.15 mL/100L
.888 mL/444mL
5 mg/mL
2 g/L
.04 mL/100mL
.55 %
.15 mL/100mL
.15 mL/100mL
.115 kg/100L
0.55 %
.46 mL/100mL
.6 mL/100mL
.869 mL/289.82mL
.15 kg/100L
.15 mL/1000mL
1.5 mg/mL
.3 g/100mL
.15 g/100g
.994 mL/331.22mL
.115 mL/100mL
.115 mL/100mL
.115 L/100L
.115 kg/100L
.6 mL/100mL
.15 L/100L
.2 mg/100mL
.15 mL/100mL
0.5 %
.3 mL/100mL
.2 g/100g
0.3 %
.375 mL/100mL
.375 g/100mL
.8 %
.75 %
.3 %
0.19 %
2 mg/mL
.025 mL/100mL
3 mL/1000mL
2.5 mg/mL
0.3 %
.25 %
0.4 %
0.4 %
0.35 %
0.3 %
.0189 L/3.78L
3.06 mg/mL
0.3 %
0.2 %
.25 g/100g
.2 g/100mL
.5 mL/100mL
.1 %
1 g
0.6 %
.16 g/100g
1.7 uL/mL
.3 mL/100mL
.3 mL/100mL
.3 %
.3 g/100mL
.3 g/100g
0.25 %
.025 g/10mL
.5 %
0.3 %
0.76 %
.5 mL/125mL
1 g/100mL
.3 %
0.5 %
1 mg/g
.1 g/100g
1 mg/mL
25 g/100g
.3 mg/100mL
7 mg/100mL
.7 mL/100mL
7.57 mL/3.78L
1 mg/mL
1 %
.03 g/g
.375 mL/100mL
1 %
3.1 mg/mL
0.60 %
0.975 %
.46 g/100mL
4.6 mg/mL
.46 mL/1000mL
.46 mg/1000mL
0.46 %
.15 mL/1000mL
2.94 ug/mL
.5 %
0.30 %
3 mg/mL
10 mg/mL
.2 g/100g
2.05 mg/mL
10.35 mg/mL
10.3 mg/mL
1.0 %
7.5 mg/mL
.3 mL/100mL
18.9 g/100mL
.15 mg/100mL
.46 g/100mL
.5 %
0.60 %
.46 mL/100mL
.003 mg/mL
0.46 %
.004 g/g
.12 g/100g
5 mg/mL
3 mg/mL
0.5 %
3 mL/1000mL
.0057 g/g
1 g/100g
2 g/100g
.06 g/1000g
.3 %
.15 mg/mL
7.5 mg/500mg
3 mg/mL
2 mL/100mL
0.5 %
1.545 mg/mL
1 mL/100mL
0.33 %
.375 g/100mL
.9 g/300g
20.8 g/100mL
0.32 %
.32 %
.007 g/mL
.003 g/mL
.0005 g/g
.115 g/100g
1.0 %
0.5 %
.75 g/100mL
.46 mL/100mL
2.5 g/L
0.2 %
.115 mL/100mL
1.15 mg/mL
.25 g/100mL
10 mg/500mg
.575 mL/500mL
0.55 %
.2 g/100g
.1 mL/100mL
.15 g/100mL
1.5 g/L
6 mg/mL
.1 g/100mL
.2 mL/100mL
0.1 %
.3 g/L
3.75 mg/mL
.375 g/100g
.5 g/1000mL
.2 %
5 mg/g
7.5 mg/g
0.3 %
3 mL/1000mL
.5 mL/250mL
.003 g/g
.55 mL/100mL
0.2 %
3 mg/mL
.46 g/100mL
.1 g/100mL
.6 %
1 %
318.975 mL/2126.5mL
.3 mg/100mL
4.5 mg/mL
.5 g/100g
.5 mg/100mL
.55 mL/100mL
.1 mg/100mL
.4 mL/100mL
.2 mL/100mL
0.15 %
.562 mL/562mL
3 mg/.001L
.3 kg/100kg
.2 %
1.5 mL/L
1.5 mL/L
0.15 %
.0015 mg/mL
.003 mg/mL
.3 mg/100mL
0.3 %
.00025 g/g
.115 g/100g
3 g/L
.115 mL/100mL
.6 mL/100mL
.15 mg/100mL
.46 mg/100mL
4.6 mg/mL
3.54 mL/118mL
1.5 mg/mL
1 %
2 mg/mL
.25 g/100mL
.15 g/100mL
.1 %
1.08 g/L
1 mg
0.1 g
.15 mL/100mL
1.5 mg/100mL
5 g/L
.25 g/100mL
0.25 %
0.5 %
.25 mL/100mL
.25 %
.2 mL/100mL
3 mg/mL
4.6 mg/mL
.46 mg/mL
.3 g/100mL
.5 mL/100mL
.5 mg/100mL
.5 %
115 mg/100mL
11.7 g/100mL
0.375 %
5 g/L
.55 g/100mL
5.5 g/L
1.15 mL/L
.12 mL/100mL
.15 mL/100mL
.79 g/293g
.2 mg/100mL
1.5 mg/mL
.3 %
0.3 g
0.2 %
.5 g/100mL
1 mg/mL
0.5 %
2 g/L
.3 g/100mL
6 mg/mL
.5 g/100mL
.375 %
5 mg/mL
.003 mL/mL
29 mg/mL
3.15 g/1000mL
1.15 mg/mL
.3 g/100g
300 mg/100mL
6 1/mL
0.1 %
.15 g/100g
1.2 mL/10mL
.3 mL/100mL
.4 %
.002 g/mL
3.3 mg/221mL
6.6 1/443mL
1 mg/237mg
1.5 g/100g
.01 g/10mL
0.1 %","Triclosan is used in a variety of common household products, including soaps, mouthwashes, dish detergents, toothpastes, deodorants, and hand sanitizers.  It is also used in health care settings in surgical scrubs and personnel hand washes."
C(C(C(S(=O)(=O)N1N=C([H])C2=C(C(=C(C([H])([H])[H])S2)[H])B1O[H])([H])[H])([H])[H])([H])([H])[H],DB08605,,"6-METHYL-2(PROPANE-1-SULFONYL)-2H-THIENO[3,2-D][1,2,3]DIAZABORININ-1-OL",,small molecule,,,,,
C(C(C([H])([H])[H])(C1=C([H])C([H])=C(C(OC2=C(Cl)C([H])=C(C(C(=O)N(C(C(N([H])[H])([H])[H])([H])[H])[H])([H])[H])C([H])=C2[H])([H])[H])C([H])=C1[H])[H])([H])([H])[H],DB08610,,N-(2-AMINOETHYL)-2-{3-CHLORO-4-[(4-ISOPROPYLBENZYL)OXY]PHENYL} ACETAMIDE,,small molecule,,,,,
O(C(C(OC1=C(C2=C([H])C([H])=C(F)C(F)=C2F)C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])[H],DB08611,,"2-[(2',3',4'-TRIFLUOROBIPHENYL-2-YL)OXY]ETHANOL",,small molecule,,,,,
C(C(C(C(C(C(C(C(SC(C(=O)C(F)(F)F)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08612,,"1,1,1-TRIFLUORO-3-(OCTYLTHIO)ACETONE",,small molecule,,,,,
O(C(O[H])(C1=C([H])C([H])=C(C(=O)N2C([H])([H])C([H])([H])N3C(=NC(=C3C3=C([H])C([H])=C([H])C([H])=C3[H])[H])C2([H])[H])S1)C(F)(F)F)[H],DB08613,,"2,2,2-TRIFLUORO-1-{5-[(3-PHENYL-5,6-DIHYDROIMIDAZO[1,2-A]PYRAZIN-7(8H)-YL)CARBONYL]THIOPHEN-2-YL}ETHANE-1,1-DIOL",,small molecule,,,,,
C(N(C([H])([H])[H])C1=C([H])C([H])=C(C2=[N+](C([H])([H])[H])C3=C(C(=C(O[H])C(=C3[H])[H])[H])S2)C([H])=C1[H])([H])([H])[H],DB08615,,"2-[4-(DIMETHYLAMINO)PHENYL]-6-HYDROXY-3-METHYL-1,3-BENZOTHIAZOL-3-IUM",,small molecule,,,,,
ClC1=NC([H])=C(C(N2C([H])([H])C([H])([H])SC2=NC#N)([H])[H])C([H])=C1[H],DB08620,,"{(2Z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide",,small molecule,,,,,
O(C1(C([H])([H])C([H])([H])N(C(C(C(C2(SC([H])([H])C([H])([H])S2)C2=C([H])C([H])=C(F)C([H])=C2[H])([H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])C1=C([H])C([H])=C(Cl)C([H])=C1[H])[H],DB08622,,"4-(4-CHLORO-PHENYL)-1-{3-[2-(4-FLUORO-PHENYL)-[1,3]DITHIOLAN-2-YL]-PROPYL}-PIPERIDIN-4-OL",,small molecule,,,,,
ClC1=C([H])C([H])=C(N(S(=O)(=O)C2=C([H])C3=C(C(C(N(C3([H])[H])[H])([H])[H])([H])[H])C([H])=C2[H])[H])C([H])=C1[H],DB08631,,"N-(4-CHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE",,small molecule,,,,,
O(C(=O)C1=C([H])C(C(O[H])=O)=C([H])C(C(O[H])=O)=C1[H])[H],DB08632,,"1,3,5-BENZENETRICARBOXYLIC ACID",,small molecule,,,,,
C(C(C([H])([H])[H])(C1=C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])N(C(OC(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])C(=O)N([H])C1=O)[H])([H])([H])[H],DB08634,,6-BENZYL-1-BENZYLOXYMETHYL-5-ISOPROPYL URACIL,,small molecule,,,,,
C(N(C(C(C(C(C(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])C1=C([H])C([H])=C(C(=C(C2=C([H])C([H])=C([N+]([O-])=O)C([H])=C2[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB08635,,N-(TRANS-4'-NITRO-4-STILBENYL)-N-METHYL-5-AMINO-PENTANOIC ACID,,small molecule,,,,,
O(C(=O)C(=O)C(=C(C1=C(O[H])C([H])=C([H])C([H])=C1[H])[H])[H])[H],DB08636,90293-62-2,2-Hydroxybenzalpyruvate,,small molecule,,,,,
C(OC1=C(C(=C(C(=O)C(O[H])=O)[H])[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB08637,,4-(2-METHOXYPHENYL)-2-OXOBUT-3-ENOIC ACID,,small molecule,,,,,
C(C1=C([H])C(C([H])([H])[H])=C(N(C2=C([H])C([H])=NC(N(C3=C([H])C([H])=C(C#N)C([H])=C3[H])[H])=N2)[H])C(C([H])([H])[H])=C1[H])([H])([H])[H],"DB08639
DB11908",244767-67-7,Dapivirine,,small molecule,,,,,
N(C(=O)C(C1=C([H])N([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H],DB08652,,2-(1H-INDOL-3-YL)ACETAMIDE,,small molecule,,,,,
N(C(C(C1=C([H])N([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])[H],DB08653,,2-(1H-INDOL-3-YL)ETHANAMINE,,small molecule,,,,,
C(C(=O)N1C2=C(C(=C(C(=C2[H])[H])[H])[H])C2=C1C(=O)C(C(C2([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08655,,"9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE",,small molecule,,,,,
O(C(=O)C(OC1=C([H])C([H])=C(C2=C([H])N([H])C(C(N(C(=O)N(C3=NC([H])=C(SC4=NC([H])=C([H])C([H])=C4[H])S3)[H])[H])([H])[H])=N2)C([H])=C1[H])([H])[H])[H],DB08657,,2-(4-(2-((3-(5-(PYRIDIN-2-YLTHIO)THIAZOL-2-YL)UREIDO)METHYL)-1H-IMIDAZOL-4-YL)PHENOXY)ACETIC ACID,,small molecule,,,,,
N(N(C(=O)C1=C(C2=C([H])C([H])=C([H])C([H])=C2[H])C2=C(C(=C(C(=C2[H])S(N([H])[H])(=O)=O)[H])[H])N1[H])[H])([H])[H],DB08659,,2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide,,small molecule,,,,,
O(C1=C([H])C([H])=C2C(=O)C3=C(C(=O)C2=C1O[H])C(O[H])=C([H])C([H])=C3O[H])[H],DB08660,,"1,2,5,8-tetrahydroxyanthracene-9,10-dione",,small molecule,,,,,
C(C(N1C2=C(C(=C(C(=C2[H])[N+]([O-])=O)[H])[H])N(C([H])([H])[H])C(=O)C2=C(C(=C(N=C12)[H])[H])[H])([H])[H])([H])([H])[H],DB08665,,"6,11-DIHYDRO-11-ETHYL-6-METHYL-9-NITRO-5H-PYRIDO[2,3-B][1,5]BENZODIAZEPIN-5-ONE",,small molecule,,,,,
N(C1=C(N=NC2=C([H])C([H])=C([H])C(C(F)(F)F)=C2[H])C(=N[H])N=N1)([H])[H],DB08666,,5-imino-4-(3-trifluoromethyl-phenylazo)-5H-pyrazol-3-ylamine,,small molecule,,,,,
N(C1=C(N=NC2=C([H])C([H])=C(F)C([H])=C2[H])C(=N[H])N=N1)([H])[H],DB08667,,4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine,,small molecule,,,,,
N(C1=C(N=NC2=C([H])C([H])=C([H])C(C(O[H])=O)=C2[H])C(=N[H])N=N1)([H])[H],DB08668,,3-(5-amino-3-imino-3H-pyrazol-4-ylazo)-benzoic acid,,small molecule,,,,,
N(C1=C(N=NC2=C(C(F)(F)F)C([H])=C([H])C([H])=C2[H])C(=N[H])N=N1)([H])[H],DB08671,,5-IMINO-4-(2-TRIFLUOROMETHYL-PHENYLAZO)-5H-PYRAZOL-3-YLAMINE,,small molecule,,,,,
C(C(C([H])([H])[H])(C1=C([H])N=C(N(C2=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C2[H])[H])S1)[H])([H])([H])[H],DB08673,,"4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE",,small molecule,,,,,
C(C(C([H])([H])[H])(C1=C([H])N([H])C(=NC(=O)C(C2=C([H])N=C([H])C([H])=C2[H])([H])[H])S1)[H])([H])([H])[H],DB08677,,N-(5-ISOPROPYL-THIAZOL-2-YL)-2-PYRIDIN-3-YL-ACETAMIDE,,small molecule,,,,,
C(C(C1=C([H])C([H])=C(N(S(O[H])(=O)=O)[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB08678,,(4-ETHYLPHENYL)SULFAMIC ACID,,small molecule,,,,,
C(C1=C(C(=S)N(C2=C([H])C(C(=NOC(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])[H])=C(Cl)C([H])=C2[H])[H])C([H])=C([H])O1)([H])([H])[H],DB08680,172998-57-1,N-{3-[(E)-(tert-butoxyimino)methyl]-4-chlorophenyl}-2-methylfuran-3-carbimidothioic acid,,small molecule,,,,,
C(C(C([H])([H])[H])(OC(=S)N(C1=C([H])C(C(=O)OC(C([H])([H])[H])(C([H])([H])[H])[H])=C(Cl)C([H])=C1[H])[H])[H])([H])([H])[H],DB08681,,1-METHYL ETHYL 2-CHLORO-5-[[[(1-METHYLETHOXY)THIOOXO]METHYL]AMINO]-BENZOATE,,small molecule,,,,,
C(C(C([H])([H])[H])(OC(=O)C1=C(Cl)C([H])=C([H])C(N(C(=O)C2=C(C([H])([H])[H])OC([H])([H])C([H])([H])S2)[H])=C1[H])[H])([H])([H])[H],DB08682,,"1-METHYL ETHYL 1-CHLORO-5-[[(5,6DIHYDRO-2-METHYL-1,4-OXATHIIN-3-YL)CARBONYL]AMINO]BENZOATE",,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(OC(S[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08684,,O-DECYL HYDROGEN THIOCARBONATE,,small molecule,,,,,
C(N1C([H])([H])C([H])([H])N(C([H])([H])[H])C2=C1C(=C(C(C(N([H])[H])([H])[H])=C2[H])[H])[H])([H])([H])[H],DB08685,,"1-(1,4-dimethyl-1,2,3,4-tetrahydroquinoxalin-6-yl)methanamine",,small molecule,,,,,
O(C(=O)C(N(C(=O)C1=C(O[H])C2=C(C(=C(C([H])=C2C(Cl)=N1)[H])[H])[H])[H])([H])[H])[H],"DB08687
DB05577",223387-75-5,FG-2216,"(((1-Chloro-4-hydroxyisoquinolin-3-yl)carbonyl)amino)acetic acid
1-Chloro-N- (hydroxyformylmethyl-4-hydroxyisoquinoline-3-carboxamide
1-Chloro-N-(hydroxyformylmethyl-4-hydroxyisoquinoline-3-carboxamide",small molecule,,,,,Investigated for use/treatment in anemia and kidney disease.
C(C(C(C(C(C(C(C(C(C(C([H])([H])[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08688,,undecan-2-one,,small molecule,,,,,
C(OC1=C(OC([H])([H])[H])C(=O)C(C(C(=C(C([H])([H])[H])C([H])([H])[H])[H])([H])[H])=C(C([H])([H])[H])C1=O)([H])([H])[H],DB08689,,UBIQUINONE-1,,small molecule,,,,,
C(OC1=C(OC([H])([H])[H])C(=O)C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C([H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])=C(C([H])([H])[H])C1=O)([H])([H])[H],DB08690,,UBIQUINONE-2,,small molecule,,,,,
C(C(OC(=O)C1=C(C(=C(N([H])[H])[H])C#N)C2=C(C(Cl)=C(Cl)C(=C2[H])[H])N1C([H])([H])[H])([H])[H])([H])([H])[H],DB08691,,"ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate",,small molecule,,,,,
N(C1=NC([H])=C([H])C(C2=C3C(=C(N=C(N([H])[H])N3C3=NC(=C(C(O[H])=C23)[H])[H])[H])[H])=N1)([H])[H],DB08694,,"9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidin-4-ol",,small molecule,,,,,
[O-][N+](=O)C1=C([H])C([H])=C(C2=NN([H])C([H])=C2[H])C([H])=C1[H],DB08695,,3-(4-nitrophenyl)-1H-pyrazole,,small molecule,,,,,
C(C1=C([H])C(C(=O)N(C2=C([H])C(Cl)=C([H])C(N3C([H])([H])C([H])([H])C([H])([H])C([H])([H])C3([H])[H])=C2[H])[H])=C([H])C(C([H])([H])[H])=C1OC(C(N([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08697,,"4-(2-aminoethoxy)-N-(3-chloro-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide",,small molecule,,,,,
C(C1=C([H])C([H])=C([H])C(C(C2=NN(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C3=C2C(N([H])[H])=NC(=N3)[H])([H])[H])=C1[H])([H])([H])[H],DB08699,,"1-tert-butyl-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine",,small molecule,,,,,
O(C(C(N(C1=C([H])C([H])=C2C(=O)N(C(=O)C3=C2C1=C(C(=C3[H])[H])[H])C1=C([H])C([H])=C([H])C(Br)=C1[H])[H])([H])[H])([H])[H])[H],DB08701,,"2-(3-BROMOPHENYL)-6-[(2-HYDROXYETHYL)AMINO]-1H-BENZO[DE]ISOQUINOLINE-1,3(2H)-DIONE",,small molecule,,,,,
O(C(=O)C1=C(C2=C([H])C([H])=C([H])C([H])=C2[H])OC(C2=C([H])C([H])=C([H])C([H])=C2[H])=C1C(O[H])=O)[H],DB08702,,"2,5-DIPHENYLFURAN-3,4-DICARBOXYLIC ACID",,small molecule,,,,,
C(C(C([H])([H])[H])(OC1=C([H])C2=C(C3=C4C(=O)N=C([H])C4=C4C5=C(N(C(C(O[H])([H])[H])([H])[H])C4=C3C(C2([H])[H])([H])[H])C([H])=C([H])C([H])=C5[H])C([H])=C1[H])[H])([H])([H])[H],DB08703,,"12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one",,small molecule,,,,,
O(C1=C(C2=C([H])C(C3=C([H])C([H])=C([H])C([H])=C3[H])=C(C#N)C(=O)N2[H])C([H])=C(Br)C([H])=C1[H])[H],DB08705,,"6-(5-BROMO-2-HYDROXYPHENYL)-2-OXO-4-PHENYL-1,2-DIHYDROPYRIDINE-3-CARBONITRILE",,small molecule,,,,,
N(C1=NC([H])=C([H])C(C2=C([H])C3=C(ON=C3C([H])=C2[H])C2=C([H])C([H])=C(Cl)C([H])=C2[H])=N1)([H])[H],DB08707,,"4-[3-(4-chlorophenyl)-2,1-benzisoxazol-5-yl]pyrimidin-2-amine",,small molecule,,,,,
FC(F)(F)C1=C([H])C(C2=NN=C3C(=C(C(N(C4(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C4([H])[H])[H])[H])=NN23)[H])[H])=C([H])C([H])=C1[H],DB08708,,"N-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine",,small molecule,,,,,
O(C(=O)C1=C2N(C(=C(C3=C([H])C([H])=C([H])C([H])=C3[H])C2=C([H])C([H])=C1[H])C1=C([H])C([H])=C([H])C([H])=C1[H])[H])[H],DB08709,,"2,3-diphenyl-1H-indole-7-carboxylic acid",,small molecule,,,,,
C(OC(=O)C1=C([H])C(OC([H])([H])[H])=C(O[H])C([H])=C1[H])([H])([H])[H],DB08711,3943-74-6,Methyl vanillate,"4-hydroxy-3-methoxy methyl benzoate
4-hydroxy-3-methoxybenzoic acid methyl ester
Methyl 3-methoxy-4-hydroxybenzoate
Methyl 4-hydroxy-3-methoxybenzoate
Vanillic acid, methyl ester",small molecule,,,,,
O(C(=O)C(C(C(C(C(C(C(C(C(C(OC(S[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB08712,,11-[(MERCAPTOCARBONYL)OXY]UNDECANOIC ACID,,small molecule,,,,,
C(N1N=NC(C2=C([H])C(C([H])([H])[H])=C(OC(C(C(C3=C([H])C(C([H])([H])[H])=NO3)([H])[H])([H])[H])([H])[H])C(C([H])([H])[H])=C2[H])=N1)([H])([H])[H],DB08713,,"2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2N-METHYL-2H-TETRAZOL-5-YL]-PHENOL",,small molecule,,,,,
C(C1=NOC(C(C(C(OC2=C(C([H])([H])[H])C([H])=C(N3N=NC(C([H])([H])[H])=N3)C([H])=C2C([H])([H])[H])([H])[H])([H])[H])([H])[H])=C1[H])([H])([H])[H],DB08714,,"2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[4-METHYL-2H-TETRAZOL-2-YL]-PHENOL",,small molecule,,,,,
C(C1=NC(C2=C([H])C(C([H])([H])[H])=C(OC(C(C(C3=C([H])C(C([H])([H])[H])=NO3)([H])[H])([H])[H])([H])[H])C(C([H])([H])[H])=C2[H])=C([H])O1)([H])([H])[H],DB08715,,"2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2-METHYL-4-ISOXAZOLYL]-PHENOL",,small molecule,,,,,
C(C(C1=C(C2=C([H])C(O[H])=C(O[H])C([H])=C2[H])SC([H])=C1[H])([H])[H])([H])([H])[H],DB08718,,"4-(3-ethylthiophen-2-yl)benzene-1,2-diol",,small molecule,,,,,
C(C1=NOC(C(C(C(C(C(OC2=C(Cl)C([H])=C(C3=NC([H])([H])C([H])([H])O3)C([H])=C2[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])=C1[H])([H])([H])[H],DB08719,,"5-(5-(6-CHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE",,small molecule,,,,,
C(C1=NOC(C(C(C(C(C(OC2=C([H])C([H])=C(C3=NC([H])([H])C([H])([H])O3)C([H])=C2[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])=C1[H])([H])([H])[H],DB08720,,"5-(5-(4-(4,5-dihydro-2-oxazoly)phenoxy)pentyl)-3-methyl osoxazole",,small molecule,,,,,
O(C(C(OC(OC(C1=NOC(C(C(C(C(C(OC2=C(Cl)C([H])=C(C3=NC([H])([H])C([H])([H])O3)C([H])=C2Cl)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB08721,,"5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole",,small molecule,,,,,
C(C1=NOC(C(C(C(C(C(OC2=C(Cl)C([H])=C(C3=NC([H])([H])C([H])([H])O3)C([H])=C2Cl)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])=C1[H])([H])([H])[H],DB08723,,"5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE",,small molecule,,,,,
C(C1=NOC(C(C(C(C(C(C(C(OC2=C([H])C([H])=C(C3=NC([H])([H])C([H])([H])O3)C([H])=C2[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])=C1[H])([H])([H])[H],DB08726,,"5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole",,small molecule,,,,,
C(C1=NOC(C(C(C(OC2=C(Cl)C([H])=C(C3=NC([H])([H])C([H])([H])O3)C([H])=C2Cl)([H])[H])([H])[H])([H])[H])=C1[H])([H])([H])[H],DB08728,,"5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole",,small molecule,,,,,
C(C(C(C1=NN(C([H])([H])[H])C2=C1N=C(N(C2=O)[H])C1=C(OC(C([H])([H])[H])([H])[H])SC(S(N([H])[H])(=O)=O)=C1[H])([H])[H])([H])[H])([H])([H])[H],DB08729,,"5-ethoxy-4-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)thiophene-2-sulfonamide",,small molecule,,,,,
FC1=C([H])C(N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])=C([H])C(C(=O)N(C2=C([H])C3=C(C(=C(N3C(C(C3=C([H])C([H])=NC([H])=C3[H])([H])[H])([H])[H])[H])[H])C([H])=C2[H])[H])=C1[H],DB08730,,3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE,,small molecule,,,,,
C(C1(C([H])([H])[H])N=C(N([H])[H])N=C(N([H])[H])N1OC(C(C(OC1=C([H])C(Cl)=C(Cl)C([H])=C1Cl)([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08734,,"6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE",,small molecule,,,,,
C(OC1=C([H])C(=O)N(C([H])([H])[H])C2=C1C(=C(C1=C2OC([H])([H])O1)[H])[H])([H])([H])[H],DB08744,,"6-methoxy-9-methyl[1,3]dioxolo[4,5-h]quinolin-8(9H)-one",,small molecule,,,,,
ClC1=C([H])C([H])=C(C(=C(S(=O)(=O)N2C([H])([H])C([H])([H])N(C(C3(C([H])([H])C([H])([H])N(C4=C([H])C([H])=NC([H])=C4[H])C([H])([H])C3([H])[H])[H])([H])[H])C(=O)C2([H])[H])[H])[H])C([H])=C1[H],DB08745,,4-[[(1E)-2-(4-CHLOROPHENYL)ETHENYL]SULFONYL]-1-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]PIPERAZINONE,,small molecule,,,,,
ClC1=C([H])C([H])=C(C(=C(S(=O)(=O)N2C([H])([H])C([H])([H])N(C(C3(C([H])([H])C([H])([H])N(C4=C([H])C([H])=NC([H])=C4[H])C([H])([H])C3([H])[H])[H])([H])[H])C([H])([H])C2([H])[H])[H])[H])C([H])=C1[H],DB08746,,1-[[(1E)-2-(4-CHLOROPHENYL)ETHENYL]SULFONYL]-4-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]PIPERAZINE,,small molecule,,,,,
C(N(C([H])([H])[H])C1=C([H])C([H])=C(C(O[H])=O)C([H])=C1[H])([H])([H])[H],DB08748,,4-(DIMETHYLAMINO)BENZOIC ACID,,small molecule,,,,,
C(N(C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])C(=O)C(C(N1C([H])([H])C2=C(C(=C(C(=C2[H])C(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])[H])[H])N=C1N([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08749,,3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE,,small molecule,,,,,
N(C(C1=C([H])C([H])=C(C(=O)N2C([H])([H])C([H])([H])C3(N([H])C4=C(C(=C(C(F)=C4C(N([H])[H])=N3)[H])[H])[H])C([H])([H])C2([H])[H])C([H])=C1[H])([H])[H])([H])[H],DB08750,,"1-[4-(AMINOMETHYL)BENZOYL]-5'-FLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLIN]-4'-AMINE",,small molecule,,,,,
C(N(C(C(N(C([H])([H])[H])C1=C([H])C([H])=C([N+]([O-])=O)C2=NON=C12)([H])[H])([H])[H])C(C([H])([H])[H])=O)([H])([H])[H],DB08751,,"N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE",,small molecule,,,,,
C(C(=O)OC1=C(OC(C([H])([H])[H])=O)C([H])=C(C(=C(C(=O)N(C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])[H])[H])[H])C([H])=C1[H])([H])([H])[H],DB08753,,"4-{(1E)-3-OXO-3-[(2-PHENYLETHYL)AMINO]PROP-1-EN-1-YL}-1,2-PHENYLENE DIACETATE",,small molecule,,,,,
O(C1=C([H])C([H])=C(C(C(N(C(=O)C(=C(C2=C([H])C(O[H])=C(O[H])C([H])=C2[H])[H])[H])[H])([H])[H])([H])[H])C([H])=C1[H])[H],DB08754,,"(2E)-3-(3,4-DIHYDROXYPHENYL)-N-[2-(4-HYDROXYPHENYL)ETHYL]ACRYLAMIDE",,small molecule,,,,,
N(N(C(=O)C1=C([H])C([H])=C(C2=C(Cl)C([H])=C([H])C([H])=C2[H])O1)[H])([H])[H],DB08757,,5-(2-chlorophenyl)furan-2-carbohydrazide,,small molecule,,,,,
N(N(C(=O)C1=C([H])N2C(=C(C3=C(C2=N1)C([H])=C([H])C([H])=C3[H])[H])[H])[H])([H])[H],DB08758,,"IMIDAZO[2,1-A]ISOQUINOLINE-2-CARBOHYDRAZIDE",,small molecule,,,,,
N(S(=O)(=O)C1=NC2=C(C(=C(O[H])C(=C2[H])[H])[H])S1)([H])[H],DB08765,,"6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE",,small molecule,,,,,
C(OC1=C([H])C([H])=C(C(C(N([H])[H])=O)([H])[H])C([H])=C1[H])([H])([H])[H],DB08767,,2-(4-METHOXYPHENYL)ACETAMIDE,,small molecule,,,,,
C(C(C([H])([H])[H])=C(C(N(C1=NC([H])=NC2=C1N=C(N2[H])[H])[H])([H])[H])[H])([H])([H])[H],DB08768,,N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE,,small molecule,,,,,
N(C1=NC(N(C(C(C2=C([H])C([H])=C(O[H])C([H])=C2[H])([H])[H])([H])[H])[H])=NC2=NC(=NN12)C1=C([H])C([H])=C([H])O1)([H])[H],DB08770,,"4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol",,small molecule,,,,,
O(C(=O)C(C1=NN(C(C2=NC3=C(C(=C(C(=C3[H])C(F)(F)F)[H])[H])S2)([H])[H])C(=O)C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])[H],DB08772,,"3,4-DIHYDRO-4-OXO-3-((5-TRIFLUOROMETHYL-2-BENZOTHIAZOLYL)METHYL)-1-PHTHALAZINE ACETIC ACID",,small molecule,,,,,
O(C1=C([H])C([H])=C(C2=C([H])C3=C(C(=C(O[H])C(=C3[H])[H])[H])S2)C([H])=C1[H])[H],DB08773,,RALOXIFENE CORE,,small molecule,,,,,
C(C(=O)N(C1=NC2=C(C(=O)N(C(C(C2([H])[H])([H])[H])([H])[H])[H])S1)[H])([H])([H])[H],DB08776,,"N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE",,small molecule,,,,,
O=C1N([H])C([H])=NC2=C1C1=C(S2)C([H])([H])C([H])([H])C([H])([H])C1([H])[H],DB08777,,"5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE",,small molecule,,,,,
C(C(C([H])([H])[H])(C([H])([H])[H])N(C1=NC(N([H])[H])=C(C(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])S1)[H])([H])([H])[H],DB08778,,"[4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone",,small molecule,,,,,
C(SC1=NC(O[H])=C(C(C2=C([H])C([H])=C([H])S2)([H])[H])N1[H])([H])([H])[H],DB08779,,2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol,,small molecule,,,,,
C1(C([H])([H])N(C2=NC([H])=NC3=C2N=C(N3[H])[H])C([H])([H])C([H])([H])O1)([H])[H],DB08780,,6-MORPHOLIN-4-YL-9H-PURINE,,small molecule,,,,,
N(C(C(C1=C([H])C([H])=C(S(N([H])[H])(=O)=O)C([H])=C1[H])([H])[H])([H])[H])([H])[H],DB08782,,4-(2-AMINOETHYL)BENZENESULFONAMIDE,,small molecule,,,,,
O(C(=O)C1=C([H])C([H])=C([H])N=C1N(C1=C([H])C([H])=C(Cl)C([H])=C1[H])[H])[H],DB08784,,2-(4-CHLORO-PHENYLAMINO)-NICOTINIC ACID,,small molecule,,,,,
C(C1=C([H])C(=O)OC2=C1C(=C(C(=C2[H])[H])[H])[H])([H])([H])[H],DB08785,,4-METHYL-2H-CHROMEN-2-ONE,,small molecule,,,,,
C(OC(C(OC1=NC(N([H])[H])=NC(C([H])([H])[H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB08786,,4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine,,small molecule,,,,,
N(C1=NC([H])=C(N=NC2=C([H])C([H])=C([H])C([H])=C2[H])C(C2=C(Cl)C([H])=C(Cl)C([H])=C2[H])=N1)([H])[H],DB08787,,"4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine",,small molecule,,,,,
C(C(OC1=C([H])C([H])=C(C2=C3C(N([H])[H])=C(SC3=NC(N([H])[H])=C2C#N)C(N([H])[H])=O)C([H])=C1[H])([H])[H])([H])([H])[H],DB08788,,"3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE",,small molecule,,,,,
C(C(N(C(=O)C1=C([H])C2=C(N=C(N([H])[H])N=C2C2=C(Cl)C([H])=C(Cl)C([H])=C2[H])S1)[H])([H])[H])([H])([H])[H],DB08789,,"2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE",,small molecule,,,,,
O(C(=O)C1=C([H])N(C2=C([H])C([H])=C([H])C([H])=C2[H])N=C1[H])[H],DB08790,,1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID,,small molecule,,,,,
N(C(=O)C1=C([H])C2=C(C(=C(N2S(=O)(=O)C2=C([N+]([O-])=O)C([H])=C([H])C([H])=C2[H])[H])[H])N=C1[H])([H])[H],DB08791,,"1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE",,small molecule,,,,,
C(N(C(=O)C(Cl)(Cl)[H])C1=C([H])C([H])=C(O[H])C([H])=C1[H])([H])([H])[H],DB08792,579-38-4,Diloxanide,,small molecule,Protozoa,,,,"Diloxanide is used alone as a primary agent in the treatment of asymptomatic (cyst passers) intestinal amebiasis caused by Entamoeba histolytica. Diloxanide may also be used concurrently, or sequentially, with other agents such as the nitroimidazoles (eg. metronidazole) in the treatment of invasive or extraintestinal forms of amebiasis."
C(C(OC(=O)C(C1=C(O[H])C2=C(C(=C(C(=C2[H])[H])[H])[H])OC1=O)(C1=C(O[H])C2=C(C(=C(C(=C2[H])[H])[H])[H])OC1=O)[H])([H])[H])([H])([H])[H],DB08794,548-00-5,Ethyl biscoumacetate,"Ethyl bis(4-hydroxy-2-oxo-2h-1-benzopyran-3-yl)acetate
Ethyldicoumarol",small molecule,,,,,
O=C(OC(C(OC(C(N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])N1C2=C(C(=C(C(=C2[H])[H])[H])[H])SC2=C1N=C(C(=C2[H])[H])[H],DB08796,2167-85-3,Pipazethate,Pipazetate,small molecule,Humans and other mammals,,,,For the treatment of cough.
N(C(=O)C1=C(O[H])C([H])=C([H])C([H])=C1[H])([H])[H],DB08797,65-45-2,Salicylamide,"2-Carbamoylphenol
2-Carboxamidophenol
2-Hydroxybenzamide
o-hydroxybenzamide
OHB
Salicilamida
Salicylamidum
Salicylic acid amide",small molecule,Humans and other mammals,Tablet,Oral,,
C(C1=C(C([H])([H])[H])N=C(N(S(=O)(=O)C2=C([H])C([H])=C(N([H])[H])C([H])=C2[H])[H])O1)([H])([H])[H],DB08798,729-99-7,Sulfamoxole,"2-(P-Aminobenzenesulfonamido)-4,5-dimethyloxazole
2-(P-Aminobenzolsulfonamido)-4,5-dimethyloxazol
4-Amino-N-(4,5-dimethyl-2-oxazolyl)benzenesulfonamide
4,5-Dimethyl-2-sulfanilamidooxazole
N(Sup 1)-(4,5-dimethyl-2-oxazolyl)sulfanilamide
N1-(4,5-Dimethyl-2-oxazolyl)sulfanilamide
Oxasulfa
P-Aminobenzenesulfonyl-2-amino-4,5-dimethyloxazole
Sulfadimethyloxazole
Sulfamoxol
Sulfamoxolum
Sulphamoxole",small molecule,Enteric bacteria and other eubacteria,,,,For the treatment of bacterial infection.
C(N(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])(C1=NC([H])([H])C([H])([H])N1[H])([H])[H],DB08799,91-75-8,Antazoline,Antazoline,small molecule,Humans and other mammals,"Liquid
Capsule, gelatin coated
Solution / drops
Solution","Ophthalmic
Oral
Ophthalmic
Ophthalmic",,"Used to relieve nasal congestion and in eye drops, usually in combination with naphazoline, to relieve the symptoms of allergic conjunctivitis."
C(N(C([H])([H])[H])C(C(N(C(C1=C([H])C([H])=C(Cl)C([H])=C1[H])([H])[H])C1=NC([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],"DB08800
DB07523",59-32-5,Chloropyramine,"Chloropyramine
Chlorpyramine
Halopyramine",small molecule,Humans and other mammals,,,,"For the treatment of allergic conjunctivitis, allergic rhinitis, bronchial asthma, and other atopic (allergic) conditions."
C(C(C([H])([H])[H])(C1=C(OC(C2=NC([H])([H])C([H])([H])N2[H])([H])[H])C([H])=C(C([H])([H])[H])C([H])=C1[H])[H])([H])([H])[H],DB08803,24243-97-8,Tymazoline,Thymazen,small molecule,,,,,For the treatment of Inflammation of the lining of the nose and paranasal sinuses and allergic inflammation of nasopharyngeal.
C(N(C(=S)N(C(C(SC(C1=C(C([H])([H])[H])N([H])C([H])=N1)([H])[H])([H])[H])([H])[H])[H])[H])([H])([H])[H],DB08805,34839-70-8,Metiamide,"Methiamide
Metiamida
Metiamidum",small molecule,,,,,"Potential in the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion."
C(C(=O)OC(C(=O)N(C(C(C(OC1=C([H])C(C(N2C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])([H])[H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])([H])([H])[H],DB08806,78628-28-1,Roxatidine acetate,Pifatidine,small molecule,Humans and other mammals,,,,"For the treatment of disorders of the upper gastro-intestinal region that are due to an excess of hydrochloric acid in the gastric juice, i.e. duodenal ulcers, benign gastric ulcers. Also for prophylaxis of recurrent gastric and duodenal ulcers"
O(C(=O)C(Cl)(Cl)[H])[H],DB08809,79-43-6,Dichloroacetic Acid,"DCA
dichloracetic acid
dichloroacetate",small molecule,,Liquid,Topical,100 %,
C(C(=O)OC1=C(C(O[H])=O)C([H])=C([H])C(C(F)(F)F)=C1[H])([H])([H])[H],DB08814,322-79-2,Triflusal,Triflusal,small molecule,Humans and other mammals,,,,"Triflusal is indicated as prophylaxis of thromboembolic disorders.[L1185] It has been registered in Spain and in other countries of Europe, South America and South Korea for the prevention of Stroke and myocardial infarction.[T93]"
C(C(C([H])([H])[H])(C([H])([H])[H])C1=C([H])C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])=C(N(C(=O)C2=C([H])N([H])C3=C(C(=C(C(=C3[H])[H])[H])[H])C2=O)[H])C([H])=C1O[H])([H])([H])[H],"DB08820
DB05989",873054-44-5,Ivacaftor,"Ivacaftorum
N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide",small molecule,Humans and other mammals,"Granule
Granule
Granule
Granule
Tablet
Tablet, film coated
Tablet
Tablet, film coated
Kit","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","50 mg/1
50 mg
75 mg/1
75 mg
150 mg
150 mg/1","When used as monotherapy as the product Kalydeco, ivacaftor is indicated for the managmenet of CF in patients age 2 years and older who have a mutation in the CFTR gene that is responsive to ivacaftor potentiation. Ivacaftor received expanded approval in May 2017 for the following 33 CFTR mutations: E56K, P67L, R74W, D110E, D110H, R117C, R117H, G178R, E193K, L206W, R347H, R352Q, A455E, S549N, S549R, G551D, G551S, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, G1244E, S1251N, S1255P, D1270N, and G1349D [L768, FDA Label].
When used in combination with the drug [DB09280] as the product Orkambi, ivacaftor is indicated for the management of CF patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene."
C(C(OC1=NC2=C(C(=C(C(C(=O)OC(C3=C(C([H])([H])[H])OC(=O)O3)([H])[H])=C2N1C(C1=C([H])C([H])=C(C2=C(C3=NOC(=O)N3[H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H])[H])[H])[H])([H])[H])([H])([H])[H],"DB08822
DB05358",863031-21-4,Azilsartan medoxomil,"Azilsartan
Azilsartan kamedoxomil
Azilsartan m��doxomil
Azilsart��n medoxomilo
Azilsartanum medoxomilum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral","40 mg/1
40 mg
80 mg/1
80 mg",Treatment of hypertension (alone or as an adjunct).
C(N1C([H])=C([H])C(=O)C(O[H])=C1C([H])([H])[H])([H])([H])[H],DB08826,30652-11-0,Deferiprone,"1,2-Dimethyl-3-hydroxypyrid-4-one
3-Hydroxy-1,2-dimethyl-4(1H)-pyridone
APO-066
Deferipron
Deferiprona
D��f��riprone
Deferiproni
Deferipronum
Deferypron
Dimethylhydroxypyridone
PL-1",small molecule,Humans and other mammals,"Solution
Solution
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral","100 mg/mL
100 mg
1000 mg
500 mg
1000 mg
500 mg/1
500 mg",Deferiprone is indicated in thalassemia syndromes when first line chelation agents are not adequate to treat transfusional iron overload.
FC(F)(F)C(N(C(=O)C1(C(C(C(C(N2C([H])([H])C([H])([H])C(N(C(=O)C3=C(C4=C([H])C([H])=C(C(F)(F)F)C([H])=C4[H])C([H])=C([H])C([H])=C3[H])[H])([H])C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C2=C(C(=C(C(=C2[H])[H])[H])[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])[H])([H])[H],DB08827,182431-12-5,Lomitapide,"AEGR 733
BMS 201038",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule
Capsule
Capsule
Capsule
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg
10 mg/1
20 mg/1
20 mg
30 mg/1
40 mg/1
5 mg
5 mg/1
60 mg/1","Used in homozygous familial hypercholesterolemia (HoFH) patients to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C)."
C(S(=O)(=O)C1=C([H])C(Cl)=C(C(=O)N(C2=C([H])C(C3=NC([H])=C([H])C([H])=C3[H])=C(Cl)C([H])=C2[H])[H])C([H])=C1[H])([H])([H])[H],DB08828,879085-55-9,Vismodegib,"Hedgehog Antagonist GDC-0449
Vismodegibum",small molecule,Humans and other mammals,"Capsule
Capsule","Oral
Oral","150 mg
150 mg/1","Vismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation."
C(C([N+](C(C([H])([H])[H])([H])[H])(C(C([H])([H])[H])([H])[H])C(C([H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08837,66-40-0,Tetraethylammonium,,small molecule,Humans and other mammals,,,,Tetraethylammonium is an experimental drug with no approved indication.
N(C(C(C(C(N(C(N([H])[H])=N[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB08838,306-60-5,Agmatine,"(4-aminobutyl) guanidine
(4-aminobutyl)guanidine
1-amino-4-guanidobutane
N-(4-aminobutyl)guanidine",small molecule,Humans and other mammals,,,,"Agmatine is being studied experimentally for several indications such as cardioprotection, diabetes, decreased kidney function, neuroprotection (stroke, severe CNS injuries, epilepsy, glaucoma, and neuropathic pain), and psychiatric conditions (depression, anxiety, schizophrenia, and cognition). As an investigational drug, agamatine is being studied in a non-blinded prospective case study in the United States looking at patients who have been diagnosed with small fiber peripheral neuropathy."
N(C(C(C1=C([H])N([H])C2=C1C(=C(O[H])C(=C2[H])[H])[H])([H])[H])([H])[H])([H])[H],DB08839,50-67-9,Serotonin,"3-(2-Aminoethyl)-1H-indol-5-ol
5-HT
5-Hydroxytryptamine
Enteramine
s��rotonine
thrombocytin
thrombotonin",small molecule,,,,,
N(C(C(C1=C([H])C([H])=C(O[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H],DB08841,51-67-2,Tyramine,,small molecule,,,,,
N(C1=NC(N([H])[H])=C2N=C(N(C(C(OC(P(O[H])(O[H])=O)([H])[H])([H])[H])([H])[H])C2=N1)[H])([H])[H],DB08843,113852-41-8,GS 0573,"9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine",small molecule,,,,,
O=C1N([H])C2=C(C(=O)N(C(=O)N2[H])[H])N1[H],"DB08844
DB01696",69-93-2,Uric Acid,"2,6,8-Trihydroxypurine
7,9-dihydro-1H-purine-2,6,8(3H)-trione
Urate",small molecule,Humans and other mammals,,,,"At present (August 2013), there is no approved indication for uric acid.  The potential therapeutic use for uric acid is as an adjunct in acute ischemic stroke."
O(C(=O)C(C(C(=O)C(O[H])=O)([H])[H])([H])[H])[H],"DB08845
DB02926
DB03806",328-50-7,Oxogluric acid,"2-Ketoglutaric acid
2-Oxo-Glutaric Acid
2-oxoglutaric acid
2-oxopentanedioic acid
alfa-ketoglutaric acid
alpha-Ketoglutaric acid
Ketoglutaric acid
Oxoglurate
��-Ketoglutarate",small molecule,Humans and other mammals,,,,��-��-Ketoglutarate is not approved for any indication in the world but is an investigational drug in the United States. The potential indications for ��-Ketoglutarate are in patients with the metabolic disorder propionic acidemia and in trauma patients with muscle loss. 
O(C1=C([H])C2=C3C4C(OC2=O)=C(O[H])C(O[H])=C([H])C=4C(=O)OC3=C1O[H])[H],"DB08846
DB08468",476-66-4,Ellagic Acid,"2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione",small molecule,Humans and other mammals,,,,"Ellagic acid is being investigated for use in follicular lymphoma, brain injury in intrauterine growth restricted babies, obese adolescents, and solar lentigines."
O(C(=O)C1=C([H])C([H])([H])C([H])([H])N([H])C1([H])[H])[H],DB08848,498-96-4,Guvacine,,small molecule,Humans and other mammals,,,,There is no approved indication for guvacine.
C(C1=C([H])C(C(=C(C#N)[H])[H])=C([H])C(C([H])([H])[H])=C1N(C1=C([H])C([H])=NC(N(C2=C([H])C([H])=C(C#N)C([H])=C2[H])[H])=N1)[H])([H])([H])[H],"DB08864
DB08592
DB05083",500287-72-9,Rilpivirine,"4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile",small molecule,"Humans and other mammals
Human Immunodeficiency Virus","Tablet
Tablet, film coated
Tablet
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral","25 mg
25 mg
25 mg/1","Rilpivirine, in combination with other agents, is indicated for the treatment of HIV-1 infections in antiretroviral treatment-naive patients with HIV-1 RNA ���100,000 copies/mL and CD4+ cell count >200 cells/mm3.[L1030] The FDA combination therapy approval of rilpivirine and dolutegravir is indicated for adults with HIV-1 infections whose virus is currently suppressed (< 50 copies/ml) on a stable regimen for at least six months, without history of treatment failure and no known substitutions associated to resistance to any of the two components of the therapy.[L1031]"
C(C(C(C(C(C(C(C(C1=C([H])C([H])=C(C(C(C(N([H])[H])(C(O[H])([H])[H])C(O[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08868,162359-55-9,Fingolimod,Fingolimodum,small molecule,Humans and other mammals,"Capsule
Capsule","Oral
Oral",".5 mg/1
0.5 mg",Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
C(OC1=C(OC([H])([H])[H])C([H])=C2C(OC3=C([H])C([H])=C(N(C(=O)C4(C([H])([H])C4([H])[H])C(=O)N(C4=C([H])C([H])=C(F)C([H])=C4[H])[H])[H])C([H])=C3[H])=C(C(=NC2=C1[H])[H])[H])([H])([H])[H],"DB08875
DB05153",849217-68-1,Cabozantinib,,small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Capsule
Capsule
Kit","Oral
Oral
Oral
Oral
Oral","20 mg/1
40 mg/1
60 mg/1
20 mg/1
20 mg",For the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
C(C(O[H])=C(C#N)C(=O)N(C1=C([H])C([H])=C(C(F)(F)F)C([H])=C1[H])[H])([H])([H])[H],"DB08880
DB03805",163451-81-8,Teriflunomide,"(Z)-2-cyano-alpha,alpha,alpha-trifluoro-3-hydroxy-p-crotonotoluidide
A 77-1726
A 771726
A771726
HMR 1726
Teriflunomida
T��riflunomide
Teriflunomidum",small molecule,Humans and other mammals,"Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral","14 mg
14 mg
14 mg/1
7 mg/1",Used in the treatment of relapsing forms of multiple sclerosis (MS).
C(C(C(S(=O)(=O)N(C1=C([H])C([H])=C(F)C(C(=O)C2=C([H])N([H])C3=NC(=C(C([H])=C23)C2=C([H])C([H])=C(Cl)C([H])=C2[H])[H])=C1F)[H])([H])[H])([H])[H])([H])([H])[H],"DB08881
DB05238",918504-65-1,Vemurafenib,BRAF(V600E) Kinase Inhibitor RO5185426,small molecule,Humans and other mammals,"Tablet
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral","240 mg
240 mg
240 mg/1","Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.[A31270] The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.[A31271] 
Vemurafenib approval was extended in 2017, for its use as a treatment of adult patients with Erdheim-Chester Disease whose cancer cells present BRAF V600 mutation.[L1013] Erdheim-Chester disease is an extremely rare histiocyte cell disorder that affects large bones, large vessels, central nervous system, as well as, skin and lungs. It is reported an association of Erdheim-Chester disease and V600E mutation.[A31272]"
O=C1N(C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C(C2=NC([H])=C([H])C([H])=C2[H])C([H])=C1C1=C(C#N)C([H])=C([H])C([H])=C1[H],DB08883,380917-97-5,Perampanel,"3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one
perampanel
p��rampanel
Perampanelum",small molecule,Humans and other mammals,"Kit
Suspension
Suspension
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral",".5 mg/mL
0.5 mg
10 mg/1
10.0 mg
12 mg/1
12.0 mg
2 mg/1
2.0 mg
4 mg/1
4.0 mg
6 mg/1
6.0 mg
8 mg/1
8.0 mg
10 mg
12 mg
2 mg
4 mg
6 mg
8 mg",Used in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.
C(C(OC(=O)C(C(C(C(=C(C(C(=C(C(C(=C(C(C(=C(C(C(=C(C(C([H])([H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],"DB08887
DB06291",86227-47-6,Icosapent ethyl,"Eicosapentaenoic acid ethyl ester
Ethyl Eicosapentaenoate
Ethyl icosapentate 
Ethyl-Eicosapentaenoic Acid
Ethyl-EPA",small molecule,Humans and other mammals,"Capsule
Capsule","Oral
Oral","1000 mg/1
500 mg/1",Icosapent ethyl is used as adjunct therapy to reduce triglyceride (TG) levels in adults with severe (>500 mg/dL) hypertriglyceridemia. 
C(N(C(=O)C1=NC([H])=C([H])C(OC2=C([H])C(F)=C(N(C(=O)N(C3=C([H])C(C(F)(F)F)=C(Cl)C([H])=C3[H])[H])[H])C([H])=C2[H])=C1[H])[H])([H])([H])[H],DB08896,755037-03-7,Regorafenib,"Regorafenib
R��goraf��nib
Regorafenibum",small molecule,Humans and other mammals,"Tablet
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral","40 mg
40 mg
40 mg/1","Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate."
C(N(C(=O)C1=C(F)C([H])=C(N2C(=S)N(C3=C([H])C(C(F)(F)F)=C(C#N)C([H])=C3[H])C(=O)C2(C([H])([H])[H])C([H])([H])[H])C([H])=C1[H])[H])([H])([H])[H],"DB08899
DB05094",915087-33-1,Enzalutamide,,small molecule,Humans and other mammals,"Capsule
Capsule","Oral
Oral","40 mg
40 mg/1",Enzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.
C(N1C([H])([H])C([H])([H])N(C(C2=C(C(F)(F)F)C([H])=C(N(C(=O)C3=C([H])C(C#CC4=C([H])N=C5C(=C(C(=NN45)[H])[H])[H])=C(C([H])([H])[H])C([H])=C3[H])[H])C([H])=C2[H])([H])[H])C([H])([H])C1([H])[H])([H])([H])[H],"DB08901
DB06300",943319-70-8,Ponatinib,"Ponatinib
Ponatinibum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral","15 mg
45 mg
15 mg/1
30 mg/1
45 mg/1","Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy."
C(OC(=O)C(=C(C(=O)OC([H])([H])[H])[H])[H])([H])([H])[H],DB08908,624-49-7,Dimethyl fumarate,"(E)-But-2-enedioic acid dimethyl ester
1,2-bis(methoxycarbonyl)-trans-ethylene
dimethyl (E) butenedioate
Dimethyl trans-ethylenedicarboxylate
Fumaric acid, dimethyl ester
trans-1,2-Ethylenedicarboxylic acid dimethyl ester
trans-Butenedioic acid dimethyl ester",small molecule,Humans and other mammals,"Capsule
Capsule
Capsule, delayed release
Capsule, delayed release
Capsule, delayed release
Kit","Oral
Oral
Oral
Oral
Oral","120 mg/1
240 mg/1
120 mg
120.0 mg
240 mg",Used in multiple sclerosis patients with relapsing forms.
O=C(C(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])OC(C(C(OC(=O)C(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])(OC(=O)C(C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])[H])([H])[H],"DB08909
DB06170",611168-24-2,Glycerol Phenylbutyrate,"Glyceryl Tri-4-Phenylbutyrate
GPB
GT4P",small molecule,Humans and other mammals,"Liquid
Liquid","Oral
Oral","1.1 g/mL
1.1 g",Glycerol phenylbutyrate is a nitrogen-binding agent for the chronic management of adult and pediatric patients ���2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. 
C(N1C(=O)C(C([H])([H])[H])=C2N(C(=O)N(C3(C([H])([H])C3([H])[H])[H])C(=O)C2=C1N(C1=C(F)C([H])=C(I)C([H])=C1[H])[H])C1=C([H])C(N(C(C([H])([H])[H])=O)[H])=C([H])C([H])=C1[H])([H])([H])[H],DB08911,871700-17-3,Trametinib,"GSK 1120212
Trametinib Dimethyl Sulfoxide 
Trametinibum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","0.5 mg
1 mg
2 mg
.5 mg/1
0.5 mg
1 mg/1
2 mg/1
2 mg","Trametinib is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test. "
C(C(C([H])([H])[H])(C([H])([H])[H])C1=NC(C2=C([H])C([H])=C([H])C(N(S(=O)(=O)C3=C(F)C([H])=C([H])C([H])=C3F)[H])=C2F)=C(C2=NC(N([H])[H])=NC([H])=C2[H])S1)([H])([H])[H],DB08912,,Dabrafenib,Dabrafenib,small molecule,Humans and other mammals,"Capsule
Capsule
Capsule
Capsule","Oral
Oral
Oral
Oral","50 mg
50 mg/1
75 mg/1
75 mg",Dabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
Cl[Ra]Cl,"DB08913
DB05677
DB09566",444811-40-9,Radium Ra 223 Dichloride,"RADIUM CHLORIDE RA-223
Radium Ra-223 dichloride
Radium-223 chloride
Radium-223 dichloride",small molecule,Humans and other mammals,Injection,Intravenous,30 uCi/mL,Used in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant.
N(C1=C([H])C([H])=C(S(=O)(=O)C2=C([H])C([H])=C(N(C(C(O[H])=O)([H])[H])[H])C([H])=C2[H])C([H])=C1[H])([H])[H],DB08926,80-03-5,Acediasulfone,Bentrofene,small molecule,,,,,
C(C(N(C(=O)N1C([H])([H])C([H])([H])N(C(C(C(C(C2=C([H])C([H])=C(F)C([H])=C2[H])(C2=C([H])C([H])=C(F)C([H])=C2[H])[H])([H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])[H])([H])[H])([H])([H])[H],DB08927,75558-90-6,Amperozide,,small molecule,Humans and other mammals,,,,
C(OC(=O)N(C([H])([H])[H])C1=C(N([H])[H])N=C(C2=NN(C(C3=C(F)C([H])=C([H])C([H])=C3[H])([H])[H])C3=NC(=C(C([H])=C23)[H])[H])N=C1N([H])[H])([H])([H])[H],DB08931,625115-55-1,Riociguat,"Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminate
Riociguat
Riociguatum",small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","0.5 mg
1 mg
1.5 mg
2 mg
2.5 mg
.5 mg/1
0.5 mg
1 mg/1
1 mg
1.5 mg
1.5 mg/1
2 mg/1
2 mg
2.5 mg
2.5 mg/1","Riociguat is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class.
Riociguat is indicated for the treatment of adults with pulmonary arterial hypertension (PAH), (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening. Efficacy was shown in patients on Riociguat monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominately patients with WHO functional class II���III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%)."
C(C(C(N(S(=O)(=O)N(C1=C(C2=C([H])C([H])=C(Br)C([H])=C2[H])C(OC(C(OC2=NC([H])=C(Br)C([H])=N2)([H])[H])([H])[H])=NC([H])=N1)[H])[H])([H])[H])([H])[H])([H])([H])[H],DB08932,441798-33-0,Macitentan,Macitentanum,small molecule,Humans and other mammals,"Tablet
Tablet, film coated","Oral
Oral","10 mg
10 mg/1",Macitentan is indicated for patients with pulmonary arterial hypertension.
C(C(OC(=O)C(SC(C(C1(N([H])C(C(O[H])=O)([H])C([H])([H])S1)[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08939,53943-88-7,Letosteine,,small molecule,,,,,
C(C(=O)C(C(C1(C(=O)N(C2=C([H])C([H])=C([H])C([H])=C2[H])N(C2=C([H])C([H])=C([H])C([H])=C2[H])C1=O)[H])([H])[H])([H])[H])([H])([H])[H],DB08940,853-34-9,Kebuzone,ketophenylbutazone,small molecule,,,,,
C(N1C(C(=O)N=C2N([H])OC(C([H])([H])[H])=C2[H])=C(O[H])C2=C(C(=C(C(=C2[H])[H])[H])[H])S1(=O)=O)([H])([H])[H],DB08942,34552-84-6,Isoxicam,,small molecule,Humans and other mammals,,,,
O(C(C(OC(C(OC(C(OC(C(O[H])=NC1=C(I)C(C(O[H])=O)=C(I)C([H])=C1I)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])=NC1=C(I)C(C(O[H])=O)=C(I)C([H])=C1I)[H],DB08945,51022-74-3,Iotroxic acid,"Acido iotroxico
Acidum iotroxicum",small molecule,,,,,
C(C(O[H])=NC(C1=C(I)C(N=C(C([H])([H])[H])O[H])=C(I)C(C(O[H])=O)=C1I)([H])[H])([H])([H])[H],DB08948,440-58-4,Iodamide,"Ametriodinic acid
Radiomiro
Rayomiro
Triomiro",small molecule,,,,,
O(C(=NC1(C([H])([H])C([H])([H])N(C(C(C2=C([H])N([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])[H],DB08950,26844-12-2,Indoramin,"Indoramina
Indoramine",small molecule,,,,,
C(C(C1=C([H])N([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])(C1(C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H])[H])([H])[H],DB08953,63758-79-2,Indalpine,,small molecule,,,,,
C(C(C(O[H])(C1=C([H])C([H])=C(O[H])C([H])=C1[H])[H])(N1C([H])([H])C([H])([H])C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])C([H])([H])C1([H])[H])[H])([H])([H])[H],DB08954,23210-56-2,Ifenprodil,,small molecule,,,,,
O(C(C(N(C(C(C(C(C(C(N(C(C(O[H])(C1=C([H])C(O[H])=C(O[H])C([H])=C1[H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])(C1=C([H])C(O[H])=C(O[H])C([H])=C1[H])[H])[H],DB08957,3215-70-1,Hexoprenaline,,small molecule,,,,,
C(C(C(C(C(C(C([H])([H])[H])([H])[H])(C(N1C([H])([H])N(C(C(C(C([H])([H])[H])([H])[H])(C(C(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])C([H])([H])C(C([H])([H])[H])(N([H])[H])C1([H])[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08958,141-94-6,Hexetidine,"Esetidina
Hex��tidine",small molecule,,Liquid,Buccal,0.1 %,
C([N+](C([H])([H])[H])(C([H])([H])[H])C(C(C(C(C(C([N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08960,60-26-4,Hexamethonium,"N,N,N,N',N',N'-hexamethylhexane-1,6-diaminium",small molecule,,,,,
N(S(=O)(=O)C1=C(Cl)C([H])=C(N(C(C2=C([H])C([H])=C([H])S2)([H])[H])[H])C(C2=NN([H])N=N2)=C1[H])([H])[H],DB08961,27589-33-9,Azosemide,"2-chloro-5-(1H-tetrazol-5-yl)-N4-2-thenylsulfanilamide
5-(4'-chloro-5'-sulfamoyl-2'-thenylaminophenyl)tetrazole
azosemida
azos��mide
azosemidum",small molecule,,,,,
C(N(C(C(=O)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H])([H])[H])C(C1=C(Cl)C([H])=C([H])C([H])=C1N=C(O[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB08968,18053-31-1,Fominoben,"Fominoben
Fominoben hcl
PB-89 [as hydrochloride]",small molecule,,,,,
FC(F)(F)C(OC(C(F)(F)F)([H])[H])([H])[H],DB08969,333-36-8,Flurothyl,Flurotyl,small molecule,,,,,
C(OC(O[H])=NC1=NC2=C(C(=C(C(=C2[H])[H])C(=O)C2=C([H])C([H])=C(F)C([H])=C2[H])[H])N1[H])([H])([H])[H],DB08974,31430-15-6,Flubendazole,,small molecule,,,,,
O(C(=O)C(C(C(=O)C1=C([H])C2=C(C3=C4C2=C(C(=C([H])C4=C([H])C([H])=C3[H])[H])[H])C([H])=C1[H])([H])[H])([H])[H])[H],DB08975,519-95-9,Florantyrone,,small molecule,,,,,
O(C1=NC([H])([H])C2(C([H])([H])C([H])([H])N(C(C(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])([H])[H])C([H])([H])C2([H])[H])O1)[H],DB08979,5053-06-5,Fenspiride,Eurespal,small molecule,,,,,
O(C(=O)C(C(C(=O)C1=C([H])C([H])=C(C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])[H],DB08981,36330-85-5,Fenbufen,"3-(4-Biphenylylcarbonyl)propionic acid
3-(4-Phenylbenzoyl)propionic acid
4-(4-Biphenylyl)-4-oxobutyric acid
4-Biphenyl-4-yl-4-oxobutanoic acid
Fenbufen
gamma-oxo(1,1'-Biphenyl)-4-butanoic acid",small molecule,,,,,
C(C(C([H])([H])[H])(OC1=C([H])C([H])=C(Cl)C([H])=C1[H])C(=O)OC(C(OC(=O)C1=C([H])N=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB08983,31637-97-5,Etofibrate,Etofibrate,small molecule,,,,,
O(C(C(OC(C(OC(=O)C1=C(N(C2=C([H])C([H])=C([H])C(C(F)(F)F)=C2[H])[H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB08984,30544-47-9,Etofenamate,Etofenamate,small molecule,,,,,
C(C(N(C(C([H])([H])[H])([H])[H])C(=O)C1=C([H])C(OC([H])([H])[H])=C(O[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB08989,304-84-7,Etamivan,Ethamivan,small molecule,,,,,
C(C(OC(C(N1C([H])([H])C([H])([H])N(C(C(C([H])([H])[H])(C(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])[H])([H])[H])C([H])([H])C1([H])[H])([H])[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB08990,10402-90-1,Eprazinone,"Eprazinone
��prazinone",small molecule,,,,,
C(OC1=C([H])C(C([H])([H])[H])=NN1C1=NC(C([H])([H])[H])=C([H])C(OC([H])([H])[H])=N1)([H])([H])[H],DB08991,18694-40-1,Epirizole,"4-methoxy-2-(5-methoxy-3-methylpyrazol-1-yl)-6-methylpyrimidine
Epirizole
Mebron
Methopyrimazole
Polihexanid",small molecule,,,,,
O(C(C(N(C(C(O[H])([H])[H])([H])[H])C1=NC(C2=C([H])C([H])=C([H])C([H])=C2[H])=C(C2=C([H])C([H])=C([H])C([H])=C2[H])O1)([H])[H])([H])[H])[H],DB08994,18471-20-0,Ditazole,"2,2'-(4,5-Diphenyloxazol-2-ylazanediyl)diethanol",small molecule,,,,,
C(N(C([H])([H])[H])C(C(C(N1C2=C(C(=C(C(=C2[H])[H])[H])[H])C(C([H])([H])[H])(C([H])([H])[H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB08996,4757-55-5,Dimetacrine,"3-(9,9-dimethylacridin-10-yl)-N,N-dimethyl-propan-1-amine
Dimetacrine
Istonil
Istonyl
Linostil
Miroistonil",small molecule,Humans and other mammals,,,,
C(N(C(C(ON=C1C2=C(C(=C(C(=C2[H])[H])[H])[H])C([H])=C([H])C2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB08998,24701-51-7,Demexiptiline,,small molecule,,,,,
O(C(=N[H])C1(C([H])([H])C([H])([H])N(C(C(C(N2C3=C(C(=C(C(=C3[H])[H])[H])[H])C([H])([H])C([H])([H])C3=C2C(=C(Cl)C(=C3[H])[H])[H])([H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H],DB09003,47739-98-0,Clocapramine,"Clocapramine
Clocapramine hcl
Y-4153 [as hydrochloride]",small molecule,,,,,
C(C(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])(C(C([H])([H])[H])(O[H])C(C1=C([H])C([H])=C(Cl)C([H])=C1[H])([H])[H])[H])([H])([H])[H],DB09004,14860-49-2,Clobutinol,,small molecule,,,,,
C(C(C(C([H])([H])[H])(OC1=C([H])C([H])=C(C2(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H])C2=C([H])C([H])=C(OC(C([H])([H])[H])(C(C([H])([H])[H])([H])[H])C(O[H])=O)C([H])=C2[H])C([H])=C1[H])C(O[H])=O)([H])[H])([H])([H])[H],DB09006,30299-08-2,Clinofibrate,,small molecule,,,,,
C(C(C(C(C(C(N=C(O[H])N1C([H])=C(F)C(O[H])=NC1=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB09010,61422-45-5,Carmofur,,small molecule,,,,,
ClC(C(C(=O)N(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H])([H])[H])([H])[H],DB09011,501-68-8,Beclamide,"Benzchlorpropamide
Benzylamide",small molecule,Humans and other mammals,,,,"Has been used in the management of epilepsy and epilepsy related behavioural disorders.  It was used for generalised tonic-clonic seizures, and was not effective for absence seizures.
More recently focus has shifted to the use of beclamide in behavioural disorders. In mentally handicapped epileptic patients it has been found to decrease anxiety, antisocial and demanding behaviours, and impulsivity. Mood stabilizing effects were also noted. [2]
Additionally, due to its effects on monoamines, beclamide may have a potential place in treating conditions such as tardive dyskinesia and hyperkinetic syndromes. [2]"
C(C1=NN=C2C(N=C(C3=C(N12)SC(Br)=C3[H])C1=C(Cl)C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB09017,57801-81-7,Brotizolam,"Brotizolam
Brotizolamum",small molecule,,,,,Brotizolam is indicated for the short-term treatment (2-4 weeks) of severe or debilitating insomnia. 
C(C(N(C(C([H])([H])[H])([H])[H])C(C(N=C(O[H])C1=C([H])C(Br)=C(N([H])[H])C([H])=C1OC([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB09018,4093-35-0,Bromopride,"4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
Bromoprid
Bromoprida
Bromopride
Bromopridum",small molecule,,,,,"Bromopride in indicated in the treatment of nausea and vomiting, including PONV (post-operative nausea and vomiting), gastroesophageal reflux disease (GERD/GORD), as well as endoscopy preparation and radiographic studies of the GI tract. "
C(N(C(C1=C([H])C(Br)=C([H])C(Br)=C1N([H])[H])([H])[H])C1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])[H])([H])([H])[H],DB09019,3572-43-8,Bromhexine,"3,5-Dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha-2-diamine
Bromexina
Bromhexina
Bromhexinum
Fluibron
N-Cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl)amine
Tauglicolo",small molecule,,,,,
C(C(=O)OC1=C([H])C([H])=C(C(C2=C([H])C([H])=C(OC(C([H])([H])[H])=O)C([H])=C2[H])(C2=NC([H])=C([H])C([H])=C2[H])[H])C([H])=C1[H])([H])([H])[H],DB09020,603-50-9,Bisacodyl,"Bisacodilo
Bisacodyl
Bisacodyle
Bisacodylum
Phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate (ester)
Spirolax",small molecule,,"Tablet
Kit; powder, for solution; tablet, delayed release
Suppository
Suppository
Tablet, delayed release
Tablet, coated
Tablet
Tablet, delayed release
Tablet, sugar coated
Suppository
Suspension
Pill
Tablet
Enema
Kit
Tablet
Suppository
Suppository
Tablet
Kit
Kit
Enema; suspension
Capsule, gelatin coated
Tablet","Topical
Oral
Rectal
Rectal
Oral
Oral
Oral
Oral
Oral
Rectal
Rectal
Oral
Oral
Rectal
Oral
Oral
Rectal
Rectal
Oral
Oral; Rectal
Rectal
Oral
Oral","5 mg/1
.01 g/2g
10 mg/1
5 mg/1
5 mg/1
5.0 mg
5 mg
5 mg/1
5 mg
10 mg
5 mg/5mg
5 mg/5mg
10 mg/30mL
10 mg/2000mg
10 mg
5 mg
2 mg
5 mg/1
5 mg/1", Indicated for cleansing of the colon as a preparation for colonoscopy in adults. 
C(N(C(C12C([H])([H])C([H])([H])C(C3=C1C([H])=C([H])C([H])=C3[H])([H])C1=C2C(=C(C(=C1[H])[H])[H])[H])([H])[H])[H])([H])([H])[H],DB09021,17243-39-9,Benzoctamine,"N-Methyl-9,10-ethanoanthracene-9(10H)-methanamine",small molecule,,,,,
C(C(N(C(C([H])([H])[H])([H])[H])C(C(OC(=O)C(O[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB09023,302-40-9,Benactyzine,,small molecule,,,,,
O(B1OC([H])([H])C2=C1C(=C(C(F)=C2[H])[H])[H])[H],"DB09041
DB05058",174671-46-6,Tavaborole,"5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole
5-Fluoro-2,1-benzoxaborol-1(3H)-ol",small molecule,"Yeast and other Trichophyton or Microsporum fungi
Dermatophytic fungi including Trichophyton, Microsporum and Epidermophyton",Solution,Topical,43.5 mg/mL,Indicated for the treatment of onychomycosis (a fungal infection) of the toenails due to <i>Trichophyton rubrum</i> or <i>Trichophyton mentagrophytes</i>. 
C(N(C(=O)C(C([H])([H])[H])(C([H])([H])[H])C1=C([H])C(C(F)(F)F)=C([H])C(C(F)(F)F)=C1[H])C1=C(C2=C(C([H])([H])[H])C([H])=C([H])C([H])=C2[H])C([H])=C(N2C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C2([H])[H])N=C1[H])([H])([H])[H],DB09048,290297-26-6,Netupitant,"2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide",small molecule,Humans and other mammals,Capsule,Oral,,Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy.
C(C1=C([H])N=C(C(O[H])=O)C([H])=[N+]1[O-])([H])([H])[H],DB09055,51037-30-0,Acipimox,,small molecule,,,,,Used in the treatment of hyperlipidemias (abnormally elevated levels of any or all lipids and/or lipoproteins in the blood).
C(C(C([H])([H])[H])(OC1=C(N(C2=NC(N(C3=C(S(=O)(=O)C(C([H])([H])[H])(C([H])([H])[H])[H])C([H])=C([H])C([H])=C3[H])[H])=C(Cl)C([H])=N2)[H])C([H])=C(C([H])([H])[H])C(C2(C([H])([H])C([H])([H])N([H])C([H])([H])C2([H])[H])[H])=C1[H])[H])([H])([H])[H],DB09063,1032900-25-6,Ceritinib,"c��ritinib
N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide",small molecule,,"Capsule
Capsule","Oral
Oral","150 mg
150 mg/1",Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
C(C1=C([H])C(C([H])([H])[H])=C(SC2=C(N3C([H])([H])C([H])([H])N([H])C([H])([H])C3([H])[H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])([H])[H],"DB09068
DB05700",508233-74-7,Vortioxetine,"Vortioxetina
Vortiox��tine
vortioxetinum",small molecule,,"Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg/1
15 mg/1
20 mg/1
5 mg/1
10 mg
15 mg
20 mg
5 mg",Vortioxetine is indicated for the treatment of major depressive disorder (MDD).
C(OC1=C([H])C([H])=C(C(N2C([H])([H])C([H])([H])N([H])C([H])([H])C2([H])[H])([H])[H])C(OC([H])([H])[H])=C1OC([H])([H])[H])([H])([H])[H],DB09069,5011-34-7,Trimetazidine,"1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride",small molecule,,,,,Trimetazidine is indicated for use in angina pectoris.
C(C(=O)C1=C(C([H])([H])[H])C2=C(N=C(N(C3=NC([H])=C(N4C([H])([H])C([H])([H])N([H])C([H])([H])C4([H])[H])C([H])=C3[H])[H])N=C2N(C2(C([H])([H])C([H])([H])C([H])([H])C2([H])[H])[H])C1=O)[H])([H])([H])[H],DB09073,571190-30-2,Palbociclib,"6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one",small molecule,,"Capsule
Capsule
Capsule
Capsule
Capsule
Capsule","Oral
Oral
Oral
Oral
Oral
Oral","100 mg/1
100 mg
125 mg/1
125 mg
75 mg
75 mg/1","Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. "
O(C1=NN=C(C(C2=C([H])C(C(=O)N3C([H])([H])C([H])([H])N(C(=O)C4(C([H])([H])C4([H])[H])[H])C([H])([H])C3([H])[H])=C(F)C([H])=C2[H])([H])[H])C2=C(C(=C(C([H])=C12)[H])[H])[H])[H],"DB09074
DB05940",763113-22-0,Olaparib,4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one,small molecule,,"Capsule
Capsule
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral","50 mg
50 mg/1
100 mg/1
150 mg/1","* Indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
* Indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
* Indicated for the treatment of patients with germline breast cancer susceptibility gene (BRCA) mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, who have been previously treated with chemotherapy."
O(C(C1=C([H])C([H])=C([H])C([H])=C1[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C12C([H])([H])C([H])([H])[N+](C(C(OC(C3=C([H])C([H])=C([H])C([H])=C3[H])([H])[H])([H])[H])([H])[H])(C(C1([H])[H])([H])[H])C([H])([H])C2([H])[H])[H],DB09076,869185-19-3,Umeclidinium,1-[2-(benzyloxy)ethyl]-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane,small molecule,Humans and other mammals,"Powder, metered
Powder
Powder, metered
Aerosol, powder
Powder","Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Oral
Respiratory (inhalation)","55 ��g
62.5 ug/1
62.5 mcg","Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)."
C(OC1=C(C(O[H])=N[H])C([H])=C2C(OC3=C([H])C(Cl)=C(N(C(O[H])=NC4(C([H])([H])C4([H])[H])[H])[H])C([H])=C3[H])=C(C(=NC2=C1[H])[H])[H])([H])([H])[H],DB09078,417716-92-8,Lenvatinib,"4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide
Lenvatinib Mesylate",small molecule,,"Capsule
Capsule
Capsule
Capsule
Capsule
Capsule
Capsule
Capsule
Kit","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg/1
10 mg
14 mg
18 mg
20 mg
24 mg
4 mg/1
8 mg","Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer."
C(OC(=O)C1=C([H])C2=C(C(=C(N(C3=C([H])C([H])=C(N(C([H])([H])[H])C(=O)C(N4C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C4([H])[H])([H])[H])C([H])=C3[H])[H])C3=C([H])C([H])=C([H])C([H])=C3[H])C(O[H])=N2)C([H])=C1[H])([H])([H])[H],DB09079,656247-17-5,Nintedanib,"methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate",small molecule,,"Capsule
Capsule
Capsule
Capsule","Oral
Oral
Oral
Oral","100 mg
100 mg/1
150 mg/1
150 mg",Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).
C(OC1=C(OC([H])([H])[H])C(=O)C(C(C(C(C(C(C(C(C(C(C(C(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])=C(C([H])([H])[H])C1=O)([H])([H])[H],DB09081,58186-27-9,Idebenone,"2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-1,4-benzoquinone
2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
2,3-dimethoxy-5-methyl-6-(10'-hydroxydecyl)-1,4-benzoquinone
6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone
6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-p-benzoquinone
id��b��none",small molecule,,"Tablet
Tablet, film coated","Oral
Oral","150 mg
150 mg","Idebenone is indicated for use by the European Medicines Agency (EMA) for the treatment of visual impairment in adolescent and adult patients with
Leber���s Hereditary Optic Neuropathy (LHON). It is not currently approved for use by either the Food and Drug Administration (USA) or Health Canada [L885]."
C(C(C(C(N(C1=C([H])C([H])=C(C(=O)OC(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB09085,94-24-6,Tetracaine,"2-(dimethylamino)ethyl 4-(butylamino)benzoate
2-(Dimethylamino)ethyl p-(butylamino)benzoate
Amethocaine
Amethocaine HCl
Di��thylamino��thanol ester der p-butylaminobenz��s��ure
Dicaine
Medihaler-Tetracaine
Metraspray
p-(butylamino)benzoic acid ��-(dimethylamino)ethyl ester 
p-Butylaminobenzoyl-2-dimethylaminoethanol
Tetraca��na
T��traca��ne
Tetracaine HCl",small molecule,,"Gel
Ointment
Cream
Aerosol, spray
Solution
Aerosol
Cream
Gel
Aerosol, metered
Spray
Solution / drops
Solution / drops
Cream
Cream
Injection, powder, for solution
Cream
Gel
Gel
Gel
Cream
Solution
Solution / drops
Powder, for solution
Kit
Liquid
Liquid
Liquid
Liquid
Aerosol, metered
Aerosol, metered
Patch
Gel
Injection
Solution
Gel
Spray
Liquid
Gel
Cream
Liquid
Gel
Aerosol","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Dental
Topical
Nasal
Ophthalmic
Ophthalmic
Topical
Topical
Subarachnoid
Topical
Dental; Topical
Buccal
Oral; Topical
Topical
Ophthalmic
Ophthalmic
Intraspinal
Infiltration; Topical
Infiltration; Subcutaneous; Topical
Parenteral; Topical
Infiltration
Infiltration; Subcutaneous
Dental
Oral; Topical
Cutaneous
Topical
Subarachnoid
Ophthalmic
Topical
Topical
Ophthalmic
Topical
Topical
Topical
Topical
Oral","40 mg
2 g/100g
10 mg/mL
0.5 %
1 %
20 mg/mL
20 mg/1000mg
10 mg/mL
20 mg/g
2 mg/100mg
0.5 %
.5 %
20 mg
754 mg
11.6 mg
20 mg/1000mL
10 mg/mL
5 mg/mL
20 mg/g
25 mg/5mL
2 %
2 %",The combination lidocaine and tetracaine patch is indicated for local dermal analgesia for superficial dermatological procedures and superficial venous access.  The combination lidocaine and tetracaine cream is intended to provide topical local analgesia for superficial dermatological procedures.
C(OC1=C(O[H])C([H])=C([H])C(C(C(=C([H])[H])[H])([H])[H])=C1[H])([H])([H])[H],DB09086,97-53-0,Eugenol,,small molecule,,"Liquid
Paste
Liquid
Liquid
Liquid
Gel
Gel
Gel
Liquid","Dental
Dental
Dental
Oral
Dental
Topical
Topical
Topical
Topical","850 mg/mL
100 %
850 mg/mL
13 mg/g
8 mg/g
12 mg/g
850 mg/mL",Eugenol is not currently available in any FDA-approved drug products. There are a number of unapproved OTC products that advertise it for the use of toothache.  Eugenol is is also commonly used in combination with zinc oxide in dental procedures for the cementation of temporary prostheses and the temporary restoration of teeth and cavities.
C(OC1=C([H])C(Br)=C(C([N+]2(C(C(OC(C(C3(C([H])([H])C([H])([H])C4(C([H])([H])C3(C4(C([H])([H])[H])C([H])([H])[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])([H])[H])C([H])=C1OC([H])([H])[H])([H])([H])[H],DB09090,59995-65-2,Pinaverium,,small molecule,,"Tablet
Tablet","Oral
Oral","100 mg
50 mg","Indicated for the treatment and relief of symptoms associated with irritable bowel syndrome (IBS) associated with abdominal pain, bowel disturbances and intestinal discomfort, as well as the treatment of symptoms related to functional disorders of the biliary tract. "
C(OC1=C([H])C(C2(C(C(O[H])=O)([H])C(C(O[H])([H])[H])([H])C(O[H])([H])C3=C2C(=C2OC([H])([H])OC2=C3[H])[H])[H])=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])([H])([H])[H],DB09094,9000-55-9,Podophyllin,Podophyllum resin,small molecule,Various viruses,"Liquid
Tincture
Liquid
Ointment","Topical
Topical
Topical
Topical","1 mg/4mL
250 mg",25% podophyllin (in benzoin tincture) is indicated for the removal of soft genital (venereal) warts (condylomata acuminata).
O=C(OOC(=O)C1=C([H])C([H])=C([H])C([H])=C1[H])C1=C([H])C([H])=C([H])C([H])=C1[H],DB09096,94-36-0,Benzoyl peroxide,"Benzoyl benzenecarboperoxoate
Bepio",small molecule,Propionibacterium acnes,"Cream
Liquid
Gel
Shampoo, suspension
Lotion
Lotion
Cream
Lotion
Solution
Gel
Gel
Kit; liquid; lotion
Cream
Liquid
Cream
Liquid
Cream
Lotion
Cream
Kit; lotion
Liquid, extended release
Gel; kit; lotion
Aerosol, foam
Cream
Cream
Cream
Lotion
Lotion
Solution
Gel
Gel
Gel
Liquid
Gel
Kit
Aerosol, foam
Aerosol, foam
Cloth
Soap
Lotion
Aerosol, foam
Aerosol, foam
Gel
Gel
Kit
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Gel
Solution
Gel
Gel
Aerosol, foam
Cream
Cream
Gel
Gel
Emulsion
Lotion
Gel
Emulsion
Emulsion
Emulsion
Emulsion
Emulsion
Gel
Gel
Cloth
Solution
Cloth
Lotion
Cream
Gel
Aerosol
Cream
Lotion
Liquid
Gel
Liquid
Lotion
Liquid
Cream
Liquid
Lotion
Liquid
Cream
Cloth
Kit; lotion
Lotion
Cream
Cream
Gel
Cream
Soap
Cream
Gel
Solution
Solution
Solution
Solution
Lotion
Solution
Lotion
Gel; lotion
Cloth
Liquid, extended release
Liquid
Gel
Gel
Liquid
Lotion
Lotion
Ointment
Cream
Cream
Gel
Gel
Lotion
Gel
Cream
Cream
Cream
Cream
Gel
Suspension
Lotion
Lotion
Cream
Cream
Cream
Gel
Kit
Paste
Gel
Gel
Lotion
Cream
Suspension
Jelly
Cream
Lotion
Lotion
Gel
Solution
Cream
Lotion
Lotion
Lotion
Liquid
Liquid
Swab
Stick
Cream
Cream
Cloth
Cloth
Cream
Cream
Cream
Soap
Soap
Soap
Soap
Soap
Soap
Liquid
Liquid
Kit; lotion; solution
Gel
Gel
Lotion
Solution
Lotion
Lotion
Gel; kit
Cream
Lotion
Cream
Cream
Cream
Gel
Lotion
Gel
Lotion
Gel
Lotion
Cream
Liquid
Cream
Aerosol, foam
Aerosol, foam
Lotion
Cream; kit; lotion
Cream; gel; kit; lotion
Gel
Gel
Lotion
Lotion
Kit
Liquid
Paste
Swab
Lotion
Gel
Gel
Gel
Lotion
Gel; kit; paste
Cream
Lotion
Soap
Swab
Gel
Gel
Ointment","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","28.3 g/100g
5 mL/100mL
25 mg/mL
100 mg/1000mL
50 mg/1000mL
10 g/100mL
30 mg/g
5.0 %
1 mg/g
3.5 g/100mL
25 mg/g
4.25 g/170g
3.4 g/136g
25 mg/mL
50 mg/g
10 mL/100mL
100 mg/g
44 mg/mL
2.5 g/100g
5.5 g/100mL
.026 mg/mg
1.4 g/28g
5 g/100mL
20 %
2.6 g/100mL
2.6 %
10 %
5 %
5 %
2.5 %
3.18 g/60g
9.8 g/100g
60 mg/1
7 g/100g
3 g/100mL
53 mg/g
98 mg/g
100 mg/g
50 mg/g
10 g/100g
2.5 g/100g
30 mg/mL
5 g/100g
60 mg/mL
90 mg/mL
50 mg/1000mg
2.5 %
2.5 g/100g
35 mg/g
5.3 g/100g
3.29 g/56g
2.5 mL/100mL
5 g/100mL
5.0 %
42.5 mg/mL
40 mg/g
55 mg/g
100 mg/g
25 mg/g
50 mg/g
52.5 mg/g
70 mg/mL
4 mg/100mg
8 mg/100mg
3.2 g/100g
5 %
9 g/100g
5 mL/100mL
1.125 g/15g
5.00 %
2.5 %
5.0 %
5 %
5.57 mg/g
25 mg/g
.006 mg/.024mg
3 %
30 mg/mL
3.7 %
3.5 %
3.5 %
5 %
5 %
2.5 %
25 mg/mL
.8 mg/29.6mg
61.62 mg/mL
4 g/100g
100 mg/g
104 mg/10g
20 %
10 mg/mL
10 mg/g
5 mg/mL
5 mg/g
10 %
5 g/100mL
2.5 g/100mL
2.5 %
2.5 %
4.5 mg/100mL
.1 mg/g
135 mg/g
25 mg/mL
3 g/120g
1.5 g/60g
25 mg/mL
5 %
10 g/100g
4 %
5.6 g/56g
3 mL/60mL
45 mg/mL
51.9 mg/100mL
10 %
20 %
2.5 %
5.3 g/100g
10 g/100mL
10 g/100g
55 mg/mL
2.2 mg/40mL
1 g/100g
5 g/100mL
5 g/100g
5 %
3.5 %
35 mg/mL
35 mg/mL
37 mg/mL
37 mg/mL
2.5 %
2.5 mg/g
.05 mL/mL
5.0 %
7 mg/g
2.5 g/100mL
2.5 g/100g
3.0 %
100 mg/g
50 mg/g
100 mg/mL
50 mg/mL
25 mg/1
50 mg/g
100 mg/mL
50 mg/mL
70 mg/g
42.5 mg/g
146.7 mg/g
30 mg/g
58.7 mg/g
.5 g/10g
1 g/10g
11.3 g/1
5.65 g/1
10 %
5 %
4 %
10 %
10 g/100g
5 g/100g
5 g/100g
.063 mg/2.5mL
.063 mg/2.5mL
70 mg/mL
.06 g/g
7 mg/100mL
7 mg/100mL
.025 g/1000mL
.25 g/1000mL
2.5 g/100mL
2.5 mg/100mL
2.5 mg/100mL
2.5 mL/100mL
2.5 mL/100mL
3 %
52.5 mg/mL
7.5 mL/100mL
2.95 mL/59mL
55 mg/g
95 mg/g
2.50 %
2.5 %
100 mg/mL
50 mg/mL
100 mg/mL
50 mg/mL
2.5 %
3.5 %
25 mg/mL
25 mg/g
4 %
8 %
3 %
4 %
2.5 g/100g
60 mg/g
2.75 mg/1
8.5 g/100g
8.5 mg/100g
100 mg/g","Benzoyl peroxide is indicated for the treatment of mild to moderate acne vulgaris and rosacea. Combined with other agents, it may be used in the treatment of more severe acne."
C(C(O[H])(C1(N([H])C(=O)C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])N([H])C(=O)C(C(C([H])([H])[H])(O[H])[H])([H])N([H])C(=O)C(C(C(C(C(N([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])N([H])C(=O)C(C(C2=C([H])N([H])C3=C2C(=C(C(=C3[H])[H])[H])[H])([H])[H])([H])N([H])C(=O)C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])N([H])C(=O)C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])N([H])C(=O)C(C(C(N([H])[H])=O)([H])[H])([H])N([H])C(=O)C(C(C(C(C(N([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])N([H])C(=O)C(N(C(=O)C(N(C(=O)C(C([H])([H])[H])(N([H])[H])[H])[H])([H])[H])[H])([H])C([H])([H])SSC([H])([H])C(C(O[H])=O)([H])N([H])C(=O)C(C(O[H])([H])[H])([H])N([H])C1=O)[H])[H])([H])([H])[H],DB09099,38916-34-6,Somatostatin,,small molecule,,"Powder, for solution
Liquid; powder, for solution","Intravenous
Intravenous",3 mg,"For the symptomatic treatment of acute bleeding from esophageal varices. Other treatment options for long-term management of the condition may be considered if necessary, once initial control has been established."
O(S(=O)(=O)C(C(S[H])([H])[H])([H])[H])[H],DB09110,3375-50-6,Coenzyme M,"2-Mercaptoethane
2-Mercaptoethanesulfonate
2-mercaptoethanesulfonic acid
2-mercaptoethanesulphonic acid
2-mercaptoethylsulfonate
2-sulfanylethylsulfonate
Coenzima M
Coenzym M
CoM
HS-CoM
reduced coenzyme M
reduced CoM
��-mercaptoethanesulfonic acid",small molecule,,"Injection, solution
Solution
Tablet, film coated
Solution
Solution
Liquid","Intravenous
Intravenous
Oral
Intravenous
Intravenous; Oral
Intravenous; Oral","100 mg/mL
100 mg/mL
400 mg/1
100 mg
100 mg
100 mg",Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis. (2)
O(N=O)[H],DB09112,7782-77-6,Nitrous acid,"dioxonitric acid
hydroxidooxidonitrogen
nitrosyl hydroxide",small molecule,,"Kit
Injection, solution
Solution","Intravenous
Intravenous","30 mg/mL
30 mg",For sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning that is judged to be life-threatening [FDA Label].
O(C1=C(I)C([H])=C(I)C2=C(C(=C(N=C12)[H])[H])[H])[H],DB09115,83-73-8,Diiodohydroxyquinoline,"Diiodohydroxyquin
Diiodohydroxyquinoline
Iodoquinol
Ioquin",small molecule,,"Gel
Tablet
Tablet
Cream
Suppository
Cream","Topical
Oral
Oral
Topical
Vaginal
Vaginal","210 mg
650 mg",Used in the treatment of amoebiasis.
[N-]=C=[N-],DB09116,156-62-7,Calcium carbimide,"calcium cyanamide
carbimida calcica
carbimide calcique
Cyanamide calcique
Cyanamide, calcium salt (1:1)
Lime nitrogen
Lime-nitrogen
methanediimine, calcium salt (1:1)
Nitrogen lime",small molecule,Humans and other mammals,Tablet,Oral,50 mg,"Calcium carbimide has not been approved by the FDA but the intended indication is for the treatment of alcoholism.[T74] This medication was marketed in Canada, United Kingdom and Europe under the trade name of Temposil for the sole use of alcoholism treatment.[L1114]"
C(C1(OC(C([H])([H])[H])([H])OC(C([H])([H])[H])([H])O1)[H])([H])([H])[H],DB09117,123-63-7,Paraldehyde,,small molecule,,Liquid,Intramuscular; Intravenous,100 %,Paraldehyde was used historically as a sedative and hypnotic [A19735]. It has been used in the treatment of seizures as an anticonvulsant [A19736].
O=C1N([H])C2=C(C(=C(C(OC(C(C(C(N3C([H])([H])C([H])([H])N(C4=C([H])C([H])=C([H])C5=C4C(=C(S5)[H])[H])C([H])([H])C3([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])=C2[H])[H])[H])C([H])=C1[H],DB09128,913611-97-9,Brexpiprazole,,small molecule,,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral",".25 mg/1
.5 mg/1
0.25 mg
0.5 mg
1 mg
1 mg/1
2 mg
2 mg/1
3 mg
3 mg/1
4 mg
4 mg/1",As an adjunctive treatment of major depressive disorder (MDD) and for treatment of schizophrenia. 
[Cu],DB09130,7440-50-8,Copper,"cobre
cuivre
cuprum
Kupfer",small molecule,,"Tablet
Capsule
Tablet, extended release
Tablet
Tablet
Tablet, effervescent
Tablet, chewable
Tablet, film coated
Solution
Solution
Liquid
Capsule
Intrauterine device
Tablet
Powder
Tablet, coated
Capsule, gelatin coated
Capsule, liquid filled","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intravenous
Intravenous
Intravenous
Oral
Intrauterine
Oral
Oral
Oral
Oral
Oral","3 mg
5 mg
2 mg
5 mg
0.4 mg
313.4 mg/1",For use in the supplementation of total parenteral nutrition and in contraception with intrauterine devices [FDA Label] [L801].
Cl[Cu]Cl,DB09131,7447-39-4,Cupric Chloride,"Copper chloride
Copper(2+) chloride
copper(II) chloride
Cupric chloride anhydrous",small molecule,Humans and other mammals,"Injection, solution
Liquid
Solution","Intravenous
Intravenous
Intravenous",.4 mg/mL,For use as a supplement to intravenous solutions given for total parenteral nutrition (TPN).
O(C(=O)C(N1C([H])([H])C([H])([H])N(C(C([O-])=O)([H])[H])C([H])([H])C([H])([H])N(C(C([O-])=O)([H])[H])C([H])([H])C([H])([H])N(C(C([O-])=O)([H])[H])C([H])([H])C1([H])[H])([H])[H])[H],DB09132,72573-82-1,Gadoteric acid,"[2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl-��4N1,N4,N7,N10)tetraacetato(3���)]gadolinium
DOTA-Gd
Gadoterate
Gd-DOTA",small molecule,,"Injection
Solution","Intravenous
Intravenous","376.9 mg/mL
376.9 mg","Gadoteric acid is indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity."
C(N(C(=O)C1=C(I)C(N(C(C([H])([H])[H])=O)[H])=C(I)C(C(O[H])=O)=C1I)[H])([H])([H])[H],DB09133,2276-90-6,Iothalamic acid,"1-deoxy-1-(methylamino)-D-glucitol 5-acetamido-2,4,6 triiodo-N-methylisophthalamate
Iotalamic acid
Iothalamate",small molecule,,"Injection
Injection
Solution
Solution
Solution
Injection
Solution
Solution
Liquid
Injection
Solution
Injection, solution
Solution","Intravascular
Intravascular
Intravascular
Intravenous
Intravenous
Intravascular
Intravascular
Intravascular
Urethral
Ureteral
Urethral
Intravenous
Intra-arterial; Intravenous","600 mg/mL
300 mg/mL
300 mg
54.3 %
66.8 %
430 mg/mL
430 mg
600 mg
430 mg
172 mg/mL
172 mg
.275 mCi/mL","Conray is indicated for use in excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography, contrast enhancement of computed tomographic brain images, cranial computerized angiotomography, intravenous digital subtraction angiography and arterial digital subtraction angiography.
Conray may also be used for enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space."
O(C(C(N(C(=O)C(O[H])([H])[H])C1=C(I)C(C(=O)N(C(C(O[H])(C(O[H])([H])[H])[H])([H])[H])[H])=C(I)C(C(=O)N(C(C(O[H])(C(O[H])([H])[H])[H])([H])[H])[H])=C1I)([H])[H])([H])[H])[H],DB09134,87771-40-2,Ioversol,"N,N'-Bis (2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl) -glycolamido] -2,4,6-triiodoisophthalamide
Optiray",small molecule,,"Solution
Solution
Injection
Solution
Injection
Solution
Injection
Solution
Injection
Solution","Intravenous
Intravascular
Intra-arterial; Intravenous
Intravascular; Subarachnoid
Intra-arterial; Intravenous
Intravascular
Intra-arterial; Intravenous
Intravascular
Intra-arterial; Intravenous
Intravascular","34 %
34 %
509 mg/mL
51 %
636 mg/mL
64 %
678 mg/mL
68 %
741 mg/mL
74 %","Optiray 350 is indicated in adults for peripheral and coronary arteriography and left ventriculography. Optiray 350 is also indicated for contrast enhanced computed tomographic imaging of the head and body, intravenous excretory urography, intravenous digital subtraction angiography and venography. Optiray 350 is indicated in children for angiocardiography.
Optiray 320 is indicated in adults for angiography throughout the cardiovascular system. The uses include cerebral, coronary, peripheral, visceral and renal arteriography, venography, aortography, and left ventriculography. Optiray 320 is also indicated for contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography.
Optiray 320 is indicated in children for angiocardiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography.
Optiray 300 is indicated for cerebral angiography and peripheral arteriography. Optiray 300 is also indicated for contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography.
Optiray 240 is indicated for cerebral angiography and venography. Optiray 240 is also indicated for contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urography."
C(C(=O)N(C(C(O[H])(C(O[H])([H])[H])[H])([H])[H])C1=C(I)C(C(=O)N(C(C(O[H])(C(O[H])([H])[H])[H])([H])[H])[H])=C(I)C(C(=O)N(C(C(O[H])([H])[H])([H])[H])[H])=C1I)([H])([H])[H],DB09135,107793-72-6,Ioxilan,"Ioxilane
Ioxilanum
N-(2,3-dihydroxypropyl)-N���-(2- hydroxyethyl)-5-[N-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide",small molecule,,"Injection, solution
Injection, solution","Intravascular
Intravascular","300 mg/mL
350 mg/mL","When administered  intra-arterially, Ioxilan is indicated for the following diagnostic tests: cerebral arteriography (300 mgI/mL),  coronary arteriography and left ventriculography (350 mgI/mL), visceral angiography(350 mgI/mL), aortography(350 mgI/mL), and peripheral arteriography(350 mgI/mL).
When administered intravenously, Ioxilan is indicated for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body (300 and 350 mgI/mL)."
C(C(N(C(C([H])([H])[H])([H])[H])C1=C([H])C([H])=C(C(=C2C([H])=C([H])C(=[N+](C(C([H])([H])[H])([H])[H])C(C([H])([H])[H])([H])[H])C([H])=C2[H])C2=C(S([O-])(=O)=O)C([H])=C([H])C(S([O-])(=O)=O)=C2[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB09136,68238-36-8,Isosulfan blue,,small molecule,,"Injection, solution
Solution
Injection, solution
Solution","Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous","50 mg/5mL
10 mg/mL
10 mg/mL
10 mg","Isosulfan Blue is a synthetic visual lymphatic imaging agent. Isosulfan blue upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities. "
C(C1=C([H])C(C([H])([H])[H])=C(N(C(=O)C(N(C(C(O[H])=O)([H])[H])C(C(O[H])=O)([H])[H])([H])[H])[H])C(C([H])([H])[H])=C1Br)([H])([H])[H],DB09137,1415247-71-0,Technetium Tc-99m mebrofenin,"Bis(2-[[2-(3-bromo-2,4,6-trimethylanilino)-2-oxoethyl]-(carboxymethyl)amino]acetate) technetium
Technetium (99mTc) mebrofenin
Technetium Tc 99m diisopropyl-iminodiacetic acid
Technetium Tc 99m DISIDA
Technetium Tc 99m Mebrofenin
Technetium Tc-99m mebrofenin kit",small molecule,,"Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solution","Intravenous
Intravenous
Intravenous","45 mg/1
45 mg/10mL
10 mg/1",Technetium Tc 99m Mebrofenin is indicated as a hepatobiliary imaging agent.
[O-]P([O-])(=O)C(P([O-])([O-])=O)([H])[H],DB09138,121524-79-6,Technetium Tc-99m medronate,"99m Tc medronate
99m Tc-medronate
99mTc medronate
99mTc-medronate
AN-MDP
Cis-Mdp
Tc 99m Mdp
Tc-99m Mdp
Technetium (99mTc) medronic acid
Technetium (99mTc) Methylenediphosphonate
Technetium 99mTc medronic acid
Technetium methylene diphosphonate
Technetium Tc 99m medronate
Technetium Tc 99m medronic acid
Technetium Tc 99M Mpi Mdp
Technetium tc-99m medronate kit",small molecule,,"Injection, powder, lyophilized, for solution
Injection, powder, for solution","Intravenous
Intravenous","20 mg/10mL
25 mg/1",Technetium Tc 99m Medronate is indicated for use as a bone imaging agent to delineate areas of altered osteogenesis.
O(C(P(O[H])(O[H])=O)(P(O[H])(O[H])=O)[H])[H],DB09139,72945-61-0,Technetium Tc-99m oxidronate,"99mtc-HDP
Oxidronic acid 99mtc-complex
Technetium (99mTc) oxidronate
Technetium 99mtc oxidronate
Technetium Tc 99m oxidronate
Technetium Tc-99m oxidronate kit",small molecule,Humans and other mammals,"Injection, powder, lyophilized, for solution",Intravenous,3.15 mg/1,"Technetium Tc-99m oxidronate is indicated in adult and pediatric patients to be used in skeletal imaging for diagnosis of areas that can present altered osteogenesis. When administered intravenously, it is able to generate a clear image of the bones which allows the physician to diagnose any bone problem.[L1141] It is important to point out that this drug has to be manipulated only under the service of a nuclear specialist.[L1140] The approved indications for a bone scan are 1) visualization of tumor metastasis in bone, 2) osteomyelitis, 3) fracture, 4) stress fracture, 5) avascular necrosis, 6) osteoporosis and 7) prosthetic joint evaluation. From all the major indications, the detection of a metastatic disease is the most common because it presents a 95% of sensitivity and lesion detection can be done 6 months earlier than with X-ray studies.[L1139]"
O=O,DB09140,7782-44-7,Oxygen,"Dioxygen
Molecular oxygen
Oxygen USP
Pure oxygen",small molecule,Humans and other mammals,"Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas; liquid
Gas
Gas
Liquid
Gas
Gas","Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Cutaneous; Respiratory (inhalation)
Nasal
Nasal
Nasal; Respiratory (inhalation)
Nasal; Respiratory (inhalation)
Rectal
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Nasal; Oral
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)","195 mL/1000mL
200 mL/L
210 mL/L
20 %
20 L/100L
950 mL/L
50 mL/L
80 L/100L
90 L/100L
96 L/100L
40 L/100L
95 L/100L
25 L/100L
30 L/100L
21 L/100L
23 L/100L
992 mL/L
210 mL/L
99 L/100L
1 L/L
995 mL/L
990 mL/L
.99 L/L
.995 L/L
100 L/99L
1000 mL/L
93 mL/L
930 mL/L
99 mL/L
99 L/L
99 L/100L
99.1 L/L
99.4 L/100L
99.5 L/L
99.5 L/100L
99.6 %
99.6 L/100L
99.6 L/L
99.8 L/100L
99.8 L/L
99.9 L/L
99.9 L/100L
990 mL/L
990 1/L
990 L/L
991 mL/L
992 L/1000L
992 mL/L
992 mL/1000mL
992 1/L
995 mL/100L
995 mL/L
995 L/L
996 mL/L
997 mL/L
998 mL/L
999 mL/L
999 L/1000L
1.13835106 kg/L
1000 g/L
210 mg/kg
99 L/100L
99 1/100L
992 L/1000L
995 mL/L
999 L/1000L
99.0 %
99.95 %
992 mL/100mL
.99 kg/kg
11321 L/11321L
196 L/196L
240 L/240L
396 L/396L
659 L/659L
1567 L/1567L
6931 L/6931L
3453 L/3453L
8688 L/8688L
99.9 %
99.99 %
100 %
99.5 %
250 mL/L
300 mL/L
330 mL/L
400 mL/L
500 mL/L
600 mL/L
800 mL/L
900 mL/L
99.5 %
1 L/L
99.2 %
1 L/L
99 %
100 %","Oxygen therapy in clinical settings is used across diverse specialties, including various types of anoxia, hypoxia or dyspnea and any other disease states and conditions that reduce the efficiency of gas exchange and oxygen consumption such as respiratory illnesses, trauma, poisonings and drug overdoses. Oxygen therapy tries to achieve hyperoxia [L745] to reduce the extent of hypoxia-induced tissue damage and malfunction. "
C(N(C1=C([H])C([H])=C(C(=C(C2=C([H])C([H])=C(OC(C(OC(C(OC(C(F)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C2[H])[H])[H])C([H])=C1[H])[H])([H])([H])[H],DB09148,902143-01-5,Florbetaben (18F),Florbetaben F-18,small molecule,,"Injection, solution
Injection, solution","Intravenous
Intravenous","135 mCi/mL
300 MBq/ml",Florbetaben is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate ��-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer���s Disease (AD) and other causes of cognitive decline.
C(N(C1=C([H])C([H])=C(C(=C(C2=C([H])N=C(OC(C(OC(C(OC(C(F)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C2[H])[H])[H])C([H])=C1[H])[H])([H])([H])[H],DB09149,956103-76-7,Florbetapir (18F),"[18F]Florbetapir
4-{(E)-2-[6-(2-{2-[2-(18F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-N-methylaniline
Florbetapir F-18
Florbetapir F18
florbetapir-fluorine-18",small molecule,,"Injection, solution
Injection, solution
Injection, solution","Intravenous
Intravenous
Intravenous","1900 MBq/ml
51 mCi/mL
800 MBq/ml",Florbetapir 18F is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate ��-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.
C(N(C1=C(F)C([H])=C(C2=NC3=C(C(=C(O[H])C(=C3[H])[H])[H])S2)C([H])=C1[H])[H])([H])([H])[H],DB09151,765922-62-1,Flutemetamol (18F)," 2-[3-(18F)fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol
[18F]-Flutemetamol
flutemetamol (18F)
Flutemetamol F 18
Flutemetamol F-18
Flutemetamol F18",small molecule,,Solution,Intravenous,4.05 mCi/mL,Flutemetamol F18 is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate �� amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. 
N#N,DB09152,7727-37-9,Nitrogen,,small molecule,Humans and other mammals,"Gas
Liquid
Liquid
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Liquid
Liquid
Liquid
Gas
Liquid
Liquid
Gas
Gas
Gas
Gas
Liquid
Liquid
Emulsion","Respiratory (inhalation)
Topical
Topical
Cutaneous; Respiratory (inhalation)
Endosinusial
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Topical
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Cutaneous
Respiratory (inhalation)
Intravenous","99.0 %
99.5 %
100 %
99 L/100L
995 mL/L
90 L/100L
900 mL/L
99 mL/100mL
99 mL/L
99 L/L
99 L/100L
99.1 L/L
99.5 L/L
99.5 L/100L
99.9 L/L
990 mL/L
990 L/L
992 mL/L
992 L/1000L
995 mL/L
999 mL/L
99 L/100L
990 L/L
997 mL/L
100 %
999 L/1000L
99 %
99 %
99.5 %
999 L/1000L
992 mL/L
1 L/L",Liquid nitrogen is used mainly as a cryogenic agent for the treatment of various benign and malignant skin lesions. 
[He],DB09155,7440-59-7,Helium,"[He]
atomic helium",small molecule,Humans and other mammals,"Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas","Intracoronary; Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)","992 mL/L
99 L/100L
990 mL/L
992 mL/L
995 mL/L
999 mL/L
100 %
99 %","For use in patients who are not getting enough oxygen into their blood due to blockages in the lungs from pathological conditions or injuries. Suggested potential benefit in upper airway obstruction, in severe asthma, and in exacerbations of COPD/COLD. Helium may be used in place of carbon monoxide during laparoscopic surgeries as it lowers the risk of developing respiratory acidosis in selected patients. "
C(OC(C(O[H])=NC1=C(I)C(C(O[H])=NC(C(O[H])(C(O[H])([H])[H])[H])([H])[H])=C(I)C(C(=O)N(C([H])([H])[H])C(C(O[H])(C(O[H])([H])[H])[H])([H])[H])=C1I)([H])[H])([H])([H])[H],DB09156,73334-07-3,Iopromide,"N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methylisophthalamide",small molecule,,"Injection
Injection
Injection
Injection
Solution
Solution
Solution","Intra-arterial
Intra-arterial
Intra-arterial
Intra-arterial; Intravenous
Intravascular
Intravascular
Intravascular","498.72 mg/mL
623.4 mg/mL
768.86 mg/mL
311.7 mg/mL
50 %
62 %
77 %","Iopromide, as the product Iovist, is indicated for use as an X-ray contrast agent in the following procedures:
Intra-arterial digital subtraction angiography (IA-DSA) (150 mg I/mL) 
Cerebral arteriography and peripheral arteriography (300 mg I/mL) 
Coronary arteriography and left ventriculography, visceral angiography and aortography (370 mg I/mL) 
Peripheral venography (240 mg I/mL) 
Excretory urography (300 mg I/mL)
Contrast computed tomography (CT) imaging of head and body (300 mg I/mL and 370 mg I/mL) "
O=C=O,DB09157,124-38-9,Carbon dioxide,,small molecule,Humans and other mammals,"Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas
Gas","Respiratory (inhalation)
Intragastric
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)","100 mL/L
99 L/100L
1 g/g
1000 mL/L
900 mL/L
99 kg/100kg
99 L/100L
990 mL/L
990 g/kg
991 mL/L
992 mL/L
995 mL/L
100 %
99.0 %
50 mL/L
200 mL/L
99 %","Carbon dioxide is commonly used as an insufflation gas for minimal invasive surgery (laparoscopy, endoscopy, and arthroscopy) to enlarge and stabilize body cavities to provide better visibility of the surgical area. It has been used also in cryotherapy and as respiratory stimulant before and after anesthesia.  It could be used also in expansion of blood vessels if required, to increase carbon dioxide level after rapid breathing, and to stimulate breathing after a period of nonbreathing. "
C(C1=C(N=NC2=C(O[H])C3=C(N([H])[H])C(=C(C([H])=C3C([H])=C2S([O-])(=O)=O)S([O-])(=O)=O)[H])C([H])=C([H])C(C2=C([H])C(C([H])([H])[H])=C(N=NC3=C(O[H])C4=C(N([H])[H])C(=C(C([H])=C4C([H])=C3S([O-])(=O)=O)S([O-])(=O)=O)[H])C([H])=C2[H])=C1[H])([H])([H])[H],DB09158,72-57-1,Trypan blue,,small molecule,Humans and other mammals,"Solution / drops
Injection, solution
Injection, solution","Intraocular
Intraocular; Ophthalmic
Intraocular; Ophthalmic","0.06 %
.75 mg/.5mL
.3 mg/.5mL","Trypan blue is indicated for use as an aid in ophthalmic surgery by staining the epiretinal membranes during ophthalmic surgical vitrectomy procedures, facilitating removal of the tissue. "
C(OC(C([H])([H])[H])(C([H])([H])[H])C([N+]#[C-])([H])[H])([H])([H])[H],DB09161,109581-73-9,Technetium Tc-99m sestamibi,"99m Tc-sestamibi
99m-Tc sestamibi
99mTc sestamibi
99mTc-sestamibi
Sestamibi
Technetium (99m Tc) sestamibi
Technetium (99mTc) sestamibi
Technetium Tc 99m sestamibi",small molecule,,"Injection
Injection, powder, lyophilized, for solution
Injection
Injection, powder, for solution","Intravenous
Parenteral
Intravenous
Intravenous","1 mg/10mL
1 mg/5mL
1 mg/mL
1 mg/mL",Technetium Tc 99m Sestamibi is indicated for: 1) detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects); and 2) evaluating myocardial function and developing information for use in patient management decisions.
C(C(C([H])([H])[H])(C1=C([H])C([H])=C([H])C(C(C([H])([H])[H])(C([H])([H])[H])[H])=C1N(C(=O)C(N(C(C(O[H])=O)([H])[H])C(C(O[H])=O)([H])[H])([H])[H])[H])[H])([H])([H])[H],DB09164,,Technetium Tc-99m disofenin,"99mTc-DISIDA
99mTc-Disofenin
Technetium (99mTc) disofenin
Technetium Tc 99m Disofenin
Technetium-99m-Diisopropyliminodiacetic Acid",small molecule,,"Injection, powder, lyophilized, for solution",Intravenous,20 mg/10mL,"Technetium Tc99m Disofenin is indicated as a hepatobiliary imaging agent. Hepatolite is indicated in the diagnosis of acute cholecystitis as well as to rule out the occurrence of acute cholecystitis in suspected patients with right upper quadrant pain, fever, jaundice, right upper quadrant tenderness and mass or rebound tenderness, but not limited to these signs and symptoms."
C(C(C1=C([H])C2=C(N3C(C([H])([H])[H])=NN=C3C(N=C2C2=C(Cl)C([H])=C([H])C([H])=C2[H])([H])[H])S1)([H])[H])([H])([H])[H],DB09166,40054-69-1,Etizolam,"4-(o-Chlorophenyl)-2-ethyl-9-methyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine",small molecule,,,,,"Indicated for the treatment of generalized anxiety disorder with depression, panic disorder and insomnia."
C(N(C([H])([H])[H])C(C(C(=C1C2=C(C(=C(C(=C2[H])[H])[H])[H])C([H])([H])SC2=C1C(=C(C(=C2[H])[H])[H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB09167,113-53-1,Dosulepin,"(3E)-3-dibenzo[b,e]thiepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepin
Dosulepina
Dosul��pine
Dosulepinum
Dothiepin
trans-dothiepin",small molecule,,,,,"Indicated in the treatment of symptoms of depressive illness, especially where an anti-anxiety effect is required."
C(C(C(=O)N(C1=C([H])C([H])=C([H])C([H])=C1[H])C1(C([H])([H])C([H])([H])N(C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB09168,,4-Phenylfentanyl,,small molecule,,,,,
C(C(C(C(=O)N(C1(C([H])([H])C([H])([H])N(C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB09173,1169-70-6,Butyrfentanyl,"Butyr-fentanyl
Butyrylfentanyl",small molecule,,,,,
O=C(N(C1(C([H])([H])C([H])([H])N(C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])[H])C1=NC([H])=C([H])N=C1[H])C1=C([H])C([H])=C([H])O1,DB09175,117523-47-4,Mirfentanil,,small molecule,,,,,
C(C(C(=O)N(C1(C([H])([H])C([H])([H])N(C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])[H])C1=C([H])C([H])=C(F)C([H])=C1[H])([H])[H])([H])([H])[H],DB09177,90736-23-5,p-Fluorofentanyl,"4-Fluorofentanyl
Parafluorofentanyl",small molecule,,,,,
C(C(C(=O)N(C1(C([H])([H])C(C([H])([H])[H])([H])N(C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])C([H])([H])C1(C([H])([H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB09178,42045-97-6,Phenaridine,"2,5-Dimethylfentanyl",small molecule,,,,,
C(C(C(=O)N(C1=C([H])C([H])=C([H])C([H])=C1[H])C1(C(OC([H])([H])[H])([H])[H])C([H])([H])C([H])([H])N(C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])([H])[H])([H])([H])[H],DB09179,60618-49-7,R-30490,,small molecule,,,,,
C(C(C(=O)N(C1(C([H])([H])C([H])([H])N(C(C(C2=C([H])C([H])=C([H])S2)([H])[H])([H])[H])C([H])([H])C1([H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB09180,1165-22-6,Thienylfentanyl,Thiofentanyl,small molecule,,,,,
C(C(N1N=NN(C(C(N2C([H])([H])C([H])([H])C(N(C(=O)C(C([H])([H])[H])([H])[H])C3=C(F)C([H])=C([H])C([H])=C3[H])(C3=C([H])C([H])=C([H])C([H])=C3[H])C([H])([H])C2([H])[H])([H])[H])([H])[H])C1=O)([H])[H])([H])([H])[H],DB09181,120656-74-8,Trefentanil,,small molecule,,,,,
C(C(C(=O)N(C1(C([H])([H])C([H])([H])N(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])C([H])([H])C1([H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB09182,1474-02-8,Benzylfentanyl,,small molecule,,,,,
C(OC1=C(C2=C([H])C([H])=C3C(=C(N(S(C([H])([H])[H])(=O)=O)[H])C(=C([H])C3=C2[H])[H])[H])C([H])=C(N2C([H])=C([H])C(=O)N([H])C2=O)C([H])=C1C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])([H])([H])[H],DB09183,1132935-63-7,Dasabuvir," Sodium 3-(3-tert-butyl-4-methoxy-5-{6�� [(methylsulfonyl)amino]naphthalene-2-yl}phenyl)-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-ide hydrate (1:1:1)
N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide",small molecule,Hepatitis C Virus,"Tablet, film coated
Kit; tablet
Kit","Oral
Oral",250 mg,"Dasabuvir, in combination with [DB09296], [DB09297], and [DB00503] (as Viekira Pak) is indicated for the treatment of patients with HCV genotype 1a with [DB00811] or genotype 1b without [DB00811] including those with compensated cirrhosis [FDA Label]."
C(N1C([H])([H])C([H])([H])C23N([H])C(=O)C([H])([H])C([H])(C2([H])C1([H])[H])C1=C(C(=C(C(Cl)=C1[H])[H])[H])O3)([H])([H])[H],DB09187,70384-91-7,Lortalamine,,small molecule,,,,,
C(N(C1(C([H])([H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])C2=C(C(=C(C(=C2[H])[H])[H])[H])C1([H])[H])[H])[H])([H])([H])[H],DB09193,61764-60-1,"CP-39,332",,small molecule,,,,,
C(C(N1C(=O)N(C(C(C(N2C([H])([H])C([H])([H])N(C3=C([H])C([H])=C([H])C(Cl)=C3[H])C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])N=C1C(C([H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB09194,52942-31-1,Etoperidone,,small molecule,Humans and other mammals,,,,"Etoperidone has been studied for the treatment of depression[T47], tremors in Parkinson, extrapyramidal symptoms[L1041] and male impotence[L1042]. It is not certain if it was ever approved and marketed but its current status is withdrawn."
C(C1=C([H])C(C(C(N2C([H])([H])C([H])([H])N(C3=C([H])C([H])=C([H])C(Cl)=C3[H])C([H])([H])C2([H])[H])([H])[H])([H])[H])=NN1[H])([H])([H])[H],DB09197,20326-12-9,Mepiprazole,,small molecule,,,,,For the treatment of anxiety neuroses.
C(OC1=C(C2(C([H])([H])C2([H])[H])[H])C([H])=C([H])C([H])=C1[H])(C1=NC([H])([H])C([H])([H])N1[H])([H])[H],DB09202,59939-16-1,Cirazoline,,small molecule,,,,,
C(C(C([H])([H])[H])(C1=C([H])C(OC(C([H])([H])[H])=O)=C(C([H])([H])[H])C([H])=C1OC(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB09205,54-32-0,Moxisylyte,,small molecule,Humans and other mammals,,,,"By the WHO, moxisylyte is indicated for the symptomatic management of sequelae of cerebral infarction or hemorrhage.[T91] The cerebral infarction is characterized by the blockage of the artery either by the formation of a thrombus or an embolus.[A31644] 
On the other hand, the FDA classified moxisylyte for the reversal of phenylephrine-induced mydriasis in patients who have narrow anterior angles and are at risk of developing an acute attack of angle-closure glaucoma.[L1172]  Closed-angle glaucoma is caused by the contact between the iris and the trabecular meshwork. This contact will damage the aqueous outflow by the meshwork thus, increasing eye pressure and producing the symptoms of glaucoma.[A31645] Mydriasis is referred to the dilatation of the pupils and this standard body function is known to be a trigger factor for the development of acute closed-angle glaucoma.This risk is explained by the generation of a pupillary block, which is the contact between the pupillary margins and the lens, thus preventing flow from the aqueous humor to the anterior chamber and followed by an increased pressure gradient.[L1173] 
Moxisylyte is also approved in France as the first drug for the treatment of impotence.[A31647]"
C(OC1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C2N=C(N=C(N([H])[H])C2=C1[H])N1C([H])([H])C([H])([H])N(C(=O)OC(C(C([H])([H])[H])(C([H])([H])[H])O[H])([H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB09206,35795-16-5,Trimazosin,,small molecule,,,,,
O(C(=N[H])C(N1C([H])([H])C([H])([H])C([H])([H])C1=O)([H])[H])[H],DB09210,7491-74-9,Piracetam,,small molecule,,,,,"Indicated in adult patients suffering from myoclonus of cortical origin, irrespective of aetiology, and should be used in combination with other anti-myoclonic therapies [L1125]."
C(C(C(O[H])=O)(C1=C([H])C([H])=C(C(C2(C([H])([H])C([H])([H])C([H])([H])C2=O)[H])([H])[H])C([H])=C1[H])[H])([H])([H])[H],DB09212,68767-14-6,Loxoprofen,,small molecule,,,,,"Loxoprofen is non-steroidal anti-inflammatory medication (NSAID) indicated for pain and inflammation related to musculoskeletal and joint disorders [L1226].   In addition to its effects on pain, it is an antipyretic and anti-inflammatory medication [L1227]."
C(N1C2=C(OC(=O)N(C2=O)C2=NC([H])=C([H])C([H])=C2[H])C2=C(C(=C(C(=C2[H])[H])[H])[H])S1(=O)=O)([H])([H])[H],DB09215,90101-16-9,Droxicam,,small molecule,,,,,Droxicam is an NSAID previously used for the treatment of inflammation and rheumatoid arthritis [L1119].
C(C1=C(Cl)C([H])=C([H])C([H])=C1N(C1=C(C(O[H])=O)C([H])=C([H])C([H])=C1[H])[H])([H])([H])[H],DB09216,13710-19-5,Tolfenamic Acid,,small molecule,Humans and other mammals,,,,"In the information for tolfenamic acid, it is stated that this drug, being an NSAID, is effective in treating the pain associated with the acute attack of migraines in adults.[L1293]"
C(C1(C([H])([H])[H])OC(=O)C(OC(C2(C([H])([H])C2([H])[H])[H])([H])[H])=C1C1=C([H])C([H])=C(S(C([H])([H])[H])(=O)=O)C([H])=C1[H])([H])([H])[H],DB09217,189954-96-9,Firocoxib,,small molecule,,,,,Used for the treatment of pain inflammation and fever in horses and dogs.
C(C1=C(Cl)C([H])=C([H])C([H])=C1N(C1=NC([H])=C([H])C([H])=C1C(O[H])=O)[H])([H])([H])[H],DB09218,17737-65-4,Clonixin,,small molecule,Humans and other mammals,,,,Used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation.
O(C1=C([H])C([H])=C(C2(OC3=C(C(=C(C(=C3[H])[H])[H])[H])N([H])C2=O)C2=C([H])C([H])=C(O[H])C([H])=C2[H])C([H])=C1[H])[H],DB09219,17692-24-9,Bisoxatin,,small molecule,Humans and other mammals,,,,For use in the treatment of constipation in the absence of bowel obstruction and for surgical preparation of the colon [L926].
[O-][N+](=O)OC(C(N(C(=O)C1=C([H])N=C([H])C([H])=C1[H])[H])([H])[H])([H])[H],DB09220,65141-46-0,Nicorandil,"2-Nicotinamidoethyl nitrate
BRN 0481451
N-(2-Hydroxyethyl)nicotinamide nitrate
N-(2-Hydroxyethyl)nicotinamide nitrate (ester)
Nicorandilum
SG-75",small molecule,,,,,Indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes. 
C(C(N1C([H])([H])C([H])([H])N(C2=C([H])C(C3=C([H])C([H])=C(F)C([H])=C3[H])=C3C(C(C(C(C(C([H])([H])C3=N2)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])([H])[H])([H])([H])[H],DB09223,132810-10-7,Blonanserin,,small molecule,,,,,Used for the treatment of schizophrenia [L1097].
C(C1(C([H])([H])C([H])([H])N(C(C(C(C(=O)C2=C([H])C([H])=C(F)C([H])=C2[H])([H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])[H])([H])([H])[H],DB09224,3575-80-2,Melperone,,small molecule,,,,,"For the treatment of schizophrenia, sleep, disorders, agitation and mentally confused states [L1317, L1319, L1322].  "
C(N(C([H])([H])[H])C(C(OC1=C([H])C2=C(C(=C(C(=C2[H])[H])[H])[H])SC2=C1C(=C(Cl)C(=C2[H])[H])[H])([H])[H])([H])[H])([H])([H])[H],DB09225,26615-21-4,Zotepine,,small molecule,Humans and other mammals,,,,"Zotepine, like other atypical antipsychotics, is considered as the first-line treatment in newly diagnosed schizophrenia. It is usually thought to be an option of choice for managing acute schizophrenic episodes when discussion with the patient is not possible. Zotepine, as an atypical antipsychotic, is used in patients who are suffering unacceptable side effects from conventional antipsychotics or in relapse patients that were inadequately controlled.[T108] 
It is important to consider that the indications stated above are related to atypical antipsychotics, that zotepine is not currently FDA, Canada or EMA approved and that studies have not shown any additional benefit when compared with other approved atypical antipsychotics.[A31857]
Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels and behaves. It is usually marked for a loose reality perspective delineated by hallucinations, delusions and thought and movement disorders.[L1320]"
C(OC(=O)C1=C(C([H])([H])[H])N([H])C(C([H])([H])[H])=C(C(=O)OC(C2(C([H])([H])OC3(C([H])([H])C([H])([H])N(C4=C([H])C([H])=C(Cl)C([H])=C4[H])C([H])([H])C3([H])[H])O2)[H])([H])[H])C1(C1=C([H])C([N+]([O-])=O)=C([H])C([H])=C1[H])[H])([H])([H])[H],DB09233,113759-50-5,Cronidipine,,small molecule,,,,,
C(C(OC(=O)C1=C(C([H])([H])[H])N([H])C(C([H])([H])[H])=C(C(=O)OC(C([H])([H])[H])([H])[H])C1(C1=C([H])C([H])=C([H])C2=NON=C12)[H])([H])[H])([H])([H])[H],DB09234,72803-02-2,Darodipine,,small molecule,,,,,
C(C(OC(=O)C1=C(C([H])([H])[H])N([H])C(C([H])([H])[H])=C(C(=O)OC(C([H])([H])[H])([H])[H])C1(C1=C(C(=C(C(=O)OC(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])[H])[H])C([H])=C([H])C([H])=C1[H])[H])([H])[H])([H])([H])[H],DB09236,103890-78-4,Lacidipine,,small molecule,,,,,"Indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents, including ��-adrenoceptor antagonists, diuretics, and ACE-inhibitors [L1126]."
C(C(C(OC(C(OC(=O)C1=C(C([H])([H])[H])N([H])C(C([H])([H])[H])=C(C(=O)OC(C(OC(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C1(C1=C([H])C([H])=C([H])C([N+]([O-])=O)=C1[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB09240,22609-73-0,Niludipine,,small molecule,,,,,
C(OC1=C(N(C2=NC([H])([H])C([H])([H])N2[H])[H])C(Cl)=NC(C([H])([H])[H])=N1)([H])([H])[H],DB09242,75438-57-2,Moxonidine,"(2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8- quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid",small molecule,Humans and other mammals,,,,For the treatment of mild to moderate essential or primary hypertension [L1025]. Effective as most first-line antihypertensives when used as monotherapy [A27137].
N(N(C1=NN=C(C(N([H])[H])=O)C([H])=C1[H])[H])([H])[H],DB09243,3614-47-9,Hydracarbazine,,small molecule,Humans and other mammals,,,,Was used for the treatment of hypertension [A19790].
C(C(C([H])([H])[H])(N(N(C(=O)C(OC1=C([H])C([H])=C(Cl)C([H])=C1[H])([H])[H])[H])[H])[H])([H])([H])[H],DB09247,3544-35-2,Iproclozide,,small molecule,,,,,For the treatment of depression.
C(C(C([H])([H])[H])(C([H])([H])[H])C(=O)N(N(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H])[H])([H])([H])[H],DB09252,306-19-4,Pivhydrazine,"Pivalylbenzhydrazine
Pivazide",small molecule,,,,,For the treatment of depression.
N(C(=O)C(N1C([H])([H])C2=C(C(=C(C(=C2[H])[H])[H])[H])OC1=O)([H])[H])([H])[H],DB09254,18464-39-6,Caroxazone,,small molecule,Humans and other mammals,,,,For the treatment of depression.
O(C1=C([H])C(=O)N([H])C([H])=C1Cl)[H],DB09257,103766-25-2,Gimeracil,"5-Chloro-2,4-dihydroxypyridine
5-Chloro-4-hydroxy-2-pyridone
gimestat
Teysuno
Ts-1 (TN)",small molecule,,Capsule,Oral,,"Gimeracil is used as an adjunct to antineoplastic therapy. When used within the product Teysuno, gimeracil is indicated for the treatment of adults with advanced gastric (stomach) cancer when given in combination with cisplatin."
C(C1=NC([H])=C([H])N1C(C(C(C(N([H])[H])=O)(C1=C([H])C([H])=C([H])C([H])=C1[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB09262,170105-16-5,Imidafenacin,,small molecule,Humans and other mammals,,,,Used in the treatment of overactive bladder [FDA Label].
[O-]C(=O)C(N(C(C([O-])=O)([H])[H])C1=C(C#N)C(C(C([O-])=O)([H])[H])=C(C([O-])=O)S1)([H])[H],DB09267,135459-87-9,Strontium ranelate,,small molecule,Humans and other mammals,Granule,Oral,2 g,"Strontium ranelate is therapeutically indicated for the treatement of severe osteoperosis in: a) postmenopasual women, and b) adult men, who are at high risk of fractures, for whom treatment with other medical products approved for the treatment of osteoperosis is not possible due to, for example, contraindications or intolerance. [L1127]
In postmenopausal women, strontium ranelate can also reduce the risk of vertebral and hip fractures [L1127]."
O(S(=O)(=O)OC1=C([H])C([H])=C(C(C2=C([H])C([H])=C(OS(O[H])(=O)=O)C([H])=C2[H])(C2=NC([H])=C([H])C([H])=C2[H])[H])C([H])=C1[H])[H],DB09268,10040-34-3,Picosulfuric acid,"Picosulfate
Picosulphate",small molecule,Humans and other mammals,"Liquid
Powder, for solution
Powder, metered","Oral
Oral
Oral",,For cleansing of the colon as a preparation for colonoscopy in adults.
O(C(=O)C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H],DB09269,103-82-2,Phenylacetic acid,"benzeneacetic acid
��-toluic acid
��-phenylacetic acid",small molecule,Humans and other mammals,"Injection, solution, concentrate",Intravenous,,For use as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.
C(OC1=C(OC([H])([H])[H])C(=O)C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C([H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])=C(C([H])([H])[H])C1=O)([H])([H])[H],DB09270,303-98-0,Ubidecarenone,"Coenzyme Q-10
Coenzyme Q10",small molecule,Humans and other mammals,"Capsule
Capsule
Solution
Tablet
Capsule
Capsule
Tablet
Capsule
Capsule
Capsule
Capsule
Powder
Capsule
Tablet
Capsule
Tablet
Capsule
Capsule
Capsule, gelatin coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","50 mg
100 mg
10 mg
50.0 mg
12 mg
100 mg
60 mg
80 mg
15 mg
30 mg
10 mg
60 mg
25 mg
20 mg","The diet supplements containing ubidecarenone are indicated, as stated in the product label, to assist individuals with cardiovascular complaints including congestive heart failure and systolic hypertension. In the product, ubidecarenone is used to increase the cardiac input as well as for the prevention of several other diseases like Parkinson, fibromyalgia, migraine, periodontal disease and diabetes, based on preclinical studies.[L1064] It is important to highlight that these products are not FDA approved and it is recommended to use under discretion."
C(N1C2=C(N(C(C3(OC([H])([H])C([H])([H])O3)[H])([H])[H])C(=N2)[H])C(=O)N(C([H])([H])[H])C1=O)([H])([H])[H],DB09273,69975-86-6,Doxofylline,Doxophylline,small molecule,Humans and other mammals,,,,"Indicated for the treatment of chronic obstructive pulmonary disease (COPD), bronchial asthma and pulmonary disease with spastic bronchial component."
O(C(=O)C(C(O[H])(C(C([O-])=O)([H])[H])C(O[H])=O)([H])[H])[H],DB09275,57644-54-9,Bismuth Subcitrate,"Bismuth tripotassium dicitrate
Tripotassium dicitratobismuthate",small molecule,Humans and other mammals,Capsule,Oral,,"For the treatment of peptic ulcer and gastro-oesophageal reflux disease (GORD).
Treatment of inflammatory and erosive-ulcerous diseases of gastric and duodenal mucosa:  gastritis, ulcer disease of the stomach and duodenum, functional non-ulcerous dyspepsia, erosive duodenitis, post-operative inflammatory and erosive changes ��� anastomositis, peptic ulcer of anastomosis"
[C],"DB09278
DB05269",64365-11-3,Activated charcoal,"Activated carbon
Carbo activates
Carbo activatus
Carbo vegetabilis
Carbon
Carbon, Activated
Carbon, decolorizing
Charcoal activated
Charcoal-activated
Charcoal, Activated
Charcoal,activated
Medicinal carbon
Medicinal charcoal",small molecule,Humans and other mammals,"Suspension
Capsule
Capsule
Capsule
Powder, for solution
Powder
Capsule
Capsule
Suspension
Suspension
Suspension
Suspension
Suspension
Tablet
Capsule
Pellet
Tablet
Powder
Liquid
Liquid
Suspension
Liquid
Gel","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Topical","208 mg/mL
225 mg
260 mg
280 mg
1 g
100 %
170 mg
208 mg
222 mg
50 g
200 mg
230 mg
162 mg
25 g/25g
1000 mg/g
50 g
15 g
50 g/240mL
2 g/100mL",Used as a antidote to treat poisonings following excessive oral ingestion of certain medications or poisons. 
C(C(C(C(C1=NC(C([H])([H])[H])=C(C(C(=S)N(C([H])([H])[H])C([H])([H])[H])([H])[H])C(=O)N1C(C1=C([H])C([H])=C(C2=C(C3=NN=NN3[H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB09279,247257-48-3,Fimasartan,,small molecule,Humans and other mammals,,,,Used for the treatment of hypertension and heart failure [A20319].
C(C1=C(C2=C([H])C(C(O[H])=O)=C([H])C([H])=C2[H])N=C(N(C(=O)C2(C([H])([H])C2([H])[H])C2=C([H])C3=C(OC(F)(F)O3)C([H])=C2[H])[H])C([H])=C1[H])([H])([H])[H],DB09280,936727-05-8,Lumacaftor,"3-(6-{[1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)cyclopropane-1-carbonyl]amino}-3-methylpyridin-2-yl)benzoic acid
lumacaftor",small molecule,,"Tablet
Tablet, film coated","Oral
Oral",,"When given in combination with [DB08820] as the fixed dose combination product Orkambi, lumacaftor is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene [FDA Label]."
[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O,DB09281,14987-04-3,Magnesium Trisilicate,,small molecule,,"Tablet, chewable
Tablet","Oral
Oral",,"For the treatment of peptic ulcers.
Relieving indigestion and heartburn."
C(C(OC(=O)[N-]C1=C([H])[N+](N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])=NO1)([H])[H])([H])([H])[H],DB09282,25717-80-0,Molsidomine,,small molecule,,,,,"The indications for use of molsidomine include ischemic heart disease, angina, chronic heart failure, and pulmonary hypertension [L1370, L1371]."
C(C(N(C(C([H])([H])[H])([H])[H])C1=C([H])C(C([H])([H])[H])=NC2=NC(=NN12)[H])([H])[H])([H])([H])[H],DB09283,15421-84-8,Trapidil,,small molecule,Humans and other mammals,,,,Used in the treatment of chronic stable angina [A19770].
C(C(N(C(C([H])([H])[H])([H])[H])C(C(N1C(=N[H])ON=C1C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB09284,318-23-0,Imolamine,,small molecule,Humans and other mammals,,,,Imolamine is indicated for the treatment of angina pectoris. The hydrochloride form is used as a local anesthetic.[T83]
FC(F)(F)C1=C([H])C(N(C2=NC([H])=C([H])C([H])=C2C(=O)OC(C(N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])([H])[H])([H])[H])[H])=C([H])C([H])=C1[H],DB09285,65847-85-0,Morniflumate,,small molecule,,,,,"Morniflumate is indicated for the treatment of inflammatory conditions affecting the airways, ENT system, urogenital tract and bone and joint systems in adults. In Italy, morniflumate is also indicated for the treatment of pain associated with ear, nose, throat (ENT) and gastrointestinal inflammatory conditions in children.  Morniflumate is a well established NSAID that has been in use for over three decades in Italy (particularly for the treatment of upper respiratory tract infections in children), France, Belgium, Austria, Switzerland, Spain and Portugal; it has a generally favorable tolerability profile."
N(C(=O)C1(C([H])([H])C([H])([H])N(C(C(C(C(=O)C2=C([H])C([H])=C(F)C([H])=C2[H])([H])[H])([H])[H])([H])[H])C([H])([H])C1([H])[H])N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])([H])[H],DB09286,1893-33-0,Pipamperone,"Carpiperone
Floropipamide
Fluoropipamide",small molecule,,,,,Treatment of chronic psychoses and states of aggressiveness of various origins [L1515].
C(C(N(C(C([H])([H])[H])([H])[H])C(C(=O)OC1=C([H])C([H])=C(N(C(C([H])([H])[H])=O)[H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB09288,66532-85-2,Propacetamol,,small molecule,Humans and other mammals,,,,Propacetamol is a paracetamol prodrug of intravenous administration used to control fever and pain of perioperative period in multimodal analgesia therapy.[L1511]
C(N1C([H])([H])C([H])([H])C2=C(C3=C(C(C4=C2C([H])=C([H])C([H])=C4[H])([H])[H])C([H])=C([H])C([H])=C3[H])C1([H])[H])([H])([H])[H],DB09304,57262-94-9,Setiptiline,,small molecule,Humans and other mammals,,,,For the treatment of depression [A19792].
C(OC1=C([H])C2=C(N3C([H])([H])C([H])([H])N(C([H])([H])[H])C4=NC(C(C2=C34)([H])[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB09306,54188-38-4,Metralindole,"Incasan
Inkazan",small molecule,,,,,Investigated for the treatment of depression.
[Xe],DB09315,14932-42-4,Xenon-133,"Xenon (133 xe)
Xenon (133Xe) gas
Xenon Xe 133
Xenon XE-133
Xenon, Xe-133",small molecule,Humans and other mammals,"Gas
Gas
Gas
Gas","Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)
Respiratory (inhalation)","10 mCi/1
20 mCi/1
10 mCi/mL
5 mCi/mL",Inhalation of Xenon Xe 133 Gas has proved valuable for the evaluation of pulmonary function and for imaging the lungs. It may also be applied to assessment of cerebral flow. 
Cl[Tl],DB09316,7791-12-0,Thallous Chloride,"Thallium chloride
thallium monochloride
Thallium(I) chloride
Thallous Chloride Tl-201",small molecule,Humans and other mammals,"Injection, powder, lyophilized, for solution
Injection, solution
Injection, solution","Intravenous
Intravenous
Intravenous","1 mCi/mL
1 mCi/mL
2 mCi/mL","For use as a diagnostic radiopharmaceutical.
It is indicated to help diagnose heart disease (eg, coronary artery disease, heart attack). It is also used for the diagnosis of parathyroid problems. "
O=[Zn],DB09321,1314-13-2,Zinc oxide,"��xido de cinc
oxyde de zinc
Zinc (as oxide)
Zinc (as zinc oxide)
Zinc white
Zinci oxydum
Zincum oxydatum
Zinkoxid",small molecule,Humans and other mammals,"Lotion
Stick
Aerosol, spray
Solution
Cream; kit
Lotion
Cream
Cream
Cream
Lotion
Cream
Stick
Lotion
Stick
Ointment
Powder
Powder
Ointment
Lipstick
Patch
Cream
Spray
Cream
Lotion
Powder
Cream
Cream
Ointment
Cream
Cream
Cream
Lotion
Ointment
Cream
Ointment
Cream
Cream
Lotion
Cream
Stick
Cream
Stick
Ointment
Cream
Cream
Cream
Poultice
Powder
Cream
Cream
Cream
Lotion
Stick
Emulsion
Lipstick
Lotion
Cream
Lotion
Lotion
Ointment
Cream
Cream
Liquid
Spray
Spray
Paste
Cream
Cream
Cream
Suppository
Ointment
Lotion
Stick
Cream
Cream
Ointment
Lotion
Ointment
Cream
Paste
Cream
Lipstick
Lotion
Lotion
Lotion
Cream
Ointment
Cream
Cream
Lotion
Cream
Cream
Cream
Cream
Paste
Ointment
Cream
Cream
Paste
Cream
Cream
Ointment
Cream
Ointment
Cream
Gel
Ointment
Ointment
Cream
Liquid
Ointment
Ointment
Ointment
Powder
Lotion
Cream
Cream
Cream
Cream
Cream
Cream
Cream
Emulsion
Lotion
Cream
Cream
Lotion
Cream
Cream
Lotion
Patch
Liquid
Powder
Patch
Cream
Liquid
Paste
Cream
Lotion
Cream
Lotion
Cream
Powder
Stick
Cream
Ointment
Paste
Cream
Liquid
Lotion
Ointment
Ointment
Ointment
Lotion
Lotion
Spray, suspension
Cream
Powder
Powder
Lotion
Paste
Cream
Powder
Liquid
Cream
Liquid
Cream
Powder
Kit
Powder
Cream, augmented
Ointment
Cream
Ointment
Lotion
Lotion
Cream
Lotion
Paste
Lotion
Liquid
Lotion / shampoo
Cream
Cream
Cream
Ointment
Lotion
Cream
Cream
Suspension
Ointment
Lotion
Cream
Cream
Ointment
Suppository
Cream
Dressing
Dressing
Gel
Ointment
Ointment
Cream
Cream
Paste
Plaster
Lotion
Stick
Cream
Cream
Cream
Cream
Cream
Lotion
Lotion
Cream
Cream
Cream
Lotion
Cream
Lotion
Ointment
Spray, metered
Lotion
Kit
Lotion
Lotion
Gel
Tablet
Cream
Kit; lotion
Cream
Lotion
Capsule
Cream
Lipstick
Cream
Ointment
Cream
Paste
Paste
Lotion
Cream
Ointment
Lotion
Capsule, liquid filled
Tablet, film coated
Tablet, coated
Cream
Cream
Lotion
Liquid
Cream
Liquid
Lotion
Cream
Cream
Cream
Cream
Stick
Cream
Cream
Lotion
Cream
Dressing
Dressing
Paste
Cream
Cream
Stick
Cream
Cream
Plaster
Lotion
Powder
Tablet, chewable
Cream
Cream
Kit
Cream
Aerosol, foam
Powder
Powder
Emulsion
Liquid
Cream
Cream
Powder
Lotion
Lotion
Paste
Lipstick
Lotion
Ointment
Ointment
Cream
Cream
Aerosol, foam
Cream
Cream
Cream
Cream
Lotion
Liquid
Sponge
Emulsion
Cream
Spray
Stick
Gel
Cream
Cream
Cream
Cream
Cream
Liquid
Lotion
Lotion
Lotion
Spray
Stick
Lipstick
Cream
Aerosol, spray
Stick
Lotion
Ointment
Cream
Lotion
Cream
Paste
Stick
Cream
Cream
Cream
Spray
Cream
Stick
Lotion
Cream
Paste
Lotion
Spray
Cream
Cream
Paste
Ointment
Ointment
Aerosol
Lotion
Paste
Powder
Capsule, gelatin coated
Powder
Lotion
Cream
Cloth
Stick
Stick
Lotion
Cream
Cream
Lotion
Cream
Ointment
Cream
Ointment
Ointment
Ointment
Cream
Ointment
Ointment
Cream
Ointment","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous; Topical; Transdermal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Rectal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Oral
Topical
Topical
Topical
Rectal
Rectal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Rectal; Topical
Rectal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Cutaneous
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Oral
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","20 mg/mL
87 mg/g
120 mg/mL
144 mg/mL
4.97 g/100mL
140 mg/mL
12 mg/100mL
17 g/100g
5.5 g/100g
5.5 g/100g
22.5 g/100g
4.14 g/18.4g
3.8 g/100g
5 g/100g
9.1 g/100g
160 mg/g
8 g/100g
10 g/100g
10 g/99g
20 g/100g
8.5 g/100g
17.1 g/57g
10 g/10g
130 g/g
16.51 g/127g
23.8 g/85g
2.75 g/11g
20 g/100g
11.3 %
150 mg/g
16 g/100g
16 g/100g
120 mg/mL
12 g/100mL
18.75 g/100mL
8 g/100g
20 g/100mL
22.5 g/100g
18.75 mL/100mL
22.5 g/100mL
10 g/100mL
.113 g/g
20 g/100g
12 %
5.0016 g/100mL
1.92 g/100mL
14 g/100mL
15.4 g/100g
19 g/100mL
8.05 g/100g
140 mg/mL
17 mL/100mL
19.7 g/100mL
18 g/100mL
17.75 g/71g
16 g/113g
40 g/113g
10 g/100mL
4 g/100g
10 g/100g
45.2 g/113g
14.69 g/113g
12 g/100g
120 mg/g
.2 g/g
20 mg/100mL
.0686 mg/g
.4 g/g
200 mg/g
13 kg/100kg
20 %
20 %
.013 g/g
66 mg/mL
10 g/100g
17.5 g/100g
12.5 g/100g
.9 g/100mL
5 g/100g
95 mg/mL
95 mg/mL
15.25 g/100g
12 g/100mL
15 g/100g
400 mg/g
400 mg/g
.113 kg/g
.4 g/g
532 mg/g
19 g/100mL
4.9 g/100g
12 %
96 mg/g
100 mg/g
100 mg/mL
65 mg/g
10 g/100g
.01248 g/g
250 mg/g
19 g/100g
21 g/100g
15.004 g/100g
22 g/100g
13.8 g/100mL
25 g/100mL
75 g/1000g
60 g/1000g
225 mg/100mL
59.02 g/454g
181.6 g/454g
1.1 g/10g
100 mg/mL
163.2 mg/mL
177 mg/mL
13.6 g/100mL
168 mg/mL
101 mg/mL
19 g/100g
13.8 g/100mL
8.3 g/100g
25 mL/100mL
.65 mg/130mL
200 mg/mL
.125 mL/mL
160 mg/mL
190 mg/g
190 mg/mL
.07 g/g
.02 g/g
13 mg/g
.1 g/g
400 mg/g
1.6 g/20mL
160 mg/mL
25 g/100g
50 mg/g
150 mg
19 g/100mL
9.3 g/100mL
12 g/100mL
.03 g/mL
.0192 g/g
.0291 g/g
13.5 g/100g
25 %
14.5 mg/mL
24.5 g/100g
1.6 g/100g
.0192 g/g
.02 g/g
13.0 %
10 %
100 mg/g
10 mL/100mL
200 mg/mL
250 g/1000g
15 g/100mL
15 g/100g
16.96 mg/80mL
.0157 g/mL
.48 g/30mL
.016 g/mL
9.45 mg/mL
6.8 g/100mL
170 mg/g
113.6 g/284g
7.9 mg/100mL
21 g/100g
14 g/100mL
18 g/100g
200 mg/mL
.0098 g/g
400 mg/g
1.7 g/1
50 mg/mL
19.8 g/165g
24.6 g/205g
96 mg/g
9.6 g/100g
1.8 g/100g
3.8 g/100g
40 g/100g
28.3 %
.25 mg/mg
17 g/100g
24 mg/g
3.5 mL/50mL
105 mg/mL
9.9 g/100g
8.3 g/83g
5.5 g/55g
13 g/100g
189 mg/mL
7.85 g/50mL
24 g/68mL
24.96 g/100g
22 g/100mL
8.8 g/88mL
182.4 mg/mL
216 mg/mL
20 g/100g
.12 mL/mL
185 mg/g
185 mg/g
17 g/100mL
10 g/100g
114 mg/mL
.08 g/56g
250 mg/g
180 mg
25 g/100g
13.0 %
2.4 g/.259mL
.038 g/g
.13 mg/2.5mL
5 g/mL
7.5 g/100g
1 g/5g
.0098 g/mL
13.5 g/100g
76 mg/mL
7.5 mL/100mL
.1 g/g
130 mg/g
4.9 g/100mL
18.5 g/100g
227.5 mg/g
230 mg/mL
227.5 mg/g
49.5 mg/mL
4.45 g/100g
25 g/1
20 g/100g
13 g/100mL
.9 mL/30mL
35 mg/g
8 g/90mL
.26 g/1.54g
.75 g/5mL
18 g/100g
306.1 mg/g
100 mg/g
2 kg
140 mg/mL
12 mg/.1g
12 mg/100mg
10 g/100mL
21 g/100mL
40 g/100g
5 %
19 g/142g
25 g/142g
12.5 g/100g
.462 g/4.62g
23.7 g/118.294g
.085 g/g
55 mg/g
.0702 mg/g
200 mg/g
223 mg/g
10.8 g/96g
2.94 g/28g
186 mg/mL
20 g/100mL
8.82 g/90mL
220 mg/g
12 g/100mL
17 g/100mL
186 mg/mL
190 mg/mL
170 mg/mL
43.4 g/177mL
28.9 g/118mL
25 g/100g
50 mg/mL
12.9 mL/52mL
1.24 mL/5mL
32.3 mL/130mL
20 g/100g
18 g/100g
882.7 mg/9.1g
24.5 g/100g
30 mg/mL
9 g/75g
15 g/100mL
10 g/100mL
100 mg/mL
200 mg/g
200 ug/g
176.7 mg/g
.12 g/g
.2 g/g
25 g/100g
1.15 g/40mL
22 g/100g
22.5 g/100mL
10 %
12.8 g/100g
20 mL/100mL
24 mL/120mL
10 mL/50mL
.135 mg/g
5 mg/cm2
13 g/100g
40 g/100g
6.87 g/34.35g
125 mg/g
.69 g/3g
2 g/100g
146 mg/mL
14 g/100g
20 g/100g
6.5 g/100g
7.6 g/100g
210 mg/mL
1.96 g/100g
22 g/100g
8 g/100g
15 %
15 %
.2 kg/kg
1.8 g/100g
20 g/100g
200 mg/g
15 g
20 %
20 g
186 mg/g
40 %","For adjunctive treatment of diaper dermatitis. Also, it can be used to treat minor skin irritations (eg, cuts, burns, and scrapes, poison ivy).
Zinc oxide can be used in ointments, creams, and lotions to protect against sunburn and other damage to the skin caused by ultraviolet light."
C(OC1=C([H])C(N(C([H])([H])[H])C(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])=C(N(C(=O)C(=C([H])[H])[H])[H])C([H])=C1N(C1=NC(C2=C([H])N(C([H])([H])[H])C3=C2C(=C(C(=C3[H])[H])[H])[H])=C([H])C([H])=N1)[H])([H])([H])[H],DB09330,1421373-65-0,Osimertinib,"Mereletinib
N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide",small molecule,,"Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral","40 mg
80 mg
40 mg
40 1/1
80 1/1
80 mg","Osimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA- approved test, who have progressed on or after EGFR-TKI therapy."
C(C1=C(OP([O-])([O-])=O)C2=C(C(=C(C([H])=C2C(OP([O-])([O-])=O)=C1[H])[H])[H])[H])([H])([H])[H],DB09332,131-13-5,Kappadione,Menadiol sodium diphosphate,small molecule,,,,,"Anticoagulant-induced prothrombin deficiency caused by coumadin or indanedione derivatives,
prophylaxis and therapy of hemorrhagic disease of the newborn, hypoprothrombinemia due to antibacterial therapy,
hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K (for example, obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis, other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism) [L1545, L1546]."
C(N(C([H])([H])[H])C(=NC1=C(I)C(C(C(C(O[H])=O)([H])[H])([H])[H])=C(I)C([H])=C1I)[H])([H])([H])[H],DB09333,5587-89-3,Iopodic acid,Ipodate,small molecule,Humans and other mammals,Capsule,Oral,500 mg,"Iopodic acid is available as a cholecystographic agent. This denomination indicates the iopodic acid is a radiopaque substance that can be used to visualize the gallbladder and biliary channels in abdominal X-ray.[L1587, A32087] An abdominal X-ray uses a minimal amount of ionizing radiation to produce pictures of the inside of the abdominal cavity. It is commonly used to evaluate the stomach, liver, intestines, and spleen.[L1589]
Iopodic acid has also been indicated for the treatment of hyperthyroidism such as Graves disease.[A32085, A32086] Hyperthyroidism refers to any condition where there is too much thyroid hormone produced in the body (overactive thyroid). When the overactivity involves the entire thyroid gland, it is known as Grave's disease.[L1590]"
C(C(C(OC1=C(C(=O)OC(C(N(C(C([H])([H])[H])([H])[H])C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C([H])C(N([H])[H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB09342,86-43-1,Propoxycaine,,small molecule,,,,,"Propoxycaine is a local anesthetic medication.  It was used beginning in the 1950s during dental procedures [L1591].  It has been combined with procaine to accelerate its onset of action and provide longer-lasting anesthetic effect [L1592].
It was produced for use when amide local anesthetics were contraindicated due to allergy or when several amide anesthetics were unsuccessful [L1592]."
ClC1=C(C(N2C([H])([H])C([H])([H])C([H])([H])C2=N[H])([H])[H])N([H])C(=O)N([H])C1=O,DB09343,183204-74-2,Tipiracil,"5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione
5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]-1H-pyrimidine-2,4-dione
TPI",small molecule,Humans and other mammals,"Tablet
Tablet, film coated","Oral
Oral",,"Tipiracil, in combination with trifluridine, is indicated for the treatment of refractory mestastatic colorectal cancer patients who keep progressing despite of treatment with standard chemotherapy and biologics.[A31256]"
C(C(C(C(OC1=C([H])C([H])=C(OC(C(C(N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB09345,140-65-8,Pramocaine,Pramoxine,small molecule,,"Kit
Kit
Suppository
Cream
Liquid; spray
Liquid
Stick
Aerosol, spray
Cream
Liquid
Cloth
Spray
Liquid
Cream
Suspension
Cream
Stick
Cream
Cloth
Cream
Cream
Ointment
Ointment
Gel
Lotion
Cream
Lotion
Cloth
Swab
Lotion
Aerosol, foam
Solution / drops
Swab
Ointment
Aerosol
Aerosol, foam
Aerosol, foam
Lotion
Cloth
Cream
Solution
Cream
Spray","Oral
Rectal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Rectal; Topical
Topical
Topical
Rectal
Topical
Topical
Rectal
Topical
Topical
Topical
Topical
Topical
Auricular (otic)
Topical
Rectal; Topical
Rectal
Topical
Rectal
Topical
Topical
Topical
Topical
Rectal; Topical; Vaginal
Topical","5 mg/g
1 %
1.18 mg/mL
1 g/100mL
1 mg/1
1 g/57g
1 %
10 mg/g
1.0 %
1 %
10 1/mL
10 mg/mL
10 mg/1000mg
1 %
10 mg/g
10 mg/g
150 mg/15g
1 mg/mL
10 mg/g
0.5 %
1 %
1 %
10 mg/mL","It is indicated for  temporary relief of pain and pruritus from minor lip and skin irritations as well as for temporary relief from pain, burning, itching and discomfort associated with hemorrhoids and other anorectal/anogenital disorders. "
C(N(C(C([H])([H])[H])=O)C1=C(I)C(N(C(C([H])([H])[H])=O)[H])=C(I)C(C(O[H])=O)=C1I)([H])([H])[H],DB09346,1949-45-7,Metrizoic acid,,small molecule,,,,,For use as a contrast medium [L1597].
C(C(=O)N(C1=C(I)C(C(O[H])=O)=C(I)C([H])=C1I)[H])([H])([H])[H],DB09347,85-36-9,Acetrizoic acid,"Acide acetrizoique
Urokonic acid",small molecule,Humans and other mammals,,,,Acetrizoic acid indication was to be used as a contrast agent for X-ray. Some information indicates its nephrotropic property as one of the characteristics for the utilization of acetrizoic acid.[A32135] The X-ray imaging depends on the difference in tissue density which is provided by an X-ray attenuation between the area of interest and the surrounding tissue. The use of contrast agents will provoke a contrast enhancement or opacification and it will improve the differentiation of pathological processes from normal tissue.[T125]
O=C1C([H])([H])C([H])([H])O1,DB09348,57-57-8,beta-Propiolactone,"Propiolactone
��-propiolactone",small molecule,"Humans and other mammals
Fungi
Bacteria
Various viruses",,,,"��-propiolactone was used for vaccines, tissue grafts, surgical instruments, and enzymes, as a sterilant of blood plasma, water, milk and nutrient broth as a vapor-phase disinfectant in enclosed spaces. Its sporicidal action is used against vegetative bacteria, pathologic fungi, and viruses.[L1717] It is no longer used in medical procedures or in food.[A32144]"
C(C(C(C(OC(C(OC(C(OC(C1=C([H])C2=C(OC(O2)([H])[H])C([H])=C1C(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB09350,51-03-6,Piperonyl butoxide,,small molecule,Head lice,"Kit
Kit
Rinse
Aerosol; shampoo
Oil
Gel
Liquid; shampoo
Kit
Aerosol
Shampoo","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical",,"For the treatment of head, pubic (crab), and body lice."
N(C1=C([H])C([H])=C(S(=O)(=O)N(C(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])[H])C([H])=C1[H])([H])[H],DB09355,127-71-9,Sulfabenzamide,"N-Benzoylsulfanilamide
N-Sulfanilylbenzamide
Sulfabenzamida
Sulfabenzamidum
Sulfabenzoylamide
Sulfamylbenzamide",small molecule,,,,,
C(C(C(OC(=O)C(N1C([H])=C(I)C(=O)C(I)=C1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB09366,587-61-1,Propyliodone,"Propiliodona
Propiodone
Propyliodonum",small molecule,,,,,
C(C1(C([H])([H])[H])C(=C(C(=C(C(=C(C(=C(C2=[N+](C(C(C(C(S([O-])(=O)=O)([H])[H])([H])[H])([H])[H])([H])[H])C3=C(C4=C([H])C([H])=C([H])C([H])=C4C(=C3[H])[H])C2(C([H])([H])[H])C([H])([H])[H])[H])[H])[H])[H])[H])[H])[H])N(C(C(C(C(S([O-])(=O)=O)([H])[H])([H])[H])([H])[H])([H])[H])C2=C1C1=C([H])C([H])=C([H])C([H])=C1C(=C2[H])[H])([H])([H])[H],DB09374,3599-32-4,Indocyanine green,"Cardio-Green
Fox Green
sodium 4-(2-{7-[1,1-dimethyl-3-(4-sulfonatobutyl)-1H-benzo[e]indolium-2-yl]hepta-2,4,6-trien-1-ylidene}-1,1-dimethyl-1,2-dihydro-3H-benzo[e]indol-3-yl)butane-1-sulfonate",small molecule,,"Kit
Powder
Kit
Injection, powder, lyophilized, for solution
Kit","Intravenous
Intravenous
Intravenous","25 mg
25 mg/1","For Determining Cardiac Output, Hepatic Function and Liver Blood Flow
For ophthalmic angiography"
C(C(C(C(C(C(C(C(C(C(C(C(=O)OC(C(N(C(=O)C([N+]1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB09376,109260-82-4,Lapyrium,,small molecule,,,,,"Used as a surfactant, antistatic agent, and biocide in cosmetic products [A19426]."
C(C(C12C([H])([H])C([H])([H])C3([H])C(C(C(C4=C([H])C(=O)C([H])([H])C([H])([H])C43[H])([H])[H])([H])[H])([H])C1([H])C([H])([H])C([H])([H])C2(O[H])C#C[H])([H])[H])([H])([H])[H],DB09389,6533-00-2,Norgestrel,"17-ethynyl-17-hydroxy-18a-homoestr-4-en-3-one
LD norgestrel
Methylnorethindrone",small molecule,,"Kit
Kit
Tablet
Tablet","Oral
Oral
Oral",0.075 mg,Norgestrel in combination with ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
O(P(O[H])(O[H])=O)[H],DB09394,,Phosphoric acid,,small molecule,,"Capsule
Solution
Liquid
Injection, solution
Liquid
Gel
Liquid
Injection
Paste","Oral
Oral
Dental
Intravenous
Oral
Topical
Dental; Topical
Intravenous
Dental",,"Phosphoric acid is used in dentistry and orthodontics as an etching solution, to clean and roughen the surfaces of teeth where dental appliances or fillings will be placed."
O(P([O-])([O-])=O)[H],DB09414,7758-11-4,Dipotassium phosphate,"Di-potassium hydrogen phosphate
Dibasic potassium phosphate
Dipotassium acid phosphate
Dipotassium hydrogen monophosphate
Dipotassium hydrogen orthophosphate
Dipotassium hydrogen phosphate
Dipotassium monophosphate
Kali phosphoricum
Phosphoric acid, dipotassium salt
Phosphoric acid, potassium salt (1:2)
Potassium phosphate dibasic
Potassium phosphate, dibasic
Potassium phosphate,dibasic
Secondary potassium phosphate",small molecule,,"Liquid
Liquid
Injection
Liquid
Injection, solution
Injection, solution, concentrate
Aerosol
Powder
Solution","Intravenous
Buccal
Intravenous
Intravesical
Intravenous
Intravenous
Oral
Oral
Intravenous",,"As a food additive, dipotassium phosphate is used in imitation dairy creamers, dry powder beverages, mineral supplements, and starter cultures. It is used in non-dairy creamers to prevent coagulation. Dipotassium phosphate is also used to make buffer solutions and it is used in the production of trypticase soy agar which is used to make agar plates for culturing bacteria."
O(C(=O)C(N(C(C(N(C(C(N(C(C([O-])=O)([H])[H])C(C([O-])=O)([H])[H])([H])[H])([H])[H])C(C([O-])=O)([H])[H])([H])[H])([H])[H])C(C(O[H])=O)([H])[H])([H])[H])[H],DB09425,135998-32-2,Indium In-111 pentetate,"Indium (111In) pentetic acid
Indium In 111 pentetate
Indium In-111 pentetate",small molecule,,"Solution
Solution","Intrathecal
Intrathecal","3.75 mCi/1.5mL
1 mCi/mL",Pentetate Indium Disodium In 111 is recommended for use in radionuclide cisternography.
O(C(C(O[H])(C(O[H])([H])[H])[H])([H])[H])[H],"DB09462
DB04077",56-81-5,Glycerin,"1,2,3-propanetriol
1,2,3-trihydroxypropane
Glycerin, anhydrous
Glycerin,anhydrous
Glycerine
glyc��rine
Glycerinum
Glycerol
glyc��rol
Glyzerin
Monoctanoin component D
��ls����
Propanetriol
Trihydroxypropane",small molecule,,"Cream
Liquid
Liquid
Liquid
Soap
Solution
Patch
Solution
Cream
Cream
Cream
Liquid
Suppository
Suppository
Cream
Cream
Cream
Kit
Cream
Emulsion
Cream
Gel
Emulsion
Liquid
Gel
Liquid
Gel
Gel
Aerosol, foam
Cream
Solution
Patch
Cream
Liquid
Cream
Cream
Cream
Liquid
Cream
Solution
Cream
Solution
Cream
Patch
Patch
Patch
Patch
Injectable foam
Patch
Patch
Patch
Cream
Patch
Cream
Powder
Solution / drops
Lotion
Lotion
Cream
Cream
Cream
Shampoo
Cream
Gel
Liquid
Shampoo
Cream
Spray
Liquid
Liquid
Cream
Solution
Solution
Liquid
Patch
Emulsion
Solution
Solution
Cream
Cream
Cream
Cream
Liquid
Patch
Patch
Patch
Liquid
Gel
Liquid
Liquid
Liquid
Cream
Solution
Spray
Patch
Liquid
Liquid
Cream
Powder
Cream
Shampoo
Liquid
Patch
Cream
Lotion
Lotion
Gel
Liquid
Gel
Gel
Cream
Cream
Lotion
Cream
Ointment
Spray
Liquid
Cream
Liquid
Cream
Cream
Gel
Cream
Liquid
Cream
Liquid
Solution / drops
Kit
Cream
Cream
Lotion
Liquid
Cream
Cream
Patch
Patch
Patch
Cream
Gel
Kit
Injection, solution
Liquid
Liquid
Cream
Patch
Soap
Cream
Jelly
Cream
Shampoo
Emulsion
Gel
Liquid
Liquid
Liquid
Cream
Liquid
Liquid
Cream
Liquid
Cream
Gel
Liquid
Gel
Liquid
Liquid
Cream
Cream
Spray
Cream
Liquid
Liquid
Lotion
Gel
Gel
Paste, dentifrice
Emulsion
Solution / drops
Gel
Gel
Gel
Cream
Kit
Liquid
Liquid
Cream
Liquid
Liquid
Cream
Liquid
Gel
Cream
Liquid
Cream
Cream
Liquid
Cream
Liquid
Cream
Liquid
Liquid
Liquid
Liquid
Liquid
Cream
Patch
Gel
Patch
Kit
Kit
Swab
Liquid
Patch
Liquid
Gel
Gel
Solution
Cream
Patch
Liquid
Liquid
Lotion
Liquid
Lotion
Cream
Patch
Liquid
Gel
Gel
Spray
Liquid
Cream
Cream
Lotion
Solution
Cream
Liquid
Liquid
Cream
Liquid
Liquid
Liquid
Cream
Cream
Cream
Cream
Cream
Gel
Liquid
Cream
Gel
Patch
Cream
Gel
Patch
Patch
Patch
Cream
Cream
Spray
Liquid
Liquid
Suppository
Suppository
Suppository
Liquid
Liquid
Liquid
Suppository
Suppository
Suppository
Liquid
Cream
Liquid
Liquid
Suppository
Injection
Solution
Gel
Liquid
Cream
Cream
Solution
Cream
Cream
Cream
Cream
Cream
Lotion
Liquid
Solution
Shampoo
Cream
Liquid
Liquid
Solution
Spray
Cream
Cream
Shampoo
Cream
Emulsion
Lotion
Spray
Spray
Cream
Cream
Liquid
Cream
Cream
Cream
Liquid
Cream
Liquid
Emulsion
Emulsion
Solution / drops
Liquid
Lotion
Cream
Cream
Patch
Gel
Liquid
Solution
Cream
Cream
Cream
Liquid
Lotion
Cream
Patch
Liquid
Liquid
Liquid
Liquid
Cream
Powder
Liquid
Swab
Patch
Liquid
Patch
Liquid
Cream
Patch
Liquid
Patch
Gel
Liquid
Cream
Liquid
Liquid
Liquid
Liquid
Cream
Gel
Cream
Liquid
Liquid
Liquid
Gel
Shampoo
Cream
Oil
Liquid
Gel
Cream
Gel
Gel
Gel
Gel
Cream
Swab
Swab
Swab
Swab
Swab
Swab
Solution
Cream
Cream
Cream
Ointment
Soap
Patch
Liquid
Patch
Liquid
Cream
Cream
Cream
Patch
Liquid
Liquid
Spray
Cream
Shampoo
Swab
Patch
Gel
Patch
Enema
Liquid
Patch
Patch
Liquid
Cream
Spray
Lotion
Cream
Gel
Liquid
Emulsion
Cream
Liquid
Paste
Solution
Gel
Cream
Emulsion
Liquid
Liquid
Gel
Soap
Liquid
Emulsion
Cream
Cream
Cream
Cream
Shampoo
Solution / drops
Solution / drops
Solution / drops
Lotion
Liquid
Liquid
Liquid
Soap
Liquid
Liquid
Patch
Liquid
Patch
Gel
Soap
Solution
Solution
Suppository
Liquid
Emulsion
Liquid
Liquid
Liquid
Liquid
Solution
Liquid
Liquid
Cream
Lotion
Cream
Lotion
Lotion
Lotion
Lotion
Cream
Cream
Liquid
Liquid
Solution
Gel
Liquid
Cream
Emulsion
Injection
Spray
Patch
Lotion
Cream
Solution
Shampoo
Liquid
Liquid
Cream
Cream
Emulsion
Cream
Gel
Liquid
Soap
Cloth
Cream
Gel
Emulsion
Solution
Solution
Cream
Cream
Cream
Cream
Cream
Cream
Patch
Patch
Patch
Patch
Cream
Liquid
Liquid
Liquid
Liquid
Liquid
Patch
Liquid
Patch
Liquid
Cream
Cream
Liquid
Cream
Soap
Cream
Lotion
Soap
Cream
Cream
Patch
Gel
Gel
Gel
Gel
Liquid
Cream
Patch
Cream
Liquid
Spray
Cream
Cream
Cream
Cream
Lotion
Lotion
Cream
Patch
Liquid
Cream
Cream
Patch
Liquid
Cream
Cream
Cream
Gel
Patch
Cream
Solution / drops
Cream
Gel
Gel
Cream
Cream
Injection, solution
Injection, solution
Liquid
Cream
Cream
Liquid
Cream
Gel
Cream
Liquid
Solution
Patch
Shampoo
Cream
Solution
Liquid
Injectable foam
Cream
Cream
Cream
Shampoo
Cream
Lotion
Cream
Cream
Lotion
Injectable foam
Cream
Cream
Gel
Cream
Liquid
Cream
Cream
Patch
Cream
Emulsion
Lotion
Cream
Liquid
Liquid
Lotion
Liquid
Cream
Cream
Liquid
Liquid
Liquid
Solution
Cream
Liquid
Liquid
Liquid
Liquid
Gel
Gel
Lotion
Cream
Liquid
Cream
Gel
Cream
Liquid
Cream
Liquid
Gel
Gel
Cream
Cream
Suppository
Cream
Patch
Extract
Patch
Liquid
Cream
Emulsion
Cream
Concentrate
Gel
Gel
Gel
Patch
Lotion
Suppository
Gel
Kit
Liquid
Gel
Liquid
Shampoo
Solution
Cream","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Rectal
Rectal
Topical
Topical
Topical
Oral; Topical
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Auricular (otic)
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Ophthalmic
Ophthalmic
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Intradermal
Topical
Topical
Topical
Topical
Topical
Topical
Enteral
Topical
Topical
Topical
Topical
Rectal
Rectal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Dental
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral; Topical
Buccal; Topical
Topical
Auricular (otic)
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Ophthalmic
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Rectal; Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Rectal
Rectal
Rectal
Topical
Oral; Topical
Rectal
Rectal
Rectal
Rectal
Oral; Topical
Rectal; Topical
Intradermal; Subcutaneous
Oral
Rectal
Cutaneous; Intradermal; Subcutaneous
Unknown
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Ophthalmic
Topical
Topical
Topical
Topical
Topical
Vaginal
Topical
Vaginal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Rectal
Topical
Topical
Topical
Topical
Topical
Oral
Oral
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Oral
Topical
Topical
Topical
Rectal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Vaginal
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Percutaneous
Dental
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Ophthalmic
Ophthalmic
Ophthalmic
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Rectal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Oral
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Intravenous
Topical
Topical
Topical
Topical
Ophthalmic
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Ophthalmic
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Nasal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Ophthalmic
Topical
Topical
Topical
Topical
Topical
Intradermal; Subcutaneous
Intradermal; Subcutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Irrigation
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Rectal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Vaginal
Vaginal
Vaginal
Topical
Topical
Rectal
Topical
Topical
Topical
Vaginal
Vaginal
Topical
Topical
Topical","4 g/200mL
13 mg/mL
.19 g/6.5g
.067 mL/2mL
15 g/100g
10 g/100mL
1.84 g/23mL
1.8 g/101
28 mL/140mL
.08 g/g
.07 mg/mL
.08 mg/mL
1.614 g/1
2 g/1
11.55 g/55mL
24.6 g/120mL
12.1 g/55mL
31.5 g/150mL
4 mg/mL
6 mg/150mL
2.55 g/50mL
1.9 g/50mL
6.2 g/31mL
5.2 g/200mL
16 g/200mL
.54 mg/mL
2.85 g/50g
6.22 g/100mL
1.3 g/26mL
1.8 g/60mL
4.5 g/150mL
5 g/25g
8.81 g/25g
8.006 g/100mL
25 g/100g
5 g/50mL
2.8 g/35mL
1.2 g/20mL
1.65 g/120mL
3 g/30mL
1.89 g/27g
2.7 g/27g
7 g/100g
1.65 g/22mL
12 g/120mL
1.5 g/25g
.8 g/8g
1.2 g/20g
1.8 g/9g
1.7 g/8.5g
.084 g/mL
.0000167 g/g
6 g/100mL
13 g/100mL
11 g/100mL
5 mg/50mL
4 mg/40mL
3.075 g/100g
8.06 g/100g
11.985 g/100g
3.075 g/100mL
3.845 g/100g
6.46 mg/100mL
.075 g/75mL
10 g/100g
3.1406 mL/200mL
4.9947 mL/50mL
9.5 g/100mL
11 g/100mL
2.5 g/100g
1.75 g/25g
9.6 mg/120mL
41.85 mg/150mL
8.13 mg/150mL
1.21 mg/30mL
30 g/150mL
.9 g/30g
1.2 mg/10mL
10.82 g/100mL
1.92 mg/32mL
.6 g/20g
1.8 mg/30mL
8.13 g/100g
13.5 g/45g
.02 g/mL
25 g/100mL
6 mg/150mL
2.7 mg/90mL
19.6 g/200mL
.5 g/50mL
.5 g/25mL
4 g/100g
5 g/100mL
2 g/100g
1.8 g/100mL
.15 g/100mL
.01 g/mL
.01 g/mL
9 g/51
10 g/50g
2 g/100mL
5 g/100g
40 g/100mL
.01 g/100mL
.16 g/160mL
30.75 g/150mL
31.2 g/150mL
32.12 g/400mL
12.9 g/150mL
5 g/100mL
.012 g/100mL
4 g/100mL
.7675 g/100g
6.5 g/100g
15 g/150mL
3 mg/mL
4.8 g/120mL
1.5 mg/30mL
2.5 mg/mL
200 mg/mL
.08 g/mL
.09 g/mL
.08 g/mL
.0433 g/mL
.0279 g/mL
2.1 g/101
2.94 g/101
2.1 g/7.5g
6.88 mg/160mL
5.6 mg/80mL
.525 mL/mL
.04 mg/mL
.08 g/g
1 g/100mL
.22 g/22g
.1 g/100g
7 mg/35mL
19.312 g/48.28g
26 mg/130mL
.001 g/100mL
10 g/100mL
.2 g/100mL
2.8 g/1
5.4 g/1
1 kg/20kg
15.585 g/100mL
11.3 g/100mL
20.009 g/100mL
11.0005 g/100mL
10.05 g/100mL
10.0002 g/100mL
91.16098 g/100mL
26 g/200mL
37.5 g/150mL
30.78 mL/100mL
1.6 g/100mL
4.073 g/100mL
1.77 g/50g
.13 g/100mL
1.9 g/30g
6 g/100g
10.01 g/100mL
2 mL/40mL
3.75 g/15g
.5 g/2g
7.68 g/120g
9.6 g/120mL
.57 g/100mL
5.088 mL/100mL
1.729 g/100g
5.006 g/100mL
2.53045 g/100g
7.05 g/100mL
8.05 g/100mL
1 g/100mL
4.07 g/100mL
4.04 g/100mL
4 g/100mL
.5 g/100mL
8 g/100mL
5 g/100mL
3 g/100mL
6.1000565 g/100mL
7.1270547 g/100mL
3 g/100mL
16 g/100mL
10 g/100mL
6 g/100mL
4.044 g/100mL
.0125 g/mL
6.3 g/18g
35 1/18g
1 g/100mL
1 g/100g
200 mg/.5mL
1.3 g/25mL
4.8 g/160mL
14.4 g/120mL
24 g/120mL
4.97 mg/mL
1 g/25mL
1.75 mg/101
10.87 g/100mL
4.102 g/100mL
10.2 g/100mL
12 g/100g
5 g/100mL
.025 g/100g
10 g/100g
20 g/100g
30 g/100mL
5 g/100mL
5 g/100mL
.935 g/100mL
53.67 g/250mL
4 g/20mL
35 mg/mL
1 g/100g
2 g/100mL
12 g/100mL
.01 g/100mL
.01 g/100mL
.0798 g/mL
11 g/100mL
1 g/100g
4 g/100mL
10.5 mg/mL
31.65 g/155mL
8.15 g/40mL
25 g/100mL
30 mL/150mL
.02 g/2mL
29 mg/145mL
20 g/100g
70.4 mg/1
1.25 mg/25mL
41.85 g/150mL
3.36 g/51
3.36 g/101
3.36 mg/32mL
4.83 g/23mL
4.6 g/23mL
.5 mg/mL
995 mg/mL
1.3 g/1
1.2 g/1
2.1 g/1
100 %
12.5 g/1
2.09 g
1 g
90 %
100 %
100 %
91 %
.53 g/mL
.5 mg/mL
100 mg/mL
10.20052486 g/100g
8.7 g/145mL
6.5 g/130mL
11.7 g/130mL
10 g/100g
1.07 g/20mL
10 g/100mL
3 g/100mL
7 g/100mL
4 mg/mL
3.88 mg/mL
28 %
30 g/150mL
9 g/300mL
15.96 g/120mL
.4 g/40mL
.1 g/100mL
.1 g/100g
.2 g/100mL
4 g/50mL
12 g/120mL
10.5 g/150mL
12 g/150mL
7.2 g/120mL
3.5 g/50mL
2.5 g/50mL
2.00008 g/100mL
11 mg/mL
13 mg/mL
8 mg/mL
5.740794 g/100mL
.175 mg/5mL
.0001 g/mL
.034 g/mL
.02 g/mL
1 g/100mL
2.5 g/250mL
8 g/200mL
1.67 mg/33mL
.66 mg/33mL
20 g/100g
.04 g/g
15 g/100mL
6 g/100g
31 mg/155mL
11.57 mg/50mL
9 mg/45mL
.8 mg/81
28 mg/140mL
5 mg/25mL
5 g/25g
28 mg/140mL
11 g/100g
9 g/100g
8 g/100g
8 g/100g
.1 g/g
.002 g/mL
.25 g/2.5mL
2.5 g/25mL
.3 g/1.5mL
1.08 g/27mL
.1 g/1.5mL
.06 g/1.5mL
1.61 g/30mL
.2 g/1.5mL
1 g/25mL
5.5 g/100mL
10.013 g/100mL
8.013 g/100mL
5 g/100g
3.2 g/100mL
3 g/100g
4.001 g/100mL
18 g/100mL
11 g/100mL
8.001 g/100mL
3.02 g/100mL
5.5 g/100mL
2 g/100mL
2 g/100g
4 g/100mL
1.5 g/100mL
1 g/100mL
4.2 g/100mL
1.5 g/100mL
6.59 g/10mL
8.99 g/10mL
2 g/10mL
2.01 g/10mL
.579998 g/100mL
7.5 1/1
7.5 g/100g
7.5 mL/100mL
.43 mL/10mL
500 mg/mL
7.5 g/100g
1.94 mg/60mL
30 mg/mL
.4 mg/40mL
10 mg/mL
40 mg/g
12 g/60g
8.7675 g/100g
.34 g/17g
.04 g/g
.00007 g/mL
.02 g/mL
.00001 mg/mL
2 g/10g
.24 g/8mL
.5 mg/mL
29.5 mg/mL
.10295 g/mL
2 g/100mL
.075 g/1
.13 g/3g
4.8 g/120mL
.14 g/7g
80 mL/100mL
.0224 g/mL
.16 g/1.6g
3 g/101
.01 g/g
4.2 g/100g
4.8 g/80mL
15 g/300mL
2.005 g/100mL
4 g/100g
.05205 g/mL
.075205 g/mL
11.45 g/50mL
2 g/100g
6 g/100mL
10 g/200mL
8.6 g/200mL
9 g/150mL
.15 g/150mL
50 %
1 g/100g
8.75 g/100g
.8 g/100mL
.29 g/30mL
1.4 g/50mL
1.97 g/30mL
3.14 g/50mL
7.5 g/300g
.2 g/100mL
2 g/1000mL
.25 g/100mL
16 mg/200mL
10.5 g/100g
4.975 g/100mL
19.91 g/100g
12 g/100g
1.01 mg/2.8mL
.58 mg/2.8mL
5.56 mg/27mL
.57 mg/2.8mL
5.55 mg/27mL
180 mg/g
8 g/100g
69.8 g/100mL
1 g/1
.29 g/5mL
3.5 mg/35mL
30 g/100g
2.145 g/100g
3.055 g/100g
3.005 g/100g
7.35 g/30mL
5 g/100g
2 g/100mL
5.05 g/100mL
20 mg/100mL
24 g/120g
.5 g/200mL
3.38 g/200mL
1.22 g/200mL
6.84 g/180mL
37.8 g/180mL
7 g/35mL
.05 g/mL
7 g/100g
2.37 g/40mL
9 g/100mL
4.5 mg/100mL
7 g/100mL
6 g/100mL
.5 g/100mL
7.5 g/30g
4 g/100mL
1.2 g/100mL
.02 mg/mL
.19 g/8g
.8 g/100g
.05 g/100g
2.92 mg/50mL
2.35 mg/125mL
2.55 mg/50mL
9.6 mg/160mL
7.81 mg/150mL
5 g/100g
28 g/140mL
15 g/150g
2.6 g/40mL
.21 mg/121
2.53 mg/150mL
1.87 mg/150mL
.25 g/20mL
7.8 mg/mL
1.98 mg/mL
.25 mg/mL
.8 g/16mL
.56 g/14mL
.33 g/3mL
2 g/25mL
2.04 g/30mL
.100005 g/g
.03 mg/mL
15 g/100g
4 g/200mL
1.5 g/50g
.03 g/g
.05 g/mL
.07 g/mL
.9 g/9g
.02 g/g
.018 mg/mL
.000001 g/g
.5 g/100g
6 g/100mL
.4 g/100mL
.4 g/100g
15 mg/100mL
10 mg/100mL
6 g/100g
5 mg/mL
13.8 mg/100mL
2.661 g/100mL
.02 g/100mL
.1 g/100mL
5.05 g/100g
2.1 g/7g
1.33 mg/30mL
19.2 g/48g
16.8 g/48g
2.49 mL/50mL
9 g/75mL
7.5 g/150mL
6 g/120mL
1.69 mg/60mL
.8 g/101
5.92 g/150mL
3.3 g/50g
5.82 g/60mL
1.96 g/28g
13.5 g/150mL
3.5 g/70g
4.2 g/20g
6 g/30mL
5 g/25g
1.37 mg/101
10 g/50mL
36 g/160mL
60 g/300mL
146.88 g/300mL
5.15 mL/100mL
5.6 g/50g
.5 mL/mL
.06 g/mL
.03 g/mL
.04 g/mL
.16 g/mL
1.6 mg/80mL
4.65 mg/155mL
8 g/40mL
.03 g/mL
2.6 %
1.84 g/23g
.04 g/mL
6 g/30g
.12 mg/101
6 g/200mL
16.5 g/150mL
10.16 g/40mL
.03 g/g
18 g/90mL
2 g/100g
24 g/80g
12742.339 mg/145mL
5926.7425 mg/35mL
5.05 g/50g
8377.386 mg/60mL
1 g/45g
78.1 g/95g
.252 g/45g
5.04 g/30mL
5287.8 mg/140mL
2.1 g/70g
3147.5 mg/50mL
1.5 g/30g
4910.1 mg/50mL
9694.3 mg/140mL
503 mg/50mL
1510.8 mg/140mL
1762.6 mg/140mL
14100.8 mg/140mL
.008 g/100mL
3.5 g/100mL
32.7 g/150mL
.1 g/g
.1 g/mL
.02 mg/mL
.015 g/mL
12.3 g/100mL
.06 g/mL
.04 g/mL
.04 g/5mL
1.005 g/100g
.01 mg/mL
2 g/100mL
15 g/100mL
8.28 g/180mL
.05 g/mL
.001 g/mL
.04 g/g
.015 g/mL
5 mg/mL
.06 g/g
3.43 g/50mL
2.59 g/150mL
91.16 g/100mL
91.16098 g/100g
5 g/100g
4 g/100g
83 g/100g
6 mg/150mL
2.3 g/23mL
13.226 g/100mL
10 g/100mL
.2 g/100mL
.2 g/100mL
2.04 g/100mL
6.2 g/100mL
7 g/100mL
.17 g/g
.306 g/101
.11 g/101
1.57 g/35g
23 %
2.145 g
3.55 g/100mL
.3 g/100mL
.1 g/100mL
.5 g/100mL
2.5 g/100mL
.25 g/5mL
.16 g/8g","It is used as a solvent, emollient, pharmaceutical agent, and sweetening agent."
[O-]C1=C([H])C([H])=C([H])C2=C(C(=C(N=C12)[H])[H])[H],DB09473,65389-08-4,Indium In-111 oxyquinoline,"In-111 oxyquinoline
Indium (111 In) oxyquinoline
Indium (In111) oxine
Indium (In111) oxyquinoline
Indium 111In oxyquinoline
Indium In-111 oxine
Indium In111 oxine
Indium-111 oxine
Indium-111 oxyquinoline",small molecule,,"Solution
Solution","Intravenous
Intravenous","2 mCi/mL
1 ug/mL",Indium In 111 oxyquinoline is indicated for radiolabeling autologous leukocytes.
C(N(C(=O)C(C(=O)N(C([H])([H])[H])C1=C(I)C(C(=O)N(C(C(O[H])([H])[H])(C(O[H])(C(O[H])([H])[H])[H])[H])[H])=C(I)C(C(=O)N(C(C(O[H])([H])[H])(C(O[H])(C(O[H])([H])[H])[H])[H])[H])=C1I)([H])[H])C1=C(I)C(C(=O)N(C(C(O[H])([H])[H])(C(O[H])(C(O[H])([H])[H])[H])[H])[H])=C(I)C(C(=O)N(C(C(O[H])([H])[H])(C(O[H])(C(O[H])([H])[H])[H])[H])[H])=C1I)([H])([H])[H],DB09487,79770-24-4,Iotrolan,"Iotrolanum
Iotrolum",small molecule,,,,,
C(C1=C([H])C([H])=C(C(=C(C(N2C([H])([H])C([H])([H])C([H])([H])C2([H])[H])([H])[H])[H])C2=C([H])C([H])=C([H])C(C(=C(C(O[H])=O)[H])[H])=N2)C([H])=C1[H])([H])([H])[H],DB09488,87848-99-5,Acrivastine,(2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}acrylic acid,small molecule,,Capsule,Oral,,"For the relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion."
Cl[In](Cl)Cl,DB09490,50800-85-6,Indium In-111 chloride,"111indium trichloride
Indium chloride (111incl3)
Indium chloride In-111
Indium In 111 chloride
Indium In 111m chloride
Indium In-111m chloride
Indium-111 chloride",small molecule,Humans and other mammals,"Solution
Solution
Kit","Intravenous
Intravenous","5 mCi/.5mL
10 mCi/mL",Indium In-111 Chloride is indicated for radio labeling of monoclonal antibodies in preparations used for in vivo diagnostic imaging procedures. Indiclor is also indicated for radiolabeling Zevalin in preparations used for radio immunotherapy procedure
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB09494,36653-82-4,Cetyl alcohol,"hexadecan-1-ol
palmityl alcohol",small molecule,,Lotion,Topical,80 mg/100mL,"No therapeutic indications in medicinal products. Indicated to be used as an indirect additive in food contact substances, or an ingredient in commercial or cosmetic products. "
C(OC1=C([H])C([H])=C(C(=O)C(C(=O)C2=C([H])C([H])=C(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C([H])=C2[H])([H])[H])C([H])=C1[H])([H])([H])[H],DB09495,70356-09-1,Avobenzone,"Butyl Methoxydibenzoylmethane
Parsol 1789",small molecule,,"Gel
Lotion
Cream
Salve
Aerosol
Kit
Cream, augmented
Gel
Cream
Spray
Cloth
Gel; kit; lotion
Aerosol, foam
Lotion
Jelly
Kit; stick
Kit
Soap
Spray
Lipstick
Solution
Ointment
Tablet
Aerosol, spray
Kit
Suspension
Cream
Cream
Powder
Kit; lotion
Cream; kit
Stick
Emulsion
Liquid
Spray
Paste
Kit
Liquid; spray
Oil","Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Oral
Topical
Topical
Topical","30 mg/mL
.64 g/90mL
100 g/3g
3 g/100g","Sun protection factor, added in the sunscreen products for its wide spectrum ultraviolet absorption properties. "
O(S(O[H])(=O)=S)[H],DB09499,13686-28-7,Thiosulfuric acid,"Monosulfanemonosulfonic acid
Sulfurothioic S-acid",small molecule,Humans and other mammals,"Lotion
Kit
Solution
Powder
Capsule
Injection, solution
Liquid
Solution","Topical
Intravenous
Oral; Topical
Oral
Intravenous
Intravenous
Intravenous","250 mg
250 mg/mL
250 mg
25 %","Antidote: Sodium thiosulfate is indicated to counteract or neutralize actions of poisons, e.g. cyanide poisoning. 
Antineoplastic adjunct: "
C(OC1=C([H])C([H])=C(O[H])C([H])=C1[H])([H])([H])[H],DB09516,,Mequinol,4-Methoxyphenol,small molecule,,Solution,Topical,,
O(C1=C([H])C([H])=C(O[H])C([H])=C1[H])[H],DB09526,123-31-9,Hydroquinone,"1,4-benzenediol
1,4-dihydroxybenzene
4-Hydroxyphenol
benzene-1,4-diol
p-Benzenediol
p-Hydroquinone
p-hydroxyphenol
quinol",small molecule,,"Gel
Gel
Gel
Cream
Liquid
Cream
Gel
Lotion
Cream
Cream
Lotion
Kit
Cream
Cream
Lotion
Lotion
Lotion
Cream
Cream
Cream
Cream
Lotion
Gel
Lotion
Gel
Gel
Lotion
Cream
Cream
Cream
Cream
Cream
Cream
Cream
Cream
Emulsion
Emulsion
Cloth
Cream
Liquid
Gel
Cream
Emulsion
Kit
Liquid
Liquid
Solution
Lotion
Lotion
Cream
Lotion
Lotion
Lotion
Lotion
Kit
Cream
Liquid
Gel
Kit
Cream
Liquid
Liquid
Liquid
Liquid
Lotion
Cream
Gel
Gel
Lotion
Cream
Liquid
Liquid","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","2 g/100g
2 %
20 mg/mL
1 g/50g
20 mg/mL
2 g/100mL
2 g/14.25g
4 g/100mL
10 mL/500mL
10 mL/500mL
2 g/100mL
4 %
.02 mg/g
2 g/100mL
40 mg/g
2 %
20 mg/g
1.5 %
4 mL/200mL
4 mL/200mL
.02 g/g
2 %
20 mg/g
40 mg/g
20 mg/mL
100 mg/5mg
5 mg/100mg
1 g/50mL
2 g/50mL
2 g/100g
40 mg/g
40 mg/mL
1.9 g/100g
.02 g/g
.04 g/g
2 g/100mL
.04 g/g
30 mg/mL
1.695 g/113g
40 mg/g
40 mg/g
40 mg/mL
40 mg/mL
.05 mg/2.5mL
1.95 1/100mL
.02 g/g
2 mg/100mL
.015 g/g
.04 g/g
1.2 mL/60mL
2 mL/100mL
4 g/100mL
4 %
2 mg/100mL
2 mL/100mL
8 g/100g
.02 g/g
.08 g/g
.02 g/g
19 mg/g
.6 g/30g
1 g/50g
1 g/51g
2 g/100mL
40 g/2mL","Hydroquinone is used as an OTC topical lightening agent for disorders of hyperpigmentation including melasma, post-inflammatory hyperpigmention, sunspots and freckles. "
C(C1(C([H])([H])[H])C2(C(C([H])([H])C1(C(S(O[H])(=O)=O)([H])[H])C(=O)C2=C(C1=C([H])C([H])=C(C(=C2C3(C(C([H])([H])C(C(S(O[H])(=O)=O)([H])[H])(C3(C([H])([H])[H])C([H])([H])[H])C2=O)([H])[H])[H])[H])C([H])=C1[H])[H])([H])[H])[H])([H])([H])[H],DB09534,92761-26-7,Ecamsule,Terephthalylidene dicamphor sulfonic acid,small molecule,Humans and other mammals,"Aerosol
Spray
Stick
Gel
Cream
Lotion
Emulsion
Liquid","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical",,Applied topically to filter out UVA rays.
O=[Ti]=O,DB09536,13463-67-7,Titanium dioxide,,small molecule,,"Solution
Cream
Cream
Cream
Powder
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Powder
Powder
Powder
Powder
Powder
Powder
Powder
Powder
Liquid
Liquid
Liquid
Liquid
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Powder
Powder
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Lipstick
Powder
Stick
Stick
Stick
Stick
Stick
Stick
Powder
Powder
Powder
Powder
Cream
Cream
Cream
Cream
Lotion
Cream
Powder
Cream
Stick
Kit
Liquid
Powder
Liquid
Cream
Cream
Cream
Cream
Powder
Cream
Cream
Cream
Cream
Cream
Cream
Cream
Liquid
Cream
Cream
Cream
Cream
Powder
Stick
Lotion
Lotion
Lotion
Lotion
Lotion
Powder
Cream
Aerosol
Cream
Lotion
Liquid
Liquid
Liquid
Powder
Poultice
Powder
Powder
Cream
Powder
Cream
Cream
Cream
Liquid
Cream
Cream
Powder
Cream
Lotion
Cream
Cream
Cream
Cream
Powder
Powder
Spray
Cream
Cream
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Powder
Powder
Powder
Powder
Powder
Liquid
Powder
Powder
Powder
Powder
Powder
Cream
Cream
Cream
Lotion
Stick
Lotion
Cream
Paste
Cream
Cream
Cream
Cream
Cream
Powder
Stick
Stick
Stick
Stick
Liquid
Liquid
Liquid
Cream
Cream
Cream
Cream
Emulsion
Liquid
Emulsion
Cream
Solution
Liquid
Liquid
Liquid
Solution
Solution
Stick
Paste
Paste
Cream
Cream
Cream
Stick
Powder
Cream
Cream
Powder
Cream
Cream
Cream
Cream
Suspension
Suspension
Suspension
Cream
Lipstick
Cream
Cream
Cream
Gel
Cream
Lotion
Lotion
Lotion
Lotion
Lotion
Cream
Lotion
Powder
Cream
Lotion
Powder
Cream
Cream
Cream
Cream
Powder
Powder
Liquid
Powder
Liquid
Liquid
Powder
Cream
Cream
Liquid
Cream
Lotion
Lotion
Cream
Lotion
Stick
Cream
Powder
Liquid
Lotion
Lotion
Suspension
Stick
Lotion
Liquid
Liquid
Liquid
Liquid
Lotion
Cream
Cream
Cream
Oil
Cream
Cream
Cream
Cream
Cream
Cream
Cream
Cream
Cream
Paste
Cream
Cream
Powder
Powder
Stick
Liquid
Stick
Emulsion
Emulsion
Emulsion
Powder
Cream
Cream
Stick
Cream
Cream
Cream
Cream
Powder
Cream
Lotion
Lotion
Cream
Emulsion
Cream
Cream
Cream
Cream, augmented
Lotion
Lotion
Lotion
Spray, suspension
Liquid
Powder
Powder
Powder
Powder
Cream
Cream
Lotion
Cream
Cream
Cream
Powder
Paste
Powder
Lotion / shampoo
Lotion
Emulsion
Cream
Liquid
Liquid
Cream
Cream
Cream
Cream
Cream
Powder
Powder
Liquid
Cream
Cream
Powder
Cream
Cream
Suspension
Lotion
Spray
Emulsion
Lotion
Cream
Cream
Lotion
Gel
Cream
Lotion
Cream
Lotion
Lotion
Lotion
Cream
Cream
Powder
Cream
Cream
Cream
Cream
Powder
Cream
Cream
Cream
Cream
Cream
Cream
Cream
Cream
Liquid
Cream
Cream
Cream
Cream
Cream
Liquid
Liquid
Powder
Lipstick
Powder
Lotion
Lotion
Liquid
Lotion
Lotion
Lotion
Cream
Lotion
Powder
Liquid
Cream
Cream
Emulsion
Emulsion
Emulsion
Lotion
Cream
Cream
Cream
Lotion
Lotion
Lotion
Cream
Powder
Cream
Emulsion
Emulsion
Lotion
Cream
Cream
Cream
Powder
Cream
Powder
Cream
Cream
Cream
Lotion
Lotion
Powder
Powder
Powder
Powder
Powder
Powder
Powder
Powder
Powder
Cream
Cream
Cream
Cream
Powder
Cream
Cream
Lotion
Cream
Cream
Powder
Cream
Liquid
Liquid
Stick
Liquid
Liquid
Powder
Powder
Powder
Paste
Cream
Cream
Cream
Lotion
Liquid
Cream
Lotion
Cream
Lotion
Lotion
Powder
Powder
Powder
Powder
Powder
Cream
Emulsion
Emulsion
Emulsion
Cream
Liquid
Stick
Stick
Stick
Stick
Cream
Lotion
Powder
Aerosol, foam
Cream
Cream
Cream
Powder
Lotion / shampoo
Lotion
Spray, suspension
Lotion / shampoo
Stick
Aerosol, spray
Powder
Lotion
Lotion
Lotion
Cream
Liquid
Sponge
Cream
Cream
Lotion
Lotion
Cream
Cream
Cream
Cream
Lotion
Lotion
Aerosol; lotion
Lotion
Aerosol; lotion
Lotion
Cream
Cream
Powder
Cream
Paste
Emulsion
Liquid
Cream
Cream
Cream
Lotion
Liquid
Patch
Powder
Cream
Lotion
Lotion
Emulsion
Cream
Cream
Lotion
Lotion
Lotion
Lotion
Ointment
Lotion
Lotion
Stick
Liquid
Stick
Cream
Cream
Cream
Cream
Cream
Cream
Powder
Lotion
Lotion
Kit
Kit
Lotion","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Cutaneous
Cutaneous
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Cutaneous
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Cutaneous
Cutaneous
Cutaneous
Cutaneous
Cutaneous
Cutaneous
Cutaneous
Topical
Topical
Cutaneous
Topical
Cutaneous
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","1.44 g/40g
3.71 mg/40mL
2.78 mg/30mL
.57 g/8g
.02 g/4.5g
.11 g/4.5g
.15 g/4.5g
.16 g/4.5g
.17 g/4.5g
.18 g/4.5g
.03 g/4.5g
.22 g/4.5g
.13 g/4.5g
.09 g/4.5g
.08 g/1.1g
.01 g/1.1g
.26 g/1.1g
.23 g/1.1g
.22 g/1.1g
.04 g/1.1g
.07 g/5g
.31 g/5g
.37 g/5g
.12 g/5g
.67 g/8g
.68 g/8g
.47 g/8g
.52 g/8g
.16 g/6g
.06 g/6g
.19 g/6g
.65 g/5mL
.02 g/3.5g
.12 g/3.5g
.05 g/3.5g
.17 g/3.5g
.04 g/3.5g
.07 g/3.5g
.2 g/3.5g
.1 g/3.5g
.15 g/3.5g
.29 g/3.5g
.14 g/3.5g
.13 g/3.5g
.014 g/3.5g
.01 g/3.5g
1.03 g/11g
1.63 g/11g
.11 g/g
.129 g/g
.03 g/g
.097 g/g
.107 g/g
.005 g/g
.081 g/g
.12 g/25g
.47 g/10g
.4 g/10g
.85 mg/.085g
.015 g/.085g
.017 g/.085g
.005 g/.085g
.42 g/3.5g
.3 g/3.5g
.23 g/3.5g
.36 g/3.5g
78.6 mg/mL
121.6 mg/mL
77.2 mg/mL
5 %
2.4 %
1.8 %
1.7 g/12g
2.46 g/30mL
8.8 %
8.9 %
9.8 g/100g
45 mL/100mL
6.4 %
8 %
7.3 %
7.6 %
6.9 g/100g
1.72 g/50g
2.6 g/50g
115.2 mg/mL
.0934 g/g
4.64 mL/50mL
40.25 mg/mL
7.5 %
4.4 %
18.8 mg/mL
4.8 %
2.5 %
2.5 %
2.2 %
6.48 %
8.1 %
9.72 %
6 g/100mL
10 g/100g
8.46 g/100g
170 mg/mL
60 mg/mL
33.2 mg/mL
110 mg/mL
62 mg/mL
25 g/100g
12 g/100g
1.2 g/10g
.3 g/2g
20 g/100g
3.42 g/30mL
47 mg/mL
3.85 g/100mL
0.038 mg
3.25 g/35mL
3.69 g/40g
24 g/100g
4.33 %
10.145 %
69 mg/mL
6.45 g/100g
6.4 g/100g
12.1 mg/100mL
6 g/100g
8.4 g/100g
15.8 g
19.8 g
6.2 g
5.7 g
7.7 g
8.2 g
8.4 g
7.5 g
7.3 g
7 g
6.2 g
11.1 g
5.6 g
.89 g/5g
.98 g/5g
.55 g/5g
.67 g/5g
.28 g/5g
120 mg/mL
8.5 g/100mL
36.5 mg/mL
10.157 g/100g
5.8 %
5.8 g/100g
11.2 %
8.8 %
8.2 %
14.85 %
9.9 %
15 g/100g
10.0 %
4 g/100g
4 %
7.5 %
47 mg/mL
20 mg/mL
25 mg/mL
70 mg/mL
68 mg/mL
63 mg/mL
23 mg/mL
62 mg/mL
19 mg/mL
30 mg/mL
84 mg/mL
18.9 mg/mL
18.9 mg/mL
81 mg/mL
70 mg/mL
70 mg/mL
81 mg/mL
80 mg/5g
684 mg/12g
1.896 g/12g
.65625 g/31.25g
656 mg/31.25g
3960 mg/40g
1.31 g/8g
12.1 %
24 %
13.8 %
4.2 %
50 mg/mL
75 mg/mL
2 mL/100mL
20 %
11.8 %
8.5 %
4.0 %
1.52 g/6.5g
1.8 g/100g
9 g/100g
4.9 mg/.1g
49 mg/g
7.8 mL/100mL
3.225 %
2 %
10 mg/mL
104 mg/mL
.97 mL/100mL
68 mg/mL
30 mg/g
61 mg/mL
3 %
71 uL/mL
210 mg/2mL
5.53 g/100g
21.9 mg/mL
1 mg/mL
1.38 g/50mL
2.905 g/100mL
5.8 %
.494 g/13g
5 mL/100mL
2.2 g/100g
4.2 mL/100mL
1 mL/100mL
4 g/100g
10.08 g/100g
4.2 mg/100mg
4.05 g/50g
2.14 g/60mL
5 g/100g
9 %
2 mL/100mL
.04 g/g
3.5 g/35g
3.7 %
3.5 %
7.2 %
12 %
3 %
5 g
53.9 mg/mL
97 mg/mL
83 mg/mL
84 mg/mL
78 mg/mL
4.03 g
5.6601 g/100mL
4.2 g/100mL
10 mL/100mL
5 g/100mL
5 g/100mL
7.5 g/100mL
1.35 g/45g
3 g/100g
3.15 g/45g
7 g/100g
3.168 g/45g
6.8 %
3.4 %
4.2 g/100g
4.01 mL/35mL
2.35 g/10g
2.35 g/10g
20 mg/g
4 %
23 g/100g
10.4 %
5.68 %
6.37 %
1.96 g/100g
20.78 %
31.6 mg/mL
2.886 g/60g
1.77 mL/100mL
765 mg/9g
4.48 g/45g
5 %
54 mg/mL
25.8 mg/mL
37.4 mg/mL
74 mg/mL
.38 mg/45mL
121.6 mg/g
1.5 g/50g
110 mg/mL
78.5 mg/mL
150 mg/mL
7.8 g/100mL
5 %
1.179423 g/9g
.895536 g/9g
.9558 g/12g
13.1 g/100g
86.4 mg/mL
106.6 mg/mL
5.5 mL/50mL
1.26 g/50mL
11 %
2.4 g/30g
.05 g/g
.55 g/11g
8 %
2.8 mL/40mL
2.522 g/25mL
2.31 g/20mL
3.09 g/30mL
115 mL/L
153.2 mg/mL
154.3 mg/mL
151.4 mg/mL
5.35 g/100mL
3.0 %
100 mg/g
32.6 mg/mL
61 mg/g
12.1 g/100g
.92 g/13g
11.8 g
5.269 g/100mL
33.9 mg/mL
4.9 %
1.8 mL/30mL
2.7 %
19.9 mL/100mL
11.5 mg/mL
15.3 mg/mL
80 mg/mL
70 mg/mL
2 %
4.2 g/100mL
.04601 g/mL
4.3 mL/100mL
3.8 g/100g
16 g/100g
7 g/100g
7.5 mg/g
3.77 mL/50mL
9.3 mg/g
3.25 mL/35mL
.98 g/11g
3.5 mL/50mL
3.57 mL/50mL
2.28 g/10g
4 %
1.19 mL/35mL
12 %
1.36 mL/50mL
1.98 g/17g
5.85 g/50mL
.1175 1/50mL
1.45 mL/50mL
95 mg/g
18.8 mg/g
24 mg/mL
66 mg/mL
75 mg/g
41.1 mg/g
28 mg/mL
29 mg/mL
32 mg/mL
9.1 %
7.25 %
480 mg/mL
77 mg/mL
7.6 mL/100mL
2.1 g/100g
2.4 mL/100mL
1.18 mL/60mL
2.1 mL/60mL
.65 g/g
.66 g/g
85 mg/g
22 %
.8 g/35mL
.87 mL/35mL
3.95 g/100g
102 mg/mL
76.5 mg/mL
2.94 g/70mL
2.06 g/12g
39 mg/mL
.93 mL/30mL
31 mg/mL
.2625 mg/2.5mL
7.2 g
1.52 g/7g
1.68 g/12g
1.68 g/12g
3.26 g/35mL
8.0 %
16 %
.02 g/20g
4 mg/100mL
4 mL/100mL
4.7 mL/100mL
.24 g/10g
2.38 g/10g
.07 g/g
.21 g/g
1.43 g/6g
.358 g/8.33g
.38 g/4.25g
.72 g/8g
.387 g/4.3g
6 mg/100mL
2.6 mg/100mL
2.96 mg/100mL
2.59 g/50g
.84 g/12g
1.4 mL/100mL
956.25 mg/4.25g
4 g/100g
2.32 g/25g
12.5 %
2 %
11.5 %
7.4 %
5.2 %
4.8 %
6 %
8.60 %
11.00 %
14.3 %
3.5 %
4 mg/mL
52.8 mg/mL
61.6 mg/mL
9.1 %
5.6 g/100mL
5.6 g/100mL
100 mg/mL
40 uL/mL
6.96 %
2.866 g/44.4mL
5 g/100mL
.54 g/12g
864 mg/12g
540 mg/12g
22.7 %
24.6 %
10.7 %
12.7 %
11.45 %
11.1 %
1488 mg/36.3g
13.9 %
250 mg/10g
410 mg/10g
.6 g/9g
.55 g/9g
.04 g/5.5g
6.9 g/100mL
3 g/100g
9.7 %
8.86 %
3.1 g
.7 g/10g
80 mg/mL
8.46 %
120 mg/g
170 mg/g
4.5 %
1 g/66mL
1 g/88mL
1 g/.88mL
12 mg/mL
4.7 mL/100mL
8.1 %
9.72 %
10 %
5.67 %
6.1 %
3.9 %
8.9 %
6.5 %
5.6 %
10.4 %
4.86 %
4.1 %
3.9 %
4.82 %
1.6 mL/30mL
25 mg/mL
6.3 g/100g
17.5 %
17 %
29.2 mg/mL
29.2 mg/mL
3.5 g/100g
4.65 g/100g
.81 g/45g
4 %
5 g/100mL
.001 g/30g
2.381 g/10g
8.3 g/100g
45 mg/mL
50 mg/mL
68 mg
1.5 g
19 mg/mL
4.8 %
6.83 %
4000 mg/50mL
81 mg/mL
6.8 %
6 %
24.15 g/100g
156.752 mg/mL
.002 g/3.5g
4.3 %
25 g/100g
3.8 g/100mL
2.05 mg/100mL
1.02 mg/50mL
.5 mL/100mL
2 g/100g
1.809 mL/30mL
.08 g/g
82 mg/mL","In the pharmaceutical industry, titanium dioxide is used in most sunscreens to block UVA and UVB rays, similar to zinc oxide. It is also commonly used as pigment for pharmaceutical products such as gelatin capsules, tablet coatings and syrups."
C(OC(=O)C1=C(O[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB09543,119-36-8,Methyl salicylate,"2-(Methoxycarbonyl)phenol
2-Carbomethoxyphenol
2-Hydroxybenzoic acid methyl ester
Betula oil
Gaultheria oil
Methyl 2-hydroxybenzoate
Methyl o-hydroxybenzoate
Natural wintergreen oil
Oil of wintergreen
Spicewood Oil
Sweet birch oil
Teaberry oil",small molecule,Humans and other mammals,"Aerosol, spray
Rinse
Spray
Mouthwash
Solution
Oil
Powder
Lotion
Lotion
Spray
Gel
Salve
Liquid
Oil
Ointment
Cream
Patch
Paste
Liquid
Solution
Liquid
Stick
Oil
Ointment
Kit
Liquid
Ointment
Oil
Patch
Lotion
Mouthwash
Liniment
Jelly
Gel
Lotion
Emulsion
Liquid
Gel
Patch
Aerosol, spray
Aerosol, foam
Plaster
Plaster
Liquid
Kit
Liquid
Patch
Patch
Mouthwash
Emulsion
Cream
Patch
Ointment
Ointment
Cream
Oil
Liquid
Plaster
Poultice
Poultice
Liquid","Cutaneous; Topical; Transdermal
Oral
Topical
Buccal
Topical
Percutaneous; Topical; Transdermal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous; Topical; Transdermal
Topical
Topical
Transdermal
Oral
Topical
Topical
Topical
Oral; Topical
Respiratory (inhalation)
Topical
Topical
Topical
Topical
Oral
Topical
Nasal
Topical
Topical
Topical
Topical
Percutaneous; Topical; Transdermal
Percutaneous; Topical; Transdermal
Percutaneous; Topical; Transdermal
Percutaneous; Topical; Transdermal
Transdermal
Topical
Cutaneous; Topical; Transdermal
Topical
Topical
Topical
Dental
Topical
Topical
Transdermal
Topical
Topical
Topical
Transdermal
Topical
Topical; Transdermal
Transdermal
Transdermal
Topical","23 g/100g
10 g/g
10 g/100mL
250 mg/mL
980 mg/mL
3 g/100mL
60 g/100mL
13.5 g/100g
10.5 g/100g
105 mg/mL
105 mg/g
20 g/100g
40 g/100mL
10 g/100g
10 mg/100mg
10 g/100g
10 %
100 mg/g
10.5 g/90g
15.75 g/150g
160 mg/17g
105 mg/17.5g
200 mg/g","Ointments or liniments containing methyl salicylate are applied topically as counter irritant for relief of acute pain associated with lumbago,sciatica and rheumatic conditions. Local analgesics for human and veterinary medicine."
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C([N+](C([H])([H])[H])(C([H])([H])[H])C(C(N(C(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])([H])[H])C1=NC([H])=C([H])C([H])=N1)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB09552,25466-36-8,Thonzonium,Tonzonium,small molecule,,Suspension,Auricular (otic),,Used as a monocationic surfactant and detergent to help penetration of active ingredients through cellular debris for its antibacterial action.
O([Se](O[H])(=O)=O)[H],DB11068,7783-08-6,Selenic acid,,small molecule,,"Capsule
Tablet","Oral
Oral",,
O(C1=C(C(=O)OC2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C([H])C([H])=C1[H])[H],DB11071,118-55-8,Phenyl salicylate,,small molecule,,"Capsule
Tablet
Liquid","Oral
Oral
Oral",,
F[H],DB11072,7664-39-3,Hydrofluoric acid,,small molecule,,"Gel
Aerosol, foam
Disc
Aerosol","Dental
Dental
Topical
Dental",,
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C([N+]1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],"DB11073
DB05748",7773-52-6,Cetylpyridinium,,small molecule,,"Solution
Spray
Mouthwash
Rinse
Rinse
Rinse
Mouthwash
Liquid
Mouthwash
Mouthwash
Liquid
Mouthwash
Rinse
Spray
Liquid
Lozenge
Lozenge
Mouthwash
Mouthwash
Liquid; mouthwash
Solution
Solution
Mouthwash
Rinse
Rinse
Mouthwash
Rinse
Rinse
Rinse
Rinse
Rinse
Mouthwash
Rinse
Mouthwash
Liquid
Mouthwash
Ointment
Lozenge
Powder
Mouthwash
Paste
Liquid
Liquid
Lozenge
Rinse
Spray
Spray
Liquid; mouthwash
Rinse
Mouthwash
Liquid
Mouthwash
Mouthwash
Liquid
Liquid
Kit
Kit
Mouthwash
Spray
Lozenge
Aerosol","Topical
Topical
Oral
Oral
Oral
Oral
Oral
Oral; Topical
Buccal
Buccal
Dental
Topical
Oral
Oral
Oral
Oral
Oral
Buccal
Buccal
Buccal
Buccal
Oral
Buccal
Dental
Dental
Dental
Oral
Topical
Oral
Oral
Oral
Buccal
Oral
Oral
Dental
Oral
Topical
Oral
Topical
Oral
Dental
Oral
Buccal; Topical
Buccal
Oral
Topical
Topical
Oral
Dental
Oral
Oral
Buccal; Topical
Oral
Dental
Topical
Buccal
Topical
Oral
Oral; Topical",".7 mg/mL
.07 mL/100L
.07 kg/100L
.7 mg/mL
.07 kg/100L
0.05 %
.5 mg/mL
.7 mg/mL
.3394 g/473mL
.825 mg/mL
.85 mg/mL
.05 g/100mL
1.4 mg
0.5 mg
0.07 %
.283 g/473mL
0.075 %
.75 mg/mL
15 mg/20mL
10.5 mg/20mL
.5 mg/mL
.7 mg/mL
.014 g/mL
.02 g/20mL
.014 g/20mL
0.07 %
.05 g/mL
0.07 %
.005 g/100mL
.07 g/mL
1.34 mg
.7 mg/mL
1 mg/100mL
.05 mL/100mL
.05 g/100g
.05 %
.07 g/100g
.05 %
.001 mL/mL
.47 mL/474mL
500 ug/mL
0.05 %
.027 mL/60mL
1.5 mg",
O(C(C(N(C(C(O[H])([H])[H])([H])[H])C(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])[H],DB11079,2174-16-5,Trolamine salicylate,,small molecule,,"Cream
Ointment
Cream
Lotion
Spray
Spray
Cream
Spray
Liquid
Gel
Lotion
Lotion
Cream
Cream
Cream
Cream
Patch
Gel
Cream
Cream
Patch
Cream
Lotion
Liquid","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical","10 g/100mL
13.3 %
10 g/100g
10 %
100 mg/mL
.1 g/100mL
8.5 g/85g
10 g/100mL
10 g/100g
15 %
10.0 %
13.3 %
15 %
100 mg/g
12.5 %
10 g/1
20 %
10 %
10 g/100mL
100 mg/mL","Indicated for the temporary relief of aches, and pains of muscles and joints associated with backache, lumbago, strains, bruises, sprains and arthritic or rheumatic pain, pain of tendons and ligaments [L1791]."
[O-][N+](=O)O[Ag],DB11080,,Silver nitrate,,small molecule,,"Stick
Liquid
Liquid
Liquid
Solution
Swab
Swab","Topical
Topical
Topical
Topical
Topical
Topical
Topical",".025 g/g
.1 g/10g
.25 g/10g
.005 g/mL
75 mg/mg",
Cl[Al](Cl)Cl,DB11081,7446-70-0,Aluminum chloride,Aluminium chloride,small molecule,,"Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Gel
Solution
Liquid
Liquid
Packing
Packing
Gel
Solution
Gel
Solution
Solution
Cream
Packing
Liquid
Solution
Solution
Liquid
Spray
Lotion
Liquid","Topical
Topical
Topical
Topical
Topical
Dental
Topical
Dental; Oral; Topical
Dental
Dental
Dental; Topical
Dental
Topical
Dental
Topical
Topical
Topical
Topical
Dental
Dental
Topical
Dental
Topical
Epidural
Topical
Topical","15 g/100mL
20 %
.12 mg/mL
12 mg/mL
25 %
150 mg/mL
8.75 g/35g
100 mg
250 mg
1 mg
1 mg
200 mg
7500 mg/30mL
15 g/100mL
15 g/100mL
250 mg/g
140 mg/mL
250 mg/g
.0625 g/g
5.325 g/35.5mL
15 mg/mL",
O(C1=C([H])C(O[H])=C([H])C([H])=C1[H])[H],DB11085,108-46-3,Resorcinol,,small molecule,,"Gel
Paste
Liquid
Lotion
Cream
Ointment
Ointment","Topical
Topical
Topical
Topical
Topical
Rectal
Topical",,
O(O[H])[H],DB11091,7722-84-1,Hydrogen peroxide,,small molecule,,"Spray
Mouthwash
Paste, dentifrice
Liquid
Liquid
Gel
Solution
Spray
Liquid
Spray, metered
Cream
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Lotion
Solution
Solution
Solution
Solution
Solution
Solution
Spray
Spray
Spray
Liquid
Liquid
Liquid
Liquid
Liquid
Solution
Solution
Liquid
Mouthwash
Liquid
Liquid
Liquid
Mouthwash
Gel
Liquid
Mouthwash
Rinse
Swab
Gel, dentifrice
Gel
Kit
Cloth
Mouthwash
Rinse
Paste, dentifrice
Kit
Liquid
Spray
Liquid
Spray, metered","Topical
Oral
Dental
Topical
Topical
Dental
Topical
Topical
Topical
Topical
Topical
Oral
Oral; Topical
Oral; Topical
Topical
Topical
Topical
Topical
Oral; Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Dental
Oral
Oral
Oral
Oral
Dental
Dental
Buccal
Buccal
Topical
Dental
Oral
Topical
Topical
Dental
Dental
Oral
Topical
Oral
Topical","3 g/100mL
150 mg/100L
3 mL/100mL
3 g/100mL
8.57 g/100mL
40 mg/100mg
30 mL/L
3 g/100g
3.54 mL/119mL
1.5 %
.015 mg/mL
2.65 mL/100mL
3 mL/100mL
.3 kg/100L
30 mL/L
8.57 g/100mL
3 kg/100L
3 mL/100mL
.03 mL/mL
.3 kg/100L
3 mL/100mL
3 mg/100mL
30 mg/mL
3.57 mL/118mL
30 mg/mL
43.275 g/L
6 g
2.65 mL/100mL
6 ml
6 %
3 %
3 g
3 %
30 mg/mL
15 mg/mL
15 mg/mL
.015 mL/mL
1.5 %
17 mg/g
1.7 %
15 mg/mL
15 mg/mL
30 mg/mL
35 mL/100mL
3 g/100g
.03 mL/mL
1588 mg/mL
.15 mL/100mL
2.14 g/100g
1.5 %
3 mL/100mL
.42 g/15g
3.57 mL/119mL",
C(C(C([H])([H])[H])(C1(C([H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])C1(OC(=O)C1=C(N([H])[H])C([H])=C([H])C([H])=C1[H])[H])[H])[H])([H])([H])[H],DB11096,134-09-8,Meradimate,"Menthyl anthranilate
Menthyl-O-aminobenzoate",small molecule,,"Ointment; stick
Spray
Lotion
Ointment
Stick
Cream
Lipstick
Lotion
Liquid","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical",,
FS(F)(F)(F)(F)F,DB11104,2551-62-4,Sulfur hexafluoride,"hexafluoridosulfur
Sulfur fluoride
sulfur(6+) fluoride
sulfur(VI) fluoride
Sulphur hexafluoride",small molecule,Humans and other mammals,"Kit
Injection, powder, for solution
Powder, for suspension","Intravenous
Intravenous","8 ��l/ml
8 mcl","Echocardiography: Sulfur hexafluoride is indicated for use in adult patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricularendocardial border. 
Ultrasonography of the Liver: Sulfur hexafluoride is indicated for use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions."
C(N1C2=C(N=C(Br)N2[H])C(=O)N(C([H])([H])[H])C1=O)([H])([H])[H],DB11106,606-04-2,Pamabrom,,small molecule,,"Capsule
Capsule, liquid filled
Tablet, film coated
Tablet
Capsule
Capsule
Tablet, film coated
Tablet, coated
Tablet","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","50 mg/1
50 mg/1
50 mg/1
50 mg
50 mg",
ClCl,DB11109,,Chlorine,,small molecule,,"Powder, for solution",Topical,.16 g/2g,
O(S(=O)(=O)C1=C([H])C2=C(N=C(N2[H])C2=C([H])C([H])=C([H])C([H])=C2[H])C([H])=C1[H])[H],DB11115,27503-81-7,Ensulizole,phenylbenzimidazole sulfonic acid,small molecule,,"Spray
Liquid
Emulsion
Liquid
Jelly
Liquid
Liquid
Gel
Lotion
Cream
Liquid
Gel
Lotion
Powder
Suspension
Spray
Cream
Gel
Kit
Emulsion
Cream
Cream; liquid","Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical",".03 mg/mL
3 %
3 g/100mL
40 mg
30 mg/mL
3.2 %
1 %
1 %
3.5 %
4 %",Indicated to be used as an UV-B-absorbing molecule in sunscreen formulations. 
C(C1=C([H])C(O[H])=C([H])C(C([H])([H])[H])=C1Cl)([H])([H])[H],DB11121,88-04-0,Chloroxylenol,"2-chloro-5-hydroxy-1,3-dimethylbenzene
2-chloro-5-hydroxy-m-xylene
2-Chloro-m-xylenol
3,5-dimethyl-4-chlorophenol
4-chloro-1-hydroxy-3,5-dimethylbenzene
4-chloro-3,5-dimethylphenol
4-chloro-m-xylenol
chloro-xylenol
p-chloro-3,5-xylenol
p-chloro-m-xylenol
parachlorometaxylenol
PCMX",small molecule,,"Liquid
Jelly
Soap
Liquid
Liquid
Lotion
Soap
Soap
Soap
Solution
Liquid
Liquid
Liquid
Soap
Soap
Soap
Liquid
Gel
Soap
Soap
Gel
Liquid
Soap
Soap
Gel
Soap
Soap
Lotion
Soap
Liquid; soap
Lotion
Ointment
Liquid
Soap
Ointment
Soap
Solution
Solution
Ointment
Cream
Soap
Soap
Soap
Soap
Liquid
Liquid
Soap
Soap
Liquid
Liquid
Shampoo
Lotion; soap
Liquid
Soap
Liquid
Liquid
Liquid
Solution
Solution
Liquid
Liquid
Sponge
Liquid
Solution
Solution
Solution
Liquid
Solution
Solution
Lotion
Solution
Lotion; soap
Liquid
Solution
Soap
Liquid
Aerosol, foam
Lotion
Soap
Solution
Solution
Liquid
Liquid
Liquid
Soap
Soap
Liquid
Liquid
Liquid
Lotion
Liquid
Soap
Gel
Soap
Solution
Solution
Solution
Aerosol, foam
Liquid
Gel
Solution
Soap
Solution
Soap
Soap
Liquid
Gel
Liquid
Soap
Solution
Swab
Liquid
Liquid
Liquid
Soap
Lotion
Liquid
Liquid
Cloth
Soap
Sponge
Sponge
Soap
Liquid
Liquid
Solution
Liquid
Solution / drops
Liquid
Lotion
Solution
Solution
Lotion
Liquid
Lotion
Gel
Soap
Liquid
Liquid
Liquid
Soap
Soap
Liquid
Liquid
Cream
Lotion
Solution
Solution
Solution
Solution
Liquid
Solution
Solution
Solution
Solution
Lotion
Aerosol, foam
Lotion
Liquid
Liquid
Soap
Aerosol, foam
Soap
Liquid
Aerosol
Solution
Liquid
Solution
Solution
Lotion
Soap
Liquid
Liquid
Liquid
Soap
Liquid
Liquid
Gel
Liquid
Liquid
Liquid
Soap
Liquid
Soap
Solution
Liquid
Lotion
Liquid
Soap
Liquid
Liquid
Gel
Cloth
Gel
Liquid
Gel
Liquid
Liquid
Soap
Liquid
Soap
Liquid
Liquid
Liquid
Liquid
Liquid; shampoo","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical; Vaginal
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Auricular (otic)
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","1 g/100mL
2.1 mL/100mL
1.49 %
1.0 %
.005 mL/mL
5 g/1000mL
250 g/1000mL
1.5 g/100mL
0.5 %
3.09 mg/mL
6.046 g/L
40 g/kg
.3 g/100g
5 mL/1000mL
2.5 mg/mL
1.0 %
6.1 g/L
4 g/1000mL
10 mg/mL
.3 kg/100kg
1 g/100g
.25 mg/100mL
4 mL/800mL
3 g/1000mL
.45 g/100mL
3.6 mL/800mL
6 mg/1000mL
.6 %
0.6 %
1.5 mg
.5 g/100mL
25 g/100g
8 mg
.3 mg/100mL
30 mg/mL
3.0 %
.25 %
.75 g/100g
3 mg/mL
15 g/L
10.1 mg/mL
4 mg/mL
.5 mL/100mL
2.5 mg/mL
.003 g/mL
5 %
5 mg/100mL
.5 %
.95 mL/100mL
.002 g/mL
.6 %
4.8 %
10 %
4.8 g/100mL
1 mg/100mL
3.09 1/mL
.15 g/100mL
3 %
1.1 %
.9 mg/100mL
1 mL/100mL
100 mg/mL
10 mg/mL
5 mg/mL
.8 mL/100mL
0.25 %
.6 mL/100mL
0.8 %
7.5 mg/mL
0.50 %
2 g/100L
1 mL/100mL
.5 %
2.5 mg/.001L
.3 g/100mL
3.3 g/100g
0.50 %
.663 g/221mL
.5 g/100g
2.5 g/1000mL
3.75 mg/mL
3.5 g/100mL
.003 mg/mL
1.5 g/100mL
10.22 g/1000mL
4 mg/mL
5 mg/mL
.75 g/100mL
1.75 %
17.5 g/L
.0175 L/L
.005 g/mL
10.22 g/1000mL
.05 g/59g
.5 mg/100mL
10.11 g/L
.5 mL/100mL
.1 g/L
.5 mg/100mL
5 mg/mL
.95 g/g
6 mg/mL
.95 mL/100mL
6.12 mg/mL
.3 g/100g
.005 mg/mL
0.3 %
6 mg/mL
.25 %
.5 %
15.75 g/1000mL
0.5 %
25 g/1000mL
33 mg/mL
40 mg/mL
.005 g/mL
.6657 mg/221.8mL
1.5 %
0.6 %
0.525 %
.25 %
.6 %
5.2 mg/mL
5.25 mg/mL
.3 %
2.949 g/100mL
.08 mg/100mL
1 %
30 mg/10mL
.7 %
.01 mg/mL
.5 mg/100mL
7.5 mg/mL
10 mg/mL
.006 mg/mL
.006 g/mL
.5 g/100mL
0.5 %
1.25 g/100mL
1.25 %
1.75 %
33 mg/mL
3.3 %
3.3 mg/100mL
4 mg/100mL
0.5 %
.5 mL/100mL
0.3 %
.6 mL/100mL
5 g/L
.3 g/100mL
5 mg/mL
.33 mg/1000mL
1.0 %
.1 %
3.82 g/100mL
1 g/100mL
10 g/L
1 g/100mL
0.51 %
.001 mg/100mL
1 %
12.604 g/100mL
189 g/1000mL
3 %
3 %
.75 g/100mL
.25 %
2 %
.3 mL/100mL
3 mg/mL
.05 g/100mL
2.75 g/100mL
2.75 %
2.75 g/100mL
1 %
.3 g/100mL
3.6 g/mL
3.09 g/mL
3.06 mg/mL
.5 g/100g
.52 g/100mL
0.52 %
0.5 %
0.6 %
0.65 %
5 mg/mL
2081980 mg/208198mL
.5 %
.03 g/10mL
.3 g/10mL
.04 g/10mL
.04 g/10L","The predominant medical applications for which chloroxylenol is formally indicated for therapeutic use is as an application to the skin for use in cuts, bites, stings, abrasions, and for use as antiseptic hand cleaner [L1993]."
[O-]Cl,DB11123,14380-61-1,Hypochlorite,,small molecule,,"Solution
Solution
Solution
Solution
Solution
Liquid
Liquid","Topical
Topical
Topical
Topical
Topical
Topical
Topical","5 g
5 mg/mL
2.5 mg/mL
1.25 mg/mL
.125 mg/mL
0.057 %
0.114 %",
C(C(C([H])([H])[H])(C([H])([H])[H])C(C(C([H])([H])[H])(C([H])([H])[H])C1=C([H])C([H])=C(OC(C(OC(C([N+](C([H])([H])[H])(C([H])([H])[H])C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB11125,121-54-0,Benzethonium,,small molecule,,"Kit
Kit
Swab
Swab
Swab
Liquid
Lotion
Soap
Solution
Liquid
Cream
Solution
Cream
Shampoo
Shampoo
Liquid
Solution
Solution
Liquid
Soap
Solution
Solution
Cream
Liquid
Spray
Spray
Liquid
Soap
Ointment
Cream
Cream
Solution
Solution
Lotion
Liquid
Gel
Liquid
Spray
Lotion
Gel
Aerosol, foam
Swab
Lotion / shampoo
Lotion
Cloth
Liquid
Cream
Gel
Liquid
Solution
Liquid
Aerosol, spray
Liquid
Lotion
Cloth
Liquid
Liquid
Spray
Solution
Liquid
Liquid
Kit
Liquid
Liquid
Liquid
Solution
Spray
Spray
Spray
Kit
Solution
Liquid
Spray
Spray
Solution
Aerosol
Liquid
Gel
Ointment
Spray
Soap
Cloth
Cloth
Lotion
Liquid
Powder
Cloth
Cloth
Cloth
Swab
Swab
Spray
Swab
Liquid
Liquid
Lotion
Soap
Lotion","Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Auricular (otic)
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical",".115 g/100g
.3 g/100g
.2 g/100g
.2 g/100g
2 mg/mL
.13 mg/mg
1 mg/mL
0.14 %
1 mg
.2 1/100g
0.5 %
1 mL/1000mL
100 mg/100mL
1 mL/L
.1 g/100mL
.2 g/100mL
.1 g/100g
.12 g/100mL
.2 g/100g
.1 mL/100mL
1.3 g/981mL
.1 g/100mL
1 mg/mL
.2 g/100g
0.2 %
195 mg/100mL
7.56 g/100mL
0.2 %
.2 g/100g
.2 g/100mL
.105 g/100mL
.2 mg/100mL
0.2 %
0.2 %
.2 g/100mL
.002 g/mL
.3 g/1001
2 mg/g
0.20 %
2 mg/mL
0.13 %
.13 g/100mL
.2 mL/100mL
.1 mg/100mL
1.98 mg/g
30 mL/1000mL
.06 mg/mL
1.8 mg/mL
60 mg/g
.001 mL/mL
.13 g/100mL
1 mg/50mL
2 mg/mL
.09 mg/9mL
.1 g/100g
1.3 mg/L
.013 1/mL
1.3 ug/mL
2 mg/mL
2.5 g/L
.13 mL/mL
1 mg/13mL
.2 mL/100mL
0.19 mg
0.1 %
2 mg/mL
.33 mL/251mL
.001 mg/1
.12 g/100g
2 g/L
0.5 %
0.3 %
.009 g/3g
.3 g/1
.3 mL/1
.3 1/1001
1.3 mg/mL
3 mg/100mg
0.2 %
.02 g/10mL
2 mg/mL
2 mg/mL
192.3 mg/1000mg",Indicated as an antiseptic agent. No therapeutic indications for clinical use. 
[Se] |^3:0|,DB11135,7782-49-2,Selenium,"Selen
Selenio
S��l��nium
Selenium elemental
Selenium metallicum
Selenium, elemental",small molecule,,"Capsule
Tablet, extended release
Powder
Liquid
Solution
Liquid
Tablet
Capsule
Capsule
Tablet, extended release
Tablet
Tablet
Tablet
Liquid
Tablet, coated
Tablet","Oral
Oral
Oral
Intravenous
Intravenous
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Intravenous
Oral
Oral","40 mcg
200 mcg
100 mcg
50 mcg
200 mcg
50 mcg
100 mcg
40 mcg
60 mcg",For the supplementation of total parenteral nutrition to prevent hyposelenemia [FDA Label].
[Mo],DB11137,7439-98-7,Molybdenum,,small molecule,,"Capsule
Liquid
Tablet, coated
Tablet","Oral
Oral
Oral
Oral",,
O(C1=C([H])C([H])=C([H])C2=C(C(=C(N=C12)[H])[H])[H])[H],DB11145,148-24-3,Oxyquinoline,"8-Hydroxyquinoline
hydroxybenzopyridine
Hydroxyquinoline
oxine
Phenopyridine",small molecule,,"Lozenge
Liquid
Aerosol
Packing
Gel
Liquid
Jelly","Oral
Topical
Topical
Dental
Topical
Dental
Vaginal",,
C(C(C(C(OC(=O)C1=C([H])C([H])=C(N([H])[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB11148,94-25-7,Butamben,Butyl aminobenzoate,small molecule,,"Aerosol, spray
Solution
Liquid
Aerosol
Gel
Gel","Topical
Topical
Topical
Topical
Topical
Dental; Topical",,
ClC1=C([H])C([H])=C(N(C(=O)N(C2=C([H])C(Cl)=C(Cl)C([H])=C2[H])[H])[H])C([H])=C1[H],DB11155,101-20-2,Triclocarban,,small molecule,,"Cream
Cream
Soap
Soap
Soap
Soap
Soap
Soap
Soap
Soap
Soap
Soap
Soap
Soap
Soap
Soap
Soap
Soap
Soap
Soap
Soap
Soap
Soap
Soap
Soap
Liquid
Soap
Liquid
Soap
Soap
Soap","Topical
Topical
Topical
Cutaneous
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Cutaneous
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","459 mg/150mL
153 mg/50mL
15 mg/g
.3 g/100g
.1 g/100g
.16 g/100g
1.5 %
2.6 g/10g
1.3 g/10g
1 %
1.5 mg/100mg
1.5 g
.29 g/100g
1.017 g/339g
.339 g/113g
.6 1/1
113 g/113g
.6 g/100g
6 mg/g
.3 g/100g
.33 mg/100mg
.744 g/99.225g
.45 g/90g
1.5 g/100g
.67 g/86g
1.5 mg/1000mL
4 mg/g
1.5 mL/L
.3 g/g
1.356 g/113g",
C(N1C([H])([H])C([H])([H])C([H])([H])N=C1C(=C(C1=C([H])C([H])=C([H])S1)[H])[H])([H])([H])[H],DB11156,15686-83-6,Pyrantel,"pirantel
pyrantel
Pyrantelum",small molecule,Humans,"Tablet
Tablet
Paste
Tablet, chewable
Suspension
Liquid
Suspension
Suspension
Tablet
Suspension","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","125 mg
35 mg
125 mg
250 mg/1
144 mg/mL
5 mL/250mL
5 g/100mL
50 mg/mL
180 mg/1
50 mg","For the treatment of enterobiasis including roundworm (ascariasis), pinworm (enterobius) and hookworm (strongyloides) and hookworm (ancylostoma) in the pyrantel pamoate form [L1893].
Pyrantel is available in various formulations for humans, dogs, and cats as the pamoate (US Pharmacopeia nomenclature) or embonate (European Pharmacopoeia nomenclature) salt, which contains 34.7% pyrantel base combined with pamoic acid [L1893]. [L1900], [A32283].
Pyrantel pamoate (embonate) ingested orally is effective for removal and control of ascarid and hookworm infections in puppies and dogs (adult Toxocara canis, Toxascaris leonina, Ancylostoma tubaeforme, An. braziliense, Uncinaria stenocephala), cats (adult Toxocara cati, Toxa. leonina, An. caninum, An. braziliense, U. stenocephala), horses and ponies (adult and immature Parascaris equorum, adult Strongylus vulgaris, S. edentatus, S. equinus, Cyathostomes (Triodontophorus spp., Cyathostomum spp., Cylicodontophorus spp., Cylicocyclus spp., Cylicostephanus spp., Poteriostomum spp.), Oxyuris equi, Anoplocephala perfoliata), swine (adult Ascaris suum, Oesophagostomum dentatum), and humans (adult A. lumbricoides, Enterobius vermicularis, An. duodenale, Necator americanus) [L1900]."
O(C1=C2C(C(C3=C([H])C([H])=C([H])C(O[H])=C3C2=O)([H])[H])=C([H])C([H])=C1[H])[H],DB11157,1143-38-0,Anthralin,Dithranol,small molecule,Humans,"Ointment
Ointment
Cream
Cream
Cream
Lotion
Cream
Cream
Cream
Shampoo
Cream","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical","1 %
2 %
0.1 %
0.2 %
0.4 %
0.4 %
1 g/100g
3 %
1 %
1 g/100g
.012 g/g","Stable plaque psoriasis of the skin and scalp [L1933].
It is also used topically in the management of psoriasis, dermatoses, and alopecia areata. Anthralin is also used in biomedical research due to its effect on EGFR autophosphorylation [L1936]."
C(N(C([H])([H])[H])C(C(OC1=C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])([H])[H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])([H])[H],DB11160,92-12-6,Phenyltoloxamine,,small molecule,,"Liquid
Tablet
Tablet, extended release
Suspension","Oral
Oral
Oral
Oral",,
[O-]C(=O)C1=NC([H])=C([H])C([H])=C1[H],DB11175,,Zinc picolinate,,small molecule,,"Capsule, gelatin coated",Oral,,
C(C(N(C(C1=C([H])C(S([O-])(=O)=O)=C([H])C([H])=C1[H])([H])[H])C1=C([H])C([H])=C(C(C2=C([H])C([H])=C(S([O-])(=O)=O)C([H])=C2[H])=C2C([H])=C([H])C(=[N+](C(C([H])([H])[H])([H])[H])C(C3=C([H])C([H])=C([H])C(S([O-])(=O)=O)=C3[H])([H])[H])C([H])=C2[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB11183,5141-20-8,Light green SF yellowish,"A F Green No.2
A.F. Green No. 2
Acid Brilliant Green SF
Acid green
Acid green 5
Acid Green A
C.I. Acid Green 5
Lichtgruen
Light Green G
Light Green SF
Wool Brilliant Green SF",small molecule,,Strip,Ophthalmic,1.5 mg/1.5mg,
O(C(=O)C(N(C(C(O[H])=O)([H])[H])C(C1=C([H])C2=C(OC3=C(C42OC(=O)C2=C4C(=C(C(=C2[H])[H])[H])[H])C([H])=C(C(N(C(C(O[H])=O)([H])[H])C(C(O[H])=O)([H])[H])([H])[H])C(O[H])=C3[H])C([H])=C1O[H])([H])[H])([H])[H])[H],DB11184,1461-15-0,Oftasceine,,small molecule,,Strip,Ophthalmic,.5 mg/.5mg,
C(OC1=C(S(O[H])(=O)=O)C([H])=C(C(=O)C2=C([H])C([H])=C([H])C([H])=C2[H])C(O[H])=C1[H])([H])([H])[H],DB11185,4065-45-6,Sulisobenzone,,small molecule,,"Swab
Cream
Emulsion
Gel
Spray
Lotion","Topical
Topical
Topical
Topical
Topical
Topical",2 g/100g,
C(C(N(C(C([H])([H])[H])([H])[H])C(C(OC(C(OC(=O)C1(C([H])([H])C([H])([H])C([H])([H])C1([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB11186,77-23-6,Pentoxyverine,Carbetapentane,small molecule,,"Liquid
Syrup","Oral
Oral",,
[B],DB11203,,Boron,,small molecule,,Wafer,Oral,,
C(C(C(C(C(C(C([H])([H])[H])([H])[H])(C(OC1=C([H])C(O[H])=C(C2=NC(C3=C(O[H])C([H])=C(OC(C(C(C([H])([H])[H])([H])[H])(C(C(C(C([H])([H])[H])([H])[H])([H])[H])([H])[H])[H])([H])[H])C([H])=C3[H])=NC(C3=C([H])C([H])=C(OC([H])([H])[H])C([H])=C3[H])=N2)C([H])=C1[H])([H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB11206,187393-00-6,Bemotrizinol,BEMT,small molecule,,"Liquid
Cream
Emulsion
Stick
Lotion
Spray","Topical
Topical
Topical
Topical
Topical
Topical",,
[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O,DB11212,7778-50-9,Potassium dichromate,,small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(O[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB11220,557-61-9,Octacosanol,"cluytyl alcohol
montanyl alcohol
n-octacosanol
Octacosanol
Octacosyl alcohol",small molecule,,,,,
C(C(C([H])([H])[H])=C(C(C(C(C([H])([H])[H])=C(C(=C(C(C([H])([H])[H])=C(C(=C(C(C([H])([H])[H])=C(C(=C(C(=C(C([H])([H])[H])C(=C(C(=C(C([H])([H])[H])C(=C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C([H])([H])[H])[H])([H])[H])([H])[H])[H])[H])[H])[H])[H])[H])[H])[H])[H])[H])[H])[H])[H])[H])[H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB11231,502-65-8,Lycopene,,small molecule,,Tablet,Oral,,
C(OC1=C([H])C([H])=C(C(N(C(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])C2=NC([H])=C([H])C([H])=N2)([H])[H])C([H])=C1[H])([H])([H])[H],DB11235,91-85-0,Thonzylamine,neohetramine,small molecule,,Liquid,Oral,,
C([Si]1(C([H])([H])[H])O[Si](C([H])([H])[H])(C([H])([H])[H])O[Si](C([H])([H])[H])(C([H])([H])[H])O[Si](C([H])([H])[H])(C([H])([H])[H])O[Si](C([H])([H])[H])(C([H])([H])[H])O1)([H])([H])[H],DB11244,,Cyclomethicone 5,,small molecule,,"Liquid
Liquid
Liquid
Liquid
Cream
Cream
Liquid
Liquid","Topical
Topical
Topical
Topical
Topical
Topical
Topical
Topical",".16 g/.6g
.18 g/.6g
.2 g/.6g
.17 g/8.5g
3.6 g/30mL
.35 mg/20mg
80 g/200mL",
C(C(C(C(C(C(C1=C(O[H])C([H])=C(O[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB11254,136-77-6,Hexylresorcinol,,small molecule,,"Spray
Spray
Spray
Solution
Solution
Lozenge
Lozenge
Lozenge
Lozenge","Oral
Oral
Topical
Topical
Oral; Topical
Oral
Oral
Oral
Oral","1 mg/mL
1.1 mg/mL
1.1 mg/mL
2.4 mg
3.5 mg
2.4 mg/1",
O=C(O[Cr](OC(=O)C1=NC([H])=C([H])C([H])=C1[H])OC(=O)C1=NC([H])=C([H])C([H])=C1[H])C1=NC([H])=C([H])C([H])=C1[H],DB11255,14639-25-9,Chromium picolinate,Chromium(III) picolinate,small molecule,,"Capsule
Capsule, gelatin coated","Oral
Oral",,
C(OC1=C(O[H])C([H])=C(C2=C([H])C(=O)C3=C(C(=C(O[H])C(=C3O[H])[H])[H])O2)C([H])=C1[H])([H])([H])[H],DB11259,,Diosmetin,"5,7,3'-trihydroxy-4'-methoxyflavone",small molecule,,"Cream
Cream
Cream","Topical
Topical
Topical",".1 g/100g
.11 mL/100mL
.055 mL/100mL",
O(C1=C(O[H])C([H])=C(C(=O)[H])C([H])=C1[H])[H],DB11268,,Protocatechualdehyde,"3,4-dihydroxybenzaldehyde
3,4-Dihydroxybenzaldehyde
protocatechuic aldehyde
Rancinamycin IV",small molecule,,"Cream
Emulsion","Topical
Topical",".032 mL/100mL
.0315 mL/100mL",
C(C(N(C(C([H])([H])[H])([H])[H])C1=C([H])C([H])=C(C(C2=C([H])C([H])=C([H])C([H])=C2[H])=C2C([H])=C([H])C(=[N+](C(C([H])([H])[H])([H])[H])C(C([H])([H])[H])([H])[H])C([H])=C2[H])C([H])=C1[H])([H])[H])([H])([H])[H],DB11279,633-03-4,Brilliant green,"Basic Bright Green
Brilliant green CI 42040
Ethanaminium",small molecule,,"Swab
Solution
Liquid","Topical
Topical
Topical",,
C(C(C(C(OC(C1=C([H])C(OC([H])([H])[H])=C(O[H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB11299,82654-98-6,Vanillyl butyl ether,"4-(Butoxymethyl)-2-methoxyphenol
Butyl vanillyl ether",small molecule,,"Cream
Cream","Topical
Topical",1.53 g/153g,
O(C(C(OC1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])[H],DB11304,,Phenoxyethanol,,small molecule,,"Jelly
Liquid
Soap
Liquid
Shampoo
Gel","Topical
Topical
Topical
Topical
Topical
Topical","2.5 %
1.7 %
1.7 %",
O(C(C(OC(=O)C1=C(O[H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])[H],DB11323,87-28-5,Glycol salicylate,,small molecule,,"Patch
Liquid
Plaster","Topical
Topical
Topical",,
O(B(O[H])O[H])[H],DB11326,10043-35-3,Boric acid,"boracic acid
hydrogen borate
orthoboric acid",small molecule,,"Powder
Powder, for solution
Powder
Lotion
Powder
Liquid
Liquid
Emulsion
Suppository
Solution
Lotion
Liquid
Liquid
Ointment
Powder
Liquid
Solution / drops
Jelly","Topical
Topical
Nasal; Ophthalmic; Topical
Ophthalmic
Topical
Ophthalmic
Ophthalmic
Topical
Rectal
Topical
Ophthalmic
Ophthalmic
Ophthalmic
Topical
Topical
Topical
Ophthalmic
Vaginal","100 %
2.5 %
2.5 %
7 mg/100mL
1.2 %
21.644 mg/14mL",
[O-][N+]1=C(SSC2=[N+]([O-])C([H])=C([H])C([H])=C2[H])C([H])=C([H])C([H])=C1[H],DB11327,3696-28-4,Dipyrithione,"Bispyrithione
Dipiritiona
Dipyrithionum
Omadine disulfide
OMDS
Pyrithione disulfide
Pyrithione disulphide",small molecule,,"Liquid
Shampoo","Topical
Topical",,
C(N(C1=NC([H])=NC2=C1N(C(=N2)[H])[H])[H])(C1=C([H])C([H])=C([H])O1)([H])[H],DB11336,525-79-1,Kinetin,,small molecule,,Lotion,Topical,,
C(C(C(O[H])([H])[H])=C(C(N(C1=NC([H])=NC2=C1N=C(N2[H])[H])[H])([H])[H])[H])([H])([H])[H],DB11337,1637-39-4,Zeatin,"(E)-2-methyl-4-(1H-purin-6-ylamino)-2-buten-1-ol
(E)-2-methyl-4-(1H-purin-6-ylamino)but-2-en-1-ol
(E)-2-Methyl-4-(1H-purin-6-ylamino)but-2-en-1-ol
(E)-2-methyl-4-(purin-6-ylamino)-2-buten-1-ol
(E)-zeatin
N6-(4-Hydroxyisopentenyl)adenine
trans-Zeatin",small molecule,,Lotion,Topical,,
C(OC1=C(OC([H])([H])[H])C(O[H])=C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C([H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])C(C([H])([H])[H])=C1O[H])([H])([H])[H],DB11340,,Ubiquinol,,small molecule,,Capsule,Oral,,
O([Si]([H])([H])[H])[H],DB11343,70131-67-8,Silanol,,small molecule,,Powder,Topical,34.1 g/100g,
[Rb] |^1:0|,DB11346,7440-17-7,Rubidium,,small molecule,,Cream,Topical,,
[O-]P([O-])([O-])=O,"DB11348
DB11052
DB11053",10103-46-5,Calcium Phosphate,"Calcium phosphates
Phosphoric acid, calcium salt",small molecule,Humans and other mammals,"Paste
Paste
Granule
Capsule, gelatin coated
Liquid
Paste
Tablet
Capsule, liquid filled
Paste, dentifrice
Capsule","Oral
Oral
Oral
Oral
Oral
Dental
Oral
Oral
Dental
Oral","18.6 g/100g
15.11 g/100g","For use as an over the counter calcium and phosphate supplement, antacid, or a source of calcium and phosphate in toothpaste [FDA Label] [L851]."
C(OC1=C(O[H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB11359,90-05-1,Guaiacol,"1-hydroxy-2-methoxybenzene
2-methoxyl-4-vinylphenol
2-methoxyphenol
o-guaiacol
o-hydroxyanisole
o-Methoxyphenol
Pyrocatechol monomethyl ether
Pyroguaiac acid",small molecule,,"Ointment
Liquid
Suppository
Liquid
Paste
Lozenge","Topical
Intramuscular
Rectal
Dental
Dental
Oral",,"It is used medicinally as an expectorant, antiseptic, and local anesthetic. Guaiacol is used in traditional dental pulp sedation, and has the property of inducing cell proliferation; guaiacol is a potent scavenger of reactive oxygen radicals and its radical scavenging activity may be associated with its effect on cell proliferation. "
C(C(C([H])([H])[H])(N(C(C(C(C(OC(C(=O)N(S(C([H])([H])[H])(=O)=O)[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])C1=NC(C2=C([H])C([H])=C([H])C([H])=C2[H])=C(C2=C([H])C([H])=C([H])C([H])=C2[H])N=C1[H])[H])([H])([H])[H],DB11362,475086-01-2,Selexipag,,small molecule,Humans and other mammals,"Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet
Tablet, coated
Tablet, coated
Tablet, coated
Tablet, coated
Tablet, coated
Tablet, coated
Tablet, coated
Tablet, coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Tablet, film coated
Kit","Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral
Oral","1000 mcg
1200 mcg
1400 mcg
1600 mcg
200 mcg
400 mcg
600 mcg
800 mcg
1000 ug/1
1200 ug/1
1400 ug/1
1600 ug/1
200 ug/1
400 ug/1
600 ug/1
800 ug/1
1000 ��g
1200 ��g
1400 ��g
1600 ��g
200 ��g
400 ��g
600 ��g
800 ��g",Selexipag is indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.
C(C(C1=C([H])C2=C(C(C([H])([H])[H])(C([H])([H])[H])C3=C(C2=O)C2=C(C(=C(C(=C2[H])[H])C#N)[H])N3[H])C([H])=C1N1C([H])([H])C([H])([H])C(N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])([H])C([H])([H])C1([H])[H])([H])[H])([H])([H])[H],DB11363,,Alectinib,"9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile",small molecule,,"Capsule
Capsule","Oral
Oral","150 mg/1
150 mg","Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials."
C(N(C(=O)C1=C(O[H])C2=C(C(=C(C(=C2[H])[H])[H])[H])N(C([H])([H])[H])C1=O)C1=C([H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],DB11366,84088-42-6,Roquinimex,Linomide,small molecule,,,,,"Investigated as a treatment for some cancers (including as adjuvant therapy after bone marrow transplantation in acute leukemia) and autoimmune diseases, such as multiple sclerosis and recent-onset type I diabetes."
FC1=C([H])C([H])=C(C(=O)C(C(C(N2C([H])([H])C([H])([H])N(C3=NC([H])=C([H])C([H])=C3[H])C([H])([H])C2([H])[H])([H])[H])([H])[H])([H])[H])C([H])=C1[H],DB11376,1649-18-9,Azaperone,"1-(3-(4-Fluorobenzoyl)propyl)-4-(2-pyridyl)piperazine
1-(4-Fluorophenyl)-4-[4-(2-pyridinyl)-1-piperazinyl]-1-butanone
4'-fluoro-4-(4-(2-Pyridyl)-1-piperazinyl)butyrophenone
Azaperon
Azaperona
Azaperonum
NSC 170976
Stresnil",small molecule,,,,,
C(C(C([H])([H])[H])(O[H])C(Cl)(Cl)Cl)([H])([H])[H],DB11386,57-15-8,Chlorobutanol,Chloretone,small molecule,,"Solution / drops
Ointment
Paste
Lozenge
Liquid","Auricular (otic)
Nasal
Dental
Oral
Topical",,
[O-][N+](=O)N=C1N([H])C([H])([H])C([H])([H])N1C(C1=C([H])N=C(Cl)C([H])=C1[H])([H])[H],"DB11421
DB07980",105827-78-9,Imidacloprid,"(2E)-1-[(6-chloropyridin-3-yl)methyl]-N-nitroimidazolidin-2-imine
1-((6-chloro-3-Pyridinyl)methyl)-N-nitro-2-imidazolidinimine
1-((6-chloro-3-Pyridyl)methyl)-N-nitro-2-imidazolidinimine
IMD",small molecule,,,,,
C(C(C([H])([H])[H])=C(C(C(C(C([H])([H])[H])=C(C(C(C(C([H])([H])[H])=C(C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C(C(C(=C(C([H])([H])[H])C([H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB11460,111-02-4,Squalene,"(all-e)-2,6,10,15,19,23-Hexamethyl-2,6,10,14,18,22-tetracosahexaene
Spinacene
Supraene",small molecule,,,,,
C(C(C1(C([H])([H])C2=C(C(=C(C(=C2[H])[H])[H])[H])C1([H])[H])C1=C([H])N=C([H])N1[H])([H])[H])([H])([H])[H],DB11481,104054-27-5,Atipamezole,,small molecule,,,,,For the reversal of the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs.
O(C(=O)C1=C([H])N(C2=C([H])C([H])=C(F)C([H])=C2[H])C2=C(C(N3C([H])([H])C([H])([H])N([H])C([H])([H])C3([H])[H])=C(F)C([H])=C2C1=O)[H])[H],DB11491,98105-99-8,Sarafloxacin,,small molecule,,,,,
C(N1C([H])([H])C([H])([H])N(C(C2=C([H])C([H])=C(C(=O)N(C3=C([H])C(N=C4N([H])C(C5=C([H])N=C([H])C([H])=C5[H])=C([H])S4)=C(C([H])([H])[H])C([H])=C3[H])[H])C([H])=C2[H])([H])[H])C([H])([H])C1([H])[H])([H])([H])[H],DB11526,790299-79-5,Masitinib,"AB 1010
AB-1010
AB1010",small molecule,,,,,
C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])([H])[H],"DB11558
DB01900",108-88-3,Toluene,,small molecule,,,,,"Used for the removal of ascarids (Toxocara canis and Toxascaris leonina) and hookworms (Ancylostoma caninum and Uncinaria stenocephala) and as an aid in removing tapeworms (Taenia pisiformis, Dipylidium caninum, and Echinococcus granulosus) from dogs and cats."
O(C(=O)C(SC1=NN=C(Br)N1C1=C([H])C([H])=C(C2(C([H])([H])C2([H])[H])[H])C2=C(C(=C(C([H])=C12)[H])[H])[H])([H])[H])[H],DB11560,878672-00-5,Lesinurad,"{[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid",small molecule,,"Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral","200 mg
200 mg/1","For use, in combination with a xanthine oxidase inhibitor, for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone."
N(C1=C2C(=C(C(=C([H])C2=NC2=C(C(=C(C([H])=C12)[H])[H])[H])[H])[H])[H])([H])[H],DB11561,90-45-9,Aminacrine,"10-amino-5-azaanthracene
5-aminoacridine
9-acridinamine
9AA
aminacrin
aminoacridina
aminoacridine
aminoacridinum",small molecule,,,,,
O(S(=O)(=O)C1=C([H])C2=C(N(C(C2=O)=C2N([H])C3=C(C(=C(C(=C3[H])[H])S(O[H])(=O)=O)[H])C2=O)[H])C([H])=C1[H])[H],DB11577,483-20-5,Indigotindisulfonic Acid,"5,5'-indigotindisulfonic Acid
Blue X
Indigo carmine acid
Indigotindisulfonate
Saxon blue",small molecule,,"Injection, solution
Solution","Intramuscular; Intravenous
Intramuscular; Intravenous","8 mg/mL
0.8 %",Used as a dye in renal function testing for the detection of nitrates and chlorates.
C(C1(C([H])([H])[H])C([H])([H])C([H])([H])C(C(N2C([H])([H])C([H])([H])N(C3=C([H])C(OC4=C([H])N=C5N(C(=C([H])C5=C4[H])[H])[H])=C(C(=O)N(S(=O)(=O)C4=C([H])C([N+]([O-])=O)=C(N(C(C5(C([H])([H])C([H])([H])OC([H])([H])C5([H])[H])[H])([H])[H])[H])C([H])=C4[H])[H])C([H])=C3[H])C([H])([H])C2([H])[H])([H])[H])=C(C2=C([H])C([H])=C(Cl)C([H])=C2[H])C1([H])[H])([H])([H])[H],DB11581,1257044-40-8,Venetoclax,"4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide",small molecule,,"Kit
Kit; tablet
Tablet
Tablet
Tablet
Tablet, film coated
Tablet, film coated
Tablet, film coated","Oral
Oral
Oral
Oral
Oral
Oral
Oral","10 mg
100 mg
50 mg
10 mg/1
100 mg/1
50 mg/1","For the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy."
C(C(C(C(C(C(C(C(C(C(C(C(C(C(C(C([N+](C([H])([H])[H])(C([H])([H])[H])C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB11583,10328-34-4,Cetalkonium,"Benzylhexadecyldimethylammonium
Cetalkonium cation
Cetalkonium ion",small molecule,,"Lozenge
Gel","Oral
Dental; Topical",,
[C-]#[O+],DB11588,630-08-0,Carbon monoxide,"carbon(II) oxide
Carboneum oxygenisatum
CO",small molecule,,Gas,Respiratory (inhalation),,
[Ne],DB11589,7440-01-9,Neon,"Ne
ne��n
n��on
Neon",small molecule,,Gas,Respiratory (inhalation),,
C(C([Hg]SC1=C(C([O-])=O)C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB11590,54-64-8,Thimerosal,"[(o-carboxyphenyl)thio]ethylmercury sodium salt
ethyl(2-mercaptobenzoato-S)mercury sodium salt
ethylmercurithiosalicylate sodium
ethylmercurithiosalicylic acid sodium salt
mercurothiolate
o-(ethylmercurithio)benzoic acid sodium salt
sodium ethylmercurithiosalicylate
sodium merthiolate
Thiomersal
thiomersalate
Thiomersalum
Tiomersal",small molecule,Humans,,,,"Used as preservative in some cosmetics, topical pharmaceuticals, and biological drug products, which includes vaccines [L1671, L1672, L1673]."
C(C(OC(C(N1C(C2(C([H])([H])C([H])([H])N(C(C(C3=C([H])C([H])=C(C(C([H])([H])[H])(C([H])([H])[H])C(O[H])=O)C([H])=C3[H])([H])[H])([H])[H])C([H])([H])C2([H])[H])[H])=NC2=C1C(=C(C(=C2[H])[H])[H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB11591,202189-78-4,Bilastine,,small molecule,Humans and other mammals,Tablet,Oral,20 mg,For symptomatic relief of nasal and non-nasal symptoms of seasonal rhinitis in patients 12 years of age and older and for symptomatic relief in chronic spontaneous urticaria in patients 18 years of age and older [FDA Label].
O=C1N([H])C2=C(C(=C(C(=C2[H])[H])[H])[H])C(=O)O1,DB11593,118-48-9,Isatoic anhydride,"1,2-dihydro-3,1-benzoxazine-2,4-dione
1h-benz(d)(1,3)oxazine-2,4-dione
2,4-dioxo-1,2-dihydro-4h-3,1-benzoxazine
2h-3,1-benzoxazine-2,4(1h)-dione
3,1-benzoxazine-2,4(1h)-dione
Isatoic acid anhydride
N-carboxyanthranilic anhydride",small molecule,,,,,
C(C(C(C(C(C(C(C(C(C(C(C([N+](C([H])([H])[H])(C([H])([H])[H])C(C(OC1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])([H])[H],DB11594,13900-14-6,Domiphen,"(beta-phenoxyethyl)dimethyldodecylammonium
1-dodecanaminium, n,n-dimethyl-n-(2-phenoxyethyl)
Dodecyldimethyl(2-phenoxyethyl)ammonium
Domiphen cation
Domiphen ion
Phenododecinium",small molecule,,"Lozenge
Powder
Mouthwash
Cream
Dressing","Oral
Topical
Oral
Topical
Topical","1.5 mg
.15 %","Anti-infective (topical), it is used for the treatment of Acute Infectious Dental Diseases and other conditions."
C(C(O[H])(C(OC(C1(OC(OC2(C(C(OC(C(C([H])([H])[H])(O[H])[H])([H])[H])([H])[H])([H])OC(OC(C(C([H])([H])[H])(O[H])[H])([H])[H])([H])C(OC(C(C([H])([H])[H])(O[H])[H])([H])[H])([H])C2(OC(C(C([H])([H])[H])(O[H])[H])([H])[H])[H])[H])([H])C(OC(C(C([H])([H])[H])(O[H])[H])([H])[H])([H])C(OC(C(C([H])([H])[H])(O[H])[H])([H])[H])([H])C1(OC(C(C([H])([H])[H])(O[H])[H])([H])[H])[H])[H])([H])[H])([H])[H])[H])([H])([H])[H],DB11602,9004-62-0,Hydroxyethyl cellulose,"2-Hydroxyethyl cellulose ether
Cellulose hydroxyethyl ether
Cellulose hydroxyethylate
hydroxyethylcellulose",small molecule,Humans and other mammals,"Cream
Liquid
Solution / drops
Solution
Liquid","Topical
Topical
Ophthalmic
Ophthalmic
Ophthalmic",6 mg/mL,"For alleviating surface irritation in topical ocular administrations, such as artificial tear solutions. Hydroxyethyl cellulose is also found in topical formulations to aid in more efficient drug diffusion across the membranes. "
C(C(C(=O)C(C(C(N(C([H])([H])[H])C([H])([H])[H])([H])[H])([H])[H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C1=C([H])C([H])=C([H])C([H])=C1[H])([H])[H])([H])([H])[H],DB11609,467-85-6,Normethadone,"6-dimethylamino-4,4-diphenyl-3-hexanone
Desmethylmethadone
Isomethadone I",small molecule,,Solution / drops,Oral,,For use in the treatment of cough when other less potent treatments have failed [FDA Label].
C(C1=C([H])C(C(N2C([H])([H])C([H])([H])C(=C3C4=C(C(=C(Cl)C(=C4[H])[H])[H])C([H])([H])C([H])([H])C4=C3N=C(C(=C4[H])[H])[H])C([H])([H])C2([H])[H])([H])[H])=C([H])N=C1[H])([H])([H])[H],DB11614,158876-82-5,Rupatadine,,small molecule,,"Solution
Tablet","Oral
Oral","1 mg
10 mg",For the symptomatic relief of nasal and non-nasal symptoms of seasonal allergic rhinitis and perennial allergic rhinitis in patients 2 years of age and older [FDA Label]. Also used for the symptomatic relief of chronic spontaneous urticaria in patients 2 years of age and older.
N(C(C(C(C(C(C(O[H])(P(O[H])(O[H])=O)P(O[H])(O[H])=O)([H])[H])([H])[H])([H])[H])([H])[H])([H])[H])([H])[H],DB11620,79778-41-9,Neridronic Acid,"(6-amino-1-hydroxyhexylidene)diphosphonic acid
Neridronate",small molecule,,,,,
FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F,DB11625,678-26-2,Perflenapent,PERFLENAPENT,small molecule,,,,,
O(C1=C([H])C(C2=C3N([H])C(C(=C3[H])[H])=C(C3=C([H])C(O[H])=C([H])C([H])=C3[H])C3=NC(C(C3([H])[H])([H])[H])=C(C3=C([H])C(O[H])=C([H])C([H])=C3[H])C3=C(C([H])=C(N3[H])C(C3=C([H])C(O[H])=C([H])C([H])=C3[H])=C3C(=C([H])C2=N3)[H])[H])=C([H])C([H])=C1[H])[H],DB11630,122341-38-2,Temoporfin,"2,3-dihydro-5,10,15,20-tetra(m-hydroxyphenyl)porphyrin
m-THPC
meso-tetrahydroxyphenylchlorin",small molecule,,"Injection, solution",Intravenous,1 mg/ml,"For use in the treatment of patients with advanced squamous cell carcinoma of the head and neck failing standard therapies and who are unsuitable for radiotherapy, surgery, or systemic chemotherapy [FDA Label]."
C(C1=C(C2=NOC(C3=C([H])C(O[H])=C(O[H])C([N+]([O-])=O)=C3[H])=N2)C(Cl)=[N+]([O-])C(C([H])([H])[H])=C1Cl)([H])([H])[H],DB11632,923287-50-7,Opicapone,,small molecule,,"Capsule
Capsule","Oral
Oral","25 mg
50 mg",
